<SEC-DOCUMENT>0001193125-25-180860.txt : 20250814
<SEC-HEADER>0001193125-25-180860.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814164518
ACCESSION NUMBER:		0001193125-25-180860
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IO Biotech, Inc.
		CENTRAL INDEX KEY:			0001865494
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				870909276
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41008
		FILM NUMBER:		251220347

	BUSINESS ADDRESS:	
		STREET 1:		OLE MAALOES VEH 3
		CITY:			COPENHAGEN
		STATE:			G7
		ZIP:			2200
		BUSINESS PHONE:		4570702980

	MAIL ADDRESS:	
		STREET 1:		OLE MAALOES VEH 3
		CITY:			COPENHAGEN
		STATE:			G7
		ZIP:			2200
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>iobt-20250630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-08-14T10:56:15.1433+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:iobt="http://www.iobiotech.com/20250630" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_a95f82bb-27df-43b1-9e33-21da51c0291a" name="dei:DocumentFiscalPeriodFocus" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206">Q2</ix:nonNumeric><ix:nonNumeric id="F_2cb2a08b-8490-4335-ae72-bd1d91de3a36" name="dei:CurrentFiscalYearEndDate" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206">--12-31</ix:nonNumeric><ix:nonNumeric id="F_db6e2f12-6192-41ec-b8c9-f3665923d3b5" name="dei:AmendmentFlag" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206">false</ix:nonNumeric><ix:nonNumeric id="F_c30c62f6-4cf7-4fdc-8c6a-fdd14abf1c7c" name="dei:EntityCentralIndexKey" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206">0001865494</ix:nonNumeric><ix:nonFraction id="F_ca33a566-dcf4-4f72-ba6a-d32418d6e108" name="us-gaap:CommitmentsAndContingencies" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_9c97d54b-107e-404a-bf3e-be0a3cbc6df3" name="us-gaap:CommitmentsAndContingencies" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_c1d7c3c7-ae73-414f-87de-ed2f7e40d4eb" name="us-gaap:PreferredStockValue" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_71b397df-eb05-435a-99ba-0c4e164daeb0" name="us-gaap:PreferredStockValue" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_0847deca-10d0-4530-aa33-3be6c7b7efa2" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206">http://fasb.org/us-gaap/2025#AccountingStandardsUpdate202307Member</ix:nonNumeric><ix:nonFraction id="F_abd02c4f-a3cd-4435-8a7f-dd7df01461bf" name="us-gaap:NumberOfOperatingSegments" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonNumeric id="F_aca2c24e-8e92-4826-9175-474c6929666f" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonNumeric id="F_ebc813a3-04f0-49f3-9868-9cfe7dc3008b" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206">http://fasb.org/us-gaap/2025#ProfitLoss</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="iobt-20250630.xsd"/></ix:references><ix:resources><xbrli:context id="C_806e2b05-4b7e-4476-94b2-2b7dd866dc79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_809916c8-d68a-4b98-8df0-358a4bf20dc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82fdbb77-bcb9-4016-b1f8-453bf41699c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ProfessionalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83a70f6f-685c-4644-a42c-ad925d97fe65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84fe0d8c-d67b-4ce3-b0ba-ff27aff9c03f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86041aa9-6c80-4439-9ee6-0fefaad23a00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8833db9a-d541-4dd5-b81a-904e800f12d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89f6ff06-e47d-417a-8e01-b65c0b1d729b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b2efd79-bc0d-46d6-b1bc-dd8287dadebc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iobt:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c35e721-a83d-4a8e-a7a6-c6064ec92392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d8a2973-4e93-4574-bc7f-1eb8bff4409d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">iobt:CommonStockWarrantsIssuedToEIBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9056ec8b-e4b6-4e0a-a202-17751c0d78db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90915382-ac57-414d-9f3c-555baa2c95a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90f4ecd9-d648-4156-a8e7-4757b344ff98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_934a4cc1-65a5-4fa7-9f5b-91cb5496af79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEquityAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94559174-350f-4655-96db-1060692d7265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9509aacb-0807-473e-b712-615fcaf1f276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-19</xbrli:startDate><xbrli:endDate>2024-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_961273d7-9799-42fe-8b40-c4dc80cf3e1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e6bbdd8-4ed3-4cbf-a612-855c1debc82d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0871b16-5115-452a-8aa3-17c1815473f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a14ce688-5adf-4041-9ce6-8681b682eb22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a158b0d3-0349-47ae-a852-f27a63e1f600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1eaf344-05b7-4fe9-bc2d-b42ce849911a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ClinicalTrialRelatedActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1efa8f3-3329-44e8-97a1-ee569efea2b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1fefede-ee93-4a78-8157-b3a7150dc5ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PersonnelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a201864f-0cd6-476c-97c7-14da7f8984f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a29b1256-ec9a-45be-98bb-bec426c92507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3a82724-39ac-4bbf-87e1-409ddfd8aea1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iobt:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a438d86c-ada7-4302-94e2-dc378d64a260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5b8b85f-9da7-4446-9f08-8ee19839e7c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:PreferredClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6b6d898-f2a2-4264-a194-96e339c5adc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8388fe4-cbac-4ad5-980a-b3e752b591be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-24</xbrli:startDate><xbrli:endDate>2025-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab6be8c6-2dae-4f77-8832-45ca8119a732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac5e1a5c-cbf1-4bda-90cf-e92f72ffc842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ChemistryManufacturingAndControlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_add64041-4ed9-4f0a-a7fb-8e35e7a09b6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae54636d-9518-4a0c-85b6-4e9e7bfcb7d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0860219-0067-45f9-9914-90dc829092a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b53454c8-bc99-4563-a8bb-336e5ba907a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5d3ce4a-d401-4cbf-bc28-337d54b8c30e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b73d57d8-d103-4c28-a629-6ab0d371bfb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be42f9d7-7aab-4ef2-a21e-2e34278195bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be8705f1-03eb-4e49-85f3-b10301c865b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfbeb53d-249c-4965-bee1-58424b490ed9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c135a808-e5bb-419e-a467-b4017e11a0d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1ad9cef-5ed5-4764-8224-38b467103b9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1b2dce0-7fe8-4aa8-bdb1-7da29994522e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c45f3c11-25c4-4f36-b9c4-195bc4846b79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c467807b-b9cd-4abf-a2c2-779eebbaff94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:OtherCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c62e54bd-498f-4c0a-88c7-5e544580ae36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:PreferredClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9ac1ffc-962f-4af6-b379-9a18ad414f27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca567592-c0e0-4b20-a4ed-3220891a696b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_caf14b74-474c-4188-88f8-9d1a26cd9cf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbc7cec8-5118-48e5-8682-ee34f6d86898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cda39673-240f-4ea4-b28d-573ba9ac932f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ProfessionalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf6e89c2-68e9-4989-9bcc-71a8d4f206fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ChemistryManufacturingAndControlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d039cccf-0ad2-4c2d-8c00-3f2cb7a6da02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1ac30d3-46ee-4e40-ad99-548007da67c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-19</xbrli:startDate><xbrli:endDate>2024-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1ac8d94-9bfe-4efa-86ce-70e44c8190dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">iobt:LeaseCommencementOnOctoberTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2d4d909-7247-47da-8942-e7d0085430d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">iobt:LeaseCommencementOnDecemberTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4e7dd4f-2821-44b8-998f-65cfe834fa7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d77d1227-8aa0-44ec-aa93-20c58573316a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-24</xbrli:startDate><xbrli:endDate>2025-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7ad6dd6-35af-4f8a-aac7-f313a381b605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">iobt:LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9cf7434-a99c-426e-ba30-efa367120587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9eac608-430c-4093-aaf6-37dfe968a3a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DividendsAxis">iobt:O2025Q1DividendsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da9f479f-4bef-4055-ba48-4ce7e429d95d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:OtherCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcee008c-dfa3-43d1-b9c1-5d5957ec1dec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd160d99-0b92-4fa0-b879-249e802cf09f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df699447-5212-44fe-9bb9-541bf78efe2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e39d7aaf-45f1-49d8-b933-d2049d7a30c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PreclinicalStudiesAndActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6b863ab-f667-455a-800d-d455c93b3ab4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-24</xbrli:startDate><xbrli:endDate>2025-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e967bb70-74f8-4aa9-a3ea-389fe5eeaa26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ChemistryManufacturingAndControlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea2ebe70-c654-4e26-87a4-0f7c15e0ea44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea4234a6-3d5f-4c04-b955-28240861f2c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ece426e2-ea1d-461c-9e88-f9dddd35c1c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed3915fc-fc74-40d9-ad4d-e15fa899e8b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef72a604-f4f2-4a0d-adba-eaaf1803b560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f03f590f-3e44-4ac1-9039-13057aba247a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandTwentyThreeInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f08bf985-a9db-49be-bd46-d4eda7a2c58c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f19d5a95-b1ed-473d-a534-3f3d6090cd35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f81c1fb3-24f9-45eb-95d6-3d58f5c1bf71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-24</xbrli:startDate><xbrli:endDate>2025-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f81d0ad5-24f5-440e-b388-92bb80345764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc2eaac8-ff9c-4b6b-9667-7650678ab73e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc8b2cef-3f0c-4673-bc7b-e631da99dff6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ClinicalTrialRelatedActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07d945e9-2951-4202-ae7e-2b4ac20b2b1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e1d0a4d-d812-461f-aec2-4c14dea78aaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0fe7e5da-4225-4e64-8f1a-304a1362ffeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_101f5b3f-2579-4748-bcd4-04070eb2ce6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iobt:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_109f1d22-8cd3-493e-ab7e-5ad075bd7dcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12c9ea54-3647-4df4-9107-48c806489a8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">iobt:LeaseCommencementOnMarchTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_132052a7-d00c-4cb3-9ad6-e77324375e94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1434ccee-3c92-4bb3-9b9d-6f650436ace2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_168c3e7e-9d8e-427e-8f70-1ecd3c073fd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16b635b3-2fb2-4918-9590-c3e68b0c0739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1829c523-648e-4a02-8109-0deb1191ed06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ProfessionalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b0fada8-8afd-4aa2-8081-cb2a8058b81f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PreclinicalStudiesAndActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c31d0c7-7684-473b-9386-127c8dea9206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d4a8f2a-a146-4860-99dd-0f7ae3dbbe1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1db878a1-26bf-48ae-8c27-edb9a58074e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1dfbcdf2-7303-4e39-a3bd-fd5f426fbf73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iobt:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e0ec6e5-7239-40d3-8f87-70637b9c4213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e241c91-5715-488d-a31b-90976e18ef81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ProfessionalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2130d49e-92a6-4472-a00f-3b63ffde0b9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21938b85-ef8d-4d5c-9762-a35f1259aa3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23f0e49a-26af-436d-a252-4c3c0051cbd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-07</xbrli:startDate><xbrli:endDate>2023-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26bef08c-05c8-4a89-94f6-05ba69278969"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b8ecfa6-15a8-4675-8200-6867ed419829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-24</xbrli:startDate><xbrli:endDate>2025-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d7f3f8f-ddd0-48bc-b68a-50c26ed152f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ClinicalTrialRelatedActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2dce093a-2adb-4a4a-8fc5-39fd85ae7014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f3ed9a6-4829-4c38-92f5-f9f01e3bbb26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_304a194f-57dd-4a19-bedc-cdfd57a688a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">iobt:LeaseCommencementOnJuneTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31556d6d-fe87-49c2-bbf3-1900c78c9c40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEquityAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_320ef1d4-ce99-4066-9e33-b688a26543ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_329921d0-d469-45e2-ae77-6ca463b6325e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3312f560-ea95-4c4d-b954-f433c8050666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-07</xbrli:startDate><xbrli:endDate>2023-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34603f30-56ca-4356-8f77-419b1978063a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-24</xbrli:startDate><xbrli:endDate>2025-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35ff612b-5ba4-4688-aed0-aa185853966a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36ff792f-bd4e-446c-b141-ce575eb25023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-19</xbrli:startDate><xbrli:endDate>2024-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37646e78-6337-438c-8dbe-8a3712d470ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3764f78d-6235-4496-a19e-2de9bd33fad6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:OtherCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_389775bc-ae88-489c-8c1c-85a0ed058e9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-24</xbrli:startDate><xbrli:endDate>2025-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38e73190-243c-4f4c-acfe-c43cdf009a58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3adaf1b6-8e71-4415-9436-0d74420cbb54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ba08ec9-fc01-4790-9392-b29be37fb6b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c22dc6f-5520-49c4-8ebf-ac7d5b76711c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iobt:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ce8c578-aa0a-4ee8-a8d4-b0a4fac4e5ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41b1f416-58f2-4b5c-99cf-ca18ff696ab3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41eb296d-58a9-41d3-ac9d-5e2d3cb0a7a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PersonnelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_438a86b3-b95d-4e7a-bf73-767445f988d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PreclinicalStudiesAndActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43a993b5-927a-4fb4-ad4d-c154c853f2a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_444ecd94-9413-4f58-9283-c0e742cfcbad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_474458dc-a129-4f50-994f-7df9fe0827f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEquityAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_490dd48a-6429-4e12-b498-a5cc551a31c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-19</xbrli:startDate><xbrli:endDate>2024-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a17c158-ee71-4938-91a0-7a0dbd466b03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b7ed800-ce67-458e-a181-b724431189ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d40a682-0751-4064-bb08-df58960d326c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-24</xbrli:startDate><xbrli:endDate>2025-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e98906e-1cac-4433-be9f-7d243d541dcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f1f2469-2895-4c93-a281-ddfa3fa3a80f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">iobt:CommonStockWarrantsIssuedToEIBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fdff8d0-846c-4e02-aaa4-5c470eaf7625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_527af978-7806-4a1e-8520-f96890860ee1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-09</xbrli:startDate><xbrli:endDate>2023-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_545accb2-04f0-4670-bdc6-0b24c21df653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_556c8daa-bb23-4277-a055-75e799014084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55aaab1d-0030-4d3d-8a11-599b6fe6903f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ClinicalTrialRelatedActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56d189f5-8762-4d45-aa40-9a14717e05b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b150492-18b8-4ea5-b79f-6a9eee4738eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b1915ad-890a-47af-9868-ded5e38e7f5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5be29099-873c-44cb-9847-39038a293dac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cc831a0-a0fc-49d9-95ba-356e8a3a7fb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d5c2036-4d47-45b2-abc2-ce62234c7b0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e0098f9-fc3d-4792-a5bc-ef3eeb5b4648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fa6d61c-8fbd-4763-8701-fc3239e4a315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60dc3163-f2cf-4d9a-bd0c-4ced094cf2aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">iobt:LeaseCommencementOnDecemberTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_626b865b-fabe-418d-8e2b-8f5f5a575c6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62d03c66-fb1f-4bda-9c1b-02dea4a59e4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6561fedd-443a-4a83-8643-efd575ae4790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ChemistryManufacturingAndControlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65d8cb5b-0a18-41c9-981b-c844905fa72f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PersonnelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c0dfbea-5705-4f01-91ec-a344114fb10f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6dce96c8-4c75-416e-bf89-e8c89509910e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ef232e1-8f2b-4eec-9dd0-c1e56fcf4bb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PersonnelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72045b9f-3820-4aad-a93e-3694b13e20c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:OtherCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73b1457e-202f-4b74-987b-acf3673e19af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75035fee-9a60-4e72-991b-0ba8a07ca63f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-19</xbrli:startDate><xbrli:endDate>2024-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75fb5f36-7e2a-4032-ac5b-b93710ea8e93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_778386da-0eec-4652-a846-c64fb6f85ac0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_785749e1-bfed-43d5-a943-0f70e8cc76bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PreclinicalStudiesAndActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a8a9344-a835-4ba9-8433-bf16f27259e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ae94389-ebe2-4996-bb29-68980b435b79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b18d373-032b-4323-90f2-5980a3f2eeb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e2345a4-e132-4d97-885c-dbc51fa34b9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001865494</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Lease"><xbrli:measure>iobt:Lease</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>iobt:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>iobt:Segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, DC 20549</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6fa6611-8a85-4b32-8fb8-a68c6bf97288" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_16d0da36-e978-458f-bd25-9afd25a37132" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c12b6bbb-11d5-487d-8e8f-06673cff4426" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc06333d-f053-4472-92b5-fa142dd05c2c" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_2918f48e-84e9-4451-b76a-99401fba9d3e" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:DocumentTransitionReport" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from __________________ to  __________________</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01194a4f-bf20-4ee1-85a5-915ddb4f12e4" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-41008</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img135872921_0.jpg" alt="img135872921_0.jpg" style="width:73px;height:78px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9bd90bee-f260-4b46-ae0f-32751b30f944" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO Biotech, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_965cc23b-86b9-4615-9576-4e5437322437" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_23538084-3417-4814-bfad-f881e30e1609" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">87-0909276</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_62f1c622-9255-4786-aac8-3bf02240e599" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ole Maal&#248;es Vej 3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_d8e30914-6826-4573-8745-753f295cdbaf" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">DK-2200</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_bf2f1a7c-8c12-4d2e-a318-5f27308622c5" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Copenhagen N</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_79511320-0cbd-476d-a446-fe175043d18e" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Denmark</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NA</span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88df452d-2cf8-473c-8a6e-ee7d91c11dbd" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+45</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57afe4ec-c4f0-4dcf-ab5d-401c0b3b903f" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7070 2980</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_2cc17b59-ec6b-4903-b424-c66bdbdadd48" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e26426ed-d304-40b4-a0ef-dac069346824" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IOBT</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">The </span><span style="font-size:9pt;"><ix:nonNumeric id="F_9d355b37-1755-4e24-9c74-84e078908081" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="text-indent:5.333%;font-size:10pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_886257b8-fe57-45bf-bd8e-6d7deca7612c" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7f9492f-e534-4679-9497-4e0d70bbac8f" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:19.019%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:55.716%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:20.34%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1.922%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_623fdf77-71ed-460f-9fda-e711fa07d071" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_81154ddb-6b1b-4d91-a038-062be6230f64" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntitySmallBusiness" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_02afc14e-0ad3-4668-96e9-c57771dc7735" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10ab989e-f6f8-40ce-9f51-023bf3d9fe8b" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  &#9744;    No  </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40661ce9-caf1-4b43-91e6-0ef5733a2727" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of August 11, 2025, the registrant had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60ea0df2-ea49-48ed-81f7-2b982a72f102" contextRef="C_c1b2dce0-7fe8-4aa8-bdb1-7da29994522e" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, $0.001 par value per share, outstanding.</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10.1%;box-sizing:content-box;"/>
     <td style="width:82.82%;box-sizing:content-box;"/>
     <td style="width:7.08%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ifinancial_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">FINANCIAL INFORMATION</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Interim Financial Statements (Unaudited)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations_comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_convertible_preference_shares"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_quantitative_qualitative_disclosu"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iior_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_riskfactors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_unregistered_sales_equity_securit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_defaults_upon_senior_securities"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;intends,&#8221; &#8220;target,&#8221; &#8220;projects,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q, in our Annual Report on Form 10-K for the year ended December 31, 2024 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Some of the key factors that could cause actual results to differ from our expectations include:</span></p><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, progress and the success of our clinical trials of IO102-IO103, our lead investigational therapeutic cancer vaccine candidate, which in the U.S. is now known as Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (imsapepimut and etimupepimut, adjuvanted), IO112, IO170 and any other product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the results of our trials will be sufficient to support domestic or foreign regulatory approvals for Cylembio, and potential future clinical trials of IO112, IO170 or any other product candidates we may develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability or inability to obtain approval of Cylembio from applicable regulatory authorities or our failure to obtain regulatory approval to expand Cylembio&#8217;s indications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability or inability to successfully commercialize Cylembio, or our other product candidates, if approved by applicable regulatory authorities, or to maintain applicable regulatory approvals for Cylembio or our other product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory actions with respect to our product candidates or our competitors&#8217; products and product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain, including on an expedited basis, and maintain regulatory approval for Cylembio, IO112, IO170 or any other product candidates we may develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcomes of our preclinical studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and conduct our clinical programs on our expected timelines;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of development of any of our product candidates or clinical development programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and success of our remediation of the material weakness in our internal control over financial reporting;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectation about the period of time over which our existing capital resources will be sufficient to fund our operating expenses and capital expenditures;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential attributes and clinical benefits of the use of Cylembio, IO112, IO170 or any other product candidate, if approved by the relevant regulatory bodies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully establish or maintain collaborations or strategic relationships for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate and degree of market acceptance of Cylembio, IO112, IO170 or any other product candidates we may identify and pursue, if approved by the relevant regulatory bodies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain orphan drug designation, Breakthrough Therapy Designation (&#8220;BTD&#8221;), PRIME designation or other approval for any product candidates we may identify;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding government and third-party payor coverage and reimbursement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to manufacture, including through contract manufacturing organizations (&#8220;CMOs&#8221;), Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, IO112, IO170 or any other product candidate in conformity with the requirements of the Food and Drug Administration (&#8220;FDA&#8221;) and other applicable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully build a sales force, commercial infrastructure, medical affairs and other product launch functions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to compete with companies currently producing or engaged in the clinical development of treatments for the disease indications that we pursue and treatment modalities that we develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reliance on third parties to conduct our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reliance on third-party CMOs to manufacture and supply our product candidates for us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to retain and recruit key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain intellectual property protection for Cylembio, IO112, IO170 or any other product candidates we may identify and pursue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company (&#8220;EGC&#8221;) under the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;);</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial performance;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of significant public health emergencies or geopolitical events on any of the foregoing or any other aspects of our business operations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of laws and regulations, including legislative developments; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.66525540221037%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments and projections relating to our competitors or our industry.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, Part II, Item 1A - &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q, and those described elsewhere in this Quarterly Report on Form 10-Q and in our Quarterly Reports on Form 10-Q for the quarter ended March 31, 2025. Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, industry, and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Quarterly Report on Form 10-Q also contains estimates, projections, and other information concerning our industry, our business, and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates, and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections, or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by third parties, industry, medical and general publications, government data, and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except where the context otherwise requires, in this Quarterly Report on Form 10-Q, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;IO Biotech,&#8221; and &#8220;the Company&#8221; refer to IO Biotech, Inc. and, where appropriate, its consolidated subsidiaries.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iii</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trademarks</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have registered various trademarks that we use in connection with the operation of our business. This Quarterly Report on Form 10-Q includes trademarks, service marks, and trade names owned by us or other companies. All trademarks, service marks, and trade names included in this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks and trade names in this report may be referred to without the &#174; and &#153; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iv</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ifinancial_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I&#8212;FINANCI</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AL INFORMATION</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Interim Financi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">al Statements (Unaudited)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO BIOTECH, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Balance </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sheets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.673%;box-sizing:content-box;"/>
     <td style="width:1.74%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.923%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.74%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.923%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5638863-bc77-4755-80f9-9fb77c562d4d" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,131</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e907031-65a3-4e89-9fda-d0be09ec7c37" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,031</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d053f13f-ea58-4973-8e2d-a740411e8286" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,849</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6423ae0d-8a2c-45c7-96e1-a3b931e34afb" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,920</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ee6db8e-d53a-40a6-83bd-738239b6aa06" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,980</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_777bb397-a210-4779-8e8c-1c6411e5a5ad" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,951</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3434fbc-64d9-4238-9a39-5abb248139be" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d4bb448-0cf1-42bc-9a85-4a12ee250e05" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb5e10d4-500c-4230-8b20-b9957609c4f2" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">603</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0578f6b5-9087-4795-9f25-b7c812eb0ccb" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">638</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use lease asset</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e29b23e-40ca-41d5-8f22-6dfef70307f0" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,470</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd535fc8-cc65-4841-a951-24df6fc7d20a" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,725</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b178c158-d9b6-43e0-a5bb-ad7d708a2005" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,005</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc0779e8-eebc-46b1-a7e2-21ecbf673467" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total non-current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b64d6c99-99f4-4603-bac8-d03f1fe1cc4e" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,346</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26edf073-ec9f-4cb4-90cb-424846f4f8fa" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,748</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_596d32e5-cb43-4fd1-9b8b-f6184f5343a7" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,326</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_345c0e9e-9466-4987-976c-07c5f82fb3a5" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,699</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39582774-0d0c-41f9-add2-890eb0d4b548" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,537</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7da2c698-25fb-4bc6-8806-2bb21a675a25" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,661</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability - current</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faa7fcf3-4216-4e35-b349-bf2eaf47a3af" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4d9e209-d87c-4241-8265-52ad8073d077" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">717</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b262b39-1035-462a-9fa8-c673d21265d8" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,592</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab915ee0-0ee5-40d9-ac54-091efe5e84ce" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,108</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e9b01a0-5784-4252-a448-9e211d48d2ae" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,897</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42c7f256-72dc-46cd-87af-faac5a7cbbf7" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,486</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability - non-current</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_750529b3-046e-4fc3-a61f-ee4628e3ac60" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">868</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef76f139-f4e3-49db-b283-bdbaf7f1d3be" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,198</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan debt, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04556912-e8cd-4231-92b4-873404d98039" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,720</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4852c0e3-e463-425b-a523-fb44db477c66" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88169603-d399-42da-8b65-72633b78ba6a" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:CommonStockWarrantsLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,249</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6355d07-4acd-4f49-bbcc-2f43ce0cdcce" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="iobt:CommonStockWarrantsLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total non-current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbc9a72f-0dd4-4ff6-9a53-b3cf974c03b2" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,837</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ab44d05-af7c-4444-b502-7e0cc334e144" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,198</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ee0f135-e651-4899-9506-1a19b0c6d85e" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,734</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6ec5c09-db34-4016-9bad-53c09fa85521" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,684</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_ca33a566-dcf4-4f72-ba6a-d32418d6e108;"><span style="-sec-ix-hidden:F_9c97d54b-107e-404a-bf3e-be0a3cbc6df3;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 10)</span></span></span></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, par value of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c1cf44b-15ee-4b1c-bf52-6b63097e7131" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_509276a3-fc87-4424-adea-4dd34e91cc9a" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;per share; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16f07f30-8444-4e67-b35e-420a8dc20cb6" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c1dfcf0e-2a00-4ea4-9f7c-5085956d3cae" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5148a7c-c8c6-47d8-ac44-dbf66200f0d2" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d411780a-c5d2-40bd-8982-8c69edf25e43" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_551103d4-fbce-4212-b4f5-98ad13cff449" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_529ae9e7-530c-4706-915d-8f1e3f7c79c7" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding as of June 30, 2025 and December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_c1d7c3c7-ae73-414f-87de-ed2f7e40d4eb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_71b397df-eb05-435a-99ba-0c4e164daeb0;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, par value of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22ba888b-20ef-4789-b1f1-983762707d82" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3acf51e1-61ce-40d5-9078-69fedefb2a24" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;per share; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16a835c3-e41e-4002-84d7-bfec628263a7" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_46a4e928-7ecb-4454-a079-c1ddef177a05" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized at June 30, 2025 and December 31, 2024; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8eba27e9-ffc8-45c0-9d13-586d71f29ded" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c232cca1-55a3-40de-ae8e-78a6a5201bff" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0edf2ab3-575a-4e13-a384-2447c6f3bdb4" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_31b45a11-3c7b-4e7f-88ab-bfe6ec47132e" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_589a6056-ea6c-48f4-91c5-4d8c2e997029" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abb7dd47-4b0b-43b4-9a55-2167f5384de3" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a74c7bef-c547-4709-bd3a-27a820de9424" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">416,289</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d142f1f7-f4ee-4b6d-899a-0dcfc6785a8e" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">413,113</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4c15386-94dc-48ff-bb81-7a5b6086073b" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">407,951</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5421e4c3-6ae2-42f6-bf4c-a50d0bb6f440" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">359,313</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abbced40-b1bf-4e0e-bf17-fae76f40e0fb" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,812</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34898936-f51a-4912-b8d9-661392149057" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,851</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da50392f-8868-4d2e-93d7-418c0d23e990" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,592</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6448e6ea-a73b-439c-a096-5e9eefafd9cc" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,015</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6389f639-a182-4299-bdff-4f0a5ec0d9bc" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,326</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_040bdac4-44cf-4e37-b4ef-2afa600f4cc7" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,699</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to the unaudited interim consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO BIOTECH, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations_comprehensive_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:51.52%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.28%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89d7eb74-fc28-47f1-afce-489f8713e3f0" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,652</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daeb7dc1-89d7-4898-b35a-3433af72277a" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,848</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0e1a913-1dff-416f-97f9-1233a563e4d7" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,027</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6156b53e-5729-441a-a009-07cab65672f2" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,159</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65606a1e-0fbf-4661-9bb2-e341e4e08b46" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,518</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f10d7455-0053-4ce7-9ac0-b304ee2d5410" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,685</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e72ee9ad-3c82-4684-b49f-c83496753912" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,727</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3689087-68b1-4565-acf3-2cdb671b5bc1" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,571</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af97bb79-f4f0-41eb-923d-6079cfe650f6" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,170</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d063dc50-429c-4d5a-9b8f-6ec46272d376" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,533</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a780552b-acf0-4384-b837-7e37f555a768" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,754</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c72e77e-25e2-4662-ab20-0e9b04361d9b" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,730</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b919a5c-4f82-491e-86fc-34459a6d1f37" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,170</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14c61d06-337a-46b9-98de-21a63c037734" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,533</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4b2d460-7e5c-42dc-846f-ad4f7c328480" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,754</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ec39869-1114-410d-8c6a-d2e777a2b961" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,730</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (expense) income</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency exchange loss, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3ccc3db-cf20-4989-9cdd-af3198b69bb9" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">374</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12f0f648-294c-4e1a-b1bc-6c9902945d65" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6f20faf-d9d7-4554-a89f-01662e86c3db" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">479</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f168b88-0431-4b37-8c2c-72145112c98f" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">552</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aea6e14e-7560-40e2-9812-50ca6b6bb704" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">285</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3623417f-f272-4426-997f-ba6f4f30a586" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,311</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4e264cc-b6ec-4cbc-b358-0c2634a9ce93" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">699</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e94ba359-169e-4e07-ba5f-618f17479f98" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,928</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55a510eb-93b7-49bc-8a5d-7e16148008d1" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:InvestmentIncomeInvestmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94277fdd-b3e7-4c42-ab6d-00b3a86f5f34" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:InvestmentIncomeInvestmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a9c4f96-f81d-4526-8501-6bad6bdd8765" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:InvestmentIncomeInvestmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84ffdb43-5599-4b6b-947d-689e30145d99" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:InvestmentIncomeInvestmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a0e5d6c-cd6f-41a7-bfde-ff5962fcf74c" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,587</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d7d4ade-059f-406c-a5a4-455494fe1244" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_292f2780-4fb6-40ac-9c09-c7828d1e9ad6" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,587</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d9a347a-d755-4008-b686-8ebb528e2d58" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other (expense) income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ed46e14-7c2c-45f0-a7f7-ed5e6c39d855" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,929</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38dd6259-cdff-4bff-93ad-abd7b9b1485a" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,221</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1db46409-a3c5-43a1-97cd-51163e2f3bed" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,620</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2459fd78-8c2d-4a54-9466-e51082e0ef94" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,376</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income tax expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f32ef92-dd55-43b9-9e75-3807510ed266" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,099</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fab6942-3ced-4b84-a660-70ad906153da" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,312</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b083447c-48b7-44ea-a3a9-e1ac37b07b1b" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,374</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2c85978-e07d-4693-bb70-29b86fa6acfc" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,354</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9adfc096-e407-4c37-a7f8-3ccc73bd0ff1" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ad538fb-4ee9-488a-bcdb-912251782901" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">374</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_774f4691-04fd-4dc2-9d71-0bf73c39d569" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d3053da-6ecb-4b00-9b36-5b0f3876d5f2" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">789</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27b81041-06e2-48cd-a363-7c557fc5a9ac" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,217</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_080e2f7b-d03d-4733-ba8f-07aee1c9f2b4" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,686</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c28cbba-269f-4877-97d5-92dd6b0d3f8a" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,638</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8aa841bd-1740-4db1-8c84-0170decb99bb" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,143</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db371866-cdb1-4674-a4d2-c51e57d47ad3" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,217</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de03117a-5c74-44aa-9f9b-c4ae071830f2" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,686</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f1d29e0-84f1-4b62-b5ce-476bf88e1024" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,638</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0386b742-dcc6-4f28-8730-73d204742780" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,143</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1f1af6c-db64-404e-8d0a-5264fb6c17c1" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c5b025df-00f9-40da-91d7-60d2d03c0e5e" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.40</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26d03f9f-3958-4eca-aa08-4baddfa075c1" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c8266040-e9dc-4f4d-a6b5-d500d7bcc352" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.31</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abdd2030-e8f2-462e-8687-ffafe875616c" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7fd8e719-b678-4351-aaa0-be04f9a40eae" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.74</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de7913b8-c515-430e-b25a-0edd632f1fc7" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9d6e32ed-b15c-408b-b9a3-44c18e2c87bb" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.61</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of shares used in computing net loss per common share, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22d22239-055d-422b-8236-010863e19f03" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_45e56538-7830-440f-a900-ed093fd1ced4" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f337ff22-f9e5-491e-a6bb-bd695f995b14" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_115646af-b53d-42e4-8e33-a7b4465fe9f4" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65b8e0a7-7b96-4736-b201-c5b2ca05939b" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ce27c122-193b-43d9-9513-04ef48d0b275" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0254da77-1ec5-4133-a485-2b2c8a2d0e9a" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3238e8e4-67db-4e49-afda-d98fa6d0ec21" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0114f0e-edd5-49a6-a5b1-c0604ec2e0c1" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,217</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18300458-0a22-492e-a28d-5e82c9687f55" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,686</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2a0e17d-97b9-481b-8b20-f61431e6a1fa" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,638</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcf221db-d599-4cba-ba06-7c9551e778cf" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,143</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency translation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f521acc-2ff7-4b0e-835c-482f53e047ca" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">220</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37eb50d5-ac8f-4463-aedc-fa3b6ed058f6" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">151</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_051f2d8e-c601-4c19-8e26-74efae61dc9c" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddc51add-522a-4ca8-af0d-f6f14c4c65b6" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a30dcf8a-bfdd-43a2-b78f-dcc3eae4d032" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,437</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12316039-0ca1-44d9-9898-2e1bc95c7ac8" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,837</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7168ef35-af3a-4e4a-bc9d-5a9405816c71" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,599</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36738c80-8a03-4a03-b73a-48dba354ad54" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,100</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to the unaudited interim consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO BIOTECH, INC.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_convertible_preference_shares"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:26.005%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.722%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.242%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.242%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.242%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.242%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.302000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Other<br/>Comprehensive</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, January 1, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbbf2530-e16c-4987-83b9-f463ee8979e7" contextRef="C_21938b85-ef8d-4d5c-9762-a35f1259aa3d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0df734d8-e7ef-4f9a-b780-12b5bc69e34d" contextRef="C_21938b85-ef8d-4d5c-9762-a35f1259aa3d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_514f62d7-9bf0-4210-a976-9a3bcf730f01" contextRef="C_ece426e2-ea1d-461c-9e88-f9dddd35c1c7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">406,587</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be5a38f5-0118-43de-bc08-a5bb9c0b93c4" contextRef="C_3ba08ec9-fc01-4790-9392-b29be37fb6b3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,669</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29a7ed0f-46f0-4a6b-906c-9173d5dd3225" contextRef="C_3ce8c578-aa0a-4ee8-a8d4-b0a4fac4e5ee" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">263,822</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_750cd5ce-aa36-4b66-9184-9cb279cb7f7c" contextRef="C_3adaf1b6-8e71-4415-9436-0d74420cbb54" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,162</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b26fb4b-8bab-4b19-a218-2219ef1d3796" contextRef="C_43a993b5-927a-4fb4-ad4d-c154c853f2a2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,210</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9baa79f-e76f-4f6b-af1f-961b561c94d0" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,210</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency translation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d89d099-a89f-48a7-a662-dc4dcc762742" contextRef="C_b53454c8-bc99-4563-a8bb-336e5ba907a2" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e78b82a3-eda5-4b1c-a0cd-f5116da60828" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3445143-a539-4603-9a54-72c4448dff65" contextRef="C_626b865b-fabe-418d-8e2b-8f5f5a575c6a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,143</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ab67ee7-f432-4465-a3c9-874a441535be" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,143</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, June 30, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d812cbdf-70e8-4ad4-a4c2-03fd22ed5e6d" contextRef="C_89f6ff06-e47d-417a-8e01-b65c0b1d729b" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eff546cc-b598-4de0-b923-3d54547edb08" contextRef="C_89f6ff06-e47d-417a-8e01-b65c0b1d729b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e90c65dc-786a-4ebe-b955-c388fc0e9ceb" contextRef="C_c45f3c11-25c4-4f36-b9c4-195bc4846b79" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">409,797</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80ff5783-4595-4779-beda-cd2ee9769059" contextRef="C_2dce093a-2adb-4a4a-8fc5-39fd85ae7014" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,626</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc9d98b7-a0b1-4bc2-868f-8cfa4e70552d" contextRef="C_62d03c66-fb1f-4bda-9c1b-02dea4a59e4e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">303,965</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ddf0d37-cea7-4e63-933e-acbcb8962546" contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,272</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, January 1, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7138c3c-7cf2-4e34-857d-f4ec8dd964c6" contextRef="C_7a8a9344-a835-4ba9-8433-bf16f27259e7" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bd43a09-95d9-4b7b-94de-c7964f71a852" contextRef="C_7a8a9344-a835-4ba9-8433-bf16f27259e7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9c56a2a-7f41-4695-b636-21747f880a19" contextRef="C_f81d0ad5-24f5-440e-b388-92bb80345764" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">413,113</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_644647e2-0960-4e91-94b2-071b9d80ac09" contextRef="C_2f3ed9a6-4829-4c38-92f5-f9f01e3bbb26" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,851</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a77dfa89-5677-43da-ad96-af215f808098" contextRef="C_b0860219-0067-45f9-9914-90dc829092a2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">359,313</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_039ef1b0-1293-4889-a2db-c0817298c584" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,015</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e6a0116-f731-4767-be61-20727751a3d5" contextRef="C_5e0098f9-fc3d-4792-a5bc-ef3eeb5b4648" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,176</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15ef1af7-803c-479b-968a-de713a0277e6" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,176</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency translation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85141a5c-a007-4c7e-943f-a88ddbac8ec9" contextRef="C_8c35e721-a83d-4a8e-a7a6-c6064ec92392" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14056fe0-0695-4073-a2fa-d27835c6d0c1" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_348927f3-5481-4b11-ba5f-ea0aca67565f" contextRef="C_4a17c158-ee71-4938-91a0-7a0dbd466b03" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,638</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57e6e3ac-11c2-480a-b81e-ac4dea35caf2" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,638</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, June 30, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5c87f81-4f18-4a8f-b086-fce81e30de91" contextRef="C_8833db9a-d541-4dd5-b81a-904e800f12d5" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b371cfd-f384-4f15-b3f7-12671e6b77d0" contextRef="C_8833db9a-d541-4dd5-b81a-904e800f12d5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6627c89-6e3b-459f-8f4a-71a08943c334" contextRef="C_1db878a1-26bf-48ae-8c27-edb9a58074e0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">416,289</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf846328-1d90-4b2f-8469-44d590ac5719" contextRef="C_ca567592-c0e0-4b20-a4ed-3220891a696b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,812</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3ac7bfc-a761-4000-9a04-961d6abc7673" contextRef="C_1e0ec6e5-7239-40d3-8f87-70637b9c4213" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">407,951</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e8ab1ae-1cdc-4be3-97c4-12bc536dc529" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,592</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to the unaudited interim consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO BIOTECH, INC.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:61.912%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.043000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.043000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash flows from operating activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_816e3d13-5a64-4037-9fe3-db3fa399c078" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,638</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72628ff4-136a-4724-b841-6c9481fc3ffb" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,143</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment to reconcile net loss to net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43de4ca3-b84b-46d9-9920-dfe9f06ff348" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_568febbe-2fed-455d-9718-e5d4005d9fbd" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4c86de3-002b-418a-a7b4-0e81f600edc7" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,176</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc6afe99-b081-46e0-a7e1-c98dd74e9406" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,210</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fe669c7-a27a-4b3b-8285-0b91d9369c5c" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5b2e743-14a2-4f0f-944c-1404a7d44fe3" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of right of use lease asset</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ca3fe63-610d-431f-aedc-fadfc98795bf" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03b8972b-65fe-4e9e-ac13-cd4a6318940c" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53f7f5e9-7c82-411e-955b-f232bebb8b37" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">479</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8aa06ed-ffd1-4f8d-86b4-f1588106fff7" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">552</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f08dbdb1-8b24-4e37-98d8-cc5d1b0dc83f" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,587</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ddbd4a8-315a-4d88-9c52-f06f4b981c9f" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99d10232-1e60-4ead-89c7-f2b8c556b462" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">636</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76003efc-79a6-4a2b-91ef-12f23d9ced81" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,843</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea5a591e-526b-4e21-be76-77762bb4f6df" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">882</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb74a8aa-bf46-4ffd-9c5b-1dd0324e3d6f" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">787</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5afd2e24-4511-4006-be6d-bdb0a5fedc9a" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">877</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d6bac6e-49da-4fe7-9044-8fbe00b3077b" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,139</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a07d4d15-b699-4ee9-bea4-06af0c56b76c" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="iobt:IncreaseDecreaseInLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">418</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f76cffc3-1dc2-486d-8999-cd50482f41f2" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="iobt:IncreaseDecreaseInLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">312</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_247205fc-66d1-4a7e-b991-4a8fdc0340f5" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">152</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3b6b243-65ef-45aa-b53e-00f4d718fa5e" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,155</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:7.413%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac6f27f6-b666-4aa3-8760-ef524ea7dc23" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42,893</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bf83f6f-c329-433d-9268-6bd49a6fc467" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,914</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash flows from investing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7b45cf9-1a42-43ce-aac9-468a4db6a513" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5981c606-1840-4640-87ad-c89c1fac7cf6" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:7.413%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2abba1e2-403b-4f3c-bf21-cef9e82cfddb" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9379ff07-9924-449f-b2ca-92c8084c484e" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash flows from financing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Proceeds from the issuance of debt</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73149cbd-55b0-4953-9762-dd3d6ebc2c6b" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,720</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de6df037-5cfc-4863-922c-bcea83a260dd" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Payments of debt issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65e8927c-41ad-47be-a1c4-5a5010d069ff" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">233</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52b34255-3a45-4674-856c-2ed4850eb84e" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:7.413%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67b902e0-fb07-423d-84b8-049be57e7f65" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,487</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_858e9909-79ac-464b-a3f9-5e4dd5b4bcc7" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80b61e48-d021-4186-b478-7085a929a0c5" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">31,460</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5be0fe1-4883-4943-97ad-95cade348ffc" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,937</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c87281b5-415b-437b-bf3e-6d2da10bc052" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">440</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e7abe24-d3b6-4bd3-aaba-539d805c89c6" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">509</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f07da8f3-7732-4a3a-9762-549112236911" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,299</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16571d0e-e50a-47d8-9803-731fa9763182" contextRef="C_3adaf1b6-8e71-4415-9436-0d74420cbb54" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,461</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37a3b7f7-1931-4b82-b305-960a008034aa" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,399</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f41e2e2-0240-435d-8049-ac61bbc3982d" contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,015</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Components of cash, cash equivalents, and restricted cash</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0fc22c4-4bb6-4a15-8cbc-b31abc9bd100" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,131</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20881b2d-2115-4e3c-88dc-c136f92b3e57" contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,747</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b7ab601-ee7c-4cf2-9101-1b49688d595b" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20527ea8-1808-4e56-95d1-5ca0b3b257fb" contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">268</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b97f28a6-af72-4f91-8408-00821a518436" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,399</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_765948c5-a927-4fde-b47d-987c7f61604e" contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,015</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to the unaudited interim consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(unaudited)</span></p><div><ix:nonNumeric id="F_c342a4c4-8f84-47fb-a7a1-6c9e44b27a1b" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_c342a4c4-8f84-47fb-a7a1-6c9e44b27a1b_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Description of Business, Organization and Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on our T-win</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform. As used in these financial statements, unless the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to IO Biotech, Inc. and its subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Reorganization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO Biotech ApS was incorporated in Denmark in December 2014. In November 2021, we completed a corporate reorganization (the &#8220;Corporate Reorganization&#8221;) whereby IO Biotech ApS became a wholly-owned subsidiary of the Company. In connection with the corporate reorganization, each issued and outstanding Class A ordinary share ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_068b2219-68b7-4666-a3c3-c7f3f1e27241" contextRef="C_07d945e9-2951-4202-ae7e-2b4ac20b2b1a" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value) was exchanged on a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6ff9f42-1f6f-471c-8280-008ee6701a67" contextRef="C_0fe7e5da-4225-4e64-8f1a-304a1362ffeb" name="us-gaap:CommonStockConversionBasis"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-one</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> basis into shares of common stock of the Company ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37544492-7fb7-4157-9b35-f42271042941" contextRef="C_b5d3ce4a-d401-4cbf-bc28-337d54b8c30e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b2ad7080-f031-48b8-bc4f-b52f37c52c32" contextRef="C_a5b8b85f-9da7-4446-9f08-8ee19839e7c1" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value). Each Class B and Class C preference share of IO Biotech ApS was exchanged on a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec2ae415-d2cc-4dc0-b9bc-716a8b3b3130" contextRef="C_90f4ecd9-d648-4156-a8e7-4757b344ff98" name="us-gaap:CommonStockConversionBasis"><ix:nonNumeric id="F_9576ff8a-9e96-4fc9-a45c-08df5e448a0d" contextRef="C_c62e54bd-498f-4c0a-88c7-5e544580ae36" name="us-gaap:CommonStockConversionBasis"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-one</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> basis into shares of Class B and Class C preferred stock of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO Bio US, Inc., a wholly owned subsidiary of IO Biotech ApS, was incorporated in Delaware in May 2021. IO Biotech Limited, a wholly owned subsidiary of IO Biotech ApS, was incorporated in the UK in August 2021. In November 2021, the Company engaged in a series of transactions, referred to collectively as the Corporate Reorganization. As a result of the Corporate Reorganization, IO Biotech ApS became a wholly-owned subsidiary of IO Biotech, Inc. IO Biotech, Inc. is a holding company formed in October 2021, which, prior to our initial public offering (&#8220;IPO&#8221;), had nominal assets and no liabilities, contingencies, or commitments, and which has not conducted any operations prior to our IPO other than acquiring the entire issued and outstanding stock of IO Biotech ApS. The Company, IO Biotech ApS, and the holders of all of the issued and outstanding equity interests of IO Biotech ApS entered into a Share Contribution and Exchange Agreement, dated as of October 29, 2021, pursuant to which the Corporate Reorganization was effected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IPO</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2021, we completed our IPO, selling an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68a32b03-e710-42b6-be78-0f7d0afbbf03" contextRef="C_961273d7-9799-42fe-8b40-c4dc80cf3e1d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,222,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35a82d25-67f1-46c1-934c-91392399fbf2" contextRef="C_1434ccee-3c92-4bb3-9b9d-6f650436ace2" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2c8602c-7291-4eb4-82fb-69a914abc9c2" contextRef="C_7e2345a4-e132-4d97-885c-dbc51fa34b9a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,072,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock sold pursuant to the underwriters&#8217; exercise of their option to purchase additional shares of common stock. We received net proceeds from the IPO, after deducting underwriting discounts and commissions and other offering costs, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02e3f5a2-2a8f-49b2-be75-caedf35f2106" contextRef="C_dd160d99-0b92-4fa0-b879-249e802cf09f" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">103.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immediately prior to the consummation of the IPO, all outstanding shares of our Class A ordinary shares and Class B and Class C convertible preference shares were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af6de972-f439-4d91-bedb-82da005227f6" contextRef="C_7b18d373-032b-4323-90f2-5980a3f2eeb4" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">20,592,413</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock. Upon the closing of the IPO on November 9, 2021, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbfa222c-fb34-44bd-9d3c-557f550f9c18" contextRef="C_7b18d373-032b-4323-90f2-5980a3f2eeb4" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">28,815,267</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were issued and outstanding. Our common stock began trading on the Nasdaq Global Market on November 5, 2021 under the symbol &#8220;IOBT.&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 9, 2021, we amended and restated the certificate of incorporation of IO Biotech, Inc. to authorize the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ab25a23-f349-4797-acfa-ac7d6ddb2119" contextRef="C_7b18d373-032b-4323-90f2-5980a3f2eeb4" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70609921-4f36-4b07-b4d1-fa82384e7866" contextRef="C_f19d5a95-b1ed-473d-a534-3f3d6090cd35" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock. The shares of preferred stock are currently undesignated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">August 2023 Private Placement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 9, 2023, the Company completed a private placement transaction (the &#8220;Private Placement&#8221;), pursuant to which we sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c407a20b-9087-4062-a7ac-8a753506f995" contextRef="C_b73d57d8-d103-4c28-a629-6ab0d371bfb8" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa370d81-5d79-4d37-ab89-34e47506069d" contextRef="C_6dce96c8-4c75-416e-bf89-e8c89509910e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1920f27-b9d9-44f5-93a9-d2b7b2071144" contextRef="C_b73d57d8-d103-4c28-a629-6ab0d371bfb8" name="iobt:WarrantsIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fb079a6-e15f-4fc1-9a9d-f2e017ae6c6e" contextRef="C_2130d49e-92a6-4472-a00f-3b63ffde0b9b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;Warrants&#8221;) to certain institutional investors and existing shareholders (the &#8220;Purchasers&#8221;). Each Purchaser&#8217;s Warrant is exercisable for a number of shares of common stock equal to one hundred percent of the aggregate number of shares of common stock purchased by such Purchaser. The purchase price per share of common stock and Warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_878c3870-3fba-423c-afe5-aa3b243d6166" contextRef="C_b73d57d8-d103-4c28-a629-6ab0d371bfb8" name="iobt:PurchasePricePerShareOfCommonStockAndWarrant" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.025</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Purchase Price&#8221;). The Company received net proceeds from the Private Placement, after deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fb01fde-de52-4bb4-ad1e-b7b5528b9614" contextRef="C_b73d57d8-d103-4c28-a629-6ab0d371bfb8" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in underwriting discounts and commissions and other offering costs, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cdfe404-c1dc-405d-8615-c00c83586fab" contextRef="C_0e1d0a4d-d812-461f-aec2-4c14dea78aaa" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">71.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Refer to Note 11, "Stockholders' Equity" in this Quarterly Report on Form 10-Q for additional detail on the Private Placement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_c342a4c4-8f84-47fb-a7a1-6c9e44b27a1b_1" continuedAt="F_c342a4c4-8f84-47fb-a7a1-6c9e44b27a1b_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-The-Market Equity Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 15, 2023, we filed a new prospectus supplement with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to the offer and sale of shares of our Common Stock, with an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33a2f709-475d-4bab-ba60-1140d80016ca" contextRef="C_101f5b3f-2579-4748-bcd4-04070eb2ce6f" name="iobt:CommonStockMaximumAggregateOfferingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, establishing an at-the-market equity program. We also entered into a common stock sales agreement, dated February 15, 2023 (the &#8220;Sales Agreement&#8221;) by and between the Company and Cowen and Company, LLC for shares with an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_425fa8df-88d0-4563-8a21-103d2195f7f7" contextRef="C_1dfbcdf2-7303-4e39-a3bd-fd5f426fbf73" name="iobt:CommonStockMaximumAggregateOfferingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, through which we may, from time to time, sell shares through Cowen and Company, LLC, acting as agent and/or principal. Any shares offered and sold through the at-the-market equity program will be issued pursuant to the Company&#8217;s Registration Statement on Form S-3 (File No. 333-269569), which was declared effective on February 10, 2023, the prospectus supplement related to the offering that forms a part of the registration statement, and any applicable prospectus supplements that may form a part of the registration statement in the future. The aggregate market value of shares eligible for sale under the prospectus supplement and under the Sales Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_544da53a-00ec-4661-b899-ef524c3173b8" contextRef="C_a3a82724-39ac-4bbf-87e1-409ddfd8aea1" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t issued any shares pursuant to our at-the-market equity program as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Investment Bank Term Loan Facility</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 19, 2024, the Company, through its subsidiary, IO Biotech ApS (the &#8220;Borrower&#8221;) entered into a Finance Contract (the &#8220;Finance Contract&#8221;) with the European Investment Bank (&#8220;EIB&#8221;), establishing a loan facility of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4799dd8c-dd0d-4700-b71d-ec00d1144bd2" contextRef="C_75035fee-9a60-4e72-991b-0ba8a07ca63f" name="us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">57.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that includes three committed tranches of potential financing in an aggregate principal amount of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6d44f2c-385e-4863-90a0-a1d9fda52bb9" contextRef="C_df699447-5212-44fe-9bb9-541bf78efe2d" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, subject to certain conditions precedent (the &#8220;EIB Loan Facility&#8221;), and one uncommitted accordion tranche of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67437f22-df60-41ec-a8b1-de8ab344414f" contextRef="C_75035fee-9a60-4e72-991b-0ba8a07ca63f" name="iobt:CertainConditionsPrecedentAndOneUncommittedAccordionTranche" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. See Note 8, &#8220;Term Loan Facility&#8221; in this Quarterly Report on Form 10-Q for additional detail.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance reporting capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates are in preclinical research and clinical development. There can be no assurance that our research and development will be successfully completed, that adequate protection for our intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if our product development efforts are successful, it is uncertain when, if ever, we will generate significant revenue from product sales. We operate in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, we are dependent upon the services of our employees and consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Substantial Doubt About the Company&#8217;s Ability to Continue as a Going Concern and the Going Concern Basis of Accounting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements have been prepared on a going concern basis of accounting, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, we have devoted substantially all of our efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. We have financed our operations primarily through the issuance of convertible preference shares, convertible notes, our IPO, the Private Placement and the EIB Loan Facility.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our continued discovery and development of product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if our product development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, we had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f89ca5bb-4ce3-4ecc-8115-ab26b599301a" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">408.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. We have incurred losses and negative cash flows from operations since inception, including net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c43023f1-9d48-4e8b-8d3f-5d84c49c70b1" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">48.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc9197c8-bb0b-4a66-a2f4-6df7e480d580" contextRef="C_38e73190-243c-4f4c-acfe-c43cdf009a58" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">95.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the six months ended June 30, 2025 and the year ended December 31, 2024, respectively. We expect that our operating losses and negative cash flows will continue for the foreseeable future as we continue to develop our product candidates. We currently expect that our cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43f024f5-0bf6-427e-a067-25b98efa692a" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025 along with the second tranche of the EIB Loan will not be sufficient to fund our operating expenses and capital requirements for at least 12 months from the date the financial statements are issued.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c342a4c4-8f84-47fb-a7a1-6c9e44b27a1b_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has plans to obtain sufficient additional fundraising to fulfill its operating and capital requirements for the next 12 months. The Company&#8217;s plans include continuing to fund its operating losses and capital funding needs through public or private equity or debt financings, including the draw down of the available committed tranches of the EIB loan facility defined below in Note 8, &#8220;Term Loan Facility&#8221;, strategic collaborations, licensing arrangements, or other arrangements. The Company has drawn down on the Tranche A and Tranche B loan facility in principal amount of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8aa3b237-0d30-470a-973a-f1ed1df3486c" contextRef="C_56d189f5-8762-4d45-aa40-9a14717e05b4" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90647875-48c7-4383-afd6-a20cf7704e5c" contextRef="C_320ef1d4-ce99-4066-9e33-b688a26543ee" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, on May 6, 2025 and July 4, 2025, each before payment of certain fees and transaction related expense. The business conditions of the Tranche C loan facility have not been satisfied to draw up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64655eca-7b45-4718-886f-03be57308004" contextRef="C_a1efa8f3-3329-44e8-97a1-ee569efea2b8" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of the date of these interim financial statements. Further, the Company believes that its operations are scalable and, if there is a need, certain cost reduction measures may be taken to preserve cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although management believes such plans, if executed, should provide the Company sufficient financing to meet its needs, successful completion of such plans is dependent on factors outside of the Company&#8217;s control. Our future capital requirements will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, prioritization and number of our research and development programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of our clinical trials, including the results of IOB-013;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs to scale up and secure manufacturing arrangements for commercial production of Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in combination with pembrolizumab as a first-line treatment in advanced melanoma;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of establishing and maintaining commercialization capabilities for Cylembio in combination with pembrolizumab as a first-line treatment in advanced melanoma, and any product candidate that obtains regulatory approval; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of sales achieved, and costs related to the commercialization of Cylembio in combination with pembrolizumab as a first-line treatment in advanced melanoma.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Therefore, sufficient additional funds may not be available on a timely basis, on favorable terms or at all. As such, management cannot conclude that such plans will be effectively implemented in due time to secure sufficient funds to finance operations at least through one year after the date that the financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, management has concluded that the aforementioned conditions, among others, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements are issued and therefore, the Company may not be able to continue its currently ongoing research and development activities as planned and realize its assets and satisfy its liabilities in the normal course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will also require additional capital to commercialize Cylembio in combination with pembrolizumab as a first-line treatment in advanced melanoma, and to continue to fund future discovery research, preclinical, clinical activities and commercialization of any of our product candidates. If we receive regulatory approval for Cylembio, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing, medical affairs, distribution and other related functions, depending on where we choose to commercialize. Additional funds for such commercialization activities and future discovery research, preclinical, clinical activities may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our growth strategy. We will seek additional funding through public financings, debt financings, collaboration agreements, strategic alliances and licensing arrangements. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining such additional financing on acceptable terms, or at all, and we may not be able to enter into collaborations or other arrangements. If we are unable to obtain funding in due time, we could be forced to delay, reduce or eliminate our research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect our business prospects, even our ability to continue operations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div><ix:nonNumeric id="F_1b436104-012a-4cf1-ac16-7ef14c405bd7" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_1b436104-012a-4cf1-ac16-7ef14c405bd7_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_ad0d1fb8-47c2-4da3-8aa0-680014e6f885" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="iobt:WarrantsPolicyPolicyTextBlock" escape="true" continuedAt="F_ad0d1fb8-47c2-4da3-8aa0-680014e6f885_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants Issued in Connection with a Sale of Common Stock or Issuance of Debt</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for warrants issued as a separable unit in connection with sale of common stock or debt as either liability or equity in accordance with Accounting Standards Codification 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_1b436104-012a-4cf1-ac16-7ef14c405bd7_1" continuedAt="F_1b436104-012a-4cf1-ac16-7ef14c405bd7_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ad0d1fb8-47c2-4da3-8aa0-680014e6f885_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered liabilities if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. If warrants do not require liability classification under ASC 815-40 or other applicable generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) the warrants should be classified as equity. The debt is measured at amortized cost and the amount of interest recognized in the consolidated statements of operations is calculated by applying the loan&#8217;s effective interest rate to its carrying amount.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The proceeds received from the sale of equity classified warrants and shares of common stock in a bundled transaction are allocated based on the relative fair values of warrants and shares with no changes in fair value of warrants recognized after the issuance date. For liability classified warrants, the stand-alone fair value of the warrants are classified as debt issuance costs that directly reduce the outstanding debt on the consolidated balance sheet upon funding. Warrants issued prior to the date of funding are accounted for as a deferred financing asset within &#8220;Prepaid expenses and other current assets&#8221; on the consolidated balance sheet and will be reclassified to debt issuance costs on the date of funding. The change in fair value of warrants each balance sheet date are recognized in the consolidated statements of operations and comprehensive loss after the issuance date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no other changes to the significant accounting policies disclosed in Note 2 to the Company&#8217;s annual financial statements for the years ended December 31, 2024 and 2023 included in our Annual Report on Form 10-K filed with the SEC on March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e5e53c33-55da-4ac3-89ab-421265b5f07f" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="iobt:UnauditedFinancialInformationPolicyPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unaudited Financial Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying unaudited interim consolidated financial statements included herein have been prepared in conformity with U.S. GAAP, and pursuant to the rules and regulations of the SEC. In the Company&#8217;s opinion, the information furnished herein reflects all adjustments, all of which are of a normal and recurring nature and necessary for a fair presentation of the financial position and results of operations for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company&#8217;s Annual Report filed on Form 10-K for the fiscal year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_1d94947c-1269-496e-9747-ce19b5ec9419" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_1d94947c-1269-496e-9747-ce19b5ec9419_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Standards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0847deca-10d0-4530-aa33-3be6c7b7efa2;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will also enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment and contain other disclosure requirements. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the financial statements. The guidance is effective in the annual periods beginning after December 15, 2023 and the Company has </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea89a353-cf57-4bb9-8414-0ddf53365c55" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the standard effective </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dfa2b0f2-1ebb-43dd-96dc-edb30e3abe8c" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Refer to Note 15, "Segments" in this Quarterly Report on Form 10-Q for additional information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Standards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, Accounting Standards Update 2023-06&#8212;Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative. ASU 2023-06 will eliminate disclosure requirements that are redundant, duplicative, overlapping, outdated, or superseded as a result of subsequent changes to SEC disclosure requirements, U.S. GAAP or technology. ASU 2023-06 is intended to better align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP. The disclosure requirements would apply prospectively in the financial statements. ASU 2023-06 will be effective for us on the date on which the SEC&#8217;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, if we are already subject to the SEC&#8217;s current disclosure requirements. For those current disclosure requirements we are not subject to, ASU 2023-06 will become effective two years after the date of such removal by the SEC. We are currently assessing the impact adoption of ASU 2023-06 will have on our financial statements and disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_1b436104-012a-4cf1-ac16-7ef14c405bd7_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1d94947c-1269-496e-9747-ce19b5ec9419_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 will require disclosure of additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state and foreign income taxes. ASU 2023-09 will also require information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold.  ASU 2023-09 will be effective for us in the annual periods beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. We are currently assessing the impact adoption of ASU 2020-06 will have on our financial statements and disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures  (Subtopic 220-40): Disaggregation of  Income Statement Expenses. ASU 2024-03 will require disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis, including purchases of inventory, employee  compensation, depreciation, intangible asset amortization and depletion for each  income statement line item that contains those expenses. ASU 2024-03 also will require certain amounts already disclosed under existing U.S. GAAP to also be disclosed as a separate category in disaggregated expense table(s), if those amounts are  recognized in the relevant expense line item. The amendments in this ASU will be effective for us in annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. We are currently assessing the impact adoption of ASU 2024-03 will have on our financial statements and disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our consolidated financial statements.</span></p></ix:continuation></div></ix:continuation></div><div><ix:nonNumeric id="F_c64fb08b-8fd5-44ea-8074-8eb2f5bbbe57" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_c64fb08b-8fd5-44ea-8074-8eb2f5bbbe57_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa3b8f0e-d551-4714-ac68-e8cf9ede2a4f" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24528679-c737-4b24-b829-97485f2d45c3" contextRef="C_ed3915fc-fc74-40d9-ad4d-e15fa899e8b3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f73b602-be1f-46b6-a474-83399c07f5b5" contextRef="C_a201864f-0cd6-476c-97c7-14da7f8984f9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e17df0d8-b43c-4136-862f-7ba04c04f40e" contextRef="C_be42f9d7-7aab-4ef2-a21e-2e34278195bb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffc417f2-188c-46f8-9660-9834d38be049" contextRef="C_168c3e7e-9d8e-427e-8f70-1ecd3c073fd2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2f15451-24cf-4ea3-8d0c-73195274c4a0" contextRef="C_3c22dc6f-5520-49c4-8ebf-ac7d5b76711c" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,249</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6db4f11-9a3a-4f83-9608-13043d3dbc6c" contextRef="C_8b2efd79-bc0d-46d6-b1bc-dd8287dadebc" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,249</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_976cfe4f-60ae-42e6-8547-ab77567133dd" contextRef="C_be42f9d7-7aab-4ef2-a21e-2e34278195bb" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,249</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d98275fc-4af1-4bee-9657-1b15015dde45" contextRef="C_bfbeb53d-249c-4965-bee1-58424b490ed9" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,249</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fa86962-39da-4c9b-88d9-756834685bc1" contextRef="C_90915382-ac57-414d-9f3c-555baa2c95a6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,134</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a0d807f-a384-429c-a783-66b9b2b3c5dd" contextRef="C_5be29099-873c-44cb-9847-39038a293dac" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,134</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e287dbf5-4abd-460a-a0d4-6c44d93544e3" contextRef="C_5b1915ad-890a-47af-9868-ded5e38e7f5a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,134</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41a1aa96-efbb-4ab4-823b-ce261c343477" contextRef="C_35ff612b-5ba4-4688-aed0-aa185853966a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,134</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Money market funds</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common stock warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 24, 2025, in connection with the EIB Loan Facility, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_1abff002-9ab3-4239-919c-eceac1caf963" contextRef="C_389775bc-ae88-489c-8c1c-85a0ed058e9b" name="iobt:WarrantsIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,623,664</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Tranche A warrants to purchase shares of the Company&#8217;s common stock at an exercise price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_6e1beaea-29f9-465d-99d4-ff2a5300d59d" contextRef="C_389775bc-ae88-489c-8c1c-85a0ed058e9b" name="iobt:StrikePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.89</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. On June 24, 2025, in connection with the EIB Loan Facility, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_e17f3ea8-891d-403d-b9cc-aee80e2a6bc6" contextRef="C_d77d1227-8aa0-44ec-aa93-20c58573316a" name="iobt:WarrantsIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,221,868</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Tranche B warrants to purchase shares of the Company&#8217;s common stock at an exercise price of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_c64fb08b-8fd5-44ea-8074-8eb2f5bbbe57_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_f77b5361-716d-4fc0-91be-0dd556e4a261" contextRef="C_d77d1227-8aa0-44ec-aa93-20c58573316a" name="iobt:StrikePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.32</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 8, &#8220;Term Loan Facility&#8221; in this Quarterly Report on Form 10-Q for additional detail on the EIB Loan Facility and warrants issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EIB warrants met the criteria for liability classification and are initially recognized on the date of issuance and subsequently measured at each balance sheet date at fair value through &#8220;Other income (expense)&#8221; on the consolidated statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the Tranche A and Tranche B warrants was determined based on the Black-Scholes option-pricing model and classified within Level 3 of the fair value hierarchy on the date of issuance. The expected volatility input used in the model was deemed unobservable (Level 3) and was determined based on share price data of the Company and comparable companies for a term equal to the remaining contractual term of the warrants. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other required inputs used in the model were considered observable (Level 1). Significant increases (decreases) in these inputs could result in a significantly lower or higher fair value measurement. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cae06177-d92e-4f9d-a4f8-f712b7603f12" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" escape="true" continuedAt="F_cae06177-d92e-4f9d-a4f8-f712b7603f12_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the Black-Scholes option-pricing model inputs used to calculate the fair value of the warrants at issuance date. </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_cae06177-d92e-4f9d-a4f8-f712b7603f12_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.59%;box-sizing:content-box;"/>
         <td style="width:2.901%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.304000000000002%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.901%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.304000000000002%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche A</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche B</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share price of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87f2164c-307a-4072-ba26-8e3424fcfcfc" contextRef="C_809916c8-d68a-4b98-8df0-358a4bf20dc9" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.92</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3450d751-53bd-4bcf-9222-913d8eb9fc76" contextRef="C_545accb2-04f0-4670-bdc6-0b24c21df653" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.39</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_310253b1-a2aa-460c-8e26-869ef1df78b4" contextRef="C_34603f30-56ca-4356-8f77-419b1978063a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">83.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2fa6135-ad67-462b-9f9b-803fe811ab25" contextRef="C_a8388fe4-cbac-4ad5-980a-b3e752b591be" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">84.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e03e5aa8-275f-40ba-a2e7-fd043d979f8f" contextRef="C_34603f30-56ca-4356-8f77-419b1978063a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e25bdf48-bf83-4f03-95f0-90d9f9d107c4" contextRef="C_a8388fe4-cbac-4ad5-980a-b3e752b591be" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_62094454-9659-4b8e-84f1-3a5ba23eaf3b" contextRef="C_34603f30-56ca-4356-8f77-419b1978063a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_52c56f30-0595-4c7a-91f0-1e7d4739ec1e" contextRef="C_a8388fe4-cbac-4ad5-980a-b3e752b591be" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_631b5cfe-56f8-4d88-b89c-83f43602cb8c" contextRef="C_34603f30-56ca-4356-8f77-419b1978063a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3b2104a-3dda-4ae2-ac6a-0670bc134e66" contextRef="C_a8388fe4-cbac-4ad5-980a-b3e752b591be" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the Black-Scholes option-pricing model inputs used to calculate the fair value of the warrants at June 30, 2025.</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.59%;box-sizing:content-box;"/>
         <td style="width:2.901%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.304000000000002%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.901%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.304000000000002%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche A</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche B</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share price of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ecb5319-d6a7-4253-9d54-72c3768870c1" contextRef="C_a29b1256-ec9a-45be-98bb-bec426c92507" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.39</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_701b0caa-32cd-483a-a7cc-2cc0c0f27198" contextRef="C_ae54636d-9518-4a0c-85b6-4e9e7bfcb7d1" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.39</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e660506d-95f6-4466-8dbe-f71a1cb39d22" contextRef="C_c135a808-e5bb-419e-a467-b4017e11a0d1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">84.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3589b6bc-dbbc-4a54-adf8-a188cfcc66b9" contextRef="C_add64041-4ed9-4f0a-a7fb-8e35e7a09b6b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">84.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_004fb922-1e07-445b-92b7-e37de5faac4c" contextRef="C_c135a808-e5bb-419e-a467-b4017e11a0d1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f0d3c7a-6e2e-4430-88f6-f3748ff17be9" contextRef="C_add64041-4ed9-4f0a-a7fb-8e35e7a09b6b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_2399076b-6091-4329-8895-c3f571eda52b" contextRef="C_c135a808-e5bb-419e-a467-b4017e11a0d1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.8</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_be0c009e-c413-4af1-b5be-00bdfcdcdfc6" contextRef="C_add64041-4ed9-4f0a-a7fb-8e35e7a09b6b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_663bb523-6b4e-4a63-9942-8e38c332cde8" contextRef="C_c135a808-e5bb-419e-a467-b4017e11a0d1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1040f577-7e46-49c3-bddf-a6155ec77252" contextRef="C_add64041-4ed9-4f0a-a7fb-8e35e7a09b6b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a529a4c-de55-48d4-b426-52efc34fa427" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows a reconciliation of the beginning and ending balances for Level 3 financial liabilities measured at fair value on a recurring basis for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:78.32%;box-sizing:content-box;"/>
         <td style="width:1.9%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.72%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.06%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 3 financial liabilities, beginning of period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54e310e4-0799-4593-bda6-1a535959f76a" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of EIB common stock warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04115ec9-d18d-431c-9307-22952160e7b9" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,662</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of EIB common stock warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_095f24cb-baf7-4c14-be05-41b061bc1952" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,587</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 3 financial liabilities, end of period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a04e7e86-ebd9-4c0c-8b05-7de294f7dd18" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,249</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53193141-583e-4cc0-be00-008810855394" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8cc3e4ee-b1f7-4541-85f3-53c40d889457" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c28b6ff6-247f-4f3d-931f-b9fc49086188" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2a8929e8-f577-4f61-9255-23dc8211d64a" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b0f21928-8894-4c0d-b06d-faaf8a44a61a" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8088fff9-9576-43b3-9f35-03907d0ee9b4" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="iobt:FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_11d26dcf-5e13-47d9-ae22-0b1967fdc0e2" contextRef="C_38e73190-243c-4f4c-acfe-c43cdf009a58" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c2891191-6a97-48bc-9cef-3a86c0bfffde" contextRef="C_38e73190-243c-4f4c-acfe-c43cdf009a58" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers among Level 1, Level 2 or Level 3 categories in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025 and the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div><ix:nonNumeric id="F_28aec814-5c7e-4888-95fa-78993d422b1a" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_28aec814-5c7e-4888-95fa-78993d422b1a_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. License and Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreements with MSD International GmbH</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2018, we entered into a clinical collaboration with MSD International GmbH (&#8220;MSDIG&#8221;), an affiliate of Merck &amp; Co. Inc., (&#8220;Merck&#8221;) to evaluate IO102 in combination with KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;pembrolizumab&#8221;) in first-line treatment of patients with metastatic non-small cell lung cancer. Under the terms of the collaboration with MSDIG, we conducted an international Phase 1/2 study to evaluate a combination therapy of IO102 and KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We sponsored the clinical trial and MSDIG provided KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to be used in the clinical trial free of charge. We and MSDIG were responsible for our own internal costs and expenses to support the study and we bore all other costs associated with conducting the study, including costs of providing IO102 for use in the study. The rights to the data from the clinical trial were shared by us and MSDIG and we maintain global commercial rights to IO102.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_28aec814-5c7e-4888-95fa-78993d422b1a_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2021, we entered into a clinical collaboration with MSDIG and MSD International Business GmbH (&#8220;MSDIB&#8221;), another affiliate of Merck (collectively, &#8220;MSD&#8221;) to evaluate IO102-IO103 in combination with KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> versus KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> alone in treatment of patients with metastatic (advanced) melanoma. Under the terms of the collaboration with MSD, we are conducting an international Phase 3 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are the sponsor of the clinical trial and MSD is providing KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to be used in the clinical trial free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trial are shared by us and MSD and we maintain global commercial rights to IO102-IO103.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, we entered into a clinical collaboration with MSD to evaluate IO102-IO103 in combination with KEYTRUDA&#174; in previously untreated patients with three different tumor types&#8212; metastatic non-small cell lung cancer (&#8220;NSCLC&#8221;), squamous cell carcinoma of the head and neck (&#8220;SCCHN&#8221;), and urothelial bladder cancer (&#8220;UBC&#8221;). Under the terms of the collaboration with MSD, we are conducting an international Phase 2 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are the sponsor of the clinical trial and MSD is providing KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to be used in the clinical trial free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trial are shared by us and MSD and we maintain global commercial rights to IO102-IO103.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, we entered into a clinical collaboration with MSD to evaluate IO102-IO103 in combination with KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as a neoadjuvant/adjuvant therapy for patients with metastatic melanoma and SCCHN. Under the terms of the collaboration with MSD, we are conducting an international Phase 2 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are sponsoring the clinical trial and MSD is providing KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to be used in the clinical trial free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trial are shared by us and MSD and we maintain global commercial rights to IO102-IO103.</span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9661af7b-f902-453e-9946-8651c22b4b2b" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Prepaid Expenses and Other Current Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87f6dec2-b3e9-469a-a39b-ed939dab23a7" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.923%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.923%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred financing asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fdf621f-2973-451a-8c4b-5839baa27d0d" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:DeferredFinancingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,657</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c422677a-9146-4dc4-9a07-2489ce0a6189" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:PrepaidTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,607</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_525b729f-c698-4da1-8506-ddef934b2645" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:PrepaidTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,292</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid contract research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d3afd05-1e03-419a-b2b1-d5eee3fba313" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:PrepaidContractResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,109</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1697a84d-a970-47de-9363-9722c347d485" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="iobt:PrepaidContractResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,119</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credit receivable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa0b065b-7eb3-4f5d-9564-93355b4d5f2b" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:ResearchAndDevelopmentTaxCreditReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">865</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e51572d-985e-4c24-970f-3e800589ea97" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="iobt:ResearchAndDevelopmentTaxCreditReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">573</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insurance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2863ac3e-7b38-4ccc-adaa-887b4e30ee57" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">639</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_485c2c7f-6d9a-46b7-83dc-994e714f6734" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Value-added tax refund receivable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29ac5aba-21d5-467d-b842-703753dc927e" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:ValueAddedTaxReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">276</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88b5e1c5-55f1-483f-8fb6-2cdf047197ed" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:ValueAddedTaxReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ae30749-c7b1-4566-9976-591d7719bfef" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">696</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_831b3c39-e3c2-437b-9e37-c2f92aa81982" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">803</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8f4861f-ac44-4d06-91d4-3ded0e37a0fe" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,849</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7054901-809a-4aa2-95e4-5c2ec93e09f1" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,920</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24ab4364-6bca-4726-9d2f-7877d47a57c0" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8866c10-d0a4-43f3-95ba-32251bdb0255" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consist of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.527%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.057%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.057%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5dc9f27-1155-4d20-8f7a-6523159b1ff5" contextRef="C_5fa6d61c-8fbd-4763-8701-fc3239e4a315" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">927</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18295564-bdcb-4569-a86f-4797a5a35743" contextRef="C_be8705f1-03eb-4e49-85f3-b10301c865b3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">839</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a916081a-b800-424f-abc5-f301cbcf5aa2" contextRef="C_778386da-0eec-4652-a846-c64fb6f85ac0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b560b5ca-474e-4ad9-8367-1b4007f3bafc" contextRef="C_109f1d22-8cd3-493e-ab7e-5ad075bd7dcb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer hardware</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50a641dc-8e56-46ee-b957-eee3df83af28" contextRef="C_4b7ed800-ce67-458e-a181-b724431189ab" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df267ebe-745c-4b42-a2b5-d7669e67116f" contextRef="C_c1ad9cef-5ed5-4764-8224-38b467103b9e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a76909e-3566-4983-9065-8a2ce1199a74" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">726</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc8d1c33-2e5a-4357-a5c4-4991abc2220e" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">577</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0155c25d-12c9-429c-87ec-8d02aba7fa5d" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">603</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edd19d03-118c-4381-95b0-0cc7db764704" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">638</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three months ended June 30, 2025 and 2024, the Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88a58f5d-3dc1-4bee-94a5-81c704d791b6" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_faf4ea3c-b4ad-41b8-bca0-95767b595430" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of depreciation expense, respectively, in the consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5a2177c-9ef7-4911-b77d-f1f08fd1c5af" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d1dd1fe1-4b3e-470a-bfd6-472e40ea8659" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of depreciation expense, respectively, in the consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_95c4eb53-cd9e-434f-8e1f-4b2fab71f5d4" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd5058fe-e927-4fa2-a010-ea4c924f4345" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_bd5058fe-e927-4fa2-a010-ea4c924f4345_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.923%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.923%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued contract research and development costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25e7ce94-7b1f-4743-a818-1d6ac8d7bfed" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:AccruedContractResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,133</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b5fe1ea-477d-4176-ad8f-a847a81bdd49" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="iobt:AccruedContractResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,070</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e7b7b6c-0a5c-471b-8274-91b14f968bf0" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,351</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d8897c1-e725-4428-9a84-554c4c948f0d" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,311</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03d43c5c-44c1-41b9-a582-f7178b770359" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f6f70ec-bd4c-4da6-a20e-9cd4030bd701" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5578d8d3-2075-4909-b204-5be810644c7c" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">416</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83b66003-236a-409b-9786-4fe9b140e248" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79195fc1-9aa3-4810-9089-7d0129ef9e6a" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,592</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_137a2e6e-016e-455a-8f78-fa2971de1606" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,108</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_bd5058fe-e927-4fa2-a010-ea4c924f4345_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_a97a054b-3148-4a9d-9ff7-58e8bf461b31" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:DebtDisclosureTextBlock" escape="true" continuedAt="F_a97a054b-3148-4a9d-9ff7-58e8bf461b31_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Term Loan Facility</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 EIB Term Loan Facility</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 19, 2024, IO Biotech ApS (the &#8220;Borrower&#8221;) entered into a Finance Contract with the EIB, establishing a loan facility of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6f980d2-42d4-4968-8ae9-f3e5ef800b04" contextRef="C_36ff792f-bd4e-446c-b141-ce575eb25023" name="us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">57.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that includes three committed tranches of potential financing in an aggregate principal amount of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44aaa34d-fbbe-4e0a-a9da-6c4222bef066" contextRef="C_84fe0d8c-d67b-4ce3-b0ba-ff27aff9c03f" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, subject to certain conditions precedent, and one uncommitted accordion tranche of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0fa4193-1eac-495b-8d86-9b82fc310dcf" contextRef="C_36ff792f-bd4e-446c-b141-ce575eb25023" name="iobt:CertainConditionsPrecedentAndOneUncommittedAccordionTranche" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Finance Contract, the Company (through the Borrower) had &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7609e98-4499-472f-a81c-d77f96fb1b95" contextRef="C_ef72a604-f4f2-4a0d-adba-eaaf1803b560" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million available to draw in an initial tranche of the term loan facility (&#8220;Tranche A&#8221;), subject to satisfaction of certain customary conditions and the issuance of warrants pursuant to a Warrant Issuance Agreement (described below). The Company satisfied the specified business conditions of the Tranche A loan to draw up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44dfacaa-f4fa-4a0c-96f5-ceee529e2208" contextRef="C_a158b0d3-0349-47ae-a852-f27a63e1f600" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the specified business conditions of the loan to draw up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b6bdcc8-cc55-490d-8b4d-1e3ad985f46f" contextRef="C_16b635b3-2fb2-4918-9590-c3e68b0c0739" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8220;Tranche B&#8221;) , before payment of certain fees and transaction expense. Tranche A and Tranche B were funded on May 6, 2025 and July 4, 2025, respectively.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Finance Contract provides for one potential additional term loan tranche in principal amount of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40237934-9966-45d8-b889-33bc6ece8868" contextRef="C_7ae94389-ebe2-4996-bb29-68980b435b79" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8220;Tranche C&#8221; and, together with Tranche A and Tranche B, each a &#8220;Tranche&#8221;), respectively, which is subject to specified conditions, including, but not limited, the issuance of warrants and achievement of certain clinical trial and other milestones. The Borrower has thirty-six months to satisfy the conditions for Tranche C, which include raising an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d06d1c73-4258-4852-955d-909ca931c60b" contextRef="C_84fe0d8c-d67b-4ce3-b0ba-ff27aff9c03f" name="iobt:LineOfCreditFacilityAdditionalBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cash and submission of an application for marketing authorization for IO102-IO103, which in the U.S. is known as Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(imsapepimut and etimupepimut, adjuvanted), in the U.S. or the EU based on positive data from a Phase 3 trial.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the Tranche A, Tranche B, and Tranche C loans bears or will bear interest at a fixed rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f8bd62a-2946-4db8-b02f-37daedc5081e" contextRef="C_9509aacb-0807-473e-b712-615fcaf1f276" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_be4e8bcb-9b7f-4e08-85d8-cb3feab0bd02" contextRef="C_490dd48a-6429-4e12-b498-a5cc551a31c4" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_44190f16-e354-4a1b-8d2d-3425d22c112f" contextRef="C_d1ac30d3-46ee-4e40-ad99-548007da67c4" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% that accrues annually and will become payable at their respective maturity dates, which will be </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1410390e-d837-429a-a46d-ce736e6f6a5a" contextRef="C_36ff792f-bd4e-446c-b141-ce575eb25023" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after disbursement of such loan.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any unpaid balance owed under the Finance Contract may be accelerated upon an Investment Cost Reduction Event, a Change-of-Control Event, a Change-of-Law Event, an Illegality Event or a Voluntary Non-EIB Prepayment Event (each as defined in the Finance Contract included within Part IV - Item 15. Exhibits, Financial Statement Schedules of the Annual Report on Form 10-K filed on March 31, 2025).</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Borrower elects to voluntarily prepay any Tranche, the Borrower will be required to additionally pay to EIB a prepayment fee ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a4a0181-3e4f-4da3-9aa2-4f233d65e111" contextRef="C_36ff792f-bd4e-446c-b141-ce575eb25023" name="iobt:PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Tranche, if repaid within twelve months of disbursement of such Tranche, to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f97e4c29-e582-4904-9e22-9880529c433b" contextRef="C_36ff792f-bd4e-446c-b141-ce575eb25023" name="iobt:PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Tranche, if repaid after the third anniversary of disbursement of such Tranche. No such prepayment fee is payable after the fourth anniversary of disbursement of the applicable Tranche.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Finance Contract also contains various financial and non-financial covenants that the Borrower must comply with, including customary conditions with respect to material adverse changes and substantial changes to the general nature of business, which leave significant discretion on the side of the EIB.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrently with the execution of the Finance Contract, the Borrower entered into a non-binding side letter, pursuant to which EIB may, in its discretion and subject to approvals by its investment committee, make available to the Borrower an additional &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56d3b814-b6bb-404d-8ce3-40d8487119c4" contextRef="C_84fe0d8c-d67b-4ce3-b0ba-ff27aff9c03f" name="iobt:LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in funding related to the Company&#8217;s ongoing clinical trials.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Finance Contract, the Company also entered into a warrant issuance agreement (the &#8220;Warrant Issuance Agreement&#8221;) on December 19, 2024, pursuant to which the Company agreed to issue to EIB certain warrants to purchase shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd6f78c4-e794-4260-91a5-c010aa70c0d1" contextRef="C_84fe0d8c-d67b-4ce3-b0ba-ff27aff9c03f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (the &#8220;Common Stock&#8221;) in connection with the disbursement of each of the Tranche A loan (such warrants, the &#8220;Tranche A Warrants&#8221;), Tranche B loan (such warrants, the &#8220;Tranche B Warrants&#8221;) and Tranche C loan (such warrants, the &#8220;Tranche C Warrants&#8221; and, together with the Tranche A Warrants and the Tranche B Warrants, the &#8220;Warrants&#8221;). The number of shares for which the Warrants will be exercisable will be determined at the time of issuance of each Warrant in accordance with the formulas set forth in the Warrant Issuance Agreement, which formulas generally provide that the number of shares will decrease as the price of the Common Stock increases.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_a97a054b-3148-4a9d-9ff7-58e8bf461b31_1" continuedAt="F_a97a054b-3148-4a9d-9ff7-58e8bf461b31_2"><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of each Warrant, each share of Common Stock issuable upon exercise thereof shall have an exercise price equal to the greater of (x) the Company&#8217;s 5-Day VWAP on the date of execution of the applicable Warrant and (y) the applicable &#8220;Minimum Price&#8221; as defined in Nasdaq Rule 5635(d), in each case subject to adjustment. The Tranche A Warrant shall become initially exercisable on the date of disbursement of the Tranche A loan; the Tranche B Warrant shall become initially exercisable on the date of disbursement of the Tranche B loan; and the Tranche C Warrant shall become initially exercisable on the date of disbursement of the Tranche C loan. Each Warrant shall be exercisable until the earlier of one day prior to the closing of an Acquisition (as such term is defined in the applicable Warrant included within Part IV - Item 15. Exhibits, Financial Statement Schedules of the Annual Report on Form 10-K filed with the SEC on March 31, 2025) and twenty years following the date of issuance.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of each Warrant, the Company will have a call option to repurchase the Warrants upon a Change of Control Event, a Qualifying Tender Offer, or a Transformational Transaction (each, as defined in the Warrant).  In connection with an exercise of the Company&#8217;s call option, the purchase price for the shares issuable upon exercise of the portion of the Warrant subject to the call option would be equal to the greater of (x) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37af30bf-6be6-49b0-8c4e-83ca62d38243" contextRef="C_36ff792f-bd4e-446c-b141-ce575eb25023" name="iobt:PercentageOfAmountDisbursedUnderFinanceContract" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the amount disbursed under the Finance Contract as of the date of the call option multiplied by a fraction, the numerator of which is (i) the number of Warrant Shares (as defined in the Warrant Agreement) purchasable under the Warrant Agreement and (ii) the denominator which is the number of shares of Common Stock purchasable with respect to all Warrants under the Warrant Issuance Agreement, whether or not remaining outstanding, and (y) the aggregate value of the Warrant Shares purchasable upon exercise of the call option in the event of any of a Qualifying Tender Offer, Transformational Transaction or other transaction, in each case as calculated in accordance with the terms of the Warrant Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Warrant Issuance Agreement, EIB will have a put option (&#8220;EIB Put Option&#8221;) to sell the Warrants to the Company on or following the maturity date of the applicable Tranche or upon the occurrence of an Event Date (as defined in the Warrant Issuance Agreement), subject to certain limitations in the event that the Company publishes a Material Press Release (as defined in the Warrant Issuance Agreement included within Part IV - Item 15. Exhibits, Financial Statement Schedules of the Annual Report on Form 10-K). The conditions for the EIB to exercise the EIB Put Option to have not been met as of June 30, 2025. In connection with an exercise of EIB&#8217;s put option, the purchase price for the shares purchasable in connection with the put option would be equal to (x) in the case of a Qualifying Tender Offer (as defined in the Warrant Issuance Agreement), the aggregate price per share of Common Stock being offered minus the aggregate Strike Price (as defined in the Warrant Issuance Agreement) payable to the Company with respect to the Warrants for which the put option is being exercised and (y) in all other cases, an amount equal to the aggregate Fair Market Value (as defined in the Warrant Issuance Agreement) of the Warrant Shares purchasable upon exercise of the put option minus the aggregate Strike Price payable to the Company with respect to the Warrants for which the put option is being exercised. Due to the terms and conditions of the EIB Put Option, we consider the EIB Put Option and the Tranche A Warrants and Tranche B Warrants under each of the Tranches are to be treated as a single compound derivative.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with EIB related to the issuance of the Warrants. Under the terms of the Registration Rights Agreement, the Company has agreed to prepare and file, by the later of (i) 30 days after the date of issuance of any of the Warrants and (ii) May 15, 2025 (the &#8220;Filing Deadline&#8221;), one or more registration statements with the Securities and Exchange Commission (the &#8220;SEC&#8221;) to register for resale the common stock issued under the Warrant Issuance Agreement and to cause the applicable registration statements to become effective within a specified period after the Filing Deadline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 24, 2025, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d577e1c9-19dd-4020-a134-123c643a82c7" contextRef="C_e6b863ab-f667-455a-800d-d455c93b3ab4" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,623,664</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Tranche A Warrants to purchase shares of the Company&#8217;s common stock at an exercise price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cb610cb-deab-4ad9-9202-f931ff6c92cc" contextRef="C_e6b863ab-f667-455a-800d-d455c93b3ab4" name="iobt:StrikePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.89</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. On June 24, 2025, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdf08516-faff-43c4-a2b1-38363fb1dba6" contextRef="C_f81c1fb3-24f9-45eb-95d6-3d58f5c1bf71" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,221,868</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Tranche B Warrants to purchase shares of the Company&#8217;s common stock at an exercise price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_227c1a5a-5d32-4ff7-9abe-e5ea1cb0a109" contextRef="C_f81c1fb3-24f9-45eb-95d6-3d58f5c1bf71" name="iobt:StrikePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.32</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share as a prerequisite to the Tranche B loan funding on July 4, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Tranche A and Tranche B Warrants were deemed to be a freestanding financial instruments as they were legally detachable and separately exercisable from the debt obligations. The Company evaluated the terms and conditions of the Warrants and concluded that they met the criteria to be classified as a liability. As such, the Company recorded the Warrants as a non-current liability on the consolidated balance sheet at fair value on the date of funding and as of June 30, 2025. On the date of funding, the Company has recorded a non-current liability related to the loan facilities based on the proceeds received less related debt issuance costs, including the fair value allocation to the respective Warrants. The Company valued the Tranche A Warrants and Tranche B Warrants at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98860f33-2ee7-4cac-a2ed-84a630566881" contextRef="C_806e2b05-4b7e-4476-94b2-2b7dd866dc79" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd690832-b769-4147-8a87-fe1238979c4b" contextRef="C_83a70f6f-685c-4644-a42c-ad925d97fe65" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, upon issuance using the Black-Scholes valuation model.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f4687b4-015f-4d49-9d44-deec1d884c6f" contextRef="C_806e2b05-4b7e-4476-94b2-2b7dd866dc79" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of outstanding term loan debt, net within non-current liabilities on the consolidated balance sheet as of June 30, 2025 related to the Tranche A loan. For the three and six months ended June 30, 2025, the Company has recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_491e3dab-5a5c-470b-b3e5-949d6fe0a940" contextRef="C_ea2ebe70-c654-4e26-87a4-0f7c15e0ea44" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a0405221-feb5-411f-9aa8-498dd67cb3e9" contextRef="C_c9ac1ffc-962f-4af6-b379-9a18ad414f27" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in non-cash interest expense related to the amortization of debt issuance costs and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5be43a1-5b7f-4010-8449-4afe41266491" contextRef="C_c9ac1ffc-962f-4af6-b379-9a18ad414f27" name="us-gaap:PaidInKindInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_86a1f5fe-2219-4a14-b70d-cd26e77d8a08" contextRef="C_ea2ebe70-c654-4e26-87a4-0f7c15e0ea44" name="us-gaap:PaidInKindInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in paid-in-kind interest with an effective interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7beee349-6973-4b7b-8f85-c762e5a93cb8" contextRef="C_806e2b05-4b7e-4476-94b2-2b7dd866dc79" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">14.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related to the Tranche A loan. The Tranche B loan was funded on July 4, 2025 and was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80847887-7827-40ce-a964-45be0176edfa" contextRef="C_83a70f6f-685c-4644-a42c-ad925d97fe65" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_EUR" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t outstanding term loan debt as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_0bb5957f-1c5b-468d-9b05-5a26323d2e1c" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" escape="true" continuedAt="F_0bb5957f-1c5b-468d-9b05-5a26323d2e1c_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term loan debt, net consisted of the following (in thousands):</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_a97a054b-3148-4a9d-9ff7-58e8bf461b31_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0bb5957f-1c5b-468d-9b05-5a26323d2e1c_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:78.48%;box-sizing:content-box;"/>
         <td style="width:2.84%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.68%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan debt principal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8af72bce-5d6e-48a6-847b-f741b845e1af" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,720</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortized paid-in-kind interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d11104e-891e-45f6-b631-78b4ad4d5d0a" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:DebtInstrumentAmortizedPaidInKindInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Unamortized debt issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_121547ee-2136-4703-83cd-bfe28ad8cb42" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,290</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency adjustments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35649409-6651-41e0-818f-6d5bd41d03da" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:DebtInstrumentCurrencyAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total term loan debt, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_816ef857-f398-480d-bcee-3a1332bc7471" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,720</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be8e84c0-026c-4637-a915-72ffe4d535ef" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future undiscounted minimum principal and interest payments under the EIB loan facility as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, were as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.823%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Future Minimum Debt Payments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remainder of 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd360e5e-b036-4e1c-8cfc-6f6afa7abebf" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a040be22-5122-4ee7-b6e3-10f0a822fc06" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ec1e867-a618-4043-b37a-b2511866a42c" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2956a1f4-94c1-47a9-9e45-f21f0f63ba3d" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_690f7ecc-ba13-4b09-91e8-70d590061a39" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfd3c1ae-6528-46ed-aeb0-d9256ad9c284" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2031</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c04fa7e2-a285-4335-8856-d7aa46792c4e" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,597</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total minimum payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b74aaa1f-7a0c-4225-aabe-67d403a1a77c" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:Long-TermDebtMaturityMinimumPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,597</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Unamortized debt issuance costs and paid-in-kind interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_423d8724-6d5f-4a96-8bd2-57848867187c" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,025</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency adjustments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5ed1c65-a517-487e-b6e1-464801d3e5c7" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:DebtInstrumentCurrencyAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total term loan debt</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c48dbf6f-c379-471b-9eaa-5cc81f7b8d1b" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,720</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_020e2345-f09c-40b1-9579-740b3635d605" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, the Company had the following Tranche A and Tranche B Warrants issued and outstanding to purchase shares of the Company's common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:42.76%;box-sizing:content-box;"/>
         <td style="width:3.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:22.84%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:3.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:22.84%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche A</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche B</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d29f5ca2-e1d5-44b4-aef8-18b7a0049770" contextRef="C_c9ac1ffc-962f-4af6-b379-9a18ad414f27" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,623,664</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_502f1285-5007-4932-81ac-ef6249aaa020" contextRef="C_329921d0-d469-45e2-ae77-6ca463b6325e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,221,868</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise Price</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4890d7ad-5849-4204-8783-3bc97387c6fd" contextRef="C_c9ac1ffc-962f-4af6-b379-9a18ad414f27" name="iobt:StrikePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.89</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2a84d7c-0e47-4e71-ac85-0fe5a6244a9e" contextRef="C_329921d0-d469-45e2-ae77-6ca463b6325e" name="iobt:StrikePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.32</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_ff7748a1-8647-4af6-9ff8-b9baea06157a" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_ff7748a1-8647-4af6-9ff8-b9baea06157a_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company is party to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3714e51b-6652-4b10-84e4-ab27f6da4d6f" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="iobt:NumberOfOperatingLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating leases for laboratory and office space. The Company&#8217;s finance leases are immaterial both individually and in the aggregate. In the consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, the Company has a right-of-use lease asset (&#8220;ROU&#8221;) balance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4decd35e-0624-4d2c-b943-f4f966e4b090" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and a current and non-current lease liability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5314da34-e15c-4f16-8fc5-53fa499e5e80" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54b3426a-bfd5-4915-acdc-26b3e6ca0e93" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, relating to the ROU lease asset. The balance of both the ROU lease asset and the lease liabilities primarily consists of future payments under the Company&#8217;s office and laboratory space leased in New York, New York, Rockville, Maryland and Copenhagen, Denmark. Rent expense for the three months ended June 30, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37659ff9-c855-42f2-a96e-97330541d3d7" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_715916b2-f66e-43db-8f25-09dda3d8291b" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. Rent expense for the six months ended June 30, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a319fcc6-5949-49cb-9c3e-561af5794b29" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8fc5d433-8e7c-45e1-84e6-7a82363ee311" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06e4e4c5-5f5a-49b3-bdbf-2d94d3b0e7cf" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="iobt:ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Qualitative information regarding the Company&#8217;s leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 is as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:22.92%;box-sizing:content-box;"/>
         <td style="width:1.3%;box-sizing:content-box;"/>
         <td style="width:10.9%;box-sizing:content-box;"/>
         <td style="width:1.3%;box-sizing:content-box;"/>
         <td style="width:10.9%;box-sizing:content-box;"/>
         <td style="width:1.3%;box-sizing:content-box;"/>
         <td style="width:16.26%;box-sizing:content-box;"/>
         <td style="width:1.3%;box-sizing:content-box;"/>
         <td style="width:16.26%;box-sizing:content-box;"/>
         <td style="width:1.3%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Location</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Type</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Nature</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Commencement</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Term Expiration</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Annual Base Rent<br/>&#160;(in Millions)</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Copenhagen, Denmark</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Office</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_d345b560-8142-4499-8b84-5fbfe3b30308" contextRef="C_12c9ea54-3647-4df4-9107-48c806489a8f" name="iobt:OperatingLeaseTermExpirationMonthYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2021</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_8c00029d-e271-4bee-b16c-50a1c87a2211" contextRef="C_12c9ea54-3647-4df4-9107-48c806489a8f" name="iobt:OperatingLeaseCommencementMonthYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2027</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b45b3b13-0118-41f6-96ed-f51c36c9f275" contextRef="C_12c9ea54-3647-4df4-9107-48c806489a8f" name="iobt:OperatingLeaseAnnualBaseRent" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Copenhagen, Denmark</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Office</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_c90f7567-a7ec-4b47-b0e4-97450f40997b" contextRef="C_d2d4d909-7247-47da-8942-e7d0085430d2" name="iobt:OperatingLeaseTermExpirationMonthYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2024</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_c85d344c-d63a-4e67-8888-e6b20ba80c93" contextRef="C_d2d4d909-7247-47da-8942-e7d0085430d2" name="iobt:OperatingLeaseCommencementMonthYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2027</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af8d9a9e-8ac9-4e93-b2a9-46b4ac7cb5eb" contextRef="C_d2d4d909-7247-47da-8942-e7d0085430d2" name="iobt:OperatingLeaseAnnualBaseRent" unitRef="U_USD" scale="3" decimals="-1" format="ixt:num-dot-decimal">0.04</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Copenhagen, Denmark</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Lab</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_4d3defd0-b1b8-40ff-83aa-8e0d2b2e954f" contextRef="C_d7ad6dd6-35af-4f8a-aac7-f313a381b605" name="iobt:OperatingLeaseTermExpirationMonthYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 2023</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_a6950efe-a734-4598-9edd-a8058ff323cc" contextRef="C_d7ad6dd6-35af-4f8a-aac7-f313a381b605" name="iobt:OperatingLeaseCommencementMonthYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2027</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44341be9-de7a-4067-b49e-df6ee97a2f51" contextRef="C_d7ad6dd6-35af-4f8a-aac7-f313a381b605" name="iobt:OperatingLeaseAnnualBaseRent" unitRef="U_USD" scale="3" decimals="-1" format="ixt:num-dot-decimal">0.04</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Newport, United Kingdom</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Office</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_a8fc691c-489a-4706-8ae8-9d7e10ad1498" contextRef="C_304a194f-57dd-4a19-bedc-cdfd57a688a1" name="iobt:OperatingLeaseTermExpirationMonthYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 2023</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_b65d1402-16f9-4778-af86-3faaaf35b964" contextRef="C_304a194f-57dd-4a19-bedc-cdfd57a688a1" name="iobt:OperatingLeaseCommencementMonthYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 2025</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aff981d6-b21c-42b9-9f1c-33a16845a434" contextRef="C_304a194f-57dd-4a19-bedc-cdfd57a688a1" name="iobt:OperatingLeaseAnnualBaseRent" unitRef="U_USD" scale="3" decimals="-1" format="ixt:num-dot-decimal">0.04</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York, New York</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Office</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_e78bcc38-721c-4e4f-9238-b73a6862f39a" contextRef="C_d1ac8d94-9bfe-4efa-86ce-70e44c8190dd" name="iobt:OperatingLeaseTermExpirationMonthYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 2021</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_cec8a779-6e1f-4c48-a3cc-4d6aaec749e3" contextRef="C_d1ac8d94-9bfe-4efa-86ce-70e44c8190dd" name="iobt:OperatingLeaseCommencementMonthYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 2027</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51101648-0aaa-4f4f-ac29-db0e13bac959" contextRef="C_d1ac8d94-9bfe-4efa-86ce-70e44c8190dd" name="iobt:OperatingLeaseAnnualBaseRent" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rockville, Maryland</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Lab</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_ef3db5a2-9c22-47f1-a112-e11de16888b1" contextRef="C_60dc3163-f2cf-4d9a-bd0c-4ced094cf2aa" name="iobt:OperatingLeaseTermExpirationMonthYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2021</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_0963d945-26e8-4ccc-9458-8dc10c116792" contextRef="C_60dc3163-f2cf-4d9a-bd0c-4ced094cf2aa" name="iobt:OperatingLeaseCommencementMonthYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 2027</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94f63c35-4207-4292-acaf-0bf01af6644a" contextRef="C_60dc3163-f2cf-4d9a-bd0c-4ced094cf2aa" name="iobt:OperatingLeaseAnnualBaseRent" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div><ix:nonNumeric id="F_f909c69b-a1d3-4241-8194-3c9e01d2e75a" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:LeaseCostTableTextBlock" escape="true" continuedAt="F_f909c69b-a1d3-4241-8194-3c9e01d2e75a_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quantitative information regarding the Company&#8217;s leases for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025 and 2024 is as follows (in thousands):</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_ff7748a1-8647-4af6-9ff8-b9baea06157a_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f909c69b-a1d3-4241-8194-3c9e01d2e75a_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.882%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.882%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_241a3712-24b0-4966-aa17-28612b37547b" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e491cbf-7646-486d-a298-554742d693c9" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">369</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_753fb302-6233-40f4-b349-87fcec32dbe7" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">413</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c36ebdf-bf68-4e16-9d85-da09e35d70e0" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">385</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities arising from obtaining right-of-use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d99cb0d-e812-47b9-9225-2dc7c2b85e20" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d4b0154-c469-4464-a1bf-996c196045e0" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remaining average lease term (years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1e2fb040-ff74-4f4b-bc46-6c0ae32d56be" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_68bd8b41-ba38-4f5e-916e-ad029e8291f8" contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5f2c534-4a2c-4142-926d-2073456af2a6" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb265a60-7623-4d80-aa5a-e35b8ef98d9a" contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5eeed218-27f0-41bd-8013-035e3e555f5b" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future lease payments (undiscounted) under noncancelable leases are as follows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.823%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Future Lease Payments</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remainder of 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1f2b344-bcf7-4e47-967a-a31d183e3060" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">419</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_695db5d5-b277-4b95-918c-1f511007c2aa" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">863</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b919347-0d8f-4dd6-91ef-611a5b9e3e22" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">470</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d04242ab-fbf1-4e84-845a-2dbb7e9e8ccb" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f571b47e-ef0a-4e4c-87eb-34abe5bb0230" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56774f73-b767-4ed1-89e9-8b1ad9e1345f" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65ba093a-50d7-49d5-b2e8-99479f44f3fa" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,752</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s leases do not provide an explicit rate. Therefore, the Company used its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company used the incremental borrowing rate on January 1, 2022 for operating leases that commenced prior to that date, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43fc3eae-4991-4980-93fb-b2c11564837b" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be party to litigation arising in the ordinary course of business. We were not subject to any material legal proceedings during the six months ended June 30, 2025 and the year ended December 31, 2024, and, to our knowledge, no material legal proceedings are currently pending or threatened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contractual Obligations and Commitments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into contracts in the ordinary course of business with third-party service providers for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e713668-ecf4-4ab4-979f-31ecd4077086" contextRef="C_a6b6d898-f2a2-4264-a194-96e339c5adc0" name="iobt:ContractualObligationsTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_08043d24-e935-4a10-9890-503f99233da9" contextRef="C_f08bf985-a9db-49be-bd46-d4eda7a2c58c" name="iobt:ContractualObligationsTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days, and therefore, we believe that our noncancelable obligations under these agreements are not material and we cannot reasonably estimate whether they will occur. However, in the event of a termination of any contracts with clinical research organizations (&#8220;CRO&#8221;) or other institutions and with respect to active patients enrolled in our clinical trials, we may be financially obligated for a period beyond the contractual termination notice periods. We may also enter into additional research, manufacturing, supplier, lease and other agreements in the future, which may require up-front payments and even long-term commitments of cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into certain types of contracts that contingently require us to indemnify various parties against claims from third parties. These contracts primarily relate to procurement, service, consultancy or license agreements under which we may be required to indemnify vendors, service providers or licensees for certain claims, including claims that may be brought against them arising from our acts or omissions with respect to our products, technology, intellectual property or services. The Company, as permitted under Delaware law and in accordance with its amended and restated certificate of incorporation and amended and restated bylaws and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, in which the officer or director incurs losses or expenses because he or she is or was serving at the Company&#8217;s request in such capacity. At the 2023 Annual Meeting of Stockholders, the Company&#8217;s stockholders approved an amendment to, and the Company subsequently amended, its amended and restated certificate of incorporation to extend the indemnification of officers pursuant to recent amendments to the General Corporation Law of the State of Delaware.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may receive indemnification claims under existing contracts in the normal course of business. In the event that one or more of these matters were to result in a claim against us, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on our future business, operating results or financial condition. It is not possible to estimate the maximum amount potentially payable under these contracts since we have no history of prior indemnification claims and the unique facts and circumstances involved in each particular claim will be determinative.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d28d6ca2-5d70-4bbd-baf7-2b5702a067fe" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Stockholders' Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common and Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the closing of our IPO in November 2021, we filed an amended and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restated certificate of incorporation, which authorized us to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_644b3e31-e67f-486e-a3a7-dd7f82feb15a" contextRef="C_7b18d373-032b-4323-90f2-5980a3f2eeb4" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a78ebef-473a-409e-a57e-545117e7864b" contextRef="C_f19d5a95-b1ed-473d-a534-3f3d6090cd35" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock. The shares of preferred stock are currently undesignated. Common stockholders are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a59a7208-f47b-44cd-bfeb-b8b4817ae1c3" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="iobt:NumberOfVotePerShare" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. Common stockholders are entitled to receive dividends, if and when declared by the Company's board of directors (&#8220;Board&#8221;). </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e924aadd-4cfb-4b9a-8b55-303bbbb90c82" contextRef="C_d9eac608-430c-4093-aaf6-37dfe968a3a7" name="iobt:DividendsDeclared" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8a05e08b-4dc7-4df5-ac53-49a79d54e642" contextRef="C_d9eac608-430c-4093-aaf6-37dfe968a3a7" name="iobt:DividendsPaid" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dividends have been declared or paid by us through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Private Placement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 7, 2023, the Company entered into a Securities Purchase Agreement, (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company agreed to sell and issue (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_648d061c-4bfa-43ab-92bc-2ef4194063b9" contextRef="C_23f0e49a-26af-436d-a252-4c3c0051cbd9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Common Stock, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c770008b-4e26-4d80-91bb-f5043586290d" contextRef="C_3312f560-ea95-4c4d-b954-f433c8050666" name="iobt:WarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Warrants in the Private Placement. Each Purchaser&#8217;s Warrant is exercisable for a number of shares of Common Stock equal to one hundred percent of the aggregate number of shares of Common Stock purchased by such Purchaser. The purchase price for each Common Stock and Warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_873c6ce0-8567-4382-93c7-06a217f3d109" contextRef="C_3312f560-ea95-4c4d-b954-f433c8050666" name="iobt:PurchasePricePerShareOfCommonStockAndWarrant" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.025</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Warrants are exercisable at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7823828c-9337-43fe-b829-358528310721" contextRef="C_3312f560-ea95-4c4d-b954-f433c8050666" name="iobt:WarrantsExercisablePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.47</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, subject to adjustment as set forth therein. The Warrants are exercisable until the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an acquisition, as defined in the Warrants. The Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the Warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Private Placement closed on August 9, 2023. The Company received </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90a22bd6-395a-4469-929f-c44a3b71be51" contextRef="C_d9cf7434-a99c-426e-ba30-efa367120587" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in gross proceeds from the Private Placement, before deducting offering expenses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8be56684-844d-4222-8057-5ab0c4bfc99a" contextRef="C_d9cf7434-a99c-426e-ba30-efa367120587" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Of the total proceeds, legal entities of certain related parties contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c5925e4-bb1f-4634-8972-b059fd1ceda9" contextRef="C_527af978-7806-4a1e-8520-f96890860ee1" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and members of management contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2d18a43-07e4-4e75-9a6d-521d43c6de73" contextRef="C_cbc7cec8-5118-48e5-8682-ee34f6d86898" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company used the net proceeds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d750e68-be73-4917-84ab-fa7da19c979e" contextRef="C_d9cf7434-a99c-426e-ba30-efa367120587" name="iobt:NetProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">71.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the Private Placement for general corporate purposes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance using the Black-Scholes valuation model and allocated proceeds from the sale proportionately to the Common Stock and Warrants, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a49565c-9e73-4415-9542-6edbf69f2330" contextRef="C_444ecd94-9413-4f58-9283-c0e742cfcbad" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">29.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the Warrants and recorded as a component of additional paid-in-capital. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64be5008-0e5d-4c84-ae34-fce5cb344db4" contextRef="C_444ecd94-9413-4f58-9283-c0e742cfcbad" name="iobt:WarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants issued and outstanding at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_997592cc-dfb0-4ef4-bc83-034c330912c9" contextRef="C_444ecd94-9413-4f58-9283-c0e742cfcbad" name="iobt:WarrantsExercisablePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.47</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share to purchase shares of the Company's common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the execution of the Purchase Agreement, the Company also entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Purchasers. Under the terms of the Registration Rights Agreement, the Company has filed the Registration Statement with the SEC to register for resale the Common Stock issued under the Purchase Agreement and the shares of Common Stock issuable upon conversion of the Warrants issued pursuant to the Purchase Agreement (the &#8220;Registrable Securities&#8221;), which Registration Statement was declared effective on September 8, 2023. The Company may be required to pay certain liquidated damages under the terms of the Registration Rights Agreement in the event sales cannot be made pursuant to the Registration Statement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of June 30, 2025 and December 31, 2024, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_448bcbbf-ebcc-46cf-8808-ea9610966ae9" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ec00aa56-b2fd-4475-850b-9d2218985255" contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_6077235e-10d2-4285-9156-b0296df1539c" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_6077235e-10d2-4285-9156-b0296df1539c_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Equity-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Equity and Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2021, our Board adopted, and our stockholders approved, the 2021 Equity and Incentive Plan (the &#8220;2021 Equity Plan&#8221;), which became effective on November 4, 2021. The 2021 Equity Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. The number of shares of our common stock reserved for issuance under the 2021 Equity Plan is equal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2a3836e-ecc6-44e7-ae3f-e762107223e2" contextRef="C_31556d6d-fe87-49c2-bbf3-1900c78c9c40" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,496,934</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> subject to an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022 and continuing until, and including, the fiscal year ending December 31, 2031, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">equal to the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5a8a87c-b081-4802-998f-610b6d5156b5" contextRef="C_474458dc-a129-4f50-994f-7df9fe0827f4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock outstanding on the first day of such fiscal year or (ii) such other amount determined by our Board</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of June 30, 2025, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8ad704c-d4cc-4227-9a7f-f960d8d489bf" contextRef="C_934a4cc1-65a5-4fa7-9f5b-91cb5496af79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">486,563</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future grant under the 2021 Equity Plan.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_6077235e-10d2-4285-9156-b0296df1539c_1" continuedAt="F_6077235e-10d2-4285-9156-b0296df1539c_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2021, our Board adopted and our stockholders approved the 2021 Employee Stock Purchase Plan (the &#8220;2021 ESPP&#8221;), which became effective on November 4, 2021. The number of shares of our common stock reserved for issuance under the 2021 ESPP is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfe9236d-036f-4f8c-a9d4-89918e3c7694" contextRef="C_26bef08c-05c8-4a89-94f6-05ba69278969" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">257,272</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to an annual increase, to be added on the first day of each fiscal year, beginning January 1, 2023, equal to the lesser of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_121aaed8-d13d-4a77-afcd-29c5302b023a" contextRef="C_556c8daa-bb23-4277-a055-75e799014084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock outstanding on the first day of such fiscal year; (2) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de93750c-1f66-4c91-83e6-582707af50ce" contextRef="C_26bef08c-05c8-4a89-94f6-05ba69278969" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">257,272</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock; or (3) such other amount as determined by our Board. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, the Board had not yet approved any offerings under the 2021 ESPP.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Inducement Award Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, our Board adopted the 2023 Inducement Award Plan (the &#8220;2023 Inducement Plan&#8221;), which became effective on September 28, 2023. The 2023 Inducement Plan provides for the grant of non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to eligible employees who satisfy the standards for inducement grants under Nasdaq Global Market rules. The number of shares of our common stock reserved for issuance under the 2023 Inducement Plan is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e09fd07-b070-4009-bb72-102c3627bf79" contextRef="C_f03f590f-3e44-4ac1-9039-13057aba247a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,976,427</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d183103-a5e7-419f-9e19-f6d1d669e21e" contextRef="C_f03f590f-3e44-4ac1-9039-13057aba247a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,666,427</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future grant under the 2023 Inducement Plan.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f1ca77a-2abd-44b7-8d14-b5013fd6236b" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our stock options activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:49.84%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.66%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.020000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.66%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>stock <br/>options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>average<br/>exercise<br/>price<br/>per share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value<br/>(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b2441f2-00d7-4a36-9f85-08277f59bc71" contextRef="C_a438d86c-ada7-4302-94e2-dc378d64a260" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,967,605</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d26307ad-ba2b-406c-8780-21bfcf1a8dc1" contextRef="C_a438d86c-ada7-4302-94e2-dc378d64a260" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.18</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_2327cf6b-a892-4085-86d5-1e568d222e35" contextRef="C_94559174-350f-4655-96db-1060692d7265" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82adb09e-f150-4ef1-8e4b-3651667c452d" contextRef="C_a438d86c-ada7-4302-94e2-dc378d64a260" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa24937c-2050-490f-a5fc-ce4a755d5a91" contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,709,284</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e66ff69-4b0b-42a0-930b-3d1cf7ae739c" contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.13</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Cancelled or forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf4d6bcf-347c-4c49-b66f-7409b847d0b2" contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">137,589</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2686103-0481-471b-8629-1b061c388ed5" contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.28</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f53ed4c0-0136-4e18-aea2-89b76bc48eb5" contextRef="C_d039cccf-0ad2-4c2d-8c00-3f2cb7a6da02" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,539,300</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9e4cf9b-d495-4807-ba15-1386fd33908c" contextRef="C_d039cccf-0ad2-4c2d-8c00-3f2cb7a6da02" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.24</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_3563557b-4f03-4c07-84f3-1d25f8c0b1bd" contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d6ef9f0-b02e-4844-ad9e-1d68a89f4e04" contextRef="C_d039cccf-0ad2-4c2d-8c00-3f2cb7a6da02" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">821</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable, June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_917883a0-cb1f-41dc-b48a-96f1cfbb36ca" contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7" name="iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,537,588</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a383dbc-835d-45db-aed0-78a48e374d45" contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7" name="iobt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.87</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_0e578eed-0086-440a-a140-2273f2d8b938" contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7" name="iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d9e1eac-110c-41ac-a3a4-1517b3967782" contextRef="C_d039cccf-0ad2-4c2d-8c00-3f2cb7a6da02" name="iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures related to equity-based compensation awards are recognized as they occur, and we reverse any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_b3bfa6d2-0d77-4fc5-90bd-642dc6c66813" contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized compensation cost related to unvested stock-based compensation arrangements that is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe0d3ca7-ffb9-4791-b1f5-9db4641c1936" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_0aa7bce6-cd34-4312-9b50-27aeaa9f905a" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair values of the stock options granted during the period ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 were estimated based on the Black-Scholes model, using the following assumptions:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:76.28%;box-sizing:content-box;"/>
         <td style="width:1.38%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.84%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3d7e0f0-f0af-4dc1-bd64-a39d8df9b614" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">84.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bd7b2b0-8741-44fc-9a32-7e066231b7ec" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">85.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_818311f8-a284-4b32-9341-9152f4244223" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6931b23-6f62-4082-ab5b-ccca24b45f4a" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_35d5f7bb-1e46-4205-97dd-8b96233f555d" contextRef="C_a6b6d898-f2a2-4264-a194-96e339c5adc0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">- </span><span><ix:nonNumeric id="F_f78bc253-fbdd-4f79-84af-cdbaec083de2" contextRef="C_f08bf985-a9db-49be-bd46-d4eda7a2c58c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c1054e5-f014-4158-8331-15987b3143f6" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f55ae4e-c352-463f-bbd5-329cf32c1573" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c255029a-cdae-480a-975e-c8ecc6b13c20" contextRef="C_86041aa9-6c80-4439-9ee6-0fefaad23a00" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">644</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a807e406-e4d4-470d-a160-3b5b16171cc6" contextRef="C_a14ce688-5adf-4041-9ce6-8681b682eb22" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">677</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c29f506d-6ed6-41f6-8c40-fb666081f72b" contextRef="C_5d5c2036-4d47-45b2-abc2-ce62234c7b0d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,262</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5684d55-20b4-4363-b13f-d9989e5a074b" contextRef="C_ea4234a6-3d5f-4c04-b955-28240861f2c5" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,290</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7fa535b-9f9a-4b14-9220-7f237a2a2b75" contextRef="C_75fb5f36-7e2a-4032-ac5b-b93710ea8e93" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">963</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72c5e024-a01a-4dd0-8d49-08fd9ea34775" contextRef="C_dcee008c-dfa3-43d1-b9c1-5d5957ec1dec" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">965</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5f081d0-f31e-4eb8-adaf-258825427b35" contextRef="C_4fdff8d0-846c-4e02-aaa4-5c470eaf7625" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,914</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_452eb95d-68b5-4d0a-82ba-4b5db6ec928e" contextRef="C_37646e78-6337-438c-8dbe-8a3712d470ab" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,920</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total equity-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_193c3ccc-057b-4786-89a5-d0fab0161353" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,607</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92f2d5fd-d12a-4e6a-a559-c5fa2b35883a" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,642</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_351efe03-f5ef-4795-828d-beb317c7fdc7" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,176</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1821cf3-d7ca-435f-85df-92fd9defe672" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,210</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6077235e-10d2-4285-9156-b0296df1539c_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83242bf9-7aa3-4104-bec7-ee51e3a3cb30" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_21e57b3a-9b96-4859-abdc-a808b892f505" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_610429df-63a0-4229-bf09-f1cc781651f8" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d8de2207-2cbd-4897-bbf9-60b86a6ac4c4" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any tax benefits for stock-based compensation during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8cdb80fa-9084-406a-8150-4821e326334b" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to taxes for earnings generated in multiple jurisdictions, both inside and outside of the United States and our tax expense is primarily affected by unrecognized tax benefits in Denmark due to the full valuation allowance. We recorded expense for income taxes of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d94ddd7-9a73-483d-bcd2-67ceaefe98a4" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50e91df0-6591-455c-b5ae-163ce9ae1f85" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the three months ended June 30, 2025 and 2024, respectively. We recorded expense for income taxes of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91e50f6d-0cb8-428b-b112-9c30e7fd52fa" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c538ce46-dd60-4f61-9ae7-8969ff73ee5e" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> during the six months ended June 30, 2025 and 2024, respectively. We continue to maintain a full valuation allowance against all of our deferred tax assets in IO Biotech ApS, IO Bio US, Inc., a wholly-owned subsidiary of IO Biotech ApS that was incorporated in Delaware in May 2021, and IO Biotech, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have evaluated the positive and negative evidence involving our ability to realize our deferred tax assets. We have considered our history of cumulative net losses incurred since inception and our lack of any commercial products. We have concluded that it is more likely than not that we will not realize the benefits of our deferred tax assets in IO Biotech ApS, IO Bio US, Inc. and IO Biotech, Inc. We reevaluate the positive and negative evidence at each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33990cbe-3a90-4253-84f7-54701c7acac4" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_761dfb27-748e-4be3-ab2b-15d96757d35d" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share is calculated as follows (in thousands except share and per share amounts):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.95%;box-sizing:content-box;"/>
         <td style="width:1.28%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.982000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.28%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.982000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.28%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.982000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.28%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.982000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7de83e56-b9ba-41ed-a639-cd4fbe5ba066" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,217</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_383d64d5-6cfe-4bdc-89f4-a7e3bf9f0d2e" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,686</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82061338-5cc2-4a97-a29c-289516194eaf" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,638</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_386c1e67-5594-40cd-8556-c9f291ddd614" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,143</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0a8bbba-db53-412a-958a-a4d80f5ad316" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,217</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffefa60c-ab88-453e-9c51-92020c901114" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,686</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_361b5578-f8b2-498d-85e6-074aa63e48ab" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,638</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c512ce33-50b3-4d93-abdc-10d1f90ce59d" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,143</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da2332d1-b90d-40ba-b196-f03adf10f2cf" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cdc9fb21-7a20-4b7e-acd2-232001281b39" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.40</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_631081e1-f01a-489a-a7ce-1f920cfea990" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_12f031d6-da52-474e-8b17-573b683f8f6e" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.31</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27dd5a8c-a616-4076-bc88-f3458ae4751d" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fdb2a521-826b-4269-b7ab-e5fac73f9b12" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.74</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dd675e8-a764-4dcd-b90e-cf7605fb8519" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b4dfb810-835a-4478-8d36-550e47833c53" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.61</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of shares used in computing net loss per common share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec119047-8c54-4b25-85ee-86bdcd6691e9" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d605bca6-4966-439b-9c01-089e7444bdda" contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01ced59d-8f6b-4c5e-b99d-c6c5b89ff41a" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3e788e71-e1f1-4048-9bba-d3c69e0246ee" contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8d44749-7d7f-4bc2-937b-768dfaeee365" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ca2f6f05-534e-4f78-bf29-e2bad7b29c3b" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eca2c9ba-b716-4369-8c8e-20076db4e54e" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_434cac38-4952-46f0-bd54-7a00c2fd52e2" contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">65,880,914</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_29d8f6fa-725c-459f-86d5-36db577a893a" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share, as their effect is anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:49.84%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.66%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed58107d-7a2b-4238-b03d-4a889122406d" contextRef="C_4e98906e-1cac-4433-be9f-7d243d541dcc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,539,300</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bac06e8-bbc6-4c1b-a6c9-a2d4b1a74372" contextRef="C_73b1457e-202f-4b74-987b-acf3673e19af" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,992,635</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d78ce85-efc4-4503-b1af-91a1658f6b7e" contextRef="C_5b150492-18b8-4ea5-b79f-6a9eee4738eb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,539,300</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89aa6813-84a3-463e-8f83-0e40e5b3a93a" contextRef="C_41b1f416-58f2-4b5c-99cf-ca18ff696ab3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,992,635</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants issued in Private Placement</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca480df5-499e-4437-bab0-ef2e203fa3cd" contextRef="C_ab6be8c6-2dae-4f77-8832-45ca8119a732" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e217762-67e7-4c9c-ba15-9cde0472184a" contextRef="C_d4e7dd4f-2821-44b8-998f-65cfe834fa7f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bded1c7f-fd5a-4b47-961d-c4a087401a8a" contextRef="C_5cc831a0-a0fc-49d9-95ba-356e8a3a7fb5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e7b7081-68f9-4206-a4a5-88f405d504c0" contextRef="C_132052a7-d00c-4cb3-9ad6-e77324375e94" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">37,065,647</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock warrants issued to the EIB</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6004d5f2-a4b3-45e7-8268-8c59a87c0757" contextRef="C_4f1f2469-2895-4c93-a281-ddfa3fa3a80f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,845,532</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90208480-c8df-4c31-835f-44f8f4ab7c7a" contextRef="C_8d8a2973-4e93-4574-bc7f-1eb8bff4409d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,845,532</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_7f3734f2-68bc-4b31-a5b4-f19e7998f6bd" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="F_7f3734f2-68bc-4b31-a5b4-f19e7998f6bd_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Segments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_abd02c4f-a3cd-4435-8a7f-dd7df01461bf;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment focused on developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on our T-win</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b84a72bb-e157-490d-8c62-88b031636437" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the chief operating decision maker (&#8220;CODM&#8221;), our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_aca2c24e-8e92-4826-9175-474c6929666f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> manages our company, reviews operating results, assesses performance and allocates resources on an aggregate basis using </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ebc813a3-04f0-49f3-9868-9cfe7dc3008b;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consolidated net income or loss</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as the key measure of segment profit or loss.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As such, results of our operations are reported on a consolidated basis for purposes of management and segment reporting. Please refer to the consolidated financial statements for further information related to these measures of segment performance.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_7f3734f2-68bc-4b31-a5b4-f19e7998f6bd_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_263ea4fc-2fac-4da7-acc6-cf88f2b608b0" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, research and development and general and administrative expenses are significant segment expenses regularly provided to the CEO with the following categories (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.91%;box-sizing:content-box;"/>
         <td style="width:1.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.318%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.718%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.318%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.318%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three months ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six months ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial-related activities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fca8dd3b-74fb-4f70-9ef3-b178ebc18bd2" contextRef="C_a1eaf344-05b7-4fe9-bc2d-b42ce849911a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,390</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25c34670-e750-4c1c-9b80-eb69004e61c3" contextRef="C_2d7f3f8f-ddd0-48bc-b68a-50c26ed152f4" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,637</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa77463e-f0c4-488f-90f3-10c61faa9125" contextRef="C_fc8b2cef-3f0c-4673-bc7b-e631da99dff6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,081</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab50ae34-3dfa-4dbe-86fb-82c2dee0059e" contextRef="C_55aaab1d-0030-4d3d-8a11-599b6fe6903f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,785</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eeb63c5d-3e35-4184-bd34-c3bea0ab6f1d" contextRef="C_a1fefede-ee93-4a78-8157-b3a7150dc5ea" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,531</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f292d5e-8c7d-494c-b5bd-fd5d2012cb90" contextRef="C_65d8cb5b-0a18-41c9-981b-c844905fa72f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,123</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05c8ac09-14cc-4af3-a2e6-bf60ef120d08" contextRef="C_6ef232e1-8f2b-4eec-9dd0-c1e56fcf4bb5" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,714</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a18be29-d4e9-4469-a106-08fbfd70999e" contextRef="C_41eb296d-58a9-41d3-ac9d-5e2d3cb0a7a2" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,917</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chemistry, manufacturing and control</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7d712df-7499-4662-87f3-5ec12e983671" contextRef="C_cf6e89c2-68e9-4989-9bcc-71a8d4f206fa" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,484</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2545417-74c1-451e-820a-c87a8a590725" contextRef="C_6561fedd-443a-4a83-8643-efd575ae4790" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,994</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7f9c5f9-4a3a-4ebc-9ae3-b650c7c559c8" contextRef="C_ac5e1a5c-cbf1-4bda-90cf-e92f72ffc842" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,776</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99801a0d-b63a-4c90-9355-bd15a2fa1332" contextRef="C_e967bb70-74f8-4aa9-a3ea-389fe5eeaa26" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,161</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preclinical studies and activities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b421df42-c841-43de-8500-a1dcfaa3b917" contextRef="C_1b0fada8-8afd-4aa2-8081-cb2a8058b81f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">616</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7516a267-ef67-423f-a866-36030c908a99" contextRef="C_e39d7aaf-45f1-49d8-b933-d2049d7a30c3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0ba5579-80fa-4c40-8c04-40104b3f7657" contextRef="C_785749e1-bfed-43d5-a943-0f70e8cc76bc" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,028</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a686dca1-bc37-46dc-93ea-8a157d7909c4" contextRef="C_438a86b3-b95d-4e7a-bf73-767445f988d8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">632</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ce6a0f3-acf4-413d-aa52-c77d007fee40" contextRef="C_c467807b-b9cd-4abf-a2c2-779eebbaff94" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">631</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90021deb-48ac-44af-934e-900b8cbd8407" contextRef="C_72045b9f-3820-4aad-a93e-3694b13e20c4" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">799</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05dbcf6c-4968-4009-bb04-bdde395238f1" contextRef="C_da9f479f-4bef-4055-ba48-4ce7e429d95d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">428</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0190e465-e289-4fd5-81ca-e59da9192fb0" contextRef="C_3764f78d-6235-4496-a19e-2de9bd33fad6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">664</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b86b619-df64-4741-95cc-48e91d18860a" contextRef="C_9056ec8b-e4b6-4e0a-a202-17751c0d78db" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,652</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab58f577-084b-43d0-8a38-57c7c772f1ec" contextRef="C_caf14b74-474c-4188-88f8-9d1a26cd9cf5" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,848</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99438376-54d6-4cb8-9bb5-4835bfd3ed7c" contextRef="C_9e6bbdd8-4ed3-4cbf-a612-855c1debc82d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,027</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbed4d30-8d16-4294-bf57-6fd4fa4677d7" contextRef="C_fc2eaac8-ff9c-4b6b-9667-7650678ab73e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,159</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.41%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.202%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.202%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.202%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.202%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three months ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six months ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c30aecb9-8c5b-4913-a677-921832ba9c52" contextRef="C_a1fefede-ee93-4a78-8157-b3a7150dc5ea" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,840</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a399ca03-d3df-4f52-b71a-6d331030b4bc" contextRef="C_65d8cb5b-0a18-41c9-981b-c844905fa72f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,899</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87786d58-7d44-4459-ae54-cf4a950c5f1e" contextRef="C_6ef232e1-8f2b-4eec-9dd0-c1e56fcf4bb5" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,852</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ed0b22d-086f-4e0e-96d3-13ae9cbdbefd" contextRef="C_41eb296d-58a9-41d3-ac9d-5e2d3cb0a7a2" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,693</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_094873d8-6ed2-4c93-924e-659c40bc96c3" contextRef="C_82fdbb77-bcb9-4016-b1f8-453bf41699c5" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,743</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52e8504b-d493-4192-9b56-b193927c3e9f" contextRef="C_cda39673-240f-4ea4-b28d-573ba9ac932f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">975</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb2c435d-c8b8-4329-b154-0f4b03265325" contextRef="C_1829c523-648e-4a02-8109-0deb1191ed06" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,124</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83db6511-40f7-4be7-8b47-58f7f297fde1" contextRef="C_1e241c91-5715-488d-a31b-90976e18ef81" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,048</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f97c38bc-99c3-4bfb-adbe-0d6cb6d2ed7b" contextRef="C_c467807b-b9cd-4abf-a2c2-779eebbaff94" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,935</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fce2a1d-b7d2-42fc-af86-e8717674aff2" contextRef="C_72045b9f-3820-4aad-a93e-3694b13e20c4" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,811</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2530bbb6-a4c7-428b-9a90-c84d1c83b892" contextRef="C_da9f479f-4bef-4055-ba48-4ce7e429d95d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,751</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6e51c21-4648-4438-b0ff-6faca6e27757" contextRef="C_3764f78d-6235-4496-a19e-2de9bd33fad6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,830</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7845f71-67a0-4ed8-9dc9-f345cda730e1" contextRef="C_9056ec8b-e4b6-4e0a-a202-17751c0d78db" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,518</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd91f5c5-ffc0-42ca-98b4-692a1eca719d" contextRef="C_caf14b74-474c-4188-88f8-9d1a26cd9cf5" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,685</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_161ae31f-bae7-4452-9bad-e2a42b9584cf" contextRef="C_9e6bbdd8-4ed3-4cbf-a612-855c1debc82d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,727</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6212654-4291-4cab-8399-d14a5cf9d202" contextRef="C_fc2eaac8-ff9c-4b6b-9667-7650678ab73e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,571</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06f89407-ef8a-413d-a26d-7130bc667281" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Subsequent Events</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">One Big Beautiful Bill Act</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the &#8220;Act&#8221;). The Act extends expiring, and in some cases expired, provisions of the 2017 Tax Cuts and Jobs Act (&#8220;TCJA&#8221;).  For taxable years beginning after December 31, 2024, the Act includes measures potentially affecting the Company&#8217;s income tax provision including a permanent and immediate deduction for domestic research and development expenditures, 100 percent expensing for certain business property, the expansion of section 162(m) limits on deductions of certain executive compensation, and a floor for deductions for charitable contributions where deductions are now limited to contributions in excess of 1% of a corporation's taxable income. The Act allows taxpayers that capitalized domestic R&amp;D expenditures after December 31, 2021, but before January 1 2025,  to elect to deduct any remaining unamortized amounts in the first tax year beginning after December 31, 2024, or ratably over the two-tax year period starting with the first tax year that begins after December 31, 2024. The Company is still evaluating the impact of the Act on its income tax provision.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EIB Tranche B Funding</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Finance Contract, the Company (through the Borrower) satisfied the conditions to draw &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6ee97b7-5817-4d24-a429-3b4df01b9625" contextRef="C_1d4a8f2a-a146-4860-99dd-0f7ae3dbbe1b" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the Tranche B loan facility. In connection therewith, on June 24, 2025, the Company issued to EIB the Tranche B Warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1c3608b-c916-4c92-b0c4-0e7ab87fc3fd" contextRef="C_2b8ecfa6-15a8-4675-8200-6867ed419829" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="0" decimals="2" format="ixt:num-dot-decimal">4,221,867.59</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock. The Strike Price per share of common stock is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38920728-f9a4-4378-a97c-5ba7d0c1551e" contextRef="C_4d40a682-0751-4064-bb08-df58960d326c" name="iobt:StrikePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.32</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On July 4, 2025, the Company (through the Borrower) drew upon the Tranche B loan facility to obtain &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2836a24c-bd0c-4b70-9193-c79ba1eb6d5d" contextRef="C_1d4a8f2a-a146-4860-99dd-0f7ae3dbbe1b" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before payment of certain fees and transaction related expense.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Management&#8217;s Discussion and Analysis of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Financial Condition and Results of Operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part I, Item 1A. &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025 and Part II, Item 1A. "Risk Factors" of our Quarterly Report on Form 10-Q for the three months ended March 31, 2025 filed with the SEC on May 14, 2025, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the section entitled &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in the section entitled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on our T-win</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">platform. Our T-win product candidates are designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (&#8220;TME&#8221;) by stimulating the activation and expansion of T cells against target antigen positive cells. This results in the modulation of the TME, creating a more pro-inflammatory environment, and the potentiation of anti-tumor activity by unleashing the tumor killing by T cells. We believe that our product candidates have the potential to advance the oncology treatment paradigm, amplifying immune-oncology treatment effects across the spectrum of melanoma and other tumor types.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lead therapeutic cancer vaccine candidate, IO102-IO103, which in the U.S. is known as Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (imsapepimut and etimupepimut, adjuvanted), is designed to target cancer cells and immune-suppressive cells in the TME that express indoleamine 2,3-dioxygenase (&#8220;IDO&#8221;) and programmed death ligand 1 (&#8220;PD-L1&#8221;). In an investigator-initiated, single-arm Phase 1/2 trial of 30 anti PD-1/PD-L1 na&#239;ve patients with metastatic melanoma, IO102-IO103 in combination with nivolumab, an anti-programmed cell death 1 (&#8220;PD-1&#8221;) checkpoint inhibitor, demonstrated proof of concept by increasing the overall response rate (&#8220;ORR&#8221;) and median progression free survival (&#8220;PFS&#8221;) compared to what has been reported with an anti-PD-1 antibody alone. The primary endpoint of the trial was feasibility and safety, secondary endpoints included efficacy and immunogenicity. The clinical efficacy endpoints in this trial included objective response (&#8220;OR&#8221;), PFS and overall survival (&#8220;OS&#8221;). The combination induced meaningful tumor regression and achieved rapid, deep and durable responses with a favorable tolerability profile without adding systemic toxicity to what is typically seen with an anti-PD-1 monotherapy in this patient population. As of the January 5, 2023 data cut as published in the May 2023 Journal for ImmunoTherapy of Cancer, we observed a confirmed ORR of 73% as per RECIST 1.1, a complete response rate (&#8220;CRR&#8221;) of 50% and 25.5 months of PFS. Based on the results from this study, IO102-IO103, in combination with pembrolizumab, was granted BTD by the FDA for treatment of unresectable/metastatic melanoma and we initiated a global Phase 3 trial. On August 11, 2025, the Company issued a press release announcing topline results from our Phase 3 trial of Cylembio plus KEYTRUDA&#174; (pembrolizumab) for the treatment of first-line advanced melanoma. In the trial, Cylembio plus pembrolizumab demonstrated clinical improvement in PFS compared to pembrolizumab alone, but statistical significance was narrowly missed on the primary endpoint. The randomized, open-label study enrolled 407 patients across more than 100 sites worldwide. Patients received either Cylembio in combination with pembrolizumab (n=203) or pembrolizumab alone (n=204). The primary endpoint was PFS as assessed by a blinded independent review committee per RECIST v1.1. The early and sustained separation of PFS curves demonstrated an improvement with a hazard ratio of 0.77 [95% CI: 0.58-1.00; p=0.056; threshold for significance p&#8804;0.045]. Based on an intent-to-treat analysis, patients in the study treated with Cylembio in combination with pembrolizumab achieved 19.4 months of median progression free survival compared to 11.0 months in patients treated with pembrolizumab alone. Although not yet mature, a trend toward an improvement in overall survival was also observed [HR 0.79 (95% CI: 0.57-1.10)]; the company expects OS to mature in the next six to nine months and projects results to be available in 2026.</span></p><p style="margin-left:4.4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">T-win Platform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our T-win platform is a novel approach to therapeutic cancer vaccines designed to activate pre-existing T cells to target immunosuppressive mechanisms. Our T-win product candidates are designed to employ a dual mechanism of action: (1) direct killing of immune-suppressive cells, including both tumor cells and genetically stable cells in the TME, that express IDO and/or PD-L1 (in the case of IO102-IO103), Arginase 1 (in the case of IO112) or transforming growth factor beta (&#8220;TGF&#946;&#8221;, in the case of IO170), and (2) modulation of the TME into a more pro-inflammatory, anti-tumor environment. Our T-win platform is built upon our team&#8217;s deep understanding of both the TME and a tumor&#8217;s ability to evade surveillance and destruction by the immune system. Our approach is in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contrast to previous methods that have sought to either block singular immunosuppressive pathways or to direct the immune system against specific identified antigens expressed by tumor cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing a pipeline of product candidates that leverage our T-win</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform to address targets within the TME. In addition to melanoma, we are currently evaluating IO102-IO103 in multiple solid tumor indications. We are also focusing on additional targets that play key roles in immunosuppression and that are expressed in a broad range of solid tumors. Our current pipeline of product candidates and expected upcoming milestones are summarized in the tables below.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img135872921_1.jpg" alt="img135872921_1.jpg" style="width:720px;height:369px;"/></p><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">* In combination with pembrolizumab</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> NSCLC = non-small cell lung cancer, SCCHN = squamous cell carcinoma of the head and neck</span></p><p style="margin-left:4.4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Potentially Registrational Phase 3 IOB-013/KN-D18 Trial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enrolled the first patient in a potentially registrational Phase 3 trial for IO102-IO103 in combination with pembrolizumab as first-line treatment in advanced melanoma, the IOB-013/KN-D18 trial, in May of 2022. In June 2023, we announced that we amended the protocol and increased the target number of patients to be enrolled in the Phase 3 trial from an original 300 patients to a revised 380 patients to potentially accelerate the timeline to reach the analysis of the primary endpoint of PFS. In November 2023, we fully enrolled the Phase 3 trial (380 patients) ahead of schedule with nearly half the patients enrolled during the final six months of enrollment. We included all patients who met the study criteria and who were in screening when the target enrollment was achieved, resulting in a total of 407 patients being enrolled in our IOB-013/KN-D18 trial.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The randomized, open-label study enrolled 407 patients across more than 100 sites worldwide. Patients received either Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in combination with pembrolizumab (n=203) or pembrolizumab alone (n=204). The primary endpoint was PFS as assessed by a blinded independent review committee per RECIST v1.1. The early and sustained separation of PFS curves demonstrated an improvement with a hazard ratio of 0.77 [95% CI: 0.58-1.00; p=0.056; threshold for significance p&#8804;0.045]. Based on an intent-to-treat analysis, patients in the study treated with Cylembio in combination with pembrolizumab achieved 19.4 months of median progression free survival compared to 11.0 months in patients treated with pembrolizumab alone. Although not yet mature, a trend toward an improvement in overall survival was also observed [HR 0.79 (95% CI: 0.57-1.10)]; the Company expects OS to mature over the next six to nine months and projects results to be available in 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvement in PFS was achieved across virtually all subgroups, regardless of PD-L1 status, including those with poor prognostic factors, with a profound effect in PD-L1 negative patients treated with Cylembio plus pembrolizumab (n=67) compared to patients treated with pembrolizumab monotherapy (n=63), HR: 0.54 (CI 0.35-0.85) (nominal p=0.006), with mPFS of 16.6 months vs. 3.0 months respectively.  Additionally, in a post hoc analysis of patients enrolled in this study without prior anti-PD-1 treatment (n=371), patients</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">treated with Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> plus pembrolizumab achieved improvement in PFS compared to patients treated with pembrolizumab monotherapy, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs. 11.0 months, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The combination was well tolerated, with no new safety signals observed. Injection site reactions, which were transient and resolved on treatment, were the most commonly reported adverse events in the combination arm, with 56% of patients receiving Cylembio plus pembrolizumab reporting an event. To ensure the safety of patients in the IOB-013/KN-D18 trial, safety reviews continue to be conducted by the independent data monitoring committee (&#8220;IDMC&#8221;). As of June 30, 2025, five IDMC safety reviews have been completed for an assessment of patient safety across both treatment arms in the trial. The recommendation after the IDMC reviews was that the trial continue without modifications.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO Biotech plans to meet with the FDA this fall to discuss the totality of the data and determine next steps for submission of a Biologics License Application (&#8220;BLA&#8221;).</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 IOB-022/KN-D38 Basket Trial</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also investigating IO102-IO103 in several other solid tumor indications. We are conducting a Phase 2 basket trial, the IOB-022/KN-D38 trial, which is investigating multiple first-line solid tumor indications in treatment na&#239;ve patients for metastatic disease. This basket trial is designed to investigate the safety and efficacy of IO102-IO103 in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (&#8220;NSCLC&#8221;), adenocarcinoma histology, with PD-L1 TPS &#8805; 50% (cohort A), and recurrent and/or metastatic squamous cell carcinoma of the head and neck (&#8220;SCCHN&#8221;) with CPS &#8805; 20 (cohort B). We initiated the IOB-022/KN-D38 trial in April 2022 and closed enrollment in June 2024 with 37 patients enrolled in cohort A and 21 patients enrolled in cohort B. Study protocol-specified pembrolizumab monotherapy benchmarks for the primary endpoint of ORR are Keynote-042 study (39%) for the NSCLC cohort A and Keynote-048 study (23%) for the SCCHN cohort B.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As presented at the European Society for Medical Oncology (&#8220;ESMO&#8221;) conference held in Barcelona in September 2024, results from the IOB-022/KN-D38 Phase 1/2 study of IO102-IO103 in combination with pembrolizumab in recurrent and/or metastatic SCCHN met its primary end point of ORR. Of the 21 patients enrolled in cohort B, 18 were efficacy evaluable and met the primary endpoint for this cohort with a confirmed ORR of 44.4%. Among the secondary endpoints, the data showed an encouraging 6.6-month median PFS, and a 66.7% disease control rate (&#8220;DCR&#8221;). The cohort B efficacy study results satisfied certain clinical conditions precedent in the Company's loan facility with the European Investment Bank (&#8220;EIB&#8221;) that provided the Company access to the Tranche B loan in principal amount of &#8364;12.5 million, which was drawn down on July 4, 2025. For more information on the EIB Loan Facility, please see Note 8, &#8220;Term Loan Facility&#8221; within this Quarterly Report on Form 10-Q.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As presented at the Society for Immunotherapy of Cancer (&#8220;SITC&#8221;) annual meeting in Houston, Texas in November 2024, preliminary results from the IOB-022/KN-D38 Phase 1/2 study of IO102-IO103 in combination with pembrolizumab in first line metastatic NSCLC were encouraging. Of the 37 patients enrolled in cohort A, 31 were efficacy evaluable and the data demonstrated promising activity with a 55% unconfirmed/48% confirmed ORR, respectively, in efficacy evaluable patients, an encouraging 8.1-month median PFS, no disease progression at 12 months in approximately 50% of the patients, and an 81% DCR. Duration of response (&#8220;DOR&#8221;) had not yet matured at this data cut off period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Most common reported adverse events in the trial were Grade 1-2 injection site reaction. Safety profile of the combination in this study was consistent with previously reported data when combined with anti-PD-1 monotherapy, with no added significant systemic toxicity.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 IOB-032/PN-E40 Basket Trial</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have initiated a basket trial to investigate IO102-IO103 in combination with pembrolizumab in a perioperative cancer setting. In April 2023, the FDA cleared the Company&#8217;s Investigational New Drug (&#8220;IND&#8221;) application for the evaluation of IO102-IO103 in combination with pembrolizumab, given before (neoadjuvant) and after (adjuvant) surgery in patients with resectable melanoma and SCCHN, the IOB-032/PN-E40 trial. The trial is a Phase 2, open-label, multi-cohort trial evaluating neoadjuvant and adjuvant treatment with IO102-IO103 in combination with pembrolizumab in patients with resectable melanoma (cohorts A and C) or SCCHN (cohort B). Cohorts A and B are single-arm, whereas in cohort C, melanoma patients are randomized 1:1 to neoadjuvant treatment with either combination IO102-IO103 with pembrolizumab or pembrolizumab alone.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the neoadjuvant period, treatment is every three weeks (Q3W) for three cycles (melanoma) or two to three cycles (SCCHN). Patients entering the study will be scheduled for surgery and begin neoadjuvant treatment 4-9 weeks prior to surgery. Surgery will then be followed by adjuvant treatment with the same regimen for 15 cycles. Cohort C patients with poor pathological response to pembrolizumab alone in the neo-adjuvant phase (&gt;10% residual viable tumor) may cross over to combination treatment post-surgery. The primary endpoint is major pathological response at surgery (&#8804;10% residual viable tumor; central assessment). Safety, event-free survival (&#8220;EFS&#8221;) and disease-free survival (&#8220;DFS&#8221;) are secondary endpoints. For translational research purposes, paired pre- and post-treatment tumor tissue and blood samples will be collected. As of January 2025, the study has completed enrollment for all cohorts ahead of schedule. We expect data to be available in the second half of 2025 and presented at a medical meeting in 2026.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Development</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO112 is our fully owned, novel investigational product candidate containing a single arginase 1-derived peptide designed to engage and activate arginase 1-specific human T cells. IO112 is designed to target T cells that recognize epitopes derived from arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells (&#8220;MDSCs&#8221;) including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal and prostate cancers. Arginase overexpression is a well-documented tumor escape mechanism.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arginase 1-derived peptides have been studied in two single-arm first-in-human Phase 1 trials in patients with solid tumor and hematological cancers. The two phase 1 trials have been conducted independent of the Company by the National Center for Cancer Immune Therapy using the arginase 1-derived peptide vaccine, which has shown safety and tolerability in both solid tumors and hematologic malignancies in both Phase 1 trials at the University Hospital of Herlev, Copenhagen. There were no significant safety concerns and no reported vaccine related Grade 3-4 events. Nine out of ten patients had measurable peptide specific immune responses in peripheral blood.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As presented at SITC in November 2024, preclinical data for IO Biotech&#8217;s second T-win</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vaccine candidate, IND-ready IO112 targeting Arginase 1, demonstrates anti-tumor activity with dynamic changes in the TME driven by the vaccine-targeted modulation of immunosuppressive tumor-associated macrophages (&#8220;TAMs&#8221;). The Company anticipates filing an IND for IO112 in 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to IO102, IO103 and IO112, we are evaluating additional product candidates that we believe have potential for use in solid tumors. All our compounds in preclinical development are designed to target well-documented immunosuppressive molecules that are known to be overexpressed in the TME across a wide range of tumors. These targets provide additional opportunities across multiple cancer indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that targeting TGF&#946; expressing cells in the TME via a vaccine approach presents a novel and attractive way to modulate the pathway and drive therapeutic benefit in the cancer setting. We are developing and characterizing TGF&#946;-selective peptide vaccines capable of inducing strong immune responses. Preclinical data thus far demonstrate that treatment with TGF&#946; vaccines leads to both activation of T cells and reduction of tumor growth, associated with proinflammatory signatures in the TME. We are currently conducting further experimental work to elucidate the cellular and molecular mechanisms of a TGF&#946; vaccine to support further development of a TGF&#946; vaccine (IO170) to modulate the TME for therapeutic benefit in a wide range of cancer indications. We plan to continue IND-enabling studies for IO170 in 2025 and 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 28, 2025, a poster presentation of new nonclinical data on IO170 was delivered at the American Association for Cancer Research (&#8220;AACR&#8221;) Annual Meeting in Chicago, Illinois. Murine surrogate IO170 (&#8220;mIO170&#8221;) demonstrated significant tumor growth inhibition in preclinical breast and prostate cancer models. The mIO170 treatment led to infiltration of vaccine-specific T cells with increased density of CD8+ T-cells in the tumor and reshaped the tumor microenvironment to favor immune activation. Spatial analysis in prostate tumors showed reduction in immune suppressive myeloid cell populations and increased cytotoxic T cells-tumor cell interaction.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Development of IO102 and IO103</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our development of IO102-IO103 is based on our prior separate development of IO102 and IO103. IO102 is our fully owned novel product candidate containing a single IDO1-derived peptide sequence designed to engage and activate IDO1-specific human T cells. IDO small molecule inhibitors have shown clinical potential in combination with PD-1 antibodies in early clinical trials, but have not been able to demonstrate the same level of efficacy in later-stage clinical trials. Our Phase 1 non-randomized trial of IO101, our first-generation IDO therapy, in NSCLC resulted in proof-of-concept for our approach, with 47% of patients displaying clinical benefit and an OS of 26 months in the treatment arm compared to 8 months in the group receiving standard of care. There were no Grade 3 or higher adverse events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 9, 2024, a poster presentation of new non-clinical data further supporting the dual mechanism of action of IO102-IO103 was delivered at the American Association for Cancer Research (&#8220;AACR&#8221;) Annual Meeting in San Diego, California. While further studies are needed to fully discern the relationship between IDO1+/PD-L1+ target populations within the TME and the impact of IDO1/PD-L1 targeted vaccination, we believe the data presented support the use of a dual antigen approach to reduce immunosuppression and enhance anti-tumor effects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 28 2025, a poster presentation of new non-clinical data further supporting the dual mechanism of action of IO102-IO103 was delivered at the AACR Annual Meeting in Chicago, Illinois. The data presented provided further insight into the mode of action of IO102-IO103: treatment with murine surrogate for IO102-IO103 resulted in strong T-cell responses leading to tumor growth control, where IDO1 and PD-L1 vaccine each contributing through different molecular programs. Additional gene expression profiling showed that the vaccine triggered unique molecular changes not seen with PD-1 or PD-L1 inhibitors, indicating a potentially synergistic mechanism.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Our operations to date have been financed primarily by aggregate net proceeds of $386.4 million</span><span style="color:#ffffff;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from the issuance of convertible preference shares, convertible notes, ordinary shares, our IPO, our Private Placement and the EIB Loan Facility. On May 6, 2025, we drew down on the Tranche A loan facility to obtain &#8364;10.0 million and on July 4, 2025, we drew down on the Tranche B loan facility to obtain &#8364;12.5 million, each amount before payment of certain fees and transaction related expense. Since inception, we have had significant operating losses. Our net loss was $48.6 million for the six months ended June 30, 2025, and $95.5 million and $86.1 million for the years ended December 31, 2024 and December 31, 2023, respectively. As of June 30, 2025, we had an accumulated deficit of $408.0 million and $28.1 million in cash and cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect to continue to incur significant research and development expenses and general and administrative expenses. In particular, we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, as well as hire additional personnel, pay fees to outside consultants, lawyers and accountants, and incur other increased costs associated with being a public company. In addition, if and when we seek and obtain regulatory approval to commercialize any product candidate, we will also incur increased expenses in connection with commercialization and marketing of any such product. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based upon our current operating plan, we believe that our existing cash and cash equivalents of $28.1 million as of June 30, 2025, plus &#8364;12.5 million in additional funds drawn on July 4, 2025 from the second tranche of the term loan facility with the European Investment Bank (before payment of certain fees and transaction related expenses), will be sufficient to continue funding our development activities into the first quarter of 2026. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which, though we were successful in raising additional capital through the Private Placement and the EIB Loan Facility, cannot be assured and which we may not be able to pursue successfully again in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not had any products approved for sale and, therefore, have not generated any product revenue. We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution, and associated regulatory and compliance costs. As a result, until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, including our research and development activities. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Operating Results</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative costs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development expenses consist primarily of costs incurred for the development of our product candidates and our drug discovery efforts, which include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">personnel costs, which include salaries, benefits and equity-based compensation expense;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred under agreements with outside consultants and advisors, including their fees and related travel expenses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred under agreements with third parties, including CROs that conduct research, preclinical activities and clinical trials on our behalf as well as CMOs that manufacture our product candidates for use in our preclinical and clinical trials and perform chemistry, manufacturing and control activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory and vendor expenses related to the execution of preclinical studies and planned and ongoing clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses related to research conducted by institutions, universities and hospitals as part of collaborations; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">filing and maintenance of patents and intellectual property rights, including payment to third parties for assignment of patent rights and licensing fees and milestone payments incurred under product license agreements where no alternative future use exists;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory supplies and equipment used for internal research and development activities; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we obtain grants from public and private funds for our research and development projects. The grant income for a given period is recognized as a cost reimbursement and is typically based on the time and the costs that we have spent on the specific project during that period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have historically met the requirements to receive a tax credit in Denmark of up to 5.5 million Danish Kroner per year for losses resulting from research and development costs of up to 25 million Danish Kroner per year. The tax credit is presented as a reduction to research and development expense in the consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use our personnel and infrastructure resources across multiple research and development programs directed toward identifying and developing product candidates. We have not tracked our research and development expenses on a program-by-program basis, as our lead product candidate, Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, is used in each of our three ongoing clinical trials across all target oncology indications that we are researching. Substantially all of our direct research and development expenses in the years ended December 31, 2024 and 2023 and in the six months ended June 30, 2025 were on Cylembio and consisted primarily of external costs, such as consultants, third-party contract organizations that conduct research and development activities on our behalf, costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers, and laboratory and vendor expenses related to the execution of our ongoing and planned preclinical studies and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to incur significant research and development expenses for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in conducting clinical trials, manufacturing and otherwise advancing our programs. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with product development and the current stage of development of our product candidates and programs, we cannot reasonably estimate or know the nature, timing and estimated costs necessary to complete the remainder of the development of our product candidates or programs. We are also unable to predict if, when, or to what extent we will obtain approval and generate revenues from the commercialization and sale of our product candidates. The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful completion of preclinical studies and of clinical trials for Cylembio, IO112, IO170, and our other current product candidates and any future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the length of time needed for certain data in our Phase 3 clinical trial for Cylembio (such as OS data) to reach maturity;  </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful completion of our Phase 2 basket trials, and successful enrollment and completion of any clinical trials for future product candidates;  </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">data from our clinical programs that support an acceptable risk-benefit profile of our product candidates in the intended patient populations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance for filing and approval by the FDA, regulatory authorities in Europe, or other regulatory agencies of  applications for marketing authorization, clinical trial applications and/or other regulatory filings for Cylembio, our other current product candidates and any future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintenance of a workforce of experienced scientists and others to continue to develop our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtainment and maintenance of intellectual property protection and regulatory exclusivity for our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arrangements with third-party manufacturers for, or establishment of, commercial manufacturing capabilities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishment of sales, marketing and distribution capabilities and successful launch of commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effective competition with other therapies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtainment and maintenance of coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintenance, enforcement, defense and protection of our rights in our intellectual property portfolio; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">avoidance of infringement, misappropriation or other violations with respect to others&#8217; intellectual property or proprietary rights; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintenance of a continued acceptable safety profile of our products following receipt of any marketing approvals. </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our preclinical studies and clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with the development of our current and future preclinical and clinical product candidates. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or clinical trials, we could be required to expend significant additional financial resources and time on the completion of preclinical and clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development activities account for a significant portion of our operating expenses. We expect to incur significant development expenses for the foreseeable future as we continue to implement our business strategy, which is primarily focused on advancing Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through clinical development, regulatory review and potential approval. In addition, product candidates in later stages of clinical development generally incur higher development and regulatory costs than those in earlier stages of clinical development. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our general and administrative expenses consist primarily of personnel costs, depreciation expense and other expenses for outside professional services, including legal fees relating to patent and corporate matters, human resources, audit and accounting services and facility-related fees not otherwise included in research and development expenses. Personnel costs consist of salaries, benefits and equity-based compensation expense, for our personnel in executive, finance and accounting, business operations and other administrative functions. We expect to continue to incur significant general and administrative expenses to support our continued research and development activities, manufacturing activities, and to continue to operate as a public company. These costs will likely include retaining key personnel, fees to outside consultants, lawyers and accountants, and costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, director and officer insurance premiums and investor relations costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our other income (expense), net is comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign currency exchange: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The functional currency of our subsidiaries operating in Denmark and United Kingdom is the Euro and the British Pound, respectively. Transactions denominated in currencies other than the Euro and the British Pound result in exchange gains and losses that are recorded in our consolidated statements of operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three and six months ended June 30, 2025 and 2024, we recognized interest income on account balances invested in money market funds and on account balances with banks.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: For the six months ended June 30, 2025, we recognized interest expense on outstanding debt to the European Investment Bank.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in fair value of warrants: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We issued warrants to the European Investment Bank in accordance with the warrant issuance agreement that are classified as liabilities on our consolidated balance sheet. The changes in fair value of the warrants at each balance sheet date until the warrants are exercised are recognized in the consolidated statement of income. </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparison of the three months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following sets forth our results of operations:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.020000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.66%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Three Months<br/>Ended June 30,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,652</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,848</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">804</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,518</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,685</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">833</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.7</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,170</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,533</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,637</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(23,170</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21,533</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,637</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (expense) income</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,929</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,221</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,150</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(339.9</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income tax expense</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(26,099</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(20,312</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,787</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.5</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">374</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(256</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(68.4</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(26,217</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(20,686</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,531</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.7</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses were comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:49.95%;box-sizing:content-box;"/>
     <td style="width:1.3%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.182%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.3%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.182%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.3%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.022%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.762%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Three Months<br/>Ended June 30,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial-related activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,390</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,637</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(247</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3.7</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,531</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,123</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,408</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.5</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chemistry, manufacturing and control</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,484</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,994</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(510</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(17.0</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preclinical studies and activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">616</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">295</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">321</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108.8</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">631</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">799</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(168</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21.0</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,652</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,848</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">804</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses were $16.7 million for the three months ended June 30, 2025, compared to $15.8 million for the three months ended June 30, 2024. The increase of $0.8 million was primarily related to an increase of $1.4 million in personnel expense due to an increase in headcount and contractor expenses related to the continued execution of our Phase 3 clinical trial that were offset by a decrease of $0.5 million in costs for chemistry, manufacturing and control activities related to manufacturing activities of Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, our therapeutic cancer vaccine candidate.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:51.531%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.527999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.587%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.267%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.067%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Three Months<br/>Ended June 30,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,840</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,899</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(59</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2.0</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional services</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,743</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">975</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.8</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,935</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,811</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,518</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,685</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">833</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.7</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $6.5 million for the three months ended June 30, 2025, compared to $5.7 million for the three months ended June 30, 2024. The increase of $0.8 million was related to an increase in professional services of $0.8 million primarily related to an increase in legal expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income (expense), net was comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:51.531%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.527999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.587%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.267%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.067%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Three Months<br/>Ended June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency exchange gain (loss), net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(374</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(90</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(284</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">315.6</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,311</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,026</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(78.3</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(253</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(253</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(100.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,587</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,587</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(100.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (expense) income, net</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,929</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,221</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,150</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(339.9</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income (expense), net was ($2.9) million for the three months ended June 30, 2025, compared to $1.2 million for the three months ended June 30, 2024. The decrease of $4.2 million was primarily due to a decrease of $2.6 million related to the change in fair value of the warrants issued to the EIB,  a decrease of $1.0 million in interest income recognized on our money market fund and a decrease of $0.3 million in interest expense due to our EIB debt.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparison of the six months ended June 30, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following sets forth our results of operations:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.020000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.66%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Six Months<br/>Ended June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,027</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,159</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,868</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,727</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,571</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,156</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,754</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,730</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,024</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.6</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(45,754</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(41,730</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,024</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.6</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (expense) income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,620</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,376</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,996</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(210.3</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income tax expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(48,374</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(39,354</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9,020</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.9</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">264</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">789</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(525</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(66.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(48,638</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(40,143</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8,495</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.2</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses were comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.41%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.082%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.082%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.922%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.542%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Six Months<br/>Ended June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial-related activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,081</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,785</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,714</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,917</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,797</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.2</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chemistry, manufacturing and control</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,776</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,161</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(385</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preclinical studies and activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,028</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">632</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">396</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62.7</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">428</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">664</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(236</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(35.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,027</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,159</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,868</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses were $33.0 million for the six months ended June 30, 2025, compared to $30.2 million for the six months ended June 30, 2024. The increase of $2.9 million was primarily related to an increase in personnel expense due to an increase in headcount and contractor related costs of $2.8 million.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.47%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.282%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.982000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.842%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.462%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Six Months<br/>Ended June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,852</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,693</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional services</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,124</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,048</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,076</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52.5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,751</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,830</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(79</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2.1</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,727</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,571</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,156</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $12.7 million for the six months ended June 30, 2025, compared to $11.6 million for the six months ended June 30, 2024. The increase of $1.2 million was primarily related to an increase in professional services of $1.1 million primarily related to an increase in legal expenses.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other (Expense) Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income (expense), net was comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:51.531%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.527999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.587%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.267%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.067%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Six Months<br/>Ended June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency exchange loss, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(479</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(552</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13.2</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">699</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,928</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,229</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(76.1</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(253</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(253</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(100.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,587</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,587</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(100.0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (expense) income, net</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,620</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,376</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,996</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(210.3</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other (expense) income, net was ($2.6) million for the six months ended June 30, 2025, compared to $2.4 million for the six months ended June 30, 2024. The decrease of $5.0 million was primarily due a decrease of $2.6 million related to the change in fair value of the warrants issued to the EIB and a decrease in interest income of $2.2 million recognized on our money market fund.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our operations to date have been financed primarily by aggregate net proceeds of $386.4 million from the issuance of convertible preference shares, convertible notes, ordinary shares, our IPO, our Private Placement, and the EIB Loan Facility. On May 6, 2025, we drew down on the EIB Tranche A loan facility to obtain &#8364;10.0 million and on July 4, 2025, we drew down on the EIB Tranche B loan facility to obtain &#8364;12.5 million, each amount before payment of certain fees and transaction related expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, IO Biotech ApS, our wholly-owned subsidiary, entered into the Finance Contract (the &#8220;Finance Contract&#8221;) with the EIB establishing the EIB Loan Facility, which consists of three committed tranches of potential financing in an aggregate principal amount of up to &#8364;37.5 million, subject to certain conditions precedent (the &#8220;EIB Loan Facility&#8221;). Concurrently with the execution of the Finance Contract, IO Biotech ApS entered into a non-binding side letter, pursuant to which EIB may, in its discretion and subject to approvals by its investment committee, make available to the Company an additional &#8364;20.0 million in funding related to the Company&#8217;s ongoing clinical trials. We expect to have &#8364;15.0 million in additional committed funds available contingent upon satisfying certain agreed upon conditions of the agreement and up to &#8364;20.0 million in uncommitted funds that EIB may elect to provide in its sole discretion.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 7, 2023, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company agreed to sell and issue (i) 37,065,647 shares of the Company&#8217;s Common Stock, and (ii) 37,065,647 Warrants in the Private Placement. Each Purchaser&#8217;s Warrant is exercisable for a number of shares of Common Stock equal to one hundred percent of the aggregate number of shares of Common Stock purchased by such Purchaser. The purchase price for each share of Common Stock and Warrant was $2.025. The Warrants are exercisable at an exercise price of $2.47 per share, subject to adjustment as set forth therein. The Warrants are exercisable until the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an acquisition, as defined in the Warrants. The Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the Warrants. The Private Placement closed on August 9, 2023. The Company received $75.1 million in gross proceeds from the Private Placement, before deducting offering expenses of $3.2 million. The Company intends to use the net proceeds of $71.9 million from the Private Placement for general corporate purposes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, on February 15, 2023, we filed a new prospectus supplement with the SEC with respect to the offer and sale of shares of our common stock, par value $0.001 per share, with an aggregate offering price of up to $19.5 million, establishing an at-the-market equity program. On February 15, 2023, we also entered into a Sales Agreement by and between the Company and Cowen and Company, LLC for shares with an aggregate offering price of up to $75.0 million through which we may, from time to time, sell shares through Cowen and Company, LLC, acting as agent and/or principal. Any shares offered and sold through the at-the-market equity program will be issued pursuant to the Company&#8217;s Registration Statement on Form S-3 (File No. 333-269569), which was declared effective on February 10, 2023, the prospectus supplement related to the offering that forms a part of the registration statement, and any applicable prospectus supplements that may form a part of the registration statement in the future. The aggregate market value of shares eligible for sale under the prospectus supplement and under the Sales Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. We have not currently issued any shares pursuant to our at-the-market equity program as of June 30, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently expect that our cash and cash equivalents of $28.1 million as of June 30, 2025, plus &#8364;12.5 million in additional funds drawn on July 4, 2025 from the second tranche of the term loan facility with the European Investment Bank (before payment of certain fees and transaction related expenses), will be sufficient to continue funding our development activities into the first quarter of 2026. However, additional funding will be necessary to fund our future clinical and preclinical activities. If we are unable to obtain funding, we could be forced to delay, reduce or eliminate our research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect our business prospects and our ability to continue operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:65.913%;box-sizing:content-box;"/>
     <td style="width:1.56%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.383000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.56%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.583%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Six Months<br/>Ended June 30,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(42,893</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(41,914</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(54</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(23</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,487</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(31,460</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(41,937</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Used in Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities of $42.9 million for the six months ended June 30, 2025 was primarily attributable to our net loss of  $48.6 million and a net decrease of $1.2 million in our working capital accounts, partially offset by an increase in non-cash items of $7.0 million primarily due to equity-based compensation and the change in fair value of warrants issued to the EIB.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities of $41.9 million for the six months ended June 30, 2024 was primarily attributable to our net loss of $40.1 million and a net decrease of $6.0 million in our working capital accounts, partially offset by an increase in non-cash items of $4.2 million primarily due to equity-based compensation.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Used in Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in investing activities of $0.1 million and $0.02 million for the six months ended June 30, 2025 and 2024, respectively, was related to the purchase of property and equipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Provided by Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by financing activities of $11.5 million for the six months ended June 30, 2025 was related to the net proceeds obtained from the EIB Tranche A loan facility funding. We had no cash provided by financing activities for the six months ended June 30, 2024.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses; costs related to third-party clinical research, manufacturing and development services; lease costs relating to our headquarters and our other offices, laboratories and manufacturing facility; license payments or milestone obligations that may arise; laboratory expenses and costs for related supplies; clinical costs; manufacturing costs; legal and other regulatory expenses; and general overhead costs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based upon our current operating plan, we believe that our existing cash and cash equivalents of $28.1 million as of June 30, 2025, plus &#8364;12.5 million in additional funds drawn on July 4, 2025 from the second tranche of the term loan facility with the European Investment Bank (before payment of certain fees and transaction related expenses), will be sufficient to continue funding our development activities into the first quarter of 2026. To finance our operations beyond that point we will need to raise additional capital, which, though we were successful in raising additional capital through the Private Placement, and the EIB Loan Facility, cannot be assured and which we may not be able to pursue successfully again in the future. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development and potential regulatory approval and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, potentially including collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we may need to delay, reduce or terminate planned activities to reduce costs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress, costs and results of our ongoing and planned clinical trials of Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as well as our planned trials for our other product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of discovery research, preclinical development, laboratory testing and clinical trials for our product candidates, including our ongoing clinical trials of Cylembio; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability or inability to obtain approval of Cylembio from applicable regulatory authorities or our failure to obtain regulatory approval to expand Cylembio&#8217;s indications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability or inability to successfully commercialize Cylembio, or our other product candidates, if approved by applicable regulatory authorities, or to maintain applicable regulatory approvals for Cylembio or our other product candidates, if approved; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of, and development requirements for, other product candidates that we pursue; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to enter into contract manufacturing arrangements for supply of active pharmaceutical ingredients (&#8220;API&#8221;), and manufacture of our product candidates and the terms of such arrangements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the payment or receipt of milestones and receipt of other collaboration-based revenues, if any; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of any future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount and timing of revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license other products, product candidates, technologies or data referencing rights; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the enrollment and completion of our Phase 3 clinical trial for Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Phase 2 basket trials, and any clinical trials for our existing or future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to receive additional non-dilutive funding, including grants from organizations, public institutions and foundations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addition of operational, financial and management information systems and personnel, including personnel to support our drug development, any future commercialization efforts and our transition to a public company; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:5.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.805787706420075%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating as a public company. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual Obligations and Commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2021, we entered into a lease for our office space in Copenhagen, Denmark that was amended in September 2022 and is set to expire in December 2027. The lease for our office space in Copenhagen, Denmark is terminable upon six months&#8217; notice. In January 2023, we entered into a lease for laboratory space in Copenhagen, Denmark that expires in December 2027. In December  2024, we entered into a lease for additional office space in Copenhagen, Denmark that expires in December 2027. In August 2021, we entered into a lease for laboratory facilities and office space in Rockville, Maryland that expires in May 2027. In October 2021, we entered into a lease for office space in New York, New York that expires in January 2027. In June 2023, we entered into a lease for office space in Newport, United Kingdom that expires in May 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into contracts in the ordinary course of business with third-party service providers for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice of 30 to 90 days, and therefore, we believe that our non-cancelable obligations under these agreements are not material and we cannot reasonably estimate whether they will occur. However, in the event of a termination of any contracts with CROs or other institutions and with respect to active patients enrolled in our clinical trials, we may be financially obligated for a period beyond the contractual termination notice periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also enter into additional research, manufacturing, supplier, lease and other agreements in the future, which may require up-front payments and even long-term commitments of cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our evaluation of our ability to continue as a going concern requires us to evaluate our future sources and uses of cash sufficient to fund our currently expected operations in conducting research and development activities. We evaluate the probability associated with each source and use of cash resources in making our going concern determination. The research and development of pharmaceutical products is inherently subject to uncertainty. We currently expect that our cash and cash equivalents of $28.1 million as of June 30, 2025 along with the second tranche of the EIB Loan will not be sufficient to fund our operating expenses and capital requirements for at least 12 months from the date the financial statements are issued.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We incur substantial expenses associated with clinical trials. Accounting for clinical trials relating to activities performed by CMOs, CROs and other external vendors requires management to exercise significant estimates in regard to the timing and accounting for these expenses. We estimate costs of research and development activities conducted by service providers, which include costs associated with the conduct of sponsored research, preclinical studies, contract manufacturing activities and pass-through costs. The diverse nature of services being provided under CRO and other arrangements, the different compensation arrangements that exist for each type of service and the lack of timely information related to certain clinical activities complicates the estimation of accruals for services rendered by CROs and other vendors in connection with clinical trials. We record the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and allocate these costs in the accrued and other current liabilities or prepaid expenses on the balance sheets and within research and development expense on the statements of operations. In estimating the duration of a clinical study, we evaluate the start-up treatment and wrap-up periods, compensation arrangements and services rendered attributable to each clinical trial. Fluctuations are regularly tested against payment plans and trial completion assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We make significant judgments and estimates in determining the accrued liabilities and prepaid expense balances in each reporting period. As actual costs become known, we adjust our accrued liabilities or prepaid expenses. We have not experienced any material differences between accrued costs and actual costs incurred since our inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our expenses related to clinical trials are based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions, CMOs and CROs that may be used to conduct and manage clinical trials, chemistry and testing and manufacturing services on our behalf. We generally accrue expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we modify our estimates of accrued expenses accordingly on a prospective basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We issued stock-based compensation awards through the granting of warrants and stock options, which generally vest over a four-year period. We issued 2,709,284 stock options with a weighted average exercise price of $1.13 under our 2021 Equity Plan during the six months ended June 30, 2025. We did not issue stock options from the 2023 Inducement Award Plan during the six months ended June 30, 2025.  We also issued 3,087,382 and 310,000 stock options with a weighted average exercise price of $1.60 and $1.58 to certain employees, board members and advisors from the 2021 Equity Incentive Plan and 2023 Inducement Award Plan, respectively, during the year ended December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for equity-based compensation in accordance with ASC 718, Compensation-Stock Compensation (&#8220;ASC 718&#8221;). In accordance with ASC 718, compensation cost is measured at estimated fair value and is included as compensation expense over the vesting period during which service is provided in exchange for the award on a straight-line basis. Vesting of the awards depend solely on service conditions required of the employee. The Company reverses any previously recognized compensation cost associated with forfeited awards in the period of the forfeiture occurs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use a Black-Scholes option pricing model to determine fair value of our warrants and stock options. The Black-Scholes option pricing model includes various assumptions, including the fair value of common shares, expected life of warrants and stock options, the expected volatility and the expected risk-free interest rate. These assumptions reflect our best estimates, but they involve inherent uncertainties based on market conditions generally outside our control. As a result, if other assumptions had been used, equity-based compensation cost could have been materially impacted. Furthermore, if we use different assumptions for future grants, share-based compensation cost could be materially impacted in future periods.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will continue to use judgment in evaluating the assumptions utilized for our equity-based compensation expense calculations on a prospective basis. In addition to the assumptions used in the Black-Scholes model, the amount of equity-based compensation expense we recognize in our financial statements includes warrant forfeitures as they occurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the level of historical operating results and projections for the taxable income for the future, we have determined that it is more likely than not that our net deferred tax assets will not be realized. Accordingly, we have recorded a full valuation allowance to reduce our net deferred tax assets in IO Biotech ApS, IO Bio US, Inc. and IO Biotech, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize tax benefits from uncertain tax positions only if, based on the technical merits of the position, it is more likely than not that the tax positions will be sustained on examination by the tax authority. The tax benefits recognized in the financial statements from such positions are measured based on the largest amount that is more than 50% likely to be realized upon ultimate settlement. We recognize interest and penalties related to unrecognized tax benefits within the provision for taxes in our statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate in Denmark and may be subject to audits from various tax authorities. Management&#8217;s judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against our net deferred tax assets. We will monitor the extent to which our deferred tax assets may be realized and adjust the valuation allowance accordingly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We elected to claim a research and development tax credit on the federal income tax return filed for the year ended December 31, 2023 and plan to continue to make this election on the federal income tax return filed for the year ended December 31, 2024 and 2025 based on law currently enacted. We will continue to monitor impacts of proposed or enacted law changes on the cost to benefit of making this election. The Company included $0.4 million and $0.7 million in research and development tax credits in the U.S. provision for income taxes for the six months ended June 30, 2025 and the year ended December 31, 2024, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants Issued in Connection with a Sale of Common Stock or Issuance of Debt</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for warrants issued as a separable unit in connection with sale of common stock or debt as either liability or equity in accordance with Accounting Standards Codification 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered liabilities if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. If warrants do not require liability classification under ASC 815-40 or other applicable generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) the warrants should be classified as equity. The debt is measured at amortized cost and the amount of interest recognized in the consolidated statements of operations is calculated by applying the loan&#8217;s effective interest rate to its carrying amount.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The proceeds received from the sale of equity classified warrants and shares of common stock in a bundled transaction are allocated based on the relative fair values of warrants and shares with no changes in fair value of warrants recognized after the issuance date. For liability classified warrants, the stand-alone fair value of the warrants are classified as debt issuance costs that directly reduce the outstanding debt on the consolidated balance sheet upon funding. Warrants issued prior to the date of funding are accounted for as a deferred financing asset within &#8220;Prepaid expenses and other current assets&#8221; on the consolidated balance sheet and will be reclassified to debt issuance costs on the date of funding. The change in fair value of warrants each balance sheet date are recognized in the consolidated statements of operations and comprehensive loss after the issuance date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; in the accompanying notes to our consolidated financial statements for the six months ended June 30, 2025 and 2024 appearing elsewhere in this Quarterly Report on Form 10-Q for a discussion of recently issued accounting standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company (&#8220;EGC&#8221;) Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an EGC under the JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other exemptions and reduced reporting requirements under the JOBS Act for EGCs include presentation of only two years of audited financial statements in a registration statement for an IPO and in an Annual Report on Form 10-K, an exemption from the requirement to provide an auditor&#8217;s report on internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may remain classified as an EGC until December 31, 2026, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of June 30 of any year before that time, or if we have annual gross revenues of $1.235 billion or more in any fiscal year, we would cease to be an EGC as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1.0 billion of non-convertible debt over a three-year period.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_quantitative_qualitative_disclosu"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ve Disclosures About Market Risk.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a smaller reporting company as defined by Item 10 of Regulation S-K and are not required to provide the information otherwise required under this item.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Procedures.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2025. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, mean controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company on the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including, our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the evaluation of our disclosure controls and procedures as of June 30, 2025, our Chief Executive Officer and Chief Financial Officer concluded that, as a result of a material weakness identified in our internal control over financial reporting, as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2024, our disclosure controls and procedures were not effective as of June 30, 2025. In connection with our preparation and the audit of our financial statements as of and for the year ended December 31, 2024, we identified a material weakness in our internal control over financial reporting related to the accounting for CRO related accruals and prepayments. Specifically, our controls were not effectively designed or operating to ensure that the accounting framework and processes used to support CRO-related accounting entries appropriately reflected the status and progress of ongoing clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting as defined under the Exchange Act and by the Public Company Accounting Oversight Board (United States), such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We are committed to completing the remediation of this material weakness as expeditiously as possible and expect these enhancements to be fully implemented during the fiscal year ending December 31, 2025. However, the material weakness will not be considered fully remediated until the new controls have been operational for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Internal Control</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There has been no change in our internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iior_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II&#8212;OTHER</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> INFORMATION</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Legal</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Proceedings.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be a party to litigation or subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. We are not currently a party to any material legal proceedings.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_riskfactors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk Factors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is subject to numerous risks. You should carefully consider the following risks and all other information contained in this Quarterly Report, as well as general economic and business risks, together with any other documents we file with the SEC. If any of the following events actually occur or risks actually materialize, it could have a material adverse effect on our business, operating results and financial condition and cause the trading price of our common stock to decline.</span></p><p style="text-indent:5.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of the Material and Other Risks Associated with Our Business</span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have substantial doubt about our ability to continue as a going concern and we will need to obtain substantial additional funding to continue our operations and complete the development and commercialization of our product candidates. If we are unable to raise this capital when needed, we may not be able to continue as a going concern or we may be forced to delay, reduce or eliminate our product development programs or other operations.</span></div></div><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	None of our product candidates, including IO102-IO103, our lead investigational therapeutic cancer vaccine candidate, which in the U.S. is now known as Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (imsapepimut and etimupepimut, adjuvanted),  have received marketing approval. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may never receive regulatory approval for commercial sale of Cylembio, and even if we do, we may face a longer than expected pathway to commercialize Cylembio in the U.S., which could materially adversely affect our business condition, prospects, competitive position and financial results.</span></div></div><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Our preclinical studies and clinical trials, including our Phase 3 clinical trial for Cylembio, may fail to sufficiently demonstrate the safety and efficacy of our product candidates, or may identify serious adverse or unacceptable side effects, which could prevent, delay or limit the scope of regulatory approval of our product candidates, limit their commercialization, increase our costs and/or necessitate the abandonment or limitation of the development of some of our product candidates.</span></p><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Our success and commercial opportunity largely depends on the success of our limited number of product candidates. If any of these candidates fail in clinical trials or are not approved for commercialization, our ability to generate revenue and achieve profitability could be impacted if we fail to develop additional product candidates.</span></p><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	We rely on third-party suppliers and contract manufacturing organizations (collectively, &#8220;CMOs&#8221;) to manufacture our product candidates, which can be complex and are critical to our business. Our CMOs may encounter difficulties in production, particularly with respect to process development or scale-up of our product candidates. If our CMOs encounter difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped.</span></p><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	We will need to obtain substantial additional funding to complete the development and commercialization of our product candidates. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.</span></p><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than we do.</span></p><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.</span></p><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Public health emergencies, geopolitical conflicts or other significant domestic and international events could have a material adverse impact on our business, financial condition and results of operations, including the execution of our clinical trials.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Rapid changes to U.S. policy by Congress and the Trump administration have impacted and may in the future impact, among other things, the U.S. and global economy, international trade relations, healthcare, taxation, the U.S. regulatory environment, inflation, and other areas. In parallel, disruptions at key government agencies such as the FDA, SEC, and other regulatory authorities &#8212; resulting from policy shifts, funding constraints, leadership, and personnel changes &#8212; could impair their ability to function effectively. These developments may delay or prevent regulatory approvals, hinder product development or commercialization, or otherwise interfere with governmental operations that our business depends on and could therefore have a substantial and adverse effect on our business, financial condition and results of operation and stock price.</span></p><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The proposals to revise the European Union (&#8220;EU&#8221;) legislation on pharmaceutical products could lead to uncertainties over the regulatory framework that will be applicable to medicinal products in the EU, including orphan and pediatric medicinal products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The price of our common stock may be volatile or may decline regardless of our operating performance and you may lose all or part of your investment.</span></p><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	We are subject to a variety of privacy and data security laws, and our failure to comply with them could harm our business.</span></p><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	We have identified a material weakness in our internal control over financial reporting that, if not properly remediated, could result in us being unable to provide required financial information in a timely and reliable manner. Such a failure, or any other failure, to comply with the financial reporting and internal controls requirements for publicly traded companies could have a material adverse effect on our business and stock price.</span></p><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#183;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Our internal information technology systems, or those of our third-party contract research organizations (&#8220;CROs&#8221;) or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our product candidates' development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business. Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Limited Operating History, Financial Position and Capital Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company with a limited operating history that may make it difficult to evaluate the success of our business to date and to assess our future viability. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing and optimizing our technology platform, identifying potential product candidates, undertaking research, preclinical studies and clinical trials for our product candidates, establishing and enhancing our intellectual property portfolio, and providing general and administrative support for these operations. IO102-IO103, which in the U.S. is known as Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (imsapepimut and etimupepimut, adjuvanted), is in clinical development and IO112 and IO170 are in preclinical development, and none of our product candidates have been approved for commercial sale. We have never generated any revenue from product sales and have incurred net losses each year since we commenced operations. Our net loss was $48.6 million for the six months ended June 30, 2025, and $95.5 million and $86.1 million for the years ended December 31, 2024 and December 2023, respectively. We expect that it will be at least some time, if ever, before we have a product candidate ready for regulatory approval and commercialization. If Cylembio is not approved by the FDA or is not commercialized by 2026, we expect to incur increasing levels of operating losses. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; deficit and working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To become and remain profitable, we must develop and eventually commercialize a product or products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we succeed in commercializing one or more of our product candidates, we may never generate revenue that is significant or large enough to achieve profitability. In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. Our failure to become and remain profitable would decrease the value of the Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of the Company could also cause our stockholders to lose all or part of their investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have substantial doubt about our ability to continue as a going concern and we will need to obtain substantial additional funding to continue our operations and complete the development and commercialization of our product candidates. If we are unable to raise this capital when needed, we may not be able to continue as a going concern or we may be forced to delay, reduce or eliminate our product development programs or other operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our recurring losses from operations raise substantial doubt about our ability to continue as a going concern.  As a result, the financial statements accompanying this Quarterly Report on Form 10-Q include a statement that there is substantial doubt about our ability to continue as a going concern for one year after the date the financial statements were issued, and these financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially during the next few years. The development of biopharmaceutical product candidates, especially immuno-oncology product candidates, is capital intensive. As our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our clinical, regulatory, quality and manufacturing capabilities. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently expect that our cash and cash equivalents of $28.1 million as of June 30, 2025, plus &#8364;12.5 million in additional funds drawn on July 4, 2025 from the second tranche of the term loan facility with the European Investment Bank (before payment of certain fees and transaction related expenses), will be sufficient to continue funding our development activities into the first quarter of 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has plans to obtain sufficient additional fundraising to fulfill its operating and capital requirements for the next 12 months. The Company&#8217;s plans include continuing to fund its operating losses and capital funding needs through public or private equity or debt financings, including the draw down of the available committed tranches of the EIB loan facility defined below in Note 8, &#8220;Term Loan Facility&#8221;, strategic collaborations, licensing arrangements, or other arrangements. The Company has drawn down on the Tranche A and Tranche B loan facility in principal amount of &#8364;10.0 million and &#8364;12.5 million, respectively, on May 6, 2025 and July 4, 2025, each before payment of certain fees and transaction related expense. The business conditions of the Tranche C loan facility have not been satisfied to draw up to &#8364;15.0 million as of the date of these interim financial statements. Further, the Company believes that its operations are scalable and, if there is a need, certain cost reduction measures may be taken to preserve cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although management believes such plans, if executed, should provide the Company sufficient financing to meet its needs, successful completion of such plans is dependent on factors outside of the Company&#8217;s control. Our future capital requirements will depend on many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, design, progress, timing, costs and results of drug discovery, preclinical studies and clinical trials of our product candidates, and in particular the clinical trials for Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and characteristics of product candidates that we pursue; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of clinical trials needed to obtain regulatory approvals from the FDA, the European Commission (based on recommendation from the EMA), and any other regulatory authority; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the length of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased costs associated with conducting our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully completing ongoing pre-clinical studies and clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome, timing and costs of seeking regulatory approvals from the FDA, the European Commission, and any other regulatory authority; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of manufacturing our product candidates and the costs of clinical trials in preparation for marketing approval of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing for, implementing and executing potential commercial launches of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of any third-party products used in our combination clinical trials that are not covered by such third party or other sources; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with hiring additional personnel and consultants as our preclinical, manufacturing and clinical activities increase; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the receipt of marketing approval and revenue received from any commercial sales of any of our product candidates, if approved; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of commercialization activities for any of our product candidates, if approved, including marketing, sales, compliance and distribution costs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the emergence of competing therapies and other adverse market developments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to establish and maintain strategic collaboration, licensing or other arrangements and the financial terms of such agreements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we in-license or acquire other products and technologies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount and timing of any payments we may be required to make pursuant to our current or future license agreements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our need and ability to retain key management and hire scientific, technical, business, medical, and compliance personnel; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our implementation of additional internal systems and infrastructure, including operational, financial, compliance and management information systems; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with expanding our facilities or building out our laboratory space as necessary; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effects of the disruptions to and volatility in the credit and financial markets in the United States and worldwide from public health emergencies and geopolitical conflict (such as in Ukraine and the Middle East); and  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating as a public company. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require additional capital to continue our operations and achieve our business objectives. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. Further, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide. If we are unable to raise sufficient additional capital, we may not be able to continue as a going concern, or we could be forced to curtail our planned operations and the pursuit of our growth strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially grants, collaborations, licenses or other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock. Additional debt financing, if available, may involve agreements that include covenants further limiting or restricting our ability to take specific actions, such as further limitations on our ability to incur additional debt, make capital expenditures or declare dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise funds through collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">None of our product candidates, including IO102-IO103, our lead investigational therapeutic cancer vaccine candidate, which in the U.S. is now known as Cylembio</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> (imsapepimut and etimupepimut, adjuvanted), have received marketing approval. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical trials of Cylembio, or any other future clinical trials of our product candidates, may not be successful or generate clinical data that are sufficient  to support submission, filing or approval of marketing authorizations from the FDA, European Commission (based on recommendation from the EMA), or other regulatory authorities. We have limited experience submitting INDs to the FDA. The FDA may not permit any of our future INDs, including any IND submitted for IO112, to go into effect in a timely manner or at all. Without an IND for a product candidate, we will not be permitted to conduct clinical trials in the United States for such product candidate. In addition, the Company has no experience submitting BLAs or other applications for marketing approval and FDA or other regulatory authorities may not approve our applications or may approve our application(s) in a limited manner.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biopharmaceutical development is a difficult, long, time-consuming, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical trials. For example, we have historically experienced longer than expected lead times in clinical trial site activation and patient enrollment in our clinical trials. Failure to obtain regulatory approval for our product candidates will prevent us from commercializing and marketing our product candidates. The success in the development of our product candidates will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timely and successful completion of preclinical studies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining patent, trademark and trade secret protection and regulatory exclusivity for our product candidates and otherwise protecting our rights in our intellectual property portfolio; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission of INDs and CTAs for and receipt of allowance to proceed with our planned clinical trials or other future clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiating, enrolling, and successfully completing clinical trials, including investigator-initiated clinical trials over which we have limited control; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining positive results from our preclinical studies and clinical trials that support a demonstration of efficacy, safety, and durability of effect for our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receiving approvals for commercialization of our product candidates from applicable regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, European Commission (based on recommendation from the EMA), and other regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing sales, marketing and distribution capabilities and successfully launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining a continued acceptable safety, tolerability and efficacy profile of any approved products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">setting acceptable prices for our product and obtaining coverage and adequate reimbursement from third-party payors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing our product candidates at an acceptable cost; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining and growing an organization of scientists, medical and clinical professionals and business professionals who can develop and commercialize our products and technology.  </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of these factors are beyond our control, including the time needed to adequately complete clinical testing, the regulatory submission process and potential threats to our intellectual property rights. It is possible that none of our product candidates will ever obtain regulatory approval, even if we expend substantial time and resources seeking such approval. If we do not achieve one or more of these factors in a timely manner or at all, or any other factors impacting the successful development of biopharmaceutical products occur, we could experience significant delays or an inability to successfully develop our product candidates, which would materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may never receive regulatory approval for commercial sale of Cylembio</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, and even if we do, we may face a longer than expected timeline to commercialize Cylembio in the United States, which could materially adversely affect our business condition, prospects, competitive position and financial results.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success largely depends on our lead dual peptide Cylembio, and there is no assurance that we will obtain the requisite regulatory approvals for the commercial sale of Cylembio in the United States or elsewhere. On August 11, 2025, we announced topline results from our Phase 3 trial of Cylembio in combination with pembrolizumab as a first-line treatment for patients with unresectable or metastatic (advanced) melanoma. In the study, Cylembio plus pembrolizumab demonstrated clinical improvement in PFS compared to pembrolizumab alone, but statistical significance was narrowly missed on the primary endpoint. We plan to engage with the FDA regarding the potential regulatory pathway for Cylembio. However, additional data&#8212;potentially from another Phase 3 or other clinical trial&#8212;may be required to support approval. This could extend our expected timeline to regulatory approval in the United States or other jurisdictions. We may also choose not to submit applications for regulatory approval, and any application we do submit may not be approved. If we conduct additional trials, their outcome is uncertain. These and other potential developments, including the results of any future trials, could materially and adversely affect the likelihood, timing, and cost of obtaining approval for Cylembio and, as a result, could have a substantial negative impact on our business, financial condition, results of operations, and competitive position.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance in clinical trials may not achieve favorable results in later-stage clinical trials, if any, or receive marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The research and development of drugs and biological products is extremely risky. Only a small percentage of product candidates that enter the development process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. The outcome of clinical testing is uncertain. We may face unforeseen challenges in our product candidate development strategy, and we ultimately may not be successful in our current and future clinical trials or that our product candidates will be able to receive regulatory approval. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. For example, it is not uncommon for product candidates to exhibit unforeseen safety or efficacy issues when tested in humans despite promising results in preclinical animal models. Future results of preclinical and clinical testing of our product candidates are also less certain due to the novel and relatively untested nature of the approach of our T-win</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform. In general, clinical trial failure may result from a multitude of factors including flaws in study design, dose selection, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the biopharmaceutical industry, including other immuno-oncology companies, have suffered setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates are based on novel technologies that target the highly immunosuppressive TME, which makes it difficult to predict the results, timing, and cost of product candidate development and likelihood of obtaining regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have concentrated our research and development efforts on product candidates using our T-win platform, and our future success depends on the successful development of this approach. Our product candidates target the TME, which is highly immunosuppressive. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates based on our platform technologies in clinical trials or in obtaining marketing approval thereafter, and use of our platform technologies may not ever result in marketable products. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners or establishing our own commercial manufacturing capabilities, which may prevent us from completing our clinical trials or commercializing any products on a timely or profitable basis, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the clinical trial requirements of the FDA and comparable foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be less predictable, more expensive and longer than for other, better known or extensively studied pharmaceutical or other product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The approaches offered by our products may not gain broad acceptance among doctors or patients or that governmental agencies or third-party medical insurers will be willing to provide reimbursement coverage for proposed product candidates. Since our current product candidates and any future product candidates will represent novel approaches to treating various conditions, it may be difficult, in any event, to accurately estimate the potential revenues from these product candidates. Accordingly, we may spend significant capital trying to obtain approval for product candidates that have an uncertain commercial market. The market for any products that we successfully develop will also depend on the cost of the product. We do not yet have sufficient information to reliably estimate what it will cost to commercially manufacture our current product candidates, and the actual cost to manufacture these products could materially and adversely affect the commercial viability of these products. If we do not successfully develop and commercialize products based upon our approach or find suitable and economical sources for materials used in the production of our products, we will not become profitable, which would materially and adversely affect the value of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The oncology industry is also rapidly developing, and our competitors may introduce new technologies improving the immune response to cancer that render our technologies obsolete or less attractive. New technology could emerge at any point in the development cycle of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our second product candidate, IO112, targets an immune resistance pathway known as Arginase 1 which is highly expressed in solid cancer indications. If this product candidate does not show any functionality in the solid tumor microenvironment, our development plans, financial position, results of operations and prospects may be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to develop product candidates for use in solid tumors, including IO112, but our product candidates may not show any functionality in the solid tumor microenvironment. The cellular environment in which solid tumor cells thrive is generally hostile to T cells due to factors such as the presence of immune-suppressive cells, humoral factors and limited access to nutrients. Our product candidates may not be able to access the solid tumor, and even if they do, they may not be able to exert anti-tumor effects in a hostile tumor microenvironment. In addition, the safety profile of our product candidates may differ in a solid tumor setting. As a result, our product candidates may not demonstrate efficacy in solid tumors. If we are unable to make our product candidates function in solid tumors, our development plans, financial position, results of operations and prospects may be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have experienced, and may in the future experience delays, or difficulties in clinical trial site activations and the enrollment and/or retention of patients in clinical trials, which could delay or prevent our receipt of necessary regulatory approvals of our pipeline candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients. Patient enrollment, which is an important factor in the timing of clinical trials, is affected by many factors, including clinical trial site activation, the size and nature of the patient population and competition for patients eligible for our clinical trials with competitors which may have ongoing clinical trials for product candidates that are under development to treat the same indications as one or more of our product candidates, or approved products for the conditions for which we are developing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current clinical trials are fully enrolled, but future trials may be subject to delays as a result of patient enrollment taking longer than anticipated, and current and future trial timelines may be impacted by patient withdrawal. As a result of public health emergencies and resource constraints on CROs, prospective clinical trial sites and others, we may experience longer than expected lead times in clinical trial site activation and patient enrollment in future clinical trials. Furthermore, enrollment for future clinical trials may take longer than anticipated due to other monotherapies and combination therapies being investigated in the first-line setting at this time. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate, enroll and maintain a sufficient number of eligible patients to participate in these trials as required to adequately power our studies in order to draw meaningful conclusions from them or as may be required by the FDA, European Commission (based on recommendation from the EMA), or comparable foreign regulatory authorities. We cannot predict how successful we will be at enrolling subjects in future clinical trials. Subject enrollment is affected by other factors including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pace of clinical trial site activation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the severity and difficulty of diagnosing the disease under investigation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the eligibility and exclusion criteria for the trial in question; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the patient population and process for identifying patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the trial protocol; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the perceived risks and benefits of the product candidate in the trial, including relating to cell therapy approaches; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of competing commercially available therapies and other competing therapeutic candidates&#8217; clinical trials for the disease or condition under investigation, including for melanoma and other cancers in a first-line setting; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of patients to be enrolled in our clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient referral practices of physicians; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may also modify or enhance clinical trial requirements, which may affect enrollment and retention of patients. In August 2023, the FDA published a guidance document, &#8220;Informed Consent, Guidance for IRBs, Clinical Investigators, and Sponsors,&#8221; which supersedes past guidance and finalizes draft guidance on informed consent. The FDA&#8217;s new guidance presents evolving requirements for informed consent which may affect recruitment and retention of patients in clinical trials. Effects on recruitment and retention of patients may hinder or delay a clinical trial, which may increase costs and delay clinical programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. Furthermore, we expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and we will have limited influence over their performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, preliminary and &#8220;top-line&#8221; results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publish interim, preliminary and top-line results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as more patient data become available. Preliminary or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, preliminary and top-line data that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated, and should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The regulatory approval processes of the FDA, European Commission (based on recommendation from the EMA), and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for our product candidates, our business will be substantially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The time required to obtain approval or other marketing authorizations from the FDA, European Commission (based on recommendation from the EMA), and comparable foreign regulatory authorities is unpredictable, and it typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, and the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that we may never obtain regulatory approval for any product candidates we may seek to develop in the future. Neither we nor any current or future collaborator is permitted to market any drug product candidates in the United States until we receive regulatory approval of a BLA from the FDA, and we cannot market it in the EU until we receive a MA from the European Commission (based on recommendation from the EMA), or in the UK until we receive regulatory approval from the Medicines and Healthcare Products Regulatory Agency  or other required regulatory approval in other countries. To date, we have had only limited discussions with the FDA and EMA regarding clinical development programs or regulatory approval for any product candidate within the United States and EU, respectively. In addition, we have had no discussions with other comparable foreign authorities regarding clinical development programs or regulatory approval for any product candidate outside of those jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining approval to commercialize any drug product candidate in the United States or abroad, we must demonstrate with evidence from clinical trials, and to the satisfaction of the FDA, European Commission (based on recommendation from the EMA), or other foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA, the European Commission (based on recommendations from the EMA), and other comparable foreign regulatory authorities. The FDA or European Commission (based on recommendations from the EMA) may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or after approval, or it may object to elements of our clinical development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, EMA, or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials, or with our interpretation of clinical trial results; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA, EMA, or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA, European Commission (based on recommendation from the EMA), or comparable foreign regulatory authorities for approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, European Commission (based on recommendation from the EMA), or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval policies or regulations of the FDA, European Commission, EMA, or comparable foreign authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the large number of products in development, only a small percentage successfully complete FDA, European Union, or foreign regulatory approval processes and are commercialized. The lengthy approval and marketing authorization process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval and marketing authorization to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have invested a significant portion of our time and financial resources in the development of our clinical and preclinical product candidates. Our business is dependent on our ability to successfully complete preclinical and clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, IO112, IO170 and any future product candidates in a timely manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we eventually complete clinical testing and receive approval of a BLA or other comparable foreign marketing application for Cylembio, IO112, IO170 or any future product candidates, the FDA, European Commission (based on recommendation from the EMA) or other comparable foreign regulatory authorities may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-marketing clinical trials. The FDA, European Commission (based on recommendations from the EMA) or other comparable foreign regulatory authorities may also approve or authorize for marketing a product candidate for a more limited indication or patient population than we originally request, and the FDA, European Commission (based on recommendations from the EMA) or other comparable foreign regulatory authorities may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA, EMA, or other comparable foreign regulatory authorities and regulatory review committees described above may change their policies, issue additional regulations or revise existing regulations, or take other actions, including as a result of judicial challenges to regulatory policy, which may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our preclinical studies and clinical trials, including our Phase 3 clinical trial for Cylembio, may fail to sufficiently demonstrate the safety and efficacy of our product candidates, or may identify serious adverse or unacceptable side effects, which could prevent, delay or limit the scope of regulatory approval of our product candidates, limit their commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain the requisite regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe and effective for use in each target indication. These trials are expensive and time consuming, and their outcomes are inherently uncertain. Failures can occur at any time during the development process. Preclinical studies and clinical trials often fail to demonstrate safety or efficacy of the product candidate studied for the target indication, and most product candidates that begin clinical trials are never approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The data from our clinical trials, including our Phase 3 clinical trial for Cylembio, may fail to satisfy the FDA, European Commission (based on recommendation from the EMA), or comparable foreign regulatory authorities, that our product candidates, including Cylembio, are safe and effective for their intended uses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Possible adverse reactions and adverse side effects that could occur with immuno-oncology treatments can be severe. For example, we have reported to FDA some serious and unexpected suspected adverse reactions from the IOB-012 trial to FDA, which involved pulmonary tuberculosis, enterocolitis, hypovolemic shock, and diabetic ketoacidosis. As part of routine safety monitoring and pharmacovigilance evaluation on ongoing and planned trials, we continue to review data and perform additional assessments, depending on an evaluation of the available data, we may decide or be required to perform additional preclinical studies or to halt or delay further clinical development of our product candidates or to limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our clinical trials could also be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Even if this does not occur, reports of serious reactions could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidates are associated with side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses in which the side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. The FDA, comparable regulatory authorities, or an institutional review board  or ethics committee (which are local institutional boards or committees, as applicable, that review, approve and oversee basic and clinical research conducted by the institution participating in the clinical trial), or comparable foreign regulatory authorities, may also require that we suspend, discontinue, or limit our clinical trials based on safety information, or that we conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated. Such findings could further result in regulatory authorities failing to provide marketing authorization for our product candidates or limiting the scope of the approved indication, if approved. Many product candidates that initially showed promise in early stage testing have later been found to cause side effects that prevented further development of the product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">As an organization, we may be unable to complete clinical trials that satisfy requirements for approval for any product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to successfully complete clinical trials meeting requirements for approval of the FDA, European Commission (based on recommendations from the EMA), or comparable foreign regulatory authorities, known as pivotal trials, to market any of our product candidates. Conducting and successfully completing pivotal clinical trials is a complicated process. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to BLA submission and approval of Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, IO112, IO170 or future product candidates. In order to do so, we may need to expand our clinical development and regulatory capabilities, and we may be unable to recruit and train qualified personnel. We also expect to continue to rely on third parties to conduct our pivotal clinical trials. We also may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in commercializing our product candidates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Some data for product candidates comes from clinical trials conducted outside the United States, EU and the UK, and the FDA, European Commission (based on recommendation from the EMA), or comparable foreign regulatory authorities may not accept data from such trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that the patient population in the Phase 1/2 trial with IO102-IO103 in combination with an anti-PD-1 monoclonal antibody in 30 metastatic melanoma patients is representative of the population for which we intend to label Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the United States. However, the trial was conducted in Europe, our ongoing IOB-013/KN-D18, IOB-022/KN-D38 and IOB-032/PN-E40 trials include sites outside of the United States, and we may conduct additional trials in the future outside of the United States, Europe and the United Kingdom. The acceptance of data from clinical trials conducted outside the United States or another jurisdiction by the FDA may be subject to certain conditions, and such data may not be accepted at all. Similarly, the European Commission (based on recommendation from the EMA), and other equivalent foreign regulatory authorities may not accept data from trials conducted outside their jurisdiction. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (1) the data are applicable to the U.S. population and U.S. medical practice; (2) the trials were performed by clinical investigators of recognized competence and pursuant to good clinical practice (&#8220;GCP&#8221;)  regulations; and (3) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In general, the patient population for any clinical trials conducted outside the United States must be representative of the population for whom we intend to label the product candidate in the United States. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements for clinical trials. In addition, such trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. If the FDA, European Commission (based on recommendation from the EMA), or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Breakthrough therapy designation by the FDA for any product candidate may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that the product candidate will receive marketing approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO102-IO103 combined with an anti-PD-1 monoclonal antibody in first line metastatic melanoma patients has been granted BTD from the FDA. We may also, in the future, apply for BTD, or the equivalent thereof in foreign jurisdictions (where available), for our product candidates or programs. A breakthrough therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BTD is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for BTD, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate, including the breakthrough therapy designation of IO102-IO103 combined with an anti-PD-1 monoclonal antibody in first line metastatic melanoma patients, may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even after a product candidate qualifies as a breakthrough therapy, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA, the European Commission (based on recommendation from the EMA), or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, storage, advertising, promotion, import, export, recordkeeping, monitoring, and reporting for our product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with current Good Manufacturing Practice requirements (&#8220;cGMPs&#8221;) and GCP requirements for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may require a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revision to the labeling, including limitations on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a REMS, which may include distribution or use restrictions; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to conduct additional post-market clinical trials to assess the safety of the product; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters or other regulatory enforcement action; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, the EMA will require an equivalent risk management plan. The FDA&#8217;s, European Commission&#8217;s, EMA&#8217;s, and other comparable foreign regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We anticipate that our current product candidates and any future product candidates will be used in combination with third-party drugs or biologics, some of which are still in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs or biologics.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our T-win</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform targets both immune suppressive host and tumor cells in the TME initiating a dynamic process of activating the host immune system, which response can be further exploited by concurrent or subsequent therapies as checkpoint inhibitors such as the dominant PD-1 monoclonal antibodies, pembrolizumab and nivolumab. Accordingly, it is expected that our product candidates, if approved, would be used in combination with third-party drugs or biologics. For example, IO102-IO103 in combination with an anti-PD-1 monoclonal antibody was investigated in a Phase 1/2 trial in 30 metastatic melanoma patients at Herlev University Hospital of Copenhagen, and we are conducting a Phase 3 clinical trial, the IOB-013/KN-D18 trial, combining Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with pembrolizumab in first line advanced melanoma patients. Our ability to develop and ultimately commercialize our current product candidates and any future product candidates used in combination with pembrolizumab, nivolumab, or any other checkpoint inhibitor immunotherapies will depend on our ability to access such drugs or biologics on commercially reasonable terms for the clinical trials and their availability for use with the commercialized product, if approved. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs or biologics on commercially reasonable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any failure to maintain or enter into new successful commercial relationships, or the expense of purchasing checkpoint inhibitor immunotherapies or other comparator therapies in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our current product candidates and any future product candidates as commercially viable therapies. If any of these occur, our business, financial condition, results of operations, stock price and prospects may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the development of product candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates. We are currently developing Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, IO112 and IO170 and may develop other future product candidates for use in combination with checkpoint inhibitors and other therapies. The FDA, EMA, or comparable foreign regulatory authorities may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of such trials could show that any positive previous trial results are attributable to the combination therapy and not our current product candidates and any future product candidates. It is also possible that trial results for our product candidates may differ significantly if our product candidates are investigated with different combination therapies in different trials - for example, if we were to investigate our product candidates with one anti-PD-1 monoclonal antibody in one trial and a different anti-PD-1 monoclonal antibody in another. Moreover, following product approval, the FDA, EMA, or comparable foreign regulatory authorities may require that products used in conjunction with each other be cross labeled for combined use. To the extent that we do not have rights to the other product, this may require us to work with a third party to satisfy such a requirement. Moreover, developments related to the other product may impact our clinical trials for the combination as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the other product&#8217;s safety or efficacy profile, changes to the availability of the approved product, quality, manufacturing and supply issues, and changes to the standard of care.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that any of our collaborators or suppliers cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing such checkpoint inhibitor immunotherapies. Additionally, should the supply of products from any collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source an alternative supply, or are unable to do so on commercially reasonable terms, our business, financial condition, results of operations, stock price and prospects may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our discovery and development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we believe could be pursued using our platform technologies. As a result, we may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our success largely depends on the success of our limited number of product candidates. If any of these candidates fail in clinical trials or are not approved for commercialization, our ability to generate revenue and achieve profitability could be impacted.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to focus on the development and potential regulatory approval of our lead dual antigen Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We also expect to continue to develop our other product candidates, IO112 and IO170. A key part of our strategy, however, is to continue to pursue clinical development of additional product candidates utilizing our T-win</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform. Developing, obtaining marketing approval for, and commercializing any future product candidates will require substantial additional funding and will be subject to the risks of failure inherent in drug product development. We cannot assure you that we will be able to successfully advance any future product candidates through the development process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain approval from the FDA, European Commission (based on recommendation from the EMA) or comparable foreign regulatory authorities to market any future product candidates for the treatment of tumors, we cannot assure that any such product candidates will be successfully commercialized, widely accepted in the marketplace, or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates our commercial opportunity may be limited and our business, financial condition, results of operations, stock price and prospects may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Difficulty in enrolling patients or patient withdrawal could delay or prevent clinical trials of our current product candidates and any future product candidates. We may find it difficult to enroll patients in any future trials we may conduct and our receipt of necessary regulatory approvals could be delayed or prevented as a result. For example, we have historically experienced longer than expected lead times in clinical trial site activation and patient enrollment in our clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying and qualifying patients to participate in clinical studies of our current product candidates and any future product candidates is critical to our success. The timing of completion of our clinical trials depends in part on the speed at which we can recruit patients to participate in testing our current product candidates and any future product candidates, and we may experience delays in our clinical trials if we encounter difficulties in enrollment or patient retention due to other unforeseen factors. We may not be able to initiate or continue clinical trials for our current product candidates and any future product candidates if we are unable to locate and enroll and retain a sufficient number of eligible patients to participate in these trials as required by the FDA, EMA, or comparable foreign regulatory authorities outside the United States. For example, COVID-19 impacted our ability to initiate clinical sites and recruit, enroll and retain patients, or similar public health emergencies may divert healthcare resources away from clinical trials. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our current product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the competitive trial environment, the eligibility criteria of our planned clinical trials will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure to assure their cancer is either severe enough or not too advanced to include them in a study. Additionally, the process of finding patients may prove costly. We also may not be able to identify, recruit, enroll and retain a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidates under study, the availability and efficacy of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in or, once enrolled, continue with our studies for any reason, the timeline for conducting studies and obtaining regulatory approval of potential products may be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The enrollment and retention of patients further depends on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the patient population and process for identifying patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the eligibility criteria for the clinical trial in question; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of an appropriate screening test, as necessary; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the perceived risks and benefits of the product candidate under study; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the clinical trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patient consents; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reporting of the preliminary results of any of our clinical trials; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial completion. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our current product candidates and any future product candidates, and this competition may reduce the number and types of patients available to us because some patients who might have opted to enroll in our clinical trials may instead opt to enroll in a clinical trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which may reduce the number of patients who are available for our clinical trials at such clinical trial sites. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience delays in the completion of, or termination of, any clinical trial of our current product candidates and any future product candidates, the commercial prospects of our current product candidates and any future product candidates will be harmed, and our ability to generate product revenue from such product candidates could be delayed or prevented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future growth depends, in part, on our ability to penetrate multiple markets in which we would be subject to additional regulatory burdens and other risks and uncertainties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future profitability will depend, in part, on our ability to commercialize our product candidates, if approved, in markets in the United States, Europe, the United Kingdom, and other countries where we maintain commercialization rights. As we begin to commercialize our product candidates, if approved, in multiple markets, we are subject to additional risks and uncertainties, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency exchange rate fluctuations and currency controls; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular economies and markets; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potentially adverse and/or unexpected tax consequences, including penalties due to the failure of tax planning or due to the challenge by tax authorities on the basis of transfer pricing and liabilities imposed from inconsistent enforcement; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the burden of complying with complex and changing regulatory, tax, accounting and legal requirements, many of which vary between countries; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different medical practices and customs in multiple countries affecting acceptance of drugs in the marketplace; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tariffs, trade barriers, import or export licensing requirements or other restrictive actions; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is common; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced or loss of protection of intellectual property rights in some foreign countries, and related prevalence of generic alternatives to therapeutics; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">becoming subject to the different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other risks associated with international operations may adversely affect our ability to attain or maintain profitable operations. Future sales of our products or our product candidates, if they are approved, will be dependent on purchasing decisions of and reimbursement from government health administration authorities, distributors and other organizations. As a result of adverse conditions affecting the global economy and credit and financial markets, including disruptions due to political instability, geopolitical conflict or otherwise, these organizations may defer purchases, may be unable to satisfy their purchasing or reimbursement obligations, or may affect milestone payments or royalties for our products or any of our product candidates that are approved for commercialization in the future. Should any of these risks materialize, it could have a material adverse effect on our business, prospects, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Manufacturing and Commercialization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The manufacture of our product candidates is complex and we may encounter difficulties in production, particularly with respect to process development or scale-up of our manufacturing capabilities. If we encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have not manufactured Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or any of our other product candidates at a commercial scale, situations may occur with difficulties in production, particularly in scheduling capacity or quality deviations associated with product release. Problems may also occur with delays or break-downs in logistics and shipping, difficulties with production costs and yields, quality control, and product testing, operator error, lack of availability of qualified personnel, as well as failure to comply with strictly enforced federal, state and foreign regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, if contaminations are discovered in our supply of product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any of these or other issues relating to the manufacture of our product candidates will not occur in the future. Any delay or interruption in the supply of product could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing facilities also require commissioning and validation activities to demonstrate that they operate as designed, and are subject to government inspections by the FDA, EU Member States (coordinated by the EMA) and other comparable foreign regulatory authorities. If we are unable to reliably produce products to specifications acceptable to the regulatory authorities, we may not obtain or maintain the approvals we need to manufacture our products. Furthermore, manufacturing facilities may fail to pass government inspections prior to or after the commercial launch of our product candidates, which would cause significant delays and additional costs required to remediate any deficiencies identified by the regulatory authorities. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in product candidate manufacturing or formulation may result in additional costs or delay.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As product candidates are developed through preclinical studies to later-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are optimized along the way to support continuous improvement. Such changes may also require additional testing, or notification to, or approval by the FDA, EMA, or a comparable foreign regulatory authority. This could delay completion of clinical trials, require the conduct of bridging clinical trials or studies, require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our current product candidates and any future product candidates and/or jeopardize our ability to commence product sales and generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain marketing approvals from the FDA, European Commission (based on recommendation from the EMA), or other comparable foreign regulatory agencies and are able to initiate commercialization of our clinical-stage product candidates or any other product candidates we develop, the product candidate may not achieve market acceptance among physicians, patients, hospitals, including pharmacy directors, cancer treatment centers, and third-party payors and, ultimately, may not be commercially successful. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which our product candidates are approved; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">physicians, hospitals, cancer treatment centers, and patients considering our product candidates as a safe and effective treatment; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential and perceived advantages of our product candidates over alternative treatments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product labeling or product insert requirements of the FDA, European Commission, EMA, or other comparable foreign regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations or warnings contained in the labeling approved by the FDA, European Commission, EMA, or other comparable foreign regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of our product candidates as well as competitive products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of treatment in relation to alternative treatments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount of upfront costs or training required for physicians to administer our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage from, adequate reimbursement from, and our ability to negotiate pricing with, third-party payors and government authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of comprehensive coverage and reimbursement by third-party payors and government authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative convenience, ease of product preparation and ease of administration, including as compared to alternative treatments and competitive therapies; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our sales and marketing efforts, market access and distribution support. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our product candidates, if approved, may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our product candidates. Because we expect sales of our product candidates, if approved, to generate substantially all of our product revenue for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing. Even if our product candidates, if approved, achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to successfully commercialize our product candidates, if approved, due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process, with uncertain results, that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may not be available, or may be more limited than the purposes for which the product is approved by the FDA or other comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, by any future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, there is no uniform policy among third-party payors for coverage and reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Therefore, one third-party payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a covered benefit under its health plan; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safe, effective and medically necessary; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">appropriate for the specific patient; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cost-effective; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neither experimental nor investigational. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be sure that reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reimbursement may impact the demand for, and the price of, any product for which we obtain marketing approval. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement are critical to a new product&#8217;s acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), the federal agency responsible for administering the Medicare program, revises the reimbursement amounts paid to health care providers, including the Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment System, which may result in reduced Medicare payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional policy and legislative changes. The downward pressure on healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the successful commercialization of new products. Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, on May 12, 2025, President Trump issued an Executive Order directing federal agencies including the Department of Health and Human Services (&#8220;HHS&#8221;) to pursue a &#8220;most-favored-nation&#8221; (&#8220;MFN&#8221;) pricing policy for certain prescription drugs, which would tie prices paid by Medicare to the lowest price available in certain other developed countries. The scope, timing, and implementation details of the MFN policy remain uncertain and may be subject to legal challenges, regulatory rulemaking, and changes in administrative priorities. If implemented, this policy could have a material impact on the pricing and reimbursement of our products in the United States, particularly those covered under Medicare Part B or Part D. Potential effects include reduced pricing flexibility, downward pressure on reimbursement rates, and changes to market access dynamics. The MFN policy could also influence pricing negotiations with commercial payors and international markets. Because the outcome, timing, and specifics of this policy are uncertain, we cannot predict its ultimate effect on our business, financial condition, results of operations, or prospects, but the impact could be material and adverse.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside of the United States, many countries require approval of the sale price of a product before it can be marketed, and the pricing review period only begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some of these countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if such product candidates obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reimbursement and healthcare payment systems vary significantly by country outside the United States, and many countries have instituted price ceilings on specific products and therapies. In the EU and the United Kingdom, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU, United Kingdom or at an EU Member State level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU Member States and the United Kingdom have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products in these countries, these restrictions on pricing and reimbursement could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the EU, United Kingdom or any other jurisdiction. If we, or any third parties we may engage, are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the regulatory authorities in such jurisdictions set prices or make reimbursement criteria that are not commercially attractive for us or our collaborators, our revenues and the potential profitability of our products in those countries would be negatively affected.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the market opportunities for any of our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are focused on the development of treatments for cancer. Our projections of addressable patient populations that have the potential to benefit from treatment with our product candidates are based on estimates, including estimated incidence rates of specific forms of cancer. If any of our estimates are inaccurate, the market opportunities for any of our product candidates could be significantly diminished and have an adverse and material impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no sales, marketing or distribution capabilities or experience. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. Factors that may inhibit our efforts to commercialize future products on our own include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability of sales personnel to compliantly obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing any future products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product portfolios; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of the product revenue to us are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or devote the necessary resources and attention to sell and market any future products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If granted, regulatory approval by the FDA, European Commission (based on recommendations from the EMA) or comparable foreign regulatory authorities is limited to those specific indications and conditions for which approval has been granted, and we may be subject to substantial fines, criminal penalties, injunctions, or other enforcement actions if we are determined to be promoting the use of our products for unapproved or off-label uses, or in a manner inconsistent with the approved labeling, resulting in damage to our reputation and business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We must comply with requirements concerning advertising and promotion for any product candidates for which we obtain marketing approval. Promotional communications with respect to therapeutics are subject to a variety of legal and regulatory restrictions and continuing review by the FDA, Department of Justice, HHS Office of Inspector General, state attorneys general, and members of Congress or comparable foreign regulatory and governmental authorities or bodies, as well as the public. When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the regulatory approval is limited to those specific uses and indications for which the product has been approved. If we are not able to obtain FDA or comparable foreign regulatory authority approval for desired uses or indications for our current product candidates and any future product candidates, we may not market or promote them for those indications and uses, referred to as off-label uses, and our business, financial condition, results of operations, stock price and prospects will be materially harmed. We also must sufficiently substantiate any claims that we make for our products, including claims comparing our products to other companies&#8217; products, and must abide by the FDA or a comparable foreign regulatory or governmental authority&#8217;s strict requirements regarding the content of promotion and advertising.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While physicians may choose to prescribe products for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, we and any third parties engaged on our behalf are prohibited from marketing and promoting the products for indications and uses that are not specifically approved by the FDA or comparable foreign regulatory authorities. Regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians in their choice of treatment within the practice of medicine. Regulatory authorities do, however, restrict communications by biopharmaceutical companies concerning off-label uses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are found to have impermissibly promoted any of our current product candidates and any future product candidates, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations regarding product promotion, particularly those prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted a product may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, engaging in the impermissible promotion of our products, following approval, for off-label uses can also subject us to false claims and other litigation under federal and state statutes. These include fraud and abuse and consumer protection laws, which can lead to civil and criminal penalties and fines, and agreements with governmental authorities that materially restrict the manner in which we promote or distribute therapeutic products and conduct our business. These restrictions could include corporate integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, and suspension and debarment from government contracts and refusal of orders under existing government contracts. These False Claims Act (&#8220;FCA&#8221;) lawsuits against manufacturers of drugs and biologics have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements pertaining to certain sales practices and promoting off-label uses. In addition, FCA lawsuits may expose manufacturers to follow-on claims by private payors based on fraudulent marketing practices. This growth in litigation has increased the risk that a biopharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state healthcare programs. If we do not lawfully promote our approved products, if any, we may become subject to such litigation and, if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the promotion of biopharmaceutical products are subject to additional FDA requirements and restrictions on promotional statements. If after one or more of our current or future product candidates obtains marketing approval the FDA determines that our promotional activities violate its regulations and policies pertaining to product promotion, it could request that we modify our promotional materials or subject us to regulatory or other enforcement actions, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, requests for recalls, payment of civil fines, disgorgement of money, imposition of operating restrictions, injunctions or criminal prosecution, and other enforcement actions. Similarly, industry codes in foreign jurisdictions may prohibit companies from engaging in certain promotional activities and regulatory agencies in various countries may enforce violations of such codes with civil penalties. If we become subject to regulatory and enforcement actions our business, financial condition, results of operations, stock price and prospects will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the use of our products for indications other than those approved by the FDA or comparable foreign regulatory authorities may not effectively treat such conditions. Any such off-label use of our product candidates could harm our reputation in the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use our products for these uses for which they are not approved, which could lead to product liability suits that that might require significant financial and management resources and that could harm our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain FDA or European Commission (based on recommendations from the EMA) approval of any of our product candidates in the United States or EU, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval by the FDA in the United States or the European Commission (based on recommendations from the EMA) in the EU does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in any markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Reliance on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Some of our product candidates may be studied in clinical trials sponsored by organizations or agencies other than us, or in investigator-initiated clinical trials, which means we will have minimal or no control over the conduct of such trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have supplied and may continue to supply and otherwise support third party research, including investigator-initiated clinical trials. Investigator-initiated clinical trials pose similar risks as those set forth elsewhere in this &#8220;Risk Factor&#8221; section relating to our internally-sponsored clinical trials, but because we may not be the sponsors of these trials, we have less control over the protocols, administration or conduct of these trials, including follow-up with patients and ongoing collection of data after treatment. The conduct or findings of these trials may have a negative impact on our development programs notwithstanding that we have little involvement or control over these trials. As a result, we are subject to additional risks associated with the way investigator-initiated trials are conducted. In particular, we may be named in lawsuits that would lead to increased costs associated with legal defense. Additional risks include difficulties or delays in communicating with investigators or administrators, procedural delays and other timing issues and difficulties or differences in interpreting data. Third-party investigators may design clinical trials with clinical endpoints that are more difficult to achieve, or in other ways that increase the risk of negative clinical trial results compared to clinical trials that we may design on our own. Negative results in investigator-initiated clinical trials could have a material adverse effect on our efforts to obtain regulatory approval for our product candidates and the public perception of our product candidates. As a result, our lack of control over the conduct and timing of and communications with the FDA and other regulatory authorities regarding investigator-sponsored trials may expose us to additional risks and uncertainties, many of which are outside our control, and the occurrence of which could adversely affect the commercial prospects for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct, supervise, and monitor our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs which may have an adverse effect on our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we are and expect to remain dependent on third parties to conduct our current and future preclinical studies and clinical trials. CROs that manage our preclinical studies and clinical trials as well as clinical investigators, including in investigator-initiated clinical trials, and consultants play a significant role in the conduct of our preclinical studies and clinical trials and the subsequent collection and analysis of data. The timing of the initiation and completion of these studies and trials will therefore be partially controlled by such third parties and may result in delays to our development programs. Nevertheless, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal requirements, and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with Good Laboratory Practice (&#8220;GLP&#8221;) and GCP requirements, which are regulations and guidelines enforced by the FDA, the EMA, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GLP and GCP requirements through periodic inspections of preclinical study sites, trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites, including clinical trial sites in investigator-initiated clinical trials, fail to comply with applicable GLP or GCP requirements, the data generated in our preclinical studies and clinical trials may be deemed unreliable, and the FDA, EMA, or comparable foreign regulatory authorities may require us to perform additional preclinical or clinical trials before approving our marketing applications. Further, requirements regarding clinical trial data may evolve. In June 2023, the FDA published a draft guidance, &#8220;E6(R3) Good Clinical Practice,&#8221; which seeks to unify standards for clinical trial data for ICH member countries and regions. Changes to data requirements may cause the FDA or other foreign regulatory authorities to disagree with data from preclinical studies or clinical trials, and may require further studies. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no guarantee that any CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. If any of these third parties fails to meet expected deadlines, fails to adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trials unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trials or investigator-initiated clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or any comparable foreign regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit by the FDA or any comparable foreign regulatory authority. Any such delay or rejection could prevent us from commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may be unable to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and may be unable to, or may be delayed in our efforts to, successfully commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to manufacture our product candidates, and we expect to continue to rely on third parties for the clinical as well as any future commercial supply of our lead product candidate and other future product candidates. The development of our current and future product candidates, and the commercialization of any approved products, could be stopped, delayed or made less profitable if any such third party fails to provide us with sufficient clinical or commercial quantities of such product candidates or products, fails to do so at acceptable quality levels or prices or fails to achieve or maintain satisfactory regulatory compliance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently have, and we do not plan to build, the infrastructure or capability internally to manufacture current product candidates or any future product candidates for use in the conduct of our clinical trials or, if approved, for commercial supply. We rely on, and expect to continue to rely on, CMOs. Reliance on third-party providers may expose us to more risk than if we were to manufacture our product candidates ourselves. We do not control the manufacturing processes of the CMOs we contract with and are dependent on those third parties for the production of our product candidates in accordance with relevant applicable regulations such as cGMP, which includes, among other things, quality control, quality assurance and the maintenance of records and documentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In complying with the manufacturing regulations of the FDA and other comparable foreign regulatory authorities, we and our third-party suppliers must spend significant time, money and effort in the areas of design and development, testing, production, record-keeping and quality control to assure that the products meet applicable specifications and other regulatory requirements. The failure to comply with these requirements could result in an enforcement action against us, including the seizure of products and shutting down of production. We and any of these third-party suppliers may also be subject to inspections by the FDA, EU Member States (coordinated by the EMA), or comparable foreign regulatory authorities. If any of our third-party suppliers fails to comply with cGMP or other applicable manufacturing regulations, our ability to develop and commercialize our product candidates could suffer significant interruptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any disruption, such as a fire, natural hazards, natural disasters, public health emergencies or vandalism at our CMOs, could significantly interrupt our manufacturing capability. We currently do not have alternative production plans in place or disaster-recovery facilities available. In case of a disruption, we will have to establish alternative manufacturing sources. This would require substantial capital on our part, which we may not be able to obtain on commercially acceptable terms or at all. Additionally, we would likely experience months of manufacturing delays as we build facilities or locate alternative suppliers and seek and obtain necessary regulatory approvals. If this occurs, we may be unable to satisfy manufacturing needs on a timely basis, if at all. If changes to CMOs occur, then there also may be changes to manufacturing processes inherent in the setup of new operations for our product candidates and any products that may obtain approval in the future. Any such changes could require the conduct of bridging studies before we can use any materials produced at new facilities or under new processes in clinical trials or, for any products reaching approval, in our commercial supply. Further, business interruption insurance may not adequately compensate us for any losses that may occur and, in that case, we would have to bear the additional cost of any disruption. For these reasons, a significant disruptive event of any CMOs could have drastic consequences, including placing our financial stability at risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates and any drugs that we may develop may compete with other product candidates and drugs for access to manufacturing facilities. We may not be able to enter into similar commercial arrangements with other manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we were to experience an unexpected loss of supply of or if any supplier were unable to meet our clinical or commercial demand for any of our product candidates, we could experience delays in our planned clinical studies or commercialization. For example, future public health emergencies may impact our ability to procure sufficient supplies for the development of our current and future product candidates, and the extent of such impacts will depend on the severity and duration of and the actions undertaken to contain such public health crisis or treat its effects. We could be unable to find alternative suppliers of acceptable quality and experience that can produce and supply appropriate volumes at an acceptable cost or on favorable terms. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods necessary to switch manufacturers and suppliers, if necessary, could significantly delay our clinical trials and, for any product candidates that reach approval, the commercialization of our products, which would materially adversely affect our business, financial condition and results of operation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on third-party suppliers for materials that are necessary for the conduct of preclinical studies and manufacture of our product candidates for clinical trials and potential commercial supply, and the loss of these third-party suppliers or their inability to supply us with sufficient quantities of adequate materials, or to do so at acceptable quality levels and on a timely basis, could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing and supply of our product candidates require many specialty materials and equipment, including excipients, ancillary components and reagents, which are substances used in our manufacturing processes to bring about chemical or biological reactions, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. We currently depend on a limited number of vendors for certain materials and equipment used in the manufacture and supply of our product candidates. Our use of CMOs increases the risk of delays in production or insufficient supplies as we transfer our manufacturing technology to these CMOs and as they gain experience with our supply requirements. Some of these suppliers may not have the capacity to support clinical trials and commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also do not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key materials and equipment to support clinical or commercial manufacturing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For some of these reagents, equipment, and materials, we rely and may in the future rely on sole source vendors or a limited number of vendors. The supply of the reagents and other specialty materials and equipment that are necessary to produce our product candidates could be reduced or interrupted at any time. In such case, identifying and engaging an alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers on acceptable terms, or at all. Switching suppliers or manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we may not be able to develop, manufacture and market our product candidates in a timely and competitive manner, or at all. An inability to continue to source product from any of these suppliers, which could be due to a number of issues, including regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we continue to develop and scale our manufacturing process, we expect that we will need to obtain rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to obtain rights to such materials on commercially reasonable terms, or at all. If we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business. Even if we are able to alter our process so as to use other materials or equipment, such a change may lead to a delay in our clinical development and/or commercialization plans. If such a change occurs for a product candidate that is already in clinical testing, the change may require us to perform both ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. These factors could cause the delay of studies or trials, regulatory submissions, required approvals or commercialization of product candidates that we develop, cause us to incur higher costs and prevent us from commercializing our product candidates successfully.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our reliance on third parties requires us to share certain of our trade secrets, which increases the possibility that a competitor will discover them or that such trade secrets will be misappropriated or disclosed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we rely on third parties to research and develop and to manufacture our product candidates, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s independent discovery of our trade secrets or other unauthorized use or disclosure could impair our competitive position and may have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with will likely expect to be granted rights to publish data arising out of such collaboration and any joint research and development programs may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets could impair our competitive position and have an adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may form or seek partnerships, collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such partnerships, collaborations, alliances or licensing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may form or seek partnerships or strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. For example, we have entered into collaborative agreements with Merck pursuant to which they provide the pembrolizumab used in certain of our trials. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, share the data with such collaborators, restrict our ability to utilize certain data arising out of these collaboration arrangements, issue securities that dilute our existing stockholders or take actions that disrupt our management and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy and obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, collaborations involving our product candidates are subject to numerous risks, which may include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization of our product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes, including contract disputes, may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, if we enter into additional collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Industry and Business Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA, EMA, SEC and other government agencies and regulatory authorities caused by policy changes, funding shortages, personnel layoffs and departures or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed, commercialized or approved in a timely manner or at all, or otherwise prevent those agencies from performing normal governmental functions on which the operation of our business may rely, which could negatively impact our business and stock price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability and willingness of the FDA, European Commission (based on recommendation from the EMA), and other comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including leadership, statutory, regulatory, and policy changes, government budget and funding levels, the departure of key personnel, including departures in response to recent federal worker buyout offers and layoffs, and the ability to hire and retain key personnel and accept the payment of user fees. Average review times at regulatory authorities and government agencies have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions and leadership changes at the FDA, and resulting staff and policy changes, including vaccine skepticism in the current U.S. administration, may also slow review or prevent approval of new products in the U.S., which would adversely affect our business and stock price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs in the future, it could significantly impact the ability of the FDA to review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If these disruptions were to impact regular inspections, reviews, or other regulatory activities of the FDA or other regulatory authorities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business and stock price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be exposed to significant foreign exchange risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have operations in Denmark and we incur portions of our expenses, and may in the future derive revenues, in a variety of currencies. As a result, we are exposed to foreign currency exchange risk as our results of operations and cash flows are subject to fluctuations in foreign currency exchange rates. Fluctuations in currency exchange rates have had, and will continue to have, an impact on our results as expressed in U.S. dollars. We currently do not engage in hedging transactions to protect against uncertainty in future exchange rates between particular foreign currencies and the U.S. dollar. We cannot predict the impact of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our financial condition, results of operations and cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tariffs and trade restrictions may impact our supply chain and result in higher costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in U.S. and foreign trade policy, including the imposition of tariffs, import restrictions, or other trade barriers may result in higher costs, supply chain disruptions, or delays in obtaining critical materials. If such measures are implemented, we may need to identify alternative suppliers, renegotiate supply agreements, or absorb increased costs, any of which could adversely affect our business, financial condition, and ability to manufacture, develop or commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and other comparable foreign regulatory authorities, provide accurate information to the FDA and other comparable foreign regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States, EU, United Kingdom and in other jurisdictions, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment of our business reputation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs due to related litigation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">distraction of management&#8217;s attention from our primary business; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to patients or other claimants; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize our product candidates; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for our product candidates, if approved for commercial sale. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our product liability insurance coverage is sufficient in light of our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claims or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients with cancer and other diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to, or perceived to be related to, our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may divide the attention of our management team, interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to retain key members of senior management and to attract, retain and motivate qualified personnel.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to compete in the highly competitive biopharmaceutical industry depends upon our ability to attract and retain highly qualified management, research and development, clinical, financial and business development personnel. We are highly dependent on our management, scientific and medical personnel, including Mai Britt Zocca, Ph.D., our Chief Executive Officer, Amy Sullivan, M.B.A., our Chief Financial Officer and Qasim Ahmad, M.D., our Chief Medical Officer. Our senior management may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of members of our senior management or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing members of our senior management and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers, as well as junior, mid-level and senior scientific and medical personnel. Competition to hire from this limited candidate pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to expand our clinical development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025 we had 78 full-time employees. As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical product development, regulatory affairs, manufacturing and, if any of our product candidates receives marketing approval, compliance, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We would expect to experience significant growth in the number of our employees and the scope of our operations, particularly in activities related to commercialization, including marketing, sales, market access, pricing and data analytics, regulatory, medical affairs, manufacturing and general and administrative functions, if any of our product candidates receives marketing approval and are commercialized by us. To manage any such future growth, we would need to continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Any future growth would impose significant added responsibilities on members of management, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying, recruiting, training, integrating, retaining and motivating additional employees;  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing our internal development efforts effectively, including the clinical and FDA review process for Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, IO112, IO170 and any product candidate we develop, while complying with our contractual obligations to contractors and other third parties, including our partners and collaborators; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">improving our managerial, operational and financial controls, reporting systems and procedures.  </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future financial performance and our ability to advance the development of and, if approved, commercialize Cylembio, IO112, IO170 and any other product candidate we develop will depend, in part, on our ability to effectively manage any future growth. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">As we evolve from a company that is primarily involved in clinical development to a company that is also involved in commercialization, we may need to engage third parties to provide such capabilities, which may impose added oversight responsibilities on management, may result in less control over personnel conducting related activities, and may not be on favorable terms.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we have been advancing Cylembio through clinical trials, we have been expanding our development, regulatory, manufacturing, and commercialization capabilities and may need to further contract with third parties to provide these capabilities. As our operations expand, we likely will need to manage additional relationships with such third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintaining third party relationships for these purposes will impose significant added oversight responsibilities on members of our management and other personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we enter into arrangements with third parties to perform sales, marketing or distribution services, any product revenues that we receive, or the profitability of these product revenues to us, are likely to be lower than if we were to market and sell any products that we develop without the involvement of these third parties. In addition, we may not be successful in entering into arrangements with third parties to sell and market our products or in doing so on terms that are favorable to us. We likely will have less control over such third parties than we would over employees performing such functions, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than we do.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and commercialization of new products is highly competitive. We expect to compete in the segments of the pharmaceutical, biotechnology and other related markets that pursue oncology treatments. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain regulatory approval from the FDA or other comparable foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, if ever, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. Moreover, with the proliferation of new drugs and therapies into oncology, we expect to face increasingly intense competition as new technologies become available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could render our product candidates or our technology obsolete, less competitive or uneconomical.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other products in a similar class as some of our product candidates have already been approved and other products in the same class are further along in development. As more product candidates within a particular class of biopharmaceutical products proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Consequently, the results of our clinical trials for product candidates in those classes will likely need to show a risk benefit profile that is competitive with or more favorable than those products and product candidates in order to obtain marketing approval or, if approved, a product label that is favorable for commercialization. If the risk benefit profile is not competitive with those products or product candidates, we may have developed a product that is not commercially viable, that we are not able to sell profitably or that is unable to achieve favorable pricing or reimbursement. In such circumstances, our future product revenue and financial condition would be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, there are many companies that have commercialized or are developing immuno-oncology treatments for cancer including large pharmaceutical and biotechnology companies such as Amgen, AstraZeneca, BMS, Merck, Novartis, Pfizer, Moderna, Regeneron, Roche, and Roche's subsidiary Genentech, Iovance and Shenzhen.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In first-line unresectable or metastatic melanoma specifically, the dominant market players are nivolumab, marketed by BMS and Ono Pharmaceutical Co., Ltd. (&#8220;Ono&#8221;), combination of nivolumab &amp; ipilimumab, marketed by BMS and Ono, combination of nivolumab and relatlimab (LAG-3 blocking antibody) marketed by BMS and pembrolizumab, marketed by Merck. The FDA also recently approved lifileucel (Amtagvi), a second-line treatment for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, marketed by Iovance. We are also aware of several companies testing their compounds in combination with nivolumab or pembrolizumab. In mid-stage development there is Moderna and Merck with an investigational personalized mRNA cancer vaccine, in combination with pembrolizumab and Regeneron is testing their anti-LAG3, fianlimab, in combination with their anti-PD-1, cemiplimab, in first-line melanoma. In earlier stage development there are also BioNTech with NEO-PV-01, Karyopharm with selinexor and Shenzen and HuyaBio International (&#8220;Huya&#8221;) testing tucidinostat in combination with nivolumab in first-line melanoma.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors will also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or that maybe necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety, and convenience. If we are not successful in developing, commercializing and achieving higher levels of reimbursement than our competitors, we will not be able to compete against them and our business would be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The tax authorities in the jurisdictions in which we operate may challenge our transfer pricing procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a multinational business that operates in Denmark and other tax jurisdictions, and the tax laws of those jurisdictions generally require that royalty and other payments between affiliated companies in different jurisdictions be the same as those between unrelated companies dealing at arm&#8217;s length, and that such prices are supported by contemporaneous documentation. We believe that we operate in compliance with applicable transfer pricing laws and intend to continue to do so, but our transfer pricing procedures are not binding on applicable tax authorities. If tax authorities in any of these jurisdictions were to successfully challenge our transfer prices as not reflecting arm&#8217;s length transactions, they could require us to adjust our transfer prices and thereby reallocate our income or deductions to reflect these revised transfer prices, which could result in a higher overall tax liability to us and possibly interest and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, tax authorities in the jurisdictions in which we operate may challenge our treatment of our corporate reorganization. No assets (either physical or intangible) were transferred from Denmark to the U.S. pursuant to our corporate reorganization, nor were any existing business functions or units operating from Denmark transferred from IO Biotech ApS to IO Biotech, Inc. as part of the corporate reorganization to form part of our U.S. operations. Accordingly, we did not intend to treat the corporate reorganization as a deemed sale of all or part of our business by IO Biotech ApS to IO Biotech, Inc. If Danish tax authorities were to disagree with our position and treat the corporate reorganization or any of our activities thereafter as a deemed sale, in whole or in part, of intellectual property rights and/or other assets owned by IO Biotech ApS to IO Biotech, Inc., we could be subject to a Danish tax, the current rate of which is 22%, on the gain realized calculated as the difference between the fair market value and the tax value of the assets, at the time of the deemed sale of the assets from Denmark as determined by the Danish tax authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, the nature of our operations can produce conflicting claims from tax authorities in different countries as to the profits to be taxed in the individual countries. The jurisdictions in which we operate have double tax treaties with other jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains. However, mechanisms developed to resolve such conflicting claims are largely untested, can be expected to be very lengthy, and do not always contain a mandatory dispute resolution clause. In recent years, tax authorities around the world have increased their scrutiny of company tax filings, and have become more rigid in exercising any discretion they may have.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, tax reform efforts, including with respect to transfer pricing, will require us to continually assess our organizational structure and could lead to an increased risk of international tax disputes, an increase in our effective tax rate and an adverse effect on our financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have net operating losses to be carried forward, which may become devalued if we do not generate sufficient future taxable income, applicable corporate tax rates are reduced or if we experience an ownership change.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have material gross deferred tax assets relating to IO Biotech ApS, IO Bio US, Inc. and IO Biotech, Inc., respectively. Our anticipated activities are also expected to result in future significant net operating losses in Denmark resulting in additional deferred tax assets. Utilization of most deferred tax assets is dependent on generating sufficient future taxable income in the appropriate jurisdiction and/or entity. The Company has provided a full valuation allowance on our net deferred tax assets in IO Biotech ApS, IO Bio US, Inc. and IO Biotech, Inc., respectively, as of June 30, 2025. Based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. Additionally, most of our deferred tax assets are determined by reference to applicable corporate income tax rates in Denmark and the United States. Accordingly, in the event of a reduction of any such corporate income tax rates, the carrying value of certain of our deferred tax assets would decrease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, our ability to use our net operating losses and other deferred tax assets to offset future taxable income in Denmark and the U.S. may be limited if we experience an ownership change. We may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside the Company&#8217;s control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For Danish income tax purposes, an ownership change will generally occur when one, or several shareholders together, at once or successively, acquire shares representing more than 50 percent of the share capital or voting power. Such an ownership change entails no reduction of the amount of net operating losses to be carried forward, but the utilization is restricted to exclude offsetting against positive net capital income (e.g. income from interest, dividend and royalty) on net operating losses incurred in a previous income year, where the ownership differs by 50 percent (under section 12D of the Danish Corporate Tax Act). The restriction may limit future offsetting against net operating profits, when the ownership change is due to the listing on an exchange.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For U.S. federal income tax purposes, an ownership change will generally occur when the percentage of our stock (by value) owned by one or more &#8220;5% shareholders&#8221; (as defined in the U.S. Internal Revenue Code of 1986, as amended) has increased by more than 50% over the lowest percentage owned by such shareholders at any time during the prior three years (calculated on a rolling basis). If we were to incur losses in the United States in the future, our ability to realize a tax benefit from these losses would be limited. Due to potential ownership changes under Section 382 of the Code, we may be limited in our ability to realize a tax benefit from the use of such losses, whether or not we attain profitability in future years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our ability to utilize any future net operating losses may be limited by Pub. L. 115-97, enacted in 2017 and commonly known as the Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to current taxation on some of the income of our foreign subsidiaries even absent any cash distributions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we hold directly or indirectly all of the shares of our foreign subsidiaries, including IO Biotech ApS and IO Biotech Limited, such subsidiaries are treated as controlled foreign corporations (&#8220;CFC&#8221;) for U.S. federal income tax purposes. For U.S. federal income tax purposes, IO Biotech, Inc. will therefore need to include in its taxable income each year its &#8220;global intangible low-taxed income&#8221; and IO Biotech ApS&#8217;s and IO Biotech Limited&#8217;s &#8220;subpart F income,&#8221; if any, even if no distributions are made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our foreign subsidiaries may directly become subject to U.S. federal income tax and be subject to a branch profits tax in the United States, which could reduce our after-tax returns and the value of our shares.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently intend to conduct substantially all of our businesses and operations in a manner such that our foreign subsidiaries will not be treated as engaged in a trade or business in the United States and will not be subject to additional U.S. income tax or branch profits tax. However, it is not entirely clear when a foreign subsidiary is treated as being engaged in a trade or business in the United States for U.S. federal income tax purposes. Accordingly, we cannot assure you that the Internal Revenue Service (&#8220;IRS&#8221;) will not contend, perhaps successfully, that our foreign subsidiaries were engaged in a trade or business in the United States or are subject to more U.S. income tax than they currently incur. A foreign corporation deemed to be so engaged would be subject to U.S. federal income tax on its income that is treated as effectively connected with the conduct of that trade or business, as well as to branch profits tax on its &#8220;dividend equivalent amount,&#8221; unless the corporation is entitled to relief under an applicable tax treaty, which is determined on an annual basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. We do not currently have any products on the market, but our operations and current and future arrangements with investigators, healthcare professionals, customers and third-party payors, may be subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal civil and criminal false claims laws and the Physician Payments Sunshine Act and regulations. These laws may impact, among other things, our current business operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers and other parties through which we may market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business.  See Part I, Item 1, &#8220;Government Regulations &#8211; Other Regulatory Matters &#8211; Other Healthcare Laws&#8221; of our Annual Report on our Form 10-K for the year ended December 31, 2024, for additional details.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including certain arrangements with physicians who receive stock, warrants or stock options as compensation for services provided to us, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the delay, reduction, termination or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our current product candidates and any future product candidates, restrict or regulate post-approval activities and affect our ability</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to profitably sell a product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (1) changes to our manufacturing arrangements; (2) additions or modifications to product labeling; (3) the recall or discontinuation of our products; or (4) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Affordable Care Act (the &#8220;ACA&#8221;) was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjected biological products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations, and established annual fees and taxes on manufacturers of certain branded prescription drugs and biologics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA.  Additionally, there continue to be other legislative and administrative efforts to reform the healthcare system, including those addressing drug pricing.  For example, the Inflation Reduction Act (the &#8220;IRA&#8221;), which was passed in 2022, imposes inflation rebates on drug manufacturers for products reimbursed under Medicare Parts B and D if the prices of those products increase faster than inflation; and, beginning in 2026, the IRA establishes a &#8220;maximum fair price&#8221; for a fixed number of high expenditures pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation process with CMS.  Similar efforts to control pharmaceutical and biological product pricing are also taking place at the state level. See Part I, Item 1, &#8220;Government Regulation &#8211; Healthcare Reform&#8221; of our Annual Report on our Form 10-K for the year ended December 31, 2024, for additional details.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that the ACA, IRA, new laws, and other federal and state healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates, if approved. We cannot predict the initiatives that may be adopted in the future. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Upcoming changes in the pharmaceutical product legislation in certain jurisdictions may have an adverse effect on the data and market exclusivity available for our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EU Pharma Law Review initiated by the European Commission on April 6, 2023 could have a significant impact on the Regulatory Data Protection (&#8220;RDP&#8221;) available for innovative medicinal products in the EU. If adopted as proposed by the European Commission, the EU Pharma Law Proposal would reduce the current baseline for data exclusivity from eight to six years, extendable under certain conditions.  Such RDP reduction could lead to faster access to the EU market for generics and biosimilars.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EU Pharma Law Proposal also proposes changes to the current orphan market exclusivity approach.  If adopted as proposed by the European Commission, the EU Pharma Law Proposal would in most cases reduce the current duration of orphan market exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to a variety of privacy and data security laws, and our failure to comply with them could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a large quantity of sensitive information, including confidential business and personal information in connection with the conduct of our clinical trials and related to our employees, and we are subject to laws and regulations governing the privacy and security of such information. In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws, and federal and state consumer protection laws. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues, including with respect to regulatory enforcement and private litigation, which may affect our business and is expected to increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and regulations could apply to our operations or the operations of our partners, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that may be subject to privacy and security requirements under HIPAA, as amended by HITECH and regulations promulgated thereunder. Depending on the facts and circumstances, we could be subject to significant penalties if we obtain, use, or disclose, or are subject to an actual or alleged data breach regarding, individually identifiable health information in a manner that is not authorized or permitted by HIPAA. In 2023, the SEC finalized rules requiring enhanced disclosures regarding cybersecurity risk management, strategy, and governance, as well as the timely reporting of material cybersecurity incidents. These rules mandate disclosures about our processes for identifying, assessing, and managing cybersecurity risks, the role of management and the board of directors in overseeing these risks, and specific incidents that materially affect us.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EEA, we are subject to the EU GDPR, which took effect in May 2018. The EU GDPR governs the collection, use, disclosure, transfer or other processing of personal data (i.e., data which identifies an individual or from which an individual is identifiable), including clinical trial data, and grants individuals various data protection rights (e.g., the right to erasure of personal data). The EU GDPR imposes a number of obligations on companies, including inter alia: (1) accountability and transparency requirements, and enhanced requirements for obtaining valid consent; (2) obligations to consider data protection as any new products or services are developed and to limit the amount of personal data processed; (3) obligations to implement appropriate technical and organizational measures to safeguard personal data and to report certain personal data breaches to the supervisory authority without undue delay (and no later than 72 hours where feasible); and (4) additional, more onerous requirements around the processing of special categories of personal data (including health data and genetic data). In addition, the EU GDPR prohibits the transfer of personal data from the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws unless a data transfer mechanism has been put in place. In certain cases the parties may also be required to carry out a transfer impact assessment (&#8220;TIA&#8221;), which among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under the specific safeguard will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in the EEA. The EU and the US have in place an adequacy agreement known as the EU-U.S. Data Privacy Framework (&#8220;DPF&#8221;) which allows EU organizations to transfer personal data to US companies that have self-certified their compliance under the DPF, as an additional data transfer mechanism for transfers to the US. The EU GDPR imposes substantial fines for breaches and violations (up to the greater of &#8364;20 million or 4% of consolidated annual worldwide gross revenue), and confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the EU GDPR. The EU GDPR increases our responsibility and liability in relation to personal data that we process, and additional mechanisms put in place to address compliance with the EU GDPR must be kept under review as the legislative and regulatory landscape for data protection in the EU continues to evolve.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Relatedly, following Brexit, the EU GDPR has been implemented in the United Kingdom (as the &#8220;UK GDPR&#8221;). The UK GDPR sits alongside the UK Data Protection Act 2018 which implements certain derogations in the EU GDPR into UK law. Under the UK GDPR, companies not established in the UK but that process personal data in relation to the offering of goods or services to individuals in the UK, or to monitor their behavior will be subject to the UK GDPR &#8211; the requirements of which are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to &#163;17.5 million or 4% of global turnover. The UK Government has published its own form of Standard Contractual Clauses (&#8220;SCCs&#8221;), known as the International Data Transfer Agreement and International Data Transfer Addendum to the EU SCCs. The UK Information Commissioner&#8217;s Office has also published its own version of the TIA and guidance on international transfers, although entities may choose to adopt either the EU or UK style transfer impact assessment. The UK and the US also have an adequacy agreement known as the UK-US. Data Bridge which is an extension of the DPF.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to devote additional resources to and put in place additional mechanisms ensuring compliance with the new data protection and disclosure rules. Despite our efforts to comply with these laws and regulations, the inherent complexity of data security and cyber threats, and the newness of some of these requirements, such as the SEC&#8217;s cybersecurity disclosure requirements, present a risk of non-compliance or insufficient disclosure, which could invite regulatory scrutiny and affect our operational and financial performance. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly. In addition, states are constantly adopting new laws or amending existing laws, requiring attention to frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act (the &#8220;CCPA&#8221;), which took effect on January 1, 2020, became enforceable by the California Attorney General on July 1, 2020, and was the first comprehensive state privacy law in the United States. The CCPA covers businesses operating in California and gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act (the &#8220;CPRA&#8221;), which further amended the CCPA, went into effect on January 1, 2023. The CCPA, as amended by the CPRA, imposes additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions went into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. The CCPA currently exempts certain health-related information, including clinical trial data, but the CCPA (as amended by the CPRA) may increase our compliance costs and potential liability once we become subject to the law. Similar laws have been enacted or proposed in many other states as well as at the federal level, and such laws may have potentially conflicting requirements that would make compliance challenging. These proposals and new laws generally include exemptions for HIPAA-covered and clinical trial data, but they add layers of complexity to compliance in the U.S. market, and could increase our compliance costs and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, state laws related to health privacy may result in additional compliance costs. For example, the state of Washington enacted the &#8220;My Health My Data&#8221; Act, which regulates &#8220;consumer health data,&#8221; defined as &#8220;personal information that is linked or reasonably linkable to a consumer and that identifies a consumer&#8217;s past, present, or future physical or mental health.&#8221;  The &#8220;My Health My Data&#8221; Act provides exemptions for personal data used or shared in research, including data subject to 45 C.F.R. Parts 46, 50, and 56.  Additionally, Nevada recently enacted a consumer health data privacy bill, and other states could adopt health-specific privacy laws that could impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FTC and many state attorneys general are interpreting existing federal and state consumer protection laws to impose evolving standards for the collection, use, dissemination and security of health-related and other personal information. For instance, the FTC has promulgated standards for fair information practices, which concern consumer notice, choice, security and access, and also require notice of certain health information breaches outside the HIPAA context. Privacy laws require us to publish statements that describe how we handle personal information and choices individuals may have about the way we handle their personal information. Violating individuals&#8217; privacy rights, publishing false or misleading information about security practices, or failing to take appropriate steps to keep individuals&#8217; personal information secure may constitute unfair or deceptive acts or practices in violation of Section 5 of the FTC Act. The FTC has also been active with respect to enforcement of its Health Breach Notification Rule and in scrutinizing the use and disclosure of sensitive personal information. The FTC finalized changes to the Health Breach Notification Rule in April 2024. Federal regulators, state attorneys general and plaintiffs&#8217; attorneys have been and will likely continue to be active in this space, and if we do not comply with existing or new laws and regulations related to patient health information, we could be subject to criminal or civil sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any actual or perceived failure by us to comply with applicable privacy and data security laws and regulations could result in regulatory investigations, reputational damage, orders to cease or change our processing of our data, enforcement notices, and/ or assessment notices (for a compulsory audit). We may also face civil claims including representative actions and other class action type litigation (where individuals have suffered harm), potentially amounting to significant compensation or damages liabilities, as well as associated costs, diversion of internal resources, and reputational harm.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely upon a combination of patents, know-how and confidentiality agreements to protect the intellectual property related to our products and technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent protection for our T-win</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform, product candidates and their uses, as well as our ability to operate without infringing the proprietary rights of others. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business. We cannot guarantee that our pending and future patent applications will result in patents being issued or that issued patents will afford sufficient protection of our product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or that they will effectively prevent others from commercializing competitive technologies, products or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. We enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties, but any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Composition of matter patents for biological and pharmaceutical product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. However, we cannot be certain that the claims in our pending patent applications directed to composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (&#8220;USPTO&#8221;) or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Off-label prescriptions may infringe or contribute to the infringement of method of use patents, but the practice is common and such infringement is difficult to prevent or prosecute.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal, scientific, and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including United States Supreme Court decisions, which have increased uncertainties as to the ability to enforce patent rights in the future. The standards that the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent application process is subject to numerous risks and uncertainties, and we or any of our potential future collaborators may not be successful in protecting our product candidates by obtaining and defending patents. For example, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, inventorship, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending patent applications may be challenged in patent offices in the United States and abroad. The issuance of a patent is not conclusive as to its inventorship, ownership, scope, validity or enforceability. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. For example, our pending patent applications may be subject to third-party pre-issuance submissions of prior art to the USPTO or our issued patents may be subject to post-grant review proceedings, oppositions, derivations, reexaminations, interference or inter partes review proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Any failure to obtain or maintain patent protection with respect to our product candidates or their uses could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent filing. However, trade secret protection will not protect us from innovations that a competitor develops independently of our proprietary know how. If a competitor independently develops a technology that we protect as a trade secret and files a patent application on that technology, then we may not be able to patent that technology in the future, we may require a license from the competitor to use our own know-how, and if the license is not available on commercially-viable terms, then we may not be able to launch our product. We require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, but we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, and this scenario could materially adversely affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make product candidates that are the same as or similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that noncompliance with the USPTO and foreign governmental patent agencies requirement for a number of procedural, documentary, fee payment and other provisions during the patent process can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending patent applications will not lead to issued patents; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we own or have exclusively licensed may be revoked, modified, or held invalid or unenforceable, as a result of legal challenges by our competitors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or in-license will result in issued patents with claims that directed to our product candidates or uses thereof in the United States or in other foreign countries; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the claims of any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if enforced, a court may not hold that our patents are valid, enforceable and infringed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may fail to adequately protect and police our trademarks and trade secrets; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these or similar events occur, they could significantly harm our business, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations imposed by any intellectual property licenses with third parties that we may need in the future, we could lose rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future require licenses to third-party technology and materials. Such licenses may not be available in the future or may not be available on commercially reasonable terms, or at all, which could have a material adverse effect on our business and financial condition. We may rely on third parties from whom we license proprietary technology to file and prosecute patent applications and maintain patents and otherwise protect the intellectual property we license from them. We may have limited control over these activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by these licensors will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that may be licensed to us. It is possible that the licensors&#8217; infringement proceeding or defense activities may be less vigorous than if we conduct them ourselves. Even if we acquire the right to control the prosecution, maintenance and enforcement of the licensed and sublicensed intellectual property relating to our product candidates, we may require the cooperation of our licensors and any upstream licensor, which may not be forthcoming. Therefore, we cannot be certain that the prosecution, maintenance and enforcement of these patent rights will be in a manner consistent with the best interests of our business. If we or our licensor fail to maintain such patents, or if we or our licensor lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected. In addition to the foregoing, the risks associated with patent rights that we license from third parties will also apply to patent rights we may own in the future. Further, if we fail to comply with our diligence, development and commercialization timelines, milestone payments, royalties, insurance and other obligations under our license agreements, we may lose our patent rights with respect to such agreement, which would affect our patent rights worldwide.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of our current or any future license agreements would reduce or eliminate our rights under these agreements and may result in our having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. Any of the foregoing could prevent us from commercializing our other product candidates, which could have a material adverse effect on our operating results and overall financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, intellectual property rights that we may in-license in the future may be sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently own intellectual property directed to our product candidates and other proprietary technologies, including our T-win</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform. Other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. From time to time, in order to avoid infringing these third-party patents, we may be required to license technology from additional third parties to further develop or commercialize our product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our product candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if we are able to obtain a license under such intellectual property rights, any such license may be non-exclusive, which may allow our competitors to access the same technologies licensed to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, some of our owned and in-licensed patents or patent applications or future patents may be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Furthermore, our owned and in-licensed patents maybe subject to a reservation of rights by one or more third parties. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed, misappropriated or otherwise violated their intellectual property. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidates. We cannot be certain that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. Third parties may assert infringement claims against us based on existing or future intellectual property rights. If we are found to infringe a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing candidate product or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing candidate product or product. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our investigational products or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, analysis of the scope of relevant patent claims or determination of the expiration of relevant patents, are complete or thorough. We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our product candidates, might assert are infringed by our current or future product candidates, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our product candidate. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. . Our determination of the expiration date of any patent in the United States, Europe or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. The pharmaceutical and biotechnology industries have produced a considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and  a court of competent jurisdiction may not invalidate the claims of any such U.S. patent. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may choose to challenge the enforceability or validity of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex-parte </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">re-exam, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the EPO, or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, the European Patent Office (&#8220;EPO&#8221;)  or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors or other third parties may infringe our patents, trademarks or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1). An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We employ and may employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, but we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our future patents. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;), signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review, and derivation proceedings. Further, because of a lower evidentiary standard in these USPTO post-grant proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates and other proprietary technologies we may develop or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date. Thus the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the 2013 case Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. We do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, but we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. An inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, but there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of any individual patent depends on applicable law in the country where the patent is granted. In the United States, provided all maintenance fees are timely paid, a patent generally has a term of 20 years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Even if we or our licensors obtain patents covering our product candidates, when the terms of all patents covering a product expire, our business may become subject to competition from competitive medications or vaccines, including generic medications or vaccines. Given the amount of time required for the development, testing and regulatory review and approval of new product candidates, patents protecting such candidates may expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, a patent that covers an FDA-approved drug or biologic may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, as amended (the &#8220;Hatch-Waxman Act&#8221;), which permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. In Europe, our product candidates may be eligible for term extensions based on similar legislation. In either jurisdiction, however, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Even if we are granted such extension, the duration of such extension may be less than our request. If we are unable to obtain a patent term extension, or if the term of any such extension is less than our request, the period during which we can enforce our patent rights for that product will be in effect shortened and our competitors may obtain approval to market competing products sooner. The resulting reduction of years of revenue from applicable products could be substantial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive, and even in countries where we have sought protection for our intellectual property, such protection can be less extensive than in the United States. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. In-licensing patents covering our product candidates in all countries throughout the world may similarly be prohibitively expensive, if such opportunities are available at all. And in-licensing or filing, prosecuting and defending patents even in only those jurisdictions in which we develop or commercialize our product candidates may be prohibitively expensive or impractical. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection or licensed patents to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but where enforcement is not as strong as that in the United States or Europe. These products may compete with our product candidates, and our or our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or regulations in the United States and Europe, and many companies have encountered significant difficulties in protecting and defending proprietary rights in such jurisdictions. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets or other forms of intellectual property, particularly those relating to biotechnology products, which could make it difficult for us to prevent competitors in some jurisdictions from marketing competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, are likely to result in substantial costs and divert our efforts and attention from other aspects of our business, and additionally could put our or our licensors&#8217; patents at risk of being invalidated or interpreted narrowly, could increase the risk of our or our licensors&#8217; patent applications not issuing, or could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, while damages or other remedies may be awarded to the adverse party, which may be commercially significant. If we prevail, damages or other remedies awarded to us, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition in those jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some jurisdictions, including certain European countries, compulsory licensing laws compel patent owners to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties under patents relevant to our business, or if we or our licensors are prevented from enforcing patent rights against third parties, our competitive position may be substantially impaired in such jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may rely on trade secret and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to seeking patents for some of our technology and current product candidates or any future product candidates, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Elements of our current product candidates or any future product candidates, including processes for their preparation and manufacture, as well as our T-win</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade secrets and know-how can be difficult to protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We enter into written agreements that include confidentiality and intellectual property obligations to protect each party&#8217;s property, potential trade secrets, proprietary know-how, and information. We further seek to protect our potential trade secrets, proprietary know-how, and information in part, by entering into non-disclosure and confidentiality agreements with parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we may in-license in the future. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, but we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. We would be given an opportunity to respond to those rejections, but we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and tradenames to third parties, such as distributors. These license agreements may provide guidelines for how our trademarks and tradenames may be used, but a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Common Stock</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The stock price of our common stock may be volatile or may decline regardless of our operating performance and you may lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Quarterly Report on Form 10-Q, these factors include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overall performance of the equity markets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our operating performance and the performance of other similar companies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">published opinions and third-party valuations by banking and market analysts; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results from our ongoing clinical trials and future clinical trials with our current and future product candidates or of our competitors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse results or delays in clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to obtain approval for or commercialize our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated serious safety concerns related to immuno-oncology or related to the use of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the United States and other countries; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of expenses related to future product candidates or clinical development programs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure to achieve product development goals in the timeframe we announce; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of acquisitions, strategic alliances or significant agreements by us or by our competitors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruitment or departure of key personnel; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the economy as a whole and market conditions in our industry; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading activity by a limited number of stockholders who together beneficially own a majority of our outstanding common stock; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expiration of market standoff or contractual lock-up agreements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of our public float; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">political uncertainty and/or instability in the United States and throughout the world; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any other factors discussed elsewhere in this Quarterly Report on Form 10-Q.  </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many immuno-oncology companies. Stock prices of many immuno-oncology companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. The trading prices for common stock of other biopharmaceutical companies have also been highly volatile as a result of the high inflation environment and geopolitical conflict in Ukraine and the Middle East. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If there are substantial sales of shares of our common stock, the price of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our directors, executive officers and significant stockholders, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. As of June 30, 2025 we had 65,880,914 shares of common stock outstanding. Substantially all of our outstanding shares of common stock are currently able to be sold freely in the public market, subject to certain restrictions that may apply to shares of our common stock held by our affiliates, by certain participants in our August 2023 private placement, and underlying certain warrants issuable in connection with the EIB Loan Facility. The market price of our common stock could decline as a result of the exercise of any such warrants, the sale of a substantial number of shares of our common stock in the public market or the perception in the market that the holders of a large number of shares intend to sell their shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to maintain the listing of our common stock on Nasdaq, which could adversely affect our liquidity and the trading volume and market price of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is listed on The Nasdaq Global Select Market, which imposes continued listing requirements with respect to listed securities, including a minimum bid price requirement. We may not be able to maintain compliance with the minimum bid price requirement or other applicable Nasdaq listing rules. For example, on December 26, 2024, we received notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that, because the closing bid price for our common stock had fallen below $1.00 per share for 30 consecutive trading days, we no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). While we were subsequently notified by the Listing Qualifications Staff of Nasdaq on June 3, 2025 that we had regained compliance, there is no guarantee that we will be able to resolve any Nasdaq listing deficiencies which may occur in the future. If Nasdaq delists our common stock, it is unlikely that we will be able to list our common stock on another national securities exchange and, as a result, we expect our securities would be quoted on an over-the-counter market. If this were to occur, we and our stockholders could face significant adverse consequences, including limited availability of market quotations and analyst coverage for our common stock and reduced liquidity for trading of our securities, all of which would likely reduce the market price of our common stock. In addition, our common stock could be considered a &#8220;penny stock,&#8221; which would require brokers trading in our common stock to adhere to more stringent rules and possibly result in reduced trading activity in the secondary trading market for our common stock. Delisting could result in additional adverse consequences including reduced ability to issue additional securities or obtain additional financing on terms acceptable to us, or at all, as well as the potential loss of confidence of our customers, suppliers and employees, any of which could harm our business and future prospects. Even the perception that we are at heightened risk of delisting could also result in certain of the above consequences. This perception could negatively impact the market price and trading volume of our common stock, and harm our stockholders and our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delaware law and provisions in our amended and restated certificate of incorporation and bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation and bylaws contain provisions that could depress the trading price of our common stock by acting to discourage, delay or prevent a change of control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a classified board of directors so that not all members of our board of directors are elected at one time; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">permit the board of directors to establish the number of directors and fill any vacancies and newly-created directorships; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that directors may only be removed for cause and only by the affirmative vote of the holders of at least a majority of the voting power of all then outstanding shares of our capital stock; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require super-majority voting to amend some provisions in our amended and restated certificate of incorporation and bylaws; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board of directors could use to implement a stockholder rights plan; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prohibit stockholders from calling special meetings of stockholders; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that the board of directors is expressly authorized to make, alter or repeal our bylaws; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrict the forum for certain litigation against us to Delaware; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by stockholders at annual stockholder meetings. </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any provision of our amended and restated certificate of incorporation or bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation designates a state or federal court located within the state of Delaware as the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to choose the judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf under Delaware law; (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; (3) any action arising pursuant to any provision of the Delaware General Corporation Law (&#8220;DGCL&#8221;), our amended and restated certificate of incorporation or bylaws; (4) any other action asserting a claim that is governed by the internal affairs doctrine; or (5) any other action asserting an &#8220;internal corporate claim,&#8221; as defined in Section 115 of the DGCL, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) in all cases subject to the court having jurisdiction over indispensable parties named as defendants. These exclusive-forum provisions do not apply to claims under the Securities Act or the Exchange Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. However, our amended and restated certificate of incorporation contains a federal forum provision which provides that unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this provision. This exclusive forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find the exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, or the exercise of our warrants, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner, we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the IO Biotech, Inc. 2021 Equity and Incentive Plan (the &#8220;2021 Equity Plan&#8221;), we are authorized to grant stock options and other equity-based awards to our employees, directors and consultants. In addition, pursuant to the IO Biotech, Inc. 2023 Inducement Award Plan (the &#8220;2023 Inducement Plan&#8221;), we are authorized to grant stock options and other equity-based awards to employees as an inducement for them to join us. Equity-based awards granted under the 2021 Equity Plan and the 2023 Inducement Plan would cause dilution to our stockholders. The number of shares of our common stock reserved for issuance under the 2021 Equity Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, by an amount equal to the lesser of (1) 4% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase; or (2) a lesser number of shares determined by our board of directors. If our board of directors elects to increase the number of shares available for future grant by the maximum amount each year or increases the available pool under the 2023 Inducement Plan, our stockholders may experience additional dilution, which could cause our stock price to fall. Subject to further increases by our Board, the maximum number of shares reserved for issuance under the 2023 Inducement Plan is 1,976,427 shares.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, on August 9, 2023, we completed the Private Placement in which, among other things, we issued and sold 37,065,647 warrants to purchase up to 37,065,647 shares of our common stock to the various purchasers thereunder. The purchase price for each warrant was $2.025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, on December 19, 2024, in connection with the Finance Contract, we agreed to sell and issue to the European Investment Bank certain warrants to purchase shares of the Company&#8217;s common stock in connection with the disbursement of each of the Tranche A loan (such warrants, the &#8220;Tranche A Warrants&#8221;), Tranche B loan (such warrants, the &#8220;Tranche B Warrants&#8221;) and Tranche C loan (such warrants, the &#8220;Tranche C Warrants&#8221; and, together with the Tranche A Warrants and the Tranche B Warrants, the &#8220;EIB Warrants&#8221;). The number of shares for which the EIB Warrants will be exercisable will be determined at the time of issuance of each EIB Warrant in accordance with the formulas set forth in the Warrant Issuance Agreement (as defined below), which formulas generally provide that the number of shares will decrease as the price of the common stock increases. We have issued 5,623,664 Tranche A Warrants to purchase up to 5,623,664 shares of our common stock at a purchase price per share of $0.89. We have issued 4,221,868 Tranche B Warrants to purchase up to 4,221,868 shares of our common stock at a purchase price per share of $1.32.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common shares less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced disclosure obligations regarding executive compensation; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to hold a non-binding advisory vote on executive compensation or obtain stockholder approval of any golden parachute payments not previously approved. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as an &#8220;emerging growth company&#8221; the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies, unless we later irrevocably elect not to avail ourselves of this exemption. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. We will remain an emerging growth company until the earliest of (1) the end of the fiscal year following the fifth anniversary of our initial public offering; (2) the last day of the fiscal year during which our annual gross revenues are $1.235 billion or more; (3) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; and (4) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700.0 million as of the end of the second quarter of that fiscal year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also a &#8220;smaller reporting company&#8221; meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements in our Annual Report on Form 10-K, and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250 million as of the end of that year&#8217;s second fiscal quarter and our annual revenues exceeds $100 million during such completed fiscal year, or (ii) the market value of our common stock held by non-affiliates exceeds $700 million, regardless of our annual revenue, as of the end of that year&#8217;s second fiscal quarter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investors may find our common stock less attractive to the extent we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), as well as rules subsequently implemented by the SEC and Nasdaq, have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the &#8220;Dodd-Frank Act&#8221;) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;Say on Pay&#8221; and proxy access. Recent legislation permits smaller &#8220;emerging growth companies&#8221; to implement many of these requirements over a longer period and up to five years from the pricing of our IPO. We have taken advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costlier than when we were a private company. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have identified a material weakness in our internal control over financial reporting that, if not properly remediated, could result in us being unable to provide required financial information in a timely and reliable manner. Such a failure, or any other failure, to comply with the financial reporting and internal controls requirements for publicly traded companies could have a material adverse effect on our business and stock price.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management has identified a material weakness in our internal control over financial reporting as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, relating to the design and operation of our controls to ensure that the accounting models used to support CRO-related accounting entries appropriately reflected the status and progress of ongoing clinical trials at the balance sheet date. A material weakness is a deficiency, or combination of deficiencies, in internal controls over financial reporting that results in a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. For further discussion of our internal control over financial reporting, a description of the identified material weakness and a summary of the remediation efforts we are implementing, see &#8220;Part II, Item 9A - &#8220;Controls and Procedures,&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to remediate the material weakness in a timely manner, or if additional material weaknesses in our internal control over financial reporting are discovered or occur in the future, or if we are otherwise unable to establish or maintain corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures as required by the Sarbanes-Oxley Act, the regulations of Nasdaq, the rules and regulations of the SEC, and more complex accounting rules, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and our stock price to decline. We also could become subject to litigation and regulatory enforcement actions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have taken steps to remediate the material weakness, we cannot assure you that these measures will significantly improve or remediate the material weaknesses described above. We also cannot assure you that we have identified all or that we will not have additional material weaknesses in the future. Accordingly, a material weakness may still exist when we report on the effectiveness of our internal control over financial reporting for purposes of our attestation when required by reporting requirements under the Exchange Act or Section 404 of the Sarbanes-Oxley Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we do remediate the material weakness, our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. Further, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to build our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act, the regulations of Nasdaq, the rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. Commencing with our fiscal year ending December 31, 2022, we must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Form 10-K filing for that and each subsequent year, as required by Section 404 of the Sarbanes-Oxley Act. Prior to our IPO, we were not required to test our internal controls within a specified period and, as a result, we may experience difficulty in meeting these reporting requirements. For example, our management has identified a material weakness in our internal control over<br/>financial reporting as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed<br/>with the SEC on March 31, 2025, relating to the design and operation of our controls to ensure that the accounting models used to<br/>support CRO-related accounting entries appropriately reflected the status and progress of ongoing clinical trials at the balance sheet<br/>date and additionally, in connection with the audit of our financial statements for the years ended December 31, 2021 and 2020, we and our independent registered public accounting firm identified a material weakness in our internal control over financial reporting. This material weakness was not previously remediated, and in connection with the preparation of our consolidated financial statements for the year ended December 31, 2021, the Company identified an error, which resulted in a restatement as disclosed in our Current Report on Form 8-K filed on December 17, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the SEC or other authorities.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, as described above, our management has identified a material weakness in our internal control over financial reporting as of December 31, 2024, and concluded that, due to such material weakness, our disclosure controls and procedures were not effective as of that date. For further discussion, see the previous risk factor and &#8220;Part II, Item 9A - &#8220;Controls and Procedures,&#8221; below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results of operations or the way in which such financial condition and results of operations are reported. We intend to invest resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from business activities to compliance activities. See the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Recent Accounting Pronouncements.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New income, sales, use, or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted, changed, modified, or applied adversely to us. For example, the TCJA enacted many significant changes to the U.S. tax laws. Future guidance from the IRS and other tax authorities with respect to the TCJA may affect us, and certain aspects of the TCJA could be repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) modified certain provisions of the TCJA. In addition, it is uncertain if and to what extent various states will conform to the TCJA or any newly enacted federal tax legislation. For example, the U.S. government enacted the IRA in 2022, which, among other things, significantly changes the taxation of certain business entities, including by imposing a 1% excise tax on certain share buybacks, effective for tax years beginning in 2023. If and when applicable, it is possible that the 1% excise tax on share buybacks could result in an additional tax liability over the regular federal corporate tax liability in a given year. Any resulting tax liability could adverse impact our business, financial condition, results of operation, and liquidity. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the TCJA or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one time charges, and could increase our future U.S. tax expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, recent presidential and congressional elections in the United States could also result in significant changes in, and uncertainty with respect to, tax legislation, regulation and government policy directly affecting us and our business. For example, the United States government may enact significant changes to the taxation of business entities including, among others, a permanent increase in the corporate income tax rate, an increase in the tax rate applicable to the global intangible low-taxed income and elimination of certain exemptions, and the imposition of minimum taxes or surtaxes on certain types of income. The likelihood of these changes being enacted or implemented is unclear.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will have broad discretion in the use of our existing cash and cash equivalents and may not use them effectively or in ways that increase the value of our share price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot specify with any certainty the particular uses of our existing cash and cash equivalents. We will have broad discretion in the application of our existing cash and cash equivalents, including working capital and other general corporate purposes, and you and other stockholders may disagree with how we spend or invest our cash and cash equivalents. The failure by our management to apply these funds effectively could adversely affect our business and financial condition. Pending their use, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our internal information technology systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our product candidates&#8217; development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have also outsourced elements of our operations to third parties, and as a result we manage a number of third-party contractors who have access to our confidential information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the implementation of security measures, given their size and complexity and the increasing amounts of confidential information that they maintain, our internal information technology systems and those of our third-party CROs and other contractors and consultants are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, extortion, account takeover attacks, degradation of service attacks, denial-of-service attacks, &#8220;phishing,&#8221; or social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead to data leakage. We have technology security initiatives and disaster recovery plans in place to mitigate our risk to these vulnerabilities, but these measures may not be adequately designed or implemented to ensure that our operations are not disrupted or that data security breaches do not occur. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hackers and data thieves are increasingly sophisticated and operate large-scale and complex automated attacks which may remain undetected until after they occur. We cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. Like all businesses we may be increasingly subject to ransomware or other malware that could significantly disrupt our business operations, or disable or interfere with necessary access to essential data or processes. Numerous recent attacks of this nature have also involved exfiltration and disclosure of sensitive or confidential personal or proprietary information, or intellectual property, when victim companies have not paid the cyber criminals substantial ransom payments. For example, any such event that leads to unauthorized access, use, disclosure, unavailability, or compromised integrity of personal or other sensitive or essential information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, increase the costs we incur to protect against such information security breaches, such as increased investment in technology, render key personnel unable to perform duties or communicate throughout the organization and otherwise subject us to fines and other liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The costs of mitigating cybersecurity risks are significant and are likely to increase in the future. These costs include, but are not limited to, retaining the services of cybersecurity providers; compliance costs arising out of existing and future cybersecurity, data protection and privacy laws and regulations; and costs related to maintaining redundant networks, data backups and other damage-mitigation measures. We also cannot be certain that our existing insurance coverage will continue to be available on acceptable terms or in amounts sufficient to cover the potentially significant losses that may result from a security incident or breach or that the insurer will not deny coverage of any future claim.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operations as a global company subject us to various risks, and our failure to manage these risks could adversely affect our business, results of operations, cash flows, financial condition and/or prospects.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant operational risks as a result of doing business globally, such as:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fluctuations in currency exchange rates (in particular, between U.S. dollars, Euros and Danish Kroner);</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potentially adverse tax consequences, including the complexities of foreign value-added tax systems, tax inefficiencies related to our corporate structure, and potential restrictions on the repatriation of earnings;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">export restrictions, trade regulations and foreign tax laws;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">customs clearance and shipping delays;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the burdens of complying with a wide variety of foreign laws and different legal standards; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.752626672113803%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased financial accounting and reporting burdens and complexities.  </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If one or more of these risks are realized, it could have a material adverse effect on our business, results of operations, cash flows, financial condition and/or prospect.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Global economic and political instability and conflicts, such as the conflict in Russia and Ukraine and conflicts in the Middle East, could adversely affect our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business could be adversely affected by unstable economic and political conditions within the United States and foreign jurisdictions and geopolitical conflicts, such as the conflict in Ukraine and conflicts in the Middle East. We do not have any operations in Russia or Ukraine at this time, but the current military conflict, and related sanctions, as well as export controls or actions that may be initiated by nations and regions including the United States, the EU or Russia (e.g., potential cyberattacks, disruption of energy flows, disruptions to supply chains, etc.) and other potential uncertainties could adversely affect our business. Certain of our clinical trial sites are located in Israel and conflicts in the Middle East may delay, limit or hinder ongoing, planned or future trials and affect enrollment and retention of patients. Inability to enroll or retain patients and limitations or delays in clinical trials could increase costs and cause setbacks in product development. In the event geopolitical tensions fail to abate or deteriorate further, additional governmental sanctions may be enacted adversely impacting the global economy, which could adversely affect our business, financial condition or results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and/or terrorism and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevent us from using all or a significant portion of our headquarters or other facilities, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which could have a material adverse effect on our business. In addition, the long-term effects of climate change on general economic conditions and the pharmaceutical manufacturing and distribution industry in particular are unclear, and changes in the supply, demand or available sources of energy and the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including raw materials and other natural resources, necessary to run our business.  Furthermore, certain parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our clinical trials, our development plans and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for any violations of such laws.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, &#8220;Trade Laws&#8221;) prohibit, among other things, companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect to continue our non-U.S. activities, which may increase over time. We expect to rely on third parties for research, preclinical studies, and clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, and the third parties with whom we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with whom we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. We maintain general liability insurance, but we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials, and our general liability insurance may not probe sufficient coverage against any potential liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We could be subject to securities class action litigation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or only very few securities analysts commence coverage of us, or if industry analysts cease coverage of us, the trading price for our common stock could be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to meet evolving investor, stakeholder and governmental expectations regarding environmental, social and corporate governance (&#8220;ESG&#8221;) matters may damage our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is an increasing and evolving focus from certain investors, employees and other stakeholders concerning ESG matters. Additionally, public interest and governmental pressure related to public companies&#8217; approach to ESG matters continue to grow and evolve. If our approach to these matters fail to meet the expectations and standards of investors, employees, other stakeholders and governmental authorities regarding responsible corporate citizenship in areas including environmental stewardship, Board of Directors and employee diversity, human capital management, corporate governance and transparency, we may face not only reputational harm but also regulatory scrutiny, litigation risk, and loss of business opportunities, which could have a material adverse effect on our business or financial condition.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The biopharmaceutical industry is subject to extensive regulatory obligations and policies that are subject to change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 28, 2024, the U.S. Supreme Court issued an opinion holding that courts reviewing agency action pursuant to the Administrative Procedure Act (the &#8220;APA&#8221;) &#8220;must exercise their independent judgment&#8221; and &#8220;may not defer to an agency interpretation of the law simply because a statute is ambiguous.&#8221; The decision will have a significant impact on how lower courts evaluate challenges to agency interpretations of law, including those by the FDA, DHHS, CMS and other agencies with significant oversight of the biopharmaceutical industry. The new framework is likely to increase both the frequency of such challenges and their odds of success by eliminating one way in which the government previously prevailed in such cases. As a result, significant regulatory policies will be subject to increased litigation judicial scrutiny. Any resulting changes in regulation may result in unexpected delays, increased costs, or other negative impacts on our business that are difficult to predict.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, federal agency priorities, leadership, policies, rulemaking, communications, spending and staffing may be significantly impacted by election cycles.  For example, the current presidential administration aims to significantly reduce government spending through cuts to federal healthcare programs and reductions in the workforces of key government agencies, such as the FDA, FDA, DHHS, and CMS. Efforts by the current administration to limit federal agency budgets or personnel may result in reductions to agency budgets, employees, and operations, which may lead to slower response times, less guidance from the agency, and longer review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. Any resulting changes in regulation may result in unexpected delays, increased costs, or other negative impacts on our business that are difficult to predict.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_unregistered_sales_equity_securit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Unregistered Sales of Equi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ty Securities and Use of Proceeds.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_defaults_upon_senior_securities"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Defaults Upo</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n Senior Securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Safe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ty Disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Other </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4ef9be2-9292-4f30-98e5-bcb0f8298e0e" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_946bc31e-d08a-4826-ab2a-be2ce6c77af2" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_ef1e176f-c0f1-4234-a0c3-56f800a861a6" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_7d8dc95e-af90-4865-ad62-483372d4e92c" contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. E</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">xhibits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:2.08%;box-sizing:content-box;"/>
     <td style="width:89.92%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="iobt-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="iobt-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="iobt-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2*</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="iobt-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*	Filed herewith.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">URES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:3.04%;box-sizing:content-box;"/>
     <td style="width:45.96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IO Biotech, Inc.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 14, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mai-Britt Zocca</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mai-Britt Zocca, Ph.D.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 14, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Amy Sullivan</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amy Sullivan</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>iobt-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Mai-Britt Zocca, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of IO Biotech, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:49.72%;box-sizing:content-box;"></td>
     <td style="width:4.74%;box-sizing:content-box;"></td>
     <td style="width:4%;box-sizing:content-box;"></td>
     <td style="width:41.54%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 14, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mai-Britt Zocca</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mai-Britt Zocca, Ph.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>iobt-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Amy Sullivan, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of IO Biotech, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:49.72%;box-sizing:content-box;"></td>
     <td style="width:4.74%;box-sizing:content-box;"></td>
     <td style="width:4%;box-sizing:content-box;"></td>
     <td style="width:41.54%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 14, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Amy Sullivan</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amy Sullivan</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>iobt-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report of IO Biotech, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the period ending June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:3.04%;box-sizing:content-box;"></td>
     <td style="width:46.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 14, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mai-Britt Zocca</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mai-Britt Zocca, Ph.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>iobt-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report of IO Biotech, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the period ending June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:3.04%;box-sizing:content-box;"></td>
     <td style="width:46.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: August 14, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Amy Sullivan</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amy Sullivan</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img135872921_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img135872921_0.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M227)CHZL"\\GO)9AE=O>S_4J4HN7!VL.]AQ8XX&2P\)D@
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MO*?BVM2%2EPQDI+I39V .D]
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MABZ<N[-<WK8;7%M+A,]QB#.@
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M*=SK>O-<Z;IU)>%9O^[@\%A])ZY\^C'2HHU>C/D9
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M:2HU?E(QY+ZO\-95KCV*4I=$6SVY;;_%YA0M?])6A'IDD_\ *6G@H$V=
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MVR)9"5)6E*T*)25$2DJ29*2I*BZDI)EU(R,C]#%>%IGZ
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M6V&B5W-=^7X5]%=;TO8E0.\N\=QG]WCIA8P?<A^*7#)]2T+:WK$&>(T
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MC;4&GRS]5<WI/D2VD(WYSO\ ;<M^"H/"\N4UHUQAZSXL?17*VM1 P%N%&
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MJ\>G8F5=OWO)V$\CLI=YK\Z2V)ZJ:Y=<^+".V2(A8L<J8
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M23%5DV(SE*2XT@YC45M^&\M"RB6,:/()*C:(CQV:Y;1S6RG:5MNF+]F2U/\
MCPIM;3+9+FU?)<PA?4-*6B4?:@_2B_*N!I/8656G=MX'OG5V"[CUC=,Y!@>Q
M,=@9+CEFUV$XN'-09.PYS"''?96]5,;<B38RC\D68PZROHM"B*CKFVK6EQ.V
MKK"M"6#7]MCUI[5I-B[2[H7UM"\MI=JA4BFGR\/ UJ:V--'90Z#T@
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M\RU+B6.MLUWWBSJIGF9SNGBK==VG'@@M7/+7+C>&I(P&&8,"
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M,5U5JU*U1U:TG*K)XMMXMOC;+5HT:5O2C1H1C"C%8*,4DDN)+0CDH^#L
M           .OMIZHUON[!+_ %EMK"Z#/\#RB(J%=XSDD%N=7RVS]6GVN[MD
M0+&$[T=C2XZVI45Y*767$.)2HNZWN*]K6C7MY.%:+T-?VU<*>A[3SW5K;WM"
M5M=PC4H26#36*_R/@:TIZ40M?E"^#+-N,K.1[UXLMWFR] Q$3+K*,)=2[:;"
MU!6M]7Y4DUM]\G-L#K6B4M4]*"L*Z,GK,0\VT[/5:&0[UTK]QM,PPIWCT*6J
M,W^&3X-3>K#44[O-N36RU2OLL[52P6F4=<Z:_%%<.M+7C@Y$> 3,K\
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MLN9:%QM[45G\P<\\&C');=_F5$I5,-D?5C]9K%\26R1#B%EE0@
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MONO0R*AXU;">9S7>ELBO9CQ<+UR?%@C<.(T2X
M  B&_.5\2,;'F\FYM<8\79BT?>Y;\@M88[!-MNJ=>=D/V.X<:@,+\;=6ZXM/
MZ@AQVDE&49V))-I4U;-C[J;Q.?9RJ_EW]5.3V\$'Q^RWK]'@QJ??;=14U+.L
MMCA#75@EJX:B7![26KTM7:PBCBPBK0        V^?"SS>/ASR\HJW+;=R#I;
M?!UFM-E)=>2BMI;*3-4G ,^E)<6TRVG%+^<IB4^M7:Q464Y9)6M*$B-[T95^
MYY:Y4UC=4<91X6O6CSK5QI$MW-SK]HS:,:KPLZ^$)\">/=E]5O!O9%R+"X4T
M7Z           !@!\G_*0N(7"?=&UZZP1 S>=1GK[6!DZAJ4>P\[0]24D^"E
M9&E^3B\5R3=J;_RV*QPAF,AL/W+-*5O)8TD^U+W8Z7TZ(\Y@=Y<S_:<FK747
MA7<>S#WY:$U[NF7(BM54I2U*4I1J4HS4I2C,U*49]34HSZF9F9^IB\37,_
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M2IK"WJ]^/%B],>9ZN)HV W/S=YMD\'5>-U1_+GPO!=V7UHX8OVDS;.(Z2H
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M:T[2C^G3BDN/#6^5O2^-FM%_>5<PO*M[7_5JS<GQ8ZDN)+!+B1U /2>0
M       "3;\ _P :36ULJB<V]UX^W)UQ@%VXQHW&[:)Y(V9[#I9/;*S^0Q(3
MXI&/:^GM>. 9)6F1>H4LE(.N4AZ";WYY\/3_ &JUE^?-?F->K%^KRRV_1]XL
MG<3=Q7559U>QQMZ;_+3]::];DB]7#+W=,ST5B7"
M         =&<D^/6NN5&DL_T1M*M*?B6?4C]:[(;:8794%JV92:/*:)V0VXW
M%OL;MFFID5PR-/E:)*R4VI:5>NQO:^7W4+NW>%2#QXFMJ?$UH9XLQL+?-+*I
M8W2QI5(X<:>R2XT]**T;E#QRV!Q-WOL306RXI-Y-@%VN"FQ8;6W79)12VFY^
M.973FM2S559)226);*34;C/E-ITDNMN)3>5A>T<QM(7E#].:U;4]33XT]!KC
MF>7U\JOJEA<K\RG+#'8UK4EQ-8/J>DZ!'L/       !N=^"SEP?&7FYC&(9#
M:+A:SY(LP]0Y4VZZM,&'ELZ;Y=69&ZT1I;.3#RQ_Z4;SJDM18-W+=5^Z0C&]
MF7?'95*K!8UZ'?7)ZZZ-/&XHF.Y&;?MN=1HU'A;7'Y<N#M>H_M=WB4FRP-%.
ME\@       !\J^O*G&*.YR6_GL5=%CU58WEU9RC4F-75-3#>GV4^0I*5*2Q#
MAQUN+,B,R2D_0?4(2J34(+&<FDEPMZCYG.%.#J5'A"*;;X$M+95T<J-ZW')G
MD;N??5V3[<G:&P+_ ":%"DN&Z[48^]+5%Q6@\AJ6:F\>QB+#@H]3_)'(7WE]
MI&QLJ5G'53@ERO:^=XLUFS2^GF685KZ>NK4;PX%ZJYE@N8Z!'L/
M&YGX#< /-ODMU-;+;2[%UIB&TL_EMJ-)),BP>UPJ X9&1J4J-<YI&=223(R6
MV1GZ$9'&-[ZWA9'4CMJ2A'[REY(LF&XM#QMXZ4]E.$Y?=<5UR18(BG2^@
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MM2EJ4HZ/K5JEQ5E7K-RJSDVWPMZS8NA0I6M"%O0BHT8148I;$M".7CK.T
M                            "/7]P!P,3O\ T&URCU]3%(VWQVIY3^4M
M0HSKMCEVE$OOV%]%4EKN)Q_7<N2]=,FKHEN NQ+JI:FDB9;GYO\ !WGP%9_T
MU9Z.!3U+[7H\O9(#OYD?Q]A^YV\?ZNW7>PURIZW]C3+D[7$0:1:Y28
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M)8TZ*=1\WH_>:?,R);[9A\!D%6,7A5KM4UR2]+[BDN=%>N+E*"
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MM*6,8\#?K2YWJXDN,OW<_(_V;+%.M'"^KX2GPI>K#ZJTOZ3?$;@!&R6@
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MDN]5G@O=A_&3?04W\QK_ ,;,:67Q?<HT^T_>GP\D4FO>(U8G!7(
M!--^V1P3Z9QEY#;)6P;;F9;PKL/;=63J3D1-?8-36K2VR4OQK81*V&^@EI07
M5Q*TFI1IZ)J_?NMVKZC0]FDW]J37X2X_EM0[.6W%S[==1^Q%/\;)+H@Q8X
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MO@<S5O4?Y%?"+XI>H^EN/UB%;]91^XY0[JFL;FVQFN.'KKH2E]7C(#@MXHH
M     #)/AYOZQXM\H-(;]KS>4C6V?5%O=1XY*-^PQ":;E)G%2P2%MGY;C#K2
M?%3Z]"-[U(RZD?AS*SC?V%6SEZ\&EQ/7%\TDF9+*+^669G0OX_W=1-\<7HDN
M>+:+0JML8%Q70+:KEL3ZRTA1;&NG17$NQIL"<PW)B2X[J3-+K$F.ZE:%%Z*2
MHC%"RBXR<9+"2>#-EXRC.*G%XQ:Q3X4SW1P<@  !^*4E"5+6HDI21J4I1DE*
M4I+J:E&?0B(B+U, 5@'.+>A\EN7?(;=[<M<VJSS9^1RL6D.&M3AX-3R"QS 6
M5FM2C[XN%4\!H^G1)&C\I)3T(KYRJT^!RVC:ZI0IK'WGIE]YLUISJ^_<LVN+
MW'&-2J^S[JT1^ZD8JC(&+          +!+X#<&_1_P :&H[5;'MY.Q<NVKG,
ME"B[75__ ']N<-A/NI.,P9>XJL.CK;,U/=S*D*)9$9(13F]]7Q<]J1V0C"/W
M5+RR9?6XM#P=W*4MM2<Y?><5U11N8$9)@        $1[[G#D#Y)W'3BW5S7B
M*+&N=ZYK!2Y_5G'):Y^":Z<4E)]#DQFXN2FHE>J4/MF7HKJ+%W$L]%>_DN"G
M'JE+\)5/S)O^];Y9%ZDZLNN,/Q])$V%B%5@         'ZE*EJ2E*34I1DE*
M4D9J4HSZ$E)%U,S,S]" %CU\2_#MGAEPQUUAEQ6>QVCL&.SM7;ZWV/%81\RR
MROA/,8M*[B4XU^A<>9AU*VB6IDYD:2^CIYU=:3WBS)YGF<ZL7C;P[D.#LIZ_
MK/%\C2V&P^ZN4+)\GIT9K"YJ+MU.'M22[OU5A'E3>TV7C!$C
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ML23)-9FZ<J1KB?2O.J7U-;CBE=3ZBE]Z+/X/.:JBL*=3\Q?6U_>[1L#N;?\
MQ^047)XU:6-*7U/1^XXLVO"/$I   #!;Y,=V?W>^!W)W9K$GVEO%UA;XEC3Z
M7/&^QE>R'8VN\:F1B+JMUZLN<H9E=I%^XPHSZ)(S++9%:_&YO0H/T?$3?)'O
M/I2P,)O)>_M^1W-RGA-4G&/O3[D>ARQYBL^%YFN            %F;\:V%?R
M_P" 7#_&S9]L\>@-;Y%,CFWXEL6&:X]$S2R9>;\+!HD-S\@<)TC3U\A*ZJ4?
MYCHO/*OC9Q<SV>-)<T7V5Y#9#=RC\/D-I3U/P(/GDNT^MF;HQ1F@
MK9OE=WNKD/\ (!R2SB-..=C]'G4G66(J0\;T$L;U:RS@L:55GY'4IK[Z?22;
M1/0R);DY:^B34:2N_=ZT^"R>A2:PFX=I\L^]IY,4N8UUWIOOW#/KFNGC3C/L
M1X,(=W1Q-IRYS7<,T1\          VR?"YQ.1RLYS:]CWU8BPUOI='\Z=@HD
MMFN#,8Q.?!1B&/ODHTL2OKN;S("7HJS/SUS,L^U2$+(1W>C,?V_*9N#PKU>Y
M'GUOFCCIX<"5;G95^Z9W3518V]'\R? ^RUV5SRPT;5B6(PI@V
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ME^!"@JU6=>M*O5>-2<G)OC;Q9LW0HT[:A"WHK"E3BHQ7 HK!=2.6CK.T
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MR\Q91"CS8L        (:WW.FUBMMU<:-*,2"-&#ZTRO95@PT:C+W6RLF9QR
MF49&;9OQHNL7%-H/\[;<DU?NNI,[,W$M^S:U[I^O445]58_BZBH/F3==N\MK
M)/T*<IOZ[P7\G7QD7X3TK0          D(?;C\?D[*YF95NNT@')HN.NNIL^
M!*[26U&V#LWWN'XTT^E:%-FES$6<D>;/J2TOQD*3^!F4-WVO/ RR-K%]^M/[
ML=+Z^STD^^7MA\3G$KR2QIV]/%>_/&*^[V^=$YH5078
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M:H^/GEO%ZE-R^RG)=:1&][KCX;=RZFM<H*'VY*+ZF^8KB1=AKR
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ML*-E'52IQCRM))OG>D[K'E/8
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M8?/[GX3)[BLM$O#<5RS[JZ,<3.[LVGQN?6M!K&/BJ3Y(=]]*C@66(HXV-
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M^+CP\LIT%KJ55T13;ZW$L'Y<VWBYQ5N6N[2H/#WI-)=2D3@159=(
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M-)&7?TGNX=;"ZN+?VJ<9?9>'XBM/F50[5G:W/L591^W%/\!#:%F%0
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MP=W*4]M2<Y?><5U11N8$9)@
M         !HX^X9PM.4_'%D=X;).GK?;FJ\T2LVR6<=4ZRL-=^9*CBR/":DY
MZ;?<2V.I.=O>?=XW)7N95\/.XP]NG./5VOPD*W_H^+N]*?\ HZL)=+</Q<7F
M(#@MXHH      "QF_6?_ ,%W]>]K/E_]V/\ J3V_O?R>_P#[K7O?8>^[>[S>
M^_@=W;W^3_)[O04KX7_JCP?_ ,_#_I=9L)XW_H[Q]O[;CS^#C@1,/GTL_?\
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M?&SBYGL\:2^R^SYC9#=RCX&0VE/;\/!\\EVGY3-T8HS0
M                              &MCY@<4_6?QJ\MJCQ^7V>NX&5]OA\_
M3]!YEC&<>3L\K/;X?T[W]_4_'V]_:OM[3SF[=3PL\MI<,\/M1<?.1W>VEXV[
MEW#@IJ7V91EYBM\%VFNX      $[W]4,?]G?^J^U>\?]Q?\ 2_B[T=_G^B_H
MOW7=^[X?=?Q^W][Q^GXBI/#?_G/L_P#Y>/7VB\/%7_Q_V\-'P79ZNR1K/G1_
MWI_*/_H2_P#9TU$)QNG_ .W[?Z_^\F5UOM_[GNO]G_NJ9J5$C(H
M  !.8^VKKY,+@7L62^2":M^4^?V$,TK)1JC-:OTO5*-PO^+7[NL=+I_P2(_V
MBJ-^))YO!+9;Q7WIOSEV?+F+CD51O4[J3^Y37F)"0AI/@      (JWW0O]A>
M'?\ Z6;F_P#,^NA8&X7ZMS[L/+(K#YE_H6GOU/) A_"R2I          "UCT
MYBZ<(U%JO"TM+CIQ#7&#XNEAR*Y!<9308S5U)-+A.K<=AK;*)T-I2E*;,NTS
M,RZC7VYJ>+<U*OM3D^EMFT5G2\&TI4?8IQCP:HI:CL<=!Z
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M?^[ZN_\ K$['_P#5?78J7?;_ !E?\S'RR+P^7G^ /_Q$_) WYB($Z
MB8_='R9"(W!Z&EYQ,5]_DE)>CDLR9=D1&]#-1GEHZ]JG&&YKR4F?J1.*Z?B8
ML3<%+&[>W\K_ *PJOYFMX62V?G?]5_$B1BQ2J0        Y7@=">59SAF,)C
MG,/(\KQVA*(EY,94H[BXAUY1TR%N,ICF^<CM)9K22.O4S+IU'56GX=*535V8
MM]"Q.VA#Q:\*6OM32Z7@6OXU[-I0
M                Z[V_5?7=3;0I//[7ZQKO-JKW/B\_M_J&-6<3S^'R,^;P
M^;N[>]/=TZ=2_$=UM+L7%.7!.+ZT>>[CV[2K#5C3DNE,JF1L&:N@      3+
MO_ZR/_1-_P#RA%9?_P"[_P!I_P!47!__ ,V_V7_7&COYT?\ >G\H_P#H2_\
M9TU$)5NG_P"W[?Z_^\F0K?;_ -SW7^S_ -U3-2HD9%            )V_P!N
M'_N^KO\ ZQ.Q_P#U7UV*EWV_QE?\S'RR+P^7G^ /_P 1/R0-^8B!.@
M(J7W0S+*L+X<2%--F^UE&ZV6WS0DWFV7ZG6BWVD.&7>AMY<=LU)(^BC0DS_=
M+I8.X3?BW*V=F'ED5?\ ,Q+P;-[>U4\D"($+(*E        #OCBQ6Q[GD[QR
MJ)9N%$M=\:AK91LJ)#Q1YVP<>BO&TM25I0X3;I]IF1D1_L,>/,).-A7DM:HS
M?W6>[+(J>96\'J=>FNF:+3(4$;.
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M_P 1C'9NVLJNFM:MZG\C,KD:4LZLXO4[JE_O(EGZ*'-E0
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MN]/5:6ORJZ=4S;<66&958<-!OHG'^)7GS(ACE%"IHT7*7'IA-^;R$)46F4P
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M$2NAD?0_0QX,TBI99<Q>IT*B^XS)9-)PS>TFM:N:3Z)Q+1 4*;,
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M6&&.-.2Z8L]=A/P[ZC4QP[-6#QY))EJ:-?S9\
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MB]:>!M-"2G%36IK'I/H#@^@
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MK>#GEO)ZG)Q^U%Q76T1G?"A\1NY=16N,5+[$HR?4F5RHNLU[
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MB@\RI^#F-Q2]FM-=$F;-915\?*K:M[=O3?3!&1H\1D
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M?=RUEM4''[,I1\B7,;.Q@22@
M          :B?G4RUK%?C%Y",>1")F6S-68E7$OQF3CL_:^%V%@V2'%I4I9T
M55,-/9W*2HB5TZ),RD>Z=/Q,^HO9%3?W)+RM$3WWJJENU<+;-PBN><6^I,KR
MQ<Q0(    !*D^V"UJ<O/^5NX7X_86/X?KS6M7+42_P".>875[E%]'8,E>,_:
M?H:M4[W%U_C-]I_O"O\ ?ROA1M[9;92D^9)+^9EH?+6VQKW5VUZ,(07UFY/^
M5=),&%;%M  5B'/O5QZ8YK\I-;(BKAP,>W?L!VBC.)62V\6OK^7DF)=>_P#,
MKOQFWB*[OP61]2]#%[Y/<?%97;U];E2CCRI8/K3-:\]MO@\YNK?#",:T\/=;
MQCU-&(@R1B0         #9[\,F2?I7Y-N)]GV]WNLMR[&^GC\O\ ;+6&<XAW
M=OD:Z=OUSKW=3[.G=T5T[3P.\\/$R*XC]%/[,HOS$EW/J>%O):RX9R7VH2CY
MRQM%*&PH        0B_N6-6?ICEYJ3:D5GQ0-J:3BU<M?CZ>YR;763W$*Q?\
MI="5VXYD=.UV].J?'UZF2B)-I[C7'B9;4MWKIU<>:26'6I%,?,:U\+-J5TO1
MJT<.>$GCU.)')$V*\        "<Q]MOL,LGX.9O@S[W=-UGOK*H<=CO0KQ8_
ME>,XCDL!WM+HM'GO9%H70R,OX?4E'U-*:HWWH^'FL*JU5**Z4VO)@79\N[CQ
M<EG0?I4J\NB2BUU]HD)"&D^
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M4!W\M^U;V]TO5G*+^LL5_*RS?EK<]FZN;-^O3C-?5;B_YUT$Q@5H6Z
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MNF)WN+<]B[K6C>B<%)<L7AY)=16WS(L^W8V]\EIIU'!\DUCU.'7QD,H6<4\
M         ?<QB_FXIDN/916GVV.-WE3?P#[C1TFT\^/8Q3[R(S3T?CI]>GH/
MBI!5*<J<O1DFNG0=E*HZ52-6/I1DFN9XEL#6V$6VKH%I"6;D*RA1;"(XI"FU
M.19C#<B.M3:R2MLU-.$9I,B,OP,:]23C)Q>M,VEC)3BI1]%K$]T<'(
M&#WR4Z65R!X)<G]8QH:K"WGZLO,FQF&VV;C\K+=>JC[!Q6'&))&M+\^_QB.P
M1EZ]'3+U(S(\KD=U\'FU"NWA%5$GR2[KZF87>*S^/R.YMDL9NDVO>AWX]+BD
M5FPO0UO        #;!\).WRU!\D6@G94HHM-LJ5D6H+DE.*:*4>>T,V'C$7J
M1]JC<SV-4&25$9*-/0NBNBBCN]-M\3DE;!=Z&$U]5Z?NXDJW,N_A-XJ#;PA4
M;IOZR>'WNR6)0I@V
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M>VK_ +HH"M2G0K3H5/U(2<7RIX,V>MZT+FA"XI::=2"DN22374SF ZCN
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MR5"M][OP<MA:)]ZM4T^[#2_O.)8/RZL?'S:I>R7<H4M'%*>A?=4R;\*K+I
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MEUF/@9E4RZ;[E>&,??AB^N+ECR(FU"K2Y@
M                 BV?<U[[34:QX]\:JR6GWF;99=;=RR.RZ27H])A,!>,8
MFQ+;[>YR%>7&4V#J.BNA/5'4RZDD3[<6S[5>M?26B$5!<LM+Z$ETE9?,B^[%
MM;Y=%Z9S=27)%81YFY/[)#H%EE1   !V#J;6N1[DVCKO4N(,>XRC9>;8Q@M
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MIT*JPJ0DXM<:>#-F+>O3N:$+FB\:52"E%\*DL5U',!U'<
M                          !7,_,CR)+DA\@N\+VOG%.Q/6=FQI'"UH6I
MUE%1K-R55WCL5XS\;\*TSU^YGL+01-J9EI-/<7YU75NS9? Y-2@UA4J+MRY9
M:5T1[*YC7O>_,/W'/Z\XO&E2?AQY(:'S.7::Y35V,^1D   )!7VZG&96V.8=
M[O>Z@F]BG&O$'[.O><;-<=W96PH]EBV*QEH61-.IA8VF\G$HC4IB5&C*(B-2
M5)AV^E]\/EJM(O\ ,KRP^K'!OK[*Y&R>_+[+?BLWE?37Y5M#%>_/&,>KM/B:
M1.@%3EV@      <4SO"\?V1@^9:[RR)]0Q;/<4R+"\E@=4E[W'\IJ)E'<Q.J
MT.(+W-=.<1ZI47YO4C_ =E&K.A5C6IO"I"2DN5/%=9U5Z-.XHSMZJQI5(N+7
M"I+!]3*MK?6HL@T#NO:VD\H2OZ[JW/LHP><^II3*+ L?MY5?%MXR5D1J@W4)
MEN7'7^#C#R%%Z&0ORSN87EK3NJ?H5(*72M7-J-9;ZTJ6%[5LJOITJDHOCP>&
M/(]:XCJ4>D\@        ;Y/MTM@%B'R$JQ9R1V-;5TCL?#FHRW'B;?GTTK&]
MC,NMLH(V5RX\'!Y1)4YT[&G'2(^JNBHCOI1\3)O$VTZL9=.,?Q(G/R^N/"S_
M ,+95HSCSK"?DB^LGC"I"\0         "(5]RYQ77 R#3G,3'*_I#OHR=*;-
M=801)1=5K=GD>NKF0A"36X]95!6L%Y]9DE"*^&U^*DD+'W&S#&%7+9O2N_'D
M>"DN9X/G94_S'ROLU*.;TUHE^7/E6+@^==I-\21%*%A%6@       !.$^W4Y
M:HVSQBR+C1D]NB1FW'.W4]C$>2\:IT_4F:39=G5*:-[J]-1BN5KGPEFDU(AP
MWZ]GHA)MD=5;Z9=\/?QOJ:_*KK3[\=#Z5@^-XLNKY?9K\5EDLMJ/\ZW>CA=.
M3Q7+V98KB3BN D3"%E@                                        &
M&WR!\EXO$;A_O'>7NV8V0XYA\NIP!MWM6J7L?*UHQK!FT1C)2I;,3(;1B7)0
MDC-,*,\L^B4*463R>Q>8YE2M,.Y*6,O=6F74L%QM&(S[,EE.4U[W'"I&&$??
MEHCUM-\2961R)#\M]^5*?>DR9+SDB3)D.+>?D/O+4X\^^\XI3CKSKBC4I2C-
M2E&9F?47JDDL%J-;6VWB]+9XAR<   !8?_"CQ;_NQ<#=:_6('L\]W;UW?FWE
M;[9+'ZR@POT93N>1")#'TK X=;YHZ_Z&>]*Z$7<8IC>F_P#C\WGV7C1I=R/U
M?2?/+'FP-@-S<L_;<CI]M85ZWYDOK)=E<T<-&QXFVL1TE0        0CON0^
M,YZ[Y08%R1I*[PX[R!P]-1D\EE"U(+9>L8]?2R7Y2TF;47ZO@DNF3'09)-YR
MOE+(U&2^VT]R+[QK"=C-]^C+%>[+3U2[72BF/F)EOP^9T\Q@OR[B&$O?A@NN
M/9PY&1QA-BO         S]^+#81:P^1'B)E"I1PFI6Y<>PF1))U3"6HFSVY>
MLY?G=3Z(BKBY<M+QJZ(\1J[S)/4QA]X*/Q&2W-/7^4Y?9[WF,]NQ<?#;P6E7
M'!.LH_;[GXBRM%'&Q@         !BQS9XU4_+OBWN3C_ &J8C<O.L2EHQ.RF
M]4LT>>TSC5[@MVX\AMQ]F-7Y37152?&7>[$-UK]UQ1'D,KOI9;?TKR..$):5
MPQ>B2Z&\.,QF<Y=#-LLK6$L,9P[K>R2TQ?-)+'BQ16*9#C]UB=_>8KDE;*IL
MBQJXL\?OZ><WXIM5=4TU^NM*V8UU/QRH,Z,XTXGKZ+29"]H3C4@JD'C"233X
M4]*9K74ISI5)4JB:J1;33UIIX-<S/CC[/@      #._XVN7MAPFY<ZRW,N3*
M3@[TT\)VU71B<<^J:QRI^+&R)7MFB\DR5CKS,>YB,D9>6;6LH,^U2NN(SO+5
MFF75+7^]P[4'P26KITQ?$V9S=W-I9-FU.\T^!CV:BX82U\N&B2XTBRNK;&ON
M*Z!;U,V+95=I"BV-;8P7VY4*?7SF&Y,.;#DLJ6S(BRH[J7&UH,TK0HC(S(Q1
MTHN,G&2PDG@T;&QE&<5.#3BUBFM33VGNC@Y
M             "'=]RIRR;R'.=5\-\8L4.P, 99V[M-IAU*TEF.05LJMP"CE
M)0\2F)E+B,Z98.-N(,G&;N*M)_E,65N/EW8I5,SJ+3/N0Y$\9/G>"^JRH_F-
MFOB5Z644GW:?YD_>:PBN:+;^LB+,)^5B   &?7QD\3G>9G,O4NH9T-R5@L.S
M//\ :[B$]6V=:86]%L+Z&^HEH6P63RW(M(TZDE&U(M&UFDR28P^>YC^V994N
M4_S6NS#WI:NC3+F,]NWE3SC.*5I)8T$^U/W(Z7]IX1Y9(LK6VVVFT--(0TTT
MA+;;;:4H;;;0DDH0A"2)*$(21$1$70B%':S8S5H1_8         -7/S&<75<
MJ.!NVL?J*Y=CG>KXZ-V:\989=D3'[[7\*QD7%5!C1TK?F3LBPB;;5\9A)'Y)
M<ED^AFDAG]VK_P#;\WISD\*-3N2Y)88/FE@WQ)D9WNRS]TR.K3@L:]+\R'+#
M'%+A;BY)+A:*YL74:]@       !R;"LJL<%S+$LVIU&BVP[)J'*JM:5FTI%C
MCUK%MH2DN$E9MFF3$29*Z'T_'H8ZZM.-6E*E+T91:?(U@=M&K*A6A6AZ<)*2
MY4\46MF/7M=E&/T>34[IOU.14]9>U;ZDDE3U=;PF+"$ZI)&HDFY&D),RZGTZ
MC7R<)4YNG+THMI\J-HJ<XU:<:D/0DDUR-8H^P/D^P         "#%]PKPV<T
MCR@@<D<3K#9UUR7;D3[M49GMAT>X<?C16,KBN^-)H8+,:PXURTIU7DE3EV1I
M+M9%K[FYG\58.QJ/\^AJXX/5]EXQXEV>$I/?[)W99FLQI+^GN=+XJB]+[2PE
MQOM<!'R$R("        $Y[[?KG*WOWCI(XR9S;(>VKQLKH4/'?=/I.;E&DGW
MFX6,36DN/&](>P"<XFDE=C:6H\%57U4IU]?2I]\<J^#O?CZ2_IZ[T\4]OVO2
M7'VN NW<+.U?Y?\ MM=_U5LL%]*GZK^J^Z^!=G:R08(<3T
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M^K&F_P FAKX'-Z_LK!<3[1=>X&4?!Y;+,:RPKW+T<*IK5]IXRXUV20P(:3\
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M(D]IJJ7?6AX6<*JM52E%\ZQCY$B\/E[<^-D3HMZ:5:4>9I3\LF;\Q$"=
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M^4,:5O<K9*47SI-?RLM'Y:7.%:ZLWZT837U6XO\ FB2_16Y;(
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MKJO1/OPY4N\N=+%<CX2L/F)E#J4J><T5WH80J>ZWW)<S;B_>CP$/D625(
M   !N9^!#:"=<?)+JZJD2SA5^V,0V-J^>Z9D33JIF-/YG2Q'R[5+44[*,)@,
MMDG_ (Y:#,R3W&(QO?;^/D=226,J<HSZ^R^J3)AN+<_#[Q4HMX1JPG!]':73
M**YRP1%.E]             !'C^>[XZGN1FI&>4^IJ%R=NK1M"\SF%16,J=G
M[!T]%>DV4]IF,VA2IF0Z\D27[&*E/:X_7NS6?XSJ8;13/=#.E97'[?</"UJO
MNM^K/5T2U/CPU:2 ;];OO,+3]TM8XWE"/>2USIZWSPTM<*[2TO!$'$6L4H
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MU%"9I0^%S&O;[(U9)<F+PZL#9C)[GXS*K:YUN=&#?+V5CUXF3(\)D@
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M*I2E"4H0DDI21)2E)$E*4I+H24D70B(B+T(5076?H
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ME5D\6WK;9?E"A2MJ,;>A%0HPBE%+4DM2.5CK.T
M -/?S.\!"YK\8Y=W@]/[W?NC6;;,=8IBMH]_E54ZS'<S/7'<9EY5Y'7U[<BO
M2?K]5A1VR4AMYXSDN[&<?M=_V*KPLZN$9<3]67-C@^)O@1$M\,B_><M<Z"QO
MZ&,H<,EZT.=+%?22X65[2DJ0I25)-*DF:5)41DI*B/H:5$?0R,C+U(7(4$?@
M    ):_VP6T4=G*_2LN5T62M<;1Q^%W&?<@RR'$\PE=OX)\9IHT=2_'N]?P(
M5UOY;_\ 9[I?2@^IK\1:ORTNO^U6;?L377&7X26F*[+5
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MMB+\LK.VR^UA9VD5"A!8)>=\+>MMZ6])VH/.>H
M    "#7\^'QYGQWW1_>FU=1>VTOOF\D.9;!KHZR@8%N26B18V[!H0@VX=-L)
MMEZTB%W&E$]$YE*6FDQD':VZ&<_&VOP%P_ZJBM&.N4-2YXZGQ8/7B4IOUD'[
M?>?N=K'^CKR[R6J-36^:?I+C[2T+ CTB9D    #>%]O;L[] _(SC&,.241XV
MX]6[+URXEW^B>?@5L/9\)!*4E3;4A<C7)(;49I4HUFVDS-SM5%-\J'C9+*IM
MI5(RZ^S^(FNX-SX&\,:3>"K4IPZ%VU_)YMI/H%0EZ@                 !
M@+S]^/#27R ZP5B6PHJ,;V'C\2:>L-OU4!N5DN!V4I33RVG8QR8*<CQ2Q>CH
M*?5/O(;>1U6RY'DI:D-YC)\ZNLGN/$H]ZC)]^#U27F:V/IQ6@P6?;OV6?6WA
M7'=N(KN5$M,7U8Q>V+>G8T\&5^G+KAUO+A/M>PU/O#%W*J:1R96*Y5 )Z7AV
M?X^T\3;618?=J9:;L(2TN(\["R;F075^&4TRZ1H%PY=F=IFENKBTEBMJ]:+X
M&O[)ZTV4-FV47N373M;V.$O5DO1DN&+V\:UK4TF8M#(&+
M                  #<1\7WQ(;3YYY) SW,&[77'%^DM?'D6?N,)8N,[>KI
M#)6&(ZSCRT+*9-=(U,R;=;3E=6J)9'[B2W[54:S[>.WRB#HT\)W[6B.R..IR
M\RUOB6DEV[.ZEUGE15ZV-/+(O3+;+#7&''PRU+C>@GJZ=TYK30&ML5U'J#$:
MO"-?897)K:#'ZI#GB9;[U/29DR5(6].M;>SEN+D3)LEQV5+DN+=><6XM2CJ*
MYN:]Y7E<W,G.M)XMO^VA+8EH2U%YV=G;6%O&TM(*%O!8)+^V+;UMO2WI9V:.
M@](                            =1[YTAK[DAI_8&C]IU)7.#;&QZ507
M4=/B3,AJ<4B367=0^^R^W#OL=MH[$^!(-"_;S([;G0^WH?IL[NM8W,+NW>%6
M$L5YT^)K0^)GDOK*WS&TJ65TL:%2.#\S7&G@T]C2*UOF?Q*V+PHY!YKH;8S*
MWWZ*05EB.4-178U7G>"V;CR\:R^H[^]'AL(S2FI3*%N^RL&)$52U.,+,7AE>
M8T<TLX7='4]#6V,EK3\W"L'M-=,XRJXR:_G8W&N.F,MDHO5)<NW@::V&*HR!
MBP ,O_C^V,O4W-[BEGI2'(D2FWSK6+<OL]GE3C>09- QO*$H)PTH4;N.6\I'
M0U)(^[IW)_$L;G%#XC*KBCM=&6'*EBNM(R^0W'PN=6M?4E7ACR-I2ZFRSK%$
M&R8                   !CQR<XL:1Y?ZNM-1[VPZ+E6,3C7+K)J#3#R3$K
MPH[T>)DV(7B6W)-'?04/J)+B26T\VI33[;S"W&E^VPS"ZRVX5S:2[-1:^!K@
M:VK_ )5@S'YEE=EFUL[2^@I4WJ>V+X8O8U_D::T$$SY&_B'WUP.M[',*QF=M
MKCC+G&5)M:DK'3FXNS(6DHM/M2EB$^6+V+;JR8;L$J54V"C;-#C,ATX3-LY)
MO'9YO%4Y84[W#3!O7QP>U<6M<:TND-X=T[[(YNM'&KES>B:6F/%->J^/T7PI
MO!:CQ(R*                            !Y8\=^6^Q%BL/29,EYN/&C1V
MUO/R'WEI;9889;2IQUYUQ1)2E)&I2C(B+J.&TEB]1RDV\%I;)0GQD? 5D6=N
M8_O'G/3V>(X1UCVF-<>GES*C-,K1Z/1Y6T'F%QK#"Z%:32?TAI;=S(,S*2J"
ME'CD0//=[X4>U:92U*KJ=37%>[LD^/T5LQV67NWN)4KN-[G:<*.M4M4I>_MB
MOH^D]O9VS"<>QZAQ*CJ<8Q:EJL<QNAKXM51T%%7Q:JFIZR$TEB'7UE;!:8AP
M845E!(;:;0E"$ET(A6LYSJ3=2HW*;>+;TMOA;+;ITZ=*"I4HJ-.*P22P27 D
MM1]@?)]@                               :M?E:^.N@Y_:$=KJ)BMJM
M_:U;L+[3>5RS;C-RI;K*5VVO;^:HOR8SF2(S:?*H_P"H6#4>21FVA]I[/[O9
MU/)[SM3Q=G/1->22XX]:Q7 U&-Z=WZ>?6'9A@K^GBZ<O+!\4NIX/5BG7?Y9B
M>2X)D^087F5'98SEF*7%AC^28]<Q78-K2W53*<A6-;81'DI<8E1)3*D+29?B
M7^ 7/3J0JTU5I-2IR6*:U-/4R@*M*I0JRHUHN-6#::>AIK0TSCX^SK/8ARY,
M"7%G0WEQY<*0Q+BR&S(G&),9U+S#R#,C(EM.H)1?XR'#2:P>IG*;BU):TRUO
MUQF$78>O,#S^#V>RSG#,7S"'XS2;?M<FHX-U'[#0](0:/%-+IT<<+I^"E?B>
MOE>DZ-:=%ZX2<>AX&T=O65Q;TZZU3A&72D_.<S'4=P
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M/AB;';O6\[7([6C434U0CBGK3:Q:?)C@9GC&&8
M     Z^V7J;5^Y\8E87MO7N&;*Q.7WJ>Q_.,;J<FJR>6TXR4IB+;Q93<2<TV
MZKQR&NQ]HSZH6D^ACNH7%Q:U/%MIRA46V+:?4>>YM;:\I.C=TX5*3V22:Z]O
M'K-'_(?[=+A=M5Z?<Z<OL^XY9!+\RV85#,3GVO6I+QDHWW<2RV260I0APC-+
M$.^A1T)4:4H(B3VRJRWTS2W2C<J%>"X>[+I6CIBV0O,/E]DUTW.SE4MZCV+O
M0^S+3S*21I;W3]N/SBP)^9)U-?:IWS3(4Y]/8JLD_EYF,I"",T^]I,\37XK
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MHS#222A"$I2E)$1$1".2E*3<I-N3VLE<8QC%1BDHI:$M2/;'!R
M                                   :B.=7^T1IG_=$?_4G^W5_M$?Z
M_+_F9_\ H/\ Y>)'E/\ V*K_ (EM_0_3U>OY^(B>>?XA1_PG9_VG]77_ '?F
MXS;N(X2P                                   QFY'?ZG8_V9OZ%G_:
M._U/_K!K^@_S/_ _\H[1[K+TO[__ &>LQN8^A_W;_;:M?]N<T1;8_P!(J?\
MY8G^FM_^=C_2/WX/^J?\]_XY_P!]XA+K?4_\>V>AY_,0B[UK_P!M;?U.;5Y^
M8Z@__P E0]'_ .Q'C_\ U4S$T1^[2_\ R]W^KK'_ )B/W?\ 2'?]2_\ V=_X
MQ_G.X8V\V_XSK7ZGGX^ R]CJ7^ :G^EYN+A-[V ?V8A?V,_IIG]@/[,?Z4[_
M *%_GO\ PW^=[A$JWZGK?6UDXH?I+T/J^CS',QU'<
,            !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img135872921_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img135872921_1.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )G!*T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^MG_@I;_P
M5!^ 7_!*[X5> OB_^T'X0^,'C'PU\1/B"OPVT2Q^#6@>"_$.N6NN-X<UOQ0+
MO5+;QM\0/AY80:3]@T&\A,]IJ=]>?;)+:/[!Y+RW$/XSV7_!X7_P3'NKNVMI
M_@U^W#IL,\T<4M_>_##X&26EFCL UQ<IIW[2-_?M#$#ND6TLKJX*@B*"1L*?
M./\ @\D_Y,<_9=_[.NB_]5#\2*^Z/^":W[ '_!-/Q;_P2O\ V,_B7\=OV.?V
M+;_4?$W[+GPK\0_$'XI?$'X%_!BS\1:IJ5_X4L;S5?$7B3XD:KX:M==;5;N;
MS+F^UV\UY;^9S++/>,6=CHE!04I)N[:T=MC%RFZDH1:223U5^B_S/T8_86_X
M*??L4_\ !1K0-8U7]E?XQ:?XNUWPQ;QW?C#X<:]IVH>$/B;X1M)KA+:'4-7\
M&Z]#:ZA<Z)+<2P6\?B;06UGPP]Y<1Z<-9_M$2VD?SG_P4-_X+<?LI_\ !-+X
MY_";]G[XZ_#_ /:#\6>,OC'X5TOQ?X8U/X2^%/AQKOAFQTW5O&&J>"K:#7KW
MQC\6/ >JVM\FJZ3<W$\6GZ+JENNGO!+'<R7+26D7\:G_  3TL_A9\/O^#GG0
M?"__  3GU5=1_9J'QC^*7A[1&\+ZUJGB/P=>?"&3X.^(KWXFZ?:ZU.]ZVO\
M@/1?$%MK,G@G4]0NM2L9Y=%\':G8ZO?W$>F:O+]-?\'9W_*3/]A/_LB'@O\
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MZ:E=)\UKVTWZG[(_\1B?_!,S_HAO[=?_ (;/X ?_ $3M?O-_P3[_ &]?@_\
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M?MW?&G]@WQ%^S;\6/B/\3/!O@SX5:M\#-+^"MS<?$'X@_M%^._B7HNAZ_<>
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MBTT>_P!(UGQ?\/K'5I_%OAK2=4L?$.@7NG:CK.D65G?6FN:/<VTTL.IV3S_
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M\(?\% /^"AOP'_X)T_"72?B/\81XF\4>*/'7B&'P/\&?@Q\.M+7Q#\5/C/\
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MR\?^'I9_B!J.O>._$FAZK?+9>%=.ECE\.>'/"EN+J:]=K9XI((+?]N*_D_\
M^")?_*:3_@O]_P!EPT'_ -6?\9:_7W]D?_@I+_PU/^W%^WO^QE_PIC_A!/\
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M3:L_E<^V**_G1\;?\%N_VL_V?_"NA?'S]KW_ ((Y_M#_  "_8ZUF_P!(BO\
MXYZ;\=?A?\4O'W@C2->N[:RTO7?B3^S[HN@:)XM^'MFUS=P0W<7BO7],FBN)
MK:PM?MVJWEGI]Q^\7A_XR_"OQ3\']*^/^@^//#E_\%M;^'EM\6=-^)7V]+7P
MK-\-[KP\OBN+QC-J-X+=;+14\.M_:]S<7JVS65HDK7B0/#*B2TTD^CZIIKTT
M;L_)ZC4E+9Z]FFGKULTM/,],K\1_!'_!2?XY^)?^"Y_QA_X)DWWA3X3Q? ;X
M??LUZ9\8]&\6VFA>,(_B[=>)[WP_\+=6EL=3UZ;QW/X-FT%;CQOJR1VMIX!L
MM0$-OIRMJCR17,EWY-X+_P""V'[17[5%]XC\5_\ !.#_ ()4?'#]L/\ 9R\+
M>(-3\/S_ +0WB[XX_#']EGP_XRDT*X2UUN_^%/AOXIZ/J&H>/[:WE6Y2VLHM
M0TC7?/CBL-:T?0M3>YL;+\S_ -@GX^I^TK_P=!_'SXIR_"[XI_!36KW]B"/0
M/%?PH^-'A>3PE\1? GBWPQH'P$T3Q!H>LZ:9;BUO+1+ZT>ZT'Q#IES<Z1XF\
M/W6F:_IDQM-0B1+4&E+F2TC?=73NMTG=/UL3*2]VSWE%=;--ZV>S^39_:#7P
M;I__  4.^"NI?\%"M<_X)K0>&/BBGQTT#X(P_'N\\5RZ+X37X32^#YKG1[5-
M-MM=3QM)XP?Q*)-;M6:SE\"0Z6$CN"-9+)&LOWE7Y0_\//?^-N/_  ZP_P"%
M(?\ -!_^%V_\+V_X65_U"/[5_P"$9_X5A_P@'_;#^VO^%A_]-?[)_P"6=0E>
M^E[*^]K:K7S[6\RY.UM;:I;7O=[>5^_0_5ZBOQ5_;Y_X+5?"C_@GC^V!\)_V
M8OC!\)/&/B3P_P#%GX$ZY\5= \=_#Z_OO$_C;4_'L/B7Q%X4\%_!?PI\'M/\
M(7$WB;Q%\0M;T.WTG0];E\=Z'96FK:Q9VVH6,5E'/J:?/'Q<_P""WG[7/[,?
MAFP^/7[5_P#P1M_:%^"7[&]UKNCZ;J/QNA_:!^$/CSXF^$=,U_5+32-)U7Q_
M^SQHFDVFM^ GNKVZ2R6T\7>-M(M6U6XTO1X=4GU#5[*%WRRTTWVNTK^EWJ_)
M:B<XIM-ZK?1NVB=W9:*SW>F_9G]&-%<C\/\ QWX4^*7@/P3\3? >LVWB+P-\
M1?"/AOQWX,\066_['KOA3Q=HUEX@\.ZS:>8J2?9M3TC4+.]@WHK^5.FY5;('
MS#_P4)_:Y_X8/_8W^.7[6W_"OO\ A:G_  I?0-#US_A7_P#PE?\ P@__  DG
M]L^,O#?A+[+_ ,)7_P (UXP_L?[-_P )!_:'G_\ "-ZKYWV3[)Y,7VC[3"DF
MW;JW:WF5?2_3<^S**_GV\*_\%J?VB_VFO!=E\1_^"=7_  2L^-_[87PYLM T
MN]\7_$OQ/\:_A[^S#\/5\3MH-KJ?BWP?\*]6^*'AV_U_XS7G@?6Y[CPCJ][X
M:\*V$5[KNF:A'I5O=Q+:/=U/AI_P<._ SXS> +30/A-^S)^TEX]_;FE^('C#
MX5ZK_P $_P#1= TX?&+PCXM^'\=F?&?B'QSXGO)K;PQX*^$OA^ZO%TF^^(/B
M:+2[V'6[;4M)N/",%YH^LQZ<^67;UU5UZJ]X_.Q//'OOMHTGZ-JS?DKL_H4H
MK\%/ G_!:+XH^ /VH_@I^RO_ ,%'/^"?/Q$_8!\2?M*ZZ_A7X"?$*X^.?PZ_
M:,^%'C3Q4\^F6%CX9U3QS\/-%T/1]"UN^UG6M#T1K"RG\13:3J'B'P[)X@&D
M:9JR:C%]5?\ !5__ (*1_P##L'X'?"'XS?\ "F?^%X?\+5_:5\ ?L\?\(W_P
ML3_A6G]@_P#"<^$/B-XJ_P"$O_MC_A!?'_\ :G]E_P#" ?8/^$?_ ++T[[;_
M &M]J_MNT^P?9[TY972MJ]K--/T:=OQ#F5F[[;W337JFK_@?J#117Y??\$H/
M^"D?_#S[X'?%[XS?\*9_X4?_ ,*J_:5\?_L\?\(W_P +$_X67_;W_"#>$/AS
MXJ_X2_\ MC_A!? ']E_VI_PG_P!@_P"$?_LO4?L7]D_:O[;N_M_V>R5GJ^V_
MS'=72ZN]OEO^9X1_P2,_X*3_ !S_ &^/BW_P4<\!?&'PI\)_#>C_ +('[2DW
MP<^&MS\-="\8:/J6N>&(_$WQ2T9;[QS-XH\=^,;74]>-KX(TF0W6@6?AG3_M
M%QJ+C2Q'+;16GZT:-\</@MXC^*?B_P"!GA[XO_"_7OC9\/M)T[7O'OP>T;Q_
MX3U3XI^"-#UBTT>_TC6?%_P^L=6G\6^&M)U2Q\0Z!>Z=J.LZ196=]::YH]S;
M32PZG9//_*+_ ,$$?$_Q$\%>/?\ @X(\6_"/X7_\+L^)_AW]L'Q'J_@/X1_\
M)MH?PW_X6/XHLO&/[1$VD>$/^$^\36]WX>\(?VW=K'9?\)!K-M/IVF^;]INH
MGB1@?E']FC]J3_@H]HG_  7O_P""C/Q8\(?\$K_^$W_:9\9?L^_!C2/BO^R9
M_P -P_ GPU_PIGPOIOP^_9PL_#_B_P#X7QJ?AZ7P!\1/^$ETO1O">K_V!X;T
MZUU'1O\ A-/[/O99+CPYJ32W*%W*UDE&+5VEJU'N_-N_?3J9J=HPO=N6[LWW
M[)Z^6]C^Q_\ ;'_:K^'G[$/[-/Q6_:H^*^C>,_$'P]^#^D:5K7B71_A[IVAZ
MMXROK75_$NB>%;:/0M/\2>(O">B7-PFH:]9S3IJ'B'3(ULX[F2.66=(K>;T'
MX"_&+PS^T3\#/@O^T#X*L==TOP;\=/A/\.OC%X2TSQ3:Z?9>)M.\,_$WP?H_
MC70;'Q'9:3JFMZ5::[::5K=I;ZO:Z9K6KZ?;ZA'<166J7]LD=W+\+?'+]O?X
MV_LO_P#!,KQ]^W?^T7^Q]_PK#XR?#/0+C7/&/[)/_#0/A+QK_97G?%^'X=>'
MK7_A?/@7P=X@\*WW]O>%=0T/X@^?I?@^_P#[+_M7_A%+Z$:C8WE\G<>&_P!O
M'_A(?^"7=Q_P4E_X55]D^S_L9>*OVN?^%,?\)S]HW_\ ",_"C6/B?_PK[_A8
MO_"'P;?MW]D_V'_PEG_""M]F^T?VG_PC5QY7]GR39VV^TU>Z:;TT_P"#>SN7
M=7W^S>UGMW_X&Y^A-%?SF_!/_@N-^T]^V/\ ";PE\3_V#_\ @D9\=?VC;&7P
MMIM]\2]>\5_'KX9_L]?";PWXX6W'_"7> ?A?\4/B=X;CF^.-UX+U4MH>IZIX
M?\&>'WN+^"Y\K28HXD:7[;_X)]?\%7?AC^W)X[^+'[/GBCX4_$C]E?\ ;#^
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M6]AJEQ-IT]]IFHV<-XD,ES87<*O;R?M?_P $"/\ @A;^UM_P2N_:-^,WQ?\
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M!);RR!A/=6R@.7=<\'?1*%_*UK_<.2;A-):MNWF?IC\*O^27_#?_ +$+P?\
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MES>)#"\<4\,CJY5)8V(=>@_X--X/"VJ_\$Y?B;\18]0CUWXM_$7]K7XLZO\
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M7T.[@U6/3O$*6MHFN:-<>'-2LO$EX]K\+_M-_L'_ /!>K]OWX(_$CX ?M/\
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MM=)\0RQ6\7P:FN-'C^'4#^-M4/AU]<GFUQ_%4WCV-Y9+2"V8_H]XI_X)V?\
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M:NU=)Z/7K;2SMW+FFTK=&GH[/1]+Z7];>J/SM_;U_8;_ .#@#_@HK^S3XO\
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M+*VAM89+[5?@=X'U35+UXH$C1KO4M3O+O4;^Y93->7UU<W=P\EQ/+(WXO?\
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M'Q6\/>+]%L;.]\2>'?%GQ.CM[+PGH:Z=<WMWX>U2[O=;"R&*&TG::WP/B;\
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M75PUJJA6;[;J'N_5_F5%6C%/=12_ ****104444 %%%% !1110 45\O?M/\
M[9_[-7[&>F_#/5_VD_B3_P *WT_XP_$K1OA#\.;C_A#O'WC#_A(OB)X@@NKG
M2/#WE> O"WBF?2/M<%G<O_:VNQ:9H=OY>VZU.%WC5_J&BSWMH]GWMN%UKKMO
MY>H4444 %%%?D_\ \%*?^"G_ /P[R^)/[#?P]_X4?_PM[_AL[X[1?!3^U_\
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M2ZEN?MBBBAMMW>K8))*RT2"BBBD,**** "BBB@ HHHH **** "OQM_X+F_\
M!/+XT_\ !37]BK3?V</@-XG^%_A+QQ9_&SP+\2)=5^+FM>+-!\*-H?AC0O&F
MF7]I'?>#?!/C[5SJTUQXCL7LX&T-;.2&*[::^MW2&.?]DJ*:=FFMTT_N$TFF
MGLPHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_A+OLNC:/\ VCK?VZ\\,>+H?M,7]B[KG^DK]O?]MC]D#X;_ /!/#PQ^U?\
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M$VI>&-?MRUOK.@7\W@OXJ02W6D:E 8[RPFDCV;VMYH\R0VTQ_?6MO)%]A?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)[:7MJ[VT5]7^I_1;_PB-M_T&O%?_A3:M_\ )%'_  B-M_T&O%?_ (4VK?\
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M_DBC_A$;;_H->*__  IM6_\ DBNKHH Y3_A$;;_H->*__"FU;_Y(K UWP_\
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M"?\ 8TWO_J$^,* #_A$;;_H->*__  IM6_\ DBC_ (1&V_Z#7BO_ ,*;5O\
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M<'S"2,@5Z77*W'_([Z/_ -BKXC_]._A6@!/^$1MO^@UXK_\ "FU;_P"2*/\
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M )(H_P"$1MO^@UXK_P#"FU;_ .2*ZNB@#E/^$1MO^@UXK_\ "FU;_P"2*/\
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M'$8\(Z1*MS8QP7MUJD[W%I#>Q7EAI&MM;SV)\^\ ?LS_ +7/Q;_X+'_LY_\
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M_P .?@]=?"2\^,'Q\\%?M8_$GP[!\49_B/;^,O#^J_M0^ -,T?PO\:-"AO\
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M]._M9-9USQ-HWQ8CU71=#.EQWM^D^O\ AW2+^XM=+U.6UTZX6T;/[DU_'?\
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MH\9ZS^T5_P %)OV_V^&G[1OP(_X)Z?$;]E#]G+P)\!/$VC?%OX]7WP'\;?\
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M]+;Z7NU'=Z=;^G8_M#HK^)WP/^TC^UKXX_8@_P""DGPA^"/_  5.\/7?PQ^
M?[8/PJ^$_P"S!^WQ^T]\=_"WPI\1_%_X;ZGH=_XG^)_P>\._M=^(+<Z)=?$B
MW@T[2Y?#/Q'BL]5OM1MI]4N+*>S\,^(M)ET']7/^" ?QY\-?%SX:?M,^#;'X
MN_M@_%_QG\'OBMX<\/>.M7_:B_:^^%_[=7A:QN]:\.W>H:6GP$_:4^$_AOPO
MX;\;>"[^&VN[O5HFT\W6G7OV!'^R^>;"U3A9-WV\NCM9OMOMT>@U.[2L]5>_
M3^M'O;\[?T#4445!84444 %?-GQ]_P"/GPQ_UPU;_P!&:?7TG7S9\??^/GPQ
M_P!<-6_]&:?0![#X<N;>SM_%EW=SPVMI:^)M=N;FYN94@M[:W@2"6:>>:5EC
MAAAC5I)99&5(T5G=@H)'Y>?LX_\ !9;X!_M;_'32OA)^SI^SW^V]\4_AOK/B
M?Q%X2LOVQ_#W[-VJ_P##&@U;PO::I<:FUY\8[WQ#:WVG6#7.E2Z397]_X0MK
M:\U6ZTZUA<K?03-^D=UX3TGQ[X-^*/@77OM/]A^-)O&WA/6?L4PM[S^R?$>E
M-H^H_9+AHY5@N?L=Y-Y$S12"*78YC<+M/XQ_\$[_ -BK_@J[^P5%\.OV2HOC
M7^P[\3_^"??PUO\ Q[9>'O&]]X*^+_AS]LG3/"7B2]\6>(]#L]*T334D^!W]
MK:?XNUVUU"]NO$MYXJ\ZQ;4[62>]8V9CI6L[[]+NW?7;5[::?/I+O=6VZZ7[
M66^B>MWY+Y^J:Q_P6Z^ G@7XZ^'O@Q\;OV6O^"@_[-_A[QA\5;;X,>#?VC?V
M@/V5-9^&_P"S9XL\?:IJ3:3X?T[0_B!?>);G69K+Q+=1S2Z-JUSX1M=/?3()
M];OI[#18GU 6OV@O^"VG[/'P ^//[2/[-,?[/'[<'QU^,7[+B?#/4?B-X9_9
MM_9X_P"%N13^%?B;\-=)^*5OXXT[5]+\8V6DZ+X1\)Z!K5A9>+M1^(EYX$NH
M]9>>'PW8>)=/M+K4X?Y[(O\ @V&_;JN/B?X6\;>*?BU^QEXU\2^!?V@?#OQ9
MOOVD-<\>_MEWG[1W[0>@V/Q*M?$M]I_QAT?Q/?>,_@EX1U#2_#XGET"+P'X+
MOM0O=7LM/TO7O&=Q#<:AXED_HQ^$7[ _QA\ _P#!0_\ X*G?M;:QXD^&MS\.
M/VX/AG^SKX,^%&BZ9K'BB;QMX>U3X1? ZT^&GB2?XAZ;=>#K/0M)L+[7;=[O
M0Y?#?B3Q;<7.D%9[^UTR\)L%IJFE=.^FVJUO'\TWVVZ,E.H]&K>]:[MM9Z]%
MH[=]>Z9%XX_X+:?L5>$_V6OV:OVJ/#Z?&?XNZ7^U_J7B#0OV<?@K\'_A?>>,
MOVAOBGXD\%ZQ>>'O'WA[P]\-VU33('U#P%K]C-HOB>>X\0P:1%J4EA;:9J>J
M-JVDF^_&/P;^W/X$_:"^._\ P7X\7_MI^ ?VUKS]A7P7^SK^QQKVJ_L2_&J+
MQ_\ "[XI?#CP_JOPLT:U\?:-X<^#6L?$WP;9?"SQ!XU\4V/_  E=U>^%_&'A
M>+QC87UCXK77]0MM7M[JY]K^%W_!$C]N#]GW]F#_ ()::U\"?C7^S/HG[>W_
M  37U3]K"ULO^$YC^)'B[]EWXF>#/VIOB%\1]9UO1]2U>R\&>'_B387NF>#/
M&$&E"[L?!5A/_:&K^(([6]@ETKP_KYZ+4/\ @D'_ ,%"?BI9_P#!7SQQ\?/B
MC^QUJ'QL_P""EG[/_P  /AYX=;X3O\9_"7PP\%>-/A%X=A\)7=KK&G>*_"OC
M7Q3I_A&'P_I.A0Z=K]GJWB[7->U!-1O[[PWX<CE@L4:Y%>SZVO=W5JBVT7V5
M>_>_RE\[MHUL[):?#K?5_:;5NUMS[R^(/_!5K]D']COX<?L<?"?X>?!S]J/X
MP^*?C/\ LY_#CXB? 7]E7]FGX47WQP^/?AW]GR+PGI=IX5\0>*]!D\9E(-+T
M33;7^P+J_N/&OB'5=3U/0==DL[C7ETS4=2'P[_P2N_X*!_$E_A3_ ,%;?VC_
M (G>$OVZ/VBM&\$_\%._C9H7PM_9]TKP%\1OBY^TE\.?AYK>JZ&WA7X0>&_@
M?X@UDZM\.K;X?Q:PMGXB^'T,^@Z)\/)+'5X+V"PCTZY*^H^,/^"8?[>_P8^-
MW[*'[7W["GQ<_95T_P#:'^&W[ WPO_8-_: \!?M,:5\4M;^"7C'PEX"D\,:Y
M-XI\#ZY\.]*L_'\=_)XHT&U>WMI[/PDUU8:#HTLUU8_VIK^ES_-FK_\ !$#]
MOGQ)^QM^W'\'=7_:3^ .D_&W]JW_ (*'ZC^V[JLO@B\^-'A'X*?%CPMXGTW[
M1XV^!WQ3&DV-O\3_ (>^"_$7B_4+K6#:^"=>\<ZI;6'AKPY9MXFGFOM0N+)+
MDLE=:VNW?3576RT]&[]]-'[]]GHG9)*VRM9WUU_KO^A'AC_@N#\%OB!\,/VG
MM7\)?LM?MX:-^T/^S#X0\*^,O%7[&7CW]F>ZT7]JS5/"_CKQ/HO@[0?'GASX
M40>-I;?Q#X'T34/$%GXA\<7EOXOL-4\.>";/4?$%S8I"=.%]X9_P3<_X+M6/
M[0?["GBK]J[]MCX)_%#]GC3_ (.^!?$OCSXH_M V'P2\5>%OV.OB' GQA\2?
M#KPIX7_9L\7ZWX_^(GBOXB^-XQ#X8\)>)_#3,UVOQ/DUO1=-?R1:6L?C_P#P
M2,_X(??'_P#8+_:-^/\ \7_B;J7[*OA/P)\=/V7]4^#MI\,_V9O$?[1GBC1?
MAKXOU3QYIVKS1^'Y/VC)_$OC#7?"!T+24UF76-;^(@U:3Q/K%]H\/ABUTNRB
MUV_YCX4?\$2_V[=3_P"";7Q2_P""3'[1GQN_9)B_9A\.Z#JM_P#LP?%+X/\
MA[XQ7_QOE^)<W[1#?'VPU7XYZ-XO?1/!$?@V6ZO?$'AVYT'P+=7.KV>FZ^AC
MU[4K_0[34[PM#57TYHZ]>5_%;=:-[:_.P)U-';6TM.EU;EN_/7M\KGZ:?LW?
M\%I/V6OV@/''B;X<>+/AM^U/^R/XRT+X2^)_CWH>B_MC_ Z^^#$WQ(^"G@RP
M_M;Q3\3?AK-!KOBJW\3^&M'T<2ZQ,OFV6L7.DVU]J-AI5W::=J$MKO?L3?\
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M7I?OIV%S)I6=KN]DM7IN[K[^O<]0^$__  6M^ WC[]H3X;?LX?$W]F']OO\
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M6[FM[O66L].EU633K3]#***&VVV]V[OU8))));)67H@HHHI#"N5N/^1WT?\
M[%7Q'_Z=_"M=57*W'_([Z/\ ]BKXC_\ 3OX5H ZJBBB@ HHHH **** /,_ _
MP5^#?PQ\->(O!?PU^$OPS^'O@[Q?K7B#Q)XM\)^!_ ?A;PGX:\4>(O%L:1>*
MM>\1:%H.E:?I>MZUXFBBCC\0:IJ=K<WVLQQHFHSW*HH'EG@3]B/]B_X6ZYH?
MB;X8_LB?LP?#GQ)X8\0ZCXM\->(? GP"^%/A#7/#WBO5]);0=6\3:'JWA_PG
MI]_I/B'5-"=]%U'6K"XM]2O=)=M.N;F6S8PGZ?HIW>NKUW\_45EV6FWD?/\
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M=_\ S,5X!16W]DX'_GW+_P &5/\ Y(P_MS,?^?L/_!5/_P"1/?\ _AHG6_\
MH2=*_P#"JN__ )F*/^&B=;_Z$G2O_"JN_P#YF*\ HH_LG _\^Y?^#*G_ ,D'
M]N9C_P _8?\ @JG_ /(GO_\ PT3K?_0DZ5_X55W_ /,Q1_PT3K?_ $).E?\
MA57?_P S%> 44?V3@?\ GW+_ ,&5/_D@_MS,?^?L/_!5/_Y$]_\ ^&B=;_Z$
MG2O_  JKO_YF*/\ AHG6_P#H2=*_\*J[_P#F8KP"BC^R<#_S[E_X,J?_ "0?
MVYF/_/V'_@JG_P#(GO\ _P -$ZW_ -"3I7_A57?_ ,S%'_#1.M_]"3I7_A57
M?_S,5X!11_9.!_Y]R_\ !E3_ .2#^W,Q_P"?L/\ P53_ /D3W_\ X:)UO_H2
M=*_\*J[_ /F8H_X:)UO_ *$G2O\ PJKO_P"9BO **/[)P/\ S[E_X,J?_)!_
M;F8_\_8?^"J?_P B>_\ _#1.M_\ 0DZ5_P"%5=__ #,4?\-$ZW_T).E?^%5=
M_P#S,5X!11_9.!_Y]R_\&5/_ )(/[<S'_G[#_P %4_\ Y$^N? 7B;Q;XODUO
MQ5::#X<M(;E]/T0VESXCU-I$ETB*XNVG$D7AAE:.9-:C15(5D:!\Y#*:]%^T
M>-_^@/X5_P#"CU?_ .96O.O@'_R)^I?]C+>?^FO1J]OKYK%TX4<36IP5H0FU
M%-MV5EU>K^9]=@:LZ^$P]:HTYU*:E)I))N[Z+1;=#E?M'C?_ * _A7_PH]7_
M /F5H^T>-_\ H#^%?_"CU?\ ^96NJHKF.LY7[1XW_P"@/X5_\*/5_P#YE:/M
M'C?_ * _A7_PH]7_ /F5KJJ* .5^T>-_^@/X5_\ "CU?_P"96C[1XW_Z _A7
M_P */5__ )E:ZJB@#E?M'C?_ * _A7_PH]7_ /F5H^T>-_\ H#^%?_"CU?\
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M?_"CU?\ ^96NJHH Y7[1XW_Z _A7_P */5__ )E:/M'C?_H#^%?_  H]7_\
MF5KJJ* .5^T>-_\ H#^%?_"CU?\ ^96N8\27'C,S>&?,TGPPI'B>S,6SQ!JK
MAI/L.I85RWAE-B%=Q+J)&#!0(R&++ZC7*^)_]?X5_P"QJLO_ $WZI0 ?:/&_
M_0'\*_\ A1ZO_P#,K1]H\;_] ?PK_P"%'J__ ,RM=510!ROVCQO_ - ?PK_X
M4>K_ /S*T?:/&_\ T!_"O_A1ZO\ _,K7544 <K]H\;_] ?PK_P"%'J__ ,RM
M'VCQO_T!_"O_ (4>K_\ S*UU5% '*_:/&_\ T!_"O_A1ZO\ _,K1]H\;_P#0
M'\*_^%'J_P#\RM=510!ROVCQO_T!_"O_ (4>K_\ S*T?:/&__0'\*_\ A1ZO
M_P#,K7544 <K]H\;_P#0'\*_^%'J_P#\RM'VCQO_ - ?PK_X4>K_ /S*UU5%
M '*_:/&__0'\*_\ A1ZO_P#,K1]H\;_] ?PK_P"%'J__ ,RM=510!ROVCQO_
M - ?PK_X4>K_ /S*T?:/&_\ T!_"O_A1ZO\ _,K7544 <K]H\;_] ?PK_P"%
M'J__ ,RM<]K7_";3:EX2E.D^&@;/Q!=7 $>L^(;A&+^%?$MKB>:W\'RPV,0%
MR6%U?26UJ\RPV23M?7EG;7'I=<_K,7F:CX3?R?-\CQ!<R[_LWG_9\^%?$T'G
M>;_8VJ?8]WG?9_M/V[PYO\_['_;,_P!K_P"$>UX J_:/&_\ T!_"O_A1ZO\
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MO_A1ZO\ _,K1]H\;_P#0'\*_^%'J_P#\RM=510!ROVCQO_T!_"O_ (4>K_\
MS*T?:/&__0'\*_\ A1ZO_P#,K7544 <K]H\;_P#0'\*_^%'J_P#\RM<_J?\
MPFTNM^&9SI/AH&VN-48!-9\0S1MYNESQ_O;F'P?);6@ .4:\F@$[XB@,DI"5
MZ57/ZG%OUOPU)Y._R;C5#YOV;S?(WZ7.F?M']C7WV7S/N9_M;0O.SY7F:CG[
M$P!5^T>-_P#H#^%?_"CU?_YE:/M'C?\ Z _A7_PH]7_^96NJHH Y7[1XW_Z
M_A7_ ,*/5_\ YE:/M'C?_H#^%?\ PH]7_P#F5KJJ* .5^T>-_P#H#^%?_"CU
M?_YE:/M'C?\ Z _A7_PH]7_^96NJHH Y7[1XW_Z _A7_ ,*/5_\ YE:/M'C?
M_H#^%?\ PH]7_P#F5KJJ* .5^T>-_P#H#^%?_"CU?_YE:/M'C?\ Z _A7_PH
M]7_^96NJHH Y7[1XW_Z _A7_ ,*/5_\ YE:/M'C?_H#^%?\ PH]7_P#F5KJJ
M* .5^T>-_P#H#^%?_"CU?_YE:/M'C?\ Z _A7_PH]7_^96NJHH Y7[1XW_Z
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MWB*".*#Q%J00(-2\-222/+)X:5@P98U1%B8,&=FD0HJO[I7@?Q<_Y&7PI_V
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MC6VTZQEUL]C#L_O?]?\ #ORL>VGW7W+^O^'?E;[Q_P"%M^)?^A4T/_PI[_\
M^9>C_A;?B7_H5-#_ /"GO_\ YEZ\[KYJ_97_ &A_^&F/ 'C#QS_PB'_"%?\
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M\K'MI]U]R_K_ (=^5O1/^%M^)?\ H5-#_P#"GO\ _P"9>C_A;?B7_H5-#_\
M"GO_ /YEZ\[HH]C#L_O?]?\ #ORL>VGW7W+^O^'?E;T3_A;?B7_H5-#_ /"G
MO_\ YEZ/^%M^)?\ H5-#_P#"GO\ _P"9>OG3X2_%SX>_'/P+IOQ+^%GB#_A*
M/!.KZIXKT73]:_LG6]$^T:GX(\7:[X$\46W]F^(M-TC5HO[+\5>&M;TKSI["
M*WO?L7V[3I;O3;FTO)_1Z7LJ?;\7Y>?]7]+/VM3O^"_R_J[\K>B?\+;\2_\
M0J:'_P"%/?\ _P R]'_"V_$O_0J:'_X4]_\ _,O7SI\7OBY\/?@/\-?%_P 7
MOBOX@_X17X=^ ]+_ +:\5^(?[)UO7/[*TS[3;VGVG^R?#>FZQKE]_I%U!'Y.
MFZ9>7'S[_*V*[+Z/1[*GV_%_Y^3_ !\K'M:G?\%Y>7]7]+>B?\+;\2_]"IH?
M_A3W_P#\R]'_  MOQ+_T*FA_^%/?_P#S+UYW7S5XB_:'_L#]K;X5_LM?\(A]
MK_X69\"OC!\:O^$Z_P"$@\C^Q/\ A5'C/X3>$?\ A&O^$8_L2;^TO[?_ .%H
M_P!H?VS_ ,)#8?V5_8?V3^RM1_M/[3I[]C#L_O?]?\._*R]M/NON7]?\._*W
MVS_PMOQ+_P!"IH?_ (4]_P#_ #+T?\+;\2_]"IH?_A3W_P#\R]>=U\U>+OVA
M_P#A%?VKO@E^S%_PB'V__A<7PA^./Q5_X3?_ (2#[+_PCG_"F=>^$>B?V#_P
MC7]B7']K_P#"2?\ "T_M7]J?V_I?]C_V%Y/]G:I_:GFZ<>QAV?WO^O\ AWY6
M/;3[K[E_7_#ORM]L_P#"V_$O_0J:'_X4]_\ _,O1_P +;\2_]"IH?_A3W_\
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M_P"1/U+_ +&6\_\ 37HU>WUXA\ _^1/U+_L9;S_TUZ-7M]?%YA_ON(_Z^/\
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M[PYO\_['_;,_VO\ X1[7@#H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M /%!?\()_97_  LS_A6G_"P/^*._X6U_8?\ :'_%4?\ ""U^E'_!.[_A!/\
MA>?[8'_#*?\ 9O\ PP%_Q9O_ (4A_P (-M_X4!_PNSROB-_PT;_PS%_9/_%$
M_P#"L?M?_"!?\)=_PKS_ (H;_A;W_"<_V3_Q//\ A*Z_6:B@#^?+QK<_L:2_
M&;]OZW_X*'O\*O\ AIVV^(]\?V6(OCHMHGQ#7]G6?X0^&'^ <O[!PU55\32Z
MS)\0E^(*7UQ^S#O^*[?M'P:[;ZK)_P )M;>"XXODO2H;C4?@)_P2 T?XZ>./
MV<OAU^Q_=?\ !.WPY/IWB+]L_P"!NN?'/]D*Z_:8M_"_PT?3M(^*>E6_QW^
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M/CD6_A#3-)L[8_:#_P"%1?\ "DO^"NG_  P]_P (U_PPK_P[[3^U_P#A3O\
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M W=M]W<_#GXJO^QV?V[?VDX_^"H5U\!G\++X?^%+_L0V7[93>"3\";?X5/X
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M/GPKXF@\[S?[&U3['N\[[/\ :?MWAS?Y_P!C_MF?[7_PCVO '04444 %%%%
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M>#O&'BN[TKP=XTN] C\3> M?NY8[;Q'X-\1>&-:5;675UL8?,OBO\,=4T_\
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M/&OC'P5K'A;Q/\#/$ND>*]$M/C/XE7Q%X:O?"WC'2M>\,W'B>X\*>&&_MM?
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M-W&-6L/M&1'\:O@W+X:^(GC.+XM?#.3P?\(=7\4^'_BSXKC\>>%G\-?"_7_
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M*?M3:O\ \%?_ -NK1?VZ_B!\+=(^,6@^"/#GQ(\/:5^QYH?C/Q-X;7QAX?\
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M9U>3GY9\G/R<O-R2Y;WY96L_V!>^M4.'GC4^A=?_ (JF_P!HV7_/Q%_WVO\
MC7^3)17W?^H/_4V_\L/_ +\/S;_B)G_4D_\ ,E_]X'^LW_:-E_S\1?\ ?:_X
MT?VC9?\ /Q%_WVO^-?Y,E%'^H/\ U-O_ "P_^_ _XB9_U)/_ #)?_>!_K-_V
MC9?\_$7_ 'VO^-']HV7_ #\1?]]K_C7^3)11_J#_ -3;_P L/_OP/^(F?]23
M_P R7_W@?ZS?]HV7_/Q%_P!]K_C1_:-E_P _$7_?:_XU_DR44?Z@_P#4V_\
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M^9+_ .\#_6;_ +1LO^?B+_OM?\:/[1LO^?B+_OM?\:_R9**/]0?^IM_Y8?\
MWX'_ !$S_J2?^9+_ .\#_6;_ +1LO^?B+_OM?\:/[1LO^?B+_OM?\:_R9**/
M]0?^IM_Y8?\ WX'_ !$S_J2?^9+_ .\#_6;_ +1LO^?B+_OM?\:/[1LO^?B+
M_OM?\:_R9**/]0?^IM_Y8?\ WX'_ !$S_J2?^9+_ .\#_6;_ +1LO^?B+_OM
M?\:/[1LO^?B+_OM?\:_R9**/]0?^IM_Y8?\ WX'_ !$S_J2?^9+_ .\#_6;_
M +1LO^?B+_OM?\:/[1LO^?B+_OM?\:_R9**/]0?^IM_Y8?\ WX'_ !$S_J2?
M^9+_ .\#_6;_ +1LO^?B+_OM?\:Y^]O+)O$F@S;XF\K3]>C\_P E7\KSGT=O
M+^U_V/<_9_.\K=Y/]O:3]I\G=_9NM_9O/T7_ "A**/\ 4'_J;?\ EA_]^!_Q
M$S_J2?\ F2_^\#_6;_M&R_Y^(O\ OM?\:/[1LO\ GXB_[[7_ !K_ "9**/\
M4'_J;?\ EA_]^!_Q$S_J2?\ F2_^\#_6;_M&R_Y^(O\ OM?\:/[1LO\ GXB_
M[[7_ !K_ "9**/\ 4'_J;?\ EA_]^!_Q$S_J2?\ F2_^\#_6;_M&R_Y^(O\
MOM?\:/[1LO\ GXB_[[7_ !K_ "9**/\ 4'_J;?\ EA_]^!_Q$S_J2?\ F2_^
M\#_6;_M&R_Y^(O\ OM?\:/[1LO\ GXB_[[7_ !K_ "9**/\ 4'_J;?\ EA_]
M^!_Q$S_J2?\ F2_^\#_6;_M&R_Y^(O\ OM?\:/[1LO\ GXB_[[7_ !K_ "9*
M*/\ 4'_J;?\ EA_]^!_Q$S_J2?\ F2_^\#_6;_M&R_Y^(O\ OM?\:/[1LO\
MGXB_[[7_ !K_ "9**/\ 4'_J;?\ EA_]^!_Q$S_J2?\ F2_^\#_6;_M&R_Y^
M(O\ OM?\:/[1LO\ GXB_[[7_ !K_ "9**/\ 4'_J;?\ EA_]^!_Q$S_J2?\
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MX_\ PA\6?L8Z+X<_8E^-;K^T5\7M5\#>-?"_B;7/V5[SQEIUK8> OC5XBM_
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M;7O!OQ+^%GA/QWXOT18_!VCQPV/B7XN:"NE>)O$?B;QLUO)HO@;Q1I<FH"$
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M_$[]H?Q9^U/\/KSXL_!SX6?"71_"5KXYU/X8:-I>CZEXF\>>*[_XK^-OA?\
M#CX<>'O#,WB'0M OYOB%\0/#-WJGB[5K3PEX6M/$/B(S:=%UWC+]K6'P39_"
MC0K[X!?'35?CQ\9+'Q?K'A/]E_0)/@;J?Q?L_#O@"6S7QKXI\4^)?^%W0_L\
M^&?#'AV+5_#1N-=U3XZQ6%_J7B[PMX5T6;4_&NLV_AH 'US17AOP!^/OA;]H
M7PIXA\0Z!H'C'P5KO@?Q]XJ^%GQ)^'/Q#T[2=,\=?#CXC>#9[==;\*^)(_#F
MN>*?"E_(^GZAHWB+1/$'@[Q7XJ\(>*/"VOZ#XD\->(M6T?5;2[D]RH ****
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M6O#GA..ZL\2PW.@OH_V"XM-;\ ^#7[$G_!=CPE_P48UO]OGQ[X@_X)+3ZO\
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M3]G_ .+>M76BVEK')JVBVVK? R_.JZM86%E>6VAQSMK%A\JZ7_P2_P#CO?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MULXYDO%]UO/V:?BU=_'#]JGXY>(/A[^S[\3;#]H/]E7]G#X,CX$^.O'OB5_
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M\=6N+E-.TZPL5FD=;2RM;<1P1VZ**DH*_&[_ (+V?\HR?CC_ -A_X/?^K?\
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M/VP?^B-7G_A8?#S_ .:ZC_AWQ^V#_P!$:O/_  L/AY_\UU']L93_ -#3+O\
MPMPW_P M#^PL[_Z$V:_^&[%__*3XSHK[,_X=\?M@_P#1&KS_ ,+#X>?_ #74
M?\.^/VP?^B-7G_A8?#S_ .:ZC^V,I_Z&F7?^%N&_^6A_86=_]";-?_#=B_\
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M_P#Y2?&=%?9G_#OC]L'_ *(U>?\ A8?#S_YKJ/\ AWQ^V#_T1J\_\+#X>?\
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M_HC5Y_X6'P\_^:ZC_AWQ^V#_ -$:O/\ PL/AY_\ -=1_;&4_]#3+O_"W#?\
MRT/["SO_ *$V:_\ ANQ?_P I/C.BOLS_ (=\?M@_]$:O/_"P^'G_ ,UU1/\
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M?^%N&_\ EH?V%G?_ $)LU_\ #=B__E)\9T5]F?\ #OC]L'_HC5Y_X6'P\_\
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MW_A;AO\ Y:']A9W_ -";-?\ PW8O_P"4GQG17V9_P[X_;!_Z(U>?^%A\//\
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M^@$MK+\_:7^R+^TWXM^-O[)_QC_:&_:N^&WQ&_X9.\1>//$6B>&_AC^RW?\
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M_P!N^%O&%QI33:4=(TJXA /F_P")GQ[^'7P5_::_;I\>:?\ !'^UOBI\!_\
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M NV_[\Q__$5]*T4 ?-7_  S;X(_Z!=M_WYC_ /B*/^&;?!'_ $"[;_OS'_\
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MKR/[1_8%_8RO_(W^;Y/VSXO?M77'E>;LC\SR_,V;_+3?C=L7.T6/V=8UT_\
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MX?#_ ,1_V=O'>K_%NR2RU.+X5?$6UM?'O@G]H'66::;PO#?_  QT"PDU?6K
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M<_@7XH6-\FERW&GVO]LZYI)\8:3:V=U>VJ>'?$VC/;7]_;R17D_VS0 4444
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M<^7]K_L:Y^S^=Y6[R?[>TG[3Y._^S=;^S>?HH!T%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5X'\7/^1E\*?\ 8#\3_P#I?X7KWRO _BY_R,OA
M3_L!^)__ $O\+U=/XX^IG5_AR^7_ *4CSNBBBNTXSS'XI?!KX;?&FP\&Z9\3
M/#G_  DMC\/_ (G_  ]^,OA&#^V->T;^R/B3\*O$=IXM\!>(_,\/ZII4U_\
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M66N7^I:]:Z/#K.I7]]<?1E% 'PQ\./\ @G1^S-\(=-\'Z#\-+O\ :>\&^%_
M/]EQ^#_!6C?MX_MUP^ M#LM&N([G3]'MO 4G[1\O@V7P]$\2QS>&[K0[C0+V
MU:6QO=-N+.>:"3Z1^#OP2^&?P$\+ZGX.^%?AZ?P]HFN>-O''Q'UXW_B+Q/XN
MUK7_ !W\2?$VH^,?''BK7_%'C/6O$/B?7-9\0^(M5OK^ZN]5UB\>%'AL+,6V
MG6=G:6_JU% 'DOP\^!GPM^%/B[XO>./A]X9?PYXB^._C*P^(7Q4F@U[Q+>:5
MXE\;:?X;TKPBGB:#PWJ>LWOAOPWJM[H&AZ19:U<>%=(T/_A(9=.M=0UY=2U.
M,7E>M444 %%%% !1110 5[!\*/\ F/\ _<*_]R->/U[!\*/^8_\ ]PK_ -R-
M9U?X<OE_Z4C2E_$C\_\ TEG@/Q?_ .2B>(?^X3_Z8],K^73_ (.;;O5X?V-/
M@1:3RZE!\-]0_:Q\"P_$Z2P%UY#:-#X)^(5S80ZJU@KWIL?/BN;F&-$:)]6M
M=,=5.HQ::#_47\7_ /DHGB'_ +A/_ICTRODG]HG]GGX3_M4_!SQK\"/C;X9C
M\5_#KQW816>KZ=]HFL;ZTNK.Z@U'2-;T74[9EN=+US0]5M;35-*OX&/DW=LB
MSQ7-I)<6L_T].FZN7T::=G+"T4F]K^S@TGY.UGY-[GQE6JJ.:5ZLDW&&-KMI
M;V]K--J_VDG>/FEJCU/PY;Z#9^'M!M/"JZ:GABUT;2[?PXFC/!)I":#!8P1:
M.NE26S/;2::NGK;BQ>W=X&M1$T3-&5)_ 74?V@_B/^P)_P %@?'?@C]H#XR?
M$/7/V.?VT_A-XB^*'PCO?B;X\\2>)/!GP6^(_P -;'4?$_C/PMX07Q-K6IZ?
MX0T%([;Q)%-X>\-V6C:>;?QK\+-+2)K;P_9Q#U?X;_\ !,;]NOX :+I'PW_9
MT_X*^?%+P1\$/#26NG^%O ?Q)_99^"OQT\2^'?#MG-(MKH&F?$#QKJT#V=C9
MZ<T5AIUK8^&;/2=/$,?V;2$LH[?3K?YA_P"#@+P/I7QO\"_L&_L8:>J^.OVM
MOC)\=-'TSX?^,#:0:1-HOA>T\.'PS\6_'.OV&DV\EMI_AK6KW6/#NJZMH5J;
M*P2VT6^U2UN&@\(M9W#K3J>R53V<J52C*$HIR@XS;?(Z:<)2;4D^5<T8ZN+M
M=.RP].E[;V2JPK4J\*D)N,*BG2BH^T562J4XQ3@X\SY)RT4E>S5_E?0_&?[0
M7[5/_!-;_@KG^W[\8OB+\49_AM\>]/\ &7AC]F;X*>(/&OBRZ^'OP\^%?@SQ
M58VUSK7A_P #7.KW/@RSU+4;N'2_",VM:3I=MJ#:KX+\7WCSE?%-[YU7Q_\
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M !+K.D^*-#^*%M'JVCZ?X:N=6TK0M)2VU#4?#L)BU_4=-N=.UG4;70M2&/\
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M[)?P-\4:7XB^&_[.&O?"GP+X-N[J#PU'/8>%=)^*7Q7\/ZK/K/Q033M!N)]
MOM2U7PYIVIW.FWFIPZ+<>&X]0DB3ZT\1?\$[TU[_ (*;?#O_ (*+Q_%Q;!/
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M&'+RI<G5/2FI*"5HQ2LIRNVG*5U=Z'US\ _^1/U+_L9;S_TUZ-7M]>(? /\
MY$_4O^QEO/\ TUZ-7M]?)9A_ON(_Z^/\D?<97_R+\)_UZ7YL****XSO"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE?$_\ K_"O
M_8U67_IOU2NJKE?$_P#K_"O_ &-5E_Z;]4H ZJBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *Y_68O,U'PF_D^;Y'B"YEW_9O/\ L^?"OB:#SO-_
ML;5/L>[SOL_VG[=X<W^?]C_MF?[7_P (]KW05S^LQ>9J/A-_)\WR/$%S+O\
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MRE71A_:(_;+^'&J?LI^,_P!H#PW\"]+\&_M2_%[P]\)-2^!'@KPMX\@^+/P
MU7XC>$O&/C#P7_;GQGU_XDW7A3XOZAX2B\)QZ%\3-/TGX&?"^)+Z_P!4U7PY
M?7.F>&PFNM5H-)ZZ[Z6Y5S<EY=DY:+=NS:5DVI>'FFTW'39\UU)\BJ<L6MVH
MM-[)-I-IRBG^GM%?G)\;?CA^U1\ OBS\!SX@\0_L[^//A_\ 'O\ :ET7X':#
M\$O"_P ,?B+H'QFL/ 'BM_%+1?$.S^+VH_&S7O#7B/4OACX6TK3_ (G?$W1U
M^ &B:,^@V'B7PQIOB+3[A-&\67_UKI'[1W[//B#X@^)?A+H/QX^#.M_%7P7:
MZK?>,?AGI'Q0\$:E\0?"=EH36Z:W>>)?!EGKDWB/0K71GN[5=5N-4TVUBT]K
MFW6[>$S1AJ4XMM/W6FE:5E=M75M6G=:V^)=4KHETY)1DO>4DW>*;M9V=[I-6
M>E[<K>BD[.WLU%?SF_!'QU\1_%'[/_[*/PR\">*_$WPU\<_\%8_VM/VI_P!H
MCXA_$;PI=2>'_'/A']G2/Q%XR^*7B&Y\ :J8UN?!WC#Q7\(=/^$_@/0/%-IC
M6? \GBNXUGP\_P#PD&FZ3JEM]#_MO?LR_ 7]DSX2?!_XH?LG?"/PA\%OVB]%
M_:5_9;\!_#CQA\+?#MOH7Q'^*;^-OC%X+\'^,OA]\4_&>G/;>+OC#H7CCP#>
M>*M1\:6?Q-UKQ:/%.M:=;^*/$$EWXBM(==M<E7<HN:@N6,8RG>5FG**FHQ7*
M[RY)1=GRZR25]6MGATJD:<JEI3G*$+0NO=FZ;E)\RY8\\9)-<SY8N32T3_:N
MBOS*\9_M,_MC:#^W!^S/\";GX4? +P1\#?C3XF_:*L[F_P!4\=^-?B+\=O$/
M@7X(^&&UBR^)-AHWA_0?"'PZ^%NC:YJ-_P"#[6/2M4\1_%?6'A\<:);:M!X1
MUF"^T^+8\0?'W]J#XR>+_P!HVT_97NO@5X"^'7[,>KZ_\.-4\>_'3X>^/OB:
MWQD^-7A_PAH?BWQ1X5\(Z/X0^+GP1_X5[X'^',^LVW@WQ+\0M7O_ !\_B#QC
M)KUCH?ABQL?!-S?>)-/:Q=TE)M2Y.7E:DWRJ;LI6T49)W=ET5VU?/V$_=O*"
M4H<_-S)Q47-TU=QO=N::Y8\SZM))M?H[17YKR?'[]ICXQ?LI^#OVQO@GXU_9
MS^!?@'Q#^S'IOQTO/ G[0/PB^(?Q4O;'5Y?!E_XXU6'5_BCX,_: ^".E^&O!
M=C:"STP:Q_PKGQ+?"PL[WQ?+"JWT/A73OL?]GKXKR?'?X#?!CXV3>%-1\"S?
M%SX6^ _B3+X,U:X:\U'PM)XU\,:9XB?0;F^:QTQK]M+;4#9IJ#:9IK7\427A
MTZQ,YM8G&<9-)7UBIQ>EI1=M59MK=?$D]=$];3.E*";=M).$DKWC-:\KNDF]
M'K%R2MJUI?V&BBBK,SZ@^"OASP]K7A2^GUC0M'U6:+Q#>113:EIEE?2QQ?V;
MI#^7')<PRND>]F;8I"[F9L9))]=_X03P1_T)WA;_ ,)_2O\ Y$KSOX!_\B?J
M7_8RWG_IKT:OY5+/]I'Q]^R+<_\ !U'^T-\+#!%\1OA]\7O@W_PA>H7$(N(]
M"\1>*_#>N^"--\4);.KPW5QX4G\2KXEM+6ZCDLKFZTJ&"^BELY)XV^-QT>;&
MXE+?VFGG=QC^I^@98[8#">=+\FV?UW_\()X(_P"A.\+?^$_I7_R)1_P@G@C_
M *$[PM_X3^E?_(E?S)?"3_@WY_9)^*O[&'@/X^^.OBY\:];_ &[_ (D? SP[
M\99?V^I?VD?BM%XF\/?$_P 7^"H?'%IXETB:+Q2OA!OAQH&LZM'Y$UYX?G\0
M77A*S-R?$5KJMRVI1_D'^TQ^TO?_ +=G_!,[_@@_\5?VR?AA\3?VG6UK]L+Q
M]\-?C/\ #WX0Z;KFM?&#]H?P]\.M1U?P'+:^$=)\,:]X/U_4_B1X[\-Z+8PW
M::)XGT.]U7Q;+J-]9:EIC7B16O(HI[-VO9NUK:-Z*^JT?5>:.QS:6L=TFM=+
M-Q6KMHUS+9/U/[Z?^$$\$?\ 0G>%O_"?TK_Y$H_X03P1_P!"=X6_\)_2O_D2
MOXS?^"6'CGX'_L[_ /!7'XA^%?@'\+/VI_\ @F9^Q[J'[$_B'QIJG[&O[<>G
M?&31?B#\9?B-X.U/4/%/BWXL?";X?>-M?^)SK#X,\%>'9-0U&XMO'6M^++C2
MM(\4CP]I=SHVLZWIOA3]NO$?_!>W_@GE??LK?&W]JGX!_$+Q7^TGH'P4\2_#
M;P!J/@GP-\,OB?X,\7>(OB5\8=5N='^&W@S0X/BSX*\"Q74^NW%CJ=Y=ZE9_
M;[72],TF^DD2XU.32])U,<&GHFUIK;OLG9M)WTW&IIJ[LM]WO;=J]FUKV7IL
M?KQ_P@G@C_H3O"W_ (3^E?\ R)1_P@G@C_H3O"W_ (3^E?\ R)7XU?!?_@K-
M^T-K_P <[[]EC]IO_@FO\2_V8/VE_&GP'^)/QS_9@^&S?M _"/XK:'^T:GPX
MT>YU6Y^'-I\2=)M?"OA#X:>/=4,,5N;/QE<C2/#8:6X\6ZMH:?V>NI[G[.O_
M  5%_:2\6?MJ> OV)?VQO^"=/BC]C3QW\8?AUX_^)GPAU^T_:;^$?[2>E>(O
M#_PX#2Z])XKC^%^DV%OX%5X4-O9/<ZKK#W&KR6NG+!Y%S%J!7*]=M%?=;=UK
MJO2X^9>>]M8R5GI9.ZTO=6O:]T?KS_P@G@C_ *$[PM_X3^E?_(E'_"">"/\
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MX)I?\/$?[(^ _P#P3]_L+_B@_P!B;QM_PI_[?I'[2G]I_P#)XOQJ^#_]F?\
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M_H3O"W_A/Z5_\B4?\()X(_Z$[PM_X3^E?_(E?BO\#_\ @N#\*?C%\2_V>=$
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MTK_Y$KJZ* .4_P"$$\$?]"=X6_\ "?TK_P"1*/\ A!/!'_0G>%O_  G]*_\
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MW]@[/M>N?VINTZSXS_9I_P"$O_;"^ W[5_\ PFO]G_\ "DO@M\??A!_P@/\
MPCGVO_A)O^%Y>(O@SKW_  D/_"4_V];?V+_PB_\ PJ+[)_9/_".:M_;?_"0^
M?_:>D?V3Y.I?4U%*[W\K?)*WY:#LMO._S3O^>I\/?L[_ ++?Q3_92_8:^"O[
M*'P8^,O@";XB?!+X=>#_ (?:+\8?B?\ !+Q%XO\ !>L0^'KNW&K:IJGP<\*?
M'7X<:XDNKZ2+VTT^UM/C1$NBZC/:ZE<SZY;6DNDWORQ'_P $G(-?^$G_  4$
M\+>//B_X+TGXJ?\ !06?PYK'C7Q?^SU^SYI7P.^$O@/QIX%M+G4?"GQ"T3X*
MZO\ $;XKZQXL\=^(/B'J&I_$#XU^*O''Q>UO6_BU?74.E&^\)6EA930_L111
M=_>[[+O?\PY5HK;*RU>UK?E\SS;X4:7\8-'\(067QQ\=?#;XB>/5OKZ2Y\2_
M"CX4^*/@SX0ETR213IMI!X(\7_&7X\:S;WUI$'2^U&3X@W-OJ$C+)!I>F*IB
M?\Z_V2_V,OVYOV0/@E\*_P!G7P'^V%^R?XD^%GPHM[C2=*E\7?L%_%^;Q_J>
M@WWB74_$5];ZAXFT;_@HII'AU-7<ZO>6EIJMMX&CLK8+;3S:)>&*6*X_5VBB
M[\M?)?Y!9>>GF_\ ,_+CXF_\$UO^%C:)^VGHW_"Z/[&_X:__ &L_V4_VHOM/
M_"N?[0_X5Y_PS'J'[+M__P (-Y/_  G=C_PEO_";_P##-GE?\)-YOAG_ (1K
M_A-/,_X1_7_^$=V:[] _&#]C_0/C1^TQ\+/CSXK\2)/X6\!_L[?M+_L[>)/A
M7+H5R\?CK0/VDM0^$5QK&HR>,;+Q)IMYX>31-.^%USI;Z?::)?7.K+XE-U!K
M.ARZ0B:C]C44<STUVO;YI+\D@LNW5/YI\R_'4_/S]FG]FG]KK]FO0?A3\&K/
M]K/X2?%']FWX/:9IO@7POI?Q)_93\3/^TOJ'PF\,V\FE>"/"_B?X\^#/VIO!
M_P +=7\8>&/#<&B^')/B##^RY8-XBM-%CU3Q!X:OO$FHZIK=W],_&?0OVBM=
ML-#C_9X^*?P5^%VJ6]Y=OXEO/C/\ O'/QZL-6L'AB6PMM#TWP/\ M)_LX7'A
MZ\MK@3RW=]?ZKXGAO89(H(=/T]X7N9_:J*+N]]/N7Y6L%E:VOWO\[W/S;N_^
M">[_ !>\"_M;Z-^UM\8[CXI^._VP_!OP^^'/C'Q;\%O!,_[/WA[X6>#/@]:^
M(;GX0K\#O"FN>.?CAX@\-^+? _COQ?XJ^+:>+?'?Q#^)4^I_$;60[:?9^!M)
MT/P+IMC3/V-_V@OB+\1OV?/%W[7W[4_@[XW>%/V8/%C?$WX<^"?A1^SI=_L^
MGQW\8+/PGJ?@KPQ\2OC]K&H_'3XT67C:_P#!FF:]XB\0^'/#7PO\-_ [P?'X
M^UEO$6HZ%J.D:1X=\+Z/^CE%',_Z2[6TTTT70++^F^]]>^O<_+SPW_P3:_X1
M_P  _"GP/_PN?[7_ ,*Q_P""D'Q"_P""@O\ :G_"NOL_]M_\)Y\5/C#\3/\
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MPW?^W#_T>5^U9_XD/\7?_FPH_P!1,7_T'X;_ ,%5?\_7^GH?\1)P/_0LQ?\
MX.H_Y>O]/3_3X\V+^^OYT>;%_?7\Z_S!_P#AN_\ ;A_Z/*_:L_\ $A_B[_\
M-A1_PW?^W#_T>5^U9_XD/\7?_FPH_P!1,7_T'X;_ ,%5?\_7^GH?\1)P/_0L
MQ?\ X.H_Y>O]/3_3X\V+^^OYT>;%_?7\Z_S!_P#AN_\ ;A_Z/*_:L_\ $A_B
M[_\ -A1_PW?^W#_T>5^U9_XD/\7?_FPH_P!1,7_T'X;_ ,%5?\_7^GH?\1)P
M/_0LQ?\ X.H_Y>O]/3_3X\V+^^OYT>;%_?7\Z_S!_P#AN_\ ;A_Z/*_:L_\
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M=_V?S_L^?"OB:#SO-_L;5/L>[SOL_P!I^W>'-_G_ &/^V9_M?_"/:]_F3_\
M#=_[</\ T>5^U9_XD/\ %W_YL*@F_;E_;7N)+6:?]L+]J6>6QG:ZLI9OV@OB
MS+)9W3VMS9/<VKOXN9K>=K.\N[1IH2DC6MU<VY8Q3RHQ_J)B_P#H/PW_ (*J
M_P"?K_3T/^(DX'_H68O_ ,'4?\O7^GI_I_\ FQ?WU_.CS8O[Z_G7^8/_ ,-W
M_MP_]'E?M6?^)#_%W_YL*/\ AN_]N'_H\K]JS_Q(?XN__-A1_J)B_P#H/PW_
M (*J_P"?K_3T/^(DX'_H68O_ ,'4?\O7^GI_I\>;%_?7\Z/-B_OK^=?Y@_\
MPW?^W#_T>5^U9_XD/\7?_FPH_P"&[_VX?^CROVK/_$A_B[_\V%'^HF+_ .@_
M#?\ @JK_ )^O]/0_XB3@?^A9B_\ P=1_R]?Z>G^GQYL7]]?SH\V+^^OYU_F#
M_P##=_[</_1Y7[5G_B0_Q=_^;"C_ (;O_;A_Z/*_:L_\2'^+O_S84?ZB8O\
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M'_H\K]JS_P 2'^+O_P V%'_#=_[</_1Y7[5G_B0_Q=_^;"C_ %$Q?_0?AO\
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MASX\NO TNK6AT/7O%&@>%_'>K>#M3TA-?;QSX%\7V?@'QM)X<^(_A#P?J?\
MPCTH@-]8\'X+_:T^)^KQ_%/X<?%']FSQ/\#/VD? GPC\;_%?PIX/OO&7@WXM
M?"CXP:%X6US7?#,&O?"3XC^!-5L?$>M:'%JL/@F37=&^)_P[^"?Q#L(?B'X=
MA@\'3JNHWMA]2_%/P-XG^(/AE-!\)?&3XD? S54U2TOV\:_"S2_A#J_B:6TM
MXKJ.;1'M/C9\*OC%X-&EW[W$4]W+'X2CUI);*U6QU>S@>\AN_*/@_P#LPV?P
MR^(7B#XO^,?C)\9/VA/BSKGA*S^'MIX]^,MQ\+[.Z\*?#ZTU4^()?!WA#PE\
M$_A=\&_AOHMCJ_B'R=;\1ZT/!-QXP\2W=AH=KKOB74-)\->&].T@ \-_X)9>
M!O!NC_L3? 3XJ:3?VOC+XC_M&_"[P%\=_CE\7[Q;:\\:_%CXK_$;PY:>*_%6
ML^-?$ \S4=2NO#VK:U?^$]"T>_N7A\$>']'L/!NDV>DZ;HT&FVW'_#W0=%^,
M'_!3_P#:=UOXJ1V/B;5/V3OAA^SOHW[-/A/788+_ $[X=:=\9_#_ (T\2?$S
MXR^%='OC<6]AX[\<:[HW_"MKGQYIUI:ZY9>%? EQX3M]373-7U:SN?5[']AB
MS\!:EKX_9R_::_:5_97\#>)=8U?Q/J'P>^$<_P"S_P"+OA/IWBWQ'K^M^)_%
M/B'P3X6_:/\ V?\ X]3_  O3Q/K>O7NIZUX/^%VJ>#/AQ+JC3:Y:^"[37]3U
MS5=5[CXJ_LB>$_B?XF^'WQ1L_B7\7?A7^T)\-_"3^!-(_:-^%&L>"_#_ ,2=
M?\&WL]K>ZWX5^(WAC6O ?B7X&?%'POJVKVTOB&T\+?$+X/>)/#?@?Q/J.J>)
MOAAI/@;7KZ;42 ?+/_!8*;7;;]G#X+W'A;3=)UCQ-!^W9^PW-X=TC7]:O/#6
MA:KKL7[1_@5](TW6O$6G:!XKU#0-)OM06WM=2UJQ\+>);S2K.6:^M= UB>!-
M.N?$_P#@HOXK_;*U3X"^![+XN? ;]F7P/X"E_:X_8=.L>)?AQ^UK\5/BGXOL
M98_VO?@O)IB:;X(\3?L4_!W1M5CO-46TL[^6Z^(.C-IUA/<ZE;PZK<6L6E7G
MWEXJ_8RC^)OP_P!#^'_QK_:/_:!^-,'AGXX_"#X\^'_$OB^S_9U\+^)-*\0_
M!;QCH?CKPQX8C'P@_9[^&/AN[\':GKV@V[^(H=2\.7OB>YM+F\MM*\4Z.&MF
MM?8OV@_@%X._:2\ 6/PX\<ZEXETK0]/^(_PE^)\-UX3O-+L=5;7_ (-?$WPK
M\5O#%G+/K&C:[:-H]_XA\(:99Z];I8I>W6BSWUOI^H:7?2V^HVP!^'WBGX7_
M !>MO^"B'_!1O]K7]F.QGUS]H']FGQQ^RJU]\*X;IK&Q_:=^ ?BW]F/X9WGQ
M<^ 6J7),D%GXMFLO"UGXR^!OB.XLK^+PW\5-'LK"\M)-!\7:_)#[M^SA\9;7
M]H;]NK]K/XW_ +-&J>'-9D^)G_!.+]D_Q)\(+WQ];ZO9^&HO%[>.OVJ]/TO1
MOB-8:(S^(-*3PQXYL)_#'Q)T/3F_X2+P_J6C>(M""1:WITD4?ZC?#S]GWP9\
M-/C)^T+\<-"U/Q/=^+/VE-5^&FK^.M/U:]TJ?P]I-S\*_A_8_#CP\GA.TL]%
ML-2L8+S0]/ANM976-6UZ2XU5I9[&73K-DL4\1\)?\$_?@C\//BW^UE\:OAKK
M7Q,^&_C/]L3P;!X5^(S>"O%5CHVG^$=763QK?W_Q'^$Z+H$VH>!_B+KGB7Q]
MX@\;ZUJZ:CJ6DWGCNXE\7IH4.N:EKMYJX-Z_<OP21]1_\55_PJO_ (KK_A'_
M /A-_P#A7_\ Q6/_  B?]H_\(K_PE7_".?\ %0_\(S_;'_$W_P"$?_M?[9_8
MW]J?\3'^SOLWV[_2?-K\$/V'=/\ C#^TK_P2N_8U_9OT3]EOQUX6T2?X>? S
M4H?VF?B=XU^ UC\-_"VG>!/%^A^+5^*/PJT;P!\5_B1\=-0^)VB/H\>J_"O1
MO$?PK^%T$WB2WMY/$?COP#! MY/_ $!Z'X2BT;P+H_@2?7?$GB*#2O">G^$I
MO$OB?4UU?Q?KL5CH\.CR:[XAUE[:)-3\2:FD1U#5M3>SC6]U2>XNFMD$IB'G
MW[-WP&\(?LO? CX5?L]> -2\2:QX+^$'@W2O!'AK4_&%YI>H>*+[2='C,5M<
M:Y>Z+H_A_2;G475B9Y;#1-,MF.#':1#B@1\SZ-\;OVF_B9^V1^T!\ O 4_P(
M\$_"S]G:7]GOQ!KOC#Q?X/\ B!X^^('C+1_BKX7U#7M>\!:3X<T;XA?#OPYX
M<U.9-&U:XTCXKWGB#7K7PRT>G:1>?!GQJ+^YU[2_D3P]^V'\:-%^#_PB7X%?
M"W]F7P3XQ^.?_!57]J+]D*[L9O!WBOPU\.M-T70?$7[6^HM\7M0T3P?XBCU3
M7?B?J6M?"#1/&_CUY+^SM/BAK=_XLTHWW@"[\66GC7PA^JW@GX$>$? ?QF^.
M/QRTC4?$ESXM^/UI\+;/QCIVI7FF3>'=-B^$>@:SX<\-MX9M+71[/4[.2]L=
M<NY=;.J:OK*W-U';O8+IL*2P3>&Z%^P3\'_#^E?"W2++Q)\2I;;X2?MB_$O]
MMOPV]UK'A=Y[WXK?%27XT3>(?#^MM%X.ACN?A[9M\=?%PT;2K"+3?$ENNG>'
M!?>+-1-IJ9U< \%\&_&7]OWQ7^T;\;/V19?&/['VF^*_@[X,^$OQF_X:*C^!
MWQIOO#WB/P/\8$\7>'=!^&'_  R^W[2%CJ6D>*]-\5_#CQYKNK_%[_AK'4](
M3P]!X1\.6?P7N]2\1:SXG\(<KX:_X* >-_B%^R%^SE\79?'7PT^!OQP^+'CG
MXL_#?4? ]G^RU^T5^VY<>/O$_P  _&'Q(^'/Q/O?A%\%?V?OB-X ^,UOX4&L
M?#FZ\<MXDU-_%>F>!/"FKZ/X<\7W,NLZGI^N77Z(>'/@%X.\,?M!?%']I&PU
M+Q+-XY^+?PX^%7PP\2:5>7FER>%++0/A!JWQ%UGPU>:)8PZ-;ZQ;:Q?77Q-U
MZ/7+B_UW4K*YM[32%L-/TR2WO);_ .7](_X)N_#+P=X+^!WAWX7?&'X\_"CQ
ME^SSXR_:%\5_#CXR>$M1^$6K_$6#3?VHO&_BCX@_&/P!KNF_$;X.>._A1K_@
M?7_$OB#2;RSM=0^&#^(='?P%X'N=/\21:C8:Q?:Z=?+7]+?J!\K:/_P4P^..
MI?LM^/?B1I/P[\!>(_C'\*O^"@?PK_8HO;7QEX+^.'[.'@WXF6/Q(\>?!"UT
M[QE+\./B9I6O?&O]GK4=1\#_ !PT2UO-(\7:7\5;GPAXGTG4=>M;#XB>'9]+
MTW4/KJ'XW_M!_!3]HCX"_"?]I?Q)\$/%OP^_:'\)_$S0O"WQ)^&'PP\;?"1?
M#7[07P_0?$#2_A_K]GXU^-_Q>M+S0/'GP7MO&VI>'=3AO-,O8_%'PEU];N,0
M^--!T;0Z?A[_ ()N?"+1?AUXR^'FI_$[X\>-6^(?[6_PS_;5\:>-_&GBWP?J
MOCC7OC7\,KKX-ZE:&2\M?A_IV@Z=X+\2:K\$_#E]K7A'1?#NFV&C0:QKV@?#
MQ_ WA2#PGH'A;F?^"IWP@U?]I+X$_#W]F?PUX5^(%]XE^-W[0'PDT.S^*/@*
MR\0P2_LY^'O#'B >-OB)\<]1\6Z1 NG>%[K0?AUX?\4^%?"4&MZKID'BWQKX
MQ\/^%(A>0ZI>PJ >]_L<_'3QQ^TK\._%/QLUO3/#>D_"[QG\2_&B?LW)H^FZ
MK:ZWXC^ _AW4CX9\(_$CQ9J&H>(-4M=4NOBG>:1J_P 0/"YTK1O#%K9> -?\
M)VL]CJ-^+K6+W\T_#7_!4#]H+XD2:5\7_A=\,?$?B_X0:U\9E\):%\"-$_X)
M^_M]^)OB+XA^#=M\0W^&^H?%&S_;.T715_9AM?%/V"VOOBX_@:'X>ZQX/TG1
M;67X77?Q=N_$D,_C*/\ <'PEX4\.> _"GACP-X.T>R\.^$?!GA[1?"GA7P_I
ML9AT[0_#GAW3;;1]#T>PA+,8K+3-,L[6RM8RS%(((UW'&:^/?!/[$2?"/6M1
M3X$_M0?M*_!+X5:CX^U/XB_\,]^$C^SMXO\ A%I.L^)M5C\0>-])\*R_&?\
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M6Y\.^+O"VE:]X'N?"MU+JPU, _-_P+\?/V@/V8_"?_!2[XAV]A\'?&/QQ?\
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M/+\4V7A+Q5IQTO1;KQ)ROQ._;(^(/P7T3_@I1XY^%GP@^ :^._@M^VE^Q_\
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M]0NK70-%9[301-JD%Q\9CTGC,3=VM-M>;LM#] RQM9?@[*]Z:3U6BO+7^O\
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M!XU@B\+^,M(^%6F?%-_$7A'P[\1?&/C_ ,8?$_4/'/C7QEVFL:E<?'7X2?\
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M+Q3^R]XU\0W<MS-??%#]FJ^\1Z+!X-NKZ=KCQU\!+W0-7C<ZOX$\86]M^O\
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M_P 7?AY\?/A?X&^,WPF\0_\ "5_#7XD^'K'Q5X+\2?V3KFA?VUH&I(9+*_\
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M\1Z7X>\&V'A2_P#$_B32?BCXM7Q/XPTS0=$F.OZSJ6K> ]+^'>C0^&O"WA@
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M>!?!FN'P"/V?O@=XYT^#Q':?#[0/#>@ZMXGN-5\9ZOJ?B?7K72=+T[5-?O\
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MEU#5WT^VO+JPDO$L/[5U-+'[0;2+4+R*%+B0_K^OO"WZ?CL?7=%%% !1110
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M*]5U:S\"ZA>>+/"WQM^.GCGX*^)?A=I&N>)=0\0^ _ %MHGA3]G+XZPZE?\
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M)O&W@FPU_P 5ZC\./!UK^U[H'AR'Q2^F:OJ/BBVLKG5=)E_7^BA.VW]?UYZ
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MA_\ -9_"[_PX\^(7_17Y/_#7/_\ /!H_X<>?$+_HK\G_ (:Y_P#YX-?W1?\
M""^'?^@?;_\ ?M/_ (BC_A!?#O\ T#[?_OVG_P 11_K9G_\ T'_^6N"_^9@_
MU)X8_P"A9_Y>YA_\UG\+O_#CSXA?]%?D_P##7/\ _/!H_P"''GQ"_P"BOR?^
M&N?_ .>#7]T7_""^'?\ H'V__?M/_B*/^$%\._\ 0/M_^_:?_$4?ZV9__P!!
M_P#Y:X+_ .9@_P!2>&/^A9_Y>YA_\UG\+O\ PX\^(7_17Y/_  US_P#SP:/^
M''GQ"_Z*_)_X:Y__ )X-?W1?\(+X=_Z!]O\ ]^T_^(H_X07P[_T#[?\ []I_
M\11_K9G_ /T'_P#EK@O_ )F#_4GAC_H6?^7N8?\ S6?PN_\ #CSXA?\ 17Y/
M_#7/_P#/!H_X<>?$+_HK\G_AKG_^>#7]T7_""^'?^@?;_P#?M/\ XBC_ (07
MP[_T#[?_ +]I_P#$4?ZV9_\ ]!__ ):X+_YF#_4GAC_H6?\ E[F'_P UG\+O
M_#CSXA?]%?D_\-<__P \&J=S_P $1?B+!-I\2_%F61;V\>VD<?"R]86Z)87U
MX)B;?QM<Q(&DM(X-U[-86I,X1+M[UK2QO?[KO^$%\._] ^W_ ._:?_$5@:SX
M!\//J/A1AI-O((M?N9"_V-)_LX/A;Q+%YIE&AZI]C#&40?:#?>' QF%I_;,Y
MNAX>UT_ULS__ *#_ /RUP7_S,'^I/#'_ $+/_+W,/_FL_A\_X<>?$+_HK\G_
M (:Y_P#YX-'_  X\^(7_ $5^3_PUS_\ SP:_NB_X07P[_P! ^W_[]I_\11_P
M@OAW_H'V_P#W[3_XBC_6S/\ _H/_ /+7!?\ S,'^I/#'_0L_\O<P_P#FL_A=
M_P"''GQ"_P"BOR?^&N?_ .>#1_PX\^(7_17Y/_#7/_\ /!K^Z+_A!?#O_0/M
M_P#OVG_Q%'_""^'?^@?;_P#?M/\ XBC_ %LS_P#Z#_\ RUP7_P S!_J3PQ_T
M+/\ R]S#_P":S^%W_AQY\0O^BOR?^&N?_P">#1_PX\^(7_17Y/\ PUS_ /SP
M:_NB_P"$%\._] ^W_P"_:?\ Q%'_  @OAW_H'V__ '[3_P"(H_ULS_\ Z#__
M "UP7_S,'^I/#'_0L_\ +W,/_FL_A=_X<>?$+_HK\G_AKG_^>#1_PX\^(7_1
M7Y/_  US_P#SP:_NB_X07P[_ - ^W_[]I_\ $4?\(+X=_P"@?;_]^T_^(H_U
MLS__ *#_ /RUP7_S,'^I/#'_ $+/_+W,/_FL_A=_X<>?$+_HK\G_ (:Y_P#Y
MX-'_  X\^(7_ $5^3_PUS_\ SP:_NB_X07P[_P! ^W_[]I_\11_P@OAW_H'V
M_P#W[3_XBC_6S/\ _H/_ /+7!?\ S,'^I/#'_0L_\O<P_P#FL_A=_P"''GQ"
M_P"BOR?^&N?_ .>#1_PX\^(7_17Y/_#7/_\ /!K^Z+_A!?#O_0/M_P#OVG_Q
M%'_""^'?^@?;_P#?M/\ XBC_ %LS_P#Z#_\ RUP7_P S!_J3PQ_T+/\ R]S#
M_P":S^%W_AQY\0O^BOR?^&N?_P">#1_PX\^(7_17Y/\ PUS_ /SP:_NB_P"$
M%\._] ^W_P"_:?\ Q%'_  @OAW_H'V__ '[3_P"(H_ULS_\ Z#__ "UP7_S,
M'^I/#'_0L_\ +W,/_FL_A=_X<>?$+_HK\G_AKG_^>#1_PX\^(7_17Y/_  US
M_P#SP:_NB_X07P[_ - ^W_[]I_\ $4?\(+X=_P"@?;_]^T_^(H_ULS__ *#_
M /RUP7_S,'^I/#'_ $+/_+W,/_FL_A=_X<>?$+_HK\G_ (:Y_P#YX-4Y_P#@
MB+\18KJQMU^+,KI=O.KRCX67I$'DP/,I+0^-IK9?,9=@^UW5D"3B!IY<0G^Z
M[_A!?#O_ $#[?_OVG_Q%8&I^ ?#S:UX;<:3;N([C4\R_8TE\G?IDZ@F<:'?"
MV\P_)DZMH?G?ZL2:CG[$Q_K9G_\ T'_^6N"_^9@_U)X8_P"A9_Y>YA_\UG\/
MG_#CSXA?]%?D_P##7/\ _/!H_P"''GQ"_P"BOR?^&N?_ .>#7]T7_""^'?\
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M-?W1?\(+X=_Z!]O_ -^T_P#B*/\ A!?#O_0/M_\ OVG_ ,11_K9G_P#T'_\
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M-/&'B'Q_X,\.^#?"WP\\!>%O"WC'X<_V'?\ "2>'?^@_HO\ X-+'_P"/T?\
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M?CE:V/VAO&OP"N[CQ#+9_P#"0?";29M2_?G_ (23P[_T']%_\&EC_P#'Z/\
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M8_\ Q^C_ (23P[_T']%_\&EC_P#'Z -JBL7_ (23P[_T']%_\&EC_P#'Z/\
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M1_PDGAW_ *#^B_\ @TL?_C] &U16+_PDGAW_ *#^B_\ @TL?_C]'_"2>'?\
MH/Z+_P"#2Q_^/T ;5%8O_"2>'?\ H/Z+_P"#2Q_^/T?\))X=_P"@_HO_ (-+
M'_X_0!M45B_\))X=_P"@_HO_ (-+'_X_1_PDGAW_ *#^B_\ @TL?_C] &U16
M+_PDGAW_ *#^B_\ @TL?_C]'_"2>'?\ H/Z+_P"#2Q_^/T ;5%8O_"2>'?\
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M_P"@_HO_ (-+'_X_0!M45B_\))X=_P"@_HO_ (-+'_X_1_PDGAW_ *#^B_\
M@TL?_C] &U16+_PDGAW_ *#^B_\ @TL?_C]'_"2>'?\ H/Z+_P"#2Q_^/T ;
M5<_>Q;O$F@S>3N\O3]>C\_[-O\KS7T<^7]K_ +&N?L_G>5N\G^WM)^T^3O\
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M_K_AU]X6?9_U_P .OO+]%4/[5TO_ *"5A_X&6_\ \<H_M72_^@E8?^!EO_\
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ME?\ 0,T__P  K;_XW7D'P#_Y$_4O^QEO/_37HU?RJ6?[2/C[]D6Y_P"#J/\
M:&^%A@B^(WP^^+WP;_X0O4+B$7$>A>(O%?AO7?!&F^*$MG5X;JX\*3^)5\2V
MEK=1R65S=:5#!?12V<D\;?&XZ/-C<2EO[33SNXQ_4_0,L=L!A/.E^3;/["O[
M)TK_ *!FG_\ @%;?_&Z/[)TK_H&:?_X!6W_QNOY=_A)_P;\_LD_%7]C#P'\?
M?'7Q<^->M_MW_$CX&>'?C++^WU+^TC\5HO$WA[XG^+_!4/CBT\2Z1-%XI7P@
MWPXT#6=6C\B:\\/S^(+KPE9FY/B*UU6Y;4H_R#_:8_:7O_V[/^"9W_!!_P"*
MO[9/PP^)O[3K:U^V%X^^&OQG^'OPATW7-:^,'[0_A[X=:CJ_@.6U\(Z3X8U[
MP?K^I_$CQWX;T6QANTT3Q/H=[JOBV74;ZRU+3&O$BM>113V;M>S=K6T;T5]5
MH^J\T=CFTM8[I-:Z6;BM7;1KF6R?J?Z G]DZ5_T#-/\ _ *V_P#C=']DZ5_T
M#-/_ / *V_\ C=?Q9?\ !+#QS\#_ -G?_@KC\0_"OP#^%G[4_P#P3,_8]U#]
MB?Q#XTU3]C7]N/3OC)HOQ!^,OQ&\':GJ'BGQ;\6/A-\/O&VO_$YUA\&>"O#L
MFH:C<6WCK6_%EQI6D>*1X>TNYT;6=;TWPI^W7B/_ (+V_P#!/*^_96^-O[5/
MP#^(7BO]I/0/@IXE^&W@#4?!/@;X9?$_P9XN\1?$KXPZK<Z/\-O!FAP?%GP5
MX%BNI]=N+'4[R[U*S^WVNEZ9I-])(EQJ<FEZ3J8X-/1-K36W?9.S:3OIN-33
M5W9;[O>V[5[-K7LO38_9/^R=*_Z!FG_^ 5M_\;H_LG2O^@9I_P#X!6W_ ,;K
M\/?A;_P5O_:7U3XRZC^R]^T+_P $Q?B3^SO^U-XT^!OCWXW?LM?"F;]H_P"#
M_P 1/#O[1T/@&T-[J/@-/BMIUAX<\(?"[QK);YN+JS\6_:;/0;>WN6\0W>FW
M$FD6NK]O^S/_ ,%2/CSXQ_; \'_L4?MM?\$^_&G[#GQ;^+G@'QI\0_@;?+\?
MOAK^TGX+^(ND_#NW2_\ &%A>>)_AKH^C:?X7UC3=,:2^CM'?68V$'V:^N--N
M;W28]13BU?;3S3^:L]5YJ]NNP^9>>]M8R5GI9.ZTO=6O:]T?L7_9.E?] S3_
M /P"MO\ XW1_9.E?] S3_P#P"MO_ (W7X=^)?^"L?[6WP6_:4_9_^$O[5W_!
M+3QK\ ?@S^TY^T3X6_9H^$?QTLOVMO@/\8];U'QYXXOC:>%[W7_@[\-[34-4
M\/>'Y((;S6->U*Y\7SIH6C6<L["^OL:=7[">#_%7Q*UKX@_%WPYXL^%'_"%^
M _!NK>#[/X4_$?\ X3K0/$?_  N72M9\&:7K?BS6/^$0TVWBUGX=_P#"%^+[
MO4_ _P#9_B2>ZN?$?]D_\)+IK1:7?V\2IIK>VJONG^3W\MT--.]NCL]&K:7Z
MKMUV9Z!_9.E?] S3_P#P"MO_ (W1_9.E?] S3_\ P"MO_C=?S9?M(>&/V@M#
M_P""P_[2?[3W[+-KJOC'XN_LR?L:_L<^(/$/P(M[UHM/_:7_ &?_ !7\1?VG
M+?XV?!2PMRIAL_B?>6WA_P *>/O@MXD=9Q9?$;P#I/A>]LKG0O&FM&+W?PQ^
MU=\#?B)_P4B\ ?MD>%_&4-Y\ ;S_ ((F_%_XSR^+I;6X@FTKP5X=_:@^'.N^
M*#K6DNIO]+UWPI%I&KZ;XF\/W42:IHNNZ3J>C7L$5_9S0J^7YZ+[W;3\='UU
MML[+FW\G;\4K_C_5S]UO[)TK_H&:?_X!6W_QNC^R=*_Z!FG_ /@%;?\ QNOQ
M,_9\_P""UGPU^-?QE_9\\!7J?LHVWA']J;Q%K?A;X6VOPA_;Q^&?[0'[2_@#
M69O#&N^.?AU9?M-_LU^#_ >E6OPJD\7^&O#E]H?B6Z^''Q@^.^C_  U^*>H>
M'? OB#5;K2M7D\:6'K5[_P %&OC7KGPK^+?[5OPA_8\M_B9^QI\&_$/Q/M=2
M\:3?'AO"G[2OQ4\"_ S7]2\._%SXI? 3]G27X-ZUX$\:>%K.]\.>,;CX;Z3X
M]_:5^$_C3XFZ?X5NIK/PSH=QK?A.TU\Y7V_%?U?RW'S*U[_@_P"OF?JS_9.E
M?] S3_\ P"MO_C=']DZ5_P! S3__  "MO_C=?F5^U9_P49L?@/8_#KQ3X&\6
M?\$\[_P/\4_A+8_%7P!-^U9_P41A_8P\>_$*QU*&?4=.7X=>"O$W[-/Q/TCQ
M#X>U/2+CP^]CXJUKQQX4AAUK6)])UO2]$M=-&KWTFB?\%)8OC9X5_8]'[)7P
M:E^*GQ3_ &S?@IX@_:.\(>"_BW\0!\$_"/PK^"G@NU\)P^+_ !=\:?'OA?P1
M\<M9T2YA\9>//!OPT\,:/X#^'/Q%D\3^-M>B=KK1_!VG:UXOTU6>FF]_P#F5
M[7UW_+[]U]Y^F/\ 9.E?] S3_P#P"MO_ (W1_9.E?] S3_\ P"MO_C=?S+>*
M_BC:^%? G_!?[XG?M8?LV:1XN@\._&S]D:Y^)G[.WA[XXZ[:^'/$,^E_LG?L
MD:3IR>&_CEX:\(^'/%+>&[^[@TCQKX?UJX\ ^%?$EWHTEEI?BKP;X8U:;6-"
MT[]ROAC^T_\ \+&_:Y_:L_98_P"$'_L;_AF/P'^S+XV_X3O_ (27^T?^$W_X
M:,L_B_=?V9_PC'_"/V/_  C7_"'?\*I\O[;_ ,)#K_\ PD/]O;_LFA_V7MU%
MN+7G9)O;JHOOKK)+\?03O_7F_+R_KK]/_P!DZ5_T#-/_ / *V_\ C=']DZ5_
MT#-/_P# *V_^-U^9O[-W_!2*7XY>)/V4=/\ %'P63X9^%OVOO"/[1S_#7Q:G
MQ)'B]8OC!^S?\1/$6B:[\'M0TD^!/##_ &SQ3\*/"_B+XP^&_$J7ZQRV?A/Q
MKX9GT17T"UUW6DN?^"B&J:G\ _B?^T7X?\.?LO?#[X7^$?VG_'WP%^'_ ,0O
MVM?VPKS]FCX5_%#P9\-M<U;X>Z]\4K;XAK^SS\4+;P_?ZS\7/#?B?PCX$\"_
MV/KMKXL\.Z))XR3QSITUU:^&'5GV_J]OS_SV"Z_79]D_R:/TS_LG2O\ H&:?
M_P" 5M_\;H_LG2O^@9I__@%;?_&Z_&GP_P#\%C/#&O?LG?M-?M"Z+\+_  1\
M4O&7[*GQQ^$WP2\:^#?V=?VD/!GQI^#_ ,2+OXQ^-?A'HOA/Q+\"OVDE\*^#
M_#OC33Y/"WQ?TJ_O;'Q?X+^'%[HGQ"\/^)?AKXJ_X1R'3SXS;WVS_;!_:CT;
MXW>%_P!G7XH_LK?!WP-\4OC7\%OBY\7/V;!I/[6/B?QKX,\4ZA\%-6^'%EXY
M^'GQP\16O[*VC:M\&_$-CI_Q8\&ZE!K'@/PM\?\ PK?.OB&QT_6;R32[";6G
MROM][7:_?L[AS+OVZ/J[+[WI;N?HS_9.E?\ 0,T__P  K;_XW1_9.E?] S3_
M /P"MO\ XW7YE?\ !)WX_?M>_M'_ ++_ (1^)G[47ASX3/\ VU<?$2'0?B-X
M*^*.I>(?&/C"\\/?&/XA>$Y[#Q9\,+7]F_X-^"O =AX:TW0K'1-#U3PYXS\:
MW?BNRT^'6M<TS0-5O[VW5+^.+XT_\%?=!MW4ZCX<_85_8OU+7PRQ+]CTGXT?
MMK_$-M!L?,E9-S:WI'P=_9SUX0A=WV71OB5,L$\8U+48)5;5KM_7YV7EU"^B
M>NMK:6>O^2U/TV_LG2O^@9I__@%;?_&ZY;Q-I>F+-X7VZ=8+N\4V2MBSMQN4
MV&IDJ<1\@D D'C('I7<UROB?_7^%?^QJLO\ TWZI2&;7]DZ5_P! S3__  "M
MO_C=']DZ5_T#-/\ _ *V_P#C=:%% &?_ &3I7_0,T_\ \ K;_P"-T?V3I7_0
M,T__ , K;_XW6A10!G_V3I7_ $#-/_\  *V_^-T?V3I7_0,T_P#\ K;_ .-U
MH44 9_\ 9.E?] S3_P#P"MO_ (W1_9.E?] S3_\ P"MO_C=:%% &?_9.E?\
M0,T__P  K;_XW1_9.E?] S3_ /P"MO\ XW6A10!G_P!DZ5_T#-/_ / *V_\
MC=']DZ5_T#-/_P# *V_^-UH44 9_]DZ5_P! S3__  "MO_C=']DZ5_T#-/\
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MWV7S/N9_M;0O.SY7F:CG[$P!H?V3I7_0,T__ , K;_XW1_9.E?\ 0,T__P
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MHH S_P"R=*_Z!FG_ /@%;?\ QNC^R=*_Z!FG_P#@%;?_ !NM"B@#/_LG2O\
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M@[Q+^T38:=H7@/6M4^$VE?!>Q\!ZI\.M2^*VKZ/X>L=<M?CO;>/$^'.NZ/\
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M+1^QC_ZS3^QW2LNWX>G^2^X+ON_Z_P"&7W']&OV*S_Y]+;_OQ%_\11]BL_\
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M[K6-+_L#7[S2_$OE6L#IJO\ 8_\ 8]V4LM0N)%Y+7?VL/V@/$/[1GQZ_9S^
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M4I-V226K;>B2U;T02E&,92E)1C%.4I2:48Q2NY2;LDDDVVW9+5GJU%?'[_\
M!0;]A%#@_MG_ +*;>Z_M#?"1A^8\6XIO_#PC]A'_ */-_95_\2$^$O\ \UM=
M'U/%_P#0+B?_  15_P#D?-?><OU_ _\ 09A/_"BC_P#)^:^\^PJ*^/?^'A'[
M"/\ T>;^RK_XD)\)?_FMH_X>$?L(_P#1YO[*O_B0GPE_^:VCZGB_^@7$_P#@
MBK_\CYK[P^OX'_H,PG_A11_^3\U]Y]A45\>_\/"/V$?^CS?V5?\ Q(3X2_\
MS6T?\/"/V$?^CS?V5?\ Q(3X2_\ S6T?4\7_ - N)_\ !%7_ .1\U]X?7\#_
M -!F$_\ "BC_ /)^:^\^PJ*^/?\ AX1^PC_T>;^RK_XD)\)?_FMH_P"'A'["
M/_1YO[*O_B0GPE_^:VCZGB_^@7$_^"*O_P CYK[P^OX'_H,PG_A11_\ D_-?
M>?85%?'O_#PC]A'_ */-_95_\2$^$O\ \UM'_#PC]A'_ */-_95_\2$^$O\
M\UM'U/%_] N)_P#!%7_Y'S7WA]?P/_09A/\ PHH__)^:^\^PJ*^/?^'A'["/
M_1YO[*O_ (D)\)?_ )K:/^'A'["/_1YO[*O_ (D)\)?_ )K:/J>+_P"@7$_^
M"*O_ ,CYK[P^OX'_ *#,)_X44?\ Y/S7WGV%17Q[_P /"/V$?^CS?V5?_$A/
MA+_\UM'_  \(_81_Z/-_95_\2$^$O_S6T?4\7_T"XG_P15_^1\U]X?7\#_T&
M83_PHH__ "?FOO/L*BOCW_AX1^PC_P!'F_LJ_P#B0GPE_P#FMH_X>$?L(_\
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M?_D_-?>?85%?'O\ P\(_81_Z/-_95_\ $A/A+_\ -;1_P\(_81_Z/-_95_\
M$A/A+_\ -;1]3Q?_ $"XG_P15_\ D?-?>'U_ _\ 09A/_"BC_P#)^:^\^PJ*
M^/?^'A'["/\ T>;^RK_XD)\)?_FMH_X>$?L(_P#1YO[*O_B0GPE_^:VCZGB_
M^@7$_P#@BK_\CYK[P^OX'_H,PG_A11_^3\U]Y]A45\>_\/"/V$?^CS?V5?\
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M?)W_ -FZW]F\_10#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=0UWQ+K^K]9\6O\ @GW_ ,+1T/\ ;[T;_A;?]A?\-R>-/@QXO^T_\(%_:?\
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M%K[2]=U;3['2?#EI:>)(K>PO(]1@U+_@H7\;O#-U\5/B'XC\-?"T_ ;X ?\
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M#3_ CX47MM:^(3;Z1XEU*7PZ-0\20?\ !-+5OVU_$OQL_;\3XW?M(_"OXH>
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MC[^K/QQ_:U^(/[:/QM_9"_8X_:'^+&H_LU:#\(OCK^V+_P $T_B3IGP&\%^
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MH!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X'\7/^1E\*?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5[!\*/\ F/\ _<*_]R->/U[!\*/^8_\ ]PK_ -R-9U?X<OE_Z4C2E_$C\_\
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M65_\NNJZ]N]AJ5_NNOUZ>?1L_0BBBBD4%%%% !1110 4444 %%%% !7XW?\
M!>S_ )1D_''_ +#_ ,'O_5O^":_9&OQN_P""]G_*,GXX_P#8?^#W_JW_  37
MHY/_ ,C;*_\ L8X+_P!2:1Y6>_\ (CSG_L59C_ZB5C_/HHHHK]W/YL"BBB@
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M#BVDWA7X0?L_?![QU\-_A[%^W]^TC^P'XBU^T^)VJ>-[#QQ\<=-O/V;/@?\
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M2^'=6\1"OTZ7ZV];?+>P75DNCVTTZ6_-'Z(7O@7P3J7C#0?B'J/@[PK?^/\
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MM;+3;+[;J5[>:A=_9K:/[1?7=S=S;YYY9'YOX.?$#_A;/PB^%?Q4_LC^P/\
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MK.A?#J;P(_A;QQXP[GXC?M=^.T^,A_9A_9T^"&E_'3]HCPSX+\+^/_C4-?\
MBE<?"G]G?]G[0/&%MK$OA&T^)?QIB^&WQ#\;7OBOXBW'AS7X/AIX-^'?P)\=
M>(M2L=+?Q/\ $&Q^&'A"]TW7[PL_Z:T]>WS"Z_I/7T[_ "OIJ?==%?GY\0?V
MMOC=\"+?]E73?C[\!?A7H_C7]J#]LGPU^RS9Z3\(/VB/%WQ.\+>#?#WBCX3?
M$[XE6/Q,N?%/C3]FOX,:MKFM07WPOU3P[=_#R+P;I=BMIJ5AKL/Q#FF6XT*/
MV;]IC]H__AG:X_9SM_\ A#?^$P_X7]^T]\-/V<-__"1?\(__ ,(G_P +$TOQ
M=J7_  F6W^P];_M[^Q_^$5\C_A'=VC?VA]O\S^W+'[+Y=P6>GGHMO0+K\E]]
MK?FCZ=HK\Q_V4?\ @IAX0_:/_:H_:@_9)\4?#J^^#OQ#^!GQ'^(7AKX6WNK>
M*8_$FB_M(> ?A?XIG\$>._''@J[3P[H$.B^)/ _B>.PA\=_#*>?6M9\-Z'XJ
M\$^)X=5U?1O$+7&G<A\7/^"AOQ2T#3?V\];^&7P3T;7;+_@G'\9_AEI_Q?TF
M]U[5-?\ $WQB^ FI_!?P-\;/B_X@^&6GZ?8^&K?P7\3/!'A+QQ=ZCX5T36[O
MQYHWBZ3P/=Z/.^D7?C"RO/#)ROMT3^3:2_%H.96O?3_+7\C]9Z_.;_@JG^SQ
MXV_:L_8U\>_ 7X=:CX9TGQCX[\0?#\:/J'C&\U73_#D!\->--&\87_\ :-YH
MFB^(=3A\[3/#]Y!:?9M'O/,OY;6*;[/;O+=0_H!X<\1:)XO\/:#XL\,ZG:ZU
MX;\4:-I?B+P_K-B_FV6K:)K5C!J6DZG9R$*9+6_L+FWNK=\#?#*C8&<5D>+H
M([AO"\4BAE;Q39 @CL=.U4?U_GZUI0K3PU>CB*5E4P]6G6IN2O'GI3C.%UU7
M-%775:&.)P]/%X;$86LFZ.)H5</547RR=.M3E3FHR6S<9.S6SU/\_;Q/_P $
M7OVM/"M]+87NO_!R]EB8JTNF^(/'DT#%>I5KGX;6CD>F8U^E<O\ \.BOVI_^
M@E\+O_!WXS_^8&O]!;4?A=X9U&=I[BP@D=B22R _GD?Y]^*S_P#A3WA+_H&6
MW_?M:^F_URSO_GYAO_">/^?]7?E;Y'_4'A[_ )]XO_PJE_\ (_U=^5O\_G_A
MT5^U/_T$OA=_X._&?_S T?\ #HK]J?\ Z"7PN_\ !WXS_P#F!K_0&_X4]X2_
MZ!EM_P!^UH_X4]X2_P"@9;?]^UH_URSO_GYAO_">/^?]7?E8_P!0>'O^?>+_
M /"J7_R/]7?E;_/Y_P"'17[4_P#T$OA=_P"#OQG_ /,#1_PZ*_:G_P"@E\+O
M_!WXS_\ F!K_ $!O^%/>$O\ H&6W_?M:/^%/>$O^@9;?]^UH_P!<L[_Y^8;_
M ,)X_P"?]7?E8_U!X>_Y]XO_ ,*I?_(_U=^5O\_G_AT5^U/_ -!+X7?^#OQG
M_P#,#1_PZ*_:G_Z"7PN_\'?C/_Y@:_T!O^%/>$O^@9;?]^UH_P"%/>$O^@9;
M?]^UH_URSO\ Y^8;_P )X_Y_U=^5C_4'A[_GWB__  JE_P#(_P!7?E;_ #^?
M^'17[4__ $$OA=_X._&?_P P-'_#HK]J?_H)?"[_ ,'?C/\ ^8&O] ;_ (4]
MX2_Z!EM_W[6C_A3WA+_H&6W_ '[6C_7+._\ GYAO_">/^?\ 5WY6/]0>'O\
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M^?\ AT5^U/\ ]!+X7?\ @[\9_P#S T?\.BOVI_\ H)?"[_P=^,__ )@:_P!
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M6\+>']-C=Y(]/T/P]H=I8Z3I-BCR2.EI86EO KN[+&"S$]/10!\C>&O^"?\
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M[0%GV?\ 7_#K[SHZ*YS_ (3#PI_T,>B?^#.S_P#CM'_"8>%/^ACT3_P9V?\
M\=H"S[/^O^'7WG1T5SG_  F'A3_H8]$_\&=G_P#':/\ A,/"G_0QZ)_X,[/_
M ..T!9]G_7_#K[SHZ*YS_A,/"G_0QZ)_X,[/_P".T?\ "8>%/^ACT3_P9V?_
M ,=H"S[/^O\ AU]Y]N? /_D3]2_[&6\_]->C5^3/[-__  0W^'_[.W_!5/XY
M_P#!3VR_: \=>*=4^+FK?$_Q)HWP:O/#L>G6'A/Q%\8II[KQP^L>.O\ A*M1
MN?&OAR"XO;\^#?#+>%/#EMX7@.EPR7>KMHFGS1_I_P# ;QKX2C\(:D&\1:02
M?$EX?DO89!C^R]''+1LR@\="<XP<8(S[9_PG'A#_ *&'2_\ P)6OC,>VL9B;
M/>;3\U9'Z!EB3R_"75[4TUY.[.JK\1/VI/@[X2^.'_!9']E'P?XSU?XJ:+I-
MK_P3Y_:LUV.[^$'QT^-O[/?BEKZR^.W[-EG#!<>.?@'\0OAIXUN]&>+4;A[O
MPY=^()O#U_=1V-]?:7<WNEZ9<6G[(_\ "<>$/^AATO\ \"5H_P"$X\(?]##I
M?_@2M<:=K^:MZ>9WM75O-/[G<_!SXV? *Z_9X_X**_ Z3]F/6?C5XE^+6O?\
M$XO^"DU[\/8?CE^TO^T/^TRB_$K0M5_98;X>0:*?VF_BS\4K;PM:77B6_LTU
MFST*71-,\0!+(^)$OX],T]K/Y&_X)Z?#;X&ZY\0_V+?&]C^W1_P3W^&7[7_A
M778[[XW_  NTS]G7Q1\&/^"G_P 9_'=YX;U_1?V@O@#^UYXB^+'[>OC#XO\
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MG\<+AHO /@'Q1IL?PF_X3;X6:;XX\0Z%I_Q$\*^,VLOA]=Z]K>B:S95^NO\
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MKE?^$X\(?]##I?\ X$K1_P )QX0_Z&'2_P#P)6@#JJ*Y7_A./"'_ $,.E_\
M@2M'_"<>$/\ H8=+_P# E: .JHKE?^$X\(?]##I?_@2M'_"<>$/^AATO_P "
M5H ZJBN5_P"$X\(?]##I?_@2M'_"<>$/^AATO_P)6@#JJY_68O,U'PF_D^;Y
M'B"YEW_9O/\ L^?"OB:#SO-_L;5/L>[SOL_VG[=X<W^?]C_MF?[7_P (]KU7
M_A./"'_0PZ7_ .!*U@ZQXQ\(S:CX5D&N:5*+77[B<N6CF-N&\+^)+;SA(=&U
M,VI8W M_/6]\.LPG-K_;,ZW+>']= /2**Y7_ (3CPA_T,.E_^!*T?\)QX0_Z
M&'2__ E: .JHKE?^$X\(?]##I?\ X$K1_P )QX0_Z&'2_P#P)6@#JJ*Y7_A.
M/"'_ $,.E_\ @2M'_"<>$/\ H8=+_P# E: .JHKE?^$X\(?]##I?_@2M'_"<
M>$/^AATO_P "5H ZJBN5_P"$X\(?]##I?_@2M'_"<>$/^AATO_P)6@#JJ*Y7
M_A./"'_0PZ7_ .!*T?\ "<>$/^AATO\ \"5H ZJBN5_X3CPA_P!##I?_ ($K
M1_PG'A#_ *&'2_\ P)6@#JJ*Y7_A./"'_0PZ7_X$K1_PG'A#_H8=+_\  E:
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M(C%R=&N6A$WDY,0UW2A<&)6;3M:,"SZ, >D45RO_  G'A#_H8=+_ / E:/\
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MEMIWQ-OO!NC77CRPM[6.*".V@L_%,NJV\-ND,*0QQK&L4:J$'H7_  D.A_\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KV#X4?\Q_\
M[A7_ +D:\?KV#X4?\Q__ +A7_N1K.K_#E\O_ $I&E+^)'Y_^DL_*G]KO_DX?
MXA?]RG_Z@_AJOYL?^"_W_)BFE?\ 9>/A_P#^H]X[K^D[]KO_ ).'^(7_ '*?
M_J#^&J^;:_8<+A?KO#N#PO/[/V^4X.G[3EY^3FPU+7EYH<UNW-'U/P7&8S^S
M^*L?C?9^V^K9WCJOLN?V?/RXRL^7GY9\M^_)*W9GX??\%#O@G\7;34?V(_VW
MO@?X(U3XH>(OV6;C1;GQ]\-]#AFO_$/B+X=W]OH6IW5WX?TV&*:>>XTZ.SUW
M3+\:?;7^IQ)XDL-8AL9;/0;YDV/C!_P5_P#@-XX^$?BGP9^S/HWQ8^*7[3'C
M7PWJGA;PI\%K;X0^/+;Q3X4\4Z_:2:1;W/C4SZ.NA?9M GNQ>7MKX<US7WO)
M;>.QCEABN)+^U_:FBMI9?7A4Q$\+BUAXXN,%B(RP_MFJD*4:/ML/)5J2I5)4
MXQ3]I&O#FBI<E[WYZ>:8>5+"4\;@98J6 E/ZK.&*^KITIUI5_88J+H5G6I1J
MSFX^SEAYJ,W!S:2M^07[)_AKX5_\$LOV"?A<W[7/B+3_  7?WGC:;Q5XIOY/
M#>O^-T\-?%#Q]::A+IN@6,'@S1O%E]'JFB>$]+7P_J&MZ; VEO>V6K&VU$V>
MH0&Y^"?^"9W[=?[*W@3]IW]N[_A*_BE_97_#47[6\VM_ K_BB/B-??\ "<Z9
MXK^(/Q%_L"Z_XEOA"\_X1G[?_P )9X?_ '/C#_A'[BU^W_Z;%;?9;W[-_3G1
M4/+*L)X#ZMB*-*CET'"C3J86=:<^:BZ$W4J1Q=%-N#O'EIQ<9ZMS7NFBSBC4
MIYG]<PN(KXC-9\U>K2QM.A3I\N(CB::I49X'$.*C4BHRYJLE*G[L5"7OG\Q/
M_!73]LO]E#QC<_!/X0_#KQ_9S^,_@!^V-::M\7?#-CX"\=Z'!X3'@N]\1Z+X
MWO#?7OA#3="U^:R\0BXBN&\,W^M3ZK,SWM@+^"3[2WZC?$#_ (*U?L8>$OV>
MM3_:,\+^/=5^)/A6/QGJOPR\-Z1H'@[QEH&N>*OB3I/A[1_%%WX8M+;QOX>\
M-/I]K9Z)X@T?5-2\27\<>B6UI=-!:7.HZS&FCS?IA150P.-IU\97AC<-&6+C
M3BK8"I:DZ,7"E*-\<U*T&^925I2LURQ3@YJ9CEU7#8##5,OQDH8&=6;;S*DO
M;K$2A.M&5LM4H*4H)0<9<T(.46YR:G'^9C_@GI^U+\"OV@OVV=1_:C^/7QST
M2W_:;^+VEGX0? O]G+PEX&^*MSHOPT\'EC*FGZWX\O/ -KX6U3Q'>V]C<O'/
M#KW]BP_VIK>IW5\][K5GH?A7^F>BBNC+\)4P=&5*K6A7G.K.K.M&C.E.I.I9
MSG54\17YJDI=8.G",>6$:<5%'+FF.I9AB(5J-"IAJ<*-.A"A.O3KPI4Z2<:=
M.BX8;#.%*$;*TU5J2ES5)U92DPHHHKN/-"BBB@ HHHH _6W]@K_DC_B3_LI.
ML?\ J+^#J^VZ^)/V"O\ DC_B3_LI.L?^HOX.KY!\*?%7Q/\ M _M1_'_ ."_
MBC_@IMXR_96^,7A3XU^+O 'PG_8T^%>A_L4Z!\0M0^%/@WP9H7BG1/B@GAS]
MJ']G?X[?&#XKCXA^'KO4OB/)X]\#7&D_#33_  ZY\-Z;HD>I>"O%6LW_ .)<
M1*^=YEY8AOK_ "P[7/Z(X7=N'LI_[!(=OYI=[+]3]F:*^<?C-^T[\%_V9(/A
MSH'Q;\:^*-1\9?$1]4TCX?\ @SP7\-/'_P :/C7\3[CP=H]OJ?C/7O#7P9^
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M*[Z+4PQ.(IX3#8C%5FU1PU"KB*KBN:2IT:<JDW&*UDU&+LEN]#]!Z*_AK?\
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M./AY#\3]'T5KNQFUO4?AY-XFM-'L]2TJ_P!3EM;+5=.N+KQGX<_MG?!CX<?
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M3Z]XM@U+P9%;Z%\(O[,T;QWXR\/:G<>.?#-K?^%-%N]1F /T@HKY>\:_MC?
MKP#'X%@UZ\^*EYXE^(W@\?$#PW\-/!W[.G[1?Q%^--OX'$MC:S>*_&'P,^'W
MPJ\3_&+X=:#9ZGJ=AH6HZE\0O WA>UTWQ+=1>&-0DMO$).F!^O\ [9?[-7A_
MX5_#'XS'XF0>)O GQL.EI\''^''A?QM\5O&'Q5N-6L)=5AL?AU\,OAEX:\7?
M$SQIJ=AI-M?:KXATOP[X0U'4?"NEZ7K.H^)K72++1M5GLP#Z>KV#X4?\Q_\
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M%% !1110 4444 %%%% !7@?Q<_Y&7PI_V _$_P#Z7^%Z]\KP/XN?\C+X4_[
M?B?_ -+_  O5T_CCZF=7^'+Y?^E(^ O''[!W[(WQ(_:4\$?M?^./@AX9\0_M
M&_#FRTVQ\'_$N\OO$<=WI:Z+-/<:'>3^'K36[?PAK&LZ%-<2-H6OZWX?U+7-
M% A33-0M$MK=8OKFBBNTXSX4_;W^#7Q)^-/A/]FC3/AGX<_X26^^'_[=G['/
MQE\70?VQH.C?V1\-OA5\:O#OBWQ[XC\SQ!JFE0W_ /8/AZQNM0_L?3)+W7M4
M\K[)HVEZC?/';/\ '?\ P4]_8-^+_P 4HO$OQ4_9%T;3M6\<_&F[^!_@']J7
MX476N:+X3TSXO^!OA7\4?"WC;X<_%JQU?7=0TC0[?XM? RZT1[""?5+ZW;QG
M\)=6\0^$&N;K5= \#:7)^U]%'?S_ ,DOT _$KXE_LE^/?"7[6W[47Q6UWX(_
MM=_M&?#+]I?5/A[XS\,WG[)'[<OBS]F_7?A[J7@OX3^!_A3X@\ _%+X;:C^V
M!^R1X&\3Z3J9\*GQ+X)\:Z!J'C;6TL-1U7PGXDT_1K72=$O-7D_:3_8-\1_M
M8?"'X ?L3^ OACXN_8[_ &9?A+\*+#Q%:?%G6_$W@/X@_%WP%KDGPTU?X=^$
MOV<? ,.F?%3XDZQ,-'TOQ/JFC_M%^*M=\3W_ (3\;^ =/O\ X5^!_%GC/3?'
M^I>-_"W[8T4 ?D)\1?!O[5?BWPU^P7\5[_\ 9,.G?$']CC]HO7KCXC_ ;X1^
M.O@K9:7XQ\"GX"_%;X'6_C_]G&^\7?$SPKX,L_A]<W?C;0O$GA;P%\5/%'PU
M\>:)X7M]0T#5='CU32;"37/0?^"K.J:KJW_!,?\ :!UJ7PUJ'AK7-3\"_#O5
M)/!WBF^T5-5T#5;WXA^ ;M_#7B/4_"&H^,_#JZAI5Y(=+U>^\+ZOXKT47,%Q
M<:+J.NV(MKFZ_3JO./BY\)/A[\=OAWXE^$_Q5\/_ /"4^ /&$%C;>(M _M76
M]#_M&#3=5L=;LD_M7PYJ6D:U:>3J>FV5SNL=1M7D\CR96DMY)HI #X-NO#/[
M0G[37[5O[)OQ+\8_LY>,_P!FGX=_LG:E\5/'_B'5/B7\0_@UXD\0?%#QM\1O
MA/XK^$&D^#/AQIWP+^)_Q-<^!]%B\3ZAXP\3>(_B/<> =0U-]/\ "FDV/@F]
M-WKIT/X*LO _QL_9=TK_ ((Q^$=?^#FK^+OBYX(_:<_;;O\ 4/A%X>\9_#FV
M\0ZOI?BGX)?M>^(RGA_Q3J_BJS^&LVO#P'XB7Q'HVG:YXU\/Z/J.I1VOAS6_
M$GA66YN]1TO^BZO-_%_PB^'GCSQM\)OB-XK\/?VKXR^!OB'Q-XJ^%NL_VMKE
MC_PB^O\ C'P+XC^&GB.__L_3=3L]*UO^T?!/BSQ!HOV7Q%8ZO96G]H?VE86]
MKJUK97]L ?C1\=/V+/VE_P!L?_ALSXO:AX%N?V=O$'Q9\)?L=>!/@W\&?''Q
M6L=*\7^)]*_9*^.&I_'O7-2^+WCG]G+Q=X^T#X>7?Q.U37]3\ >"=2^'/CSQ
MEXC\#Z39:?XUNM0TS5KB;PU:?1G[./P,T-_B-=?$+5_V._VXOA!\4](^"OCK
MPCH7Q(_:G_;8@_:@\)V%IXVO?!L_BGX:^#+2Z_;S_:6U73[KQ-JN@Z%K)URZ
M^&OA32KRQ\$K+J>MZ1J?]D:/J/ZIT4 ?C'^R_P#LG_'_ .'6C_\ !&^U\8^
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M:*+?Y_<&Q^*?QB_9Q^*>N_M7ZI^UAJW[/?[6?Q"\"_&_]GGX1> ]6^%G[/\
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MM\;^%M"UN6]T^WU8:9I7BGQ+I::7K.F"W\0WVHQZQ8:3^N'PH_YC_P#W"O\
MW(UX_7L'PH_YC_\ W"O_ '(UG5_AR^7_ *4C2E_$C\__ $EGY4_M=_\ )P_Q
M"_[E/_U!_#5?-M?27[7?_)P_Q"_[E/\ ]0?PU7S;7[7D_P#R*<K_ .Q=@O\
MU&I'\\9[_P CS.?^QKF/_J76/QL^'?C2T\$?\$F/@=>ZKX(^'OC?P]KNE?#_
M ,'^*!\7O#?_  F'PB\%^'?%7Q2CTC4OB9\4?"X>!]<\#_#U+A/%&L6*WVD(
MW]GP2W.O>'K.*XUS3_GSPW=>$]&?_@H5X1^$_CW]GOQ=\+M0_P"">?B_Q9=1
M?LF_#&]^$WP#E\?V^G?%#0[[4],\/V_Q4^+G@S6_'$7AT:/IOBKQ5X-\0VD=
MQ;0Z-X>\0:<NL^')96_H6HK&65N2PZ]NK8?#4\/%^RES>[1J49R3C6C%1J*:
MDX3C4<>6T9I2;6]/.5!XI_5F_K.*J8F4?;QY+SQ%'$0C)2P\I.5)TG&,X2I*
M7.I2@W!)_D3\5OAG\/\ X:_LN?L^:S8^$%TCX8?$+QQ\!M0_;=\9:;!JVH>*
M/'/P87X?^*+G5]6^-GCA)KSQQXQ\$P>--0\*V7CZ_P#%>L:O96?PYU'Q/IVL
MO!X.EU>%?'-8E^%MO\;?VAW_ ."<\7PYDUK_ (=T_%6?PC%^SJFBMX!;XM2>
M/M'M]/N?!\7@IE^'4OQ&2&WT3[9_80DU:6^M?"D/BJ.>--)@;]J?'5EX_P!0
M\/7%M\,_$W@_PCXL:XM6M=:\=>!M:^(GAZ&U28->PW'AC0/B'\+]2N;BX@W1
MVMS'XNM([.8B>:TOD4V[>+?"SX$>+?#_ ,5?%?QV^+_Q+T[XF?%/7_!^E_#3
M1/\ A$/ DWPP^'/@?X<Z7J \02Z+X<\'ZAXT^)/B*YUWQ%XJFN==\4^)_$?C
M_7)+U8-#TG1=-\/:;H[07\ULODZE.%**C3_=IU8TZ494%"G4C)T:GME.GS2?
M-R1H27M)RFYV;:NAFD(TJM2M-RJ_OG&A*K6G#$.I5HR@L13]@Z=3DC%P]I+$
MP?LJ<(*G>$5/\W?V4_A[\"M?^)_P7U7P;^TG^Q0WB>'PIXPT#XC?!3X:?!2X
M^&O[07QPT+7_  #?Z=XN\$?M(Z;XT_:D^(WCKQIXB\/:U86GCOQ=/\2_A]K'
MC6V\5>&-7N]6OK--;\5-J':_LC>$?V-OAU<_MF>!_$'A7X%^!/B9H7Q:_:KM
M?%?A72- \*^%OC#IW[,NH:O!X@L8=/TCPS9V'Q*C^%$_@;4=!OM 'AN Z"+6
M325T/;>06D<7[#45M2RR%+V3C['FIRJ-WHU)PDJE*G2=HU<14E!_NH/W9\EK
MKDYI.;QK9O4K>VC/ZQR584HKEQ%*G.+HUJE6+E*CA*4*D?WLU:5/G3Y7[3EB
MH'!_"S_A"/\ A6/PX_X5E_R3?_A _"'_  K[_D+_ /(D?\(]IW_")_\ (P?\
M3[_D _8/^0W_ ,3?_H)?Z;YU=Y117I17+&,?=]V*7NQY8Z*WNQN^6/:-W9:7
M>YY$Y<TI2]Y\TG*\Y<TM6W[TK+FEWE97=W97L%%%%,D**** "BBB@#];?V"O
M^2/^)/\ LI.L?^HOX.KX%_9O_P""Y'P__:)_X*I_'/\ X)A67[/_ (Z\+:I\
M(]6^)_AO1OC+>>(H]1L/%GB+X.S3VOCA-8\"_P#"*Z=<^"O#D]Q97X\&^)F\
M5^([;Q1 -+FDM-(;6]/AD^^OV"O^2/\ B3_LI.L?^HOX.KZ*T+X'?!7PO\2?
M%?QF\-?!_P"%WAWXP>.[*STWQQ\5M"^'_A/2?B3XRT[3TACL+#Q7XZL-)M_%
M'B*RL8[:WCL[75]4O(+9((5AC18D"_B7$5O[;S.ZO^_=M=GRPU/Z(X7O_J]E
M%G;_ &6%]+W7-+3R_KT?J-%%%>(?0'F7QKO[[2O@U\6]4TN]N]-U/3?AEX]O
M].U&PN9K.^L+ZS\*ZK<6E[97=N\=Q:W=K<1QSVUS!)'-!-&DL3JZJP_)[]DO
M]OK_ (5C^Q7_ ,$I_"OQ$\'_ +2?[3/[0W[6W['WAWQCX6'@.PTGXA>,?'OB
MKX<_#7X2:MX[N_B!X\^)7Q \(Z5H&K:[_P +$MM9/CWXE>*]'\&/)I^MMXM\
M;Z'J=SH5OKWZ[_$SPU?>,_AO\0?!^ERVD&I^*_!'BOPUIT]_)-%8PWVNZ#?Z
M7:2WLMO!=7$=I'<74;W,D%K<S)"KM%!,X6-OS%_9T_8(^,'PB/\ P21/B3Q)
M\-;[_A@K]DOXK? ;XP?V'K'BBY_X23Q?XY^&GP,\&Z3J7PV^W^#M,_MCPW;Z
MI\,M>GU&\\4?\(=JD-A=Z1+;:/=W%Q>VMA2M;7>[?RMIKVN2[W5OZNX_I<]L
ML/\ @I'\$K7X3_'7XD_$CP9\8O@WXG_9Q^)GAOX,?%#X"^.?#'AGQ#\<;;XL
M?$&P\$:G\(O ?A+0/@]XU^*?@[XB:U\9[/XE> 9/AE-X"\=>(](UEO$]K'J6
MIZ-)INO+I'SE8?M,?&#XA?\ !4O]DWX<^(_A1^TS^S)X<N_V3?VR?$_B3X1_
M%SQ'\,+OPM\0KW2O''[+-EX*\=(?V>_C;\;_ (0>)=5\+G4/&FC65KK'B>/X
MA^"HM6O+J\\/:)X>\<:!JGB:;XO?\$Z?C!\0?%W[<GQ#\+_$#X;^%/'/Q5_:
MW_8U_;#_ &5=3U>V\3>)M#T/QY^R)\'/@)X5L?#GQO\ #UO8>'IH/#?CCQ;\
M)_$GA_4)?!NN^(K[2?!GB>R\76GG>)--_P"$5KTWPI\"?VR/B-^W5\#_ -K'
MX]^%_P!F;X6>"O@O\ OV@O@Y:?#[X0_&CXI_&[Q1K&M?&7Q/\%_$4/BVY\7^
M,_V>/@!I,>EQ0?#!]*E\,1>%H[O198%U=/$_BA/$IT;P8:+L]/N;BM%WM)M=
M;6OIN)W=M_B73=*2NWVT5^B?GLN5^ 7[<OP:\!?LF?L61_#NW_;"_:A\9?M)
M^%_$LG[/_P //'=[\/O&O[7OQ8T7P+??;/B%XP^)/C3Q3X]\"_!C1K/P!8:M
MIMSXH\9>-OBEX5\.PVNH^&/#NFZAJ?BW7=!\/ZG]E:M\??BMIWPO\+>/[/\
M8B_:?U[Q7X@UK4-*U;X(:3XL_8OA^*'@>QLI=3CMO$GBG5M<_:[T7X+7>BZL
MEA:SZ?!X*^+WC#Q%'%K6F#5= TR:+6(=)_.+X*_\$]/VG/V:/AE_P3]\8_"_
M6/@-XP_:3_8\^"WQ;_9[^(G@7QGXP^(7A;X,?&#X7_&KQ5X-\7:];Z!\6-)^
M&/B_QG\/O%/@SQ'\._"6O^&?$$OP0\46FNVTWB?PGKNA6L6I:1XF\/\ IW[5
M_P"RM^TG^U=%^RIX]^)GP(_8Y^)UQ\&?%GQ@N_BI^Q%\8/CE\0?&_P"RE\18
MO'?A&3PU\/?BJ/B9JW[(&J76N?%'X1-82_\ "*Z%XP_96O=!L]/^*/Q$&F^)
M=,UW1O#NO:B66G:[U>_6RM=:-6U\]P5TNNB5M.EE=[/6]].RVZOF?VFO^"J/
MB7P7^R'\0/CY^SY^S9\5/$GQ(^%7[1'A7]G#XR?#7XE6/PCTZ\_9^^(C_%GX
M1^%/$7ACXIV:_M%>$M.\3WGB_P %_%'1+_X3>)_@5XX^+/@C4-0\8^!O%'B+
M6[+P(VN:C:_2&J_&C3O$7[1/[#=G\1?"W[6O[/7Q.^)5A^U0WA3X%ZGXP^"\
MW@'5;?P1X6\-OK]W^TC8?"/XJ_%?PAXFGLM'ET[Q+\%&\'>,_$<FAZEK&I2^
M)H]#U"6XT^V^$/ ?_!*_XU^'?V&/V[?V=[.P_9-^#OCK]I']KC0/VL/@K\/_
M (&6'BW1/V<OAE_PAVD?LI>(O"WPCU=(O 'AC6-.TD>._P!GW5_"OB3QOX3\
M!#^V="U>+XHZ=X \/ZSK-U\*?#OW9J7P-_:*^+/[1?[#_P"T;\4/#WP5^&NH
M?L\6?[4]A\2_ O@+XM^.?BS9W$7QA\)>%_"O@.X\"^+_ !#\"?@W/X@D0>'Y
M-0\76^O^$_!JZ&;E+31KCQ4(VNF;MMIHWJMWHK=7I?3]07,[7O\ 9TM_>U_"
MS^_MIQ>I?\%4O@_8>&_$?QEA^"?[2FK?L>>$_%MWX2U_]N+2O"OPPG_9[M%T
MC5X/"OB;QG:>&;CXNVO[4&M_"WPGXY>^\&Z_\5- _9SU3X?Q3Z)KGC+3_$.H
M?"W39O'U>C>+OV]]'T[X]?$K]FOX5_LT_M._M&_%7X3^%?AGXZ\8VWP@T;X*
MZ5X+M/!OQ6L-<O/#6MQ?%'XX?''X-?#3[5YVAR6)\'W?BRT\?ZT9Y]:\'^$O
M$_A3PWXU\0^%_BVW_81_;;\-_L:^*?\ @E[X/\0_LUQ_LJZSX,\4_ '0?VIM
M5\8_$4?M">&OV7O'MG=6.O>#;O\ 9@3X.WWPV\1_%+0/!FO>(?A)H'Q(/[4.
MB:3JL$&A_&#5?!%GKJ:C\.KC[E_9_P#V6O$7P6_:K_:I^, U#PY)\,OC#\+?
MV0/AU\-M&L]2UB]\7Z.G[.GACXJ^'=>;Q;#?:+9Z9!!?)XUT+^P;G3-<UNYO
MTM=4EU2#29(K9+Q/EMTZ]=U=6;\WK=7^2ZM<S_7R>MTKK57MKK\^G#0_\%,?
MA)XJ\(?LNZ[\%/A/\>?V@O&?[6_@[Q]\0/AI\&_AUHOPP\*?$K1/"'PD;1--
M^+NK_$B;X\_%CX,_#?P1)\,_&/B7P]\//$.C7_Q$FU_4O&FJ?8?!^E>*--TO
M7=6TKZ>\5?#S1_VFOA5X7LOBCX>^/OP::^GTWQ9>>#?"O[0'CGX%?%7PMK$-
MGJ%FOA[Q3\1/V//CE9Q:K!;Q:C<'4]!T'XJ>+/ VHWB:?J$C:E>:5IEU9_EM
M9_\ !.[XB:7^QO\  G]E[XB_LC?L-?MBZC\/IOCQ>ZIXJ^,/[07Q0^#6J_"_
M4?B=\6O%/C71]6^ 7CSPK^QO\9/B-X7\4W'A[7M.&K>.?"FL?"/Q;X5\1^']
M.E\-ZCJS6UCK=C^F7['OPD^*7P*_9G^#_P )OC;\6M2^.7Q7\&^%C9>.OBCJ
MU_XIU>Z\2:Y>ZGJ&KS0Q:SXYUWQ-XUUS3?#L.H0^%]&UWQAKVI^*=;T?1;'5
M?$%Q_:UY=QH.R6G?Y]?/3IND^P*[;OLUM;;1::K76_5]FC\X?^"</[/?AWQ5
MKW[2_C?Q=\6OVQO&.M_ K_@H%^T5\,_AK:^,OV^_VY/%WA33/ 7PP\2:-#X*
M\+>(/ ?B/]H?4_ WC_2=,AN)H;R'XA>'/%+>((9&B\1OJ\9VU^6WPS^-OANZ
M_8S^/_Q?U[XN_P#!52Y_;-\'_'#]L)_AM\4?#_C[_@H_-^S#X6\2_#W]IWXG
M:1\$F\9>-OB1JS?\$LM$^"'@?2M$\):7\76^->IVOP4\,_#_ $CQ99?%8V36
M&M11?T;?L=?L]^-/V>[3]IF#QIJ?AC4W^,_[8OQ^_:$\+GPQ>ZK>K8>"_BIK
M.F:CX>TS7SJNBZ*;7Q/9P64J:S9:<-4TJWE:-;'6M10LZ?!G[/W[,/\ P4?^
M 7[._C_]D[PYX._8F/AGQW\6/VE==L_V@]7_ &A?C9XG\0>$/!W[2'QQ^(/Q
M&NO$$W[,_P#PR-X9T+QQXH\">&?B!<06O@.?]I;PCH'B_7M(@M+SQ[X=TK4)
MKNU:?G_+UMLG??=7W):?NZ?9=]+^][MMMGH]3(^(-CXK_:"_X*"?L,_!_P"*
M/QE^*X\$>+?^";?QB^,OCK2OV7_VI/C_ / ?X=^./BUHGQ"_9NTFS\>Z7KW[
M.WQ/^&E_XKT&.U\9^*E\)SWVI7VF3Z'K<5RENY^RR1?0_AB\^(7['G[:'P'_
M &;XOBQ\2/B]^S-^U;X%^,L?PW\-?&KQ;JWQ5^*/P#^,?P8@A^)NKV^D_'+Q
ME/JGQ=^)WPN^)_@OQ+XE:;3?C?XS^)?B_P"'GB;P9X>TCP1XQTWX=ZK9^"/#
M?EY_88_:+_9S^-G[$/Q!_91T;X(_&#P3^R5^P5XC_8CN/#G[0/QU^(_P1\2:
MQ;76L?!*Z\/>-;+7O _[./[1UI>"WTSX0-;ZCHMQINBQ17&LPIID\5CIZ6\G
MU'\+?V<_C3XT_:&\.?M<?M;:]\.[?Q[\// /C3X=? O]G_X+7WB/Q3\*?@=8
M_$#7+)_B%XXU/XM^-O#O@7Q;\;_BK\0?#_A7P;I:^)G^%/P7\,_#KPN-<\!Z
M'X&\1WM]K?Q+\5C:LM=.6UO/7IT=]6_Q=]:6^UG=?=975^O5===?-?>M%%%0
M4%%%% !7XW?\%[/^49/QQ_[#_P 'O_5O^":_9&OQN_X+V?\ *,GXX_\ 8?\
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MW7?%7A#7=%\4^$->T'Q;X.\;^ /%_C+P#XKT'5H9M!\47UY8ZQ9:;X=\4?\
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M]G+]H#XD?'77OAG8?%_Q3\!_ \OP 3QI\)? &J:S=>&-.UCXF>-O&OQZ\&_
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MA_\ $/XB>(?@=X8\2+K2> -;U#1[GPQ#\%/V@_B5\2_ WC#0V6VU5E\6>'_
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MZ5I?@RRUC7=9O?L\5_K.L:A,J32I:6-MJ.M:UJ$T=GI]I?:E=P6\WY4>'_\
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MUEN!5.'\]6>'HPI0;Z*5248N3LHIN3:2;/P#,Z,:_$>:4JD_9TI9OF+JU/\
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M[;K\1XB_Y'>9?]A#_P#2(']$\+?\D]E/_8)#_P!*D%%%%>*>^%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7BGQX^'/@WXK^$+#P
M'\0/"/ACQWX0U[Q)I4>K^%?&.@Z5XG\.:I]ACO-3L/[1T/6[2]TR^^Q:G9V6
MHV?VFUE^S7UI;7D/EW%O#(OM=<KXG_UWA;_L:K+_ --^J4XRE&2E%N,HM2C*
M+:E&2=TTUJFGJFM4]4*48RC*,HJ49)QE&23C*+5G&2=TTTVFFK-:,_'SQO\
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MCCZF=7^'+Y?^E(\[HHHKM.,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M>/B+_P (WQA_\HJZJB@#E?\ A,M%_P">/B+_ ,(WQA_\HJ/^$RT7_GCXB_\
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M_P"45=510!RO_"9:+_SQ\1?^$;XP_P#E%1_PF6B_\\?$7_A&^,/_ )15U5%
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MH_MZP_YYZK_X(==_^5M;-%=FO=?<_P#,Y-.S^]?Y&-_;UA_SSU7_ ,$.N_\
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M/QTMK+2)M>USPFEAJL.GZ,WU5^P/\:O#'QN^"NJ:KHGQA_:*^+OB/P?XZO\
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M,/!J%.E"%#"T84*%*G3I0ITX0ITJ<8I0A&[3E*\Y2DRBBBN@Y0HHHH ****
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M36-3TOP-I/B/Q3;^%/A5+^U1X>^'GC1);>R\6P:/I.HW^G0>[P_ G]H'X?\
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M_COXK^#_ (:\#:-X9LM>\0ZSXJ^)WQ@\#:9X>T_1&L=>N+#7]>\':3XF]-^
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M76]E8&*VUGQ=?C]FG]F>2/6[&2XN[&RM'\.^)$BL&,T>M0-<2V,8!]<4444
M%>P?"C_F/_\ <*_]R->/U[!\*/\ F/\ _<*_]R-9U?X<OE_Z4C2E_$C\_P#T
MEG\Z/_!1?_D\KXQ?]T]_]57X'K\YO'.G?%+4/[+_ .%:>,O 'A+R?MO]M?\
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M ,=RK#=7#1^#?&?ASQ/(L%C+8P7T[)HFI7S"&SFU/38;J0C9;RZA8QS,CW<
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MC_\ (_U9^5_YD**_IO\ ^'#_ ((_Z&;XO_\ @X\(?_,#1_PX?\$?]#-\7_\
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M[_LWG_9\^%?$T'G>;_8VJ?8]WG?9_M/V[PYO\_['_;,_VO\ X1[7@#H****
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C@ KV#X4?\Q__ +A7_N1HHK.K_#E\O_2D:4OXD?G_ .DL_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>iobt-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-08-14T10:56:16.0537+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.iobiotech.com/20250630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iobt="http://www.iobiotech.com/20250630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" namespace="http://xbrl.sec.gov/ecd/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" namespace="http://xbrl.sec.gov/country/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" namespace="http://xbrl.sec.gov/stpr/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited" id="StatementConsolidatedBalanceSheetsUnaudited">
        <link:definition>75010 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical" id="StatementConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>75020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited2" id="StatementConsolidatedStatementsOfCashFlowsUnaudited2">
        <link:definition>75030 - Statement - Consolidated Statements of Cash Flows (Unaudited) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2">
        <link:definition>75040 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>75050 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited" id="StatementConsolidatedStatementsOfStockholdersEquityUnaudited">
        <link:definition>75060 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical">
        <link:definition>75070 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" id="StatementConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>75080 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity" id="Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity">
        <link:definition>995455 - Disclosure - Description of Business, Organization and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995475 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements" id="Role_DisclosureLicenseAndCollaborationAgreements">
        <link:definition>995485 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>995495 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>995505 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacility" id="DisclosureTermLoanFacility">
        <link:definition>995515 - Disclosure - Term Loan Facility</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>995525 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeases1" id="DisclosureLeases1">
        <link:definition>995535 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995545 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquity1" id="DisclosureStockholdersEquity1">
        <link:definition>995555 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation" id="Role_DisclosureEquityBasedCompensation">
        <link:definition>995565 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995575 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>995585 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegments" id="DisclosureSegments">
        <link:definition>995595 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>995605 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995615 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>995625 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>995635 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>995645 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>995655 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityTables" id="DisclosureTermLoanFacilityTables">
        <link:definition>995665 - Disclosure - Term Loan Facility (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995675 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables" id="Role_DisclosureEquityBasedCompensationTables">
        <link:definition>995685 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareTable" id="Role_DisclosureNetLossPerShareTable">
        <link:definition>995695 - Disclosure - Net Loss Per Share (Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsTables" id="DisclosureSegmentsTables">
        <link:definition>995705 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" id="Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails">
        <link:definition>995715 - Disclosure - Description of Business, Organization and Liquidity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995725 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" id="DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails">
        <link:definition>995735 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995745 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails" id="DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails">
        <link:definition>995755 - Disclosure - Fair Value Measurements - Summary of Black-Scholes Option-Pricing Model Inputs to Calculate the Fair Value of Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLevel3FinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsSummaryOfLevel3FinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995765 - Disclosure - Fair Value Measurements - Summary of Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>995775 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>995785 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>995795 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>995805 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails" id="DisclosureTermLoanFacilityAdditionalInformationDetails">
        <link:definition>995815 - Disclosure - Term Loan Facility - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails" id="DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails">
        <link:definition>995825 - Disclosure - Term Loan Facility - Schedule of Term Loan Debt, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails" id="DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails">
        <link:definition>995835 - Disclosure - Term Loan Facility - Schedule of Future Undiscounted Minimum Principal and Interest Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails" id="DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails">
        <link:definition>995845 - Disclosure - Term Loan Facility - Schedule of Warrants Issued and Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995855 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails" id="DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails">
        <link:definition>995865 - Disclosure - Leases - Schedule of Qualitative Information Regarding Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails" id="DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails">
        <link:definition>995875 - Disclosure - Leases - Schedule of Quantitative information Regarding Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails" id="DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails">
        <link:definition>995885 - Disclosure - Leases - Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995895 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>995905 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails" id="Role_DisclosureEquityBasedCompensationAdditionalInformationDetails">
        <link:definition>995915 - Disclosure - Equity-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails" id="DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails">
        <link:definition>995925 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails" id="DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails">
        <link:definition>995935 - Disclosure - Equity-Based Compensation - Summary of Assumptions for Estimated Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails" id="Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails">
        <link:definition>995945 - Disclosure - Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995955 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails" id="Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails">
        <link:definition>995965 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Ordinary Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>995975 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" id="DisclosureNetLossPerShareAdditionalInformationDetails">
        <link:definition>995985 - Disclosure - Net Loss Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails" id="DisclosureSegmentsAdditionalInformationDetails">
        <link:definition>995995 - Disclosure - Segments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails" id="DisclosureSegmentsScheduleOfExpensesBySegmentDetails">
        <link:definition>996005 - Disclosure - Segments - Schedule of Expenses by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>996015 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="iobt-20250630.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited" xlink:href="iobt-20250630.xsd#StatementConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="iobt-20250630.xsd#StatementConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="iobt-20250630.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:href="iobt-20250630.xsd#StatementConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" xlink:href="iobt-20250630.xsd#StatementConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="iobt-20250630.xsd#StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity" xlink:href="iobt-20250630.xsd#Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="iobt-20250630.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="iobt-20250630.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements" xlink:href="iobt-20250630.xsd#Role_DisclosureLicenseAndCollaborationAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="iobt-20250630.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="iobt-20250630.xsd#DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacility" xlink:href="iobt-20250630.xsd#DisclosureTermLoanFacility" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="iobt-20250630.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeases1" xlink:href="iobt-20250630.xsd#DisclosureLeases1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="iobt-20250630.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquity1" xlink:href="iobt-20250630.xsd#DisclosureStockholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation" xlink:href="iobt-20250630.xsd#Role_DisclosureEquityBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="iobt-20250630.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="iobt-20250630.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegments" xlink:href="iobt-20250630.xsd#DisclosureSegments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="iobt-20250630.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="iobt-20250630.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="iobt-20250630.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="iobt-20250630.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="iobt-20250630.xsd#DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="iobt-20250630.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityTables" xlink:href="iobt-20250630.xsd#DisclosureTermLoanFacilityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesTables" xlink:href="iobt-20250630.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables" xlink:href="iobt-20250630.xsd#Role_DisclosureEquityBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareTable" xlink:href="iobt-20250630.xsd#Role_DisclosureNetLossPerShareTable" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsTables" xlink:href="iobt-20250630.xsd#DisclosureSegmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" xlink:href="iobt-20250630.xsd#Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="iobt-20250630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" xlink:href="iobt-20250630.xsd#DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="iobt-20250630.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails" xlink:href="iobt-20250630.xsd#DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLevel3FinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="iobt-20250630.xsd#DisclosureFairValueMeasurementsSummaryOfLevel3FinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="iobt-20250630.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="iobt-20250630.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="iobt-20250630.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="iobt-20250630.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails" xlink:href="iobt-20250630.xsd#DisclosureTermLoanFacilityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails" xlink:href="iobt-20250630.xsd#DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails" xlink:href="iobt-20250630.xsd#DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails" xlink:href="iobt-20250630.xsd#DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="iobt-20250630.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails" xlink:href="iobt-20250630.xsd#DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails" xlink:href="iobt-20250630.xsd#DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails" xlink:href="iobt-20250630.xsd#DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="iobt-20250630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="iobt-20250630.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:href="iobt-20250630.xsd#Role_DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails" xlink:href="iobt-20250630.xsd#DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails" xlink:href="iobt-20250630.xsd#DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails" xlink:href="iobt-20250630.xsd#Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="iobt-20250630.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails" xlink:href="iobt-20250630.xsd#Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="iobt-20250630.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:href="iobt-20250630.xsd#DisclosureNetLossPerShareAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails" xlink:href="iobt-20250630.xsd#DisclosureSegmentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails" xlink:href="iobt-20250630.xsd#DisclosureSegmentsScheduleOfExpensesBySegmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="iobt-20250630.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited2" xlink:href="iobt-20250630.xsd#StatementConsolidatedStatementsOfCashFlowsUnaudited2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2" xlink:href="iobt-20250630.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CommonStockWarrantsIssuedToEIBMember" xlink:label="iobt_CommonStockWarrantsIssuedToEIBMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LaboratoryMember" xlink:label="iobt_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche" xlink:label="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PeriodForSatisfyingConditions" xlink:label="iobt_PeriodForSatisfyingConditions"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DividendsPaid" xlink:label="iobt_DividendsPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_UnauditedFinancialInformationPolicyPolicyTextBlock" xlink:label="iobt_UnauditedFinancialInformationPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_UnderwritingAgreementMember" xlink:label="iobt_UnderwritingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" xlink:label="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_SalesAgreementMember" xlink:label="iobt_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" xlink:label="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsPolicyPolicyTextBlock" xlink:label="iobt_WarrantsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" xlink:label="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PersonnelMember" xlink:label="iobt_PersonnelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement" xlink:label="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures" xlink:label="iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock" xlink:label="iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_O2025Q1DividendsMember" xlink:label="iobt_O2025Q1DividendsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_NumberOfOperatingLease" xlink:label="iobt_NumberOfOperatingLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember" xlink:label="iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheCMember" xlink:label="iobt_CreditFacilityTrancheCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInvestmentExpense" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DividendsDeclared" xlink:label="iobt_DividendsDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseAmendedBaseRent" xlink:label="iobt_OperatingLeaseAmendedBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_NumberOfVotePerShare" xlink:label="iobt_NumberOfVotePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement" xlink:label="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest" xlink:label="iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheTwoMember" xlink:label="iobt_CreditFacilityTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MD" xlink:label="stpr_MD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheAMember" xlink:label="iobt_CreditFacilityTrancheAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CommonStockWarrantsLiabilitiesNoncurrent" xlink:label="iobt_CommonStockWarrantsLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ContractualObligationsTerminationNoticePeriod" xlink:label="iobt_ContractualObligationsTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantLiabilitiesMember" xlink:label="iobt_WarrantLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_AccruedContractResearchAndDevelopmentCostsCurrent" xlink:label="iobt_AccruedContractResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheBMember" xlink:label="iobt_CreditFacilityTrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CommonStockWarrantsMember" xlink:label="iobt_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_SecuritiesPurchaseAgreementMember" xlink:label="iobt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_UndesignatedPreferredStockMember" xlink:label="iobt_UndesignatedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PreferredClassCMember" xlink:label="iobt_PreferredClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:label="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember" xlink:label="iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PaymentsOfStockAndWarrantIssuanceCosts" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfContributionsToCorporationsTaxableIncome" xlink:label="iobt_PercentageOfContributionsToCorporationsTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember" xlink:label="iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseAnnualBaseRent" xlink:label="iobt_OperatingLeaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LaboratoryEquipmentMember" xlink:label="iobt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_IncreaseDecreaseInLeaseLiability" xlink:label="iobt_IncreaseDecreaseInLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" xlink:label="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember" xlink:label="iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember" xlink:label="iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="iobt_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LoanFacilityWithEuropeanInvestmentBankMember" xlink:label="iobt_LoanFacilityWithEuropeanInvestmentBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember" xlink:label="iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails" xlink:label="iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_Long-TermDebtMaturityMinimumPayment" xlink:label="iobt_Long-TermDebtMaturityMinimumPayment"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantIssuanceAgreementAndFinanceContractMember" xlink:label="iobt_WarrantIssuanceAgreementAndFinanceContractMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ConsultantsAndOtherCostsMember" xlink:label="iobt_ConsultantsAndOtherCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ChemistryManufacturingAndControlMember" xlink:label="iobt_ChemistryManufacturingAndControlMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_O2024Q3DividendsMember" xlink:label="iobt_O2024Q3DividendsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PreclinicalStudiesAndActivitiesMember" xlink:label="iobt_PreclinicalStudiesAndActivitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DebtInstrumentCurrencyAdjustments" xlink:label="iobt_DebtInstrumentCurrencyAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PurchasePricePerShareOfCommonStockAndWarrant" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember" xlink:label="iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsExercisablePricePerShare" xlink:label="iobt_WarrantsExercisablePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalLeasesNetInvestmentInDirectFinancingAndSalesTypeLeasesAbstract" xlink:label="us-gaap_CapitalLeasesNetInvestmentInDirectFinancingAndSalesTypeLeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct" xlink:label="iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DebtInstrumentAmortizedPaidInKindInterest" xlink:label="iobt_DebtInstrumentAmortizedPaidInKindInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_AtTheMarketEquityProgramMember" xlink:label="iobt_AtTheMarketEquityProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix" xlink:label="iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CommonStockMaximumAggregateOfferingAmount" xlink:label="iobt_CommonStockMaximumAggregateOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DeferredFinancingAssets" xlink:label="iobt_DeferredFinancingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_NetProceedsFromIssuanceOfPrivatePlacement" xlink:label="iobt_NetProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsIssued" xlink:label="iobt_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseTermExpirationMonthYear" xlink:label="iobt_OperatingLeaseTermExpirationMonthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StrikePricePerShare" xlink:label="iobt_StrikePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OtherCostsMember" xlink:label="iobt_OtherCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfAmountDisbursedUnderFinanceContract" xlink:label="iobt_PercentageOfAmountDisbursedUnderFinanceContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ClinicalTrialRelatedActivitiesMember" xlink:label="iobt_ClinicalTrialRelatedActivitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheOneMember" xlink:label="iobt_CreditFacilityTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseCommencementMonthYear" xlink:label="iobt_OperatingLeaseCommencementMonthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OfficeAndLaboratoryMember" xlink:label="iobt_OfficeAndLaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember" xlink:label="iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_NoncashInterestExpenseDebt" xlink:label="iobt_NoncashInterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:label="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ProfessionalServicesMember" xlink:label="iobt_ProfessionalServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsExercisePricePerShare" xlink:label="iobt_WarrantsExercisePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember" xlink:label="iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OfficeMember" xlink:label="iobt_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_FairValueOfTrancheBWarrants" xlink:label="iobt_FairValueOfTrancheBWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockWarrantsIssuedToEIBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Issued to EIB Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockWarrantsIssuedToEIBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Warrants Issued to EIB.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockWarrantsIssuedToEIBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants Issued to the EIB</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Level 3 financial liabilities, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Level 3 financial liabilities, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certain Conditions Precedent, and One Uncommitted Accordion Tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Certain conditions precedent, and one uncommitted accordion tranche.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certain conditions precedent, and one uncommitted accordion tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total term loan debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Term loan debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Term Loan Debt, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PeriodForSatisfyingConditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period for satisfying conditions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PeriodForSatisfyingConditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period for Satisfying Conditions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PeriodForSatisfyingConditions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period for satisfying conditions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DividendsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dividends paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DividendsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DividendsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_UnauditedFinancialInformationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unaudited financial information, policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_UnauditedFinancialInformationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unaudited Financial Information Policy Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_UnauditedFinancialInformationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unaudited Financial Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of EIB common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Undiscounted Minimum Principal and Interest Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock and warrant issued during period value issued for private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock And Warrant Issued During Period Value Issued For Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares and warrants in private placement, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants Issued in Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities, convertible preference shares and stockholders' deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_UnderwritingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_UnderwritingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid contract research and development costs current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Contract Research And Development Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid contract research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock and warrant issued during period shares issued for private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock And Warrant Issued During Period Shares Issued For Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares and warrants in private placement, net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level1 To Level2 Transfers Amount1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Liabilities Level1 To Level2 Transfers Amount1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Earnings Per Share, Basic and Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options exercisable intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Policy .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued in Connection with a Sale of Common Stock or Issuance of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to reconcile net loss to net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2023 Inducement Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Inducement Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three inducement incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PersonnelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PersonnelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PersonnelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value Added Tax Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value-added tax refund receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of prepayment fee on repayment of tranche within twelve months of disbursement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Prepayment Fee on Repayment of Tranche Within Twelve Months of Disbursement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayment fee on repayment of tranche within twelve months of disbursement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from IPO, after deducting underwriting discounts, commissions and offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A Ordinary Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrants, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options exercisable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CEO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Income Tax Provision For Expensing Certain Business Property After Deduction For Domestic Research And Development Expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of income tax provision for expensing certain business property after deduction for domestic research and development expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of income tax provision for expensing certain business property after deduction for domestic research and development expenditures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Qualitative Information Regarding Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Qualitative Information Regarding Leases [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of Qualitative Information Regarding Leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_O2025Q1DividendsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">O 2025 Q1 Dividends [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_O2025Q1DividendsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">O 2025 Q1 Dividends.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_O2025Q1DividendsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">O 2025 Q1 Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Discount (Premium)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of operating lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions for Estimated Fair Value of Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement on December Two Thousand Twenty One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement on december two thousand twenty one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use lease asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility Tranche C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Credit Facility Tranche C.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche C</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Investment Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign currency (gain) loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Foreign currency loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DividendsDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dividends declared.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DividendsDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DividendsDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseAmendedBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease amended base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseAmendedBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease amended base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseAmendedBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Amended Base Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding potentially dilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right of use lease asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease liability, to be paid, after year four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Warrants, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Warrants, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Expenses and Other Current Assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfVotePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of vote per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfVotePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Vote Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NumberOfVotePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of votes per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares of common stock reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Lender [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Prepayment Fee on Repayment of Tranche After Third Anniversry of Disbursement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayment fee on repayment of tranche after third anniversry of disbursement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of prepayment fee on repayment of tranche after third anniversry of disbursement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Unamortized debt issuance costs and paid-in-kind interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Debt Issuance Costs And Paid In Kind Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, unamortized debt issuance costs and paid in kind interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche B</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Credit facility tranche two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Equity-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Collaboration Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remainder of 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Unamortized debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MD_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MARYLAND</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MD_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rockville, Maryland</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility Tranche A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Credit Facility Tranche A.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche A</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value of $0.001 per share; 5,000,000 shares authorized, no shares issued and outstanding as of June 30, 2025 and December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockWarrantsLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockWarrantsLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Liabilities Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockWarrantsLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants liabilities noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price per share, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ContractualObligationsTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual obligations termination notice period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ContractualObligationsTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligations Termination Notice Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ContractualObligationsTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual obligations termination notice period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 10)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AccruedContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued contract research and development costs current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AccruedContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contract Research And Development Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AccruedContractResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued contract research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class B Preference Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-average exercise price per share, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-average exercise price per share, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche B</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility Tranche B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Credit Facility Tranche B.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual term (in years), Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares used in computing net loss per common share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_UndesignatedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Undesignated preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_UndesignatedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undesignated Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_UndesignatedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undesignated Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferredClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred class c.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferredClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Class C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreferredClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class C Preference Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credit receivable current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credit Receivable Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stockholders' deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement on June Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement on june two thousand twenty three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">June 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of stock and warrant issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock And Warrant Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares and warrants in private placement, net of issuance costs of $3,188</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Common shares and warrants issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign currency loss (gain)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign currency loss (gain)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency exchange loss, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfContributionsToCorporationsTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of contributions to corporation's taxable income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfContributionsToCorporationsTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Contributions to Corporation's Taxable Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfContributionsToCorporationsTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of contributions to corporation's taxable income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Black-Scholes Option-Pricing Model Inputs to Calculate the Fair Value of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers into Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement on December Two Thousand Twenty Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement on december two thousand twenty four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standards update [extensible enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan debt principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease annual base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease annual base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total equity-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DK_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DENMARK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DK_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Copenhagen, Denmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of cash, cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_IncreaseDecreaseInLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_IncreaseDecreaseInLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) In Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_IncreaseDecreaseInLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level2 To Level1 Transfers Amount1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Liabilities Level2 To Level1 Transfers Amount1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement on March Two Thousand Twenty One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement on march two thousand twenty one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four EIB Term Loan Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Four EIB Term Loan Facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 EIB Term Loan Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_NY_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New York, New York</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_NY_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NEW YORK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LineOfCreditFacilityAdditionalBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional borrowing capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LineOfCreditFacilityAdditionalBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Additional Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LineOfCreditFacilityAdditionalBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility additional borrowing capacity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Amount Outstanding During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares used in computing net loss per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrants, Cancelled or forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Warrants, Cancelled or forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LoanFacilityWithEuropeanInvestmentBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">EIB Loan Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LoanFacilityWithEuropeanInvestmentBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Facility With European Investment Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LoanFacilityWithEuropeanInvestmentBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan facility with european investment bank.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of shares that may be issued under the plan as a proportion of outstanding capital stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Conversion Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock conversion basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity and Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Equity And Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one equity and incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total general and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Interest Rate During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional borrowing capacity ongoing trails</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Additional Borrowing Capacity Ongoing Trails</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility additional borrowing capacity ongoing trails.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Standards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_Long-TermDebtMaturityMinimumPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_Long-TermDebtMaturityMinimumPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Minimum Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_Long-TermDebtMaturityMinimumPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term debt, maturity, minimum payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantIssuanceAgreementAndFinanceContractMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Issuance Agreement and Finance Contract [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantIssuanceAgreementAndFinanceContractMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant Issuance Agreement and Finance Contract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantIssuanceAgreementAndFinanceContractMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Issuance Agreement and Finance Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConsultantsAndOtherCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consultants And Other Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConsultantsAndOtherCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consultants and other costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConsultantsAndOtherCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consultants and Other Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ConsultantsAndOtherCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Consultants and other costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability - current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ChemistryManufacturingAndControlMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chemistry, Manufacturing and Control</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ChemistryManufacturingAndControlMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chemistry, Manufacturing And Control [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ChemistryManufacturingAndControlMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Chemistry, manufacturing and control.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ChemistryManufacturingAndControlMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Chemistry, manufacturing and control</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual term (in years), Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer hardware</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows paid for amounts included in the measurement of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_O2024Q3DividendsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">O 2024 Q3 Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_O2024Q3DividendsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">O 2024 Q3 Dividends.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_O2024Q3DividendsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">O 2024 Q3 Dividends [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreclinicalStudiesAndActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preclinical Studies And Activities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreclinicalStudiesAndActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preclinical studies and activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreclinicalStudiesAndActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preclinical Studies and Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PreclinicalStudiesAndActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preclinical studies and activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of EIB common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other noncurrent assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DebtInstrumentCurrencyAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Currency Adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DebtInstrumentCurrencyAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, currency adjustments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DebtInstrumentCurrencyAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share of common stock and warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Price Per Share of Common Stock and Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price per share of common stock and warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to class A ordinary shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">October 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement on October Two Thousand Twenty One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement on october two thousand twenty one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsExercisablePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Price of Common Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsExercisablePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercisable Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsExercisablePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercisable price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalLeasesNetInvestmentInDirectFinancingAndSalesTypeLeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases, Net Investment in Direct Financing and Sales Type Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business, organization and liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Organization And Liquidity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business Organization And Liquidity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business, organization and liquidity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Organization And Liquidity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business Organization And Liquidity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contribution Percentage In Excess Of Corporate Taxable Income Applicable As Per One Big Beautiful Bill Act</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contribution percentage in excess of corporate taxable income applicable as per One Big Beautiful Bill Act.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution percentage in excess of corporate taxable income applicable as per One Big Beautiful Bill Act</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price per share, Cancelled or forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remainder of 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DebtInstrumentAmortizedPaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Amortized Paid In Kind Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DebtInstrumentAmortizedPaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, amortized paid in kind interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DebtInstrumentAmortizedPaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized paid-in-kind interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED KINGDOM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Newport, United Kingdom</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AtTheMarketEquityProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Equity Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AtTheMarketEquityProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At-The-Market Equity Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_AtTheMarketEquityProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market equity program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol(s)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2031</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Six</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal in year six.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockMaximumAggregateOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, maximum aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockMaximumAggregateOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Maximum Aggregate Offering Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CommonStockMaximumAggregateOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, maximum aggregate offering amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeferredFinancingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Financing Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeferredFinancingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred financing assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_DeferredFinancingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred financing asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other (expense) income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Options Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Proceeds From Issuance Of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from issuance of private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities measured at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseTermExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Term Expiration Month Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseTermExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease term expiration month year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseTermExpirationMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value of $0.001 per share; 300,000,000 shares authorized at June 30, 2025 and December 31, 2024; 65,880,914 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StrikePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Strike Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StrikePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Strike price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_StrikePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strike price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OtherCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OtherCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OtherCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfAmountDisbursedUnderFinanceContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Amount Disbursed Under Finance Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfAmountDisbursedUnderFinanceContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of amount disbursed under finance contract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_PercentageOfAmountDisbursedUnderFinanceContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of amount disbursed under finance contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preference shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lender Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income taxes expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ClinicalTrialRelatedActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Related Activities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ClinicalTrialRelatedActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trial-related activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ClinicalTrialRelatedActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Trial-Related Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ClinicalTrialRelatedActivitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Clinical trial-related activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Warrants, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants granted transferred to plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche A</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_CreditFacilityTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Credit facility tranche one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseCommencementMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Month Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseCommencementMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement month year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OperatingLeaseCommencementMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common shares , net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and Laboratory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office and Laboratory [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OfficeAndLaboratoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Expenses by Segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement on January Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement on january two thousand twenty three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">January 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NoncashInterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NoncashInterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Interest Expense Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_NoncashInterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash interest expense debt.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award equity instruments other than options exercisable in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Exercisable In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price per share, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ProfessionalServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Professional Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ProfessionalServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ProfessionalServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Professional services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_ProfessionalServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility, aggregate principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsExercisePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercise Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsExercisePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercise price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsExercisePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining average lease term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued to the European Investment Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued to the european investment bank.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued to the European Investment Bank</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Common shares issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability - noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, liability, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Quantitative Information Regarding Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Warrants Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other (expense) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preference share issued upon conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paid-in-Kind Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paid-in-kind interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Avaliable amount to draw</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Current Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax benefits for stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares sold, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets Measured at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business, Organization and Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ManagementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Management [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ManagementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Management</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Earnings Per Share Basic By Common Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueOfTrancheBWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Tranche B Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueOfTrancheBWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of tranche B warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="iobt_FairValueOfTrancheBWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Tranche B Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants available for future grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost, recognition period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office furniture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_CommonStockWarrantsIssuedToEIBMember" xlink:to="iobt_CommonStockWarrantsIssuedToEIBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LaboratoryMember" xlink:to="iobt_LaboratoryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche" xlink:to="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PeriodForSatisfyingConditions" xlink:to="iobt_PeriodForSatisfyingConditions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DividendsPaid" xlink:to="iobt_DividendsPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_UnauditedFinancialInformationPolicyPolicyTextBlock" xlink:to="iobt_UnauditedFinancialInformationPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:to="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_UnderwritingAgreementMember" xlink:to="iobt_UnderwritingAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" xlink:to="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" xlink:to="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_SalesAgreementMember" xlink:to="iobt_SalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" xlink:to="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_WarrantsPolicyPolicyTextBlock" xlink:to="iobt_WarrantsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" xlink:to="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PersonnelMember" xlink:to="iobt_PersonnelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement" xlink:to="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures" xlink:to="iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock" xlink:to="iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_O2025Q1DividendsMember" xlink:to="iobt_O2025Q1DividendsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_NumberOfOperatingLease" xlink:to="iobt_NumberOfOperatingLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember" xlink:to="iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_CreditFacilityTrancheCMember" xlink:to="iobt_CreditFacilityTrancheCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DividendsDeclared" xlink:to="iobt_DividendsDeclared_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_OperatingLeaseAmendedBaseRent" xlink:to="iobt_OperatingLeaseAmendedBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_NumberOfVotePerShare" xlink:to="iobt_NumberOfVotePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement" xlink:to="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest" xlink:to="iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_CreditFacilityTrancheTwoMember" xlink:to="iobt_CreditFacilityTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MD" xlink:to="stpr_MD_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:to="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_CreditFacilityTrancheAMember" xlink:to="iobt_CreditFacilityTrancheAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_CommonStockWarrantsLiabilitiesNoncurrent" xlink:to="iobt_CommonStockWarrantsLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ContractualObligationsTerminationNoticePeriod" xlink:to="iobt_ContractualObligationsTerminationNoticePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_WarrantLiabilitiesMember" xlink:to="iobt_WarrantLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_AccruedContractResearchAndDevelopmentCostsCurrent" xlink:to="iobt_AccruedContractResearchAndDevelopmentCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassBMember" xlink:to="us-gaap_PreferredClassBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_CreditFacilityTrancheBMember" xlink:to="iobt_CreditFacilityTrancheBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_CommonStockWarrantsMember" xlink:to="iobt_CommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_SecuritiesPurchaseAgreementMember" xlink:to="iobt_SecuritiesPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_UndesignatedPreferredStockMember" xlink:to="iobt_UndesignatedPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PreferredClassCMember" xlink:to="iobt_PreferredClassCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:to="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember" xlink:to="iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PaymentsOfStockAndWarrantIssuanceCosts" xlink:to="iobt_PaymentsOfStockAndWarrantIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PercentageOfContributionsToCorporationsTaxableIncome" xlink:to="iobt_PercentageOfContributionsToCorporationsTaxableIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember" xlink:to="iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_OperatingLeaseAnnualBaseRent" xlink:to="iobt_OperatingLeaseAnnualBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LaboratoryEquipmentMember" xlink:to="iobt_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DK" xlink:to="country_DK_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_IncreaseDecreaseInLeaseLiability" xlink:to="iobt_IncreaseDecreaseInLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" xlink:to="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember" xlink:to="iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember" xlink:to="iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NY" xlink:to="stpr_NY_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="iobt_LineOfCreditFacilityAdditionalBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LoanFacilityWithEuropeanInvestmentBankMember" xlink:to="iobt_LoanFacilityWithEuropeanInvestmentBankMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionBasis" xlink:to="us-gaap_CommonStockConversionBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember" xlink:to="iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails" xlink:to="iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_Long-TermDebtMaturityMinimumPayment" xlink:to="iobt_Long-TermDebtMaturityMinimumPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_WarrantIssuanceAgreementAndFinanceContractMember" xlink:to="iobt_WarrantIssuanceAgreementAndFinanceContractMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ConsultantsAndOtherCostsMember" xlink:to="iobt_ConsultantsAndOtherCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsDomain" xlink:to="us-gaap_DividendsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ChemistryManufacturingAndControlMember" xlink:to="iobt_ChemistryManufacturingAndControlMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_O2024Q3DividendsMember" xlink:to="iobt_O2024Q3DividendsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PreclinicalStudiesAndActivitiesMember" xlink:to="iobt_PreclinicalStudiesAndActivitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DebtInstrumentCurrencyAdjustments" xlink:to="iobt_DebtInstrumentCurrencyAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PurchasePricePerShareOfCommonStockAndWarrant" xlink:to="iobt_PurchasePricePerShareOfCommonStockAndWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember" xlink:to="iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_WarrantsExercisablePricePerShare" xlink:to="iobt_WarrantsExercisablePricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesNetInvestmentInDirectFinancingAndSalesTypeLeasesAbstract" xlink:to="us-gaap_CapitalLeasesNetInvestmentInDirectFinancingAndSalesTypeLeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct" xlink:to="iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DebtInstrumentAmortizedPaidInKindInterest" xlink:to="iobt_DebtInstrumentAmortizedPaidInKindInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_AtTheMarketEquityProgramMember" xlink:to="iobt_AtTheMarketEquityProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix" xlink:to="iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_CommonStockMaximumAggregateOfferingAmount" xlink:to="iobt_CommonStockMaximumAggregateOfferingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_DeferredFinancingAssets" xlink:to="iobt_DeferredFinancingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_NetProceedsFromIssuanceOfPrivatePlacement" xlink:to="iobt_NetProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_WarrantsIssued" xlink:to="iobt_WarrantsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_OperatingLeaseTermExpirationMonthYear" xlink:to="iobt_OperatingLeaseTermExpirationMonthYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_StrikePricePerShare" xlink:to="iobt_StrikePricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_OtherCostsMember" xlink:to="iobt_OtherCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_PercentageOfAmountDisbursedUnderFinanceContract" xlink:to="iobt_PercentageOfAmountDisbursedUnderFinanceContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ClinicalTrialRelatedActivitiesMember" xlink:to="iobt_ClinicalTrialRelatedActivitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_CreditFacilityTrancheOneMember" xlink:to="iobt_CreditFacilityTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_OperatingLeaseCommencementMonthYear" xlink:to="iobt_OperatingLeaseCommencementMonthYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_OfficeAndLaboratoryMember" xlink:to="iobt_OfficeAndLaboratoryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember" xlink:to="iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_NoncashInterestExpenseDebt" xlink:to="iobt_NoncashInterestExpenseDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:to="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_ProfessionalServicesMember" xlink:to="iobt_ProfessionalServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_WarrantsExercisePricePerShare" xlink:to="iobt_WarrantsExercisePricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember" xlink:to="iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_OfficeMember" xlink:to="iobt_OfficeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iobt_FairValueOfTrancheBWarrants" xlink:to="iobt_FairValueOfTrancheBWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CommonStockWarrantsLiabilitiesNoncurrent" xlink:label="iobt_CommonStockWarrantsLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="iobt_CommonStockWarrantsLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInvestmentExpense" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_7"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_8"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PaymentsOfStockAndWarrantIssuanceCosts" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_PaymentsOfStockAndWarrantIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_IncreaseDecreaseInLeaseLiability" xlink:label="iobt_IncreaseDecreaseInLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="iobt_IncreaseDecreaseInLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacility" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeases1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsPolicyPolicyTextBlock" xlink:label="iobt_WarrantsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_UnauditedFinancialInformationPolicyPolicyTextBlock" xlink:label="iobt_UnauditedFinancialInformationPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iobt_WarrantsPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iobt_UnauditedFinancialInformationPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock" xlink:label="iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareTable" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_SalesAgreementMember" xlink:label="iobt_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LoanFacilityWithEuropeanInvestmentBankMember" xlink:label="iobt_LoanFacilityWithEuropeanInvestmentBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheAMember" xlink:label="iobt_CreditFacilityTrancheAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheBMember" xlink:label="iobt_CreditFacilityTrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheCMember" xlink:label="iobt_CreditFacilityTrancheCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PreferredClassCMember" xlink:label="iobt_PreferredClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_AtTheMarketEquityProgramMember" xlink:label="iobt_AtTheMarketEquityProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_UndesignatedPreferredStockMember" xlink:label="iobt_UndesignatedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsIssued" xlink:label="iobt_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PurchasePricePerShareOfCommonStockAndWarrant" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CommonStockMaximumAggregateOfferingAmount" xlink:label="iobt_CommonStockMaximumAggregateOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche" xlink:label="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="iobt_SalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="iobt_LoanFacilityWithEuropeanInvestmentBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockConversionBasis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheCMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_PreferredClassCMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iobt_AtTheMarketEquityProgramMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_UndesignatedPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_WarrantsIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="srt_StatementScenarioAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_SharePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_PurchasePricePerShareOfCommonStockAndWarrant" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_CommonStockMaximumAggregateOfferingAmount" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CommonStockWarrantsMember" xlink:label="iobt_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantLiabilitiesMember" xlink:label="iobt_WarrantLiabilitiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="iobt_CommonStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="iobt_WarrantLiabilitiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LoanFacilityWithEuropeanInvestmentBankMember" xlink:label="iobt_LoanFacilityWithEuropeanInvestmentBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheOneMember" xlink:label="iobt_CreditFacilityTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" xlink:label="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheTwoMember" xlink:label="iobt_CreditFacilityTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" xlink:label="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsIssued" xlink:label="iobt_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StrikePricePerShare" xlink:label="iobt_StrikePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsExercisePricePerShare" xlink:label="iobt_WarrantsExercisePricePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="iobt_LoanFacilityWithEuropeanInvestmentBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_WarrantsIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_StrikePricePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_WarrantsExercisePricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheOneMember" xlink:label="iobt_CreditFacilityTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheTwoMember" xlink:label="iobt_CreditFacilityTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_SharePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLevel3FinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DeferredFinancingAssets" xlink:label="iobt_DeferredFinancingAssets"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_FairValueOfTrancheBWarrants" xlink:label="iobt_FairValueOfTrancheBWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" xlink:label="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:label="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="iobt_DeferredFinancingAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="iobt_FairValueOfTrancheBWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidInsurance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LaboratoryEquipmentMember" xlink:label="iobt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_AccruedContractResearchAndDevelopmentCostsCurrent" xlink:label="iobt_AccruedContractResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="iobt_AccruedContractResearchAndDevelopmentCostsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantIssuanceAgreementAndFinanceContractMember" xlink:label="iobt_WarrantIssuanceAgreementAndFinanceContractMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheAMember" xlink:label="iobt_CreditFacilityTrancheAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember" xlink:label="iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheBMember" xlink:label="iobt_CreditFacilityTrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LoanFacilityWithEuropeanInvestmentBankMember" xlink:label="iobt_LoanFacilityWithEuropeanInvestmentBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheCMember" xlink:label="iobt_CreditFacilityTrancheCMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche" xlink:label="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PeriodForSatisfyingConditions" xlink:label="iobt_PeriodForSatisfyingConditions"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="iobt_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement" xlink:label="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement" xlink:label="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails" xlink:label="iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfAmountDisbursedUnderFinanceContract" xlink:label="iobt_PercentageOfAmountDisbursedUnderFinanceContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StrikePricePerShare" xlink:label="iobt_StrikePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_NoncashInterestExpenseDebt" xlink:label="iobt_NoncashInterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="iobt_WarrantIssuanceAgreementAndFinanceContractMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="iobt_LoanFacilityWithEuropeanInvestmentBankMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheCMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_PeriodForSatisfyingConditions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_LineOfCreditFacilityAdditionalBorrowingCapacity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_PercentageOfAmountDisbursedUnderFinanceContract" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_StrikePricePerShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_NoncashInterestExpenseDebt" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_PaidInKindInterest" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DebtInstrumentAmortizedPaidInKindInterest" xlink:label="iobt_DebtInstrumentAmortizedPaidInKindInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DebtInstrumentCurrencyAdjustments" xlink:label="iobt_DebtInstrumentCurrencyAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="iobt_DebtInstrumentAmortizedPaidInKindInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="iobt_DebtInstrumentCurrencyAdjustments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix" xlink:label="iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_Long-TermDebtMaturityMinimumPayment" xlink:label="iobt_Long-TermDebtMaturityMinimumPayment"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest" xlink:label="iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DebtInstrumentCurrencyAdjustments" xlink:label="iobt_DebtInstrumentCurrencyAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="iobt_Long-TermDebtMaturityMinimumPayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="iobt_DebtInstrumentCurrencyAdjustments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheAMember" xlink:label="iobt_CreditFacilityTrancheAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheBMember" xlink:label="iobt_CreditFacilityTrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StrikePricePerShare" xlink:label="iobt_StrikePricePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_StrikePricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OfficeAndLaboratoryMember" xlink:label="iobt_OfficeAndLaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_NumberOfOperatingLease" xlink:label="iobt_NumberOfOperatingLease"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OfficeMember" xlink:label="iobt_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MD" xlink:label="stpr_MD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LaboratoryMember" xlink:label="iobt_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseAnnualBaseRent" xlink:label="iobt_OperatingLeaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseAmendedBaseRent" xlink:label="iobt_OperatingLeaseAmendedBaseRent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DK" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_OfficeAndLaboratoryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NY" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_NumberOfOperatingLease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_OfficeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MD" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_LaboratoryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseAnnualBaseRent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseAmendedBaseRent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseTermExpirationMonthYear" xlink:label="iobt_OperatingLeaseTermExpirationMonthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember" xlink:label="iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OfficeMember" xlink:label="iobt_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseCommencementMonthYear" xlink:label="iobt_OperatingLeaseCommencementMonthYear"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember" xlink:label="iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LaboratoryMember" xlink:label="iobt_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseAnnualBaseRent" xlink:label="iobt_OperatingLeaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember" xlink:label="iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MD" xlink:label="stpr_MD"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember" xlink:label="iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember" xlink:label="iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember" xlink:label="iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DK" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseTermExpirationMonthYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_OfficeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseCommencementMonthYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_LaboratoryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NY" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseAnnualBaseRent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MD" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ContractualObligationsTerminationNoticePeriod" xlink:label="iobt_ContractualObligationsTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iobt_ContractualObligationsTerminationNoticePeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_SecuritiesPurchaseAgreementMember" xlink:label="iobt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_O2024Q3DividendsMember" xlink:label="iobt_O2024Q3DividendsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_UndesignatedPreferredStockMember" xlink:label="iobt_UndesignatedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_O2025Q1DividendsMember" xlink:label="iobt_O2025Q1DividendsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_NumberOfVotePerShare" xlink:label="iobt_NumberOfVotePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DividendsDeclared" xlink:label="iobt_DividendsDeclared"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DividendsPaid" xlink:label="iobt_DividendsPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsIssued" xlink:label="iobt_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PurchasePricePerShareOfCommonStockAndWarrant" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsExercisablePricePerShare" xlink:label="iobt_WarrantsExercisablePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_NetProceedsFromIssuanceOfPrivatePlacement" xlink:label="iobt_NetProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_DividendsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="iobt_SecuritiesPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsDomain" xlink:to="iobt_O2024Q3DividendsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_UndesignatedPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsDomain" xlink:to="iobt_O2025Q1DividendsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_NumberOfVotePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_Dividends" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_DividendsDeclared" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_DividendsPaid" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_TitleOfIndividualAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_WarrantsIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_PurchasePricePerShareOfCommonStockAndWarrant" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_WarrantsExercisablePricePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_NetProceedsFromIssuanceOfPrivatePlacement" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember" xlink:label="iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" xlink:label="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:label="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures" xlink:label="iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfContributionsToCorporationsTaxableIncome" xlink:label="iobt_PercentageOfContributionsToCorporationsTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct" xlink:label="iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="iobt_PercentageOfContributionsToCorporationsTaxableIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember" xlink:label="iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CommonStockWarrantsIssuedToEIBMember" xlink:label="iobt_CommonStockWarrantsIssuedToEIBMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="iobt_CommonStockWarrantsIssuedToEIBMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheOneMember" xlink:label="iobt_CreditFacilityTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ClinicalTrialRelatedActivitiesMember" xlink:label="iobt_ClinicalTrialRelatedActivitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PersonnelMember" xlink:label="iobt_PersonnelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ChemistryManufacturingAndControlMember" xlink:label="iobt_ChemistryManufacturingAndControlMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PreclinicalStudiesAndActivitiesMember" xlink:label="iobt_PreclinicalStudiesAndActivitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ProfessionalServicesMember" xlink:label="iobt_ProfessionalServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OtherCostsMember" xlink:label="iobt_OtherCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ConsultantsAndOtherCostsMember" xlink:label="iobt_ConsultantsAndOtherCostsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_ClinicalTrialRelatedActivitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_PersonnelMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_ChemistryManufacturingAndControlMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_PreclinicalStudiesAndActivitiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_ProfessionalServicesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_OtherCostsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_ConsultantsAndOtherCostsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheTwoMember" xlink:label="iobt_CreditFacilityTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LoanFacilityWithEuropeanInvestmentBankMember" xlink:label="iobt_LoanFacilityWithEuropeanInvestmentBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_UnderwritingAgreementMember" xlink:label="iobt_UnderwritingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StrikePricePerShare" xlink:label="iobt_StrikePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheBMember" xlink:label="iobt_CreditFacilityTrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="iobt_LoanFacilityWithEuropeanInvestmentBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iobt_UnderwritingAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="iobt_StrikePricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CommonStockWarrantsLiabilitiesNoncurrent" xlink:label="iobt_CommonStockWarrantsLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="iobt_CommonStockWarrantsLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:label="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PaymentsOfStockAndWarrantIssuanceCosts" xlink:label="iobt_PaymentsOfStockAndWarrantIssuanceCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iobt_PaymentsOfStockAndWarrantIssuanceCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:label="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_SalesAgreementMember" xlink:label="iobt_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LoanFacilityWithEuropeanInvestmentBankMember" xlink:label="iobt_LoanFacilityWithEuropeanInvestmentBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheAMember" xlink:label="iobt_CreditFacilityTrancheAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheBMember" xlink:label="iobt_CreditFacilityTrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheCMember" xlink:label="iobt_CreditFacilityTrancheCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PreferredClassCMember" xlink:label="iobt_PreferredClassCMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_AtTheMarketEquityProgramMember" xlink:label="iobt_AtTheMarketEquityProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_UndesignatedPreferredStockMember" xlink:label="iobt_UndesignatedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsIssued" xlink:label="iobt_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PurchasePricePerShareOfCommonStockAndWarrant" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CommonStockMaximumAggregateOfferingAmount" xlink:label="iobt_CommonStockMaximumAggregateOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche" xlink:label="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="iobt_SalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="iobt_LoanFacilityWithEuropeanInvestmentBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockConversionBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_PreferredClassCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iobt_AtTheMarketEquityProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_UndesignatedPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_WarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_PurchasePricePerShareOfCommonStockAndWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_CommonStockMaximumAggregateOfferingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" xlink:to="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CommonStockWarrantsMember" xlink:label="iobt_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantLiabilitiesMember" xlink:label="iobt_WarrantLiabilitiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="iobt_CommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="iobt_WarrantLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LoanFacilityWithEuropeanInvestmentBankMember" xlink:label="iobt_LoanFacilityWithEuropeanInvestmentBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheOneMember" xlink:label="iobt_CreditFacilityTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" xlink:label="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheTwoMember" xlink:label="iobt_CreditFacilityTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" xlink:label="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsIssued" xlink:label="iobt_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StrikePricePerShare" xlink:label="iobt_StrikePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsExercisePricePerShare" xlink:label="iobt_WarrantsExercisePricePerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="iobt_LoanFacilityWithEuropeanInvestmentBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_WarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_StrikePricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iobt_WarrantsExercisePricePerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheOneMember" xlink:label="iobt_CreditFacilityTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheTwoMember" xlink:label="iobt_CreditFacilityTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLevel3FinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LaboratoryEquipmentMember" xlink:label="iobt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantIssuanceAgreementAndFinanceContractMember" xlink:label="iobt_WarrantIssuanceAgreementAndFinanceContractMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheAMember" xlink:label="iobt_CreditFacilityTrancheAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember" xlink:label="iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheBMember" xlink:label="iobt_CreditFacilityTrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LoanFacilityWithEuropeanInvestmentBankMember" xlink:label="iobt_LoanFacilityWithEuropeanInvestmentBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheCMember" xlink:label="iobt_CreditFacilityTrancheCMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche" xlink:label="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PeriodForSatisfyingConditions" xlink:label="iobt_PeriodForSatisfyingConditions"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="iobt_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement" xlink:label="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement" xlink:label="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails" xlink:label="iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfAmountDisbursedUnderFinanceContract" xlink:label="iobt_PercentageOfAmountDisbursedUnderFinanceContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StrikePricePerShare" xlink:label="iobt_StrikePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_NoncashInterestExpenseDebt" xlink:label="iobt_NoncashInterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="iobt_WarrantIssuanceAgreementAndFinanceContractMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="iobt_LoanFacilityWithEuropeanInvestmentBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_PeriodForSatisfyingConditions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_LineOfCreditFacilityAdditionalBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_PercentageOfAmountDisbursedUnderFinanceContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_StrikePricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_NoncashInterestExpenseDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_PaidInKindInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheAMember" xlink:label="iobt_CreditFacilityTrancheAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheBMember" xlink:label="iobt_CreditFacilityTrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StrikePricePerShare" xlink:label="iobt_StrikePricePerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="iobt_StrikePricePerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OfficeAndLaboratoryMember" xlink:label="iobt_OfficeAndLaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_NumberOfOperatingLease" xlink:label="iobt_NumberOfOperatingLease"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OfficeMember" xlink:label="iobt_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MD" xlink:label="stpr_MD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LaboratoryMember" xlink:label="iobt_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseAnnualBaseRent" xlink:label="iobt_OperatingLeaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseAmendedBaseRent" xlink:label="iobt_OperatingLeaseAmendedBaseRent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DK" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_OfficeAndLaboratoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NY" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_NumberOfOperatingLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_OfficeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MD" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_LaboratoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseAnnualBaseRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseAmendedBaseRent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseTermExpirationMonthYear" xlink:label="iobt_OperatingLeaseTermExpirationMonthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember" xlink:label="iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OfficeMember" xlink:label="iobt_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseCommencementMonthYear" xlink:label="iobt_OperatingLeaseCommencementMonthYear"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember" xlink:label="iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LaboratoryMember" xlink:label="iobt_LaboratoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY" xlink:label="stpr_NY"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OperatingLeaseAnnualBaseRent" xlink:label="iobt_OperatingLeaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember" xlink:label="iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MD" xlink:label="stpr_MD"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember" xlink:label="iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember" xlink:label="iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember" xlink:label="iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DK" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseTermExpirationMonthYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_OfficeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseCommencementMonthYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iobt_LaboratoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NY" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iobt_OperatingLeaseAnnualBaseRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MD" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ContractualObligationsTerminationNoticePeriod" xlink:label="iobt_ContractualObligationsTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iobt_ContractualObligationsTerminationNoticePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis" xlink:label="us-gaap_DividendsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_SecuritiesPurchaseAgreementMember" xlink:label="iobt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_O2024Q3DividendsMember" xlink:label="iobt_O2024Q3DividendsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain" xlink:label="us-gaap_DividendsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_UndesignatedPreferredStockMember" xlink:label="iobt_UndesignatedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_O2025Q1DividendsMember" xlink:label="iobt_O2025Q1DividendsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_NumberOfVotePerShare" xlink:label="iobt_NumberOfVotePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DividendsDeclared" xlink:label="iobt_DividendsDeclared"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DividendsPaid" xlink:label="iobt_DividendsPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsIssued" xlink:label="iobt_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PurchasePricePerShareOfCommonStockAndWarrant" xlink:label="iobt_PurchasePricePerShareOfCommonStockAndWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsExercisablePricePerShare" xlink:label="iobt_WarrantsExercisablePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_NetProceedsFromIssuanceOfPrivatePlacement" xlink:label="iobt_NetProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_DividendsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="iobt_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsDomain" xlink:to="iobt_O2024Q3DividendsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DividendsAxis" xlink:to="us-gaap_DividendsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iobt_UndesignatedPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsDomain" xlink:to="iobt_O2025Q1DividendsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_NumberOfVotePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_Dividends" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_DividendsDeclared" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_DividendsPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_WarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_PurchasePricePerShareOfCommonStockAndWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_WarrantsExercisablePricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="iobt_NetProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember" xlink:label="iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" xlink:label="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:label="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" xlink:label="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures" xlink:label="iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PercentageOfContributionsToCorporationsTaxableIncome" xlink:label="iobt_PercentageOfContributionsToCorporationsTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct" xlink:label="iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="iobt_PercentageOfContributionsToCorporationsTaxableIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember" xlink:label="iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CommonStockWarrantsIssuedToEIBMember" xlink:label="iobt_CommonStockWarrantsIssuedToEIBMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="iobt_CommonStockWarrantsIssuedToEIBMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheOneMember" xlink:label="iobt_CreditFacilityTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ClinicalTrialRelatedActivitiesMember" xlink:label="iobt_ClinicalTrialRelatedActivitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PersonnelMember" xlink:label="iobt_PersonnelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ChemistryManufacturingAndControlMember" xlink:label="iobt_ChemistryManufacturingAndControlMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PreclinicalStudiesAndActivitiesMember" xlink:label="iobt_PreclinicalStudiesAndActivitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ProfessionalServicesMember" xlink:label="iobt_ProfessionalServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_OtherCostsMember" xlink:label="iobt_OtherCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ConsultantsAndOtherCostsMember" xlink:label="iobt_ConsultantsAndOtherCostsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_ClinicalTrialRelatedActivitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_PersonnelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_ChemistryManufacturingAndControlMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_PreclinicalStudiesAndActivitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_ProfessionalServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_OtherCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iobt_ConsultantsAndOtherCostsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheTwoMember" xlink:label="iobt_CreditFacilityTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LoanFacilityWithEuropeanInvestmentBankMember" xlink:label="iobt_LoanFacilityWithEuropeanInvestmentBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_UnderwritingAgreementMember" xlink:label="iobt_UnderwritingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_StrikePricePerShare" xlink:label="iobt_StrikePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CreditFacilityTrancheBMember" xlink:label="iobt_CreditFacilityTrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="iobt_LoanFacilityWithEuropeanInvestmentBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iobt_UnderwritingAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="iobt_StrikePricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iobt_CreditFacilityTrancheBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="iobt_CommonStockWarrantsLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_CommonStockWarrantsLiabilitiesNoncurrent" xlink:label="iobt_CommonStockWarrantsLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInvestmentExpense" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="iobt_IncreaseDecreaseInLeaseLiability" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="15" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="17" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_IncreaseDecreaseInLeaseLiability" xlink:label="iobt_IncreaseDecreaseInLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="iobt_DeferredFinancingAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="iobt_FairValueOfTrancheBWarrants" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidTaxes" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DeferredFinancingAssets" xlink:label="iobt_DeferredFinancingAssets"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_FairValueOfTrancheBWarrants" xlink:label="iobt_FairValueOfTrancheBWarrants"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" xlink:label="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:label="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="iobt_AccruedContractResearchAndDevelopmentCostsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_AccruedContractResearchAndDevelopmentCostsCurrent" xlink:label="iobt_AccruedContractResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="iobt_DebtInstrumentAmortizedPaidInKindInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="iobt_DebtInstrumentCurrencyAdjustments" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DebtInstrumentAmortizedPaidInKindInterest" xlink:label="iobt_DebtInstrumentAmortizedPaidInKindInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DebtInstrumentCurrencyAdjustments" xlink:label="iobt_DebtInstrumentCurrencyAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="iobt_Long-TermDebtMaturityMinimumPayment" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="iobt_DebtInstrumentCurrencyAdjustments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="iobt_Long-TermDebtMaturityMinimumPayment" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="iobt_Long-TermDebtMaturityMinimumPayment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="iobt_Long-TermDebtMaturityMinimumPayment" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="iobt_Long-TermDebtMaturityMinimumPayment" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="iobt_Long-TermDebtMaturityMinimumPayment" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="iobt_Long-TermDebtMaturityMinimumPayment" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="iobt_Long-TermDebtMaturityMinimumPayment" xlink:to="iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest" xlink:label="iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_Long-TermDebtMaturityMinimumPayment" xlink:label="iobt_Long-TermDebtMaturityMinimumPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_DebtInstrumentCurrencyAdjustments" xlink:label="iobt_DebtInstrumentCurrencyAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix" xlink:label="iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="iobt-20250630.xsd#iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember" name="TwoThousandAndTwentyOneEquityAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_WarrantsExercisablePricePerShare" name="WarrantsExercisablePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_ChemistryManufacturingAndControlMember" name="ChemistryManufacturingAndControlMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_PercentageOfContributionsToCorporationsTaxableIncome" name="PercentageOfContributionsToCorporationsTaxableIncome" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="iobt_OperatingLeaseAnnualBaseRent" name="OperatingLeaseAnnualBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_CommonStockWarrantsIssuedToEIBMember" name="CommonStockWarrantsIssuedToEIBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_OfficeAndLaboratoryMember" name="OfficeAndLaboratoryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember" name="TwoThousandTwentyFourEIBTermLoanFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_PreclinicalStudiesAndActivitiesMember" name="PreclinicalStudiesAndActivitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" name="FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_CreditFacilityTrancheAMember" name="CreditFacilityTrancheAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_CreditFacilityTrancheTwoMember" name="CreditFacilityTrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_OperatingLeaseCommencementMonthYear" name="OperatingLeaseCommencementMonthYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_OtherCostsMember" name="OtherCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember" name="LeaseCommencementOnDecemberTwoThousandTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix" name="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_UnderwritingAgreementMember" name="UnderwritingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement" name="PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_CreditFacilityTrancheBMember" name="CreditFacilityTrancheBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_NetProceedsFromIssuanceOfPrivatePlacement" name="NetProceedsFromIssuanceOfPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember" name="LeaseCommencementOnDecemberTwoThousandTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember" name="LeaseCommencementOnOctoberTwoThousandTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails" name="LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement" name="PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_O2024Q3DividendsMember" name="O2024Q3DividendsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures" name="PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" name="FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_PrepaidContractResearchAndDevelopmentCostsCurrent" name="PrepaidContractResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_O2025Q1DividendsMember" name="O2025Q1DividendsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_PersonnelMember" name="PersonnelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_WarrantsIssued" name="WarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember" name="LeaseCommencementOnJuneTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest" name="DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_ClinicalTrialRelatedActivitiesMember" name="ClinicalTrialRelatedActivitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_DebtInstrumentAmortizedPaidInKindInterest" name="DebtInstrumentAmortizedPaidInKindInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_CreditFacilityTrancheCMember" name="CreditFacilityTrancheCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_Long-TermDebtMaturityMinimumPayment" name="Long-TermDebtMaturityMinimumPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_DescriptionOfBusinessOrganizationAndLiquidityTable" name="DescriptionOfBusinessOrganizationAndLiquidityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_NumberOfVotePerShare" name="NumberOfVotePerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="iobt_PaymentsOfStockAndWarrantIssuanceCosts" name="PaymentsOfStockAndWarrantIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_PreferredClassCMember" name="PreferredClassCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_DividendsPaid" name="DividendsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" name="StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche" name="CertainConditionsPrecedentAndOneUncommittedAccordionTranche" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_DividendsDeclared" name="DividendsDeclared" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_NumberOfOperatingLease" name="NumberOfOperatingLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_ProfessionalServicesMember" name="ProfessionalServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_LoanFacilityWithEuropeanInvestmentBankMember" name="LoanFacilityWithEuropeanInvestmentBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_WarrantIssuanceAgreementAndFinanceContractMember" name="WarrantIssuanceAgreementAndFinanceContractMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_CommonStockWarrantsLiabilitiesNoncurrent" name="CommonStockWarrantsLiabilitiesNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_WarrantsExercisePricePerShare" name="WarrantsExercisePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_NoncashInterestExpenseDebt" name="NoncashInterestExpenseDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_OperatingLeaseAmendedBaseRent" name="OperatingLeaseAmendedBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems" name="DescriptionOfBusinessOrganizationAndLiquidityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_DeferredFinancingAssets" name="DeferredFinancingAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_StrikePricePerShare" name="StrikePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember" name="WarrantsIssuedToTheEuropeanInvestmentBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_PurchasePricePerShareOfCommonStockAndWarrant" name="PurchasePricePerShareOfCommonStockAndWarrant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_LaboratoryMember" name="LaboratoryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_UnauditedFinancialInformationPolicyPolicyTextBlock" name="UnauditedFinancialInformationPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_CommonStockMaximumAggregateOfferingAmount" name="CommonStockMaximumAggregateOfferingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_CreditFacilityTrancheOneMember" name="CreditFacilityTrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_WarrantsPolicyPolicyTextBlock" name="WarrantsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_FairValueOfTrancheBWarrants" name="FairValueOfTrancheBWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_ConsultantsAndOtherCostsMember" name="ConsultantsAndOtherCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember" name="LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_PeriodForSatisfyingConditions" name="PeriodForSatisfyingConditions" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_PercentageOfAmountDisbursedUnderFinanceContract" name="PercentageOfAmountDisbursedUnderFinanceContract" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_WarrantLiabilitiesMember" name="WarrantLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_AccruedContractResearchAndDevelopmentCostsCurrent" name="AccruedContractResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_IncreaseDecreaseInLeaseLiability" name="IncreaseDecreaseInLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_OperatingLeaseTermExpirationMonthYear" name="OperatingLeaseTermExpirationMonthYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent" name="ResearchAndDevelopmentTaxCreditReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_AtTheMarketEquityProgramMember" name="AtTheMarketEquityProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_OfficeMember" name="OfficeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_DebtInstrumentCurrencyAdjustments" name="DebtInstrumentCurrencyAdjustments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" name="StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_ContractualObligationsTerminationNoticePeriod" name="ContractualObligationsTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct" name="ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="iobt_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_TwoThousandTwentyThreeInducementIncentivePlanMember" name="TwoThousandTwentyThreeInducementIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock" name="ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="iobt_LineOfCreditFacilityAdditionalBorrowingCapacity" name="LineOfCreditFacilityAdditionalBorrowingCapacity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember" name="LeaseCommencementOnMarchTwoThousandTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 11, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IO Biotech, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001865494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0909276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Ole Maal&#248;es Vej 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Copenhagen N<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">DK-2200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">7070 2980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">IOBT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,131<span></span>
</td>
<td class="nump">$ 60,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,849<span></span>
</td>
<td class="nump">4,920<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">38,980<span></span>
</td>
<td class="nump">64,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">603<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use lease asset</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">3,346<span></span>
</td>
<td class="nump">2,748<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">42,326<span></span>
</td>
<td class="nump">67,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,537<span></span>
</td>
<td class="nump">4,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability - current</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">13,592<span></span>
</td>
<td class="nump">14,108<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,897<span></span>
</td>
<td class="nump">19,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability - noncurrent</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan debt, net</a></td>
<td class="nump">6,720<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_CommonStockWarrantsLiabilitiesNoncurrent', window );">Common stock warrants</a></td>
<td class="nump">13,249<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">20,837<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">40,734<span></span>
</td>
<td class="nump">20,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value of $0.001 per share; 5,000,000 shares authorized, no shares issued and outstanding as of June 30, 2025 and December 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value of $0.001 per share; 300,000,000 shares authorized at June 30, 2025 and December 31, 2024; 65,880,914 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">416,289<span></span>
</td>
<td class="nump">413,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(407,951)<span></span>
</td>
<td class="num">(359,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6,812)<span></span>
</td>
<td class="num">(6,851)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">1,592<span></span>
</td>
<td class="nump">47,015<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 42,326<span></span>
</td>
<td class="nump">$ 67,699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_CommonStockWarrantsLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants liabilities noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_CommonStockWarrantsLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 16,652<span></span>
</td>
<td class="nump">$ 15,848<span></span>
</td>
<td class="nump">$ 33,027<span></span>
</td>
<td class="nump">$ 30,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,518<span></span>
</td>
<td class="nump">5,685<span></span>
</td>
<td class="nump">12,727<span></span>
</td>
<td class="nump">11,571<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">23,170<span></span>
</td>
<td class="nump">21,533<span></span>
</td>
<td class="nump">45,754<span></span>
</td>
<td class="nump">41,730<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(23,170)<span></span>
</td>
<td class="num">(21,533)<span></span>
</td>
<td class="num">(45,754)<span></span>
</td>
<td class="num">(41,730)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Currency exchange loss, net</a></td>
<td class="num">(374)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="num">(479)<span></span>
</td>
<td class="num">(552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">1,311<span></span>
</td>
<td class="nump">699<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInvestmentExpense', window );">Interest expense</a></td>
<td class="num">(253)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="num">(2,587)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,587)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(2,929)<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
<td class="num">(2,620)<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(26,099)<span></span>
</td>
<td class="num">(20,312)<span></span>
</td>
<td class="num">(48,374)<span></span>
</td>
<td class="num">(39,354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes expense</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,217)<span></span>
</td>
<td class="num">(20,686)<span></span>
</td>
<td class="num">(48,638)<span></span>
</td>
<td class="num">(40,143)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (26,217)<span></span>
</td>
<td class="num">$ (20,686)<span></span>
</td>
<td class="num">$ (48,638)<span></span>
</td>
<td class="num">$ (40,143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used in computing net loss per common share, basic</a></td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used in computing net loss per common share, diluted</a></td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (26,217)<span></span>
</td>
<td class="num">$ (20,686)<span></span>
</td>
<td class="num">$ (48,638)<span></span>
</td>
<td class="num">$ (40,143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="num">(220)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (26,437)<span></span>
</td>
<td class="num">$ (20,837)<span></span>
</td>
<td class="num">$ (48,599)<span></span>
</td>
<td class="num">$ (40,100)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInvestmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the generation of investment income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInvestmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 133,162<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 406,587<span></span>
</td>
<td class="num">$ (9,669)<span></span>
</td>
<td class="num">$ (263,822)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">3,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(40,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,143)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">96,272<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">409,797<span></span>
</td>
<td class="num">(9,626)<span></span>
</td>
<td class="num">(303,965)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">133,162<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">406,587<span></span>
</td>
<td class="num">(9,669)<span></span>
</td>
<td class="num">(263,822)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(95,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">47,015<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">413,113<span></span>
</td>
<td class="num">(6,851)<span></span>
</td>
<td class="num">(359,313)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">3,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(48,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,638)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 1,592<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 416,289<span></span>
</td>
<td class="num">$ (6,812)<span></span>
</td>
<td class="num">$ (407,951)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (48,638)<span></span>
</td>
<td class="num">$ (40,143)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">3,176<span></span>
</td>
<td class="nump">3,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest expense</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use lease asset</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency loss</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="nump">2,587<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(636)<span></span>
</td>
<td class="num">(2,843)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(882)<span></span>
</td>
<td class="num">(787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">1,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_IncreaseDecreaseInLeaseLiability', window );">Lease liability</a></td>
<td class="num">(418)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(152)<span></span>
</td>
<td class="num">(3,155)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(42,893)<span></span>
</td>
<td class="num">(41,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="nump">11,720<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="num">(233)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">11,487<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(31,460)<span></span>
</td>
<td class="num">(41,937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(440)<span></span>
</td>
<td class="num">(509)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">60,299<span></span>
</td>
<td class="nump">143,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">28,399<span></span>
</td>
<td class="nump">101,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Components of cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">28,131<span></span>
</td>
<td class="nump">100,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 28,399<span></span>
</td>
<td class="nump">$ 101,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (26,217)<span></span>
</td>
<td class="num">$ (20,686)<span></span>
</td>
<td class="num">$ (48,638)<span></span>
</td>
<td class="num">$ (40,143)<span></span>
</td>
<td class="num">$ (95,500)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Organization and Liquidity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business, Organization and Liquidity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Description of Business, Organization and Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on our T-win</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform. As used in these financial statements, unless the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to IO Biotech, Inc. and its subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Reorganization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO Biotech ApS was incorporated in Denmark in December 2014. In November 2021, we completed a corporate reorganization (the &#8220;Corporate Reorganization&#8221;) whereby IO Biotech ApS became a wholly-owned subsidiary of the Company. In connection with the corporate reorganization, each issued and outstanding Class A ordinary share ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value) was exchanged on a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> basis into shares of common stock of the Company ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value). Each Class B and Class C preference share of IO Biotech ApS was exchanged on a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> basis into shares of Class B and Class C preferred stock of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IO Bio US, Inc., a wholly owned subsidiary of IO Biotech ApS, was incorporated in Delaware in May 2021. IO Biotech Limited, a wholly owned subsidiary of IO Biotech ApS, was incorporated in the UK in August 2021. In November 2021, the Company engaged in a series of transactions, referred to collectively as the Corporate Reorganization. As a result of the Corporate Reorganization, IO Biotech ApS became a wholly-owned subsidiary of IO Biotech, Inc. IO Biotech, Inc. is a holding company formed in October 2021, which, prior to our initial public offering (&#8220;IPO&#8221;), had nominal assets and no liabilities, contingencies, or commitments, and which has not conducted any operations prior to our IPO other than acquiring the entire issued and outstanding stock of IO Biotech ApS. The Company, IO Biotech ApS, and the holders of all of the issued and outstanding equity interests of IO Biotech ApS entered into a Share Contribution and Exchange Agreement, dated as of October 29, 2021, pursuant to which the Corporate Reorganization was effected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IPO</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2021, we completed our IPO, selling an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,222,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,072,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock sold pursuant to the underwriters&#8217; exercise of their option to purchase additional shares of common stock. We received net proceeds from the IPO, after deducting underwriting discounts and commissions and other offering costs, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immediately prior to the consummation of the IPO, all outstanding shares of our Class A ordinary shares and Class B and Class C convertible preference shares were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,592,413</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock. Upon the closing of the IPO on November 9, 2021, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,815,267</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were issued and outstanding. Our common stock began trading on the Nasdaq Global Market on November 5, 2021 under the symbol &#8220;IOBT.&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 9, 2021, we amended and restated the certificate of incorporation of IO Biotech, Inc. to authorize the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock. The shares of preferred stock are currently undesignated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">August 2023 Private Placement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 9, 2023, the Company completed a private placement transaction (the &#8220;Private Placement&#8221;), pursuant to which we sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (the &#8220;Warrants&#8221;) to certain institutional investors and existing shareholders (the &#8220;Purchasers&#8221;). Each Purchaser&#8217;s Warrant is exercisable for a number of shares of common stock equal to one hundred percent of the aggregate number of shares of common stock purchased by such Purchaser. The purchase price per share of common stock and Warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Purchase Price&#8221;). The Company received net proceeds from the Private Placement, after deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in underwriting discounts and commissions and other offering costs, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Refer to Note 11, "Stockholders' Equity" in this Quarterly Report on Form 10-Q for additional detail on the Private Placement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-The-Market Equity Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 15, 2023, we filed a new prospectus supplement with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to the offer and sale of shares of our Common Stock, with an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, establishing an at-the-market equity program. We also entered into a common stock sales agreement, dated February 15, 2023 (the &#8220;Sales Agreement&#8221;) by and between the Company and Cowen and Company, LLC for shares with an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, through which we may, from time to time, sell shares through Cowen and Company, LLC, acting as agent and/or principal. Any shares offered and sold through the at-the-market equity program will be issued pursuant to the Company&#8217;s Registration Statement on Form S-3 (File No. 333-269569), which was declared effective on February 10, 2023, the prospectus supplement related to the offering that forms a part of the registration statement, and any applicable prospectus supplements that may form a part of the registration statement in the future. The aggregate market value of shares eligible for sale under the prospectus supplement and under the Sales Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t issued any shares pursuant to our at-the-market equity program as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Investment Bank Term Loan Facility</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 19, 2024, the Company, through its subsidiary, IO Biotech ApS (the &#8220;Borrower&#8221;) entered into a Finance Contract (the &#8220;Finance Contract&#8221;) with the European Investment Bank (&#8220;EIB&#8221;), establishing a loan facility of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that includes three committed tranches of potential financing in an aggregate principal amount of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, subject to certain conditions precedent (the &#8220;EIB Loan Facility&#8221;), and one uncommitted accordion tranche of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. See Note 8, &#8220;Term Loan Facility&#8221; in this Quarterly Report on Form 10-Q for additional detail.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance reporting capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates are in preclinical research and clinical development. There can be no assurance that our research and development will be successfully completed, that adequate protection for our intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if our product development efforts are successful, it is uncertain when, if ever, we will generate significant revenue from product sales. We operate in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, we are dependent upon the services of our employees and consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Substantial Doubt About the Company&#8217;s Ability to Continue as a Going Concern and the Going Concern Basis of Accounting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements have been prepared on a going concern basis of accounting, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, we have devoted substantially all of our efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. We have financed our operations primarily through the issuance of convertible preference shares, convertible notes, our IPO, the Private Placement and the EIB Loan Facility.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our continued discovery and development of product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if our product development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, we had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">408.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. We have incurred losses and negative cash flows from operations since inception, including net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the six months ended June 30, 2025 and the year ended December 31, 2024, respectively. We expect that our operating losses and negative cash flows will continue for the foreseeable future as we continue to develop our product candidates. We currently expect that our cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of June 30, 2025 along with the second tranche of the EIB Loan will not be sufficient to fund our operating expenses and capital requirements for at least 12 months from the date the financial statements are issued.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has plans to obtain sufficient additional fundraising to fulfill its operating and capital requirements for the next 12 months. The Company&#8217;s plans include continuing to fund its operating losses and capital funding needs through public or private equity or debt financings, including the draw down of the available committed tranches of the EIB loan facility defined below in Note 8, &#8220;Term Loan Facility&#8221;, strategic collaborations, licensing arrangements, or other arrangements. The Company has drawn down on the Tranche A and Tranche B loan facility in principal amount of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, on May 6, 2025 and July 4, 2025, each before payment of certain fees and transaction related expense. The business conditions of the Tranche C loan facility have not been satisfied to draw up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of the date of these interim financial statements. Further, the Company believes that its operations are scalable and, if there is a need, certain cost reduction measures may be taken to preserve cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although management believes such plans, if executed, should provide the Company sufficient financing to meet its needs, successful completion of such plans is dependent on factors outside of the Company&#8217;s control. Our future capital requirements will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, prioritization and number of our research and development programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of our clinical trials, including the results of IOB-013;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs to scale up and secure manufacturing arrangements for commercial production of Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in combination with pembrolizumab as a first-line treatment in advanced melanoma;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of establishing and maintaining commercialization capabilities for Cylembio in combination with pembrolizumab as a first-line treatment in advanced melanoma, and any product candidate that obtains regulatory approval; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of sales achieved, and costs related to the commercialization of Cylembio in combination with pembrolizumab as a first-line treatment in advanced melanoma.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Therefore, sufficient additional funds may not be available on a timely basis, on favorable terms or at all. As such, management cannot conclude that such plans will be effectively implemented in due time to secure sufficient funds to finance operations at least through one year after the date that the financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, management has concluded that the aforementioned conditions, among others, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements are issued and therefore, the Company may not be able to continue its currently ongoing research and development activities as planned and realize its assets and satisfy its liabilities in the normal course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will also require additional capital to commercialize Cylembio in combination with pembrolizumab as a first-line treatment in advanced melanoma, and to continue to fund future discovery research, preclinical, clinical activities and commercialization of any of our product candidates. If we receive regulatory approval for Cylembio, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing, medical affairs, distribution and other related functions, depending on where we choose to commercialize. Additional funds for such commercialization activities and future discovery research, preclinical, clinical activities may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our growth strategy. We will seek additional funding through public financings, debt financings, collaboration agreements, strategic alliances and licensing arrangements. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining such additional financing on acceptable terms, or at all, and we may not be able to enter into collaborations or other arrangements. If we are unable to obtain funding in due time, we could be forced to delay, reduce or eliminate our research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect our business prospects, even our ability to continue operations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants Issued in Connection with a Sale of Common Stock or Issuance of Debt</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for warrants issued as a separable unit in connection with sale of common stock or debt as either liability or equity in accordance with Accounting Standards Codification 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered liabilities if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. If warrants do not require liability classification under ASC 815-40 or other applicable generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) the warrants should be classified as equity. The debt is measured at amortized cost and the amount of interest recognized in the consolidated statements of operations is calculated by applying the loan&#8217;s effective interest rate to its carrying amount.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The proceeds received from the sale of equity classified warrants and shares of common stock in a bundled transaction are allocated based on the relative fair values of warrants and shares with no changes in fair value of warrants recognized after the issuance date. For liability classified warrants, the stand-alone fair value of the warrants are classified as debt issuance costs that directly reduce the outstanding debt on the consolidated balance sheet upon funding. Warrants issued prior to the date of funding are accounted for as a deferred financing asset within &#8220;Prepaid expenses and other current assets&#8221; on the consolidated balance sheet and will be reclassified to debt issuance costs on the date of funding. The change in fair value of warrants each balance sheet date are recognized in the consolidated statements of operations and comprehensive loss after the issuance date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no other changes to the significant accounting policies disclosed in Note 2 to the Company&#8217;s annual financial statements for the years ended December 31, 2024 and 2023 included in our Annual Report on Form 10-K filed with the SEC on March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unaudited Financial Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying unaudited interim consolidated financial statements included herein have been prepared in conformity with U.S. GAAP, and pursuant to the rules and regulations of the SEC. In the Company&#8217;s opinion, the information furnished herein reflects all adjustments, all of which are of a normal and recurring nature and necessary for a fair presentation of the financial position and results of operations for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company&#8217;s Annual Report filed on Form 10-K for the fiscal year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Standards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0847deca-10d0-4530-aa33-3be6c7b7efa2;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will also enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment and contain other disclosure requirements. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the financial statements. The guidance is effective in the annual periods beginning after December 15, 2023 and the Company has </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the standard effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Refer to Note 15, "Segments" in this Quarterly Report on Form 10-Q for additional information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Standards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, Accounting Standards Update 2023-06&#8212;Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative. ASU 2023-06 will eliminate disclosure requirements that are redundant, duplicative, overlapping, outdated, or superseded as a result of subsequent changes to SEC disclosure requirements, U.S. GAAP or technology. ASU 2023-06 is intended to better align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP. The disclosure requirements would apply prospectively in the financial statements. ASU 2023-06 will be effective for us on the date on which the SEC&#8217;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, if we are already subject to the SEC&#8217;s current disclosure requirements. For those current disclosure requirements we are not subject to, ASU 2023-06 will become effective two years after the date of such removal by the SEC. We are currently assessing the impact adoption of ASU 2023-06 will have on our financial statements and disclosures.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 will require disclosure of additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state and foreign income taxes. ASU 2023-09 will also require information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold.  ASU 2023-09 will be effective for us in the annual periods beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. We are currently assessing the impact adoption of ASU 2020-06 will have on our financial statements and disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures  (Subtopic 220-40): Disaggregation of  Income Statement Expenses. ASU 2024-03 will require disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis, including purchases of inventory, employee  compensation, depreciation, intangible asset amortization and depletion for each  income statement line item that contains those expenses. ASU 2024-03 also will require certain amounts already disclosed under existing U.S. GAAP to also be disclosed as a separate category in disaggregated expense table(s), if those amounts are  recognized in the relevant expense line item. The amendments in this ASU will be effective for us in annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. We are currently assessing the impact adoption of ASU 2024-03 will have on our financial statements and disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,134</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,134</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,134</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,134</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Money market funds</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common stock warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 24, 2025, in connection with the EIB Loan Facility, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">5,623,664</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Tranche A warrants to purchase shares of the Company&#8217;s common stock at an exercise price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">0.89</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. On June 24, 2025, in connection with the EIB Loan Facility, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">4,221,868</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Tranche B warrants to purchase shares of the Company&#8217;s common stock at an exercise price of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">1.32</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 8, &#8220;Term Loan Facility&#8221; in this Quarterly Report on Form 10-Q for additional detail on the EIB Loan Facility and warrants issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EIB warrants met the criteria for liability classification and are initially recognized on the date of issuance and subsequently measured at each balance sheet date at fair value through &#8220;Other income (expense)&#8221; on the consolidated statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the Tranche A and Tranche B warrants was determined based on the Black-Scholes option-pricing model and classified within Level 3 of the fair value hierarchy on the date of issuance. The expected volatility input used in the model was deemed unobservable (Level 3) and was determined based on share price data of the Company and comparable companies for a term equal to the remaining contractual term of the warrants. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other required inputs used in the model were considered observable (Level 1). Significant increases (decreases) in these inputs could result in a significantly lower or higher fair value measurement. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the Black-Scholes option-pricing model inputs used to calculate the fair value of the warrants at issuance date. </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.59%;box-sizing:content-box;"></td>
         <td style="width:2.901%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.304000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.901%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.304000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche A</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche B</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share price of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.92</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.39</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the Black-Scholes option-pricing model inputs used to calculate the fair value of the warrants at June 30, 2025.</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.59%;box-sizing:content-box;"></td>
         <td style="width:2.901%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.304000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.901%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.304000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche A</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche B</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share price of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.39</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.39</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.8</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows a reconciliation of the beginning and ending balances for Level 3 financial liabilities measured at fair value on a recurring basis for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:78.32%;box-sizing:content-box;"></td>
         <td style="width:1.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.06%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 3 financial liabilities, beginning of period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of EIB common stock warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,662</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of EIB common stock warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,587</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 3 financial liabilities, end of period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers among Level 1, Level 2 or Level 3 categories in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025 and the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. License and Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreements with MSD International GmbH</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2018, we entered into a clinical collaboration with MSD International GmbH (&#8220;MSDIG&#8221;), an affiliate of Merck &amp; Co. Inc., (&#8220;Merck&#8221;) to evaluate IO102 in combination with KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;pembrolizumab&#8221;) in first-line treatment of patients with metastatic non-small cell lung cancer. Under the terms of the collaboration with MSDIG, we conducted an international Phase 1/2 study to evaluate a combination therapy of IO102 and KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We sponsored the clinical trial and MSDIG provided KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to be used in the clinical trial free of charge. We and MSDIG were responsible for our own internal costs and expenses to support the study and we bore all other costs associated with conducting the study, including costs of providing IO102 for use in the study. The rights to the data from the clinical trial were shared by us and MSDIG and we maintain global commercial rights to IO102.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2021, we entered into a clinical collaboration with MSDIG and MSD International Business GmbH (&#8220;MSDIB&#8221;), another affiliate of Merck (collectively, &#8220;MSD&#8221;) to evaluate IO102-IO103 in combination with KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> versus KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> alone in treatment of patients with metastatic (advanced) melanoma. Under the terms of the collaboration with MSD, we are conducting an international Phase 3 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are the sponsor of the clinical trial and MSD is providing KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to be used in the clinical trial free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trial are shared by us and MSD and we maintain global commercial rights to IO102-IO103.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, we entered into a clinical collaboration with MSD to evaluate IO102-IO103 in combination with KEYTRUDA&#174; in previously untreated patients with three different tumor types&#8212; metastatic non-small cell lung cancer (&#8220;NSCLC&#8221;), squamous cell carcinoma of the head and neck (&#8220;SCCHN&#8221;), and urothelial bladder cancer (&#8220;UBC&#8221;). Under the terms of the collaboration with MSD, we are conducting an international Phase 2 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are the sponsor of the clinical trial and MSD is providing KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to be used in the clinical trial free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trial are shared by us and MSD and we maintain global commercial rights to IO102-IO103.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, we entered into a clinical collaboration with MSD to evaluate IO102-IO103 in combination with KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as a neoadjuvant/adjuvant therapy for patients with metastatic melanoma and SCCHN. Under the terms of the collaboration with MSD, we are conducting an international Phase 2 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are sponsoring the clinical trial and MSD is providing KEYTRUDA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to be used in the clinical trial free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trial are shared by us and MSD and we maintain global commercial rights to IO102-IO103.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Prepaid Expenses and Other Current Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred financing asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,657</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,607</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,292</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid contract research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,109</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,119</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credit receivable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">865</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">573</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insurance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">639</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Value-added tax refund receivable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">276</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">365</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">696</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">803</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,849</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,920</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consist of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.527%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.057%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.057%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">927</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">839</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer hardware</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">726</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">577</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">603</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">638</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three months ended June 30, 2025 and 2024, the Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of depreciation expense, respectively, in the consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of depreciation expense, respectively, in the consolidated statements of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Facility<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan Facility</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Term Loan Facility</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 EIB Term Loan Facility</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 19, 2024, IO Biotech ApS (the &#8220;Borrower&#8221;) entered into a Finance Contract with the EIB, establishing a loan facility of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that includes three committed tranches of potential financing in an aggregate principal amount of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, subject to certain conditions precedent, and one uncommitted accordion tranche of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Finance Contract, the Company (through the Borrower) had &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million available to draw in an initial tranche of the term loan facility (&#8220;Tranche A&#8221;), subject to satisfaction of certain customary conditions and the issuance of warrants pursuant to a Warrant Issuance Agreement (described below). The Company satisfied the specified business conditions of the Tranche A loan to draw up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the specified business conditions of the loan to draw up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8220;Tranche B&#8221;) , before payment of certain fees and transaction expense. Tranche A and Tranche B were funded on May 6, 2025 and July 4, 2025, respectively.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Finance Contract provides for one potential additional term loan tranche in principal amount of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8220;Tranche C&#8221; and, together with Tranche A and Tranche B, each a &#8220;Tranche&#8221;), respectively, which is subject to specified conditions, including, but not limited, the issuance of warrants and achievement of certain clinical trial and other milestones. The Borrower has thirty-six months to satisfy the conditions for Tranche C, which include raising an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cash and submission of an application for marketing authorization for IO102-IO103, which in the U.S. is known as Cylembio</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(imsapepimut and etimupepimut, adjuvanted), in the U.S. or the EU based on positive data from a Phase 3 trial.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the Tranche A, Tranche B, and Tranche C loans bears or will bear interest at a fixed rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% that accrues annually and will become payable at their respective maturity dates, which will be </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after disbursement of such loan.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any unpaid balance owed under the Finance Contract may be accelerated upon an Investment Cost Reduction Event, a Change-of-Control Event, a Change-of-Law Event, an Illegality Event or a Voluntary Non-EIB Prepayment Event (each as defined in the Finance Contract included within Part IV - Item 15. Exhibits, Financial Statement Schedules of the Annual Report on Form 10-K filed on March 31, 2025).</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Borrower elects to voluntarily prepay any Tranche, the Borrower will be required to additionally pay to EIB a prepayment fee ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Tranche, if repaid within twelve months of disbursement of such Tranche, to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Tranche, if repaid after the third anniversary of disbursement of such Tranche. No such prepayment fee is payable after the fourth anniversary of disbursement of the applicable Tranche.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Finance Contract also contains various financial and non-financial covenants that the Borrower must comply with, including customary conditions with respect to material adverse changes and substantial changes to the general nature of business, which leave significant discretion on the side of the EIB.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrently with the execution of the Finance Contract, the Borrower entered into a non-binding side letter, pursuant to which EIB may, in its discretion and subject to approvals by its investment committee, make available to the Borrower an additional &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in funding related to the Company&#8217;s ongoing clinical trials.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Finance Contract, the Company also entered into a warrant issuance agreement (the &#8220;Warrant Issuance Agreement&#8221;) on December 19, 2024, pursuant to which the Company agreed to issue to EIB certain warrants to purchase shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (the &#8220;Common Stock&#8221;) in connection with the disbursement of each of the Tranche A loan (such warrants, the &#8220;Tranche A Warrants&#8221;), Tranche B loan (such warrants, the &#8220;Tranche B Warrants&#8221;) and Tranche C loan (such warrants, the &#8220;Tranche C Warrants&#8221; and, together with the Tranche A Warrants and the Tranche B Warrants, the &#8220;Warrants&#8221;). The number of shares for which the Warrants will be exercisable will be determined at the time of issuance of each Warrant in accordance with the formulas set forth in the Warrant Issuance Agreement, which formulas generally provide that the number of shares will decrease as the price of the Common Stock increases.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of each Warrant, each share of Common Stock issuable upon exercise thereof shall have an exercise price equal to the greater of (x) the Company&#8217;s 5-Day VWAP on the date of execution of the applicable Warrant and (y) the applicable &#8220;Minimum Price&#8221; as defined in Nasdaq Rule 5635(d), in each case subject to adjustment. The Tranche A Warrant shall become initially exercisable on the date of disbursement of the Tranche A loan; the Tranche B Warrant shall become initially exercisable on the date of disbursement of the Tranche B loan; and the Tranche C Warrant shall become initially exercisable on the date of disbursement of the Tranche C loan. Each Warrant shall be exercisable until the earlier of one day prior to the closing of an Acquisition (as such term is defined in the applicable Warrant included within Part IV - Item 15. Exhibits, Financial Statement Schedules of the Annual Report on Form 10-K filed with the SEC on March 31, 2025) and twenty years following the date of issuance.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of each Warrant, the Company will have a call option to repurchase the Warrants upon a Change of Control Event, a Qualifying Tender Offer, or a Transformational Transaction (each, as defined in the Warrant).  In connection with an exercise of the Company&#8217;s call option, the purchase price for the shares issuable upon exercise of the portion of the Warrant subject to the call option would be equal to the greater of (x) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the amount disbursed under the Finance Contract as of the date of the call option multiplied by a fraction, the numerator of which is (i) the number of Warrant Shares (as defined in the Warrant Agreement) purchasable under the Warrant Agreement and (ii) the denominator which is the number of shares of Common Stock purchasable with respect to all Warrants under the Warrant Issuance Agreement, whether or not remaining outstanding, and (y) the aggregate value of the Warrant Shares purchasable upon exercise of the call option in the event of any of a Qualifying Tender Offer, Transformational Transaction or other transaction, in each case as calculated in accordance with the terms of the Warrant Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Warrant Issuance Agreement, EIB will have a put option (&#8220;EIB Put Option&#8221;) to sell the Warrants to the Company on or following the maturity date of the applicable Tranche or upon the occurrence of an Event Date (as defined in the Warrant Issuance Agreement), subject to certain limitations in the event that the Company publishes a Material Press Release (as defined in the Warrant Issuance Agreement included within Part IV - Item 15. Exhibits, Financial Statement Schedules of the Annual Report on Form 10-K). The conditions for the EIB to exercise the EIB Put Option to have not been met as of June 30, 2025. In connection with an exercise of EIB&#8217;s put option, the purchase price for the shares purchasable in connection with the put option would be equal to (x) in the case of a Qualifying Tender Offer (as defined in the Warrant Issuance Agreement), the aggregate price per share of Common Stock being offered minus the aggregate Strike Price (as defined in the Warrant Issuance Agreement) payable to the Company with respect to the Warrants for which the put option is being exercised and (y) in all other cases, an amount equal to the aggregate Fair Market Value (as defined in the Warrant Issuance Agreement) of the Warrant Shares purchasable upon exercise of the put option minus the aggregate Strike Price payable to the Company with respect to the Warrants for which the put option is being exercised. Due to the terms and conditions of the EIB Put Option, we consider the EIB Put Option and the Tranche A Warrants and Tranche B Warrants under each of the Tranches are to be treated as a single compound derivative.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with EIB related to the issuance of the Warrants. Under the terms of the Registration Rights Agreement, the Company has agreed to prepare and file, by the later of (i) 30 days after the date of issuance of any of the Warrants and (ii) May 15, 2025 (the &#8220;Filing Deadline&#8221;), one or more registration statements with the Securities and Exchange Commission (the &#8220;SEC&#8221;) to register for resale the common stock issued under the Warrant Issuance Agreement and to cause the applicable registration statements to become effective within a specified period after the Filing Deadline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 24, 2025, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,623,664</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Tranche A Warrants to purchase shares of the Company&#8217;s common stock at an exercise price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.89</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. On June 24, 2025, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,221,868</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Tranche B Warrants to purchase shares of the Company&#8217;s common stock at an exercise price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.32</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share as a prerequisite to the Tranche B loan funding on July 4, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Tranche A and Tranche B Warrants were deemed to be a freestanding financial instruments as they were legally detachable and separately exercisable from the debt obligations. The Company evaluated the terms and conditions of the Warrants and concluded that they met the criteria to be classified as a liability. As such, the Company recorded the Warrants as a non-current liability on the consolidated balance sheet at fair value on the date of funding and as of June 30, 2025. On the date of funding, the Company has recorded a non-current liability related to the loan facilities based on the proceeds received less related debt issuance costs, including the fair value allocation to the respective Warrants. The Company valued the Tranche A Warrants and Tranche B Warrants at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, upon issuance using the Black-Scholes valuation model.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of outstanding term loan debt, net within non-current liabilities on the consolidated balance sheet as of June 30, 2025 related to the Tranche A loan. For the three and six months ended June 30, 2025, the Company has recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in non-cash interest expense related to the amortization of debt issuance costs and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in paid-in-kind interest with an effective interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related to the Tranche A loan. The Tranche B loan was funded on July 4, 2025 and was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t outstanding term loan debt as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term loan debt, net consisted of the following (in thousands):</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:78.48%;box-sizing:content-box;"></td>
         <td style="width:2.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.68%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan debt principal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,720</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortized paid-in-kind interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Unamortized debt issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency adjustments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total term loan debt, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,720</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future undiscounted minimum principal and interest payments under the EIB loan facility as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, were as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.823%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Future Minimum Debt Payments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remainder of 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2031</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,597</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total minimum payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,597</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Unamortized debt issuance costs and paid-in-kind interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency adjustments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total term loan debt</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,720</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, the Company had the following Tranche A and Tranche B Warrants issued and outstanding to purchase shares of the Company's common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:42.76%;box-sizing:content-box;"></td>
         <td style="width:3.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:3.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche A</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche B</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,623,664</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,221,868</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise Price</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.89</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.32</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued contract research and development costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,133</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,070</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,351</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,311</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">692</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">416</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,592</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,108</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company is party to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">five</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating leases for laboratory and office space. The Company&#8217;s finance leases are immaterial both individually and in the aggregate. In the consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, the Company has a right-of-use lease asset (&#8220;ROU&#8221;) balance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and a current and non-current lease liability of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, relating to the ROU lease asset. The balance of both the ROU lease asset and the lease liabilities primarily consists of future payments under the Company&#8217;s office and laboratory space leased in New York, New York, Rockville, Maryland and Copenhagen, Denmark. Rent expense for the three months ended June 30, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. Rent expense for the six months ended June 30, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Qualitative information regarding the Company&#8217;s leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 is as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:22.92%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:10.9%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:10.9%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:16.26%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:16.26%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Location</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Type</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Nature</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Commencement</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Term Expiration</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Annual Base Rent<br/>&#160;(in Millions)</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Copenhagen, Denmark</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Office</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2021</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2027</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Copenhagen, Denmark</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Office</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2024</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2027</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Copenhagen, Denmark</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Lab</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 2023</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2027</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Newport, United Kingdom</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Office</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 2023</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 2025</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York, New York</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Office</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 2021</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 2027</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rockville, Maryland</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Lab</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2021</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 2027</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quantitative information regarding the Company&#8217;s leases for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025 and 2024 is as follows (in thousands):</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.882%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.882%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">359</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">369</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">413</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">385</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities arising from obtaining right-of-use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remaining average lease term (years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future lease payments (undiscounted) under noncancelable leases are as follows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.823%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Future Lease Payments</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remainder of 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">419</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">863</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">470</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,752</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s leases do not provide an explicit rate. Therefore, the Company used its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company used the incremental borrowing rate on January 1, 2022 for operating leases that commenced prior to that date, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be party to litigation arising in the ordinary course of business. We were not subject to any material legal proceedings during the six months ended June 30, 2025 and the year ended December 31, 2024, and, to our knowledge, no material legal proceedings are currently pending or threatened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contractual Obligations and Commitments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into contracts in the ordinary course of business with third-party service providers for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days, and therefore, we believe that our noncancelable obligations under these agreements are not material and we cannot reasonably estimate whether they will occur. However, in the event of a termination of any contracts with clinical research organizations (&#8220;CRO&#8221;) or other institutions and with respect to active patients enrolled in our clinical trials, we may be financially obligated for a period beyond the contractual termination notice periods. We may also enter into additional research, manufacturing, supplier, lease and other agreements in the future, which may require up-front payments and even long-term commitments of cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into certain types of contracts that contingently require us to indemnify various parties against claims from third parties. These contracts primarily relate to procurement, service, consultancy or license agreements under which we may be required to indemnify vendors, service providers or licensees for certain claims, including claims that may be brought against them arising from our acts or omissions with respect to our products, technology, intellectual property or services. The Company, as permitted under Delaware law and in accordance with its amended and restated certificate of incorporation and amended and restated bylaws and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, in which the officer or director incurs losses or expenses because he or she is or was serving at the Company&#8217;s request in such capacity. At the 2023 Annual Meeting of Stockholders, the Company&#8217;s stockholders approved an amendment to, and the Company subsequently amended, its amended and restated certificate of incorporation to extend the indemnification of officers pursuant to recent amendments to the General Corporation Law of the State of Delaware.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may receive indemnification claims under existing contracts in the normal course of business. In the event that one or more of these matters were to result in a claim against us, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on our future business, operating results or financial condition. It is not possible to estimate the maximum amount potentially payable under these contracts since we have no history of prior indemnification claims and the unique facts and circumstances involved in each particular claim will be determinative.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Class of Stock Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Stockholders' Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common and Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the closing of our IPO in November 2021, we filed an amended and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restated certificate of incorporation, which authorized us to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock. The shares of preferred stock are currently undesignated. Common stockholders are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. Common stockholders are entitled to receive dividends, if and when declared by the Company's board of directors (&#8220;Board&#8221;). </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dividends have been declared or paid by us through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Private Placement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 7, 2023, the Company entered into a Securities Purchase Agreement, (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company agreed to sell and issue (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Common Stock, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Warrants in the Private Placement. Each Purchaser&#8217;s Warrant is exercisable for a number of shares of Common Stock equal to one hundred percent of the aggregate number of shares of Common Stock purchased by such Purchaser. The purchase price for each Common Stock and Warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Warrants are exercisable at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.47</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, subject to adjustment as set forth therein. The Warrants are exercisable until the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an acquisition, as defined in the Warrants. The Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the Warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Private Placement closed on August 9, 2023. The Company received </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in gross proceeds from the Private Placement, before deducting offering expenses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Of the total proceeds, legal entities of certain related parties contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and members of management contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company used the net proceeds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the Private Placement for general corporate purposes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance using the Black-Scholes valuation model and allocated proceeds from the sale proportionately to the Common Stock and Warrants, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was allocated to the Warrants and recorded as a component of additional paid-in-capital. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants issued and outstanding at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.47</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share to purchase shares of the Company's common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the execution of the Purchase Agreement, the Company also entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Purchasers. Under the terms of the Registration Rights Agreement, the Company has filed the Registration Statement with the SEC to register for resale the Common Stock issued under the Purchase Agreement and the shares of Common Stock issuable upon conversion of the Warrants issued pursuant to the Purchase Agreement (the &#8220;Registrable Securities&#8221;), which Registration Statement was declared effective on September 8, 2023. The Company may be required to pay certain liquidated damages under the terms of the Registration Rights Agreement in the event sales cannot be made pursuant to the Registration Statement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of June 30, 2025 and December 31, 2024, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,880,914</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Equity-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Equity and Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2021, our Board adopted, and our stockholders approved, the 2021 Equity and Incentive Plan (the &#8220;2021 Equity Plan&#8221;), which became effective on November 4, 2021. The 2021 Equity Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. The number of shares of our common stock reserved for issuance under the 2021 Equity Plan is equal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,496,934</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> subject to an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022 and continuing until, and including, the fiscal year ending December 31, 2031, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">equal to the lesser of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock outstanding on the first day of such fiscal year or (ii) such other amount determined by our Board</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of June 30, 2025, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">486,563</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future grant under the 2021 Equity Plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2021, our Board adopted and our stockholders approved the 2021 Employee Stock Purchase Plan (the &#8220;2021 ESPP&#8221;), which became effective on November 4, 2021. The number of shares of our common stock reserved for issuance under the 2021 ESPP is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,272</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to an annual increase, to be added on the first day of each fiscal year, beginning January 1, 2023, equal to the lesser of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock outstanding on the first day of such fiscal year; (2) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,272</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock; or (3) such other amount as determined by our Board. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, the Board had not yet approved any offerings under the 2021 ESPP.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2023 Inducement Award Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, our Board adopted the 2023 Inducement Award Plan (the &#8220;2023 Inducement Plan&#8221;), which became effective on September 28, 2023. The 2023 Inducement Plan provides for the grant of non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to eligible employees who satisfy the standards for inducement grants under Nasdaq Global Market rules. The number of shares of our common stock reserved for issuance under the 2023 Inducement Plan is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,976,427</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,666,427</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future grant under the 2023 Inducement Plan.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our stock options activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:49.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.020000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>stock <br/>options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>average<br/>exercise<br/>price<br/>per share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value<br/>(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,967,605</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.18</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,709,284</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.13</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Cancelled or forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,589</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.28</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,539,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">821</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable, June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,537,588</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.87</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures related to equity-based compensation awards are recognized as they occur, and we reverse any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, there was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized compensation cost related to unvested stock-based compensation arrangements that is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair values of the stock options granted during the period ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 were estimated based on the Black-Scholes model, using the following assumptions:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:76.28%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.84%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">677</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,262</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">963</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">965</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,920</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total equity-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,607</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,642</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,176</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any tax benefits for stock-based compensation during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to taxes for earnings generated in multiple jurisdictions, both inside and outside of the United States and our tax expense is primarily affected by unrecognized tax benefits in Denmark due to the full valuation allowance. We recorded expense for income taxes of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the three months ended June 30, 2025 and 2024, respectively. We recorded expense for income taxes of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> during the six months ended June 30, 2025 and 2024, respectively. We continue to maintain a full valuation allowance against all of our deferred tax assets in IO Biotech ApS, IO Bio US, Inc., a wholly-owned subsidiary of IO Biotech ApS that was incorporated in Delaware in May 2021, and IO Biotech, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have evaluated the positive and negative evidence involving our ability to realize our deferred tax assets. We have considered our history of cumulative net losses incurred since inception and our lack of any commercial products. We have concluded that it is more likely than not that we will not realize the benefits of our deferred tax assets in IO Biotech ApS, IO Bio US, Inc. and IO Biotech, Inc. We reevaluate the positive and negative evidence at each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share is calculated as follows (in thousands except share and per share amounts):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.95%;box-sizing:content-box;"></td>
         <td style="width:1.28%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.982000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.28%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.982000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.28%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.982000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.28%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.982000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,217</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,686</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,638</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,143</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,217</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,686</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,638</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,143</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.40</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.31</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.74</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.61</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of shares used in computing net loss per common share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,880,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,880,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,880,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,880,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share, as their effect is anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:49.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,539,300</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,992,635</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,539,300</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,992,635</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants issued in Private Placement</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock warrants issued to the EIB</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,845,532</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,845,532</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Segments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_abd02c4f-a3cd-4435-8a7f-dd7df01461bf;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment focused on developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on our T-win</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the chief operating decision maker (&#8220;CODM&#8221;), our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_aca2c24e-8e92-4826-9175-474c6929666f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> manages our company, reviews operating results, assesses performance and allocates resources on an aggregate basis using </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ebc813a3-04f0-49f3-9868-9cfe7dc3008b;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consolidated net income or loss</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as the key measure of segment profit or loss.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As such, results of our operations are reported on a consolidated basis for purposes of management and segment reporting. Please refer to the consolidated financial statements for further information related to these measures of segment performance.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, research and development and general and administrative expenses are significant segment expenses regularly provided to the CEO with the following categories (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.91%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.318%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.718%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.318%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.318%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three months ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six months ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial-related activities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,390</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,637</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,081</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,785</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,531</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,123</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,714</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,917</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chemistry, manufacturing and control</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,484</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,994</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,776</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preclinical studies and activities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">616</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">295</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">632</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">631</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">799</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">428</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">664</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,652</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,848</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,159</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.41%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three months ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six months ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,840</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,899</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,852</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,693</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,743</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">975</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,124</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,048</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,935</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,811</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,751</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,830</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,518</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,727</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,571</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Subsequent Events</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">One Big Beautiful Bill Act</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the &#8220;Act&#8221;). The Act extends expiring, and in some cases expired, provisions of the 2017 Tax Cuts and Jobs Act (&#8220;TCJA&#8221;).  For taxable years beginning after December 31, 2024, the Act includes measures potentially affecting the Company&#8217;s income tax provision including a permanent and immediate deduction for domestic research and development expenditures, 100 percent expensing for certain business property, the expansion of section 162(m) limits on deductions of certain executive compensation, and a floor for deductions for charitable contributions where deductions are now limited to contributions in excess of 1% of a corporation's taxable income. The Act allows taxpayers that capitalized domestic R&amp;D expenditures after December 31, 2021, but before January 1 2025,  to elect to deduct any remaining unamortized amounts in the first tax year beginning after December 31, 2024, or ratably over the two-tax year period starting with the first tax year that begins after December 31, 2024. The Company is still evaluating the impact of the Act on its income tax provision.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EIB Tranche B Funding</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Finance Contract, the Company (through the Borrower) satisfied the conditions to draw &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the Tranche B loan facility. In connection therewith, on June 24, 2025, the Company issued to EIB the Tranche B Warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,221,867.59</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock. The Strike Price per share of common stock is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.32</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On July 4, 2025, the Company (through the Borrower) drew upon the Tranche B loan facility to obtain &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before payment of certain fees and transaction related expense.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_WarrantsPolicyPolicyTextBlock', window );">Warrants Issued in Connection with a Sale of Common Stock or Issuance of Debt</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants Issued in Connection with a Sale of Common Stock or Issuance of Debt</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for warrants issued as a separable unit in connection with sale of common stock or debt as either liability or equity in accordance with Accounting Standards Codification 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered liabilities if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. If warrants do not require liability classification under ASC 815-40 or other applicable generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) the warrants should be classified as equity. The debt is measured at amortized cost and the amount of interest recognized in the consolidated statements of operations is calculated by applying the loan&#8217;s effective interest rate to its carrying amount.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The proceeds received from the sale of equity classified warrants and shares of common stock in a bundled transaction are allocated based on the relative fair values of warrants and shares with no changes in fair value of warrants recognized after the issuance date. For liability classified warrants, the stand-alone fair value of the warrants are classified as debt issuance costs that directly reduce the outstanding debt on the consolidated balance sheet upon funding. Warrants issued prior to the date of funding are accounted for as a deferred financing asset within &#8220;Prepaid expenses and other current assets&#8221; on the consolidated balance sheet and will be reclassified to debt issuance costs on the date of funding. The change in fair value of warrants each balance sheet date are recognized in the consolidated statements of operations and comprehensive loss after the issuance date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no other changes to the significant accounting policies disclosed in Note 2 to the Company&#8217;s annual financial statements for the years ended December 31, 2024 and 2023 included in our Annual Report on Form 10-K filed with the SEC on March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_UnauditedFinancialInformationPolicyPolicyTextBlock', window );">Unaudited Financial Information</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unaudited Financial Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying unaudited interim consolidated financial statements included herein have been prepared in conformity with U.S. GAAP, and pursuant to the rules and regulations of the SEC. In the Company&#8217;s opinion, the information furnished herein reflects all adjustments, all of which are of a normal and recurring nature and necessary for a fair presentation of the financial position and results of operations for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company&#8217;s Annual Report filed on Form 10-K for the fiscal year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Standards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0847deca-10d0-4530-aa33-3be6c7b7efa2;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will also enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment and contain other disclosure requirements. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the financial statements. The guidance is effective in the annual periods beginning after December 15, 2023 and the Company has </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the standard effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Refer to Note 15, "Segments" in this Quarterly Report on Form 10-Q for additional information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Standards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, Accounting Standards Update 2023-06&#8212;Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative. ASU 2023-06 will eliminate disclosure requirements that are redundant, duplicative, overlapping, outdated, or superseded as a result of subsequent changes to SEC disclosure requirements, U.S. GAAP or technology. ASU 2023-06 is intended to better align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP. The disclosure requirements would apply prospectively in the financial statements. ASU 2023-06 will be effective for us on the date on which the SEC&#8217;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, if we are already subject to the SEC&#8217;s current disclosure requirements. For those current disclosure requirements we are not subject to, ASU 2023-06 will become effective two years after the date of such removal by the SEC. We are currently assessing the impact adoption of ASU 2023-06 will have on our financial statements and disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 will require disclosure of additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state and foreign income taxes. ASU 2023-09 will also require information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold.  ASU 2023-09 will be effective for us in the annual periods beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. We are currently assessing the impact adoption of ASU 2020-06 will have on our financial statements and disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures  (Subtopic 220-40): Disaggregation of  Income Statement Expenses. ASU 2024-03 will require disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis, including purchases of inventory, employee  compensation, depreciation, intangible asset amortization and depletion for each  income statement line item that contains those expenses. ASU 2024-03 also will require certain amounts already disclosed under existing U.S. GAAP to also be disclosed as a separate category in disaggregated expense table(s), if those amounts are  recognized in the relevant expense line item. The amendments in this ASU will be effective for us in annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. We are currently assessing the impact adoption of ASU 2024-03 will have on our financial statements and disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_UnauditedFinancialInformationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited financial information, policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_UnauditedFinancialInformationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_WarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Policy .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_WarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Assets Measured at Fair Value</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,134</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,134</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,134</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,134</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Black-Scholes Option-Pricing Model Inputs to Calculate the Fair Value of Warrants</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the Black-Scholes option-pricing model inputs used to calculate the fair value of the warrants at issuance date. </span>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.59%;box-sizing:content-box;"></td>
         <td style="width:2.901%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.304000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.901%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.304000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche A</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche B</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share price of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.92</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.39</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the Black-Scholes option-pricing model inputs used to calculate the fair value of the warrants at June 30, 2025.</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.59%;box-sizing:content-box;"></td>
         <td style="width:2.901%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.304000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.901%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.304000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche A</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche B</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share price of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.39</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.39</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.8</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows a reconciliation of the beginning and ending balances for Level 3 financial liabilities measured at fair value on a recurring basis for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:78.32%;box-sizing:content-box;"></td>
         <td style="width:1.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.06%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 3 financial liabilities, beginning of period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of EIB common stock warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,662</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of EIB common stock warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,587</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 3 financial liabilities, end of period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred financing asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,657</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,607</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,292</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid contract research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,109</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,119</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credit receivable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">865</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">573</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insurance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">639</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Value-added tax refund receivable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">276</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">365</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">696</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">803</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,849</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,920</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consist of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.527%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.057%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.057%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">927</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">839</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer hardware</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">726</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">577</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">603</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">638</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued contract research and development costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,133</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,070</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,351</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,311</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">692</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">416</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,592</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,108</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Facility (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Term Loan Debt, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term loan debt, net consisted of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:78.48%;box-sizing:content-box;"></td>
         <td style="width:2.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.68%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan debt principal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,720</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortized paid-in-kind interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Unamortized debt issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency adjustments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total term loan debt, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,720</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Undiscounted Minimum Principal and Interest Payments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future undiscounted minimum principal and interest payments under the EIB loan facility as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, were as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.823%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Future Minimum Debt Payments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remainder of 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2031</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,597</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total minimum payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,597</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Unamortized debt issuance costs and paid-in-kind interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency adjustments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total term loan debt</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,720</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Issued and Outstanding</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025, the Company had the following Tranche A and Tranche B Warrants issued and outstanding to purchase shares of the Company's common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:42.76%;box-sizing:content-box;"></td>
         <td style="width:3.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:3.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche A</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Tranche B</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,623,664</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,221,868</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise Price</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.89</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.32</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock', window );">Schedule of Qualitative Information Regarding Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Qualitative information regarding the Company&#8217;s leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 is as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:22.92%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:10.9%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:10.9%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:16.26%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:16.26%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Location</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Type</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Nature</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Commencement</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Term Expiration</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Annual Base Rent<br/>&#160;(in Millions)</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Copenhagen, Denmark</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Office</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2021</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2027</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Copenhagen, Denmark</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Office</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2024</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2027</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Copenhagen, Denmark</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Lab</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 2023</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2027</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Newport, United Kingdom</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Office</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 2023</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 2025</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York, New York</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Office</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 2021</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 2027</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rockville, Maryland</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Operating</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Lab</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2021</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 2027</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Quantitative Information Regarding Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quantitative information regarding the Company&#8217;s leases for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025 and 2024 is as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.882%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.882%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">359</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">369</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">413</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">385</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities arising from obtaining right-of-use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remaining average lease term (years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future lease payments (undiscounted) under noncancelable leases are as follows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.823%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Future Lease Payments</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remainder of 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">419</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">863</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">470</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,752</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Qualitative Information Regarding Leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our stock options activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:49.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.020000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of <br/>stock <br/>options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>average<br/>exercise<br/>price<br/>per share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>average<br/>remaining<br/>contractual<br/>term<br/>(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value<br/>(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,967,605</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.18</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,709,284</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.13</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Cancelled or forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,589</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.28</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding, June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,539,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">821</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable, June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,537,588</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.87</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions for Estimated Fair Value of Options</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair values of the stock options granted during the period ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 were estimated based on the Black-Scholes model, using the following assumptions:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:76.28%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.84%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Equity-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">677</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,262</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">963</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">965</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,920</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total equity-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,607</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,642</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,176</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Table)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per common share is calculated as follows (in thousands except share and per share amounts):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.95%;box-sizing:content-box;"></td>
         <td style="width:1.28%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.982000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.28%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.982000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.28%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.982000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.28%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.982000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,217</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,686</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,638</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,143</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,217</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,686</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,638</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,143</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.40</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.31</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.74</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.61</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of shares used in computing net loss per common share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,880,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,880,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,880,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,880,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share, as their effect is anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:49.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,539,300</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,992,635</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,539,300</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,992,635</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants issued in Private Placement</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,065,647</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock warrants issued to the EIB</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,845,532</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,845,532</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Expenses by Segment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, research and development and general and administrative expenses are significant segment expenses regularly provided to the CEO with the following categories (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.91%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.318%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.718%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.318%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.318%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three months ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six months ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial-related activities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,390</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,637</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,081</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,785</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,531</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,123</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,714</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,917</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chemistry, manufacturing and control</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,484</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,994</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,776</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preclinical studies and activities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">616</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">295</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">632</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">631</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">799</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">428</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">664</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,652</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,848</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,159</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.41%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.202%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three months ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six months ended June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,840</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,899</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,852</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,693</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,743</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">975</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,124</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,048</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,935</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,811</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,751</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,830</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,518</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,727</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,571</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Organization and Liquidity - Additional Information (Details)<br> $ / shares in Units, $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 19, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 04, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 06, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 09, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (407,951)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (407,951)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (359,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,217)<span></span>
</td>
<td class="num">$ (20,686)<span></span>
</td>
<td class="num">(48,638)<span></span>
</td>
<td class="num">$ (40,143)<span></span>
</td>
<td class="num">(95,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,131<span></span>
</td>
<td class="nump">$ 100,747<span></span>
</td>
<td class="nump">$ 28,131<span></span>
</td>
<td class="nump">$ 100,747<span></span>
</td>
<td class="nump">$ 60,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from IPO, after deducting underwriting discounts, commissions and offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preference share issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,592,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember', window );">EIB Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod', window );">Loan facility | &#8364;</a></td>
<td class="nump">&#8364; 57.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, aggregate principal amount | &#8364;</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche', window );">Certain conditions precedent, and one uncommitted accordion tranche | &#8364;</a></td>
<td class="nump">&#8364; 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheAMember', window );">Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,623,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Avaliable amount to draw | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheBMember', window );">Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,221,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheBMember', window );">Tranche B | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Avaliable amount to draw | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheCMember', window );">Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Avaliable amount to draw | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common stock conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember', window );">Class B Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common stock conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iobt_PreferredClassCMember', window );">Class C Preference Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common stock conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iobt_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,072,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,222,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock shares sold, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_WarrantsIssued', window );">Warrants Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PurchasePricePerShareOfCommonStockAndWarrant', window );">Purchase price per share of common stock and warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Maximum | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iobt_AtTheMarketEquityProgramMember', window );">At-The-Market Equity Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_CommonStockMaximumAggregateOfferingAmount', window );">Common stock, maximum aggregate offering price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iobt_AtTheMarketEquityProgramMember', window );">At-The-Market Equity Program | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems', window );"><strong>Description Of Business Organization And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_CommonStockMaximumAggregateOfferingAmount', window );">Common stock, maximum aggregate offering price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain conditions precedent, and one uncommitted accordion tranche.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_CommonStockMaximumAggregateOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, maximum aggregate offering amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_CommonStockMaximumAggregateOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of business, organization and liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_PurchasePricePerShareOfCommonStockAndWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price per share of common stock and warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_PurchasePricePerShareOfCommonStockAndWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of basis for conversion of convertible common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount borrowed under the credit facility at any time during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=iobt_PreferredClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=iobt_PreferredClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=iobt_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=iobt_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iobt_AtTheMarketEquityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iobt_AtTheMarketEquityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=iobt_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=iobt_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting standards update [extensible enumeration]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate202307Member<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets Measured at Fair Value (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 22,670<span></span>
</td>
<td class="nump">$ 46,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">13,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">13,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">22,670<span></span>
</td>
<td class="nump">46,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">22,670<span></span>
</td>
<td class="nump">46,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">22,670<span></span>
</td>
<td class="nump">$ 46,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">13,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">$ 13,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=iobt_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=iobt_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 24, 2025</div></th>
<th class="th"><div>Apr. 24, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1', window );">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1', window );">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Transfers into Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfers out of Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember', window );">EIB Loan Facility | Tranche A | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_WarrantsIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,623,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StrikePricePerShare', window );">Strike price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember', window );">EIB Loan Facility | Tranche B | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_WarrantsIssued', window );">Warrants issued</a></td>
<td class="nump">4,221,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StrikePricePerShare', window );">Strike price per share</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Liabilities Level1 To Level2 Transfers Amount1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Liabilities Level2 To Level1 Transfers Amount1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_StrikePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strike price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_StrikePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Black-Scholes Option-Pricing Model Inputs to Calculate the Fair Value of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 24, 2025</div></th>
<th class="th"><div>Apr. 24, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheOneMember', window );">Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">19 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheTwoMember', window );">Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price of common stock</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Level 3 financial liabilities, beginning of period</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of EIB common stock warrants</a></td>
<td class="nump">10,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value of EIB common stock warrants</a></td>
<td class="nump">2,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Level 3 financial liabilities, end of period</a></td>
<td class="nump">$ 13,249<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DeferredFinancingAssets', window );">Deferred financing asset</a></td>
<td class="nump">$ 5,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid income taxes</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">$ 1,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PrepaidContractResearchAndDevelopmentCostsCurrent', window );">Prepaid contract research and development costs</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent', window );">Research and development tax credit receivable</a></td>
<td class="nump">865<span></span>
</td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">639<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">Value-added tax refund receivable</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 10,849<span></span>
</td>
<td class="nump">$ 4,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_DeferredFinancingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred financing assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_DeferredFinancingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_PrepaidContractResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid contract research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_PrepaidContractResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credit receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">$ (726)<span></span>
</td>
<td class="num">$ (577)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">603<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">927<span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_AccruedContractResearchAndDevelopmentCostsCurrent', window );">Accrued contract research and development costs</a></td>
<td class="nump">$ 9,133<span></span>
</td>
<td class="nump">$ 9,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation costs</a></td>
<td class="nump">3,351<span></span>
</td>
<td class="nump">4,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 13,592<span></span>
</td>
<td class="nump">$ 14,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_AccruedContractResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued contract research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_AccruedContractResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Facility - Additional Information (Details)<br> $ / shares in Units, $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 24, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 24, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 19, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 04, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 06, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 19, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 19, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Non-current liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,837<span></span>
</td>
<td class="nump">$ 20,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, noncurrent | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,720<span></span>
</td>
<td class="nump">6,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheAMember', window );">Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Avaliable amount to draw</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,623,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StrikePricePerShare', window );">Strike price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Non-current liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-kind interest | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.30%<span></span>
</td>
<td class="nump">14.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheBMember', window );">Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,221,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StrikePricePerShare', window );">Strike price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Non-current liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheCMember', window );">Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Avaliable amount to draw</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember', window );">2024 EIB Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod', window );">Loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 57.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 37.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche', window );">Certain conditions precedent, and one uncommitted accordion tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Additional borrowing capacity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement', window );">Percentage of prepayment fee on repayment of tranche within twelve months of disbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement', window );">Percentage of prepayment fee on repayment of tranche after third anniversry of disbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails', window );">Additional borrowing capacity ongoing trails | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PercentageOfAmountDisbursedUnderFinanceContract', window );">Percentage of amount disbursed under finance contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember', window );">2024 EIB Term Loan Facility | Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Avaliable amount to draw</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember', window );">2024 EIB Term Loan Facility | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember', window );">2024 EIB Term Loan Facility | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Avaliable amount to draw</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember', window );">EIB Loan Facility | Tranche A | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,623,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StrikePricePerShare', window );">Strike price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember', window );">EIB Loan Facility | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StrikePricePerShare', window );">Strike price per share | $ / shares</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember', window );">EIB Loan Facility | Tranche B | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">4,221,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StrikePricePerShare', window );">Strike price per share | $ / shares</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain conditions precedent, and one uncommitted accordion tranche.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_LineOfCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility additional borrowing capacity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_LineOfCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility additional borrowing capacity ongoing trails.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_PercentageOfAmountDisbursedUnderFinanceContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount disbursed under finance contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_PercentageOfAmountDisbursedUnderFinanceContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayment fee on repayment of tranche after third anniversry of disbursement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayment fee on repayment of tranche within twelve months of disbursement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_StrikePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strike price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_StrikePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount borrowed under the credit facility at any time during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loan Facility - Schedule of Term Loan Debt, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan debt principal</a></td>
<td class="nump">$ 11,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DebtInstrumentAmortizedPaidInKindInterest', window );">Amortized paid-in-kind interest</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt issuance costs</a></td>
<td class="num">(5,290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DebtInstrumentCurrencyAdjustments', window );">Currency adjustments</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total term loan debt</a></td>
<td class="nump">$ 6,720<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_DebtInstrumentAmortizedPaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, amortized paid in kind interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_DebtInstrumentAmortizedPaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_DebtInstrumentCurrencyAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, currency adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_DebtInstrumentCurrencyAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loan Facility - Schedule of Future Undiscounted Minimum Principal and Interest Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2025</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2030</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix', window );">2031</a></td>
<td class="nump">18,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_Long-TermDebtMaturityMinimumPayment', window );">Total minimum payments</a></td>
<td class="nump">18,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest', window );">Less: Unamortized debt issuance costs and paid-in-kind interest</a></td>
<td class="num">(12,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DebtInstrumentCurrencyAdjustments', window );">Currency adjustments</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total term loan debt</a></td>
<td class="nump">$ 6,720<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_DebtInstrumentCurrencyAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, currency adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_DebtInstrumentCurrencyAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, unamortized debt issuance costs and paid in kind interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_Long-TermDebtMaturityMinimumPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term debt, maturity, minimum payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_Long-TermDebtMaturityMinimumPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal in year six.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Facility - Schedule of Warrants Issued and Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheAMember', window );">Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">5,623,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StrikePricePerShare', window );">Strike price per share | $ / shares</a></td>
<td class="nump">$ 0.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheBMember', window );">Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">4,221,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StrikePricePerShare', window );">Strike price per share | $ / shares</a></td>
<td class="nump">$ 1.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_StrikePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strike price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_StrikePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_NumberOfOperatingLease', window );">Number of operating leases | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use lease asset</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease, liability, non-current</a></td>
<td class="nump">$ 868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_NumberOfOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_NumberOfOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Qualitative Information Regarding Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DK', window );">Copenhagen, Denmark | March 2021 | Office</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseTermExpirationMonthYear', window );">Lease commencement</a></td>
<td class="text">2021-03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseCommencementMonthYear', window );">Lease term expiration</a></td>
<td class="text">2027-12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseAnnualBaseRent', window );">Annual base rent</a></td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DK', window );">Copenhagen, Denmark | December 2024 | Office</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseTermExpirationMonthYear', window );">Lease commencement</a></td>
<td class="text">2024-12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseCommencementMonthYear', window );">Lease term expiration</a></td>
<td class="text">2027-12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseAnnualBaseRent', window );">Annual base rent</a></td>
<td class="nump">$ 40.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DK', window );">Copenhagen, Denmark | January 2023 | Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseTermExpirationMonthYear', window );">Lease commencement</a></td>
<td class="text">2023-01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseCommencementMonthYear', window );">Lease term expiration</a></td>
<td class="text">2027-12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseAnnualBaseRent', window );">Annual base rent</a></td>
<td class="nump">$ 40.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">Newport, United Kingdom | June 2023 | Office</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseTermExpirationMonthYear', window );">Lease commencement</a></td>
<td class="text">2023-06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseCommencementMonthYear', window );">Lease term expiration</a></td>
<td class="text">2025-05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseAnnualBaseRent', window );">Annual base rent</a></td>
<td class="nump">$ 40.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NY', window );">New York, New York | October 2021 | Office</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseTermExpirationMonthYear', window );">Lease commencement</a></td>
<td class="text">2021-10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseCommencementMonthYear', window );">Lease term expiration</a></td>
<td class="text">2027-01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseAnnualBaseRent', window );">Annual base rent</a></td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MD', window );">Rockville, Maryland | December 2021 | Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseTermExpirationMonthYear', window );">Lease commencement</a></td>
<td class="text">2021-12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseCommencementMonthYear', window );">Lease term expiration</a></td>
<td class="text">2027-05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_OperatingLeaseAnnualBaseRent', window );">Annual base rent</a></td>
<td class="nump">$ 300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_OperatingLeaseAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease annual base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_OperatingLeaseAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_OperatingLeaseCommencementMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement month year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_OperatingLeaseCommencementMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_OperatingLeaseTermExpirationMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease term expiration month year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_OperatingLeaseTermExpirationMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_OfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_OfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iobt_LaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Quantitative information Regarding Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 359<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining average lease term (years)</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2025</a></td>
<td class="nump">$ 419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 1,752<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease liability, to be paid, after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ContractualObligationsTerminationNoticePeriod', window );">Contractual obligations termination notice period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ContractualObligationsTerminationNoticePeriod', window );">Contractual obligations termination notice period</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ContractualObligationsTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligations termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ContractualObligationsTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 07, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 09, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_NumberOfVotePerShare', window );">Number of votes per share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">28,815,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="nump">$ 71,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_WarrantsIssued', window );">Warrants issued | shares</a></td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PurchasePricePerShareOfCommonStockAndWarrant', window );">Purchase price per share of common stock and warrant | $ / shares</a></td>
<td class="nump">$ 2.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_WarrantsIssued', window );">Warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,065,647<span></span>
</td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_PurchasePricePerShareOfCommonStockAndWarrant', window );">Purchase price per share of common stock and warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="nump">75,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_WarrantsExercisablePricePerShare', window );">Purchase Price of Common Stock and Warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_NetProceedsFromIssuanceOfPrivatePlacement', window );">Net Proceeds From Issuance Of Private Placement</a></td>
<td class="nump">71,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Securities Purchase Agreement | Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Securities Purchase Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="nump">$ 33,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement | Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,065,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iobt_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsAxis=iobt_O2025Q1DividendsMember', window );">O 2025 Q1 Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DividendsDeclared', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_DividendsPaid', window );">Dividends paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_DividendsDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends declared.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_DividendsDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_DividendsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_DividendsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_NetProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_NetProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_NumberOfVotePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of vote per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_NumberOfVotePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_PurchasePricePerShareOfCommonStockAndWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price per share of common stock and warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_PurchasePricePerShareOfCommonStockAndWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_WarrantsExercisablePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_WarrantsExercisablePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=iobt_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=iobt_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=iobt_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=iobt_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAxis=iobt_O2025Q1DividendsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAxis=iobt_O2025Q1DividendsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 04, 2021</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefits for stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember', window );">2021 Equity and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of warrants available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">2,496,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of shares that may be issued under the plan as a proportion of outstanding capital stock</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">257,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of shares that may be issued under the plan as a proportion of outstanding capital stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iobt_TwoThousandTwentyThreeInducementIncentivePlanMember', window );">2023 Inducement Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of warrants available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iobt_TwoThousandTwentyThreeInducementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iobt_TwoThousandTwentyThreeInducementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Stock Options Activity (Details) - Warrant - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Beginning balance</a></td>
<td class="nump">8,967,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Warrants, Granted</a></td>
<td class="nump">2,709,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Warrants, Cancelled or forfeited</a></td>
<td class="num">(137,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Ending balance</a></td>
<td class="nump">11,539,300<span></span>
</td>
<td class="nump">8,967,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable', window );">Number of Warrants, Exercisable</a></td>
<td class="nump">5,537,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price per share, Beginning balance</a></td>
<td class="nump">$ 5.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price per share, Granted</a></td>
<td class="nump">1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price per share, Cancelled or forfeited</a></td>
<td class="nump">4.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price per share, Ending balance</a></td>
<td class="nump">4.24<span></span>
</td>
<td class="nump">$ 5.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, Exercisable</a></td>
<td class="nump">$ 6.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted-average remaining contractual term (in years), Outstanding</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted-average remaining contractual term (in years), Exercisable</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 821<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercisable intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award equity instruments other than options exercisable in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Assumptions for Estimated Fair Value of Options (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility minimum</a></td>
<td class="nump">84.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility maximum</a></td>
<td class="nump">85.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate minimum</a></td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate maximum</a></td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 1,607<span></span>
</td>
<td class="nump">$ 1,642<span></span>
</td>
<td class="nump">$ 3,176<span></span>
</td>
<td class="nump">$ 3,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">644<span></span>
</td>
<td class="nump">677<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation</a></td>
<td class="nump">$ 963<span></span>
</td>
<td class="nump">$ 965<span></span>
</td>
<td class="nump">$ 1,914<span></span>
</td>
<td class="nump">$ 1,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes expense</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 374<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and Diluted Net Loss Per Ordinary Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (26,217)<span></span>
</td>
<td class="num">$ (20,686)<span></span>
</td>
<td class="num">$ (48,638)<span></span>
</td>
<td class="num">$ (40,143)<span></span>
</td>
<td class="num">$ (95,500)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (26,217)<span></span>
</td>
<td class="num">$ (20,686)<span></span>
</td>
<td class="num">$ (48,638)<span></span>
</td>
<td class="num">$ (40,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used in computing net loss per common share, basic</a></td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used in computing net loss per common share, diluted</a></td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="nump">65,880,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding potentially dilutive securities</a></td>
<td class="nump">11,539,300<span></span>
</td>
<td class="nump">8,992,635<span></span>
</td>
<td class="nump">11,539,300<span></span>
</td>
<td class="nump">8,992,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants Issued in Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding potentially dilutive securities</a></td>
<td class="nump">37,065,647<span></span>
</td>
<td class="nump">37,065,647<span></span>
</td>
<td class="nump">37,065,647<span></span>
</td>
<td class="nump">37,065,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=iobt_CommonStockWarrantsIssuedToEIBMember', window );">Common Stock Warrants Issued to the EIB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding potentially dilutive securities</a></td>
<td class="nump">9,845,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,845,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=iobt_CommonStockWarrantsIssuedToEIBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=iobt_CommonStockWarrantsIssuedToEIBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">Chief Executive Officer [Member]<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment Reporting, Expense Information Used by CODM, Description</a></td>
<td class="text">As the chief operating decision maker (&#8220;CODM&#8221;), our Chief Executive Officer manages our company, reviews operating results, assesses performance and allocates resources on an aggregate basis using consolidated net income or loss as the key measure of segment profit or loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration', window );">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</a></td>
<td class="text">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Schedule of Expenses by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">$ 16,652<span></span>
</td>
<td class="nump">$ 15,848<span></span>
</td>
<td class="nump">$ 33,027<span></span>
</td>
<td class="nump">$ 30,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">6,518<span></span>
</td>
<td class="nump">5,685<span></span>
</td>
<td class="nump">12,727<span></span>
</td>
<td class="nump">11,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">16,652<span></span>
</td>
<td class="nump">15,848<span></span>
</td>
<td class="nump">33,027<span></span>
</td>
<td class="nump">30,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">6,518<span></span>
</td>
<td class="nump">5,685<span></span>
</td>
<td class="nump">12,727<span></span>
</td>
<td class="nump">11,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iobt_ClinicalTrialRelatedActivitiesMember', window );">Clinical trial-related activities | CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">6,390<span></span>
</td>
<td class="nump">6,637<span></span>
</td>
<td class="nump">14,081<span></span>
</td>
<td class="nump">13,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iobt_PersonnelMember', window );">Personnel | CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">6,531<span></span>
</td>
<td class="nump">5,123<span></span>
</td>
<td class="nump">12,714<span></span>
</td>
<td class="nump">9,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">2,840<span></span>
</td>
<td class="nump">2,899<span></span>
</td>
<td class="nump">5,852<span></span>
</td>
<td class="nump">5,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iobt_ChemistryManufacturingAndControlMember', window );">Chemistry, manufacturing and control | CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">2,484<span></span>
</td>
<td class="nump">2,994<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
<td class="nump">5,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iobt_PreclinicalStudiesAndActivitiesMember', window );">Preclinical studies and activities | CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iobt_ProfessionalServicesMember', window );">Professional services | CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">1,743<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="nump">3,124<span></span>
</td>
<td class="nump">2,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iobt_OtherCostsMember', window );">Other costs | CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">799<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">$ 1,935<span></span>
</td>
<td class="nump">$ 1,811<span></span>
</td>
<td class="nump">$ 3,751<span></span>
</td>
<td class="nump">$ 3,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iobt_ClinicalTrialRelatedActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iobt_ClinicalTrialRelatedActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iobt_PersonnelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iobt_PersonnelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iobt_ChemistryManufacturingAndControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iobt_ChemistryManufacturingAndControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iobt_PreclinicalStudiesAndActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iobt_PreclinicalStudiesAndActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iobt_ProfessionalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iobt_ProfessionalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iobt_OtherCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iobt_OtherCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - Tranche B<br> $ / shares in Units, &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 24, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 04, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 04, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StrikePricePerShare', window );">Strike price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,221,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember', window );">EIB Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StrikePricePerShare', window );">Strike price per share</a></td>
<td class="nump">1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember', window );">EIB Loan Facility | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iobt_StrikePricePerShare', window );">Strike price per share</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">4,221,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember', window );">EIB Loan Facility | Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">4,221,867.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Avaliable amount to draw | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | EIB Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Avaliable amount to draw | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iobt_StrikePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strike price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iobt_StrikePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iobt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iobt_CreditFacilityTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=iobt_LoanFacilityWithEuropeanInvestmentBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>173</ContextCount>
  <ElementCount>267</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75050 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75060 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75080 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Description of Business, Organization and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity</Role>
      <ShortName>Description of Business, Organization and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Term Loan Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacility</Role>
      <ShortName>Term Loan Facility</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeases1</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquity1</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Term Loan Facility (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityTables</Role>
      <ShortName>Term Loan Facility (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacility</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeases1</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Net Loss Per Share (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareTable</Role>
      <ShortName>Net Loss Per Share (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Description of Business, Organization and Liquidity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails</Role>
      <ShortName>Description of Business, Organization and Liquidity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Fair Value Measurements - Summary of Black-Scholes Option-Pricing Model Inputs to Calculate the Fair Value of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Black-Scholes Option-Pricing Model Inputs to Calculate the Fair Value of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Fair Value Measurements - Summary of Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLevel3FinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Term Loan Facility - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails</Role>
      <ShortName>Term Loan Facility - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Term Loan Facility - Schedule of Term Loan Debt, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails</Role>
      <ShortName>Term Loan Facility - Schedule of Term Loan Debt, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Term Loan Facility - Schedule of Future Undiscounted Minimum Principal and Interest Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails</Role>
      <ShortName>Term Loan Facility - Schedule of Future Undiscounted Minimum Principal and Interest Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Term Loan Facility - Schedule of Warrants Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails</Role>
      <ShortName>Term Loan Facility - Schedule of Warrants Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Leases - Schedule of Qualitative Information Regarding Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Qualitative Information Regarding Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Leases - Schedule of Quantitative information Regarding Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Quantitative information Regarding Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Leases - Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails</Role>
      <ShortName>Leases - Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Equity-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Equity-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Equity-Based Compensation - Summary of Assumptions for Estimated Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails</Role>
      <ShortName>Equity-Based Compensation - Summary of Assumptions for Estimated Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Ordinary Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and Diluted Net Loss Per Ordinary Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Segments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails</Role>
      <ShortName>Segments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Segments - Schedule of Expenses by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails</Role>
      <ShortName>Segments - Schedule of Expenses by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="iobt-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="iobt-20250630.htm">iobt-20250630.htm</File>
    <File>iobt-20250630.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img135872921_0.jpg</File>
    <File>img135872921_1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="564">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "iobt-20250630.htm": {
   "nsprefix": "iobt",
   "nsuri": "http://www.iobiotech.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "iobt-20250630.htm"
     ]
    },
    "schema": {
     "local": [
      "iobt-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 225,
   "keyCustom": 42,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 33,
   "hidden": {
    "total": 12,
    "http://fasb.org/us-gaap/2025": 8,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 173,
   "entityCount": 1,
   "segmentCount": 64,
   "elementCount": 571,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 564,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
     "longName": "75010 - Statement - Consolidated Balance Sheets (Unaudited)",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical",
     "longName": "75020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
     "longName": "75050 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_a0871b16-5115-452a-8aa3-17c1815473f3",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0871b16-5115-452a-8aa3-17c1815473f3",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited",
     "longName": "75060 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_3adaf1b6-8e71-4415-9436-0d74420cbb54",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b0357848-8a70-4e7d-8b7c-77576974cdd3",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "75080 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_a0871b16-5115-452a-8aa3-17c1815473f3",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity",
     "longName": "995455 - Disclosure - Description of Business, Organization and Liquidity",
     "shortName": "Description of Business, Organization and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995475 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements",
     "longName": "995485 - Disclosure - License and Collaboration Agreements",
     "shortName": "License and Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "longName": "995495 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "longName": "995505 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacility",
     "longName": "995515 - Disclosure - Term Loan Facility",
     "shortName": "Term Loan Facility",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "995525 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeases1",
     "longName": "995535 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995545 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquity1",
     "longName": "995555 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation",
     "longName": "995565 - Disclosure - Equity-Based Compensation",
     "shortName": "Equity-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995575 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShare",
     "longName": "995585 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegments",
     "longName": "995595 - Disclosure - Segments",
     "shortName": "Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSubsequentEvents",
     "longName": "995605 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995615 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "iobt:WarrantsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "iobt:WarrantsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "995625 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "995635 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "995645 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "995655 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityTables",
     "longName": "995665 - Disclosure - Term Loan Facility (Tables)",
     "shortName": "Term Loan Facility (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesTables",
     "longName": "995675 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "iobt:ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "iobt:ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables",
     "longName": "995685 - Disclosure - Equity-Based Compensation (Tables)",
     "shortName": "Equity-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareTable",
     "longName": "995695 - Disclosure - Net Loss Per Share (Table)",
     "shortName": "Net Loss Per Share (Table)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsTables",
     "longName": "995705 - Disclosure - Segments (Tables)",
     "shortName": "Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
     "longName": "995715 - Disclosure - Description of Business, Organization and Liquidity - Additional Information (Details)",
     "shortName": "Description of Business, Organization and Liquidity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dd160d99-0b92-4fa0-b879-249e802cf09f",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995725 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails",
     "longName": "995735 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Summary of Assets Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_be42f9d7-7aab-4ef2-a21e-2e34278195bb",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be42f9d7-7aab-4ef2-a21e-2e34278195bb",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "995745 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails",
     "longName": "995755 - Disclosure - Fair Value Measurements - Summary of Black-Scholes Option-Pricing Model Inputs to Calculate the Fair Value of Warrants (Details)",
     "shortName": "Fair Value Measurements - Summary of Black-Scholes Option-Pricing Model Inputs to Calculate the Fair Value of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_809916c8-d68a-4b98-8df0-358a4bf20dc9",
      "name": "us-gaap:SharePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLevel3FinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995765 - Disclosure - Fair Value Measurements - Summary of Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Summary of Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_1df79142-ea8b-41b1-a655-b2d3ed78f113",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1df79142-ea8b-41b1-a655-b2d3ed78f113",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "995775 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "iobt:DeferredFinancingAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "iobt:DeferredFinancingAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "995785 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "995795 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_a0871b16-5115-452a-8aa3-17c1815473f3",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0871b16-5115-452a-8aa3-17c1815473f3",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "995805 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "iobt:AccruedContractResearchAndDevelopmentCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "iobt:AccruedContractResearchAndDevelopmentCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
     "longName": "995815 - Disclosure - Term Loan Facility - Additional Information (Details)",
     "shortName": "Term Loan Facility - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_806e2b05-4b7e-4476-94b2-2b7dd866dc79",
      "name": "us-gaap:LiabilitiesNoncurrent",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails",
     "longName": "995825 - Disclosure - Term Loan Facility - Schedule of Term Loan Debt, Net (Details)",
     "shortName": "Term Loan Facility - Schedule of Term Loan Debt, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails",
     "longName": "995835 - Disclosure - Term Loan Facility - Schedule of Future Undiscounted Minimum Principal and Interest Payments (Details)",
     "shortName": "Term Loan Facility - Schedule of Future Undiscounted Minimum Principal and Interest Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails",
     "longName": "995845 - Disclosure - Term Loan Facility - Schedule of Warrants Issued and Outstanding (Details)",
     "shortName": "Term Loan Facility - Schedule of Warrants Issued and Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_c9ac1ffc-962f-4af6-b379-9a18ad414f27",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "995855 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_a0871b16-5115-452a-8aa3-17c1815473f3",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0871b16-5115-452a-8aa3-17c1815473f3",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails",
     "longName": "995865 - Disclosure - Leases - Schedule of Qualitative Information Regarding Leases (Details)",
     "shortName": "Leases - Schedule of Qualitative Information Regarding Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_12c9ea54-3647-4df4-9107-48c806489a8f",
      "name": "iobt:OperatingLeaseTermExpirationMonthYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "iobt:ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_12c9ea54-3647-4df4-9107-48c806489a8f",
      "name": "iobt:OperatingLeaseTermExpirationMonthYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "iobt:ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails",
     "longName": "995875 - Disclosure - Leases - Schedule of Quantitative information Regarding Leases (Details)",
     "shortName": "Leases - Schedule of Quantitative information Regarding Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails",
     "longName": "995885 - Disclosure - Leases - Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases (Details)",
     "shortName": "Leases - Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995895 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_a6b6d898-f2a2-4264-a194-96e339c5adc0",
      "name": "iobt:ContractualObligationsTerminationNoticePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a6b6d898-f2a2-4264-a194-96e339c5adc0",
      "name": "iobt:ContractualObligationsTerminationNoticePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "995905 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "iobt:NumberOfVotePerShare",
      "unitRef": "U_Vote",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails",
     "longName": "995915 - Disclosure - Equity-Based Compensation - Additional Information (Details)",
     "shortName": "Equity-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails",
     "longName": "995925 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Activity (Details)",
     "shortName": "Equity-Based Compensation - Schedule of Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_a438d86c-ada7-4302-94e2-dc378d64a260",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
     "longName": "995935 - Disclosure - Equity-Based Compensation - Summary of Assumptions for Estimated Fair Value of Options (Details)",
     "shortName": "Equity-Based Compensation - Summary of Assumptions for Estimated Fair Value of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails",
     "longName": "995945 - Disclosure - Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Details)",
     "shortName": "Equity-Based Compensation - Schedule of Equity-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_a0871b16-5115-452a-8aa3-17c1815473f3",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0871b16-5115-452a-8aa3-17c1815473f3",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995955 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_a0871b16-5115-452a-8aa3-17c1815473f3",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails",
     "longName": "995965 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Ordinary Share (Details)",
     "shortName": "Net Loss Per Share - Basic and Diluted Net Loss Per Ordinary Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_a0871b16-5115-452a-8aa3-17c1815473f3",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "995975 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_4e98906e-1cac-4433-be9f-7d243d541dcc",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4e98906e-1cac-4433-be9f-7d243d541dcc",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails",
     "longName": "995995 - Disclosure - Segments - Additional Information (Details)",
     "shortName": "Segments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c31d0c7-7684-473b-9386-127c8dea9206",
      "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails",
     "longName": "996005 - Disclosure - Segments - Schedule of Expenses by Segment (Details)",
     "shortName": "Segments - Schedule of Expenses by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_a0871b16-5115-452a-8aa3-17c1815473f3",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9056ec8b-e4b6-4e0a-a202-17751c0d78db",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "996015 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_545accb2-04f0-4670-bdc6-0b24c21df653",
      "name": "us-gaap:SharePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2b8ecfa6-15a8-4675-8200-6867ed419829",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iobt-20250630.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting standards update [extensible enumeration]",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r138",
      "r139",
      "r140",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r219",
      "r220",
      "r253",
      "r255",
      "r256",
      "r266",
      "r267",
      "r275",
      "r324",
      "r325",
      "r326",
      "r327",
      "r407",
      "r408",
      "r409",
      "r410",
      "r426",
      "r427",
      "r428",
      "r429",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r467",
      "r468",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r516",
      "r517",
      "r538",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r874"
     ]
    },
    "iobt_AccruedContractResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "AccruedContractResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued contract research and development costs current.",
        "label": "Accrued Contract Research And Development Costs Current",
        "terseLabel": "Accrued contract research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r115",
      "r653"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r51",
      "r123",
      "r649",
      "r682",
      "r686",
      "r1134"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10",
      "r17",
      "r470",
      "r473",
      "r558",
      "r677",
      "r678",
      "r1008",
      "r1009",
      "r1010",
      "r1064",
      "r1065",
      "r1066",
      "r1068"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r874",
      "r1204"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r1064",
      "r1065",
      "r1066",
      "r1068",
      "r1135",
      "r1207"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Equity-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]",
        "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r921",
      "r931",
      "r963"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r914",
      "r924",
      "r934",
      "r966"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r925",
      "r935",
      "r959",
      "r967",
      "r971",
      "r979"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total equity-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r411",
      "r412"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Non-cash interest expense",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r56",
      "r316",
      "r1153"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Outstanding potentially dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets",
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r85",
      "r117",
      "r146",
      "r149",
      "r150",
      "r190",
      "r201",
      "r208",
      "r211",
      "r252",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r456",
      "r460",
      "r520",
      "r636",
      "r637",
      "r644",
      "r737",
      "r825",
      "r826",
      "r840",
      "r874",
      "r889",
      "r890",
      "r902",
      "r1094",
      "r1095",
      "r1160"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total current assets",
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r124",
      "r146",
      "r149",
      "r150",
      "r252",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r456",
      "r460",
      "r520",
      "r874",
      "r1094",
      "r1095",
      "r1160"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets measured at fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r861"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r149",
      "r150",
      "r252",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r456",
      "r460",
      "r520",
      "r1094",
      "r1095",
      "r1160"
     ]
    },
    "iobt_AtTheMarketEquityProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "AtTheMarketEquityProgramMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Equity Program",
        "label": "At-The-Market Equity Program [Member]",
        "documentation": "At-the-market equity program."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalent",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r113",
      "r807"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]",
        "terseLabel": "Components of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r59",
      "r143"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r59"
     ]
    },
    "iobt_CertainConditionsPrecedentAndOneUncommittedAccordionTranche": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "CertainConditionsPrecedentAndOneUncommittedAccordionTranche",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certain Conditions Precedent, and One Uncommitted Accordion Tranche",
        "documentation": "Certain conditions precedent, and one uncommitted accordion tranche.",
        "terseLabel": "Certain conditions precedent, and one uncommitted accordion tranche"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, adopted [true false]",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r104",
      "r138",
      "r158",
      "r219",
      "r266",
      "r275",
      "r324",
      "r407",
      "r427",
      "r435",
      "r436",
      "r444",
      "r445",
      "r447",
      "r467",
      "r481",
      "r482",
      "r516",
      "r517",
      "r538",
      "r553",
      "r554",
      "r675",
      "r676"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r138",
      "r219",
      "r266",
      "r275",
      "r324",
      "r325",
      "r407",
      "r408",
      "r427",
      "r435",
      "r436",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r467",
      "r468",
      "r481",
      "r482",
      "r483",
      "r486",
      "r516",
      "r517",
      "r538",
      "r553",
      "r554",
      "r675",
      "r676",
      "r1002",
      "r1067"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect [true false]",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r159",
      "r173",
      "r254"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "iobt_ChemistryManufacturingAndControlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "ChemistryManufacturingAndControlMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chemistry, Manufacturing and Control",
        "label": "Chemistry, Manufacturing And Control [Member]",
        "documentation": "Chemistry, manufacturing and control.",
        "verboseLabel": "Chemistry, manufacturing and control"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEO",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r120",
      "r121",
      "r122",
      "r146",
      "r150",
      "r179",
      "r180",
      "r183",
      "r185",
      "r192",
      "r193",
      "r252",
      "r285",
      "r287",
      "r288",
      "r289",
      "r292",
      "r293",
      "r328",
      "r329",
      "r331",
      "r332",
      "r334",
      "r337",
      "r340",
      "r341",
      "r343",
      "r346",
      "r354",
      "r520",
      "r692",
      "r693",
      "r694",
      "r695",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r725",
      "r746",
      "r765",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r990",
      "r1059",
      "r1061",
      "r1069"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants issued",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ClinicalTrialRelatedActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "ClinicalTrialRelatedActivitiesMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Related Activities [Member]",
        "documentation": "Clinical trial-related activities.",
        "terseLabel": "Clinical Trial-Related Activities",
        "verboseLabel": "Clinical trial-related activities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r452",
      "r453"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 10)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r80",
      "r646",
      "r724"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r277",
      "r278",
      "r791",
      "r1084",
      "r1089"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Ordinary Shares",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1207"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares of common stock reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CommonStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockConversionBasis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Conversion Basis",
        "terseLabel": "Common stock conversion basis",
        "documentation": "Description of basis for conversion of convertible common stock."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "iobt_CommonStockMaximumAggregateOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "CommonStockMaximumAggregateOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, maximum aggregate offering price",
        "label": "Common Stock, Maximum Aggregate Offering Amount",
        "documentation": "Common stock, maximum aggregate offering amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r892",
      "r893",
      "r894",
      "r896",
      "r897",
      "r898",
      "r899",
      "r1064",
      "r1065",
      "r1068",
      "r1135",
      "r1203",
      "r1207"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock shares authorized",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r725"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r45",
      "r725",
      "r743",
      "r1207",
      "r1208"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "terseLabel": "Common stock, par value of $0.001 per share; 300,000,000 shares authorized at June 30, 2025 and December 31, 2024; 65,880,914 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r329",
      "r336",
      "r648",
      "r874"
     ]
    },
    "iobt_CommonStockWarrantsIssuedToEIBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "CommonStockWarrantsIssuedToEIBMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants Issued to EIB Member",
        "documentation": "Common Stock Warrants Issued to EIB.",
        "terseLabel": "Common Stock Warrants Issued to the EIB"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_CommonStockWarrantsLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "CommonStockWarrantsLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock warrants",
        "label": "Common Stock Warrants Liabilities Noncurrent",
        "documentation": "Common stock warrants liabilities noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants [Member]",
        "documentation": "Common stock warrants.",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r126",
      "r128",
      "r132",
      "r634",
      "r660",
      "r661"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer hardware",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ConsultantsAndOtherCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "ConsultantsAndOtherCostsMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants And Other Costs [Member]",
        "documentation": "Consultants and other costs.",
        "terseLabel": "Consultants and Other Costs",
        "verboseLabel": "Consultants and other costs"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ContractualObligationsTerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "ContractualObligationsTerminationNoticePeriod",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual obligations termination notice period",
        "label": "Contractual Obligations Termination Notice Period",
        "documentation": "Contractual obligations termination notice period."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "ContributionPercentageInExcessOfCorporateTaxableIncomeApplicableAsPerOneBigBeautifulBillAct",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution Percentage In Excess Of Corporate Taxable Income Applicable As Per One Big Beautiful Bill Act",
        "documentation": "Contribution percentage in excess of corporate taxable income applicable as per One Big Beautiful Bill Act.",
        "terseLabel": "Contribution percentage in excess of corporate taxable income applicable as per One Big Beautiful Bill Act"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preference share issued upon conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r28",
      "r44",
      "r69",
      "r349"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r1092"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r1092"
     ]
    },
    "iobt_CreditFacilityTrancheAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "CreditFacilityTrancheAMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility Tranche A [Member]",
        "documentation": "Credit Facility Tranche A.",
        "terseLabel": "Tranche A"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_CreditFacilityTrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "CreditFacilityTrancheBMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche B",
        "label": "Credit Facility Tranche B [Member]",
        "documentation": "Credit Facility Tranche B."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_CreditFacilityTrancheCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "CreditFacilityTrancheCMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility Tranche C [Member]",
        "documentation": "Credit Facility Tranche C.",
        "terseLabel": "Tranche C"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_CreditFacilityTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "CreditFacilityTrancheOneMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche A",
        "label": "Credit Facility Tranche One [Member]",
        "documentation": "Credit facility tranche one."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_CreditFacilityTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "CreditFacilityTrancheTwoMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche B",
        "label": "Credit Facility Tranche Two [Member]",
        "documentation": "Credit facility tranche two."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "country_DK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "DK",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DENMARK",
        "terseLabel": "Copenhagen, Denmark"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacility"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term Loan Facility",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r146",
      "r148",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r283",
      "r284",
      "r294",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r310",
      "r317",
      "r318",
      "r320",
      "r466",
      "r536"
     ]
    },
    "iobt_DebtInstrumentAmortizedPaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "DebtInstrumentAmortizedPaidInKindInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Amortized Paid In Kind Interest",
        "documentation": "Debt instrument, amortized paid in kind interest.",
        "terseLabel": "Amortized paid-in-kind interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r35",
      "r36",
      "r78",
      "r79",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r872",
      "r1057",
      "r1058",
      "r1060",
      "r1063",
      "r1085",
      "r1086",
      "r1087",
      "r1152",
      "r1154",
      "r1170"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Term loan debt principal",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r79",
      "r321"
     ]
    },
    "iobt_DebtInstrumentCurrencyAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "DebtInstrumentCurrencyAdjustments",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Currency Adjustments",
        "documentation": "Debt instrument, currency adjustments.",
        "terseLabel": "Currency adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r323",
      "r536",
      "r537",
      "r872"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r872",
      "r1057",
      "r1058",
      "r1060",
      "r1063",
      "r1085",
      "r1086",
      "r1087",
      "r1152",
      "r1154",
      "r1170"
     ]
    },
    "iobt_DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Unamortized debt issuance costs and paid-in-kind interest",
        "label": "Debt Instrument, Unamortized Debt Issuance Costs And Paid In Kind Interest",
        "documentation": "Debt instrument, unamortized debt issuance costs and paid in kind interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total",
        "negatedLabel": "Less: Unamortized debt issuance costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r322",
      "r535",
      "r536",
      "r537",
      "r836",
      "r837",
      "r872"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_DeferredFinancingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "DeferredFinancingAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Financing Assets",
        "documentation": "Deferred financing assets.",
        "terseLabel": "Deferred financing asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r26",
      "r136",
      "r810",
      "r811",
      "r813",
      "r815"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r137",
      "r190",
      "r203",
      "r211",
      "r810",
      "r825",
      "r826"
     ]
    },
    "iobt_DescriptionOfBusinessOrganizationAndLiquidityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "DescriptionOfBusinessOrganizationAndLiquidityLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business, organization and liquidity.",
        "label": "Description Of Business Organization And Liquidity [Line Items]",
        "terseLabel": "Description Of Business Organization And Liquidity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_DescriptionOfBusinessOrganizationAndLiquidityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "DescriptionOfBusinessOrganizationAndLiquidityTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business, organization and liquidity.",
        "label": "Description Of Business Organization And Liquidity [Table]",
        "terseLabel": "Description Of Business Organization And Liquidity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r374",
      "r403",
      "r404",
      "r406",
      "r851"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Summary of Black-Scholes Option-Pricing Model Inputs to Calculate the Fair Value of Warrants",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dividends, Total",
        "label": "Dividends",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r71"
     ]
    },
    "us-gaap_DividendsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends [Axis]",
        "documentation": "Information by event wherein earnings are distributed to shareholder."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1099"
     ]
    },
    "iobt_DividendsDeclared": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "DividendsDeclared",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends declared.",
        "label": "Dividends Declared",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends [Domain]",
        "documentation": "Event wherein earnings are distributed to shareholder."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1099"
     ]
    },
    "iobt_DividendsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "DividendsPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends paid.",
        "label": "Dividends Paid",
        "terseLabel": "Dividends paid"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r133",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r176",
      "r179",
      "r183",
      "r184",
      "r185",
      "r189",
      "r327",
      "r409",
      "r442",
      "r451",
      "r490",
      "r491",
      "r635",
      "r662",
      "r817"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share Basic [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r183",
      "r185"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r133",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r179",
      "r183",
      "r184",
      "r185",
      "r189",
      "r327",
      "r409",
      "r442",
      "r451",
      "r490",
      "r491",
      "r635",
      "r662",
      "r817"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r186",
      "r187",
      "r188"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419",
      "r852"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419",
      "r852"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation costs",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, recognition period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefits for stock-based compensation",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Options to Purchase Common Stock",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r96",
      "r103",
      "r104",
      "r129",
      "r130",
      "r131",
      "r155",
      "r156",
      "r157",
      "r160",
      "r168",
      "r170",
      "r172",
      "r191",
      "r253",
      "r257",
      "r267",
      "r326",
      "r355",
      "r409",
      "r425",
      "r426",
      "r438",
      "r439",
      "r440",
      "r443",
      "r450",
      "r451",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r489",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r538",
      "r540",
      "r558",
      "r658",
      "r677",
      "r678",
      "r679",
      "r699",
      "r765"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r921",
      "r931",
      "r963"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r908",
      "r918",
      "r928",
      "r960"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of warrants",
        "negatedLabel": "Change in fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLevel3FinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r508",
      "r861"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLevel3FinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r508",
      "r861"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assets Measured at Fair Value",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r492",
      "r494",
      "r495",
      "r496",
      "r497",
      "r505",
      "r508",
      "r510",
      "r518",
      "r569",
      "r570",
      "r571",
      "r804",
      "r836",
      "r837",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r861",
      "r864",
      "r871"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r497",
      "r861",
      "r1140",
      "r1145"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r501",
      "r503",
      "r504",
      "r505",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r633",
      "r861",
      "r865"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r357",
      "r362",
      "r364",
      "r494",
      "r508",
      "r518",
      "r569",
      "r804",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r861",
      "r871"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r357",
      "r362",
      "r364",
      "r366",
      "r494",
      "r495",
      "r508",
      "r518",
      "r570",
      "r804",
      "r836",
      "r837",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r861",
      "r871"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r494",
      "r495",
      "r496",
      "r497",
      "r508",
      "r518",
      "r571",
      "r804",
      "r836",
      "r837",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r861",
      "r864",
      "r871"
     ]
    },
    "iobt_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount1",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount",
        "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount1",
        "documentation": "Fair Value Liabilities Level1 To Level2 Transfers Amount1"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount1",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount",
        "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount1",
        "documentation": "Fair Value Liabilities Level2 To Level1 Transfers Amount1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r502",
      "r509"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r497",
      "r861",
      "r1140",
      "r1145"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers into Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r507",
      "r509"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers out of Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r507",
      "r509"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLevel3FinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Issuance of EIB common stock warrants",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r506",
      "r509"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLevel3FinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total",
        "terseLabel": "Change in fair value of EIB common stock warrants",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1144"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfLevel3FinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodStartLabel": "Level 3 financial liabilities, beginning of period",
        "periodEndLabel": "Level 3 financial liabilities, end of period",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r509"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r492",
      "r494",
      "r495",
      "r496",
      "r497",
      "r505",
      "r508",
      "r510",
      "r518",
      "r569",
      "r570",
      "r571",
      "r804",
      "r836",
      "r837",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r861",
      "r864",
      "r871"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1145"
     ]
    },
    "iobt_FairValueOfTrancheBWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "FairValueOfTrancheBWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Tranche B Warrants",
        "documentation": "Fair value of tranche B warrants.",
        "terseLabel": "Fair Value of Tranche B Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r319",
      "r352",
      "r466",
      "r479",
      "r515",
      "r519",
      "r522",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r643",
      "r659",
      "r832",
      "r861",
      "r862",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r875",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1136",
      "r1139",
      "r1140",
      "r1141",
      "r1143",
      "r1145",
      "r1146",
      "r1147"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total",
        "verboseLabel": "Foreign currency loss (gain)",
        "negatedLabel": "Foreign currency loss (gain)",
        "terseLabel": "Currency exchange loss, net",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r524",
      "r525",
      "r526",
      "r527",
      "r762"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Foreign currency (gain) loss",
        "negatedTerseLabel": "Foreign currency loss",
        "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r900",
      "r1149",
      "r1150",
      "r1206"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r925",
      "r935",
      "r967"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r925",
      "r935",
      "r967"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r925",
      "r935",
      "r967"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r925",
      "r935",
      "r967"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r925",
      "r935",
      "r967"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "GB",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "Newport, United Kingdom"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "Total general and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r748"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income tax expense",
        "totalLabel": "Loss before income tax expense",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r82",
      "r84",
      "r636",
      "r638",
      "r655",
      "r812",
      "r814",
      "r816",
      "r820",
      "r825",
      "r1071",
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r274",
      "r276",
      "r462",
      "r463",
      "r464",
      "r465",
      "r499",
      "r502",
      "r509",
      "r521",
      "r522",
      "r523",
      "r672",
      "r674",
      "r749",
      "r803",
      "r804",
      "r853",
      "r854",
      "r859",
      "r860",
      "r863",
      "r871",
      "r1132",
      "r1133",
      "r1174"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r276",
      "r462",
      "r463",
      "r464",
      "r465",
      "r499",
      "r502",
      "r509",
      "r521",
      "r522",
      "r523",
      "r672",
      "r674",
      "r749",
      "r803",
      "r804",
      "r853",
      "r854",
      "r859",
      "r860",
      "r863",
      "r871",
      "r1132",
      "r1133",
      "r1174"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r151",
      "r416",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r430",
      "r432",
      "r433",
      "r434",
      "r642",
      "r688",
      "r697",
      "r852"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "terseLabel": "Income tax expense (benefit)",
        "verboseLabel": "Income taxes expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r91",
      "r146",
      "r171",
      "r172",
      "r190",
      "r204",
      "r211",
      "r417",
      "r418",
      "r431",
      "r663",
      "r812",
      "r814",
      "r816",
      "r852"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "iobt_IncreaseDecreaseInLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "IncreaseDecreaseInLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in lease liability",
        "label": "Increase (Decrease) In Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "terseLabel": "Other noncurrent assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r925",
      "r935",
      "r959",
      "r967",
      "r971",
      "r979"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r907",
      "r983"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r907",
      "r983"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r907",
      "r983"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r202",
      "r211",
      "r825",
      "r1011"
     ]
    },
    "us-gaap_InvestmentIncomeInvestmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInvestmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Investment Expense",
        "terseLabel": "Interest expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of expenses related to the generation of investment income."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r900",
      "r1172"
     ]
    },
    "iobt_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory equipment."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_LaboratoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "LaboratoryMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory",
        "label": "Laboratory [Member]",
        "documentation": "Laboratory [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_LeaseCommencementOnDecemberTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "LeaseCommencementOnDecemberTwoThousandTwentyFourMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Commencement on December Two Thousand Twenty Four [Member]",
        "documentation": "Lease commencement on december two thousand twenty four.",
        "terseLabel": "December 2024"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_LeaseCommencementOnDecemberTwoThousandTwentyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "LeaseCommencementOnDecemberTwoThousandTwentyOneMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Commencement on December Two Thousand Twenty One [Member]",
        "documentation": "Lease commencement on december two thousand twenty one.",
        "terseLabel": "December 2021"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Commencement on January Two Thousand Twenty Three [Member]",
        "documentation": "Lease commencement on january two thousand twenty three.",
        "terseLabel": "January 2023"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_LeaseCommencementOnJuneTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "LeaseCommencementOnJuneTwoThousandTwentyThreeMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Commencement on June Two Thousand Twenty Three [Member]",
        "documentation": "Lease commencement on june two thousand twenty three.",
        "terseLabel": "June 2023"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_LeaseCommencementOnMarchTwoThousandTwentyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "LeaseCommencementOnMarchTwoThousandTwentyOneMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Commencement on March Two Thousand Twenty One [Member]",
        "documentation": "Lease commencement on march two thousand twenty one.",
        "terseLabel": "March 2021"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_LeaseCommencementOnOctoberTwoThousandTwentyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "LeaseCommencementOnOctoberTwoThousandTwentyOneMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 2021",
        "label": "Lease Commencement on October Two Thousand Twenty One [Member]",
        "documentation": "Lease commencement on october two thousand twenty one."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r994"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r994"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Quantitative Information Regarding Leases",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r552"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r552"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Lease Payments (Undiscounted) under Noncancelable Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r1058",
      "r1063",
      "r1170"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r1058",
      "r1063",
      "r1170"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r1058",
      "r1063",
      "r1170"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r1058",
      "r1063",
      "r1170"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r1058",
      "r1063",
      "r1170"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "iobt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfFutureLeasePaymentsUndiscountedUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease liability, to be paid, after year four.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeases1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total liabilities",
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r35",
      "r36",
      "r37",
      "r40",
      "r41",
      "r42",
      "r43",
      "r146",
      "r149",
      "r150",
      "r252",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r457",
      "r460",
      "r461",
      "r520",
      "r723",
      "r819",
      "r840",
      "r902",
      "r1094",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "terseLabel": "Total liabilities, convertible preference shares and stockholders' deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r81",
      "r651",
      "r874",
      "r889",
      "r890",
      "r1057",
      "r1062",
      "r1082",
      "r1148"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r112",
      "r146",
      "r149",
      "r150",
      "r252",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r457",
      "r460",
      "r461",
      "r520",
      "r874",
      "r1094",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total liabilities measured at fair value",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r1137"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Non-current liability",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r40",
      "r41",
      "r42",
      "r43",
      "r146",
      "r149",
      "r150",
      "r252",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r457",
      "r460",
      "r461",
      "r520",
      "r1094",
      "r1160",
      "r1161"
     ]
    },
    "iobt_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional borrowing capacity",
        "label": "Line Of Credit Facility Additional Borrowing Capacity",
        "documentation": "Line of credit facility additional borrowing capacity."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional borrowing capacity ongoing trails",
        "label": "Line Of Credit Facility Additional Borrowing Capacity Ongoing Trails",
        "documentation": "Line of credit facility additional borrowing capacity ongoing trails."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r39",
      "r1057",
      "r1060",
      "r1092",
      "r1093"
     ]
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avaliable amount to draw",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r39"
     ]
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Line of Credit Facility, Expiration Period",
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r39"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r39",
      "r1057",
      "r1060",
      "r1092",
      "r1093"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r1057",
      "r1060",
      "r1092"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan facility",
        "label": "Line of Credit Facility, Maximum Amount Outstanding During Period",
        "documentation": "Maximum amount borrowed under the credit facility at any time during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility, aggregate principal amount",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "verboseLabel": "Aggregate principal amount",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r39"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r39",
      "r284",
      "r1057",
      "r1060",
      "r1092"
     ]
    },
    "iobt_LoanFacilityWithEuropeanInvestmentBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "LoanFacilityWithEuropeanInvestmentBankMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EIB Loan Facility",
        "label": "Loan Facility With European Investment Bank [Member]",
        "documentation": "Loan facility with european investment bank."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_Long-TermDebtMaturityMinimumPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "Long-TermDebtMaturityMinimumPayment",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum payments",
        "label": "Long-Term Debt, Maturity, Minimum Payment",
        "documentation": "Long-term debt, maturity, minimum payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, current",
        "label": "Long-Term Debt, Current Maturities",
        "totalLabel": "Long-Term Debt, Current Maturities, Total",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails": {
       "parentTag": "iobt_Long-TermDebtMaturityMinimumPayment",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r147",
      "r154",
      "r312",
      "r640"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails": {
       "parentTag": "iobt_Long-TermDebtMaturityMinimumPayment",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2030",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r147",
      "r154",
      "r312",
      "r640"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails": {
       "parentTag": "iobt_Long-TermDebtMaturityMinimumPayment",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2029",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r147",
      "r154",
      "r312",
      "r640"
     ]
    },
    "iobt_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails": {
       "parentTag": "iobt_Long-TermDebtMaturityMinimumPayment",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2031",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Six",
        "documentation": "Long term debt maturities repayments of principal in year six."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails": {
       "parentTag": "iobt_Long-TermDebtMaturityMinimumPayment",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r147",
      "r154",
      "r312",
      "r640"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails": {
       "parentTag": "iobt_Long-TermDebtMaturityMinimumPayment",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r147",
      "r154",
      "r312",
      "r640"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails": {
       "parentTag": "iobt_Long-TermDebtMaturityMinimumPayment",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remainder of 2025",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1063"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfFutureUndiscountedMinimumPrincipalAndInterestPaymentsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfTermLoanDebtNetDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, noncurrent",
        "totalLabel": "Total term loan debt",
        "verboseLabel": "Term loan debt, net",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "stpr_MD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "MD",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MARYLAND",
        "terseLabel": "Rockville, Maryland"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ManagementMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "Management"
       }
      }
     },
     "auth_ref": [
      "r1077",
      "r1158"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r279",
      "r280",
      "r281",
      "r282",
      "r368",
      "r398",
      "r399",
      "r400",
      "r413",
      "r497",
      "r597",
      "r671",
      "r673",
      "r687",
      "r715",
      "r716",
      "r771",
      "r773",
      "r775",
      "r776",
      "r778",
      "r786",
      "r787",
      "r789",
      "r790",
      "r801",
      "r802",
      "r831",
      "r841",
      "r850",
      "r853",
      "r855",
      "r856",
      "r864",
      "r865",
      "r869",
      "r870",
      "r885",
      "r1096",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r279",
      "r280",
      "r281",
      "r282",
      "r368",
      "r398",
      "r399",
      "r400",
      "r413",
      "r497",
      "r597",
      "r671",
      "r673",
      "r687",
      "r715",
      "r716",
      "r771",
      "r773",
      "r775",
      "r776",
      "r778",
      "r786",
      "r787",
      "r789",
      "r790",
      "r801",
      "r802",
      "r831",
      "r841",
      "r850",
      "r853",
      "r855",
      "r856",
      "r864",
      "r865",
      "r869",
      "r885",
      "r1096",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1100",
      "r1101"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "stpr_NY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "NY",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York, New York",
        "label": "NEW YORK"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net losses",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r61",
      "r83",
      "r104",
      "r110",
      "r125",
      "r127",
      "r131",
      "r146",
      "r149",
      "r150",
      "r153",
      "r159",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r181",
      "r252",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r327",
      "r330",
      "r333",
      "r338",
      "r409",
      "r442",
      "r451",
      "r491",
      "r520",
      "r657",
      "r745",
      "r763",
      "r764",
      "r812",
      "r814",
      "r816",
      "r900",
      "r1094"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to class A ordinary shareholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common shareholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r134",
      "r164",
      "r165",
      "r166",
      "r167",
      "r176",
      "r177",
      "r182",
      "r185",
      "r330",
      "r333",
      "r338",
      "r451"
     ]
    },
    "iobt_NetProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "NetProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Proceeds From Issuance Of Private Placement",
        "label": "Net Proceeds From Issuance Of Private Placement",
        "documentation": "Net proceeds from issuance of private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r925",
      "r935",
      "r959",
      "r967"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "iobt_NoncashInterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "NoncashInterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Noncash Interest Expense Debt",
        "documentation": "Noncash interest expense debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income",
        "verboseLabel": "Other (expense) income"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_NumberOfOperatingLease": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "NumberOfOperatingLease",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Operating Lease",
        "documentation": "Number of operating lease.",
        "terseLabel": "Number of operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r1072"
     ]
    },
    "iobt_NumberOfVotePerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "NumberOfVotePerShare",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of vote per share.",
        "label": "Number Of Vote Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_O2024Q3DividendsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "O2024Q3DividendsMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "O 2024 Q3 Dividends",
        "documentation": "O 2024 Q3 Dividends.",
        "label": "O 2024 Q3 Dividends [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_O2025Q1DividendsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "O2025Q1DividendsMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "O 2025 Q1 Dividends [Member]",
        "documentation": "O 2025 Q1 Dividends.",
        "terseLabel": "O 2025 Q1 Dividends"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_OfficeAndLaboratoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "OfficeAndLaboratoryMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Laboratory.",
        "label": "Office and Laboratory [Member]",
        "terseLabel": "Office and Laboratory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_OfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "OfficeMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office",
        "label": "Office [Member]",
        "documentation": "Office [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r812",
      "r816",
      "r820",
      "r1071",
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "iobt_OperatingLeaseAmendedBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "OperatingLeaseAmendedBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease amended base rent",
        "documentation": "Operating lease amended base rent.",
        "label": "Operating Lease Amended Base Rent"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_OperatingLeaseAnnualBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "OperatingLeaseAnnualBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease annual base rent.",
        "label": "Operating lease annual base rent",
        "terseLabel": "Annual base rent"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_OperatingLeaseCommencementMonthYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "OperatingLeaseCommencementMonthYear",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Commencement Month Year",
        "documentation": "Operating lease commencement month year.",
        "terseLabel": "Lease term expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r873"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liability - current",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liability - noncurrent",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease, liability, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows paid for amounts included in the measurement of lease liabilities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r546"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use lease asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Amortization of right of use lease asset",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "iobt_OperatingLeaseTermExpirationMonthYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "OperatingLeaseTermExpirationMonthYear",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Term Expiration Month Year",
        "documentation": "Operating lease term expiration month year.",
        "terseLabel": "Lease commencement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r873"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Remaining average lease term (years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r873"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business, Organization and Liquidity",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r105",
      "r106",
      "r108",
      "r689",
      "r690"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "totalLabel": "Total non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r10",
      "r76"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "terseLabel": "Foreign currency translation",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r658"
     ]
    },
    "iobt_OtherCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "OtherCostsMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Costs [Member]",
        "documentation": "Other costs.",
        "terseLabel": "Other costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1083"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r923",
      "r933",
      "r965"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r916",
      "r926",
      "r936",
      "r968"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r916",
      "r926",
      "r936",
      "r968"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Paid-in-kind interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of debt issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "iobt_PaymentsOfStockAndWarrantIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "PaymentsOfStockAndWarrantIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of stock and warrant issuance costs.",
        "label": "Payments Of Stock And Warrant Issuance Costs",
        "terseLabel": "Issuance of common shares and warrants in private placement, net of issuance costs of $3,188",
        "negatedLabel": "Common shares and warrants issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Offering expenses",
        "negatedLabel": "Common shares issuance costs",
        "terseLabel": "Common shares issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "iobt_PercentageOfAmountDisbursedUnderFinanceContract": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "PercentageOfAmountDisbursedUnderFinanceContract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Amount Disbursed Under Finance Contract",
        "documentation": "Percentage of amount disbursed under finance contract.",
        "terseLabel": "Percentage of amount disbursed under finance contract"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PercentageOfContributionsToCorporationsTaxableIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "PercentageOfContributionsToCorporationsTaxableIncome",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of contributions to corporation's taxable income",
        "label": "Percentage Of Contributions to Corporation's Taxable Income",
        "documentation": "Percentage of contributions to corporation's taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "PercentageOfIncomeTaxProvisionForExpensingCertainBusinessPropertyAfterDeductionForDomesticResearchAndDevelopmentExpenditures",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Income Tax Provision For Expensing Certain Business Property After Deduction For Domestic Research And Development Expenditures",
        "terseLabel": "Percentage of income tax provision for expensing certain business property after deduction for domestic research and development expenditures",
        "documentation": "Percentage of income tax provision for expensing certain business property after deduction for domestic research and development expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Prepayment Fee on Repayment of Tranche After Third Anniversry of Disbursement",
        "documentation": "Percentage of prepayment fee on repayment of tranche after third anniversry of disbursement.",
        "terseLabel": "Percentage of prepayment fee on repayment of tranche after third anniversry of disbursement"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of prepayment fee on repayment of tranche within twelve months of disbursement",
        "label": "Percentage of Prepayment Fee on Repayment of Tranche Within Twelve Months of Disbursement",
        "documentation": "Percentage of prepayment fee on repayment of tranche within twelve months of disbursement."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PeriodForSatisfyingConditions": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "PeriodForSatisfyingConditions",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period for satisfying conditions",
        "label": "Period for Satisfying Conditions",
        "documentation": "Period for satisfying conditions."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PersonnelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "PersonnelMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel [Member]",
        "documentation": "Personnel.",
        "terseLabel": "Personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "iobt_PreclinicalStudiesAndActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "PreclinicalStudiesAndActivitiesMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preclinical Studies And Activities [Member]",
        "documentation": "Preclinical studies and activities.",
        "terseLabel": "Preclinical Studies and Activities",
        "verboseLabel": "Preclinical studies and activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredClassBMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Class B [Member]",
        "terseLabel": "Class B Preference Shares",
        "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_PreferredClassCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "PreferredClassCMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred class c.",
        "label": "Preferred Class C [Member]",
        "terseLabel": "Class C Preference Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r340"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock shares authorized",
        "verboseLabel": "Preferred stock, shares authorized",
        "terseLabel": "Preference shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r725"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "terseLabel": "Preference shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r340"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "terseLabel": "Preference shares outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r725",
      "r743",
      "r1207",
      "r1208"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value of $0.001 per share; 5,000,000 shares authorized, no shares issued and outstanding as of June 30, 2025 and December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r329",
      "r335",
      "r647",
      "r874"
     ]
    },
    "iobt_PrepaidContractResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "PrepaidContractResearchAndDevelopmentCostsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid contract research and development costs current.",
        "label": "Prepaid Contract Research And Development Costs Current",
        "terseLabel": "Prepaid contract research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "iobt_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r833",
      "r1083"
     ]
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid income taxes",
        "label": "Prepaid Taxes",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r834",
      "r1083"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from IPO, after deducting underwriting discounts, commissions and offering costs",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from the issuance of debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Issuance of Warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r598",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r805",
      "r811",
      "r814",
      "r816",
      "r842",
      "r843",
      "r884",
      "r885",
      "r886",
      "r888",
      "r891",
      "r993",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1090",
      "r1091",
      "r1173",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r598",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r805",
      "r811",
      "r814",
      "r816",
      "r842",
      "r843",
      "r884",
      "r885",
      "r886",
      "r888",
      "r891",
      "r993",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1090",
      "r1091",
      "r1173",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202"
     ]
    },
    "iobt_ProfessionalServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "ProfessionalServicesMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Services [Member]",
        "terseLabel": "Professional Services",
        "documentation": "Professional services.",
        "verboseLabel": "Professional services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r110",
      "r125",
      "r127",
      "r141",
      "r146",
      "r149",
      "r150",
      "r153",
      "r159",
      "r168",
      "r171",
      "r172",
      "r252",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r327",
      "r409",
      "r442",
      "r451",
      "r455",
      "r458",
      "r459",
      "r491",
      "r520",
      "r636",
      "r638",
      "r656",
      "r698",
      "r745",
      "r763",
      "r764",
      "r857",
      "r858",
      "r901",
      "r1010",
      "r1094"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r551"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r88",
      "r89",
      "r90"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r114",
      "r654"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r551",
      "r641",
      "r654",
      "r874"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r551"
     ]
    },
    "iobt_PurchasePricePerShareOfCommonStockAndWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "PurchasePricePerShareOfCommonStockAndWarrant",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share of common stock and warrant",
        "label": "Purchase Price Per Share of Common Stock and Warrant",
        "documentation": "Purchase price per share of common stock and warrant."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r279",
      "r280",
      "r281",
      "r282",
      "r356",
      "r368",
      "r398",
      "r399",
      "r400",
      "r406",
      "r413",
      "r497",
      "r572",
      "r581",
      "r597",
      "r671",
      "r673",
      "r687",
      "r715",
      "r716",
      "r771",
      "r773",
      "r775",
      "r776",
      "r778",
      "r786",
      "r787",
      "r789",
      "r790",
      "r801",
      "r802",
      "r831",
      "r841",
      "r850",
      "r853",
      "r855",
      "r856",
      "r864",
      "r865",
      "r869",
      "r870",
      "r885",
      "r894",
      "r1088",
      "r1096",
      "r1140",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r279",
      "r280",
      "r281",
      "r282",
      "r356",
      "r368",
      "r398",
      "r399",
      "r400",
      "r406",
      "r413",
      "r497",
      "r572",
      "r581",
      "r597",
      "r671",
      "r673",
      "r687",
      "r715",
      "r716",
      "r771",
      "r773",
      "r775",
      "r776",
      "r778",
      "r786",
      "r787",
      "r789",
      "r790",
      "r801",
      "r802",
      "r831",
      "r841",
      "r850",
      "r853",
      "r855",
      "r856",
      "r864",
      "r865",
      "r869",
      "r870",
      "r885",
      "r894",
      "r1088",
      "r1096",
      "r1140",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r908",
      "r918",
      "r928",
      "r960"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r152",
      "r153",
      "r221",
      "r363",
      "r367",
      "r559",
      "r560",
      "r645",
      "r652",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r742",
      "r770",
      "r1205"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related Party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r152",
      "r153",
      "r559",
      "r560",
      "r561",
      "r562",
      "r645",
      "r652",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r742",
      "r770"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r152",
      "r153",
      "r221",
      "r363",
      "r367",
      "r559",
      "r560",
      "r645",
      "r652",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r742",
      "r770",
      "r1159",
      "r1205"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Total research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r803",
      "r812",
      "r813",
      "r825",
      "r1168"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ResearchAndDevelopmentTaxCreditReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "ResearchAndDevelopmentTaxCreditReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credit receivable current.",
        "label": "Research And Development Tax Credit Receivable Current",
        "terseLabel": "Research and development tax credit receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r909",
      "r919",
      "r929",
      "r961"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r920",
      "r930",
      "r962"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r917",
      "r927",
      "r937",
      "r969"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "totalLabel": "Restricted Cash, Total",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1056",
      "r1169",
      "r1171"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r1004",
      "r1056"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r71",
      "r650",
      "r681",
      "r686",
      "r696",
      "r726",
      "r874"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r103",
      "r104",
      "r155",
      "r156",
      "r157",
      "r160",
      "r168",
      "r170",
      "r172",
      "r253",
      "r257",
      "r267",
      "r326",
      "r409",
      "r425",
      "r426",
      "r438",
      "r439",
      "r440",
      "r443",
      "r450",
      "r451",
      "r469",
      "r471",
      "r472",
      "r474",
      "r489",
      "r538",
      "r540",
      "r677",
      "r679",
      "r699",
      "r1207"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQuantitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r873"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement",
        "label": "Sales Agreement [Member]",
        "documentation": "Sales agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r109",
      "r174",
      "r369",
      "r991"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Term Loan Debt, Net",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r28",
      "r29",
      "r32",
      "r68",
      "r70",
      "r836",
      "r838",
      "r1058",
      "r1063",
      "r1152",
      "r1170"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "terseLabel": "Schedule Of Earnings Per Share Basic By Common Class [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r183",
      "r185"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationScheduleOfEquityBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Equity-based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Undiscounted Minimum Principal and Interest Payments",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r551"
     ]
    },
    "iobt_ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Qualitative Information Regarding Leases",
        "label": "Schedule of Qualitative Information Regarding Leases [Table Text Block]",
        "documentation": "Schedule of Qualitative Information Regarding Leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Expenses by Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r72"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r406"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assumptions for Estimated Fair Value of Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrants Issued and Outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "iobt_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities purchase agreement.",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r216",
      "r217",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r636",
      "r637",
      "r638",
      "r639",
      "r712",
      "r713",
      "r714",
      "r772",
      "r774",
      "r777",
      "r779",
      "r786",
      "r788",
      "r789",
      "r790",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r806",
      "r818",
      "r842",
      "r844",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r887",
      "r894",
      "r1173",
      "r1175",
      "r1176",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r824",
      "r830"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r190",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r218",
      "r821",
      "r822",
      "r823",
      "r825",
      "r827",
      "r828",
      "r829"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Expense Information Used by CODM, Description",
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r207",
      "r211"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]",
        "documentation": "Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r207",
      "r211"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Exercisable",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Exercisable",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercisable intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term (in years), Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Cancelled or forfeited",
        "negatedLabel": "Number of Warrants, Cancelled or forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price per share, Cancelled or forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Warrants, Granted",
        "terseLabel": "Number of warrants granted transferred to plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average exercise price per share, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Warrants, Beginning balance",
        "periodEndLabel": "Number of Warrants, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average exercise price per share, Ending balance",
        "periodStartLabel": "Weighted-average exercise price per share, Beginning balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted-average remaining contractual term (in years), Outstanding",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of warrants available for future grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Maximum percentage of shares that may be issued under the plan as a proportion of outstanding capital stock",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "iobt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award equity instruments other than options exercisable in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Equity Instruments Other Than Options Exercisable In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price per share, Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock shares sold, price per share",
        "label": "Share Price",
        "terseLabel": "Share price of common stock",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate intrinsic value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfAssumptionsForEstimatedFairValueOfOptionsDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfBlackscholesOptionpricingModelInputsToCalculateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r120",
      "r121",
      "r122",
      "r146",
      "r150",
      "r179",
      "r180",
      "r183",
      "r185",
      "r192",
      "r193",
      "r252",
      "r285",
      "r287",
      "r288",
      "r289",
      "r292",
      "r293",
      "r328",
      "r329",
      "r331",
      "r332",
      "r334",
      "r337",
      "r340",
      "r341",
      "r343",
      "r346",
      "r354",
      "r520",
      "r692",
      "r693",
      "r694",
      "r695",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r725",
      "r746",
      "r765",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r990",
      "r1059",
      "r1061",
      "r1069"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r45",
      "r48",
      "r49",
      "r96",
      "r103",
      "r104",
      "r129",
      "r130",
      "r131",
      "r155",
      "r156",
      "r157",
      "r160",
      "r168",
      "r170",
      "r172",
      "r191",
      "r253",
      "r257",
      "r267",
      "r326",
      "r355",
      "r409",
      "r425",
      "r426",
      "r438",
      "r439",
      "r440",
      "r443",
      "r450",
      "r451",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r489",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r538",
      "r540",
      "r558",
      "r658",
      "r677",
      "r678",
      "r679",
      "r699",
      "r765"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureLeasesScheduleOfQualitativeInformationRegardingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r216",
      "r217",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r636",
      "r637",
      "r638",
      "r639",
      "r712",
      "r713",
      "r714",
      "r772",
      "r774",
      "r777",
      "r779",
      "r786",
      "r788",
      "r789",
      "r790",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r806",
      "r818",
      "r842",
      "r844",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r887",
      "r894",
      "r1173",
      "r1175",
      "r1176",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r191",
      "r328",
      "r329",
      "r331",
      "r334",
      "r540",
      "r598",
      "r691",
      "r700",
      "r711",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r725",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r747",
      "r748",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r765",
      "r814",
      "r816",
      "r895",
      "r1205"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r109",
      "r174",
      "r369",
      "r991",
      "r992"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r191",
      "r221",
      "r328",
      "r329",
      "r331",
      "r334",
      "r540",
      "r598",
      "r691",
      "r700",
      "r711",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r725",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r747",
      "r748",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r765",
      "r814",
      "r816",
      "r895",
      "r1205"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r912",
      "r922",
      "r932",
      "r964"
     ]
    },
    "iobt_StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "StockAndWarrantIssuedDuringPeriodSharesIssuedForPrivatePlacement",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock and warrant issued during period shares issued for private placement.",
        "label": "Stock And Warrant Issued During Period Shares Issued For Private Placement",
        "terseLabel": "Issuance of common shares and warrants in private placement, net of issuance costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "StockAndWarrantIssuedDuringPeriodValueIssuedForPrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock and warrant issued during period value issued for private placement.",
        "label": "Stock And Warrant Issued During Period Value Issued For Private Placement",
        "terseLabel": "Issuance of common shares and warrants in private placement, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common shares , net of issuance costs",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r44",
      "r45",
      "r71",
      "r692",
      "r765",
      "r781"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stockholders' deficit",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r48",
      "r49",
      "r62",
      "r727",
      "r743",
      "r766",
      "r767",
      "r874",
      "r902",
      "r1057",
      "r1061",
      "r1062",
      "r1082",
      "r1148",
      "r1207"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r353",
      "r355",
      "r466",
      "r480",
      "r768",
      "r769",
      "r785"
     ]
    },
    "iobt_StrikePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "StrikePricePerShare",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityScheduleOfWarrantsIssuedAndOutstandingDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strike Price Per Share",
        "documentation": "Strike price per share.",
        "terseLabel": "Strike price per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r564"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r564"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r564"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r564"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r564"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r565"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1077",
      "r1158"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSegmentsScheduleOfExpensesBySegmentDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r319",
      "r352",
      "r466",
      "r479",
      "r515",
      "r519",
      "r522",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r643",
      "r659",
      "r861",
      "r862",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r875",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1136",
      "r1139",
      "r1140",
      "r1141",
      "r1143",
      "r1145",
      "r1146",
      "r1147"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "iobt_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Employee Stock Purchase Plan",
        "label": "Two Thousand And Twenty One Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand and twenty one employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TwoThousandAndTwentyOneEquityAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "TwoThousandAndTwentyOneEquityAndIncentivePlanMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Equity and Incentive Plan",
        "label": "Two Thousand And Twenty One Equity And Incentive Plan [Member]",
        "documentation": "Two thousand and twenty one equity and incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TwoThousandTwentyFourEIBTermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "TwoThousandTwentyFourEIBTermLoanFacilityMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Four EIB Term Loan Facility [Member]",
        "documentation": "Two Thousand Twenty Four EIB Term Loan Facility.",
        "terseLabel": "2024 EIB Term Loan Facility"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_TwoThousandTwentyThreeInducementIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "TwoThousandTwentyThreeInducementIncentivePlanMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureEquityBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2023 Inducement Incentive Plan",
        "label": "Two Thousand Twenty Three Inducement Incentive Plan [Member]",
        "documentation": "Two thousand twenty three inducement incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "iobt_UnauditedFinancialInformationPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "UnauditedFinancialInformationPolicyPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited financial information, policy.",
        "label": "Unaudited Financial Information Policy Policy [Text Block]",
        "terseLabel": "Unaudited Financial Information"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Agreement [Member]",
        "documentation": "Underwriting agreement."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_UndesignatedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "UndesignatedPreferredStockMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undesignated preferred stock.",
        "label": "Undesignated Preferred Stock [Member]",
        "terseLabel": "Undesignated Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValueAddedTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "Value-added tax refund receivable",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "iobt_WarrantIssuanceAgreementAndFinanceContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "WarrantIssuanceAgreementAndFinanceContractMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureTermLoanFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Issuance Agreement and Finance Contract [Member]",
        "documentation": "Warrant Issuance Agreement and Finance Contract.",
        "terseLabel": "Warrant Issuance Agreement and Finance Contract"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_WarrantLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "WarrantLiabilitiesMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liabilities [Member]",
        "documentation": "Warrant liabilities.",
        "terseLabel": "Warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockOptionsActivityDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsMeasuredAtFairValueDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants Issued in Private Placement",
        "label": "Warrant",
        "terseLabel": "Stock Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r892",
      "r893",
      "r896",
      "r897",
      "r898",
      "r899"
     ]
    },
    "iobt_WarrantsExercisablePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "WarrantsExercisablePricePerShare",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Price of Common Stock and Warrants",
        "label": "Warrants Exercisable Price Per Share",
        "documentation": "Warrants exercisable price per share."
       }
      }
     },
     "auth_ref": []
    },
    "iobt_WarrantsExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "WarrantsExercisePricePerShare",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Exercise Price Per Share",
        "documentation": "Warrants exercise price per share.",
        "terseLabel": "Warrants exercise price per share"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_WarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "WarrantsIssued",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureDescriptionOfBusinessOrganizationAndLiquidityAdditionalInformationDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued",
        "label": "Warrants Issued",
        "documentation": "Warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_WarrantsIssuedToTheEuropeanInvestmentBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "WarrantsIssuedToTheEuropeanInvestmentBankMember",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued to the European Investment Bank [Member]",
        "documentation": "Warrants issued to the european investment bank.",
        "terseLabel": "Warrants Issued to the European Investment Bank"
       }
      }
     },
     "auth_ref": []
    },
    "iobt_WarrantsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.iobiotech.com/20250630",
     "localname": "WarrantsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Policy [Policy Text Block]",
        "documentation": "Warrants Policy .",
        "terseLabel": "Warrants Issued in Connection with a Sale of Common Stock or Issuance of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares used in computing net loss per common share, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r185"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.iobiotech.com/20250630/taxonomy/role/Role_DisclosureNetLossPerShareBasicAndDilutedNetLossPerOrdinaryShareDetails",
      "http://www.iobiotech.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares used in computing net loss per common share, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r185"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2G",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2G",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-15"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001193125-25-180860-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-180860-xbrl.zip
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MQB:Q6G!:6U'EM!290CB-X!<$X 0%!4_#$/Q&<"$(P1#(=QHD" () ($"@F
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M:4$J$BE/5I27,C%&F\C35&>E)JAIHZ2I($EQ$!)0D5EC"%16%T1K:\F:8[6
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M_5AC^-V]_]7'&L/_(#_M-8;_07XZ7X;-?XZ?U1K#_R"_?T#Y!Y1_0/D'E']
M^0>4?T#Y!Y3_'T$1$ "IBHE]W9=^V73^::_];X0^_G(S+[H6I!-&$2SPQ-7X
MHY0YUMI:W))")ANM1H'6*/]<_B=Z90K1F&B!-9<FXZBK@4BDM#B52L0+0R$R
M4#!"$ J'2LD"@;0M&%0&) V'PZ1D)*0DA01AO_'_ ?V?VOBFC':#'T]CCX7
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M6SG/*4NISG&"G/3*JDS?CCU6BV'9[C7P^JE/UYFY0B#E,;RTYBYZLL=>4DR
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M%;I2J;19Y[@5NHS,%;KWQ<L-?7,=4RMT>;DK="/J*W3PH736LP9GLNN#->R
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MWWI5=5/1R9%1\&/2&:8&)PY_O7WC63G/TA\EH!OO"R>88SS?:S./]$9T8"L
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MG56$9PB@GM^.G*PM6.PWOO>2Z>L@VMH<#.)T1JH-57COV':\MBH4BAN5=3_
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M]K:/5.HH5:=E/\L(_##"*[+;)YXL'RJ,&Z&V,!C%),H:SWO&'G*%G[.I5_%
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MAD:(2SB9JYGE=2/MHTQM/%]HI4:E!SR]9IW"J-HF16(./ A7(4V6?V:[.1;
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M.:G8M71$PCP[NDOQ%[VD/>;:)%(+/@#59G$9<;<AI#%-0Q.)Y'0WCVZT  ]
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MA5'"L5@Y+ET3E0EB<(A5I:31;-$CT&BG+"N)M"4Z(F::E.?D.<L_?E+HPPT
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M@NR:#8X5@4#JDB'?+O!:$DU&HT7<0B7>\C%U7&N7#/LP[1X+]Y)+FM_7ZAM
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M<L#YA_'X8)2U/O@)=PPTF@*/>.+OMT&=\,Q!C*O0H2>*0Z+0!?O'(*=L>,]
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MLK_'7DZ3?W[,TM\I":]X,+$*,&7?5W> W!0K$DTU=O/4]Y6Q6GO3#=I)V^
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MJ:<<[IJ]N=_^O2AR)/9'#[49F]\9-!4!<)I\=^V_>>!1\3VVL:'7/D;=*24
MOKK/3?BS%(/-G]EG@0*/KVKY]29Z]54[7(M.>'6B@=>D%A68[7U!5G[FQT2:
MB!#^D1.FF$+';1!LD]#<@;E]'6V_ J\9KB(H&LB_N_>= 5(K(OW@:U>"%\=X
M_K,0O%GOQJSF'SK,._^BW$^_-=Y>?!TU>RW>:H!LBXQV,E\]8LDHQY^^IT;
MESR B6/]X.ENEB>NDL#.K2WV4\W&T 4EW<HU;W9[.>_H3/'ZW@-)@-0.O_^%
M%!!D@Y-.TPNZG^EXB_2'+IMX.C(T($C'*":B0=,U^9::#_2W^TMIG7A>[/L^
MU6SD\^3(B^]%1*Z_?[SMY1$85WTD/*D0-E^(3"T/KJZ-DR!DV7@'"Z!4Y]^F
MNM^.LO%(1M?75B,Y[4^S+ZB^]^ZJ)PI#$T%K4QJ39Z*J$_ 3JUJ+LR,,1%LE
MJ?J_B!'_4^:4.L\[0L<V,U3N20U08Z=HS'*Q1VN&U]',4='[.]M$B%#&DM5^
MV3ZK*>7Q@518]3K,/L(J8$4U8$*KY-IK_UNXN.#7]&LCQDK1'==C;J<(,#.^
MJAYEN*X P@E^ZVGZ43,)=='X\8_7+GSTJ??4@*C_A*DP52K@HVID-#-']&+^
MZ-[YM!F!O!X_24Y@5C8>PT#WUFOK7K#TNLP UVIK0"Z.W #QR(V-IG5OD[G>
MH>H,[I;]+.X(.U4M[YD9O(%QU^CH$_*O!DPM..XF:!/WMJU-;-#H_Z@IK5*S
M>VCS6FCF-)4,>!PQ]+2B8EN'0FML1:W'WD4YP=#S_?5>\YS$GL>LQ(LE94%>
M_$ L/IVX)NO*X6#78*[M8'Y9C[33>VP%(K=B"[_J6^2K+K1VK\@"BLH(F("7
MQJ9'.8TW DEQO$_$'J9L0:/[%@,BWQE:B,EIF<;HIR_A'"4;(;P%AX=*H6T"
M 'MM-N/FOM8($AVL:-L B!)DJ218%3)/JREG;,F,D1%YTKHO-";:5\H/N9R>
M@\0F]5MEGZJX[B^!,:$<T;]'$1"U7'R?[A^?6UA!^@!I(DA3_78-:GBK9M8U
M1#Y9?>%KS&)C?<JFU1!KW*<D!U2^KO=D/>)R=)%;X2^.E#"E-.]#<F(8>3_-
M^?' (&9 W>4X1K!J8>50A3PUR[^!9MG-*EJ1ZQU8C!&B.VO/7C?H6#6I[RT0
M;._EXVR+/?%*%G[CA9Q+4/*_3UP 7U&!2LXFCNTWMLV! _!$;;O<M?K"\+UQ
MHPNJ)8C]'0'BPT" -6+&9G)H].J)SD(^CC>4U])L#8SYY86TXO<WYU/W,'MN
M3[ILH:6B_6G6*MA"3EJQV@9^<GB4)I;=XL5ZU#1NIS=TCQ2M,\V&%Q0="--X
M(3RDTNCAW:@K9JYQ_O2MDQD-W40GQ@7#\VF!=JRY9V-7B:K.S8<%F72D[E,6
M-^+'WDB>T_'?[I;][_(0*>FYWMQA4"+%HH9*C:,2])@\_D;O#88B7UE7%W:#
M8)VDP,3X0@ _ T_.GV.42NS"7XV,F1\?Q7\EB[=UM+SN3CLY\XHEF93*$^K.
M1_'G"/:-;)UX&[_;H*!J)\PR4F<]"47.#P0)L'-\3/1:^_5X_C"$;B(/.%ZT
M Q/J]&U@NK@EJZ)%@O8/F $'(G6SSCD8X 2[[[5%<USNV9G' "M==X$+AWB:
M)3FZJ)NOGNH"J^/^4O?(OK!P]XT@\LW4I%XK.-S97,'ZE]!9Z&-94M-'(1"Q
MH=QY0$P?= 4_BE]VP&V/Y0.>(-@*QB);F<I5G)FP]!_\,C_\+Y&!"GMI=+'[
MQ^99L$=]1.0LYA9C7-X\YFU2Y2C@BJ[OTX>6.6T4M+ ()#,(@+\5W!$4& C1
MJ5#BPF9]91IFQK_Y#HT?>;B-"*W!5^.,.IV%7BVD+^9G&GB8?VS)C\KGY:)_
M69]!K,<^%8BT\.9YG+#V"F2M9!V]GH3N#)6!6T[QF09!5&':[#UZ0C@2.H")
MA8Z*6B&A"FK%;(E"2OQ3L;IN[GAAKT7*^-AXW\\8CD2.OAB[VHD@<'Y67K7@
MD+3T4-5T&(_:8Q=;.6^7];9/';65U/RLKQ(HQQO;>P08&8PU_D@T6_TO+BZC
M,6ZG*<I@T["RMY+?B6TKAYP'S-Z&K0JF!DRQY 3!Z,N_G 1326JKYBO1\&1^
M1%QD-.OG;DVF4Y22NFQY42LY&9H8CY5B-4A0 ,TA-[YQSW_#DBXFW=1ZWOW*
M-V5+^)0\GDE_9L*P(TZZONL77&)'K?92'W1Z=$7%W%XNIA;QQDZ D9&1I@L8
MG)@]"_>AFHQ+5A2("AYUACS(2)RZ)V\9(!NPX"?S0<P;6RO&D6-J0^R;2BU%
M[,O\_G1#CAE@@HHB:(9I%/]4X6_::U,/,$$;308+[UL^S70_9%GDJ':N&71)
MYP9DGZ :FZR[&A:..1WN")S9YCQ**_4*)R>W9=Y=ETWX:39TOY0/<P2G8[($
MHDRA=<Y$.<:;+XL9TF/7=9TF![YB "RLK2X=:<9&$84JI8+3I5*DJO[D8U'O
MX+&=N/J:QMSBV2&!W+/\N)NX$"FV(L>]@Q)( Z3/-1\D/HZDV0V1BK'S?59%
M%S3P'V;WP.[K]6\TF9O/-$^D*']31L7)(N=,4+96^0QAABM2:P#]25=8YR=@
M/O,# ,?5AJTAYN%"TL9'8$+40%4445&FXX&7.H;$R.J2(GVI=F!(Z].&]P2H
M$R&\G9_G),_8ST/''+7"@CW:_;K8+?U,0#=MKHH:YDJ2E^*]GY6HRS]OP_CV
MCD @>I?&\)RENZL1%'Z54*J,<X]01.54[^20F:8="AW8S[-]U\VLS$ =2C6F
M4+SP44UX/4_4P 1HO",0OR/ PT?H7<5])>NMNQ(^XR]BX/_7?=V,.<>V1[RW
MZW8.E]K=:BY/UIZQ E6G1=4%I>$U>KQZ?<_'9[<&W-F-.5_]-I(G1JI^'<Z=
M*"O4W"$\)30/7;F@+&D^,QOI/;>Z5;PC(-SQ@0GKXS?K6VK'O//,Z'>7&H[,
M%A2<_06Q4/@(ADF6=L,T=K=B37"5N'QEQAOU*2_=>C+1SB7?V) 96CL[:I6;
M3!*/DB-/ 9?H9:/ ^4&37MVL]U/N"&C$J+Z5_OQU97X*GWCDTJXU+O.F!GG9
MP$C=SN'22^B_2;X:E>*DRSD'DVX.N"-H__I2SY.86+0N=IC.*4_]<C!^?C:#
M1\%6!'TC)33RLMX=O"J@9C'0\Q]8O+KN:>9TN2- &F@G$;\6"A6J8!N-D $@
M;%^NKGEU%*I >0U6Q-3N=_:X^%(\3B2=#V%.\'[,)+$PDT(\8YT$LI[P@XC#
M@\^6"X^$"DMUO 2(2MN%<I;,1F.4';I-O%:9\WCCOVTQ- WPXE:M5HIJ^B^L
M,RNJ[+Y $/1 AT*LUT8@;8Y0<FO6T%.A:1!@10>\Q_F+EH>PHN+N$ G5'E&-
M_Y9.6X8M\;. .1>7S=AD'L<I!DZBQ?7Y02[[M5-)Y<"<5(!)I!'#Y;5D2:ST
M[&BJI]RZJS-T&%,E98E4.  6"JC]:(=-0A^-C5I[#YGG<7.F,\?7L/#/Q^[H
M &3'%159<%-Z4^XWQH9=:.E7U5=>]"\X\0V<#53-]]?%1HM;F:84Q:>HOL!^
M.Z'[E[NE^>\(HB4)UU%O2U8[OLS:LO>QDU\EIV9,*VD(88K\>%_P#P5X!A2\
MVEF7VT)SO/1<,Q!5UA*B[:2PZUK<N/0PIG'<Z1(XTTN6*:H^;J0@Y+]T5$C9
M^-;6%8TF!F]]7$]H=6-9_)F9HIVWAE$3$F9_K&%NHS(_8Z)/A5RH;*>M[L9*
M/IS5XGYJ,B>:LM<O#J"!<C*=C79H4:4$""*'"S^[29W6E<5PX:3)9.P-Q)H5
M\OBNAW_/'NC]#IK!8XU%,N-T?>([W[DVD:+FC:FLXOAH)$@_\_6ER?S2>;0G
M\"(K,EPPJ8M3W33NBX[<N^0\;JB4CA?B:Q*C@/0D7@4F(-/1P8(V0N3M3":B
MM7:AN$5.ZS! #,?+"2J2:':%#SDOX281=DI,] __MQ3WE_Q$'8B2">YIC$B.
M=S6+P"+<?;MDZ;'31A4/2;.#G/H >B=I8?2).ZM3[QT*365*T*OV3T>'^W:C
M5;\U\3@UI([N)3JXD<_G%0P;A[V876W%24)T/9M\DZH><O5S $3J-Y\"\JFF
M\]LKC1:(R9<#D2MB>O?A\^9U72+>X=:U:YL0WJ,T9!&4>5\HB%:RO&2GQ#!.
M^&4B:?@UC:QF5OSW!XI<.S#VR8_% (#.6H6ZI+:)^LM](UT['03542)'Y]*8
MNN#%V&@43X X]K09LY3YHCSJPG6WK*@:U(+R-/P0@I7.6WR=$Q,_HZ-NW3-B
M$L-39%V_6CL:/X&NMA/B&ELH$A''4$?/KI10.</00<LJ2YG2KU)I&R:/L3W[
M=N/JZN]CV7?52XS\DI9LO+HH?_L?\+M7A@/E35QGOD*$[#?YACJ4:)CY9'0?
M1SOFLQ2S(L>B$_,8\)V)<RJ#PCN-KE1[_CG2!4::6;$[%!3D6$EC<!\9^30N
M4VNS#HMKS-V:'PL!:%K!(65.=%5*-V'7[K6F6%"F6SYOU8&8%>E-OPT94<?F
M[&DA+R7;HB=IOQ52-O%-FX#J\\,L)5D=,.!1A%1E,??)(/=H3%^(%P_=7KU>
M;!).]I@8-2,TYE:%4/6)LSB4V^O7Y(<K(L\U\7%#7(\OX3"AL\)%P1[M3$V+
M8J;O(!O^3Q\%-)MRAU^817YV.90%&/<PY<:=)\)/Q11*KZUUX?I/T)303@^4
MFOOMN%R9-,A6A]JC$@VB?NL?X:[ZJ*QZ$+37$I?AO//0BO&#BZ:/CD)D"_7Y
M6]B"7((EN_,H&D[(V6D^OZK!K2P;'<$_, "W 07["XP+I!5MGCBRU;3.JIQ(
MTFM1UO4(%"M=GF%'C76HS>Q%2ZM(\EI3C=FG]?B8?TUJA9M%"$M46/.CF3D!
MIN8G;R8'E;4H2>)AC(R43.-(/J\<TE6VYH$$M5.E/P?\7/WT'PT<%Z[K!EN(
M25O:H:MG]%:JR>N(CG\$7-;?[S_+9NI]4-/(N<>S4+0OG?E[;#T"##0MJHRV
M;)L%:>,05!/K,SF/-4Q(U)MSQ(7,.C9[\I9=1;9!K/L<X96^Y*FT\::$P%_5
MK*E\!E@]_&Y4>OEZL=XOEN3Z87089ALKI8C:!1HD_I2'O::5 O_=1&V^=-?I
M_@(=&48G8P:M[GH^YU,74[XUC+/U70-$6/:8'I<)(7P&B27B=E.*_5$)U$QV
MW]XE2T^=:$AH"06F14P?&/-_W)>.$A#,D_)LT?O4)>QN"S3AM^<LKE[48J^X
M=/+7?FQ#MCT:]\N+U#7H&7!CG_KS:ECK8O<BG6D8E-, L.#M( M5Z3EOW*HK
M$90T2QZ+^]A5FC\5(.";55U(!LRM5&%@C;Y.K,4<G&Z*%';JZ!0V)5ZW^%+P
MA*)(A/IK.-_TSZ;F[DX8VS=/S;?*Y7$?I3J5E?VN_8#9VH0-@<4>)8?]W-PL
M\':I+8*V&DO'I1S_!4^2\W94A4V6-!'-)"\OSPA/S)W+Q2?,]II8ONI49&=#
M9W$KGW4_?/U_1JH_A2I\4_]:'IQY+A]XRGH-"ZQ6NKIIV;"](_CCCF!]12GQ
MCF"ZZ(X@ GI+/#:Q>WD1GN']_8W2#:OM;?XI[([ <V-5^( QN/Q_7Y\O-7YQ
MQT-F)O6*/'!6XE;S>SGDBOA8YJO,M]B1@\J3EI8[ MN2K@WIL%O\+0X3B$\;
M(9^^(U N_+%[Q/>4Q>\>,J,R <17^3?GW\7N"/Q72'?]-6]\;;,VCY]'-4'N
M"*#06PTH*,"R0.:.@%ENY(Y@3RGNCF!"K6.$OD'UCJ!__GMIQ1U!4MS\CT4]
M;W\\F5F\Z+X<6HYIQ'\7P 3D9\;]UC^]8[9$E;GM75NK?OB!?B;<;'IX.R_P
M@TP5_;;&'4%68,:/,B0P_8"$8[%PUQ]JM1*VS2NW<R79+?"_#Z0_O)OY_P!0
M2P,$%     @ IX4.6WJV<E\ZG , KT($ !(   !I;6<Q,S4X-S(Y,C%?,2YJ
M<&>DNFM8$V?W-QJ+2@$Q" @*0FI1T2*D%I *F%01$1%3CP@(J?40($(>*TB0
MD*D@)Q%3I4*%0BH(B A1(40Y9.1<2Y$S2!!R0.48F%$((YE,]O#\W_WN+_O#
MOO:+EUXQ"??<ZUYK_0YK1OM&*R,8'=SOO9^P[(MEA-_P/P3M$,&#L.S_\&=I
MD?_3-99I7Q+6?/D%8WF9SK*O"5^L6::S9IFVB4 B$):M^)\O$/[7S[(O=):O
M6*G[I9Z^ ?X%H1'ABV4Z.E\LUUFQ8OER_-,X_'/"\C4KC#?NV+/2Y,@9W:\O
MF7YW[?;]+VWV/JU?>[0+VN3X\R_Q>OIFYNO66VS>8KMUVS=.SCM=OM_EZK'/
M<[_7 >^#QXZ?..EWRC_@[+GS%Q@AH6&7(Z.N1+-CKB9<3TQ*3DF]<2?C][N9
M67_<R\XO>%!85/RPY-&SBDIAE>CYB^J&QJ;FEM:_7_W3W=/;US_P9E B5XR^
M>_]A;'QB$O[X:6Y>M8!\7ER*:QE!YW^'_O\:UQH\KB^6+]=9KKL4U[(OHI>^
ML&;YBHT[5AKO.:)[YI+)U]]=^])T[^W[3^OU;!R/0FM__J5+WVR3DWPSO!3:
M?R/[_Q98_/^OR/YW8/]/7!+"*IUE>/)TUA"H!*P*D!6"T''2KW3HX&QB\!<(
MJ-Z#>(SJWN0XPR8*?71GUW:N88BU ;SZ!;/<)=D9-#6H.SK4(C6B6)_:\T"3
ML*?V>D=HB30X[IE/"%;_KE9DA#D. O5R #H46UK##,4,N6]=+SJV;S@J'4&_
M1=9O+LQV(PR8;ROF=KLL*%?],',[?'MYN7[\U_'[&_C?:PD)KZCO6JGGI6K7
M<7#^1_2 H)HJRY8^T45-:,T@=%!+>-.AH+>RWHRI[,%>CJ_:@6,'$YM(-^A&
MW!7HN@K8K*2$CAQM^70"-D^E; H36P@' D_4Y/S[0CS <GX/WOOW60>[.?=6
MZIX]![UKJBJOO&G^)^+!?;,[WKM/+)(_4?=3S["0;0O3Q[2$%1:=SNE^*C^D
MN1BI"8*::Z.YWR*7!*&2Y.N4+<C^;N;UJN0?^U!+@0?SX>GQ.V]]5M1RMW0&
M^D.-(Z>]B@T9ZGT^H:37 /2C%+%OG2[6$I9W(V-0CHJ+3$%:@BH!9MP4[T#\
M?& @R9EZ76R*7"I'+K3Z]M6>><3^1F)X=:&%:N:N^T@BW5+ZX.U;FAD_?S)S
MJKC6N/7RYC;O4'.X!%]QK@+QA]38ZIA.#AG_[UB?WQ%-=G(+]4:P=9=EPV)_
MB8*J&\S9F"&;31%PMTRHJGMGKTJTA%_GZ$:!S._8ML=Z'81VZ]]W<:Q*WDPN
M+*R9R*X%?8'Z0>G'#.H;&O9W<KR6, \@DI)C/-> P=:<( O02[.Q1+1RSM?;
M\_-D!I"J^0NHWT-ET1.T!,A7.MAQ7%-,^1YA*6@W:E<\0 0-(\07W133$,Q\
MP#UXD9]6_N%9#R.^L1G; 3G<[/_61T<X]XP)O_5<?VQ%69MQ G2%C+A[8'IW
M-SW=C\<#1L1&WMGGE4=/HBX+V'KB#SN?K0FJ/[(O;_@IZ]*J[_XY<>#6-M*7
M<3W8:J&6\+LGTH.U\>M)&FK8VO=2Z ?P#5VE@U3@RUS4W,7L.(#F-_ <D$(A
MPRN*E<O=&3!-(7C)NVZ]$4XJ9!9B/8!%K4L1K1S= WLESG!^&#O0&3E,WM<M
M<!#>=KA;-"$)3[_>W^D?X&7:O,<CVQN,S?**R-+=]N)Y<V&(] 0P=7D^5F6@
M)<0W<.NIT)&I4BF1VRXU1V=3KP;G.%0\XE@A"05!B+DBKOPVZUV<X,233N&6
M+!I\^%ZQL$GO41C%H)_C??9!;:=#R:4+$?:U,RQ,'\"+\(;F'B#+H$,%6H(\
M'S6$AUKX$ C(SVL)#59:@OZQ1BH1]=+DX"\%V%HM =U$A>[@GT7!;O+6-]B@
MEF! \L!:L#9L4.TU&$47 8P8,R "^XJRC<U0Q2*[M03=;[BO1_"UXD\%AY"@
MA%!IY<*TM+BMF$,>B.!X0%/>\!:P-.0JT(I?@\WRK\C&R(C?E#S<HTD"W)R>
M"S^H]H;FA=*;3KMWQKFV'N3Y=&L)A[0$V3SM<TNQ9L0+6RSSJ^"YFU7]SF)4
M=]6$U*WH</"NVY7?7=VWV^_S9-R EK F54NH=Z2.)V'# '(1(P!SAP>F6E$3
M2TQ?KOX>J/>+)*6-?*W)1=?"-?69]!5"0'=<O"UMU"L)U9,/E:H%%H/,!<GQ
M["_8E@I:4TA$F5(.O?\X27S84>AM>D>2%E+>]X%-V8 0M00C*=!P"W'6$O2*
MT5V6F D).4%=C9_M=BWA>@&VS@,S9B'>H-RH2TL0@?*OL7XM(;58-:LJEH!X
MD56"BC.:^RI>%? @YN[B9_77"%&U'N_F7V?12^J5;$<5K8NRCK,'7/JE-"WA
M''TU^E4/1W<T_5A#M,6MVQA?04PX^1\DMDF$6=3DG,1/JMMA-L*)F1IE29X+
M/?<BY=\7]@_.\?>/\/MN\!S#/J:='+1S5-"ODZ! WB!MU \U#6RA0X?X!ARJ
MYJ]IBCM":J:O==]8RA8U6>, PH1NC!Y%/ NG+$2IMCU"I9NBI71TVT56667@
M@\[W+R##PN9_/P:6::KN6;[:1']Z N/PGY#0LC:U!S#(THCP7M>'-<!?PX?N
MG*Z:6B>:['LS\>J5M_A.Z%4[DBY0[PG([H,K0-D]>H6F6$F"QQI)INZ!LMB.
M%/QL669W(9XGE%>G$ ZXTXJ9B[F);S,IW\&B7R.O/6ADR=O>U>9&M=3>"@TW
ML[2\'O,@H4R32PT'$^F5TNDS\HXA_DLN"4EXP-D,4QNEENC!)]!L6J5@]2F.
M9_)>:.U"ZK1SFD^[[7[X BA_.,^\5[OM857.<HK#\XKL;8^S)['V=[GVH!%5
M-D/^['DR44M@!$+)6L(1THV[LR3H@/2SWUDY49,=K=RL)9206ZZ&V=VEE'-
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MP JX./$^$L4X+[<*:&R^&M>>*0A7V&^.L)\?VJ5D*6JKXT\5AF;95][,^ 1
MAC;M<>?-RIZ]359E(K?+.1::/\54E XU%V4 "GHB?3GV#7H FK]5M^)]?W),
M.=OR9?5"ZER.;]@03=P].^.4DZ9Q&+':;V!%.UR;W?[AEF2Q^X(/GI?MH"P>
M@(X"MP#H./^-EJ#P4NJH?T".R:D)Z'F9EB"AM9!T(]L=93.)HT0B<@%8A0!R
MH%YJ,4BG^[,'6@$CH7\43G I 7UU?7UB(;-8S&<6-IME&?[K$AT-WN>+DM$_
M9I7W\(8L5.\#)N_#B<!N &(PT +'4;Z&3V^2:GXD5:S5(S-LPV/N@+\-<> @
MB[O8R:>:G[J"S\+%"APY&JC7P35<VU ZT3T:9AV';*\[=YA,@*NXZT*W+0D'
M)7;WK'T[/Y&S\4%M_T1<.=-%S^KN[[3OOKI#WR%:_HWTAK4#7H:E.-D=YNC(
MVW$!D@;(\ *PVHZM'+_R;,I"FC+'DHS*DF]@.T(Q*^&U&8%PA]H=835:\-++
M'1Z7_9P9,_=FMC[5YNRE:,*JMFTN0G$XN?W^B\UUF#<H?C7T@8L--/"K!,H.
M+6$5#C[Z/=BWGU13FL> _!R^?5PU;#FAI@ -*KR@=3&C6<03>%>H)30'R>GX
M2_DW^-NEV%8I@G?'6_SUY68Z/*7A8;??<IOP55_RD:VZT[!L5A*HBAE@">DZ
M[)+RRB&-W>D*WB&8'L\)++0'T4W6NG#F7</V:8OH5*?U#F7-W8/2,-<@36Y?
M4D5^V-6BU)()2?I ?^3%^<"(*L-^7MRQMU@D=R-0_[>6H$,Q9N?(01Q0@?KO
MJ3*!=%7M>3@CB&7 V0AE-9'QNJC'#&"79KK)EOOW0\GRCJ1%8BK%-;1:<"NJ
MKX]S3)Z[HY*W*B L.W[2^NO.Q^G/7_3-(3.4#"001ZT,O*'OPR[R@48:$D5#
MS5AR*;J=9H5XO02A)Y1MW$8ZE,KY#G)!-XN_ZIDC(H>X7R,"S"SI/@X.'=?<
M'37W-2+%K)$F7JTV;U2Y)A6JW/@5,>3/.(CHZ@+_+&F>MT0UI49+T-"UA"=E
MP"EGUMW]Y"R%[\SB3G"OG^/O&5D- YYEW6<\UW[NPS?DHZFNQ3MVN4QSVYVF
M]D=B97;<3HG?KVB0+->V-7A-FL*-LR-G#\2[*;PFCX)_=U4@NHJMH"OKQCS5
M(/2[\8Z"4ZWVXAI*X9:*L&K_JKKK.:'V0\_FS^^\$SXM!+JIGB$"/L=/[<-Q
MA%JGGPJP@='CMW# 6YD.6>"XG2KJNPX%&M+D\X)?SR%IC*CETY]^N#-Y]<OK
M$F5H7]'S5)M/:5L!W #(>"!T0HEKL3J(I6 U>2%VL>K=;*F<P8OD&R )\J2"
MT18D]1?,'&8D1-+6LW5;^Q=1\4HD^OMN#H,!/&XN''HE?[KA=HAQF%GV75S%
M$==?Z+G2%3 [\%-UM5]?T4 ^-:A4)AT<P/2M(#]5MN81P.0/&KSDKD,*'J '
M-3>=:0:A)-.H#O,0L<D3:&?=9<7HH_)L;%EO)<N2N8B5+-<]\$)]F9W<2#&[
M8P_%Y=GE=L<$!^8#]0<^P,GHVLLMN!GEZW!,\8J^TR9W>6E('F6U\'A\Z&GP
M/\3D[#QP-2]:/IO< ;UWUXE=75HRY0K<Y"PKD4R:</9UC64<ALT*8E8F7R(F
M%S)1^J ;IA^K)1CNP1.X0O,</$-&CN*R64MH7 ^< YIQJDF\BZM+%W0[3QFT
MM[\1VP<@/[A3\1H";JOX+ACN:TP_U[B#PS,CY>W!4]/%XE="QEBL9"1ZW'9S
M9(;:]^*P9)A>7#[LQB_M]9.U*G%5OV((B5'OY Y++8"?I&NX[: 9Q08]!+$2
M*&O#I#I.8+S(A63$_0KKXKHA6?GC5S6MOSJQDMODOC:'(7>N<9<PMNSR23A8
M.#I,.YRQIU.(T]U3R7!A5<[E>KS"#=+@6=5/<&L##A'QM_$6(U.^P9JTA&5B
M9Z3M$$1. $+LR!(;N9]25ZXQ"!PP4\1MXVX=#U[9Y80[ <](A.[7%UGFU60N
MWE+978FK^>&)ZI6X6/[R_?3%7WRJ)IP?U?C2/6/!N^J(#;#? (-1\&S^RK//
M;["4\7S0&93A1A8ZDFN.Z0%J5^28ZB9LVVC)OY%GU2]V07<COH()LV RA5@+
MJ=)&W>AKI)-BQ\KG=#VD=DI$L7H*O?NT1WZ)4605X=^]3!!ZWOV5L6]EIG+P
MZM.J.S5=-G-%-U#=/D!6SA<Q4MU=7%IXOU*A?: D5L&?%MM_Z*\$4X._108A
M4*[;C"<&V?OM@)EX.P1,UY2$<+<A!0I#M],]RZ^V)LGB#Y0+ZUPG7\=&[OGE
M5^YOW)=2T=BT&L_-!L3@#+R@XO1%\:;_F$^3ZK,'ZJT=GN+L_17'$1;?,Q2V
M%. $9AG2GR7)+2PJ7EOX/K. $5TT&9"9\2@TJU]TQ?R3B?M)97-A;&A5NAOE
M=?O0!WWOFFC)1.EB$!/T4-ZP^SQ/1\C\Z^5<=ZR?]$R0")YCI=/-@5#P5Z!R
M"PAYR9/KZ=>BIV!B$[#>W4W>4>7QF',>/ESZ$*$W6*]'K""U1Z]]^!R>FA%V
MLC^\[^II2?D?JJSL2L:/X=2Y8_5@57(J1U=MC=2H\/S%)Z F(DV\/;I<_%4?
MCD5D(S0(RFI1E]DVG/0[V2\V[3-ODA*=AMP,/9KR7#(_]K=Z0V;\XM/L.[NO
M3O8T3AF.%$:MNO@B8**N[%%-=?6SX=F>B+\>Y+U6+]JQHI]Q:<$UI-@C] ZO
MZX#L&2 BMQ)U&^%153!^85MN%VBF)9SW/=@Y);9 2A2S$G/\Z!K(J9@3E$!S
ME2#\>FK%A](")*,Y>$=E7_A&'XVANZ/",$ :*,S3FYN:4-I65?/G,C"]I<R8
M:?)P]"H ]:,$J:3E#'CG-07Q"W82;05*1W;#EMZ\1F"MF,@>688+L=7(4&-)
M5*SIMBOA9$NO_DAU6[O=,?7JPI]MJP8B:48A$H]+H72?J(K#(U414C<][]UY
MZB!GP#FR7#A,BAE04%%S74R?!G=@>H50ANHB//M2H,^QA2\\A7FJWZ&%^@Z3
M0$Y 9^V9\HDJRKJ^6D>%_84/ZKW)]2-ND%5?>6U6@&?E?X+"S+.+\JIF7;T+
MVVR\M@=*A5FHF2X-H:D/^:J-N+@!?[;0-#LTJVKLFMN*^HS.)E%7H3YR7,WF
M?8%X/0@*#%VX&H,(8%[SR0!!,DJ* UBE$RYZIMF^,_PSUH5GPA]/9E\H>SAQ
M%5<&GW VU-7A#O*MQ:Z<KS0\[AIN+_@DJX7\)FN4F Q<I.H@HX>?PL2;'!NX
M1C9[R]U!; Y3TDI(.NA5Y)(AF"#DF898W"I[@&M8A/*A[7#_Q4@-W;=7[M/F
M[]!^=Z_A/RX!+L(^Y<A 7:WR9X:]54Y==_5AJ;%O<#_H$SRV<-^32P?J3P.R
M!P T11P\V:K*QI$3%]H& TIP+;H1:L6,^,@I/O3878 <K.2M#0.'^- =H,$
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MEG#@AI8PFI<##\B!9C*);7-@H%SYN+(N6D&;5N>/6]BF<:T'A>UOC8:;%77
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MD5^(4+0$-5GMAZWQ&=]?<#:&D]N*>VP6"3D R+*B2=!1.G*"?DY-G3ZO$.!
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MY;'W@3.TQV_"9P]F%(5WE8]ETV;WWHX@"8("C^4?[F> 3K%$9&.'JD*S9GX
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MP5!R>KQH.>R9+EK%^D&( ".!78N#(V:%EP7Y6?RQR(OV]*X5X<%KQ*28^O1
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M+L!T7Y:@/T!GTTM0E]=@A"-.KUM:R0+.;6AF3T_V[N[I_\@C&1[DA0*&\6C
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M$SRH^ 04EH)MP#5+1XH]59].7"$PC_:"(C/$UT<F=9$''WSB#T&R%-:)RL%
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M*/] _,]Q]@L]C?5;UBGDL$9G9P5JPM=6ER /N;HVZ(Y**E+=VU'7Q:ED&Q[
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M;7E^'(J"WQ@@>?%5FE,2-VVR;W^.ICU?(;J_-C, ]06R5O4#["O/:\-5:ZX
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M> LS*1=(H)\LAS<ISPVHS($G?J0PHU/$!Z3I):.DR+SR57=FO\Z<<ER5\V/
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MGFPDB%FK)_F^49M\'3]4[69'T$<\3O;75MIY]2^X!/D,[*[M=IS]<+"WMJA
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M9H*4QU2:F_"+J(1'@'"BD<H!^5U]O]F9T0.N<M:#BJ6^*BNS+T#4HY>WFQG
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ML"R%;F3$;+0C7Y.P#>'3O$HI5I<,M68*6=6H^HTIWJ:W M I4@IN,WBY1^C
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M+/"+2P#D^A@WS4/4<]1K_=0:LL:GG.V'=*C)J7BXX%['^:@<ERU?RY%+<2K
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M]&3DMECN8>!IV&%*LA6#LF4N:\Y5>;3"FNU]C[TYM34HA5OZ%EU7!RE2E=R
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M'G^N]V '(-QB<5C,??;WR!W(5UF:W< L"1[Y1=#^._,!PF^S7]GG.K;BPLC
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M]%?@W!GJ9QT)V<*;):S%H_=_--T"^+?>"9WG31KXEO1EFHRN])\EW")J_NK
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M;$M3]-$2YNW>56&E90>N/H\92WY;6NDO>52T'4&JGA"YMZ]Y+:SVLDI@CR9
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M<<JY7)G(9(5!1"Z(K'DGH1IZ\+/2V62PI66,4X81V<AQXHNQR^W$7"EK;'O
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M;73?_+8]S-"M^?I4(EZ*T0>:=8/'=(*Z&B]]J<C,)/6!*Q!,["T*(&R<8MS
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M&#^ACT+5,@M<:VJ.!.KU(*.T].YQ9'(L02TK<$-F]TH75;72>1#;9T??L[#
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MZ=\*ISY\^.!4VSLR\OKU/SE;V+,;VI_%8E'Q!4AYP]FFFWT0J54<-%1 3.V
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M>M3#>L[' 35]@*+>_1!QP1<J$,E@*++S/%$&KJ*^NG"TKBWYSRFW<PDIS'W
M!9$%(Y'9E9C5]Y2,TJ;G0C/?;YY_RV]%8^OAC(FJ<=O@1,>F]:I#O89 W1^
M&H]JFL]3+Y8:KHE/"N1U.U("#S;ULJF$C/NR%Z>\%5D_OKJ[H7M#8X RSG>W
MH5 <U? 6.W9Z*B[B "_HP4,D7' S)&PO[9K@B<?S'UNG#-9SP(>3>G/\>?%2
M8*]?6<IOHWS*#@0C>BK>.^1J**DA8@0+ G4H[R!@>9MJ>&1V))( 5[_Y"362
MI,560(A6?---LV3YJU\7<PE)KV;D-IH)QL*752,!UZH>JP+,!X/R?.8H'.$3
M],L46]R;E:IAY(DC&2_\=87T3'@>QY(%T1'&1*B:;P<^M%(>06WD15)U!XKQ
MYR44^>OB4$XA&M\LVM#G[5\V5E##B]1O OWMTS2KZD?]B;F63Z=W.R\VI-VZ
M #EY6^@7XEV,V6V;P9JM6<HP7V5=+KX5;H$$B5O[V1YJF0,8)BBJ*6UU]- &
M8(]Z*O.S;G5S5A"BR=0[2:TP#Q_I&Z*EMGG92(<EE8=,!R8_UDQ\U?=TVQ4T
MI>^#+AH(D]!6W5WP6DWFBJNU;8-D.5EWV/ ;;3'O(LT+U68QFKUDV1RG6(HC
M5>1"P*5H31.P4/]^1F0_&I(DC0W8OJ//K]4'/HCNW^IP.7PY8I+Q[>^YCI,A
MV20L&$G"K&!U^K!$,%BMRFVC+!2?Y&7PA="XD53%=B3*R6;V?%""!FK\FLEI
M0]M0\Y_0)>"JYGINA$8QAVWWS'ON'2 [B@X5'5<S"#%M0CB%(MDRXFSZL.]=
M8D"H-.3UZS?\R?EUB(F.#UI4BA>7&-D%)LU,;O$&PW4X1CL?.XJ>Y!& F\-?
M(EK#2I:*S=BK]=NP$'!TAD=DC@4V'P3?C19MZ_6.1#>OZVF>N9Y+NU@&(O9=
M/0A9"MV.C"3L$>^]<X/\E'<)F@_%B <8#+2NE9Z.6QN*<5?.TW JT**.&C*W
M<8<&OJRPI%E@H2#B-O8/P*O$_$&.L@[)R-%#1(")I<M5="M625N2:%Y_%9&G
MGO5]-<F55 F^0MCSKN8Q=OP>)X73I4#VT7/AI0FP7"#YGNULN(2O @I-AU3F
MC.U&DB:>H(,'44Z#_B!K"Z&?ZGN$LGGL+;S6)?C3&:S^4]CLM'N1IY)_L=%?
M197/E[4.60-F6;3SNA[<[E6,;1!G3B]\\Z^U+[?2=B'49NI2$*$;,-R"HAT-
M_JV!+$>UHID_\$3%S9BLV-YYB&XS$&LD+?#V1V7!J-N;NHBMN<R2P:CI/K%5
MPM+)[3EF28>:'O]>T]M'R/&>E775UXVD?QI)@US=Y^"AWA\,30>"4"10=QP<
M1BWGJ#JIJG[,>N4^,(8RF^%:J$5O6K1&TXJOZYNDF++7&_B-V^Z!>D6KW"2[
M,;'T+66A4":7^8/OT?FNA:O1A]WNAMUZ_P>&&"(GUN&;B/ 7+<-"^^ SR5.
MJV*:AF$PRA]GHMN525GR)X=0M^ET?!GG3]MBL_[)0GY6L6THV2PZ/\2V22/^
M]&C(J$,2UV/P,=-[]9W1P%#9S=B%)ZV=(RN 0,=%8<QZ4+< *>\@FW)D0Y9H
MY$6<S.FG+!%"GV(F0*C1YLIKBY2&B%;(O'$1S86E.83"+8I+6S ?Y.QC36@%
M-!]X!M0C'9DG^H4O$C/O8]&)B26*$<(Z I$[XI=*6\4*/890V^@+0$2':"'J
MD3-2O I)RG4W<Y72;-'YA2MO7XF>&>8*G_A/N!QYF)3GF>RO]\^T[[(O6?U-
M'EE%'I_00QQ9K?QU?C/C(FQ"6S  BI,=!99R]G(0H11DU XM?]RMJ<_9_WO_
M,N14UBUI!;U\5_(YI\MU(]^OOIV4M/=,5V7;S68(NFE(HVTD-.VG$@0>/\+V
M0Y18(#*=R7$8[:\'O;.*:\&GM4/FAKN$KFT-] _[!GBSLH;YDO,^3_G?/@)'
M%KQ&%_\8<FQO;%E-04T0C8:W0K:B]:PD?-'#VZSD-H;Y_7?PF=EK8.1&*^3:
M5%%H6RW"2CJ,\%L6BAQ&/2D6(1T2K\L%!_A;&U:\&O!7W6D,BU]S9?$'>6CX
MB6;\_D&_*4.*ZO]N-P4J.OC5W#SO@VB^;A[(*A\567-W&:Y[D+/MX"5Q3*J0
M-15P G+DR,)7@8!2:NJWJ;Z_USQW5K2=EPK?W?!HT)(WA*R*?SGH\>I]1]F3
M%L[?!*#&R ;\Z=UP),\<!.F20:%^,PA2D[,C$3NI683&I0WF0H[8)B2G/7R]
M&/V9< U9LAT:T*NABUBRALX-HBWKQ;:4LV[U:X(NN"LRZVG7;H[.E'&58>%C
MAS/QK(.[ZCX821?$7QK(P[QV"-E'S:6M1J84:2X TL]G\=2?P35$N(F&==/H
MTQ*-3Y*N"1U.<V?*F?Y@@)PQY4J0FLBQ(O]FYPV$9E[Q=%!5.!82V:'XC+4'
M!.Z\VE+@=XGMH]+:[( NPB&<A9@)"K?"<G]=%Y!6Q= <&Q#9A+V&>JEX!;(K
M[^JYN[*JD;,,,WP^RU]U_;%==B73/=F)UCZJ#7_&W#CY<[='P _K)K/<JJ@N
M#QO/G5X^\S0;^E([C$?C7 V]F?PB2/>;X6?,0F_#JE/E&DG-_$R* SZ'\]=L
M(W1&NXS+\43K>)@-4JVV2V4*.^TZO/RR14Y86!?-AC4H'5J"0I?8\:I_OE?U
M<Q:!U+VH+ T+J(I.ZANR['-O,@WC/3*4P2?@3+B&GT<X1.[? <\11T#9%!N:
M':"JDUJIF? C;4=3Y!%0K?=A\22,)>Q=JE?,_:C=!7RVT?8/C:A=JF@5H'UH
M.;^Q-%8=RA\H/!Q WX.Z7!91SCF<+/T[?%.]X;M;%VA1AFLTR\'9VG.'%4,>
M*-<1+Y0^9X?='9L6FT,G \)]XE6UI?'QI6\+8E@-7S^_JJ2.O^UA-1RJ[HYS
MKPPXB<QK^W'DO'/6$M2VQ-(ONLQ _7_WQ7G 7FLD_6(D&23BZ97A4'@+4H)'
M&$G3BXRDE[F10>"'C_#(GNY\="41'MW!2LB.P,U;+"ZN@F8B>EP[8[M%5"/I
MSYTHV2"!)SO*@@KZ^XY#KSX7Z\B$4 UH \>2].^VX)*'E)GSL^V8=OSUG[5?
M2HE'R/A.@S_>'BHS>+SMG;WF,B\6R!!( T] -S@=X9Z&2LYB_*]^\2-9,W\)
M/D"S0OE2*'=H(8!T_$%ND)Z1 1_7NVVFVX$Z2<2Q!V"O#Y^';P;3!RYJ54>>
MXU;G>&5"M)$W'?L_KGSH_-<%G(&S&MWW4 TYBWU0\X29#5L;2=%TN5V[D>2,
MKP3O%1)+UL;Y7IT9J2H*=XC4->DOMF$IOJY!!!)Q!FT)PKLXN?0=F\ZF?M?C
M 2T1UO*3U:;ZX^@OPZ?/K#:2>CJ8CV,'F2!B<K&009509Q($TV(/(\DL_@US
MMMLJG>V&KM1M->3"4=HTT1R>.K^-*$ZI(4A'*S45-DE0+'W!BM\%YQZ*<M[<
M*UKWMOASD#&3E.6707/";. ,BO4:D*YI<I'@'L_=)@GFL=<DPWN=6F$Q%DYY
MYL'XR4.<QZ\9;J6"M783$>C5#NC1=*K'[%W1!9#R9X89.ZP<<P3!^AU#0"/A
M6V&;5#)YI"8I4VB'^$FI%I@%2%(?;=R3 $T,;H?,67QE^T6=D;3T[;.H(R&_
MS=@^C%9/SC /$L+Z6$P(IQK='@XB];Z=R(P!CKMC)#&9 ^&>X'"TVI\RH-&0
M<T3.,>$FP*!46,F/L;0!A$H6(G2-M#^;LRQ6M!RA<%^#314L#M,Y=O/;(2K3
M*C1:M+%FFGF1_RBRG;\ [Z5Y&JH(^'XF6@@>:[1+,1-$3!"T.!4] R)-D2_.
M]O]T4T$FX$,8JOLI^=8+P-5$=E!L7XTF%=1ELW>M:5@CUO@</S/<)(QST9O2
M'_#VY5]]%5077J!(F)#W=>L5?TS4% DXA2%RCZ2J)OG[NE^?=>AC $-*3-E(
MBIA]0&'>I"D]NYX^$83$MT,UM_%M=>B&F35\1*N+)PAX!N9T3L7/NA+=!2+#
M:*L*U>3+G%4L$XGSTF<;$RF+5B&CM.7]NX6;D+;ZW27OR>F0LK+ DM,#+X(B
MH4Q/QH..3":'BAWNIRV,WH3_P4>^KJ3H2D"=DI)9ZQ"4Z9'B1J-BIGU0I.PB
MARC%:1L[TA/YYJS4MAGGQYIUF+TF&(-NQ!8L?=07&OI@2O9B&E]8J&(.'*#+
M=P]IU>(LVJHH_M+)$8X-MJ;[0#I366<H@$^&;0D#^6K^)YRG8C)STA!Y]$H<
MU$);!EHT#3F,I2&^JL=3/C[>=N6O &>;MTWYT,N/S N0\E<B.1I];N*MBL7>
MQ_5AF%<_;1ZGF6\A<@(*E<O%1K)^-2RI1WEY&SA+68Y2BAGF=AQ-[:ACU%!R
M)U,8;5N+K5"/%_EML#G-F>W6+:0L"8N9>?=89?;MT,AU+ZOI1,Q9E)1\IB:L
M*'6HIZQ>+H^IZ1<)_'7C?V"^!#IL-MQ<3K!R!G:.H 2A*I](I>?X#D+>72/"
M5FO%*M?=395P(+0\77S22+($&8J.H<W "?G@!RPTN9YMTPC+I;6.L_RJ!+;Q
M/H=\79>U%\E+%8#\  O64\U;OB4NIRS!XM![C OP(W*S=A$6BW(S:(O9/F "
MI;=3[&F;QOC5PQ*(B]L!<>*]%H(K5*B9B]C6AIL84TW.H6U]@$QGL8/LTF^"
MR#+ V(EP4N/OC!7[/.H3.LUM+9"N-ES<BO\IKJL;;R+T3P2$#.+K#;6-1$XL
ME&'+"%1.)\+-+(><<T)OAZV$D%]A*5%G%XWAED6*Z-D-$"0PDI_"I40B'?)J
MIHUV_##*5&FE/I F:?RA_BO@JHIL,X.5GJWD"WS'!$+]S4F$\Z"%HMEJ/2_O
M!L>.O;L:X:9QO-B?H'47<1?6D<$VSF8BC*\)I#Y)DA!9FO<^]Z;XEH(\H<I(
M,F<5!H2_*^3X$.QP^\1'\A!FHVO2;^3#0^>")M81(P8@BO%IHK#SJ\\(8+T]
M<-7T\EOX"]C'02U?2)WHN<UY L_%5A1O?N[A9KH/\6ME9-5KF[5.[*] I_I)
M463KT-KG$:'TB\5FW0GBN2,AD9E8]%W6]E 43FMTNA\-MN.+4H^C8J5L/$4M
M&RA7S<MO4^1"M=GL@S!7;-H8B"9]B<"M8I,0CLP+0>HFEJMA"CL1"<H048-?
MLLBJ\FQ;:-%;Y[4$\21G!6)[4)-,;RM#ZBTY*ZG-$U]%I&X9BZ_["NC+L=.I
MNEN HM^#>8(X=+H#_E3T&=O!4'J_,5*_#?#42>,H6D!/[Z>M[/-VTFC-V&M[
MH"AMAMB*8PL$K0Z*/'9*I*H&JJ'FU41Y6ZE_]=ZFCMLNK7_WZW'-%SJ:&_X7
M04C6!>@]V2?J@)&$?&B!:UW&!Z"VI>Y0]HS+N*&2P5Z(\M(Y;FM^*F/O0^RR
M"78U$:OIG>8%23@KN[RIRB>_S^?J_:-I*[H;OU>964D_9V6$K=O(7OF/Y%I&
MGH'O'\=YJB.?U];%;ARKG!9J$V/'=>*GB@?A#:AG&T00(<S&_(/&I%5&QC:#
MB_/S]68#L<6."-QF!\J5=7I((LC:_>0PPLT3>%,037A_0L!7?^VA_(U"K?"<
MV-KZG\_G_CSDO'6KSD%4\?$ANJ7-$ZZF8[9U.KZA(4Y+C:,YL7U0(VD\3+\.
M[SO8]$1Z*Q@C&2KQ!:R('8A=VYBN& 0?=6D1RSU;8#,/LS,&=]WO-!-4D',]
M^*3>YW9]Y#O*N$"_#CL 7-%4W34PC>9KZK@B=\S?4-:C6H!NH)F"K43$82;*
M7K"M%/2TAI@7*?GF#/8!(%2O[F*RMZB=;*C+44:>=V 5SW*D *_Q]EO#4SNM
ME PM&18J@(OBDG>\A@'6EE6B+FV:=MKLXN(,S!LPD$%I\1QG!_PO?O-Y:JLB
MS<M(DB0_J2!;4S.9I?T>8<<]%&"O>^[NP=U(TW":T-]T]Z-B_-W:Q+5.W<SJ
MO=$I9^NU77)U=732(>:'&-T'X3AG"^=5 2[0!\ M = I?E:78JB\F?\"TN&&
M'PGJP><^V'6.74#HZ%C*98=7^5*%W+$MUNRWN]%L_B*1;93"%+<?*!/,R3F
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M98R<D>.].OKX+9 D/>_<<$[-,%.^52!?\^3Z=H>D"9\2%E5G V(]"7WS0L!
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M\A:QKK\[BC'43:X2V')Y]\2&*EO'V*:3-[N^TSOJSH,LC2Q;859C)%' \!Y
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MH_FU07\:<77<5NDR=AOWP;#61+^#1>YBN55BDH9RCL@ZI!K8W.)^YNXM5=;
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MV(Z][.L?$WX#VB0C!\KZ1SND"[ES;ZGQ>)J</^&^\>CKT->2"*OVUQET>\E
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M;N[<+2B>2*HHWNDZM.?W-R5;>O?L9_=><MYWH/[76+\[58ZKP"[4;*"$+5>
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M>MX6K="(K)FB[WH3%%;,.$E^>^KY:B9Y7X[85MA UU@<V']*0Z>?O3.3P/$
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MU[^0OSD5T%9/U^0/#VU:-_3\V:]J.VN?2P_^)6'J#PV_UDQ^YGX\>#=/<VM
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MX@_/9L70)MW"1 .=4"A]/:---7"9Y<SJ8Z^-@3*#-P'G"[^-49<("4PW$)0
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M=(MV\#6L-1J]>0XK>O2-<2FZ:EQ3"T\UMV<-$AM%L'^6[ "&;4^OR8+D207
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MCE=O['@@_GJ^-<>[)Q9?^0C(M?M04UT!^4O43E>,>L$'6D1X43C;$/V^4^"
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M4!X=X7J[#'H-G<U_.<9]QO]P3H>LU!G[Z=A-(U<4[/6.=$9T7SZ6 X.M8<(
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M&33#60/YC<MAIL3_72M+D:3V/%4;>ZB[%G!EAZF7B.X/GO& ZT__XFLB.(X
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M@,T_"%YC*]6R'/"PH/\W&K)\*@O=4K9_"'P B 79=7Q+=,,JOA7GH-H[>>I
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M:?67K:Q\]L>*!6[F80&\OV:_E[Q'$T8: H[_BJ9U[W\:O1/X*R _JLN"##6
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MJPX6<"E+:%Z#T^G@U@X[V,/42^[!Q<Z!F4TW'"H)@#C+%NTN83NC0GT MMS
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MXZ9*+\)4A1^H3RGW&;^Q3M_?Q*[ U\3T 29%_M&P1M?4R;'B/'-8C!1< (^
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MF1(W8G^"7H5M&G.7H?DP0W<7@N^G:NAV*%6SF9OF3A!%5HUZ!YQ\B[BP8M,
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MBU8ARRE\KK.EPG@?W(L<0D>;]F)1'5)-L=JV/<!2,@+EC/'D+<%1QJ9'+!R
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MZ*EXO;,RAP*'"$B1:)6\)FK**ZF&G^*;D\B8^G:H]A8^MU4<K'-F]@#!75A
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M"M*A;[!O)5]>2#4LUE R\)6"!M>-B.)<9;NL=JH?-9M&UG&&%R-JV<K^3I'
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M&QED91.Q/R32O]*9\8Y4><UW=ELD)V5P8W^MNVJM)IFM@T@/(30%69*M=*V
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M*49(I"*8PZTG+@NEF,';T-W0!ZZ\**U(\R/=;6[^FR/,K,"N/(]S;?RU@H2
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MR ?OAGV7(4N=D=![%9+5_$P^*+MK2FYD]'NH=!!7R+81,'0&9&"ZNRJC&]N
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MX)=_+)5>!:Z*WS>,,TD:6;/)(L:5_1-Z[%_4PU]PYP,BJ$E: D25FM$0F.+
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ME_VY#T]'EG18)=<4!MRGKJ _"N]M.*H8WQS;$Q9E>.7"NIA-N)\7%MY/@;C
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M=E^:/3=.SYO_9A8"W<L>*+X8412^*K)N]K+Z(V"O"6+UZ#%6@ \JX_08;:V
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MGG%H$8&^4X8T654/ZX\YT0W !_38JRVL(5DR88 !SD[(5+$^.;OHS8'4JNN
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M7!WGGH'YMS_*YZYW7739ZO9I ;.>;@?L199+M,EF@ ^,1[?0UW%A-E_ N-_
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M?Q*6Y0(^=KLJC#+^Z^Z(GW_-W%UK5BTG3A$V1C1$9F6XH:)7HNKI*2-X6+J
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MEU[/JF["H2!9N$O;B,7S+M2K<LQL?0,TFC0[%7 *F6X#J[RF F&6BQJ.'DR
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M^>%K3?T*>NIV=AG15I4,_F>+N1;<,Q:JAY67+[K=+L]3EO+$16;[E&51S'6
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M)L;P5G+L9=H) X7/X2OQT*?1YKL(R07>"2-9+7LZGXS-.W++K,*$/8Z]N\H
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MKP0JQ=Y@?/P"\E&_HL%\"X8;W0[W_Z,1U+\]?@\GX8__X*>LZ?L'4$L#!!0
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M,E7#F,F%0-Y%&#6FS38P5<\H)\J+0+":3G6B3G;WRY.38I06L]X;^L2[P("
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MO<O#IC'SNU#537IRS[?+XEN:MH]'A)T7@ :$ [YU$A'NC8Q**QX[ZRKLR,'
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M[-^*.8NE.K3X5H&JERY]$&<%3J/V$DEC+&C^2)&A)" :&*=2$9W;S@+J9WA
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M">:97,A<4^0P( EN*0:@'CQBE&*EB1&ZNZ>07?8TK\BL,I%P*WE3EQ_,*J5
M6D:%M">&"@> /7:N)D,'5=UZ\AJ===(%IU)2+^!U%?*4I4I1"(Q'X>'O[M6M
MN6'S?C=#<W0;C_*M>3K99X=Q+X4,M0//B>7S"*-WX\H=FSKL'55AJ8_O?>D3
M6O6&:2$9HCP5?PF&(TN51[EDUH#*UXQVKB!U7U-^C;(MBJ T6'="I89*6@$"
MM,XA28SR@ &QB)U,Y>L#X=9O GK,M',N(FP\36>O'BF',6*1.BN-\ 9O>K##
M8^1R+!%F IIT+%5@X"*$=#2'4W,(C7*N,);>".DZY[K9\ H,J_8.K*=V5"(D
MY5/*B8V)D*(!R.L"DCAP[A31V'>N"-'=SWA;W; LNODM +!MY'V2_V:0Z'/^
M0+G]^>0D]=%*TSD<'KI1"8-=(?";CZ9NI:]F,NZO(244GAZG:A43/3DZK7;?
M_OV)^40\]=QKK)&D/)7.\T"U.G5:E!YCE7,0C9U32#=LU*0K]>ZK_WPX@6X.
M8[P*KAEMH>A_DNX\GP*> 7 CJBA!G%N%='*LB]S%H%BJM-HYN^T)9B.MQPCS
M4GI"J4RUXE*#HN"0,1IL>.QR!98[(Z)S1MB,N8LAV%C?!6_S .V_B]'QZW$2
M0F9X,/P2ZJ9M\:]F>%,KE66C^MLW<5D1:'RJ.95>&B^\![[(340\*@.$["2*
M+/5A387]<"?=W(^D@.^N"/_##,>F.KNB!S\>5V%I^OD^09%/4PEK%R5G'!F=
M B>I",@:AA&8/TQ(0G&N.GLFVOO?.^%_]SH8)V X,#9<*D_#0 )&(%#I8]!"
M&68Z2T*ODBL57GZ^'<UAXK"_D=E/3Y/OC8Y<:M!8-J1:M'D.?)]:5+@@ Z?:
MZ[QSWHYG'O&T#BIQ(6"<>KV".@#^]B1%R!&4^USG,J3BW)WMHW>KBL5_#<-0
MP=X._9X_*8;I/,.D37W]A&L6>T\$3BYR;#5-#4TPLDKJE#H1%*8N8KURN_NN
M*[6>@#$?A=:<2Y13 BO%8T#:VG2V0&R4*L30O;KTCVFD/NP0:(GMC@/38(<E
M^RLE:7'M%<@IQI"GF*=? )AT+C_KQA" X";5EC^,QCXYAX9/N];R>J1A$%8)
M9BR*HJDLD!ND,/;(PY].,PL_=?;\<%-\/S>%H][ZL9T39U=#$F[M@.)+<D"!
MB26ME1A)'IO4&HT,"P8QI6/(0S"&=BXJO0]G62#\UE#@(1@:; #:<;"UB <J
MD)(&'A"E(WG P?#."K_.1<2O(1P)]H<R;F XGS<9*1QP#YCR5%&.E2"1NLXY
MGS>IH\PZ6-*%Y(6E*!B26M<3A\ L4RAJ#_]CN2.NL]ZT#B<+LN7EL@;/=&I,
MB*)+V0U@2B/CN4<!OC1*PVYUMQA$1ZK\/Y?2 B%*:@1(Y<@C357W/)"*-<#;
M)A*%F<V[6_I[0X,35]L>:HD^BXA9S#6.B 4.8L0X@C1F&A&&<VFLH5QV-@+B
M^K["<^>U@.['[='71O85CEC9J%6.C/86<6T#LIX+Y'GP1AI 5ZIS_N]%5<G-
MMR=;E3P2[7.C<V1)\*EW,(C8G''$(O,":^P ,W5MBVZ;E/UIZ$-=' U3.N@L
M0?LV?IR',5#K;%^.D"/..68Q(B'EV@2LD T@156,G'%+F=8K#T]=G_10Q)%H
M4V):3)4Q@T4Z]XVQIB( >1OE$RDL=%/MQ&5;$"OP:';>M;B&V#8@8(]3GP<@
MX!QQCD'],;!%-;46T"O/I>BL>ZC#MN@2ZRI%1\&6< K%F,*WK  1D\XQI,BQ
MD,I8R3I7^:J;1T]K</5$IRQ-9<M83(%3*879.FE1$(QXH[6/L9.>^[Y![+I!
M+Y9> Y[0B.J<( Z#(Q-D0-2"'4FQI;9[K87O4)BY5>_-[ZLUYY=8E1F'I"NY
M1UZE6!%!(FR)2SG"A/M@0!:;E6_)78EW/?&B. *IYMX W0)/\)"J-49B8!^X
M(4S0&$/WR_BLBW@[$!5%,(FY91'17*:>]SR5_O<I>@-+'))&$YW-V^I.8\H+
M9Q,@OTF^#"E$L([$4XJ42RGQF@4$&#"@W'@L<^NE=YWEK3M50FVU^\;50274
MZ6!RCIA(Z;H^<J0)AK^44UAPI8WJ'._TZ;H+LI1^3Z?2]\ABWTR\21C%.342
M>9PL%6<9TL8+%*1DE#,)4+2SCH"GE:J[!C.5<,:="P$QE^+%;=I\JST24>28
M,V%<Z%R)@3OD:!V\.]P4&X,(Y5BR\[17 > S_*6B3,YUT/8.2Q:[5^QAF5T.
M2!^*\ #:L8+EZ3 B6N!B3132N<8("$HHBQ/U=+8(>1^*L)@V)-A<2Z$-1;7+
MP0X!!!I2F K8#V!)(.R#)423X/&F.2*?207%-<%!BZ/Q)O6MC*E<O@%ZP8H@
M9ZE1.%=6D4Y:,7VZS=HCEHECQ&.73JA4*@W-+-),";"PI5,^&$U7+VHVA,D\
M-RI2@PSA G$E,-+:^Q2;;P+SU@;265?.NJ(' .TW$&[T^@O\YZK7Z-(%3S9V
M8$4PP5LEE2&("AN!(@V8'XY*%+S5)E=8\M#9:-8.AP,L$^3[*#5)Y?^,2JW,
M+$%&I-(.U+/@I8J$=*&A](I\JSY:YR-%DJ6^J(&E1#CK4?1YY%1$&V5GX_*O
M+65C!H!&'K%ZS=,X"0DX.!%R)"D0 D\5@E54@#NP8#*UWZ*K9X45"ZM'[1B^
M3"D5*"=.$Y1+DH,>41X8E0 0Q%J*0%2(JG-QD;VYN3X'-' J]EP'I*D!),PE
M10:GQ DK6(P^8*L[BX0?/Z#UWO'_RU =SZKP&25@NEJ5(Q!8'G&?.P0"#(B3
MY9'07!O#.EL>9NET^5#%OS082%G$@6L#5DHJ",,$:!>:IT LYC#.B;/=;06]
MOO#WOI;B0I$B;R]2Y%)$BK AIH)K.'>IF$?J3<.C@(_6"$VETJ*SQ'M]4N#>
M7(S$ZY/307D60K/+4YI:>5Y@&RVW%$\(M2JX"&"$Y$:ER.T<*8HQ$DK(X#G1
MBG9VF_K,GL<MU+W.?,PUY Q1+R.+*B+O/0;CSCIDA3(HQXZ*X$E.8^="A?JD
MABY48FL:Q&L&P,VD9&O##5+1Y8CIZ%5N@L2D<Y2S8>U=E]@RG486O$[V..BZ
M!*Y36F#,4=01D\"LM=TK.[9QN[4THZC)K0 DB7+ITXD]T<@&[Y#ST>?2"*5,
MYUQNFQ<4_!_C85A-WX);QF#_]==5HHDU'((SDN?"@PD?@Y*(IZZ=UD:&B,;8
M2>6TXYT]<KR#/=2((?CF\8JD+-$88A2'2#Q'+NATTB($TH&Q!/N4H;"L+'0N
M!WG=QM!R Q4>?+*SK @!1K6F!'"_YZ*I>-'DI4HDG.$BN>MI_DQ(84/%+2.
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MRI$3PGKKX3WX@ZL83<RN,T)M@S_N26VW3A,"4FKJK6YG@.^S+V8P#MG_ 0L
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MK\U29&^;[#_Q;L\YQ:?$E3S>Z>>4[)_YID-P<RDL@0O-B2FA65-IJ,Y^@/&
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M&ZJUYCFE84$N3)/>W62>?4AIW/7A>-1H3YCY5C8>%NWPGSXW2=[U%L@.5YP
M<_R\=?#VS47.&8Y/D"]':'+)UB\BWU8*;VO"IU0[?<].19NWKY:(Q[7)[G6;
M[#Y-<9_EO,^2W;>S\GR9%L< WZETWMW XL5J%W2'IG(7OAP#,.]NLZVN60Q+
M++6XP+;VQ9=D+_T$_T[G\Z]&('_;I2_C('Q#OJA:%)HBEL<GPY>^J$\'YFPW
M_=H\:N(9QSLYV,__ *%6Q+/I4YNK$"#GEZ=EB_)VJY 2>[ZDP.?SYQ_/_.R3
MU2N& U#]"&BWFD137_P!AFR_/C5'H77&(Q-'H=HU@Z_FK)Y$\\Z_V 6?03/9
M\U>]\AY7ISL7-3PC[&^/XB^8CUG'%^/,<6>IJ2DQEK83;I]&6:=_X7.HMBX3
M6[Z8/KJ;:K[RNJ@?FZP%D/7[[5=UEV44[5,X%B<<X)W[Y"DHNJ-NSE.X>I_<
MP3=7I+RI?J,U[H^CJAP//9HP0UOT:YG'GFVQ]GGT+W940O<W^7%/"N\!/=SL
MRKU:#GZ>;,@.%?+/%R: Y^AY646VNA;:T"[*"M?XN2SA4BGW<E$X.E=O;_*.
M3XVX[U<_[AU O?LU17L\F?8HS-4)'_X]]W#O_<?L8*>S<FOI2VNRXRIY)OX$
M&&/TN9@= WPNAJU/ C#O]W<@D>AW*R?[X"9=&W>!LD.5#*-).<G;;\B;@[=[
M;_</]G[+#MZ^.7S_^]['@\/S7E9FN5MTQVXN"]'Z*C>M>?I*U0WI!5A7!-CM
MSC%&X20CSU%>P;*=?":?SP56TX>[*;FT3GG5%"TI3K(WL_/4#[-Y93]\&IJQ
MA^?['WL1]FQ%6&?MRLT1>]TU+%<G\*P9@$0)G^OC$-8KX_;+87-+DQKW:SNM
M[$,SK5ZL]6*M%VN]6+N]6#N';9_+T]#*IOIS"K.IPG$8UL67\'E0UMT1>'-X
MKHS9X6S.33VL_?EY9[^5=2\15\8MM)>(O41\VA(1%J*9NQV$S[!Z,52AA8!-
M$%$W)6(3!'5<#F#H>M+E-GO]SW$Q.NM%X:K8A/6BL!>%3UP4FOKX<QR47[LJ
M]_9A@MF;-,%>SJV*!W@OYWHY]P3EW+ <A?KSJ.S<<<;;-+&4ZW5!\"TZW+@A
M$OU[4[T/7?1B=<DLEW==K&XF>Z_VU)<^VU-?^AEN,T<38.B+VHWK&N3<9_AV
M<%87]>>X3IGY^VQR$_.WSE[-YMAX"?<F\TRP\5R6@HCU;>9NNN9]J,>#RS[&
M7@2NS)F(>QFX>3*0/5L9R#[_,Z7A%Z,F&25]&$S_3@)Q4-;C=<K O\U-KA%G
M?SN?8",-TP13MN">+<>C:;.^]T7]1R_B5N8D[&'>!HHXOA(1=[N"0VN4;SR=
M?8RJ<E!_/JU*%_QX_2<>S70::?9N-J5>7/7BZNF+JX<D4SSC;(JBK+J21W'X
M\=]?O^]S*!Y%<(E><'5%</5)%+=)HAB$(S-H<5;3FW:M0.NW-)D68;63Z255
M+ZDVB[]6+*GVGJ^H,I^KHOXC&C<JJ[5*J>2JRMZT\^@%U,H$E.P%U.8)J.=\
M,CD>MD420Q7\Y]H,0OTY-,&OG^O@QE5Q3?_ZU0NM3W.3RSZDR:7CQ38X-U7S
M3?,K0NOB^E0WY9TF.*R7<2MC&=V?/&Z@C'O.)X\^1)-B$SZ/3\LAR+5A\G/5
M,_&Q3@GW:C*U[!-,#41:FMJ<9.NE6"_%-HOW-O%PL9LK>?E\$18F $*+ ;"9
M/X](6&OD6+KI0S.E^2")7FKU4FNS>&VU4BM_ME(K_]RA$\6F4\;!^61Z,=6+
MJ<UBKM6**?%LQ93X'+X=%[98;^[2Z\D<>KFT,KG4D:)$,$B:QL];=.OI<E8-
MWYK1NDV4#[-9]&RU,K:ZH;)-5[M'=KL7S&6":OJH/*1!S$,ZKMS8DN*:G9F0
M^7SR]TUM5^[4$FJ)VU@LW,&^FT[?3:?OIG,AN6#O4XK)W7O_]^SMX<?7V?O7
M?]U[_^K@[5^S-X?O_QO^1+\='OYG^OSAX]['U[^_?OOQPXT="_E.?GW'PH<(
MH0<W+%QF+Z+CHDX)9A5L\> L>Q].RVJ4E</L35F=9 2COV438JQ3H[VO!D#F
MH"S_*-H6M],:+JDU;C%L&AV>!),>.^WE&0-( #/(SL^XLH'Y6N]D>X/!_ CE
MI'EHLR3SM6%@@J.R2B G2[%+T^FTO4-'-TX_]0AV@[&_-.$J',&K-/,<5UD<
M)U@&7\[RALN+M0G/6_Q.V6\[L^,:IE'766KK. I'9\V5H#0G]Y3V'TFE?FDC
M!<[3KINNPI,GGC]F.S/P^?M+O)-]/ YUF'^'8OBE''P)V1_#\FN;^#P>MG^G
M0"\8<3QT@ ]AL6:1">TJ%R=IF5(KRDDT6%KW$4SQ+',FM45.:P*_C.%])VNR
MG3H/-NZJ5+"V3#\?%^'+9":C,K.P\R;5[S8#V A?Q*;@&CRA*D^:ILD7U_CZ
M\<(WH/HZ]58NF]D."OC3GK4$]?TE>CA;W]1]<$.X^@!F4)X$V,TZP%*?E6/X
M,W7VA)\!H5W'R6F50W4"5#UVQYFILY2(3Y,V/=MN_B0OIU_5Q^5XX"]_^W71
ME["AP OUY:\;9KG\9<I^=<4IS.C*3V[1V$5Z:W_E6@!$1V%TY8E5^8]%,VG6
M#@AMT5-M&"32O/)] +A[LN@&V%Q?+'K=,NT/<,CT>Z#NN><7PW&8^R41^Q#$
M5)/WVTK3U+&\V1SXN67EN@!2,=648Y(D:23%=5M\*[G9B*-R"#].WJ8=^K]#
M=FQ@/M8D[FRG=,VC!FD38 P8.<D44 &-4&C)84Z^3K:E_=RD-4_$!:Q[&N>B
M#!Y5:<-;H?45YM+N3R._#,@=4!+I85/YO#UWI[M0)V*AO)\*VFO>JCX%%-TN
MCJFGBBZ5]VG_OGEIX=EI>>MQHR*2^#39<'QB84-AA.]*;P"*XY/3=I5\J%U5
MV*D:#$G!-B\V*D8#^'9"5_.QME/:2D.%01V^ @&%VVO19E'WAL.D%:Y>\I^-
M6DL3.0N)'H>IX_VKX$+S5JSMA<R;9T^&NGZ-IJ/]L[UJ,N#OI@*I-!DMW\E^
M#:W"NF:S3/..QXTV@F?-K7FSSA.].;?4VZWLA(T @0U/ \DY+$=)P4TXH55+
M;0V!")JI%;"M-,S2I=6$Y&]D#Z">.>Y*C[Q ]BTGS[& *RHW/DE=?UU(& 8L
M[&8ZDQ6]YDF)-R9O,=&TS4N4SB55GVCK@KK/&DD[4>/SBKU1YZ/CL@Y3GCVG
MP.O RX?)DJ;K_@AG%X%'^[!V)R_- [9I,HGFR>DM+PB/%MR%W7G5/V=5)9<Z
M&@""1&'03*51NJ=SAM6\S:AWL,C_?*D-[D5PL-#'T1C?+QL8@-(3Z]TD'I/Y
M?04PG&MLUC9%GT,0D['7!R+8CA YS7..04Y@)O\\[U3^(X13F.A@MCP3!T.S
M2M<L2S* 0>Z<=X^?\S1<'*HKZ"G1*&AVN&X[$?E14JP-CS1B=NQ<^IQT1M)H
M,/'&-ADE!FF^/C@DF*+T7[;=7#,()O'(EX07CAJZ3=>#1#*G80Q8)TD8D#_9
M%^-<\BN[U-0[J9/MB02:\->GG0\[&4AJ@/A3S%]G^[!4)[8H[]G-_)(#N1X#
M;\RMJMB1MUG6YGF[Q0@&<7?SC$C^\IXS7\G69S\4)S5LRVEQ ABD491 ">/)
M%V"C^7^,OX#<#_['[;31A#;_2-S*4#!S6E@&9./'R5B=;F5]HQUZ3G6)B("J
M "C.D$JJZ3\(S4?XL1[!.*%!@1.R:]',H*DP""O4-+TMJ[,,^/>/[69HV->B
M!(D.1C@\H:6K]/T<!FIFT([WM0#KW :7I+;Y8@!BIBZ]C04)! WWA$81IR\\
MZ))!>=I8M@VWF)/ZW-N5/%V3__9BN1?+#^%-@*L3']%%3\VXND2U(*-C!!,R
M423@!Y!I#;ST0,QU$K=E@Y0"[&UBO_&@916@OZK\DH9)T',J5K=;\V1JN$WQ
MV6*Q?RX-DD/C&F&0K):$R":\T[-+SRY+9Y?&A]>V,V^\:,/I!V")TB9C9T;R
M30GN"<%/'':GIZ#*&Z$_SR)C0/X3)VXR'I+) ;HA,<3YH M8*OT*J+UI\C)Y
MS*R\8P$\X5HPW[-!SP:/R@83+!_'R;(%K',2JN0E@AG,R?\)H5^#Z^*$T%L?
M]8VLTPP)3T\G?E,V7'3'0GUTI^GT#-4SU-(9:IY$)WZK=/J7(-GIQ+&6"'0!
MZ)F0;K)EP)29>B13CYO)Q3-?\*4[>SKNZ7BEBF&&7N:M],;T;KR-3=OA=.11
MU*T],!/=B\#.1?.A-PMZLN\2V2?KN1R/DF=G9C[#$V<&[<2WU-->3WNK%KFA
M3K&X17T\<7$.&W%XP:L^=2A.#Y#;LY]T\@R32*_6$VI/J*L1DJZL6P?CO(,;
M/C8*/%Z#<6?$VWO&>W)]Y /+1I)>.J*L@([\Y"QI<LHS/= 'P&G^:&(8)Q$$
M*9:J&K:!,JED=U9^24?OL_B9JHG4@ ?U=-S3\4KPP5QTQR02;.[T,I%OD0))
M$E6V9YCM/4!HB?J=.4V'T,D7 =^G&)G%1T)Q/#G)G(1]P:WIN<-Z$F@U':?Y
M$JR_E+/54WQ/\2N1W.>'BV8TJ@H['DVI< HD;!@&N&]V2#]NZ\O=R\EPQ5_=
M'J<.0@IKF/=GV+*W WNJ?PP[\,(QS+E16%;G?C:8Z0"TP30EHZRF21>%:^->
MTM?'Q6E[6+(8F_>DW)/R2@1X(L1)*-11%4*;[=,TY3) V*>C-L7EGO)ZYA2>
M)6\T9R3CJA[WLKQG@+4SP,)C%*#ITY3)YZOQ4<I4: H?-$ESOZ;E&1U7Y?CH
M.$6WP[S.LE?G5V0_3!(7?OWX:I*O\.-V]N[]P>^OYP<Z3X"Y<.R2^.AF#EK(
M!WV._";FR/=)\GV2_*V3Y'M5UZNZ);JGYH/WCY)':MAX^MM$D0+6)S4R WUD
MSM*A0+H A,LD4K\XL8#@&LKK45E/JJM&97#S.&7<C:LP'^$RQ6&-LS_55CB_
MK@F J8[,L/C7A-BGP&S_]\/Z')GUZ4?+W+8[6899XQ=I:HBF;6Z"\%H#\)_C
MHCHOH)&^>U.6OA$]KQ(BW_,P@:+QH,Q#[C>O]J8;.U<LXL9XUEZ ]0+L45V$
M=EP,@)JSID5,LOL<2+7S\&W@BU@9H.[Q1."EX\_D1C<QFJ*:+X0RY:F!&0_=
M<3H6<GTF0D_2CT+2;1AT:.5V^@"Z%D:>E,@83!T9K2+.PO (T.,LU7YAC$F2
M];"FHU;R3PLHP&($()OY1)M9Y8S6C=A"UNF=V4GI@7":))_I=7U :L\6JV0+
ML-*+UDL^;&VG+-E.#066BP,#V[S+GB![@GP<@IP8\\GXN61034*N "6??2\H
M,(GB<4^L/;&N'%14H<TH;)Q,KAH7HZ;:#A!170Z'8=#38$^#CW0$>"%/*L65
M#E*QJG$;U \4-6H0[FA2M>SA25,+SL=[:N^I?36G -/*C],8ZVGTZ#8 AJ,R
MV6R#LFX^S\J>?@G#%+%Q'J(ZYZ6;%M89IG:Q;0C30I;R;?'"=-K=AF3W@=@]
MC3_N2=<DUR!<K"3U-<PBK5/.[$E(>WZ4'57EUYEWXVSF:'[]U_V9H[EII]&,
M^A_CD]-FP;)#>/ROT^K*'])7X],ZVP.Q/QWA/PY__9"^F [3<T'/!2OA@KG"
MW^?UJGMJZZEM)9&D85*].&8ITJV(A4N!G*=C.RA<=AS, (1I(UP#T&2;;7@4
MRM,RN6N35VQ2*K:I7' VJ\!?@O0N)W[D<R1MFG(=,P0SJV9_7@FY)_.>S%="
MY@7 @9;,4RN(B;>B.5IN.R&<1R@,PE%1MQ%<\T<==5/$NB?/GCR739[S1':E
M,GT;3)A <'FYDM&TN%$Q]+ <U=G.(N)\E%8SS>4=[4MQI85)6[.V3<F<K_??
M5DB;:\VR$(=-JLG?I0O*]MSI__V:GVPON_O)U0&O:7]R;3WYG6FE_\NO]-VB
MZI<KNR]LT#"IL0Y+=U(F%#&IP@K/KK<GM>#KT+2U&36UJM\E&^Y@.SM(G5S)
MWA1A/+!UP/9DW+F!T75=#F[9UZ -UTSO<-Y1X8[-$:YK:E#?IZO!WO":%BVW
MG-.D.4!]H>_&EP*8]G*UMJN=-HIZODU"2W7G;/-]MIKO3W%95LYW.EK8=V-[
M)CO;P2;3:ET(.]E? 0),.RI<>O2E[@N@55RZQH_#I7.\F[CG];>4KI6JJD^\
M<PW7 4;93@Z.YNT"/"(K 8^WA=S3VXU/V]8?Z=3P2Y%:M-S4]F&:J@*ZM4Y)
M,6GI4RK7$'9GKD/YI !W/5>!>]IIH5F;)?0[NDLJ0;<5R\U,.JC+\UYFY[U[
MYC7\O':8WPBXS;73N*#DMR_UF9GV"&BS_]I]GE!JDPIU =H"T9A+?K7II'R6
MUJ>UWY)DFHS7%'(OJKG&&Q/_6M6^R/3Q\(QT&-(F'4Z?/PV"FW7  7J?:T#?
M:@Q8Q+:Q#WPQMT+)@G2F'EU>K/*\_]!)@*EZV/VC9)<6]7=:KBP2&JUN.E?\
M%YN<-/7P%BNKVS5&:63EW&;N9)^&@\;03=O\-3'L1-^FJ28F]0V[MS[W69.C
M\ST_W^]V7^:)IMG49G)MI916V+7%\NMQ]26<I?8R;8FU]K[I C9WMJ7[I\I^
M+@YF7CC.PAGA[J,P;+KKM2Z"J2"=RT9(PUY\T*0R1MK]"TW"4IA7V0C0\^6
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MUL02JE.G>"!<:RXZS4_ND/<P58F\UP,;(N\A[R'O]9SWO/ LBD):.M6@C\4
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M_<O*@\LT@U742T6#%9'<7L_PA$MMA 'C- &1= 3C=0"MI596BQ#CUL8 7,_
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M*IF#(@A%$(H@%$%[V<OIO'<T,1"D1/,B\P ^,PHA99L,"SG&K?Z-'99NOKV
MT-W5JN!Z0)_4$%(A4B%2(5)A#ZG0<FT+\FJPMK:]%S:#9\&!9<$0(X(PHI,-
MG?NC0EP8Z!,5=ET<@"6;.RG9S..IFX;'1_FH8K">"^NYT)HXQ7&*#]@I#]V:
M^T_7L+VF:_B1)OH0TC7K,5[_6V*MD%+<*+KE26K&B\6JR+JVH#,FC^6;/4"J
M@VP0/,"EJ![C_A,L VE.A0T^@I2>@+"2@]6*08P\JN0#"ZJ3C,@%)OU2(.GM
M!HV.\T\%B[HZRHJ.-"/]6_'!F3EXTR%%H",^8XJ(2<5,N 89<JC'/!2*8"R
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M#=3RHBF\8> Y*<)"$4=(423"N=LZ)-,0 O<$:$H61"(&VH2#R5EPX1FWEAV
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M_XJ=80Z:\K&R'BOK]U=9[[7SJO!]2O68T)!98?[R)_7"JJ(;I)6^BR#S9KU
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MEM4^IQRLMQ%45I((KLH%;FV;:UWF?3734RP24W'4=W<J"F?M4J.J<]<[)0:
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M;M:6=?>O,=BCV@MH7\ '9ED/P3JNN$O 8!Y&!Q:8N=@X#QV&\I!!UUA\^>F
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MSD#1<-S#<7\RS/D4*#J>EN\ 3[R3Z,VKZO2TPEM7^H_HLZQK.9L'A.(1":D
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MH(4E'#'%19%S4M T(;F,M66L*&2V,<#R-A!HQRM)^7H@*.'GJ<4?P$@Y/JV
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M+.ZMU!XF^(GB-X^V9.,N7. ?];R<PRKT#8B#:'O1FW<OK\L=PZA?.DG3[ E
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M57TKNVR]@P'92I6^E+ZE_-3.X0M':S50[>:AR05^A \'@U$]W+J.,?H,&@B
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M9!S5R%L<"+/&::$/S%Q+"]"7Z/\LZ9^/8V[_-G-_?!Q/)N&D^@6TA8F9^N(
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MRB_GB><\),>CHX=LHUUH<H T683$,X#H<T+((0H)J:Q7EA-D#5,@)$1 FLB
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MF6IY!Z5^''7-P-V@_&(T$2FLP9H9)+ '343GG,.@D-:\UI'SR.*C9AH>*.V
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M'Z? ;4,"T*XG-VM75.8\44 ^M?8 <T!L,5OIDZOX%D"H26O*K*$[ZY,[H@M
M&1AFF/8!LTUD@,M7![F.- #NM+C5,IL^0O7OK3D.2[U\Q5\!Q>%!Z>??%]TB
M>OP_!BWEA8JK_2[G=/I)2[^*+1TS;CE<^#S.CI]M-]0TV9F3G9[HG]<-DM98
MFF:"/0-+JD.B)BT"6"F@9/9:9W1,@JF-A^9%K)C_,IMCH*Z#O9->MER JAS6
M)8BI_F?I/V1:RQQ\L9AT@B]MM64:9LWLZIX48DQ,:M::):WZOMK(R9KKJEU;
MYC4K"R7!I+4?8,N+Q(ER#!ZXUCB9@XDF>R,N@>/,?!Z?+<_ZD/#Y+)U0:^B
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ML[ S[X9D.-W(U.R=VR#93V?SG #9N;.:!G3,>\;9'B.EG7/+ B,H@!!!7,F
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M7$]@MB9%X=U\_#$9+N\FIJU&.UH 'AJOWDZK-\L/RV91U1FWV&8M8/90YRA
MRHRJ?@\NS1M/D>!WR[D[3;E/JPR6D^J;=&LG7;9_[T7-R4:\\3+JV[\SAZFS
MU&O"I,V&:^W(;\;?'H&4DEQY+ EP9AO!0F#&(DVM0S1$3C3'DMFM_$_*(@[
M\Q&5!DP+)L%"H(*"H&,.8T&<]7JGF_+G!!C_0TY+:Y,]6U,!=IQ_:NYO5M8G
M6(H3R>MA\_=+6V!7.+[3L3+,VJC[-^.CP"97U_#LI" $*D%!2%67Q%H4!>9,
M*$DU]E>QB3%"HY 8A61T<L?!--""@Z7 F%-88"GEAH+P=S.? SDV+3:]&)3I
MM]U'K[>DQ*CZ,1D!/2N;K]"INS.%=\/G,'?C)H=JVXS4:3::LCVPPLEU_+LL
M_$T1\%,P3A.'/8?'=+FZ:2WF W#!E.?ZY<>==\O+ZDM.8UDMN#63^PM28-BM
M&3<;3TDTT6\K9<[\Z_!I0]7,21<P4B*UQ&**(LU C<;2P#%%Y@G>XK2WIHT>
MEN_F;3Y]YJ]OXYHG[\W4=X#;U*WAS^2^@3-LWL8W.9)E?DAEXO.F,Z1O0U1T
ME.?[#IF>SE/)S^G@4G^*KK>F":]X7O8PK/&NY,Z8]M_TK )8S1'P@5I1H'WE
M@/I9X@,Q(*NH1B ?!56,X)J2@\G('R]AML$2'I;VARY*5Z2_D>1I?,K"R0E8
M.1=SD;:9BQ'!J!A/6^FT%R.7T\5XTB:-F7FJMDCHF&R GX*=Y_8>.ILL]9I"
MER2J-Q?KS3PV@G$ITN;^L1RWN0HY?]>'.)ZVB4Z+M>5<65R7@=S3A^^Z?ICF
M=))J+-M^'^/8;JU-^^H2R9+;#D3YN%ET29,YH):!TGX=+HNM6P&?,[XF%_VW
MJQ451G:=29^/N3V8SJ)MT8-M=I#I/*G#BK(> 9/5V%!JO41,"S!KN=1@UNJ(
M'.>&V9K8(+:8K-<NUIQQ9+1VJ0P6&+-AP'.C8;(F% M5;P>^<@N )N6H)GLD
MI2.^C=UIKPY[KQ=3;O3\$E]@K+48D6$S5KA_D@]A6GV8SYJF;Y&PJ@#900DG
MP*E2?2) (I4XM*POMFQFE36_IUZZ4,!^<P-07,H\B >T!4XI1: HU$@8BQVW
MT6F]E21P)PKHJ@'?QI6+)Q'!][-FL7^*[NWPGHWV=[H; C;T:#^JWK;F\")U
M,UWA_DG7+B1'R,9=+D%74-*6.JVJHMJ4Z;%=IN^. ,F8$YJ*P)&U)"(N 764
MKBFR6.CHB0L[JL<%K4W4M4*UPC)5G >PB"E&44NEL9(X!/*D;):Q$3\*?&LU
MR;.<I)6Q"AYC/G3JQ7$ADJ.>*,,9PC5@$P^U0-I(CP0EGC,G?:BW\@.<=;4+
M3B%!B$)<!8&45!2%P'B4'O[6ZDD1"1\-W]K9M' :%I?RNPC@VZ(T];7 0::D
ME3J%R$D-HCB-R#.U-T0[7>NM!/#;". VY24L'E<%)2-]%#A]C<*97<I=NYZJ
MSPL-EZU]BN&ZRP.72]QRF46JK?7)%Y'ZB)Z=PQ/:0$ J+3;YPWIR4!>%2&&$
M\>(BE_*F\KC+MA4IE0&EL@USGJ+E73^1>7)#I#+DX/MRV'&'W&UOUF73%LWU
M!1Q5-.-YUY;53":SKH[L+"Q.9WZ7[Z9=S]J.^LK<W*8D71+G(>43MZW<+FOF
M4CW??-E5FZ;2P%P^G52\R46J+S/NM/51PD:: )H=+#>U0UD/O?3(V:UB[9$G
M^7'CL[/@QULWGO1M<D'FS_Q%<A!=MFQI&TZM<?*<B;4*IZ2RW-9E<])5@>>+
M^QRNM;0M4^6)%VNQG#Z?K//XI+SQWK?4K3?5U;1A\%T!S:W4V91/M@Z _ACZ
MZK_Y.)<YYD+,'E=.VG#1ZA2W.@9?5!^6)OT6LB^X:]$[AWTMEO,K4B[_Z#<\
M5@G/5CC6HE?Z^3O@&W^@WQT "O:>[NLP:^9#BZT=NN6NO%?-W0:8;"[-G\TS
MON<3O832SHA6*MN,7:K!$0@Z9K@64CBDLZ#C!'0WP2F2P=LH=:1L>S <YSPX
MGWJ,<0+W1*&0IHHAAT/-J8O.&G\SW:V'V8$$'-4C>1P"+H4]+S&O0ZE+7,Z%
M]ST#W>+5^_GOJ'HS.&UO(YUL2 O;3#\Z-<=0$R"Y#0)CA7 0*3E5@;8)%A.*
M+@AG&><^58+<G5Q?<H[&IU6.1MYWVVEKN5@I$4<<MM2Z%IHZAWRT&"STR)%U
M*M43<0<,7A/JMEP]=T:;$K:\-FR96R/U>MW.5+)_V]2YAI7B4'(<+ONK)8J9
MMNTC^M:W.6[KEGW?FVS#[DA?W4A"774%O,Q^W8CBYD+^YK*GTD;RZV_K5_[6
M7KF5!WNYNE6^5C.J_M:W^\B]"U=8>.T3KPK-IJLKW;KQ]U7H>?7NWW_\OK54
MVE!T-GD ^Y.2O:51=SQXU9%D!Q17_47V)*ME<R!']Y/) T>5>JZLG<O?K_#[
M]53A/6_<!?CTALMDY<O,X]8$V >3G W0E01<!N_3->%\T5;NJETQY1W=T,Y3
MAYE5CROXWF>ETILS\R&LM0*]Q2EO]O1,)]3T/4)MZB3CPQ:T=F^T^&-6C+/5
MS+=[VN]H8G]\>BGGRCIK(PH6M PN741*@9H:C)8$:RE-V.Y$?(=!75M5S6\O
M%;1[*ZI[2L$<QL8(B2R-H'+S6B EL$7: Z$KK0058JL7B(^U)F!&!Y/RJ8DE
MR$B1AI=Y%GRM(B'L4;<&^C><QPFLZ<AJJ3:=5VOJ^+"THB_WHLK_[.HU(W%=
M4R8"(MBG!NY*($T2NF&JI8]$,.T.T6OFLJM,3BE.N1F96?_61K%SS#\CWG<I
MP;O/#-C7@:;K+ IR\\WBIKOX;_+2&]?04=>J!F4@5^OG<(3=:\K I)W 2BU7
MNG/.$O[G:2JW2/K=NXEYLG,^RN;+0]+@?M[JJI/Z[>32]LKX&:CM_J1S&LUW
M-V4]Z1N]7H,>&S;&^J7IQZO618IZG85- V*U1I[52=+:#U>?U$=>FE7@Z4.N
MQVG[[73K:4,^L+/442 -49JF=GN+9>[^>.7'+CQTGD:YC-?MUI/<0Q;DW:)O
MF;']359OFO5Q+NE;U(Y^3"U>?9<DO:M"*7?T7X]1I5[Z\X]=V_[+H-#*#MJ"
M1:JM2H52@U(ICJ,U"#5,,1E0<$Z"<ASJY(\&,Z"6-!5#4!:VF@HP(H3TTJ,8
M5!KJZR@"RX$AHC&H-,IIQ_$URO'W;:BCU9%_ZX[ZI]G\I]P]M8\MW5MCIB=<
MRQ/-AIU-=C*DQ6R.?8/_R[VL\_A4DV+-:8YI2-&KRWFN<3QO%KF, @@Y5PK&
M<0K]Y2EO*;D8!$,>W[IR(JW]7G6#VJY:T+1M,MLJJ.F"7-YQTG5([UKVGMSP
M:>G?(0'YRBC7IKDL5AD^NPC"**-J!V:!(H@K3)'6*B))L)5>@,%@MVQI7G,N
ME'?($*I3' *G\=\1U3[J&+"B==QJ?G9IQZQKV&^2OZ]-L?SN8LO4>9/$S+NV
M--9\ "-IS?[.C.>7MH'R!F<Y7Z9(11>L1G2=Q= O,)AA,Y:O>S_A+HF[(6W7
M0V2[J#KG?:S3&0CE7$"5?^A&V;0]J?O^SFU]\4J[&A)<1KO\>"=M=^QC<-1Y
M97R-N4.>)T<=I372IHXI@1M[Y;G2-EZE0!""!JXF2 HC@ (-W!.%!0/?60%2
MTL1ZNV7$72FP[P/6]:'K9WR#@/_WK;KGN\AUKN2)D&S0Q->3VN6$\Z3)=NWA
M6SU]OS9;^J(_T[[HLO1%+WW1[](7/8N"3ATVZ\E$-_/9WLG52Q_C>*^<X..=
MV?_^%R+QZ_M[Q@ZZ_0$[$5L9=78^F5V$T(7G5^'U=:=H<3)^V<EXO8]Q32>X
M!MX[O(R_OWMW=_?B ?URL(Z50^XXG& V!DU3(S7,9 3]6+DT7#=54VJB G.U
MU%M)F53:$#%<B853B!NE$1BU$CY:(S6ME99;.O43.,%$?4+K81?"G3RDV^D_
MS#2W_R!]Q\)][A=R#.X70HDQP2OD"?. ='4-FI_SB&HG&*8@P-E66;D0TBEO
M#+*6,I#VZ1XL!*I%J+7&A&-UE.Z783=C>#CWR^OJ&WH,N.J#9K7 #I$H)>).
M$Z18D$@H6N/:1/AIJP*S,-4'Z'%Y58R_S@X\MLM_EY,:=[KP!E^8TH8#6CTK
M>?)2JN-%6*S/T[Q8M39I=BDM!TAU?$'#J?.TTY^G?MF5]6;V?Y3Y$25!8LUV
MN<Q>;M6E;>-E->IVY^%?M4LV+KMI!L3:(C9RJ'<][YH\B"=-=\CC.^&$\RC/
MT%ER#6QZ5B5MJHGM](4L^O/UL9W#V>_M0YO:WO*I7TWCS3^J?Y_,;!HN;.9_
M &>;+R?AP%D5V] ]+D-.!:RCQS6R.(W]PUB#UEM31#!U3-+:YD#'E2QFS*+0
M."(6. >=PQ&D,=.(,"QJ8PWEM7EZG8.<Z%J>@/8^:*WC.+2$>6A;' P?G[$G
MJ2<I0P:,-<2)CD@'HE&4GG@I=:!D2X>^"SX/-MA'3J0</MK?-MRWQ68W5,^#
M#D+%D3A3UP918U/Q@ZV1\H0C*S!AT4O*Y-8,LCL-0G6GP8- ZE!A&Y>2<!\O
M+MXG\-Q@*NI1J-T/T?(ESB:3V:?<_B)C4K,\@]7#BYI+EW&OQ>1940FJ*]UG
M2%31C#]7("47ITW5SJO<X,2OAK34 Y@ SR40]K^J]G]_[M!ONU @QYZ[.'!:
M8GH'["A=CB;F8K;L+FE?1S >X:_[ZUTJ$#]OPJN^-<]F3#??]]5J#;"(57#\
MX[@9V_$$D/U5_Y#U*^%2OX)>?C'7(\6_7H]=]R'8'+S^TW7WDD>^3X^D?.RE
MCAA]]%UBBM?^]]A0+J?Z,+LDZD%?^><_+>8[64*7M9**S:QQ?WR8ST#+0IT,
MB?E_K],0NC9'YE6;*9.^V"U9]G"3S=P93%*&3/=5FY8"7WQ, X^=F70LO67S
M6TE6:W=V*2SMXW8(@QV9%^I \J;+F+JQQ+EC/L6?%OZIX/FP\+N=O#X8] "M
MT\\Y+O80D%PE=O4)@>>+JIE-QK[JU;'!XNZ=G<LW.IQ?5[ZU/]OYG_[2*N#Y
MSTX+?WRLO^:L6K:'V7!/JW":PFD*I]EU.'_/=P6/,G<Q %#S(>2_^YYE^4/N
M6];^U;>D*BRHL*#"@@H+>D 6- \IC1T>D#_E 0?&+5+-=?J<<D;R']^,ISE+
MJ?FV\*3"DPI/*CSIWCSI33_>-C.8<9JL,FW&+G_*C<17C&=Q.ELV9NH+\QD4
M\_F2 R^',[8]> Y@%MT>#][-G74[]_8H#&\0Q4(W.L"U5.V3*RGSXJZD]$SA
M_J1R>OWET]DS@>A3 .^A$'(GIWU(@.:W/RAOV#-'V5+.2:0(8U\C;IA$.BJ!
M4CN/.@IM7;TUXM-PIKR2#AEOTNSEU#R$!XJ\8[7RDALJM_H&W3DSJ2VH__ER
MM,O;E/GU_M1,W[9NVU]3/^$&;)W6P7OO5"5UHF5](O'^P>N%VI\9M1?Q\PP@
MNLDL;P[*?QTR9KX8.>2I9+@V8"$8:A''(%U4K3"BQ$87B5'>'8L<ZGUO;UJO
M6TZ@_0',WI_,>/Z?R<Z][?R-KJP2WZ:J4HR(*@*L"+ BP(X&HL\)(9]6;NU.
MH:>,UBY*BXS2%$2,2I..O4 D"*D\I32PK9Z'F@NA2<T1$SB-YA8":>DM(EAB
MJ:FOJ12/)V+6W#M7A,QO?53G^\N SOLT961#3* FN%=^.4^!G8<4\6I$5LAY
MM>]9(?AG2?!% CT#B!83ZIA-*$6-MU@'%(G(LP4)4H%;Q*0@4M:."^H/9D+9
M+\LW>VOYMHH0_MP'![.]M&_^SOI\6K8QGY;=N>=,X0.'%$QWC!A>F_-?(H:'
M9"7M :[_F_T5P0^9I1=EXQE ]#EIOR]&QS"&<LUJARA..D9J3V!$=,@%;FHA
MO#!ZRTTK)%'8&8),'07BU%JD18V1L(19%8,1MGX\&_K?VXG:TW=@C\[N/U.;
MGM18GU"U?XA (?9G1NQ%^CP#B!93]YC%D Y2QB@UXA9;$"D&(\W@+^:)B[4)
M]8Y1G4,60X,(&9(1V3^-HS"-(L6.0(K=++G_Y?#BP2@.!<Q'#>;GR2U>F/@J
M.N]QZ+RIM2ZA!7>'%)(H14Q/&)+X/K7>G4S2V)!YLF%B&)<(Q?.5EW>LH#UF
MKO2X*'O_$N7G(FJ_N4_WTGM-JN)>6A<1X[5#W'&-K)01U1QKJWCML=T:USXL
M!]9//1L^6"B%L/I$*#U,%]2=R\*?7!K?'%7O7&U?).K )>I0(%HLT.,0B[N%
M5J12R33% '-%$*^)14I2C8C%DCBF5/!;"?2#%%I+D$V#"+GP$2U56L]1PQX*
M^$K(I<0""IB/$LS/DUN\,/%5%-[C4'A+R&5X(9=2!?)$?>/6QSL-F0\5"7DP
MAR8=T>31]+-E&A95PBP/$&:Y!8B?H8#=XU$2+'CN,,*$2<0#4<@$0Y'2MI;6
M<17LED?)8Z:=<Q%AXRGBCGJD',:(1>IL;:0WF!YO]SE"3@33)PSC8?J%KL7I
MP45"CI1Q# 5\ST?:#06BQ1X\9G'E=> N:HL\UP)QE0:4&R(084I&SYC&:JOL
M9*#B:BCACU(W6018$6#' ]'GA)!#;%+'A&1"U!9QT*-!7("(43PR1#P5$02'
M)7:KB<^P8NRE25TA^($2?)% SP"BQ80Z9A.*>!FBCAA93 .84)PC V85R#>I
MC-*1!\P/9D(==Y,Z14N;ND$'*$M-V*,%*']L!^<:.PDE0%GTC:/D,@- R!>C
M9FA2*\4,1LZ2B#CQ#EFN#-(R$A>M9=*9^YC1XYE=/* -O<;N[AU1%"<B%U:5
M1/,70^9%[CP#B!8[]Y@%$#5,,6\=4DQXQ(6WR 2/4:T,5X'5W/-[U4K=3  U
MAY! >YK4=5>$=_.Q>Y1HH1RINLBP(L.*##L:B#XGA!QBM! '4:L0/,)82<0Y
M-L@0CA&E-8O4*ZN9.@XSYX:APB>)%-8C6B*%+XO8B_1Y!A M%M0Q6U#,ZT""
M<8@0[! G\)=AAB,B2&V9EG6MMEHDW292^'BR;3-0>*#HH"BVT!,$!^%#.M$=
MBH ??US;9%[<>.KA#:_X2##V]>O]^R84/C]!Y.U3&]VTLXF_NKKK5M->FE[U
M:KR 5;C;Q/$RV:!,3M4ZR=VG#]L3[*-:1Y>[G;I\FD._!6QN!(DWDTF5PQ(H
MIU)4)G''IOK03A&KX(?J+)AF.8</[17 X8%75M&,Y]7'Q!'[;[Q9P-\Q_YWO
MK\PT]1>YQ)(J?$Y_AVK<5//@9A^FL!M??1HO3N%S<Q[<HEK,X $SN*9;R0Q8
M5W[D/ #R-0"7J@GSCV,7JO/LUSJI %KN-#WS0YB"^3&97.0;4J8\[+^[K%]9
M]Y[QQ^X-HVJMJQ#\.C%IW["*T.)ZN^F-770K2[!9VX5ITO,OJIESR_E)WONG
M= &L/^UF>E'!27X<SY8-K&_MOHU'NUD#8&N:F1OG=630K%JF]F\>MP#O-I9/
M8[6']OW-Z#X4>6@D*^2V(K<FX>%&!L1).D XMT^ 0$,ZM'_=M9A;O.E>6N7F
MIO>VX60V@E9($?9UC7AT FEL/9*<>B>=E(JPJSIF)*!A,HL1"4$C'K!"-E".
M5(R<<4N9UEO9:#^>G4]F%R'\WC*>W5KGJC8G*YC-^QD(I?7?OP?2_G6V^*\
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M7SV.&I,MRX%J,N\W;("F5Z\SKZYF+0A79@1PAJ2)KRFM 0#F!Z7O;"AE("1
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MVBY[[#XZVJ75UPLZYZW"$;@[3NP)2Q!:1 !U*N#[C$K&MAM2W86E_3P%[ E
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M(P-GU0,0S(+,^DG\\&Y=O\SK1JJ&EHCO@!WAY:SBYX!?^A+].L\%F?-]?[W
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M%W" W6+Y4I8MR/CS%_CKCA/B*"J7=!(FU51_88R$_E#H5J:6\B7 LJ1GT]Z
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M%#A;4',<>#LL7\SI:JE.556O%G@W9;#(<HWKFSF>Z^*3Q?!+BV_#)PE0ESA
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M&3@?^U6@2*44C 84;[AN79XHV!59TOUR,, "&FTO-LWB#'*:!Y+3^^<?9XX
M\;_6*4@+\E@V-3"!HN*+!6&R,]F)3N'!6_O$I_YQN!"FMT_;0-\Y;+%;5HJW
M\WZ'^@*$+WX#OW_L%PQ$"/*T!,+2,IJTZMVCFG.Z8'Q_A0?&Y2E%[/&'>HG8
M!@KX&O=%X%_QALOR9 &K1^6J.">57A_EGLL5Y7$!J.$4VU;+<U3VFVY!>C7H
M\$M 1 )%3;:/WM;Z?*7NV2P],,Z*5%<9Y?("[C<>+FCT[SS79_AO,'-@E6+>
MH^X_CCX<823PT[(^ ^)HG6/8UP(8],-EE(?$)YUGY:*%\UD!/]+IAPI9D_D"
MR$;^U@&%@>7Z?(;',&66AA&94[TZJP3>HRD=V!Q> -_+&I!E@4CASP(FR_KS
M.? V3$+H&>C;-^\&!HHO 0YQTG!,E80U<6#8<)SXO3?<\?X-^[LWYG^^)7,$
M3&E,X#M!_@9D62(?PP13S(VL% .9[[RGY ?O!Q\8 W(9(/S )2[GP".]'^BY
MSI+_Z0]^D $^ 9,!*QS-,C(5%VK-T?X ?._YQ09^(Q1 F\C+Y<2IL"Q/,73!
M<V2SFJ-.-HC0,[O<V-ZP.T?,E?BTJLLE.@OF95["]F9P"YBWVBU! $/[&&/L
M<%ZK-?)@L&^ ][4]C\:,0#"LR,4!-RI,%1Q/X-VOOVZ< &6I+O5!*&UQ%FA2
MMQUHP:< N&&E/WT8%XIZ5*/QYPQQ ( -[%]A& QMPM[@[J& NZ2_\EJ>.[P"
M7-8Y!*NF7' 245+OVP@V?69G\-0"=Y;K6"[Y9WBA,,45++1Z*:?W3EQ2( &
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M&V[KS2=$B%,NM2Q4<-@DS'5!)V@/INS3J.8: XQMI1<[('V)QWE0'B6;O?G
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M$QJ@B_')(]? %#XG!T43O57+$\+ R;J,"62V]24\-8D-P,[@R=U*U&01P/F
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M?1'JH$,(D>)I _",8KD%$<PFX%B'4Z)3NW(";)\W>0*G:#&^+$@W?]GH!"B
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M^;ZP>3TO&ZE3!3:]3<>_OC,!'U-G/VA1FSV')FXA/4-O,^IK7%^YHHZ[DRR
MXY_?#0&EWKVJ+E*F)CU,]!63]^]Y*94DJP8G,3EBKA9HW)SO\^/VH[#&35A:
MM+1XT[1H/.1]0.!4+67=[(U!T!B*STIT?7[M%-.'<B[$[MXI2][EDWJC>%)3
M@<5DB\FW)E4F.#L8UQM#ULLE;'O=F;!0UW=2[/%W;OHI8F(621]M;T^#22^=
M?0ALBX >8A%0:(N ;!'05Q<!66%EA=6W%+_TK2DQ/1:[YRS["AAL7=F;[?@#
M32?I=$8%X-3ZW"%"V["'^AP^TM(F-I/.3VDQWZ3W".O'FV?02W1:!'4JZWT!
ML#F%HT.'[, =4ZVW@TQ.Q8;I-C=]*G@%W&^I S<Z*8SL)$JLM!J@):K;M&6P
MS+_J%3ITV>J0"-5V(%%0PZJ-N4(7)ZV\Q-\LNEITO6D98+)PV79J]78D0AL-
M6-, _S7]64SE"/IVJZH6&_<3AO<#Z+?EBWEK3QLZ5VV,ZYLTP'WH_J1#M?\<
M"IAHUM>%;*./R^J.K#2ECS[J$X4OSRGYK1>G.)$.;RBHDUYC$DV_R)+TE,A^
MIHD<^Y[AK.F-4:&T##-0VA0 8<:L^77H-;;F[:?6C#Z8CHFG)>C&)?T@^QHN
M0RL:G9W:762*!5#S8*AY /M5S2EH!OU=S4-(PWN*6/T3%9; [:0Z4HKOF/!\
MTE#\2.=EZU(TW4]3UQ?H]->^C]J%2 LH\!NU,Z(F./1,Q/YZH3O4<#.=5I,*
M%E=.T!I378FBX,MRD7=-.Q8TP)7K\Q7Z%+$>O\=_4^HU3G[7]-BG*^LN>2O2
MA4UW@9X"S#H=V9DIEWR]/>C\$$[,XN[V'.@Y:%UU8Q!AH=:F;1CH?(VQ2,@1
MB-WU,#UZS3\[ CBO[F7\1BTQF1YY8;?""Z=5YV^PS\_<^5M#A4" #%1D2&AK
MBA5UHCS93D@E7Y *PTO\+[W##+^9+'5CX(;.T>_;ND[]G!<D$0WEQO62^NSK
MMKK8+';1)^&.A4P6WP\5WZG77->,5<G&2U TO%TWG0Y3CA5LVX,%+N/1U(K+
M:)HDY<^P V6)$ :%>Z@M&=O#[ZN7^>>DI@A;U7]2\G+A,&BL-8U=U\M@^3DS
M?R)C+W6%-CX'VY/M*U@^AH-9Y&5M9\?<!*+-D-MT9N0%=18QF81Z0O0%(;UA
M* 9.;-8M&>LE;N'D?-H:?A#%6H/5>$$3"#Z,U4-84EA5_6N-^?-E)#),[LLM
M0; +B"&=*S0DT;68@*$]FO7A^7TISL [M&/!Y)1101!O-SL%3%5E"O-3G4YS
M K+@]RF8MK,;+K,(-I(99D;B[):0[8G=;F0I8&FM:?L[^A?),;CBI>SK>VG!
MD]R(QG0Y^(9H,A73&M2:1I$OBC)O-Q$^) JR/6]W+>>+"B"_3-87-S'9[@M"
M+\ R=^>*9O0$(2>B[:)2SI$@RJ&8ON^#T4_[V&F>O9O80RZ7,UU,>*H+&OM7
MFH:8>MA[C76NIBE6_W@]<QY_P)97P\N&O8Y]HO:5JY8M\87*S">$(V7$EQ9E
M7R5_2<.UB]/)R[:?A]HMC1/#DN.ADN-K);CI64S(U"U44W= "B5Z@'2IM3E$
M[6G:G8A#Y[]=<4WFA>FOH=N\PQNN7H[0(__,5!6C"HD=9VJL$CV?='UH:$27
M7CO7G8Q,;Q=R]9OK^M8Z(ZV,OB]E+$1TC$K=;>+JI1/UE$[-V!_JDS.6LZ[0
M9(.[RH+ZY2YG5+-:P]]\3?K!I#.$(=:!0L?ZI[&G8COV_]C?8(<*]"\I8Z?N
MPUUC6EN/GN.Q)\X5A>P.*[T83M.&CJ3<XZ1AI4>C(#O<3$9^A#4FT5&4!?<7
MX[EWKA,>I6Z4I$GBQJ'ONLE3C?),I.FF[_TBFD.!OT5VU(S?&!^S?A0CC2Z:
M#;5<IAV"X< 7<%GL56%4I]TK]B>U60*P!/!-!(!RJU++DS7Y$<@Y;]I63(->
M%&0R*?1Z%$RP108;5. \ZPWK=Q_HWN?:#8K>B@6J!>7Z_*5C$=HB]!UR]!%W
M?71<?L)8A+$"24T;[U/+IJZJ07?>? PRZ7T2X!+&;1'=(OK-([H>G(*VQT;/
MS"%:0#[*?A:.[I2L5FLR@]":9/V@+#W$XQ(3I??#4J(*2@8S?VLZU,=J)Q;'
M;P''#<YB<A3QV#$O=[#)39/GG]Z\FFUXU;KUO&[Z/I:FT>9L[$PVO11,>D%.
M^L+!YU9#- 3?.?;'-8_\O;?4-_6?C1MAA3_L>Y7>P+;)8 T$2X('2X);"8J<
MAF,#_NJ/>FRVH@$<+369+7O_%6%TN]VZW/BG+A U%H<M#M\"#FL_[J#0;Z'T
M_CH.^&-MNJ?K!@P#$U>?1=6U&*0Z'Q+L+"I;5+X;C6BC;^G0A\&D*VP$_<U8
MA0;#+J#VE^U\&,<P1BJV(J""KW2OT=)BL,7@6\'@;6S<:9N\TR=Y RNWG345
M[Y8Z"6J"U+I!]:9%VVY.Y>B;:%,44+<$KDSC:<H9F!24F^X]I,]8HK!$<;N&
M[A6Q%NS>?@[Z3 ^DQ;BVF;;7+5$YV:[[6/'S^B(,MMT1'F)WA,AV1[#=$>ZN
M.X*55E9:D0I7%'I HVZQN2ZWM"0:1<)7UH:P"'@?#AUJF R2;.9PJ?Y-D^I6
M32F&T$'_Y6;9HDGCVU:7IHG%)_A@_=K+="F+WA:];\KG/G/4DKSMB#PX::?0
M5>XZ*;?W4!J;P?2-,8DZ%_@UZV9=U%596]RUN'L;ENQI7<K1M5Z@6]$@[Z)L
MR7X%9FPZ(/1QS].R-HD$6HLP(Z"I8(+<+@@%+WEY 4[KM.\5IC!C,KDF VH,
M8W'<XO@=Q$3["*><9MFTO% ZD+0GOP:]\U55GZ%:0>7OJW6?739QA/83DK_0
M\N6V;.4M<-\=@/_T!R]V7TZMX*=>&/1/,^X3)^!I][>N .9B7JI3C477F(!(
M53+X8%/JTBUU-2 -(Z1I7V.*V55K/?M'JLJP<)IAH@EDIN?%Z?&.$N"[V_:[
M<%IL/[*_NJ>H13?.?L:)B),A[>@%K;LU=2\QM*2KAT!A,E4M9AC? F?N\LU1
MCQN/V2G#V2ZTNJ FJ4_@P3N'3)T+BGGWG<9/5)#+,>&4'+\FM<FA<]S-7#))
M3N>Z")IRK*FS!C8!THD7^@U;,!YFX=:M&H=%ZJ53^>$:K"7L13@,$3;/'4?9
M;";%#B^8@(1"CV71CY;462(;("=4('5UL]:XF6;@(HY/,7@7!^N=B>&S<9[P
M=.T $3U"?&,5TYF1PQ3&29L&4XO9MZ2YN$QDXW G@'ALU9;7EBD7L-2')U:^
M!@(H@@Y7K/QZE6YF D@)'234$&I*.FA+3AL$[,R?(UEP67WY#924(SEJ%CP=
MB6H&H9X/W?K:22<(DB*F)=M0Y&W;E-PHG^FG!>\7#1,AUH#Z B\@CT:-=YML
M6M)@CIRWRX%#SRY(3L<N 8TN:VXODD;]W,+JW& AUL3#7=N%TI.%#<W)ED92
M4L.5IBJ_^++-6<5FPG8.!A]\I^6M:1I5MVV)V,VQ+Q;V3#/-WH#DL")85>=#
MY[-UO1ZS^]G0&&T@F@'>VT7(5&'<Z%KHH9Z\5X?VJ36;%31;%<VC7O7E/@R&
M9G5^M%1(][KQ"% A%;5/D6#L"$9=&>@5FG1-O7F."I<>+MRO5H-)G&_";V@W
MARO<5^R^?T3E0Y@1>_OC'_][,M[SU>9XSYN8$?O8YU<>F'C'$9:7#&R]?(CE
MS@2^C1:W0[_5H4WMAOSN9YVA]P.8B=:O3>/1#291J1/4O%7?[X7ZJ-1])W1=
M?]>L:FJYL.#K-74SFG< AU%)GX$EA'WX:(M:6\'']*_3UMAV/U]Z)3*6L>.+
M:>DK+VU0,^HV[S<!-$!1Y[1=:SSA;,PH'AX^VD>G^'NI_4Z;>YV-FL_8*G!R
M-EL'7W1+H;L);BIHF[UZMI6UJV 2W-C7G)$]/#C&KM#P9Z<=S^07,L,V%Z@W
MJG3#1=,"%6$*PH-D7MN;\63$5N4GI84_=6UN%/H[\"V?U/D([)E&"WSZ[K"^
M&6@:9^?*=-0UP-<_:#PEG\&61,T5;65K@4/GL7W=MT:\W7H6^1W-LLD.+0D5
MZ+=?>"OYOQWT99,WJ*L,XG_X\7A+O.I$+G(I8$,#.%V%T:(69.F2V@*K1=DM
M^B$'V$N).E;W'OK-,<^'P.:<&YCZ?E]SJ.]C[#NQA+>ZS>\S(]:?S^#IWS2;
MVLY_OV=)KUF]:=_\3 WGNE1KW5QL ?*==./B$;;T,?&R)SRV(?;C./$]+TC=
MX(%$YKZ%9URMAWK=*+0[M7=;4/46>?I?.(=$ M@$K%?*,(>[7ZVQL]LN!V6D
M))5RXF:;M,A&6?V/98FJPM_@)UDOJ <[/!9+GX<><*^Q)+J=.^]!=9&S/LX.
M&ER%.A/(_Y9KQ1!4M&4-JR7EHQS@1^\W*7Y\^87GFQ"25F!-?.4$U!<SV4@W
MZ29W2#\PH3'*MU$=OZ(;]DU-?K$LQ+*0+=I\B_4 NFTI2M;#8AP_&5^Y[OY,
MM5&7MTLV'99#<DU.ICF4F[LDW[AQ_.=@S"X%^5K1&- D"J]0?:Z"F3;!33?!
M[=NT'<27GRRY6G*].W(U"O A4>L+IZ?7RZGT0N+LO6[DW5YC1W9RHDF5K_N^
MW;K5">SU[= &V7D-Q&=IS]+>;=/>\9!$4_"R<7#6%05?SJAL?=T>ENS\)ZRT
M;=$YV:_O2S2D,ZY03QT=;WB]N9\>I[VS_<3-4;\E,BN+4H^(J<JQHKG>H_ :
MX>FT<Z76NDFPUJ#;7>A.5M!B*(SZ+&X\ )LP*@==Q=76U0TU^F\$^06VYI9=
M.I9&I_>BJK _.=$6E#[$@M+8%I3:@M*O+BB]"@&E#\^]?M4,*DJ3!7;X;G!+
MW)<;_1N<Y@?G(?]_[+U[<]O(L3?\]_LM4#[VB;<*HGD1*4K:;)57:^=XGVSL
M8SMOZODK!1)#$3$(,+CHDD__=/=<,.!%$BF1!,!.G9/($H"9Z>GY]67ZLGME
M!:_BDB M6G%*(_H)QG,-]_<8+T7(JVK2+%(A6[EBEK)L>Z8/;N%/K.Z]R+Z3
M/:JP:!!2SL\JF6;9!"4%0PE[G!E^&I:%CY^ %@GVL7Q$CM)IMUOM-_IYJN\S
M3\5%*@ #0*4M"VYZ[Q6-#Q,PVL]-D :DM=]?Z _HI^ QWP0TTX!]&LUH)5JX
MDEKR;MU+G5:ON\UK6[QSWNH,]S04K^K9JVIWV]9_MIINA=\Y;PT&.QGJYW=9
MLG2,E2F!&NG(&_^X3O"RZD0!WH3^8_MSI/F"OU@-@RL0H&3,H+VB_BV-!/C%
M0K2X!.4ED]=Z4QD4\)L5N+U"-@Q?2#0HX_7)*1M;YF&\R_S]4G&W5-LL>_)%
M: ;LBW_Z\ZO!JY>GGS&IM2MFGCGD$W*T@E!-/MU:)]_H[NT[F0U_D-GP\RAY
M]\N'DNFP1SY_8)\DKK5[%=TI1A1&%$84>7_"@'%0P&"=L68;Q@C_7(3O,L+O
M">'1C<SXSG#!<,%P\32X.&6X8+A@N&"X>,*6O)]AY#4#!@,& P8#QA.VY(M(
M<%A&#/8XL<>)(7Y_$-]I[P#CJ\F&NT7PMQ2E'^>I%_GI3P?EUBH0N_YG_@BH
MN%-%[R@IRE3<H0I&T:W+.M@8=-7)>,\Z&#SW'-6A$B'#3RMHLU1,MH*:V('*
M[=<<A(NSO4N2TM"-AF&F(Q]H/M!U9T2F(Q]H/M -8D2F(Q]H/M -8L2FTW$+
MW\>#]T]/<'/8V>@TQ,K5[<098J<0=UK#?N]-:3;M!]+BJ^LM6=?'9^-SL]4^
M'#>J/X&24=P$.I8Y]ND$?%T]+JP&I+\H!'0&[J#?939]M=>3S1C)&,D861N,
M[+O#TR&S*6,D8R1C)&/D*BH/VYMG'#6/1QD@&2"9^1@7"U+W6QUFS:UE]YN]
M1-VQYWGOGN>_K&T*6CU48I&XK\PY%IJ[3DALBE@=N/W.@3TRVZ4D,HLS A^>
M01F!&8&?:]BX@^'F-:D8@>O XI4@&B,PLR<C\$,N]UZOLNS-^,OX>WC\K00=
MZ\]\#<3.SFGKC'GS\'[YEXP([Q[.+]]KG;7/FN"7_QYG7J@[FSTGBYXE8B4E
M(ELD;)'L#CVZ/;=SUJXLA[-1PA#,$-Q0]F0(EA#<<?OL%VHHCU>": S!S)X,
MP0_YEMQ![\#.)49@1N!*(W EZ%A_YFL@>IZU!LR:AW?,/S=@?G]^^#JZV?\:
MIZDS2>*9=K7'$;O86;2Q:&NT:'M;!?]X)=AS6_&V>:<*!DD&20;)6H%D!3S8
ME6!/!DD&R</3D4&RBB!9 1]S);B3,9(Q\O!T9(RL($:R([D2CN3G1GBS(_G!
M?F?95"3.6Q6F_9,31.-XQC54&B+<.$Z%XU1VZ6EQS[OGE>7P:@6JL*'!6,Q8
MS%B\LYC!;O? A2)K \5U8_%*$(T1F-F3$?@A;?C4[?0Y=Y&U8<;BNM"Q;DA[
M'#C:ZYVW#NQ5J 1W;HV1',-="]<[Q7"/Q"1.A'*[.YEWIRNF5 ]K6-"QT5$9
M4<A&AW+!#]SV.?O@V>I@,&8P9C ^,!BWW5[GP+V0&8P9C!F,&8R/'HS[[MF0
MJZ@P%C,6UX6.=4/:H\#1[K!UX"X]E>!-#H.O]HX\D\L_L?^]H9*-K0RV,G88
M=LE-1!O*X)4@&N,OLR?C[P.;T3L[K2Q[,_XR_C+^-I0]&7_5E6?_P$42:@/
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MS+O3-6:JBCXL!ME4J9Z@9%.E,%6&;N_L\$%&;*LP2#-(,T@S2*\"Z=ZYVZM
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M YHHG[ONH/NX?*[F83DBTXC% HL%%@LL%O96L:9W-JCI6:F<5*@,1K$P8&'
MPH"%P<:MB=SS<Y8&-;015&0OBX5]M8D_]%&HRCY4AJ)\5;.!*ZC3;CV>TW;T
MO+VK.QSXP0.15270+,9^:+CG'':S5IIC$/GPX,6@-1B<O5F<PJ&O?EZ:& _<
M$CFW7NJ\?=UM#7YR8)0PB"-G$B<.O.&DP9TS@X],4T< N7SG]SP23J_M.MUV
MM^\Z\)&YE\#OL]B!+YQN]H'3EO,=GO'%.!%>2BDJK_NMMOD(3FR>!$!B6+SC
MY\+QR@_#G,W#B0B]3,X$!QZOR8'!O^D\&"=(T[QXY<.G7QTO\NU!X/6@W()
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MX,[Y(\90[Y]'R;M?/I3"O??(Y5N4-ZS(/NWN;+  J-F&L0!XK@#HL@#8DP!
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M.1;[LJ2"]G8(FWU5J,QZN2PW_@DCJ!.0FG!%RPEHEWF@32U- ,/4D1NG8)O
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M5F15%7::G0N;&.5@1* __;MW=[C,%_8G/)/E?\.:GJAL9M[=VA2-1-AJI=:
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MZ#  O0$^$)U"R@.Z =<JR+UCPH96Q@@5^9/?L$@/199<4<"S[,3GG [;)QV
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MXEL5CZG,B&)Z;3L6BTVU&5<#3'L P)I:N_SS9'+RJQ)UWTC4O;=*DG!5\EI
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M?XKTNFDI&V/<0%4.K #BGVS0(?W3[;XE7*@?!YZ=M1A)#)RO\M1V'SO"][7
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M,K[ U^:I_X1K(1WQR<_WT+2>R!9]_NGG7Q1&^D98Y7Z/$XFKZZ':T@5LV\W
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M;!UL7$?[-/KROA6<!6S+\'[A'?]'H5B.J%47X;$&=T(5"K!:&PHE#NF6N&K
MB30TOSUY4/=Y,GZWH#2->I[@\RKEGR)%0PR<Q/]7.U6,'*5>G.JQ+5(C4YZ:
MZ[[+)U_]\^4SB$$^TKT%G7S5>^GCJ:(Z^?Z7FTU+@$G,F$).Q10'H)L+3 Z$
MJN'ZQ09,# F_XG[ABT<F]\2]<0A42N09XD$!!EP2W.5MD' ^AD.<ZT ,)+PI
MS$@!4<;QQ,QIV7W"QU-,4I>;$$H4&N\\#ISM-]FW"PON8I*1#>\L>LM$=IQ-
MR6A:KHEDY8T$!,744_!7?-B<*>$[I#-MB9U"(D7.LR@-ZWNL:<*%5@>:^9C*
MT([R5;(U$5?-['H*Y^AYB\^]E]2Z&'\JDWD7MM.FA=RWN48*O&BW5L"D!R'G
MC@2&(O@Z/CCYQR/&!?P \5(R;X&!:B+:NT>7^Z0IK!8LQG/$8OQEP6(L6(P%
MB_$(I1I'MGR7]O,=PXRW4A])"[/:IW0';=<U-C^LSJR@Q0Q?9I$M1_K,SM4[
MF:@JC OEL_PVGKE]DZDI.T9CFL YCXKJK@ $=V'4N4H(&3N&% S T\5Y6>M^
M44RU[<I;3'1W"/Z,,S@V,H2\GUR4IKFC&XEF1&?;Z8LDP4>$E/J["? \3C*?
M+^U$G$C:<'XM>2=;@E(3$8KRS-%?\F[B8U@0+,\XC_+MC??M4E,&<M\&ARR\
M_CX#TC/B5H6MN +2BLW;\IK^">L$5M]ZD+81G!>V^H)91$Y5SU^'*V]E;.R
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MBDB('3%TII%"!&A>+2*#EX%%>;(P>O823'GRDX<@Z9AC,T+I&#82!E1\*1%
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MY^KI.18X(<I((HIPKU;_TG Y;I2]6UAZE;';PTL!FX%!5)$U,8H3;^5F'VP
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M.U!B& M[VEW&([%,2R1.2!U;A0B,OZ!EA'[U@$T!"8YOT<O4Y$B(_X3 (<X
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M,]5<-@PJZ5**^:;G-U@)HP,X?QM?8IRAM[N(Q$]7X)^OM2C&Q[IW>&Y-Z_O
M)AUGMA1"YL@CYO2+5&.0N"NP=H=EYVDURC--I8L/OQ2Y+F<R!BFM,7Q9&T\3
MYA%M.40+G*E\Q_92\DRCZW:N2@#0#&*;^@4<AFX$+,48X(-T9(7!"%& HMS.
M2BETBX4].6)NIR40?\2O<"S<-R:<C["D^1?T#$H^2S7@4L3%;/W-E#)0E@:"
M'H_(I-@'8<MHP3,HV4F&7L (&EVE06,Q0;M-:N J=T#^SU^'XKMA%?8[BI10
M2V!3=HCR'$XZ5M_R#,: F\2@OE^+N(<03E03IH[6%G:[FN&5LZ& [)I.!\%M
MW>-M,M+@CM7W\@CR#P@$_[V+$TO"DO0=B$?-2Z[+WD*#'>Q(;=.*2T!;69DV
MD*,&S<63RE2KB%7,/E>1D_;"HDY XS1KIJCQ:7N*-L-Q@O3JA^]MV P!;I.[
MNO#K9-I%_Y2$7I/.S_W*AC:!5^-T$Z1GI*V2@/-@9PS:V7>IRX.N7O95G*)"
M-#?-@%GVPDP*97U&E(FD,IRZQ/""&VMT&_H3)N'6N$8D:-Q%6-Q9$UB_"]BS
M)() ?+<EZQ_2QE\+6W=&J%RR:=?,Y(!:<LR<*\1 $6F(]J$FE+-8GJG8,2Z5
M@1&6-(6296H>\E2K$>J@W&S:;DL-"<]1",ZJE#E1RDD+R4I\1TY&_XADBMC$
M**6#>,S17W6NVX&')GMVB<5H$Q(P0B=RR$,?-S;/)I<H^S'QE9R/CT]/3EI_
MH^[BW]MVN_JG2MR=5V^4"D:G!__^SS<V/8A'_?NK-Z.[CO'@>![C>L F,(UU
M")!]FS#;">:E,%.\'^18V"8N(Q'M13OSFN6T<=P?L #@EK.W"G_NVN%Z+YU\
MXOHD_ZJH_['1P7*H>(R'4A4MA(R!+Z/\;VJF?!AM$J>:O?2&)SY<3^PIRZ9_
M?XB3R[6FW<+ 9X;D@Q/K()UFK*LPFY&">QZP1"TJ"EA,P*XOPJ/K$%,-9G]%
M0WHP=%VQ$D-"\CV#G,ALE6OVB)Q2*A-<,NE4:RYWM1+(?C''RS9Z1_38*%6C
MZ@_56?[OT(35YY]^_D5A62&EJ"S%O-IVY>Y$ZPZ]3*$5OV_^_,D/7_R!%_LK
M/8DN]4*+@,)\$L);>AB0A>[.T8FQIG;F"O'S[UY]*Y22(SP-W!S?^ROB2Z$#
MTZ^21T#%5BH?NAD$F0"]_ [Q<%7/XZEDDWQ)-,!]+\Q+X?8G-H4=OR67(WC,
M6B[](/SHVI7$I.(8Y\X8",'3W)N_OW[C724KE#L<GE]B)YEQCXYU:K7]"75;
MF^T?67<,9R]F6INW#G$3YR>2D3S!2#V#_/HC#?YYD*7"R,"A%+D""-L"[@=W
M;#"VMM)PHVV\D%]]5O)[XI@W:GH"@LG\J(R59.(X-U''=$OL5GN?,M=FQULO
M99]+QW%Q]!=S:OM&N=V+&D*R4JV90".L>)097%7AVCMRW8PA5_H"=(9":4'[
M#4^N<MAQ4I)"8]@C%,*)PW )A;2H=:D$0*(T6]%"C.6 "X_9Z+_ZH_W2+BUY
MP%,/)M& NY.,X*+4#!7A1C1I;4]Q3^RT5!A(':1+TVCY I^*I C(XD!S82,7
M.C34!-(,4[ASP52:?A>4>=8.A^^Y81L&JZR9J"MS3UXL:.T+XU@,QVE62B4N
MHI)':V<W4X%JN_N6L0]$S-!AR:;WV4*YO:EZ69X^FV01$,:(X]K#QZ)KD/<"
MEJK8E/V>:$S ED]GUD-J>AN7VZ!ZTB8J+=!;B&JC5@?C#B"<?U\=(T%?)X"M
MY*@QH:/R>"4\\%(0@Q/N(/;AX@,U0.#I%(J05Z;;YGQO2F0DC<1&CXW#!3?S
MYB_;%<6H$B8,&]:$*5V^RV^EL"\P28S\;12WRDE=U)LQ.;4UFK>&\T@[F08T
M3XG:R]C.3GVH=_KS7T)[Q*CP/^-1P?C0Z0H5/-N%7V(?,R)+1S$HKB]81#@E
M-6(<OO][<'.<F;/S12J45PWW.4IU+#''_*SQ9(.VN5I:=JD/(7>CP_XG(?G5
M*GWBG[F/Q#INX GOK,Y[]I6[:_/%7/20X DROCU3%IJ=_N+=@?@SMA[!$'OB
M4>&(.Y.%4S_2K=[#QXM,E'ZI,V8;@S_7W$F25FDQ>J+).*9'X#_=A;K %I\C
M;/$O"VQQ@2V^.VQQ:;2_4Z/=4=_-;"4VY12[?1X2F3^R\&#$7=2UW1S7M\-[
M"+124E."A4VNQ35)9IFFN-_E\^,13572<<S?; I%D1$#C:DS)'(V*X=%N",&
MZRY=/Y1; 3<>1>X1NX!\K%&C[!PK&%1)WE)Q3S(UE2Y9)97H^  A!Y; RD80
M<CQ<":NIGHUE%K%X1(.U=(F44\,EU?@HY8=$N"CHAMX!R_@^9<#,X262Z=Q(
M"+C@#IYQ&A!Q![*B:LZSQ].0$$Z1WN1ZJ.JMYM:[KNQ/W2#^IHN"D6>',A[[
MI0O: 9*USO/.B5K)3-M]6L!A1DCCY]FE:XR=%#57Q>\5(R!$QC46JU>OOR?5
M#]_VC<!/6>I=!I%'2$XE!9T*O=[ENCV&P[TVP2$**Z\<0R0-9#1:JA-XX21F
M*GF4=/RP'D33GPG:HYU6;%L#<>?'>$?MVFF"!<X'D1.NVN*[(,RNV5,S10LD
M @1&3TZ3W5;D;J[A,W5J!E34#TBGE<ZL&P#YL] H11_R-6 #C("^[68@_N-G
MPI;TD7JJ[QKIHAG@>VKRWIS$Z%.0[;T[R:991+/0;GW+1$DG+4(JS2>X(*SD
M%LROJ%0P.$\B+JO$\CNA>1A(S5S2%MX4BN$JW#(KQ%Q?H)2Z4A6,;)\UVHA3
MQ$JI-EU/11*WZDP *>(Z)AAD7P,1@9'+[<Q$WC$M:Y9-AO706'6'!-1 >*A0
M_6=@2M*$,[S?#R?&VY/B\,X](X/(3%M.TQ?G&.,2-&9$?B0:M#^O7G,?7!AA
M/MFT+7;WRU,$OR#/R\.P"N/^3?Y:+3;SCYS:S=;R<R]V=C44XVE]G;Q7?'JV
M*C0E[L/ %?OHSMYII^^&(S>^%_?Y1-VG R18QT97=,8"$Q+UX@)*R+O<\;HW
MA2)8:03 Q/X<$R8->233'O( 9D"=Z!Y/",P9<G@'DVYDQ8 +QFDCI&YIV?,5
MZFB$19TH=)U;&86F1*-?S)#DIKSWCAA7A.A'\Q(IWW[99"8HQ ?THR!K66)/
M=HEA$VU;]>(+"PMH2[!G7'6P8=#PV;[\#T-(]0.$._5,"RW#24R)OX+]LC,:
MA&YU@U"%NNH/*R'4QHB^R)J4>65!K_E](:9IM&O&Q"^AVZF%)N8FB?@Q#Z3H
MGAE:6>R#+OX%!BE@PUCVV AP=57>@(LIM2&_*9D;MDP>4T++ ([&L?:Y:TAO
M07 JHL=P:[S?%<]&1DV*\HCU 1V<0-]61$B,YR!+I7W;QNV*N"9C)04A%9RJ
M$A[?3R_6+#V@S)5O28,NXBL@)CSM:3VG-Z/#B)2<48+M'R&<J4:'E;Z2&"%0
M8!3"6P[C^/*;@)E?F59LS!=*$PY1Y3C0-=/*XL+/>72M30A;840D^(NP('*B
M+0\$CKZ)T$#*.NE$5#9H&'0N.KY\4O?MN12V:O!7C<71?3@-1QYLO'6$V'<U
MT1(:21DZ..=8\IC%"+<_UQS7Z]PD]C:J1*R[:DO,Y I0%#PI)MY$81*DF:_T
M\X8EA*O!NTG?/0,,\7/_,+*UCI%@.L)0L:*7R!Q)AS!3!3$DJTT7^<@.HV-)
MJ775*'ZL=L@4*G7H=2"6*/C'C$:P8LF-1EB+2YP%LS6C+F =2HY0'&H71Z2T
M:AO=!URWD30SL@DWW"1 U2\CG=>-E) )5H>&Z290MUC- M]+XH(XC;%)X=;H
M\13I$%$JZ*Q$I_)$Q9VGM3\O&_0H!K[@&%@G*9UVYBR)F2,0Q1 \]F'F6'P<
M6@74>Y_ZM;C$:0?.[$,ABETJ*X1;LV77H2=R,EY\02/I(]+=(-\89H#*D3^<
M6<C1&6-T4(?I-L7%5W:' J,D?V!9A"@/PQZK,:NI7$4UD?02/5]@;KR#6Q%C
MK,2RQ)[L$OLN*6J[X >WOL: .@HS=7W"+K;1.+3AH\2 A*I829T_+>=OPX&Z
M@>DP3:XK2#5P-#QW?9%:@GY5(QK8(3W]M,&XE\A[4/BUQ,&[PMH7LY$\+O<\
MRRYN\0.%L-8?M#10R^_OWPPE)'*D-N-+Z14;3@7-5J,L".A5@QF9,V+KE ^E
M B;D74[EV]!HVZ146'#Z'"!%IG%&H6-A?#4EO.P*K?D:WSNRL\S$OG@ETQZG
M]G ,UDR!1J.!%D?,POV#'N78(:Q7).]Z"F,;?UR./#J2ARMOVBZF 5>KUQ#:
MM<2\3""Q&)53606><Z(^Q@**XRK=6,6INFZ)FUS'>7.S>1O/CB^ \J0<^A.!
MN;&@BH!KEO@1NEJ7'N!%P?Y!>#WOE^T159255KOXFWR^*;C1_"#_)#3U.R:]
M'HI479@ZV[-/A3S]"(S3N9G44N[4U]'QAXG$SM/::A9<W'/'Q?UUP<4MN+@%
M%_<XN#@?O&2;:91-:-W%&+;B=FA MUC.F1MI3O :LS"(Z8"MRAHJ*?:D$A/C
M- V2+_4R^8(K3!5='"G1309NEN+*; 30GDHA7./WP) QZ=ZD$#@2HC)MY^>&
M$EO2.O<T7B<AJPN@YTU?RZ/$,4:( XCA?=V3PG3XC@ ?8J$M_+JICI7R;VP@
M+2D%< B7&+5.D2 Z):N0RC_"&H<^CD/,U92QT,CWL\8AD\T^'#2M5*%L&D,S
MN<]TPJ5,JQE"[B1\H\B;<D!&BZA;R<R'&+$'/VH[SE9:HR!UKB$*=X\@#ZYY
M8\ZOM+,T ^$6X))OX&\Z[*AZF3.OPIY=BJ\)]WKM//DN&H!48562JS[A(XSI
MMH>3=51FGN:^W!JQT='I2SV%S;[!1T3NCQTFG9UJ>W3J\PKQ)OY1<^%,T[8Q
MY$7IS85!)T&/)#Q-6##;.,=+KR[C\U,Z/$'F>/MQ)3HPGZDL\*Z2SA,5TVVD
M&74/Z_H%O;\CT\'H9>#-4<>&X3'8<O$]/KGOJ%A/3^200&C21M-\QRQ_K!-*
MO;7-Y?X9X03A+=;GW%1RM!0>B\77_3;,.I+L6T@+18GI/-T$[V/?<["HUB>+
M,/I\MV^P65KXHDP':JU)+\_F&WHD[V(/;*X137+><W)%);H_<F9R/0Y!=^=&
MEPL[32;T#O25$V!IN]B>X]8AKEJ,Q*C3SNU*:JY56QI'/^O&;<K)6.3*5-78
MP<1BT%2W"!>DX<,S'H$*=H)-B^L^B5G3:E/&013>0_Q()2KJJ<X?A%_V_\_>
M^S?';5S;HE]EZI[*>5(5R%BR+3G1JULERW:BDRC2D^R;JOL?9H A$<T $V!
M:O+I7^^U?_1N #.D9"LF8]PZUQ')&:#1Z-Z]?ZR]%LL\)1  9B F?:5.B_*
M<QLZ49)7E3(Z=U5"B3VPW<;ZH.1-7!4^-;0![MPC.\=(JD2C>LP,8U2 L3+J
M<M/&.KZ&C3PQ)EJ!(<#8JUS0?K2ZXP(.$U=4X%*^%/Z*JE-H?)$=6062I\Y&
M+H3H IT CFM$H1QBU#PL&!"EZ+##HTXCGX3?G?=WHJ ^?;9E0YFL@J^0.SO
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M9?_7?5T(29)H:GU@\GR%UGDJ26-G"]=>$@>Q9=7#&BE;L+ZI2:"90,J@TY$
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M ;KYN/NG&M(0[_;<.?+]3YG^ZB]A!1307D;R@@?WCSZ\X***:76X^]%5'32
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MDDZ%)EKRZ2;@)L+>@L[W(_0F?ON& *01EXU/$0>F4&Y]W9-A)X=EE)Q1T5"
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M<QJR,%LM%(KW2+@LF1P_)^$%5+"MPU[')</D_NMFSP+?6!:D:564';>',?<
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M+#T[#XGOX-4/^,#93\EWIR(?])W@G8BK68=#G:,(DI> 0@P%#.R8#"32A]!
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M5N2$?!/7?M/ZKIP<B2VW,[)QIXQY& FV4E- /4$<-CR8DFQ?.;P1 )O%@ .
M7^\V?Z_. 16882L$LM<,FORE2NFY VAN5@P761GR;RAJ,*(+L'K0F#<@T@ <
MEP%ZQ^,CC(@4TW@>S26;]I2\A+8",MRJ8U].(9%\27):;CI<78(*B2MY@:I$
ME%[MR! O<RI?[XBZJDVT+W188>%Q6E]J252(!1>M0\E2@]N6.P$-H!TAI+*!
M&/=LONO=S8/]UH,35RLV#J@!X"">#+RD845%BYASZ1 G^D=?<VE4EZ;RWSE
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MH&DZBF(HW(A)42W(LB%%[;.A>CQG&0U3]AS4 X'0V1.E,OL "2WFNQD&V;(
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M,TL?9QHEX8$!ACYA3V>*EQ]Y6^ILL?W@R0_QNIJ/=+LVVI5&7UJ,VPN_/%^
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M!O+[M [63@6S9.J.OB#2ITT86BSHYBE$6H(K+GZJ7.\MW' &_SV?%$@3<6^
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MR+#_-)J C4?!=+B,^.$C',8?% YCZG+FCI>!,_37)<@D'-KVNJ(Z%$/-PFG
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M""X'80@I. 9KE4Y*'=1&U_"JPJYW4$D[*Z3CW,T^SMW<'^=NQKF;CY^[V7*
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MNZ2:FOBEB/)!VUH9/3=-F[QA1T!QZ[(P1?2A8Q0)[68SJW/?U(9OPYRB]5?
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M)YA3BK+3HU.OW-:4Y6Z=[?%PF]UX!J(E=CF[Q6G^,/'S!TA\Z.!!TU%S=:T
M\_C/>9UV&888>MUF!6IFD< 5<"G8H7=977,]A<,L21!+EA/S&&D98PZ$4"$1
M[XG8U*A!3G)F(0:+[^O[Y"HR:)BC]'!B"]<>3GYPGG.-'/02\]18"$ XIE!=
M(/+0Z,H-/9+#7D ?(7EGQ#Z"KK:_6!O9@.)C>$K:3:+9QGT,>\_.F*HUNQKJ
MNE>Z#DS;"H>/N8  &W)AYSD'-Y2F9HMPX^Q#LK4R0$W!A 83CZ6K!KR]I,D
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MB-' Q3NBN^'S'?3OA!D:VHD3_M9:XK@SB0FAY))'^ _&\\D)6/X#61\^!!+
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MV03D4_CPQ^]P>/3E\W<Y&<@+3S;VZMAG)0.Z&"AV?GG")OW7X%XB1\11@-D
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M"86.4:#[7F>PP]LIB!\Y?"CQ"XY='^Z&,0 MR3.8SX-Y3>/"#XEBYD.1,S%
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M_WI.>"&GO>>1-LDI^;B*[Z+GH;=O1@UQ<@L$!$&%!9('($4N+VPB43@:W5[
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M]!I+.[X6&?+I)^1E,HQ.-R02=A4^1.1/HAWZP;CJ\$VQK^362+M!*>WGJQD
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MZ"#3P0BCOL4,N9!Y7T7^HT=NFTIDEO$LL=U]XGN^$^\_.P%1WYB!<+@""E1
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MW7U"[T?I^1-XJ<@S8RXLDAJBY%C.GYT+BD@TYP$LBI-@'""\H'LD0F$4RM;
MX;4+ERO\RXF7P0&,^X3URZ4DF'2:.1L5Y!2\,?Y:+Q\>8@HAOEJO,76?41B!
M<0'?&8CB0FS<R!$=D?./]<3B/@]3WB GZF<F*N\"R3Z0Z,0PZH=964OI$AVG
ME]5,-J[5U.2(9;GG%BJQ9%GFAU2)1>,0-55B66<I^-:RZ3+@KF8][KZ+'@?H
MWR[9MN$R<3SJ?..$V!7A#=?]S=LMYC,:YO58.<; WQ3>@T1&?XQR9E4'X=AR
M3YL0+!\MRDF9-#2>DSTWW9^_W)$UE?@\+<Z/AH* ,7)D@:&,("_==@A2Y#8B
M^Z+TA7@>HV];08HR)8BPJ_6*-C]484O 4H;CI5@YBTSQ&5.\1Q;'4+0_&W5Z
MM,A0BFOCLBC*&J5K.H!-BS!YA(]J28SK6,)QS (_0*N)0HH8.]R*Q4-8,EJV
ML,ETRI([=XH"&;_Y1*',-F >?E[*9SP"7D1S(UF:^L&(P1>62D\BYG.2QF\C
M^N:D>.3S.7F#N21\=A8H-/_^%UZ542%1Q=?$6C24%B&:7GB+: '5GAQNGJ'Q
M]V,=V:VHP**W";)B[ Q$7=X3 ]+D*>-R&(RJ$M<XO8DC%V,ON8BCS662[" H
MC3IY<XA$8XNKB%X0=(-$/]S%;1&IR)C P3<D:T$-!IFW0F961EK(S+SV5.:M
MZ,VX;?L4$%8X-JR^<G:4:O::VBUIE\.PAXD<ARDNX>I]2FK&7 <%AB_GSG!=
M80"S(YT%HM'JDI<A69CP @X.-F,5/"6=N?.=CTFVQ/3ES6J4L9H\;\TT/9C7
MW,C>K$SQF<3IK]P!.PZ'AGM638_K:'YS^0YV@H64^ DCZ/8*&,%$$/=Z)10V
M937L9)**!)HG3C$ M,MF., &WJ-;N/N-S+/QD]0'J!@U=<BLV6\4Y[DK8#7[
M1G6<O$\"G+[G+UN?A5C0XJ C$'\*OA<6YIR11Y2^44P?<R(6M+M,U("*2B,4
M<";JAHH*X0IF/0)&9%77:+F(H/%+7!:8-0;A+Q]KQB,#S%XB=$F@[M,-8E@J
M\3-6FBWUDY.]+DZ[R'2"'_PP9-@?@0UE7H]\YZ'713K2[(!$JP]3W3I<L0.[
MR/]\]\.[=\<9(NF_HP_OWBW>L?_85PER=NEC%%-@#*(9_O<NQ*35@D*?T92F
M,^Q2=1I].*;?_OCOZ.>?%K___;O%+\<_"B+L+DW;1[N4YE@RCR6PT8'F A$J
M6U8;-#!K8/V<QOYO6DHH,DI6BR9J8+YP8'(A;%5&U"5%7EVK$L'T.WSF0Q!J
MZ(UQC$L:EASBX#F)\2,.$UGG]QJGJ_6=\S+6%JM2SA<O9U6MR#Y >EF@9:&<
M]XT3VRD8:W ,<N6[J>O6S0T'U#$WJVU"I[32[RA3#>.=TK&#,S*6[Z+RS\<^
M,1WO,Y;OJ@5C,#F(\IR54EBM60+%F9_<[P@CWA? .V6Q2YB6.1B^#RB%/<@;
MS_I!LB-$>^*!9E 0GO5UR'(7EF!>?I8Z@CPI_X[*O^;RN[Q/LXO5\ #D$OZ'
M2']0N; B+/\O44#(0-3H[7!4#AOI QFC- _V&QSLRLR5)TG2@B.-17+2ZQX5
M/EG*.]=P=R /#Z7WOO)=[K"D>L+Q?:3 AN2$6QRZ='E(%* ,)CO[4EWY(3D"
M3HE8?GKAN'3UC[B\7&&ZG5\[&],9Z5GZR"U^\$%'#U/H=EP"3$:+RC!WYBOR
M7BQ)(&^\^%XC? Z%69FH;H0F27(.5W T7$5.B,2K-1'TJAXL6>0;QUO5+$<-
M>"P'^T7N80FC>!KJ9\:2HT&33&5_0Y-DUMT-6J7,O Y-,MIU.A20:<9&7Q:A
M:6P$799J)?",BQ,<XK6OH4X"IX?><(K&DT@T2:+N%TWB6-HQ=$E5QC5-B518
M2'5_6).4O^5D I%+ !?)6CK\R;X*)WC$9: &_=B*5\. 5)-C'U>G"2A^X^&@
ME4I6P*62%:"ZQV=K)8(K+"UA/Y7%#?T=6$"4A_D62QT\3#FW*I!&+6-UPL<*
M3356V?5:>3F8Q>;_LO=N78[C1H+P7\GC??AFSZFV7=V^?F?G07FKS7%6*IVE
M<A_O/O1ADI#$:8J4><E,^=<O N %) $0I$@")/4PGJX4 "("@4#<8UU$(IQG
M*2A'CM#%KYC5IP4;QY"@"\!<]K;MY)"0FG*I:ZWFHP57<N:G[:KB%E^YRER=
M2E[KB8-?THP9' 0CNZK' I?5G;L>^2A5#/%?(,9X$[J6EQ9L+$J8G>7)SY:^
M(FM?93UHB]7'\>\/ 6&UC%\&:0S?R"M3%B7:AG6N#@%A*;JO=) _U ]R<M"5
MM:#&XQM<T$Z+_FR"E?VOQ V1L')\5XD[JY<=!U?I)ZXJI>,_E6O'3Q#DOU*0
M?5(Z,S-]/>,]["%*G>0<,ZT T(0AY3PR[4]X)#-,9_V!EKLH6O)%Y.W<["T_
MK87PA>;C=BSA5F8!3PD)!<9$DJ7F?KHBZP_O$3450:5:#3EZWK/,Y1W%SA6X
M_J+458YI[XC1L%2,]:7??\KZK3$[327'&.\UJP624BAI SU.O<'S*XK1E%!K
MT-)NY^TVT],,WF*]5M,X""WJX(@;8I_1*EFE&?;8'='ZZ7Y=-$(;SSW5N4YQ
M(Y/,2Z$_^%A@QCJL30S?YUNZQF.<157Y'(8L&6M$B].4CJADO\FQY^;8>QL-
M>U0I+ 600>%=S)O6/CI?V4W7NEI-:/^9P84LFL?^7&6@X'5',K7T"E75R$*A
MVV;0Q2ET@3]PIE@YC?J&R7;N.R>>75M/0GPOT#6DP[/YXIIRX7L!LYX)7TGT
M'[ZT;&#_2I.';Q,H $^U .HZ>4+OY*?6TF4E0H#QSMIIEB]US9!*H/#GO*S;
M*,V%A@$ZDT!((#M=_8HNGZI6F4<*[//O=,1$0:VY5\>J0G9GA1!+%V7IMK>N
ME\3G1;*#KP2\123CEB7/3U<.77TB0&6^WG2U(I/[T]7MI  IM>H20S.&:VN]
MW;HV6I$HR !SY" \]9/A2=8EZFFQ\L"O5U^@9(('#X21TFW[ J64O\J#9\2R
MP&@']/&"CD%(*W%O@_! R 6K</3'LPLDLR6!Z9)7^0>OF"]^(BIR.D)KL>0A
ML2*JEIQ&1T8,$@8EYYHXN?;_R_(3*SQMWH/-/D@B3)2;=_S#:;,/T7D*'D=+
MP ]>^KTK_,&K[(M7])-7Y)OC7.QQ,%%M$ES7*#!&_CO%2(PQ$F<8B2E&8OCV
ML-QZ'$RP-R C@1]__^-/0U:VV[@QW.P'WX&B(8GE_>S&>^*3!ZO3WCUN AK-
M=7ZU>_(IN-'%QR8,F<<"!=3X'*2=HH9N1T!K?@>^;47[K!MQRB0A ^TLZ3OP
M?X!EB_;2 X>0]PR+EX-!H,A[-6<9"[#F1$"IUEY/0:H>#&FE/ACS@U#1&\CG
M#9%U$SB=B_.!=0_6N()%3-UL*4!JE!W3LE5-ON^HL_/[[@.%MAN!P)AYP']&
M[FX/\59O*+1V*!U!JV:=6_.+1&P3UT:Y1;7%P )27,0,/*;>'HN$=B/J['$9
M9T]0.'N"M&,&*L "3SG-C;MZ3R&[LBAHV;"TA-? M<<F>XBLIZXA+#^2Q^4+
M/74;QE-WQ8"#AZ:VN*L,HJL4I&Q86@?O<G;-K1[2=7_@DW]1P>X3>P3#E@@*
M@RV*(I*F^@V%;W@;Y\4?LPM>92N.HPOU!TNY;@<'H(G 42U1Q8(2I2L/7(*J
M-UBJE6(XH.@HHY+V"[@.PC!X=_W=C77$O\2GLR2;LM/U$].;'C,*WW:/$'U$
M:FQ-&>3,O@*I8I"&6':D?[K*^D?D'[K*OC1EJ,MTO!K]9$M]=4I/VYE%<?/V
M.F6Y8*3ZN+U")&H<)'JOA^6AO8+&;3TE@FOH>U:.#ZB(72\(3#1L(?W/_41\
M?*J+LOFWF#X)4P>^W*T^@R\3/9DF"?\!@2#1X+44))Z)QW.3NV6NF5$3M[/F
MS:1$;%KN!2J\I4VU5CY-?*0AR$4AJC,C7O.6T>2SGZZ8#W^Z2C]-$U&HMD<_
M7ZK!-5J(K#"*^0FU!K]>6$@:SDS2/#44&.H?Y*+*D K XU8;ZA-:3Q7(*0%5
MT2XYV7&C]'ON%:1:<@0_[6]0P#@=(S?!9H_N$MB+Y3_X;RB*28BWY?]ZEI6C
MT@,3<K P8[W*OG15?.H*OC6._6-@T.7=-#,4H P%;H&"5_S-<43D@4#G"LUJ
M1S]X4P,KVL/_P>U]LSRP<+[@[V,Y'@N3\ .^V>4_,",??-M+X&W DL QB"SO
M2Q@D1SP#)(/ QY(4AC"54P._AY0I\(]](O]+>$*Z#<(CPGR3Y/<EXZW6OT@9
M:Y^N$#3BV:8.EPL22TVN6J#Q-9<1+\ADG,0$-_"_5\6W/UT5N[JB(P"EE3^6
M)N2[O6*W=Y7O;S35NZ@Y<U[! UB!%E8+<AR;# 0OF6*:(-1,/*7"/A, H-0"
M5L,9O*#8<GWD9''C9\G%V6)7>13Z6$VU^P%#5##K%FU=VQU,<RG*O:T<!X^)
M;L #$';UJ*2UW=*U,,.FJYF^>TYYNK% 8-]@_&A6'M<SJJ.2IP^>P\H;.%;?
M-VKI@\BT) S/K'9#17@?X@_I8J.6E.@.0WH4=)E/5\5">DJF])"GGP?U% $P
M%"Y"9.-4%.X'N-*=)Z$Z/]2CTR8""G-5Z&&]*A_62&6ALGI5ZVV>Y4@;@$7M
MZZ&4_=CK[1:1Q,TTYG6TZFUG@<*5Y6]*";?CYMGV>4"\5L%3ARGS!V1UUR M
M*\\>3CL+C@#2HVN]0E"(BP9[6KWB$Y. )CT99JTQ7]I^#J2:95$YBL&E3VE$
M +&48"$8&N&EW18'"X?(OD4:!WZZ2C\W=?!YH;AY/(23@1R.T"NQ#&E&O*?N
MI%M^C&D,2TZV5S\ 9QGI)O8.FHAH\Z7'Y#.]0U?*IRZ7;/E4G. G]FD8K:G&
M@W],XN@1O2'O\UE6H:)5*9A^85%\?+#LU>?1[$,]0E4N04/ &'KW3R@& \)S
M&$#;>.?Z]!UK%@\^;>"+*:8HS7R.G2);'A* _@.^<.7Z__,J_TA6>_JDWX _
M'#Y8J0P*G1 M[<@@9INC8[Q2U6EN<T0K/9Y;U"!EH+">AE(%/<$B*D7P=ZP&
MQ"X$*9 B_T44X M6\D(G?T &/[.;/6C[#_[*)G(%%!*B$=X>*O[T#<KVX6U%
MWX\.ECM63G \LS@/_2SDW%GY5[+8<@^?.O/7*/OX54*^CG^DW[_ZOW&8H*NM
MY47#U_X<$4]>%47%!ZZ>"Q0Q?\V_>_4]1=%* XJ8ZAZ@[.X#S\$G3LUE3T&,
MLI"4=?@"4FW4:]43YHO_7Y8_"!_]E!?MO@K"*_IAO95/AL6-B.%4XX%(E.UX
MY4RQZ!F4G9"I2?',D&)VW=RGFB[]/T<,%^X=OI+$3:*A_P-E8+GD Y,#J6**
M'14HIKQ47Q6EC-VJQ^YRS,)=?590&TOA*ACS"K^EI# @%LF^(:S%$IGY[@-4
M".1 GT-PNR1TG^MMM29>GZ\9NY6K8B]7V69H\ 6S'5+=JE913^L[IPN=H@?P
M&;^R>$N6YYUHH4$Y;BW/3KP<MVEE0M)_ZS&K*3EHMF 1K4 JP! E#MU:L75S
MEGTJ#5A@UKR"1:]NAC7:] T-)P9C;) $30$> YM0S5FEH(J> *3&%9%JLH4_
M90DR@U>'&@1"3LOD MIL:4UVF=RR6=AESA1/)?:JPHRJ;J\:4Z ='$4E<P#@
M:>L%[^6XPE&M5S>!CR74V,4OYG.89BHR#4VIWO3]&/AT8-0]1H;YTE7^J4IS
MTU1-2_#WKHH/S@ '97]_@8@C^1Y414RK.KD,!NS1,/!LN9C,_^;Z3E9YK;/S
MWW5^</T?8*F\?)SYNR]E_:4@_ H@N".!4,V_3I5.QD8*G.CZ=!,XAPU>\.XC
MAEZIF(3N?*Q'A&<%KU43M#_E]?Y8&RWAX9B9WZQOOWZZ@DU<_=]B&U?,/H8W
M4W-*@*2"3Z^U7E9O%KCYH$ E*?L!^61.:+U/&;[,SR J[))^1T-AE[O#T0M.
M"*6EB/B!?QOKXQKY:(L1DRI3V2\IS0X5P5D$ UH?5^D6YHF14LU9#.PK71T+
M*4%X%<&[.&(8:*%#X:T\.*#,;ETJ+],6C.>IA !?>=4KNNQDX.$HA:,#58K5
M[52)K])^.(V()-&#:5QD%'C.I[%KX'0'B&4KP]9@/'^OM?XG*9J9!C=P$L/7
M/""U4##UGM?")5TGM:U?Q;">R7OWRMO>C+'?/.*&)EY\1194FG'6_@O8!B%8
M?.4[3X$?9O_$SXX;]1@5D!P.4)X=S+ZTWDVVA2L+I)$L)FF.>$C/FPV\JN*
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MGFP$J$4[=Y)6P'9S%[A41,.- *?NN))Q /%H0]R/WPZ6YV5E]OCNQ](0(\Z
MFTI4"=?C6ZN:Y^D7%3;OP68?))&%I<EW?!5.Q!?UX#L)M<)@**".\AO893A&
MQJYKZ <<*QQ1X/O($P!5^=T(4GQ!-.0E4YHP026'A-B>;M'6M5U!C%#3+".
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MA+XV-%<QIR^C]DTWA4)N\.\5<?.C+16WPB*JNG2B/8G+8A%(:T%U M?((H*
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MX";GKMIW/P>%8Q/QAPX+F,$>>CK9HC- .R3.FR^P+($FS[)YLT\HGA87$&8
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MF,01$6D^2U\4V0QM8*2AF-*-E\>81T1MB<< HBDVTV1?ED[1#\@9?*D4[3H
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M( W[XN8VCMGPU?=Y%[91=4'2<)F\$A/G&)G>P\R)DB.<I.OQXAD;/"4V>JE
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M$5-YO841N@I3#;_1,L5$#37C2=D&!+QCL2],D"B&G<E3R*/>E6=,DR%8)Y!
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M.HFC&!^(Z^]N$ZBM0FO?M(!2:3E]$;?R'N5<*.5S]-D7R[N1,@3^6)VQC8?
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M.:,:Y4#%HU8$J++2;"*\C JA-#F(B4,H_V7A#X:G&IV04F6M2$YEI0F':+9
M:>*C/O#9M,SPD*SM.. QD;;/8?,Z&GEK6V 4%C+#W'6)[KM$]_4<W2>Q%92]
M9F*U?*Z4<XF"',$&+]2!9WT%+R&1&L*-9HRE)IMIX<CO8!^9]4WL/61KGFAJ
M+46!@6C606S]/'\"<]:",2<)W!*)JW,/)SV/ORN9(!=!<+U&OLT359US!"Z!
M@&(F+XC*6B+*>LEFFFUH[GF,7LGP/VO:ZYQ8L,1PW+,CY'M%VHRN8:.S:"%$
M=PX2%?Q4"PD''T3TKZ-QA'9!QL4\^_$\@YXOX8>F@%'3$$8*/^RYPA"T*Q)
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M^B1K1@VADD9<?HX#=,CEUR:^]0X^JP6^V=?CK;<E7DMTUQ+==3W174M T<0
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M"!/.(1SC'?Y)S,7KU@9E&@!4+7 F;GB,OA!)M?F&#F_H<QRE>_C(&+*"%H;
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ML/:652?B@YG./",SO[[7XNFX\68[X:G79[S7-T71?'N!O,=N4=U JH@I#^Y
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MR-,%@+B[G=$><V&(1V,@J4_%D(ZTC3F.]_$U)R<?CO?M"U+^#U!+ P04
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M2# #JLL4V"V/3*^0<LQ]?1\&#$PB8@('2&7,,#H!4IHI94G_(F[5-E%\X]'
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M,#(U,#8S,"YX<V102P$"% ,4    " "GA0Y;E1@]0(T)  "W10  #P
M        @ &G% D :6]B="UE>#,Q7S$N:'1M4$L! A0#%     @ IX4.6[]K
MWF)U"0  )T4   \              ( !81X) &EO8G0M97@S,5\R+FAT;5!+
M 0(4 Q0    ( *>%#EOR2)K) @8  +XG   /              "  0,H"0!I
M;V)T+65X,S)?,2YH=&U02P$"% ,4    " "GA0Y;,JRQO^@%   Q)P  #P
M            @ $R+@D :6]B="UE>#,R7S(N:'1M4$L%!@     (  @ \@$
' $<T"0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>iobt-20250630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iobt="http://www.iobiotech.com/20250630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="iobt-20250630.xsd" xlink:type="simple"/>
    <context id="C_806e2b05-4b7e-4476-94b2-2b7dd866dc79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_809916c8-d68a-4b98-8df0-358a4bf20dc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-24</instant>
        </period>
    </context>
    <context id="C_82fdbb77-bcb9-4016-b1f8-453bf41699c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ProfessionalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_83a70f6f-685c-4644-a42c-ad925d97fe65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_84fe0d8c-d67b-4ce3-b0ba-ff27aff9c03f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-19</instant>
        </period>
    </context>
    <context id="C_86041aa9-6c80-4439-9ee6-0fefaad23a00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8833db9a-d541-4dd5-b81a-904e800f12d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_89f6ff06-e47d-417a-8e01-b65c0b1d729b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_8b2efd79-bc0d-46d6-b1bc-dd8287dadebc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iobt:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_8c35e721-a83d-4a8e-a7a6-c6064ec92392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8d8a2973-4e93-4574-bc7f-1eb8bff4409d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">iobt:CommonStockWarrantsIssuedToEIBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_9056ec8b-e4b6-4e0a-a202-17751c0d78db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_90915382-ac57-414d-9f3c-555baa2c95a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_90f4ecd9-d648-4156-a8e7-4757b344ff98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_934a4cc1-65a5-4fa7-9f5b-91cb5496af79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEquityAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_94559174-350f-4655-96db-1060692d7265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9509aacb-0807-473e-b712-615fcaf1f276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-19</startDate>
            <endDate>2024-12-19</endDate>
        </period>
    </context>
    <context id="C_961273d7-9799-42fe-8b40-c4dc80cf3e1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_9e6bbdd8-4ed3-4cbf-a612-855c1debc82d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a0871b16-5115-452a-8aa3-17c1815473f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a14ce688-5adf-4041-9ce6-8681b682eb22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a158b0d3-0349-47ae-a852-f27a63e1f600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-06</instant>
        </period>
    </context>
    <context id="C_a1eaf344-05b7-4fe9-bc2d-b42ce849911a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ClinicalTrialRelatedActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a1efa8f3-3329-44e8-97a1-ee569efea2b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_a1fefede-ee93-4a78-8157-b3a7150dc5ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PersonnelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a201864f-0cd6-476c-97c7-14da7f8984f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_a29b1256-ec9a-45be-98bb-bec426c92507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_a3a82724-39ac-4bbf-87e1-409ddfd8aea1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iobt:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a438d86c-ada7-4302-94e2-dc378d64a260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a5b8b85f-9da7-4446-9f08-8ee19839e7c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:PreferredClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_a6b6d898-f2a2-4264-a194-96e339c5adc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a8388fe4-cbac-4ad5-980a-b3e752b591be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-24</startDate>
            <endDate>2025-06-24</endDate>
        </period>
    </context>
    <context id="C_ab6be8c6-2dae-4f77-8832-45ca8119a732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_ac5e1a5c-cbf1-4bda-90cf-e92f72ffc842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ChemistryManufacturingAndControlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_add64041-4ed9-4f0a-a7fb-8e35e7a09b6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_ae54636d-9518-4a0c-85b6-4e9e7bfcb7d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_b0357848-8a70-4e7d-8b7c-77576974cdd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b0860219-0067-45f9-9914-90dc829092a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b53454c8-bc99-4563-a8bb-336e5ba907a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b5d3ce4a-d401-4cbf-bc28-337d54b8c30e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_b73d57d8-d103-4c28-a629-6ab0d371bfb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="C_be42f9d7-7aab-4ef2-a21e-2e34278195bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_be8705f1-03eb-4e49-85f3-b10301c865b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bfbeb53d-249c-4965-bee1-58424b490ed9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_c135a808-e5bb-419e-a467-b4017e11a0d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_c1ad9cef-5ed5-4764-8224-38b467103b9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c1b2dce0-7fe8-4aa8-bdb1-7da29994522e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <instant>2025-08-11</instant>
        </period>
    </context>
    <context id="C_c45f3c11-25c4-4f36-b9c4-195bc4846b79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_c467807b-b9cd-4abf-a2c2-779eebbaff94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:OtherCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_c62e54bd-498f-4c0a-88c7-5e544580ae36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:PreferredClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_c9ac1ffc-962f-4af6-b379-9a18ad414f27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_ca567592-c0e0-4b20-a4ed-3220891a696b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_caf14b74-474c-4188-88f8-9d1a26cd9cf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_cbc7cec8-5118-48e5-8682-ee34f6d86898">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="C_cda39673-240f-4ea4-b28d-573ba9ac932f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ProfessionalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_cf6e89c2-68e9-4989-9bcc-71a8d4f206fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ChemistryManufacturingAndControlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_d039cccf-0ad2-4c2d-8c00-3f2cb7a6da02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_d1ac30d3-46ee-4e40-ad99-548007da67c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-19</startDate>
            <endDate>2024-12-19</endDate>
        </period>
    </context>
    <context id="C_d1ac8d94-9bfe-4efa-86ce-70e44c8190dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">iobt:LeaseCommencementOnOctoberTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_d2d4d909-7247-47da-8942-e7d0085430d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">iobt:LeaseCommencementOnDecemberTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_d4e7dd4f-2821-44b8-998f-65cfe834fa7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d77d1227-8aa0-44ec-aa93-20c58573316a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-24</startDate>
            <endDate>2025-06-24</endDate>
        </period>
    </context>
    <context id="C_d7ad6dd6-35af-4f8a-aac7-f313a381b605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">iobt:LeaseCommencementOnJanuaryTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_d9cf7434-a99c-426e-ba30-efa367120587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="C_d9eac608-430c-4093-aaf6-37dfe968a3a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">iobt:O2025Q1DividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_da9f479f-4bef-4055-ba48-4ce7e429d95d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:OtherCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_dcee008c-dfa3-43d1-b9c1-5d5957ec1dec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_dd160d99-0b92-4fa0-b879-249e802cf09f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_df699447-5212-44fe-9bb9-541bf78efe2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-19</instant>
        </period>
    </context>
    <context id="C_e39d7aaf-45f1-49d8-b933-d2049d7a30c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PreclinicalStudiesAndActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_e6b863ab-f667-455a-800d-d455c93b3ab4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-24</startDate>
            <endDate>2025-04-24</endDate>
        </period>
    </context>
    <context id="C_e967bb70-74f8-4aa9-a3ea-389fe5eeaa26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ChemistryManufacturingAndControlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ea2ebe70-c654-4e26-87a4-0f7c15e0ea44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_ea4234a6-3d5f-4c04-b955-28240861f2c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ece426e2-ea1d-461c-9e88-f9dddd35c1c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ed3915fc-fc74-40d9-ad4d-e15fa899e8b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_ef72a604-f4f2-4a0d-adba-eaaf1803b560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-19</instant>
        </period>
    </context>
    <context id="C_f03f590f-3e44-4ac1-9039-13057aba247a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandTwentyThreeInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_f08bf985-a9db-49be-bd46-d4eda7a2c58c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_f19d5a95-b1ed-473d-a534-3f3d6090cd35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iobt:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-09</instant>
        </period>
    </context>
    <context id="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_f81c1fb3-24f9-45eb-95d6-3d58f5c1bf71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-24</startDate>
            <endDate>2025-06-24</endDate>
        </period>
    </context>
    <context id="C_f81d0ad5-24f5-440e-b388-92bb80345764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fc2eaac8-ff9c-4b6b-9667-7650678ab73e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_fc8b2cef-3f0c-4673-bc7b-e631da99dff6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ClinicalTrialRelatedActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_07d945e9-2951-4202-ae7e-2b4ac20b2b1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_0e1d0a4d-d812-461f-aec2-4c14dea78aaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="C_0fe7e5da-4225-4e64-8f1a-304a1362ffeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_101f5b3f-2579-4748-bcd4-04070eb2ce6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iobt:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="C_109f1d22-8cd3-493e-ab7e-5ad075bd7dcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_12c9ea54-3647-4df4-9107-48c806489a8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">iobt:LeaseCommencementOnMarchTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_132052a7-d00c-4cb3-9ad6-e77324375e94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_1434ccee-3c92-4bb3-9b9d-6f650436ace2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_168c3e7e-9d8e-427e-8f70-1ecd3c073fd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_16b635b3-2fb2-4918-9590-c3e68b0c0739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-04</instant>
        </period>
    </context>
    <context id="C_1829c523-648e-4a02-8109-0deb1191ed06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ProfessionalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_1b0fada8-8afd-4aa2-8081-cb2a8058b81f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PreclinicalStudiesAndActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_1c31d0c7-7684-473b-9386-127c8dea9206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_1d4a8f2a-a146-4860-99dd-0f7ae3dbbe1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-04</instant>
        </period>
    </context>
    <context id="C_1db878a1-26bf-48ae-8c27-edb9a58074e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_1df79142-ea8b-41b1-a655-b2d3ed78f113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1dfbcdf2-7303-4e39-a3bd-fd5f426fbf73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iobt:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="C_1e0ec6e5-7239-40d3-8f87-70637b9c4213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_1e241c91-5715-488d-a31b-90976e18ef81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ProfessionalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_2130d49e-92a6-4472-a00f-3b63ffde0b9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="C_21938b85-ef8d-4d5c-9762-a35f1259aa3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_23f0e49a-26af-436d-a252-4c3c0051cbd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-07</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="C_26bef08c-05c8-4a89-94f6-05ba69278969">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="C_2b8ecfa6-15a8-4675-8200-6867ed419829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-24</startDate>
            <endDate>2025-06-24</endDate>
        </period>
    </context>
    <context id="C_2d7f3f8f-ddd0-48bc-b68a-50c26ed152f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ClinicalTrialRelatedActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_2dce093a-2adb-4a4a-8fc5-39fd85ae7014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_2f3ed9a6-4829-4c38-92f5-f9f01e3bbb26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_304a194f-57dd-4a19-bedc-cdfd57a688a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">iobt:LeaseCommencementOnJuneTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_31556d6d-fe87-49c2-bbf3-1900c78c9c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEquityAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="C_320ef1d4-ce99-4066-9e33-b688a26543ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-04</instant>
        </period>
    </context>
    <context id="C_329921d0-d469-45e2-ae77-6ca463b6325e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_3312f560-ea95-4c4d-b954-f433c8050666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-07</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="C_34603f30-56ca-4356-8f77-419b1978063a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-24</startDate>
            <endDate>2025-04-24</endDate>
        </period>
    </context>
    <context id="C_35ff612b-5ba4-4688-aed0-aa185853966a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_36ff792f-bd4e-446c-b141-ce575eb25023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-19</startDate>
            <endDate>2024-12-19</endDate>
        </period>
    </context>
    <context id="C_37646e78-6337-438c-8dbe-8a3712d470ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_3764f78d-6235-4496-a19e-2de9bd33fad6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:OtherCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_389775bc-ae88-489c-8c1c-85a0ed058e9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-24</startDate>
            <endDate>2025-04-24</endDate>
        </period>
    </context>
    <context id="C_38e73190-243c-4f4c-acfe-c43cdf009a58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3adaf1b6-8e71-4415-9436-0d74420cbb54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3ba08ec9-fc01-4790-9392-b29be37fb6b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3c22dc6f-5520-49c4-8ebf-ac7d5b76711c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iobt:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_3ce8c578-aa0a-4ee8-a8d4-b0a4fac4e5ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_41b1f416-58f2-4b5c-99cf-ca18ff696ab3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_41eb296d-58a9-41d3-ac9d-5e2d3cb0a7a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PersonnelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_438a86b3-b95d-4e7a-bf73-767445f988d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PreclinicalStudiesAndActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_43a993b5-927a-4fb4-ad4d-c154c853f2a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_444ecd94-9413-4f58-9283-c0e742cfcbad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_474458dc-a129-4f50-994f-7df9fe0827f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEquityAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="C_490dd48a-6429-4e12-b498-a5cc551a31c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-19</startDate>
            <endDate>2024-12-19</endDate>
        </period>
    </context>
    <context id="C_4a17c158-ee71-4938-91a0-7a0dbd466b03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_4b7ed800-ce67-458e-a181-b724431189ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_4d40a682-0751-4064-bb08-df58960d326c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-24</startDate>
            <endDate>2025-06-24</endDate>
        </period>
    </context>
    <context id="C_4e98906e-1cac-4433-be9f-7d243d541dcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_4f1f2469-2895-4c93-a281-ddfa3fa3a80f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">iobt:CommonStockWarrantsIssuedToEIBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_4fdff8d0-846c-4e02-aaa4-5c470eaf7625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_527af978-7806-4a1e-8520-f96890860ee1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">iobt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="C_545accb2-04f0-4670-bdc6-0b24c21df653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-24</instant>
        </period>
    </context>
    <context id="C_556c8daa-bb23-4277-a055-75e799014084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iobt:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="C_55aaab1d-0030-4d3d-8a11-599b6fe6903f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ClinicalTrialRelatedActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_56d189f5-8762-4d45-aa40-9a14717e05b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-06</instant>
        </period>
    </context>
    <context id="C_5b150492-18b8-4ea5-b79f-6a9eee4738eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_5b1915ad-890a-47af-9868-ded5e38e7f5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5be29099-873c-44cb-9847-39038a293dac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5cc831a0-a0fc-49d9-95ba-356e8a3a7fb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_5d5c2036-4d47-45b2-abc2-ce62234c7b0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_5e0098f9-fc3d-4792-a5bc-ef3eeb5b4648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_5fa6d61c-8fbd-4763-8701-fc3239e4a315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_60dc3163-f2cf-4d9a-bd0c-4ced094cf2aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">iobt:LeaseCommencementOnDecemberTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iobt:LaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_626b865b-fabe-418d-8e2b-8f5f5a575c6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_62d03c66-fb1f-4bda-9c1b-02dea4a59e4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_6561fedd-443a-4a83-8643-efd575ae4790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:ChemistryManufacturingAndControlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_65d8cb5b-0a18-41c9-981b-c844905fa72f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PersonnelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_6c0dfbea-5705-4f01-91ec-a344114fb10f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_6dce96c8-4c75-416e-bf89-e8c89509910e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="C_6ef232e1-8f2b-4eec-9dd0-c1e56fcf4bb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PersonnelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_72045b9f-3820-4aad-a93e-3694b13e20c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:OtherCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_73b1457e-202f-4b74-987b-acf3673e19af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_75035fee-9a60-4e72-991b-0ba8a07ca63f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">iobt:LoanFacilityWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-19</startDate>
            <endDate>2024-12-19</endDate>
        </period>
    </context>
    <context id="C_75fb5f36-7e2a-4032-ac5b-b93710ea8e93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_778386da-0eec-4652-a846-c64fb6f85ac0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_785749e1-bfed-43d5-a943-0f70e8cc76bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iobt:PreclinicalStudiesAndActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_7a8a9344-a835-4ba9-8433-bf16f27259e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7ae94389-ebe2-4996-bb29-68980b435b79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">iobt:TwoThousandTwentyFourEIBTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iobt:CreditFacilityTrancheCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_7b18d373-032b-4323-90f2-5980a3f2eeb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
        </entity>
        <period>
            <instant>2021-11-09</instant>
        </period>
    </context>
    <context id="C_7e2345a4-e132-4d97-885c-dbc51fa34b9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001865494</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <unit id="U_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Lease">
        <measure>iobt:Lease</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Vote">
        <measure>iobt:Vote</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Segment">
        <measure>iobt:Segment</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_a95f82bb-27df-43b1-9e33-21da51c0291a">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_2cb2a08b-8490-4335-ae72-bd1d91de3a36">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_db6e2f12-6192-41ec-b8c9-f3665923d3b5">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_c30c62f6-4cf7-4fdc-8c6a-fdd14abf1c7c">0001865494</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      id="F_ca33a566-dcf4-4f72-ba6a-d32418d6e108"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      id="F_9c97d54b-107e-404a-bf3e-be0a3cbc6df3"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      id="F_c1d7c3c7-ae73-414f-87de-ed2f7e40d4eb"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      id="F_71b397df-eb05-435a-99ba-0c4e164daeb0"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_0847deca-10d0-4530-aa33-3be6c7b7efa2">http://fasb.org/us-gaap/2025#AccountingStandardsUpdate202307Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="INF"
      id="F_abd02c4f-a3cd-4435-8a7f-dd7df01461bf"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_aca2c24e-8e92-4826-9175-474c6929666f">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_ebc813a3-04f0-49f3-9868-9cfe7dc3008b">http://fasb.org/us-gaap/2025#ProfitLoss</us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_a6fa6611-8a85-4b32-8fb8-a68c6bf97288">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_16d0da36-e978-458f-bd25-9afd25a37132">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_c12b6bbb-11d5-487d-8e8f-06673cff4426">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_bc06333d-f053-4472-92b5-fa142dd05c2c">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_2918f48e-84e9-4451-b76a-99401fba9d3e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_01194a4f-bf20-4ee1-85a5-915ddb4f12e4">001-41008</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_9bd90bee-f260-4b46-ae0f-32751b30f944">IO Biotech, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_965cc23b-86b9-4615-9576-4e5437322437">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_23538084-3417-4814-bfad-f881e30e1609">87-0909276</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_62f1c622-9255-4786-aac8-3bf02240e599">Ole Maal&#xf8;es Vej 3</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_d8e30914-6826-4573-8745-753f295cdbaf">DK-2200</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_bf2f1a7c-8c12-4d2e-a318-5f27308622c5">Copenhagen N</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_79511320-0cbd-476d-a446-fe175043d18e">DK</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_88df452d-2cf8-473c-8a6e-ee7d91c11dbd">+45</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_57afe4ec-c4f0-4dcf-ab5d-401c0b3b903f">7070 2980</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_2cc17b59-ec6b-4903-b424-c66bdbdadd48">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_e26426ed-d304-40b4-a0ef-dac069346824">IOBT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_9d355b37-1755-4e24-9c74-84e078908081">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_886257b8-fe57-45bf-bd8e-6d7deca7612c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_a7f9492f-e534-4679-9497-4e0d70bbac8f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_623fdf77-71ed-460f-9fda-e711fa07d071">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_81154ddb-6b1b-4d91-a038-062be6230f64">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_02afc14e-0ad3-4668-96e9-c57771dc7735">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_10ab989e-f6f8-40ce-9f51-023bf3d9fe8b">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_40661ce9-caf1-4b43-91e6-0ef5733a2727">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_c1b2dce0-7fe8-4aa8-bdb1-7da29994522e"
      decimals="INF"
      id="F_60ea0df2-ea49-48ed-81f7-2b982a72f102"
      unitRef="U_shares">65880914</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_d5638863-bc77-4755-80f9-9fb77c562d4d"
      unitRef="U_USD">28131000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_4e907031-65a3-4e89-9fda-d0be09ec7c37"
      unitRef="U_USD">60031000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_d053f13f-ea58-4973-8e2d-a740411e8286"
      unitRef="U_USD">10849000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_6423ae0d-8a2c-45c7-96e1-a3b931e34afb"
      unitRef="U_USD">4920000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_8ee6db8e-d53a-40a6-83bd-738239b6aa06"
      unitRef="U_USD">38980000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_777bb397-a210-4779-8e8c-1c6411e5a5ad"
      unitRef="U_USD">64951000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_c3434fbc-64d9-4238-9a39-5abb248139be"
      unitRef="U_USD">268000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_0d4bb448-0cf1-42bc-9a85-4a12ee250e05"
      unitRef="U_USD">268000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_cb5e10d4-500c-4230-8b20-b9957609c4f2"
      unitRef="U_USD">603000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_0578f6b5-9087-4795-9f25-b7c812eb0ccb"
      unitRef="U_USD">638000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_9e29b23e-40ca-41d5-8f22-6dfef70307f0"
      unitRef="U_USD">1470000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_cd535fc8-cc65-4841-a951-24df6fc7d20a"
      unitRef="U_USD">1725000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_b178c158-d9b6-43e0-a5bb-ad7d708a2005"
      unitRef="U_USD">1005000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_bc0779e8-eebc-46b1-a7e2-21ecbf673467"
      unitRef="U_USD">117000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_b64d6c99-99f4-4603-bac8-d03f1fe1cc4e"
      unitRef="U_USD">3346000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_26edf073-ec9f-4cb4-90cb-424846f4f8fa"
      unitRef="U_USD">2748000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_596d32e5-cb43-4fd1-9b8b-f6184f5343a7"
      unitRef="U_USD">42326000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_345c0e9e-9466-4987-976c-07c5f82fb3a5"
      unitRef="U_USD">67699000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_39582774-0d0c-41f9-add2-890eb0d4b548"
      unitRef="U_USD">5537000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_7da2c698-25fb-4bc6-8806-2bb21a675a25"
      unitRef="U_USD">4661000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_faa7fcf3-4216-4e35-b349-bf2eaf47a3af"
      unitRef="U_USD">768000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_d4d9e209-d87c-4241-8265-52ad8073d077"
      unitRef="U_USD">717000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_5b262b39-1035-462a-9fa8-c673d21265d8"
      unitRef="U_USD">13592000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_ab915ee0-0ee5-40d9-ac54-091efe5e84ce"
      unitRef="U_USD">14108000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_0e9b01a0-5784-4252-a448-9e211d48d2ae"
      unitRef="U_USD">19897000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_42c7f256-72dc-46cd-87af-faac5a7cbbf7"
      unitRef="U_USD">19486000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_750529b3-046e-4fc3-a61f-ee4628e3ac60"
      unitRef="U_USD">868000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_ef76f139-f4e3-49db-b283-bdbaf7f1d3be"
      unitRef="U_USD">1198000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_04556912-e8cd-4231-92b4-873404d98039"
      unitRef="U_USD">6720000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_4852c0e3-e463-425b-a523-fb44db477c66"
      unitRef="U_USD">0</us-gaap:LongTermDebtNoncurrent>
    <iobt:CommonStockWarrantsLiabilitiesNoncurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_88169603-d399-42da-8b65-72633b78ba6a"
      unitRef="U_USD">13249000</iobt:CommonStockWarrantsLiabilitiesNoncurrent>
    <iobt:CommonStockWarrantsLiabilitiesNoncurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_e6355d07-4acd-4f49-bbcc-2f43ce0cdcce"
      unitRef="U_USD">0</iobt:CommonStockWarrantsLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_cbc9a72f-0dd4-4ff6-9a53-b3cf974c03b2"
      unitRef="U_USD">20837000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_8ab44d05-af7c-4444-b502-7e0cc334e144"
      unitRef="U_USD">1198000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_9ee0f135-e651-4899-9506-1a19b0c6d85e"
      unitRef="U_USD">40734000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_c6ec5c09-db34-4016-9bad-53c09fa85521"
      unitRef="U_USD">20684000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="INF"
      id="F_5c1cf44b-15ee-4b1c-bf52-6b63097e7131"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="INF"
      id="F_509276a3-fc87-4424-adea-4dd34e91cc9a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="INF"
      id="F_16f07f30-8444-4e67-b35e-420a8dc20cb6"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="INF"
      id="F_c1dfcf0e-2a00-4ea4-9f7c-5085956d3cae"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="INF"
      id="F_b5148a7c-c8c6-47d8-ac44-dbf66200f0d2"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="INF"
      id="F_d411780a-c5d2-40bd-8982-8c69edf25e43"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="INF"
      id="F_551103d4-fbce-4212-b4f5-98ad13cff449"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="INF"
      id="F_529ae9e7-530c-4706-915d-8f1e3f7c79c7"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="INF"
      id="F_22ba888b-20ef-4789-b1f1-983762707d82"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="INF"
      id="F_3acf51e1-61ce-40d5-9078-69fedefb2a24"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="INF"
      id="F_16a835c3-e41e-4002-84d7-bfec628263a7"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="INF"
      id="F_46a4e928-7ecb-4454-a079-c1ddef177a05"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="INF"
      id="F_8eba27e9-ffc8-45c0-9d13-586d71f29ded"
      unitRef="U_shares">65880914</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="INF"
      id="F_c232cca1-55a3-40de-ae8e-78a6a5201bff"
      unitRef="U_shares">65880914</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="INF"
      id="F_0edf2ab3-575a-4e13-a384-2447c6f3bdb4"
      unitRef="U_shares">65880914</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="INF"
      id="F_31b45a11-3c7b-4e7f-88ab-bfe6ec47132e"
      unitRef="U_shares">65880914</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_589a6056-ea6c-48f4-91c5-4d8c2e997029"
      unitRef="U_USD">66000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_abb7dd47-4b0b-43b4-9a55-2167f5384de3"
      unitRef="U_USD">66000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_a74c7bef-c547-4709-bd3a-27a820de9424"
      unitRef="U_USD">416289000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_d142f1f7-f4ee-4b6d-899a-0dcfc6785a8e"
      unitRef="U_USD">413113000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_f4c15386-94dc-48ff-bb81-7a5b6086073b"
      unitRef="U_USD">-407951000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_5421e4c3-6ae2-42f6-bf4c-a50d0bb6f440"
      unitRef="U_USD">-359313000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_abbced40-b1bf-4e0e-bf17-fae76f40e0fb"
      unitRef="U_USD">-6812000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_34898936-f51a-4912-b8d9-661392149057"
      unitRef="U_USD">-6851000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_da50392f-8868-4d2e-93d7-418c0d23e990"
      unitRef="U_USD">1592000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_6448e6ea-a73b-439c-a096-5e9eefafd9cc"
      unitRef="U_USD">47015000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_6389f639-a182-4299-bdff-4f0a5ec0d9bc"
      unitRef="U_USD">42326000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_040bdac4-44cf-4e37-b4ef-2afa600f4cc7"
      unitRef="U_USD">67699000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_89d7eb74-fc28-47f1-afce-489f8713e3f0"
      unitRef="U_USD">16652000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_daeb7dc1-89d7-4898-b35a-3433af72277a"
      unitRef="U_USD">15848000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_c0e1a913-1dff-416f-97f9-1233a563e4d7"
      unitRef="U_USD">33027000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_6156b53e-5729-441a-a009-07cab65672f2"
      unitRef="U_USD">30159000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_65606a1e-0fbf-4661-9bb2-e341e4e08b46"
      unitRef="U_USD">6518000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_f10d7455-0053-4ce7-9ac0-b304ee2d5410"
      unitRef="U_USD">5685000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_e72ee9ad-3c82-4684-b49f-c83496753912"
      unitRef="U_USD">12727000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_b3689087-68b1-4565-acf3-2cdb671b5bc1"
      unitRef="U_USD">11571000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_af97bb79-f4f0-41eb-923d-6079cfe650f6"
      unitRef="U_USD">23170000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_d063dc50-429c-4d5a-9b8f-6ec46272d376"
      unitRef="U_USD">21533000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_a780552b-acf0-4384-b837-7e37f555a768"
      unitRef="U_USD">45754000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_4c72e77e-25e2-4662-ab20-0e9b04361d9b"
      unitRef="U_USD">41730000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_9b919a5c-4f82-491e-86fc-34459a6d1f37"
      unitRef="U_USD">-23170000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_14c61d06-337a-46b9-98de-21a63c037734"
      unitRef="U_USD">-21533000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_b4b2d460-7e5c-42dc-846f-ad4f7c328480"
      unitRef="U_USD">-45754000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_3ec39869-1114-410d-8c6a-d2e777a2b961"
      unitRef="U_USD">-41730000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_f3ccc3db-cf20-4989-9cdd-af3198b69bb9"
      unitRef="U_USD">-374000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_12f0f648-294c-4e1a-b1bc-6c9902945d65"
      unitRef="U_USD">-90000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_d6f20faf-d9d7-4554-a89f-01662e86c3db"
      unitRef="U_USD">-479000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_0f168b88-0431-4b37-8c2c-72145112c98f"
      unitRef="U_USD">-552000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_aea6e14e-7560-40e2-9812-50ca6b6bb704"
      unitRef="U_USD">285000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_3623417f-f272-4426-997f-ba6f4f30a586"
      unitRef="U_USD">1311000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_d4e264cc-b6ec-4cbc-b358-0c2634a9ce93"
      unitRef="U_USD">699000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_e94ba359-169e-4e07-ba5f-618f17479f98"
      unitRef="U_USD">2928000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_55a510eb-93b7-49bc-8a5d-7e16148008d1"
      unitRef="U_USD">253000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_94277fdd-b3e7-4c42-ab6d-00b3a86f5f34"
      unitRef="U_USD">0</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_1a9c4f96-f81d-4526-8501-6bad6bdd8765"
      unitRef="U_USD">253000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_84ffdb43-5599-4b6b-947d-689e30145d99"
      unitRef="U_USD">0</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_2a0e5d6c-cd6f-41a7-bfde-ff5962fcf74c"
      unitRef="U_USD">2587000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_9d7d4ade-059f-406c-a5a4-455494fe1244"
      unitRef="U_USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_292f2780-4fb6-40ac-9c09-c7828d1e9ad6"
      unitRef="U_USD">2587000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_3d9a347a-d755-4008-b686-8ebb528e2d58"
      unitRef="U_USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_1ed46e14-7c2c-45f0-a7f7-ed5e6c39d855"
      unitRef="U_USD">-2929000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_38dd6259-cdff-4bff-93ad-abd7b9b1485a"
      unitRef="U_USD">1221000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_1db46409-a3c5-43a1-97cd-51163e2f3bed"
      unitRef="U_USD">-2620000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_2459fd78-8c2d-4a54-9466-e51082e0ef94"
      unitRef="U_USD">2376000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_6f32ef92-dd55-43b9-9e75-3807510ed266"
      unitRef="U_USD">-26099000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_7fab6942-3ced-4b84-a660-70ad906153da"
      unitRef="U_USD">-20312000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_b083447c-48b7-44ea-a3a9-e1ac37b07b1b"
      unitRef="U_USD">-48374000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_d2c85978-e07d-4693-bb70-29b86fa6acfc"
      unitRef="U_USD">-39354000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_9adfc096-e407-4c37-a7f8-3ccc73bd0ff1"
      unitRef="U_USD">118000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_6ad538fb-4ee9-488a-bcdb-912251782901"
      unitRef="U_USD">374000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_774f4691-04fd-4dc2-9d71-0bf73c39d569"
      unitRef="U_USD">264000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_9d3053da-6ecb-4b00-9b36-5b0f3876d5f2"
      unitRef="U_USD">789000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_27b81041-06e2-48cd-a363-7c557fc5a9ac"
      unitRef="U_USD">-26217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_080e2f7b-d03d-4733-ba8f-07aee1c9f2b4"
      unitRef="U_USD">-20686000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_1c28cbba-269f-4877-97d5-92dd6b0d3f8a"
      unitRef="U_USD">-48638000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_8aa841bd-1740-4db1-8c84-0170decb99bb"
      unitRef="U_USD">-40143000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_db371866-cdb1-4674-a4d2-c51e57d47ad3"
      unitRef="U_USD">-26217000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_de03117a-5c74-44aa-9f9b-c4ae071830f2"
      unitRef="U_USD">-20686000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_5f1d29e0-84f1-4b62-b5ce-476bf88e1024"
      unitRef="U_USD">-48638000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_0386b742-dcc6-4f28-8730-73d204742780"
      unitRef="U_USD">-40143000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="2"
      id="F_d1f1af6c-db64-404e-8d0a-5264fb6c17c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.4</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="2"
      id="F_c5b025df-00f9-40da-91d7-60d2d03c0e5e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.4</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="2"
      id="F_26d03f9f-3958-4eca-aa08-4baddfa075c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="2"
      id="F_c8266040-e9dc-4f4d-a6b5-d500d7bcc352"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="2"
      id="F_abdd2030-e8f2-462e-8687-ffafe875616c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="2"
      id="F_7fd8e719-b678-4351-aaa0-be04f9a40eae"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="2"
      id="F_de7913b8-c515-430e-b25a-0edd632f1fc7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="2"
      id="F_9d6e32ed-b15c-408b-b9a3-44c18e2c87bb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="0"
      id="F_22d22239-055d-422b-8236-010863e19f03"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="0"
      id="F_45e56538-7830-440f-a900-ed093fd1ced4"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="0"
      id="F_f337ff22-f9e5-491e-a6bb-bd695f995b14"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="0"
      id="F_115646af-b53d-42e4-8e33-a7b4465fe9f4"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="0"
      id="F_65b8e0a7-7b96-4736-b201-c5b2ca05939b"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="0"
      id="F_ce27c122-193b-43d9-9513-04ef48d0b275"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="0"
      id="F_0254da77-1ec5-4133-a485-2b2c8a2d0e9a"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="0"
      id="F_3238e8e4-67db-4e49-afda-d98fa6d0ec21"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_c0114f0e-edd5-49a6-a5b1-c0604ec2e0c1"
      unitRef="U_USD">-26217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_18300458-0a22-492e-a28d-5e82c9687f55"
      unitRef="U_USD">-20686000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_e2a0e17d-97b9-481b-8b20-f61431e6a1fa"
      unitRef="U_USD">-48638000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_dcf221db-d599-4cba-ba06-7c9551e778cf"
      unitRef="U_USD">-40143000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_9f521acc-2ff7-4b0e-835c-482f53e047ca"
      unitRef="U_USD">-220000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_37eb50d5-ac8f-4463-aedc-fa3b6ed058f6"
      unitRef="U_USD">-151000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_051f2d8e-c601-4c19-8e26-74efae61dc9c"
      unitRef="U_USD">39000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_ddc51add-522a-4ca8-af0d-f6f14c4c65b6"
      unitRef="U_USD">43000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_a30dcf8a-bfdd-43a2-b78f-dcc3eae4d032"
      unitRef="U_USD">-26437000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_12316039-0ca1-44d9-9898-2e1bc95c7ac8"
      unitRef="U_USD">-20837000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_7168ef35-af3a-4e4a-bc9d-5a9405816c71"
      unitRef="U_USD">-48599000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_36738c80-8a03-4a03-b73a-48dba354ad54"
      unitRef="U_USD">-40100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_21938b85-ef8d-4d5c-9762-a35f1259aa3d"
      decimals="INF"
      id="F_bbbf2530-e16c-4987-83b9-f463ee8979e7"
      unitRef="U_shares">65880914</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_21938b85-ef8d-4d5c-9762-a35f1259aa3d"
      decimals="-3"
      id="F_0df734d8-e7ef-4f9a-b780-12b5bc69e34d"
      unitRef="U_USD">66000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ece426e2-ea1d-461c-9e88-f9dddd35c1c7"
      decimals="-3"
      id="F_514f62d7-9bf0-4210-a976-9a3bcf730f01"
      unitRef="U_USD">406587000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3ba08ec9-fc01-4790-9392-b29be37fb6b3"
      decimals="-3"
      id="F_be5a38f5-0118-43de-bc08-a5bb9c0b93c4"
      unitRef="U_USD">-9669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3ce8c578-aa0a-4ee8-a8d4-b0a4fac4e5ee"
      decimals="-3"
      id="F_29a7ed0f-46f0-4a6b-906c-9173d5dd3225"
      unitRef="U_USD">-263822000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3adaf1b6-8e71-4415-9436-0d74420cbb54"
      decimals="-3"
      id="F_750cd5ce-aa36-4b66-9184-9cb279cb7f7c"
      unitRef="U_USD">133162000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_43a993b5-927a-4fb4-ad4d-c154c853f2a2"
      decimals="-3"
      id="F_4b26fb4b-8bab-4b19-a218-2219ef1d3796"
      unitRef="U_USD">3210000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_c9baa79f-e76f-4f6b-af1f-961b561c94d0"
      unitRef="U_USD">3210000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_b53454c8-bc99-4563-a8bb-336e5ba907a2"
      decimals="-3"
      id="F_5d89d099-a89f-48a7-a662-dc4dcc762742"
      unitRef="U_USD">43000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_e78b82a3-eda5-4b1c-a0cd-f5116da60828"
      unitRef="U_USD">43000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_626b865b-fabe-418d-8e2b-8f5f5a575c6a"
      decimals="-3"
      id="F_a3445143-a539-4603-9a54-72c4448dff65"
      unitRef="U_USD">-40143000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_8ab67ee7-f432-4465-a3c9-874a441535be"
      unitRef="U_USD">-40143000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_89f6ff06-e47d-417a-8e01-b65c0b1d729b"
      decimals="INF"
      id="F_d812cbdf-70e8-4ad4-a4c2-03fd22ed5e6d"
      unitRef="U_shares">65880914</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_89f6ff06-e47d-417a-8e01-b65c0b1d729b"
      decimals="-3"
      id="F_eff546cc-b598-4de0-b923-3d54547edb08"
      unitRef="U_USD">66000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c45f3c11-25c4-4f36-b9c4-195bc4846b79"
      decimals="-3"
      id="F_e90c65dc-786a-4ebe-b955-c388fc0e9ceb"
      unitRef="U_USD">409797000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2dce093a-2adb-4a4a-8fc5-39fd85ae7014"
      decimals="-3"
      id="F_80ff5783-4595-4779-beda-cd2ee9769059"
      unitRef="U_USD">-9626000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_62d03c66-fb1f-4bda-9c1b-02dea4a59e4e"
      decimals="-3"
      id="F_cc9d98b7-a0b1-4bc2-868f-8cfa4e70552d"
      unitRef="U_USD">-303965000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f"
      decimals="-3"
      id="F_9ddf0d37-cea7-4e63-933e-acbcb8962546"
      unitRef="U_USD">96272000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_7a8a9344-a835-4ba9-8433-bf16f27259e7"
      decimals="INF"
      id="F_f7138c3c-7cf2-4e34-857d-f4ec8dd964c6"
      unitRef="U_shares">65880914</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_7a8a9344-a835-4ba9-8433-bf16f27259e7"
      decimals="-3"
      id="F_7bd43a09-95d9-4b7b-94de-c7964f71a852"
      unitRef="U_USD">66000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f81d0ad5-24f5-440e-b388-92bb80345764"
      decimals="-3"
      id="F_b9c56a2a-7f41-4695-b636-21747f880a19"
      unitRef="U_USD">413113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2f3ed9a6-4829-4c38-92f5-f9f01e3bbb26"
      decimals="-3"
      id="F_644647e2-0960-4e91-94b2-071b9d80ac09"
      unitRef="U_USD">-6851000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b0860219-0067-45f9-9914-90dc829092a2"
      decimals="-3"
      id="F_a77dfa89-5677-43da-ad96-af215f808098"
      unitRef="U_USD">-359313000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_039ef1b0-1293-4889-a2db-c0817298c584"
      unitRef="U_USD">47015000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5e0098f9-fc3d-4792-a5bc-ef3eeb5b4648"
      decimals="-3"
      id="F_7e6a0116-f731-4767-be61-20727751a3d5"
      unitRef="U_USD">3176000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_15ef1af7-803c-479b-968a-de713a0277e6"
      unitRef="U_USD">3176000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_8c35e721-a83d-4a8e-a7a6-c6064ec92392"
      decimals="-3"
      id="F_85141a5c-a007-4c7e-943f-a88ddbac8ec9"
      unitRef="U_USD">39000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_14056fe0-0695-4073-a2fa-d27835c6d0c1"
      unitRef="U_USD">39000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_4a17c158-ee71-4938-91a0-7a0dbd466b03"
      decimals="-3"
      id="F_348927f3-5481-4b11-ba5f-ea0aca67565f"
      unitRef="U_USD">-48638000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_57e6e3ac-11c2-480a-b81e-ac4dea35caf2"
      unitRef="U_USD">-48638000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_8833db9a-d541-4dd5-b81a-904e800f12d5"
      decimals="INF"
      id="F_a5c87f81-4f18-4a8f-b086-fce81e30de91"
      unitRef="U_shares">65880914</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8833db9a-d541-4dd5-b81a-904e800f12d5"
      decimals="-3"
      id="F_4b371cfd-f384-4f15-b3f7-12671e6b77d0"
      unitRef="U_USD">66000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1db878a1-26bf-48ae-8c27-edb9a58074e0"
      decimals="-3"
      id="F_b6627c89-6e3b-459f-8f4a-71a08943c334"
      unitRef="U_USD">416289000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ca567592-c0e0-4b20-a4ed-3220891a696b"
      decimals="-3"
      id="F_cf846328-1d90-4b2f-8469-44d590ac5719"
      unitRef="U_USD">-6812000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1e0ec6e5-7239-40d3-8f87-70637b9c4213"
      decimals="-3"
      id="F_b3ac7bfc-a761-4000-9a04-961d6abc7673"
      unitRef="U_USD">-407951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_9e8ab1ae-1cdc-4be3-97c4-12bc536dc529"
      unitRef="U_USD">1592000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_816e3d13-5a64-4037-9fe3-db3fa399c078"
      unitRef="U_USD">-48638000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_72628ff4-136a-4724-b841-6c9481fc3ffb"
      unitRef="U_USD">-40143000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_43de4ca3-b84b-46d9-9920-dfe9f06ff348"
      unitRef="U_USD">125000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_568febbe-2fed-455d-9718-e5d4005d9fbd"
      unitRef="U_USD">127000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_c4c86de3-002b-418a-a7b4-0e81f600edc7"
      unitRef="U_USD">3176000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_fc6afe99-b081-46e0-a7e1-c98dd74e9406"
      unitRef="U_USD">3210000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_1fe669c7-a27a-4b3b-8285-0b91d9369c5c"
      unitRef="U_USD">253000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_d5b2e743-14a2-4f0f-944c-1404a7d44fe3"
      unitRef="U_USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_1ca3fe63-610d-431f-aedc-fadfc98795bf"
      unitRef="U_USD">336000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_03b8972b-65fe-4e9e-ac13-cd4a6318940c"
      unitRef="U_USD">298000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_53f7f5e9-7c82-411e-955b-f232bebb8b37"
      unitRef="U_USD">-479000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_d8aa06ed-ffd1-4f8d-86b4-f1588106fff7"
      unitRef="U_USD">-552000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_f08dbdb1-8b24-4e37-98d8-cc5d1b0dc83f"
      unitRef="U_USD">2587000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_5ddbd4a8-315a-4d88-9c52-f06f4b981c9f"
      unitRef="U_USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_99d10232-1e60-4ead-89c7-f2b8c556b462"
      unitRef="U_USD">636000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_76003efc-79a6-4a2b-91ef-12f23d9ced81"
      unitRef="U_USD">2843000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_ea5a591e-526b-4e21-be76-77762bb4f6df"
      unitRef="U_USD">882000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_fb74a8aa-bf46-4ffd-9c5b-1dd0324e3d6f"
      unitRef="U_USD">787000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_5afd2e24-4511-4006-be6d-bdb0a5fedc9a"
      unitRef="U_USD">877000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_3d6bac6e-49da-4fe7-9044-8fbe00b3077b"
      unitRef="U_USD">1139000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <iobt:IncreaseDecreaseInLeaseLiability
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_a07d4d15-b699-4ee9-bea4-06af0c56b76c"
      unitRef="U_USD">-418000</iobt:IncreaseDecreaseInLeaseLiability>
    <iobt:IncreaseDecreaseInLeaseLiability
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_f76cffc3-1dc2-486d-8999-cd50482f41f2"
      unitRef="U_USD">-312000</iobt:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_247205fc-66d1-4a7e-b991-4a8fdc0340f5"
      unitRef="U_USD">-152000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_b3b6b243-65ef-45aa-b53e-00f4d718fa5e"
      unitRef="U_USD">-3155000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_ac6f27f6-b666-4aa3-8760-ef524ea7dc23"
      unitRef="U_USD">-42893000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_9bf83f6f-c329-433d-9268-6bd49a6fc467"
      unitRef="U_USD">-41914000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_b7b45cf9-1a42-43ce-aac9-468a4db6a513"
      unitRef="U_USD">54000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_5981c606-1840-4640-87ad-c89c1fac7cf6"
      unitRef="U_USD">23000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_2abba1e2-403b-4f3c-bf21-cef9e82cfddb"
      unitRef="U_USD">-54000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_9379ff07-9924-449f-b2ca-92c8084c484e"
      unitRef="U_USD">-23000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_73149cbd-55b0-4953-9762-dd3d6ebc2c6b"
      unitRef="U_USD">11720000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_de6df037-5cfc-4863-922c-bcea83a260dd"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_65e8927c-41ad-47be-a1c4-5a5010d069ff"
      unitRef="U_USD">233000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_52b34255-3a45-4674-856c-2ed4850eb84e"
      unitRef="U_USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_67b902e0-fb07-423d-84b8-049be57e7f65"
      unitRef="U_USD">11487000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_858e9909-79ac-464b-a3f9-5e4dd5b4bcc7"
      unitRef="U_USD">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_80b61e48-d021-4186-b478-7085a929a0c5"
      unitRef="U_USD">-31460000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_b5be0fe1-4883-4943-97ad-95cade348ffc"
      unitRef="U_USD">-41937000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_c87281b5-415b-437b-bf3e-6d2da10bc052"
      unitRef="U_USD">-440000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_1e7abe24-d3b6-4bd3-aaba-539d805c89c6"
      unitRef="U_USD">-509000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_f07da8f3-7732-4a3a-9762-549112236911"
      unitRef="U_USD">60299000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_3adaf1b6-8e71-4415-9436-0d74420cbb54"
      decimals="-3"
      id="F_16571d0e-e50a-47d8-9803-731fa9763182"
      unitRef="U_USD">143461000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_37a3b7f7-1931-4b82-b305-960a008034aa"
      unitRef="U_USD">28399000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f"
      decimals="-3"
      id="F_8f41e2e2-0240-435d-8049-ac61bbc3982d"
      unitRef="U_USD">101015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_b0fc22c4-4bb6-4a15-8cbc-b31abc9bd100"
      unitRef="U_USD">28131000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f"
      decimals="-3"
      id="F_20881b2d-2115-4e3c-88dc-c136f92b3e57"
      unitRef="U_USD">100747000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_1b7ab601-ee7c-4cf2-9101-1b49688d595b"
      unitRef="U_USD">268000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f"
      decimals="-3"
      id="F_20527ea8-1808-4e56-95d1-5ca0b3b257fb"
      unitRef="U_USD">268000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_b97f28a6-af72-4f91-8408-00821a518436"
      unitRef="U_USD">28399000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f"
      decimals="-3"
      id="F_765948c5-a927-4fde-b47d-987c7f61604e"
      unitRef="U_USD">101015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_c342a4c4-8f84-47fb-a7a1-6c9e44b27a1b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Description of Business, Organization and Liquidity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on our T-win&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; platform. As used in these financial statements, unless the context otherwise requires, references to the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to IO Biotech, Inc. and its subsidiaries.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Corporate Reorganization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;IO Biotech ApS was incorporated in Denmark in December 2014. In November 2021, we completed a corporate reorganization (the &#x201c;Corporate Reorganization&#x201d;) whereby IO Biotech ApS became a wholly-owned subsidiary of the Company. In connection with the corporate reorganization, each issued and outstanding Class A ordinary share ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; par value) was exchanged on a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one-for-one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; basis into shares of common stock of the Company ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; par value). Each Class B and Class C preference share of IO Biotech ApS was exchanged on a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one-for-one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; basis into shares of Class B and Class C preferred stock of the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;IO Bio US, Inc., a wholly owned subsidiary of IO Biotech ApS, was incorporated in Delaware in May 2021. IO Biotech Limited, a wholly owned subsidiary of IO Biotech ApS, was incorporated in the UK in August 2021. In November 2021, the Company engaged in a series of transactions, referred to collectively as the Corporate Reorganization. As a result of the Corporate Reorganization, IO Biotech ApS became a wholly-owned subsidiary of IO Biotech, Inc. IO Biotech, Inc. is a holding company formed in October 2021, which, prior to our initial public offering (&#x201c;IPO&#x201d;), had nominal assets and no liabilities, contingencies, or commitments, and which has not conducted any operations prior to our IPO other than acquiring the entire issued and outstanding stock of IO Biotech ApS. The Company, IO Biotech ApS, and the holders of all of the issued and outstanding equity interests of IO Biotech ApS entered into a Share Contribution and Exchange Agreement, dated as of October 29, 2021, pursuant to which the Corporate Reorganization was effected.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;IPO&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2021, we completed our IPO, selling an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,222,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a price to the public of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,072,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock sold pursuant to the underwriters&#x2019; exercise of their option to purchase additional shares of common stock. We received net proceeds from the IPO, after deducting underwriting discounts and commissions and other offering costs, of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Immediately prior to the consummation of the IPO, all outstanding shares of our Class A ordinary shares and Class B and Class C convertible preference shares were converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,592,413&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock. Upon the closing of the IPO on November 9, 2021, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,815,267&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were issued and outstanding. Our common stock began trading on the Nasdaq Global Market on November 5, 2021 under the symbol &#x201c;IOBT.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 9, 2021, we amended and restated the certificate of incorporation of IO Biotech, Inc. to authorize the issuance of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of preferred stock. The shares of preferred stock are currently undesignated.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;August 2023 Private Placement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 9, 2023, the Company completed a private placement transaction (the &#x201c;Private Placement&#x201d;), pursuant to which we sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock (the &#x201c;Warrants&#x201d;) to certain institutional investors and existing shareholders (the &#x201c;Purchasers&#x201d;). Each Purchaser&#x2019;s Warrant is exercisable for a number of shares of common stock equal to one hundred percent of the aggregate number of shares of common stock purchased by such Purchaser. The purchase price per share of common stock and Warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (the &#x201c;Purchase Price&#x201d;). The Company received net proceeds from the Private Placement, after deducting $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in underwriting discounts and commissions and other offering costs, of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Refer to Note 11, "Stockholders' Equity" in this Quarterly Report on Form 10-Q for additional detail on the Private Placement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;At-The-Market Equity Program&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 15, 2023, we filed a new prospectus supplement with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) with respect to the offer and sale of shares of our Common Stock, with an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, establishing an at-the-market equity program. We also entered into a common stock sales agreement, dated February 15, 2023 (the &#x201c;Sales Agreement&#x201d;) by and between the Company and Cowen and Company, LLC for shares with an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, through which we may, from time to time, sell shares through Cowen and Company, LLC, acting as agent and/or principal. Any shares offered and sold through the at-the-market equity program will be issued pursuant to the Company&#x2019;s Registration Statement on Form S-3 (File No. 333-269569), which was declared effective on February 10, 2023, the prospectus supplement related to the offering that forms a part of the registration statement, and any applicable prospectus supplements that may form a part of the registration statement in the future. The aggregate market value of shares eligible for sale under the prospectus supplement and under the Sales Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t issued any shares pursuant to our at-the-market equity program as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;European Investment Bank Term Loan Facility&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 19, 2024, the Company, through its subsidiary, IO Biotech ApS (the &#x201c;Borrower&#x201d;) entered into a Finance Contract (the &#x201c;Finance Contract&#x201d;) with the European Investment Bank (&#x201c;EIB&#x201d;), establishing a loan facility of up to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million that includes three committed tranches of potential financing in an aggregate principal amount of up to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, subject to certain conditions precedent (the &#x201c;EIB Loan Facility&#x201d;), and one uncommitted accordion tranche of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. See Note 8, &#x201c;Term Loan Facility&#x201d; in this Quarterly Report on Form 10-Q for additional detail.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance reporting capabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our product candidates are in preclinical research and clinical development. There can be no assurance that our research and development will be successfully completed, that adequate protection for our intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if our product development efforts are successful, it is uncertain when, if ever, we will generate significant revenue from product sales. We operate in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, we are dependent upon the services of our employees and consultants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;    &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Substantial Doubt About the Company&#x2019;s Ability to Continue as a Going Concern and the Going Concern Basis of Accounting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These consolidated financial statements have been prepared on a going concern basis of accounting, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since inception, we have devoted substantially all of our efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. We have financed our operations primarily through the issuance of convertible preference shares, convertible notes, our IPO, the Private Placement and the EIB Loan Facility.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our continued discovery and development of product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if our product development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2025, we had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;408.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. We have incurred losses and negative cash flows from operations since inception, including net losses of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the six months ended June 30, 2025 and the year ended December 31, 2024, respectively. We expect that our operating losses and negative cash flows will continue for the foreseeable future as we continue to develop our product candidates. We currently expect that our cash and cash equivalents of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of June 30, 2025 along with the second tranche of the EIB Loan will not be sufficient to fund our operating expenses and capital requirements for at least 12 months from the date the financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has plans to obtain sufficient additional fundraising to fulfill its operating and capital requirements for the next 12 months. The Company&#x2019;s plans include continuing to fund its operating losses and capital funding needs through public or private equity or debt financings, including the draw down of the available committed tranches of the EIB loan facility defined below in Note 8, &#x201c;Term Loan Facility&#x201d;, strategic collaborations, licensing arrangements, or other arrangements. The Company has drawn down on the Tranche A and Tranche B loan facility in principal amount of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, on May 6, 2025 and July 4, 2025, each before payment of certain fees and transaction related expense. The business conditions of the Tranche C loan facility have not been satisfied to draw up to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of the date of these interim financial statements. Further, the Company believes that its operations are scalable and, if there is a need, certain cost reduction measures may be taken to preserve cash.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Although management believes such plans, if executed, should provide the Company sufficient financing to meet its needs, successful completion of such plans is dependent on factors outside of the Company&#x2019;s control. Our future capital requirements will depend on many factors, including, but not limited to:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the scope, prioritization and number of our research and development programs;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the scope, progress, results and costs of our clinical trials, including the results of IOB-013;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the costs, timing and outcome of regulatory review of our product candidates;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the costs to scale up and secure manufacturing arrangements for commercial production of Cylembio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in combination with pembrolizumab as a first-line treatment in advanced melanoma;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the costs of establishing and maintaining commercialization capabilities for Cylembio in combination with pembrolizumab as a first-line treatment in advanced melanoma, and any product candidate that obtains regulatory approval; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the level of sales achieved, and costs related to the commercialization of Cylembio in combination with pembrolizumab as a first-line treatment in advanced melanoma.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Therefore, sufficient additional funds may not be available on a timely basis, on favorable terms or at all. As such, management cannot conclude that such plans will be effectively implemented in due time to secure sufficient funds to finance operations at least through one year after the date that the financial statements are issued.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a result, management has concluded that the aforementioned conditions, among others, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year after the date the financial statements are issued and therefore, the Company may not be able to continue its currently ongoing research and development activities as planned and realize its assets and satisfy its liabilities in the normal course of business.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company will also require additional capital to commercialize Cylembio in combination with pembrolizumab as a first-line treatment in advanced melanoma, and to continue to fund future discovery research, preclinical, clinical activities and commercialization of any of our product candidates. If we receive regulatory approval for Cylembio, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing, medical affairs, distribution and other related functions, depending on where we choose to commercialize. Additional funds for such commercialization activities and future discovery research, preclinical, clinical activities may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our growth strategy. We will seek additional funding through public financings, debt financings, collaboration agreements, strategic alliances and licensing arrangements. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining such additional financing on acceptable terms, or at all, and we may not be able to enter into collaborations or other arrangements. If we are unable to obtain funding in due time, we could be forced to delay, reduce or eliminate our research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect our business prospects, even our ability to continue operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_07d945e9-2951-4202-ae7e-2b4ac20b2b1a"
      decimals="2"
      id="F_068b2219-68b7-4666-a3c3-c7f3f1e27241"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.16</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockConversionBasis
      contextRef="C_0fe7e5da-4225-4e64-8f1a-304a1362ffeb"
      id="F_e6ff9f42-1f6f-471c-8280-008ee6701a67">one-for-one</us-gaap:CommonStockConversionBasis>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b5d3ce4a-d401-4cbf-bc28-337d54b8c30e"
      decimals="3"
      id="F_37544492-7fb7-4157-9b35-f42271042941"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a5b8b85f-9da7-4446-9f08-8ee19839e7c1"
      decimals="3"
      id="F_b2ad7080-f031-48b8-bc4f-b52f37c52c32"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockConversionBasis
      contextRef="C_90f4ecd9-d648-4156-a8e7-4757b344ff98"
      id="F_ec2ae415-d2cc-4dc0-b9bc-716a8b3b3130">one-for-one</us-gaap:CommonStockConversionBasis>
    <us-gaap:CommonStockConversionBasis
      contextRef="C_c62e54bd-498f-4c0a-88c7-5e544580ae36"
      id="F_9576ff8a-9e96-4fc9-a45c-08df5e448a0d">one-for-one</us-gaap:CommonStockConversionBasis>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_961273d7-9799-42fe-8b40-c4dc80cf3e1d"
      decimals="0"
      id="F_68a32b03-e710-42b6-be78-0f7d0afbbf03"
      unitRef="U_shares">8222500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_1434ccee-3c92-4bb3-9b9d-6f650436ace2"
      decimals="2"
      id="F_35a82d25-67f1-46c1-934c-91392399fbf2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_7e2345a4-e132-4d97-885c-dbc51fa34b9a"
      decimals="0"
      id="F_f2c8602c-7291-4eb4-82fb-69a914abc9c2"
      unitRef="U_shares">1072500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_dd160d99-0b92-4fa0-b879-249e802cf09f"
      decimals="-5"
      id="F_02e3f5a2-2a8f-49b2-be75-caedf35f2106"
      unitRef="U_USD">103300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_7b18d373-032b-4323-90f2-5980a3f2eeb4"
      decimals="0"
      id="F_af6de972-f439-4d91-bedb-82da005227f6"
      unitRef="U_shares">20592413</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_7b18d373-032b-4323-90f2-5980a3f2eeb4"
      decimals="0"
      id="F_dbfa222c-fb34-44bd-9d3c-557f550f9c18"
      unitRef="U_shares">28815267</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_7b18d373-032b-4323-90f2-5980a3f2eeb4"
      decimals="0"
      id="F_2ab25a23-f349-4797-acfa-ac7d6ddb2119"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f19d5a95-b1ed-473d-a534-3f3d6090cd35"
      decimals="0"
      id="F_70609921-4f36-4b07-b4d1-fa82384e7866"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b73d57d8-d103-4c28-a629-6ab0d371bfb8"
      decimals="0"
      id="F_c407a20b-9087-4062-a7ac-8a753506f995"
      unitRef="U_shares">37065647</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_6dce96c8-4c75-416e-bf89-e8c89509910e"
      decimals="3"
      id="F_fa370d81-5d79-4d37-ab89-34e47506069d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <iobt:WarrantsIssued
      contextRef="C_b73d57d8-d103-4c28-a629-6ab0d371bfb8"
      decimals="0"
      id="F_b1920f27-b9d9-44f5-93a9-d2b7b2071144"
      unitRef="U_shares">37065647</iobt:WarrantsIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2130d49e-92a6-4472-a00f-3b63ffde0b9b"
      decimals="0"
      id="F_6fb079a6-e15f-4fc1-9a9d-f2e017ae6c6e"
      unitRef="U_shares">37065647</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <iobt:PurchasePricePerShareOfCommonStockAndWarrant
      contextRef="C_b73d57d8-d103-4c28-a629-6ab0d371bfb8"
      decimals="3"
      id="F_878c3870-3fba-423c-afe5-aa3b243d6166"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.025</iobt:PurchasePricePerShareOfCommonStockAndWarrant>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_b73d57d8-d103-4c28-a629-6ab0d371bfb8"
      decimals="-5"
      id="F_9fb01fde-de52-4bb4-ad1e-b7b5528b9614"
      unitRef="U_USD">3200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_0e1d0a4d-d812-461f-aec2-4c14dea78aaa"
      decimals="-5"
      id="F_3cdfe404-c1dc-405d-8615-c00c83586fab"
      unitRef="U_USD">71900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <iobt:CommonStockMaximumAggregateOfferingAmount
      contextRef="C_101f5b3f-2579-4748-bcd4-04070eb2ce6f"
      decimals="-5"
      id="F_33a2f709-475d-4bab-ba60-1140d80016ca"
      unitRef="U_USD">19500000</iobt:CommonStockMaximumAggregateOfferingAmount>
    <iobt:CommonStockMaximumAggregateOfferingAmount
      contextRef="C_1dfbcdf2-7303-4e39-a3bd-fd5f426fbf73"
      decimals="-5"
      id="F_425fa8df-88d0-4563-8a21-103d2195f7f7"
      unitRef="U_USD">75000000</iobt:CommonStockMaximumAggregateOfferingAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a3a82724-39ac-4bbf-87e1-409ddfd8aea1"
      decimals="INF"
      id="F_544da53a-00ec-4661-b899-ef524c3173b8"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
      contextRef="C_75035fee-9a60-4e72-991b-0ba8a07ca63f"
      decimals="-5"
      id="F_4799dd8c-dd0d-4700-b71d-ec00d1144bd2"
      unitRef="U_EUR">57500000</us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_df699447-5212-44fe-9bb9-541bf78efe2d"
      decimals="-5"
      id="F_c6d44f2c-385e-4863-90a0-a1d9fda52bb9"
      unitRef="U_EUR">37500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <iobt:CertainConditionsPrecedentAndOneUncommittedAccordionTranche
      contextRef="C_75035fee-9a60-4e72-991b-0ba8a07ca63f"
      decimals="-5"
      id="F_67437f22-df60-41ec-a8b1-de8ab344414f"
      unitRef="U_EUR">20000000</iobt:CertainConditionsPrecedentAndOneUncommittedAccordionTranche>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-5"
      id="F_f89ca5bb-4ce3-4ecc-8115-ab26b599301a"
      unitRef="U_USD">-408000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-5"
      id="F_c43023f1-9d48-4e8b-8d3f-5d84c49c70b1"
      unitRef="U_USD">-48600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_38e73190-243c-4f4c-acfe-c43cdf009a58"
      decimals="-5"
      id="F_bc9197c8-bb0b-4a66-a2f4-6df7e480d580"
      unitRef="U_USD">-95500000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-5"
      id="F_43f024f5-0bf6-427e-a067-25b98efa692a"
      unitRef="U_USD">28100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_56d189f5-8762-4d45-aa40-9a14717e05b4"
      decimals="-5"
      id="F_8aa3b237-0d30-470a-973a-f1ed1df3486c"
      unitRef="U_EUR">10000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_320ef1d4-ce99-4066-9e33-b688a26543ee"
      decimals="-5"
      id="F_90647875-48c7-4383-afd6-a20cf7704e5c"
      unitRef="U_EUR">12500000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_a1efa8f3-3329-44e8-97a1-ee569efea2b8"
      decimals="-5"
      id="F_64655eca-7b45-4718-886f-03be57308004"
      unitRef="U_EUR">15000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_1b436104-012a-4cf1-ac16-7ef14c405bd7">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrants Issued in Connection with a Sale of Common Stock or Issuance of Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for warrants issued as a separable unit in connection with sale of common stock or debt as either liability or equity in accordance with Accounting Standards Codification 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting for Derivative Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered liabilities if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. If warrants do not require liability classification under ASC 815-40 or other applicable generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) the warrants should be classified as equity. The debt is measured at amortized cost and the amount of interest recognized in the consolidated statements of operations is calculated by applying the loan&#x2019;s effective interest rate to its carrying amount.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The proceeds received from the sale of equity classified warrants and shares of common stock in a bundled transaction are allocated based on the relative fair values of warrants and shares with no changes in fair value of warrants recognized after the issuance date. For liability classified warrants, the stand-alone fair value of the warrants are classified as debt issuance costs that directly reduce the outstanding debt on the consolidated balance sheet upon funding. Warrants issued prior to the date of funding are accounted for as a deferred financing asset within &#x201c;Prepaid expenses and other current assets&#x201d; on the consolidated balance sheet and will be reclassified to debt issuance costs on the date of funding. The change in fair value of warrants each balance sheet date are recognized in the consolidated statements of operations and comprehensive loss after the issuance date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have been no other changes to the significant accounting policies disclosed in Note 2 to the Company&#x2019;s annual financial statements for the years ended December 31, 2024 and 2023 included in our Annual Report on Form 10-K filed with the SEC on March 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Unaudited Financial Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying unaudited interim consolidated financial statements included herein have been prepared in conformity with U.S. GAAP, and pursuant to the rules and regulations of the SEC. In the Company&#x2019;s opinion, the information furnished herein reflects all adjustments, all of which are of a normal and recurring nature and necessary for a fair presentation of the financial position and results of operations for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company&#x2019;s Annual Report filed on Form 10-K for the fiscal year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0847deca-10d0-4530-aa33-3be6c7b7efa2;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; will also enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment and contain other disclosure requirements. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the financial statements. The guidance is effective in the annual periods beginning after December 15, 2023 and the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the standard effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Refer to Note 15, "Segments" in this Quarterly Report on Form 10-Q for additional information.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the FASB issued ASU 2023-06, Accounting Standards Update 2023-06&#x2014;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative. ASU 2023-06 will eliminate disclosure requirements that are redundant, duplicative, overlapping, outdated, or superseded as a result of subsequent changes to SEC disclosure requirements, U.S. GAAP or technology. ASU 2023-06 is intended to better align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP. The disclosure requirements would apply prospectively in the financial statements. ASU 2023-06 will be effective for us on the date on which the SEC&#x2019;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, if we are already subject to the SEC&#x2019;s current disclosure requirements. For those current disclosure requirements we are not subject to, ASU 2023-06 will become effective two years after the date of such removal by the SEC. We are currently assessing the impact adoption of ASU 2023-06 will have on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 will require disclosure of additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state and foreign income taxes. ASU 2023-09 will also require information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold.  ASU 2023-09 will be effective for us in the annual periods beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. We are currently assessing the impact adoption of ASU 2020-06 will have on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures  (Subtopic 220-40): Disaggregation of  Income Statement Expenses. ASU 2024-03 will require disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis, including purchases of inventory, employee  compensation, depreciation, intangible asset amortization and depletion for each  income statement line item that contains those expenses. ASU 2024-03 also will require certain amounts already disclosed under existing U.S. GAAP to also be disclosed as a separate category in disaggregated expense table(s), if those amounts are  recognized in the relevant expense line item. The amendments in this ASU will be effective for us in annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. We are currently assessing the impact adoption of ASU 2024-03 will have on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <iobt:WarrantsPolicyPolicyTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_ad0d1fb8-47c2-4da3-8aa0-680014e6f885">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrants Issued in Connection with a Sale of Common Stock or Issuance of Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for warrants issued as a separable unit in connection with sale of common stock or debt as either liability or equity in accordance with Accounting Standards Codification 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting for Derivative Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered liabilities if they are mandatorily redeemable and they require settlement in cash or other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as liability or equity. If warrants do not require liability classification under ASC 815-40 or other applicable generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) the warrants should be classified as equity. The debt is measured at amortized cost and the amount of interest recognized in the consolidated statements of operations is calculated by applying the loan&#x2019;s effective interest rate to its carrying amount.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The proceeds received from the sale of equity classified warrants and shares of common stock in a bundled transaction are allocated based on the relative fair values of warrants and shares with no changes in fair value of warrants recognized after the issuance date. For liability classified warrants, the stand-alone fair value of the warrants are classified as debt issuance costs that directly reduce the outstanding debt on the consolidated balance sheet upon funding. Warrants issued prior to the date of funding are accounted for as a deferred financing asset within &#x201c;Prepaid expenses and other current assets&#x201d; on the consolidated balance sheet and will be reclassified to debt issuance costs on the date of funding. The change in fair value of warrants each balance sheet date are recognized in the consolidated statements of operations and comprehensive loss after the issuance date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have been no other changes to the significant accounting policies disclosed in Note 2 to the Company&#x2019;s annual financial statements for the years ended December 31, 2024 and 2023 included in our Annual Report on Form 10-K filed with the SEC on March 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</iobt:WarrantsPolicyPolicyTextBlock>
    <iobt:UnauditedFinancialInformationPolicyPolicyTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_e5e53c33-55da-4ac3-89ab-421265b5f07f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Unaudited Financial Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying unaudited interim consolidated financial statements included herein have been prepared in conformity with U.S. GAAP, and pursuant to the rules and regulations of the SEC. In the Company&#x2019;s opinion, the information furnished herein reflects all adjustments, all of which are of a normal and recurring nature and necessary for a fair presentation of the financial position and results of operations for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company&#x2019;s Annual Report filed on Form 10-K for the fiscal year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</iobt:UnauditedFinancialInformationPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_1d94947c-1269-496e-9747-ce19b5ec9419">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0847deca-10d0-4530-aa33-3be6c7b7efa2;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; will also enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment and contain other disclosure requirements. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the financial statements. The guidance is effective in the annual periods beginning after December 15, 2023 and the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the standard effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Refer to Note 15, "Segments" in this Quarterly Report on Form 10-Q for additional information.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the FASB issued ASU 2023-06, Accounting Standards Update 2023-06&#x2014;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative. ASU 2023-06 will eliminate disclosure requirements that are redundant, duplicative, overlapping, outdated, or superseded as a result of subsequent changes to SEC disclosure requirements, U.S. GAAP or technology. ASU 2023-06 is intended to better align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP. The disclosure requirements would apply prospectively in the financial statements. ASU 2023-06 will be effective for us on the date on which the SEC&#x2019;s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, if we are already subject to the SEC&#x2019;s current disclosure requirements. For those current disclosure requirements we are not subject to, ASU 2023-06 will become effective two years after the date of such removal by the SEC. We are currently assessing the impact adoption of ASU 2023-06 will have on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 will require disclosure of additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state and foreign income taxes. ASU 2023-09 will also require information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold.  ASU 2023-09 will be effective for us in the annual periods beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. We are currently assessing the impact adoption of ASU 2020-06 will have on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures  (Subtopic 220-40): Disaggregation of  Income Statement Expenses. ASU 2024-03 will require disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis, including purchases of inventory, employee  compensation, depreciation, intangible asset amortization and depletion for each  income statement line item that contains those expenses. ASU 2024-03 also will require certain amounts already disclosed under existing U.S. GAAP to also be disclosed as a separate category in disaggregated expense table(s), if those amounts are  recognized in the relevant expense line item. The amendments in this ASU will be effective for us in annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. We are currently assessing the impact adoption of ASU 2024-03 will have on our financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      id="F_ea89a353-cf57-4bb9-8414-0ddf53365c55">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      id="F_dfa2b0f2-1ebb-43dd-96dc-edb30e3abe8c">2024-12-31</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_c64fb08b-8fd5-44ea-8074-8eb2f5bbbe57">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Money market funds with maturities of 90 days or less at the date of purchase are included within cash and cash equivalents in the accompanying consolidated balance sheets and are recognized at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 24, 2025, in connection with the EIB Loan Facility, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;5,623,664&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Tranche A warrants to purchase shares of the Company&#x2019;s common stock at an exercise price of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;0.89&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. On June 24, 2025, in connection with the EIB Loan Facility, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;4,221,868&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Tranche B warrants to purchase shares of the Company&#x2019;s common stock at an exercise price of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;1.32&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Note 8, &#x201c;Term Loan Facility&#x201d; in this Quarterly Report on Form 10-Q for additional detail on the EIB Loan Facility and warrants issued.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The EIB warrants met the criteria for liability classification and are initially recognized on the date of issuance and subsequently measured at each balance sheet date at fair value through &#x201c;Other income (expense)&#x201d; on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of the Tranche A and Tranche B warrants was determined based on the Black-Scholes option-pricing model and classified within Level 3 of the fair value hierarchy on the date of issuance. The expected volatility input used in the model was deemed unobservable (Level 3) and was determined based on share price data of the Company and comparable companies for a term equal to the remaining contractual term of the warrants. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other required inputs used in the model were considered observable (Level 1). Significant increases (decreases) in these inputs could result in a significantly lower or higher fair value measurement. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table shows the Black-Scholes option-pricing model inputs used to calculate the fair value of the warrants at issuance date. &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.59%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.901%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.304000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.901%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.304000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tranche A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tranche B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share price of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table shows the Black-Scholes option-pricing model inputs used to calculate the fair value of the warrants at June 30, 2025.&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.59%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.901%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.304000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.901%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.304000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tranche A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tranche B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share price of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table shows a reconciliation of the beginning and ending balances for Level 3 financial liabilities measured at fair value on a recurring basis for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:78.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 3 financial liabilities, beginning of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issuance of EIB common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of EIB common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 3 financial liabilities, end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; transfers among Level 1, Level 2 or Level 3 categories in the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025 and the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_aa3b8f0e-d551-4714-ac68-e8cf9ede2a4f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about our financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ed3915fc-fc74-40d9-ad4d-e15fa899e8b3"
      decimals="-3"
      id="F_24528679-c737-4b24-b829-97485f2d45c3"
      unitRef="U_USD">22670000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a201864f-0cd6-476c-97c7-14da7f8984f9"
      decimals="-3"
      id="F_6f73b602-be1f-46b6-a474-83399c07f5b5"
      unitRef="U_USD">22670000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_be42f9d7-7aab-4ef2-a21e-2e34278195bb"
      decimals="-3"
      id="F_e17df0d8-b43c-4136-862f-7ba04c04f40e"
      unitRef="U_USD">22670000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_168c3e7e-9d8e-427e-8f70-1ecd3c073fd2"
      decimals="-3"
      id="F_ffc417f2-188c-46f8-9660-9834d38be049"
      unitRef="U_USD">22670000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_3c22dc6f-5520-49c4-8ebf-ac7d5b76711c"
      decimals="-3"
      id="F_a2f15451-24cf-4ea3-8d0c-73195274c4a0"
      unitRef="U_USD">13249000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_8b2efd79-bc0d-46d6-b1bc-dd8287dadebc"
      decimals="-3"
      id="F_f6db4f11-9a3a-4f83-9608-13043d3dbc6c"
      unitRef="U_USD">13249000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_be42f9d7-7aab-4ef2-a21e-2e34278195bb"
      decimals="-3"
      id="F_976cfe4f-60ae-42e6-8547-ab77567133dd"
      unitRef="U_USD">13249000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_bfbeb53d-249c-4965-bee1-58424b490ed9"
      decimals="-3"
      id="F_d98275fc-4af1-4bee-9657-1b15015dde45"
      unitRef="U_USD">13249000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_90915382-ac57-414d-9f3c-555baa2c95a6"
      decimals="-3"
      id="F_8fa86962-39da-4c9b-88d9-756834685bc1"
      unitRef="U_USD">46134000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5be29099-873c-44cb-9847-39038a293dac"
      decimals="-3"
      id="F_3a0d807f-a384-429c-a783-66b9b2b3c5dd"
      unitRef="U_USD">46134000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5b1915ad-890a-47af-9868-ded5e38e7f5a"
      decimals="-3"
      id="F_e287dbf5-4abd-460a-a0d4-6c44d93544e3"
      unitRef="U_USD">46134000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_35ff612b-5ba4-4688-aed0-aa185853966a"
      decimals="-3"
      id="F_41a1aa96-efbb-4ab4-823b-ce261c343477"
      unitRef="U_USD">46134000</us-gaap:AssetsFairValueDisclosure>
    <iobt:WarrantsIssued
      contextRef="C_389775bc-ae88-489c-8c1c-85a0ed058e9b"
      decimals="0"
      id="F_1abff002-9ab3-4239-919c-eceac1caf963"
      unitRef="U_shares">5623664</iobt:WarrantsIssued>
    <iobt:StrikePricePerShare
      contextRef="C_389775bc-ae88-489c-8c1c-85a0ed058e9b"
      decimals="2"
      id="F_6e1beaea-29f9-465d-99d4-ff2a5300d59d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.89</iobt:StrikePricePerShare>
    <iobt:WarrantsIssued
      contextRef="C_d77d1227-8aa0-44ec-aa93-20c58573316a"
      decimals="0"
      id="F_e17f3ea8-891d-403d-b9cc-aee80e2a6bc6"
      unitRef="U_shares">4221868</iobt:WarrantsIssued>
    <iobt:StrikePricePerShare
      contextRef="C_d77d1227-8aa0-44ec-aa93-20c58573316a"
      decimals="2"
      id="F_f77b5361-716d-4fc0-91be-0dd556e4a261"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.32</iobt:StrikePricePerShare>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_cae06177-d92e-4f9d-a4f8-f712b7603f12">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table shows the Black-Scholes option-pricing model inputs used to calculate the fair value of the warrants at issuance date. &lt;/span&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.59%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.901%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.304000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.901%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.304000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tranche A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tranche B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share price of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table shows the Black-Scholes option-pricing model inputs used to calculate the fair value of the warrants at June 30, 2025.&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.59%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.901%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.304000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.901%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.304000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tranche A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tranche B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share price of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:SharePrice
      contextRef="C_809916c8-d68a-4b98-8df0-358a4bf20dc9"
      decimals="2"
      id="F_87f2164c-307a-4072-ba26-8e3424fcfcfc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.92</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_545accb2-04f0-4670-bdc6-0b24c21df653"
      decimals="2"
      id="F_3450d751-53bd-4bcf-9222-913d8eb9fc76"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.39</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_34603f30-56ca-4356-8f77-419b1978063a"
      decimals="3"
      id="F_310253b1-a2aa-460c-8e26-869ef1df78b4"
      unitRef="U_pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_a8388fe4-cbac-4ad5-980a-b3e752b591be"
      decimals="3"
      id="F_f2fa6135-ad67-462b-9f9b-803fe811ab25"
      unitRef="U_pure">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_34603f30-56ca-4356-8f77-419b1978063a"
      decimals="3"
      id="F_e03e5aa8-275f-40ba-a2e7-fd043d979f8f"
      unitRef="U_pure">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_a8388fe4-cbac-4ad5-980a-b3e752b591be"
      decimals="3"
      id="F_e25bdf48-bf83-4f03-95f0-90d9f9d107c4"
      unitRef="U_pure">0.048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_34603f30-56ca-4356-8f77-419b1978063a"
      id="F_62094454-9659-4b8e-84f1-3a5ba23eaf3b">P20Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a8388fe4-cbac-4ad5-980a-b3e752b591be"
      id="F_52c56f30-0595-4c7a-91f0-1e7d4739ec1e">P20Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_34603f30-56ca-4356-8f77-419b1978063a"
      decimals="2"
      id="F_631b5cfe-56f8-4d88-b89c-83f43602cb8c"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_a8388fe4-cbac-4ad5-980a-b3e752b591be"
      decimals="2"
      id="F_f3b2104a-3dda-4ae2-ac6a-0670bc134e66"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharePrice
      contextRef="C_a29b1256-ec9a-45be-98bb-bec426c92507"
      decimals="2"
      id="F_7ecb5319-d6a7-4253-9d54-72c3768870c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.39</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_ae54636d-9518-4a0c-85b6-4e9e7bfcb7d1"
      decimals="2"
      id="F_701b0caa-32cd-483a-a7cc-2cc0c0f27198"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.39</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_c135a808-e5bb-419e-a467-b4017e11a0d1"
      decimals="3"
      id="F_e660506d-95f6-4466-8dbe-f71a1cb39d22"
      unitRef="U_pure">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_add64041-4ed9-4f0a-a7fb-8e35e7a09b6b"
      decimals="3"
      id="F_3589b6bc-dbbc-4a54-adf8-a188cfcc66b9"
      unitRef="U_pure">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_c135a808-e5bb-419e-a467-b4017e11a0d1"
      decimals="3"
      id="F_004fb922-1e07-445b-92b7-e37de5faac4c"
      unitRef="U_pure">0.048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_add64041-4ed9-4f0a-a7fb-8e35e7a09b6b"
      decimals="3"
      id="F_9f0d3c7a-6e2e-4430-88f6-f3748ff17be9"
      unitRef="U_pure">0.048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c135a808-e5bb-419e-a467-b4017e11a0d1"
      id="F_2399076b-6091-4329-8895-c3f571eda52b">P19Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_add64041-4ed9-4f0a-a7fb-8e35e7a09b6b"
      id="F_be0c009e-c413-4af1-b5be-00bdfcdcdfc6">P20Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_c135a808-e5bb-419e-a467-b4017e11a0d1"
      decimals="2"
      id="F_663bb523-6b4e-4a63-9942-8e38c332cde8"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_add64041-4ed9-4f0a-a7fb-8e35e7a09b6b"
      decimals="2"
      id="F_1040f577-7e46-49c3-bddf-a6155ec77252"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_6a529a4c-de55-48d4-b426-52efc34fa427">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table shows a reconciliation of the beginning and ending balances for Level 3 financial liabilities measured at fair value on a recurring basis for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:78.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 3 financial liabilities, beginning of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issuance of EIB common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of EIB common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 3 financial liabilities, end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_54e310e4-0799-4593-bda6-1a535959f76a"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_04115ec9-d18d-431c-9307-22952160e7b9"
      unitRef="U_USD">10662000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_095f24cb-baf7-4c14-be05-41b061bc1952"
      unitRef="U_USD">2587000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_a04e7e86-ebd9-4c0c-8b05-7de294f7dd18"
      unitRef="U_USD">13249000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="INF"
      id="F_53193141-583e-4cc0-be00-008810855394"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="INF"
      id="F_8cc3e4ee-b1f7-4541-85f3-53c40d889457"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="INF"
      id="F_c28b6ff6-247f-4f3d-931f-b9fc49086188"
      unitRef="U_USD">0</iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1>
    <iobt:FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="INF"
      id="F_2a8929e8-f577-4f61-9255-23dc8211d64a"
      unitRef="U_USD">0</iobt:FairValueLiabilitiesLevel2ToLevel1TransfersAmount1>
    <iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="INF"
      id="F_b0f21928-8894-4c0d-b06d-faaf8a44a61a"
      unitRef="U_USD">0</iobt:FairValueLiabilitiesLevel1ToLevel2TransfersAmount1>
    <iobt:FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="INF"
      id="F_8088fff9-9576-43b3-9f35-03907d0ee9b4"
      unitRef="U_USD">0</iobt:FairValueLiabilitiesLevel2ToLevel1TransfersAmount1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_38e73190-243c-4f4c-acfe-c43cdf009a58"
      decimals="INF"
      id="F_11d26dcf-5e13-47d9-ae22-0b1967fdc0e2"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_38e73190-243c-4f4c-acfe-c43cdf009a58"
      decimals="INF"
      id="F_c2891191-6a97-48bc-9cef-3a86c0bfffde"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_28aec814-5c7e-4888-95fa-78993d422b1a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. License and Collaboration Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Clinical Trial Collaboration and Supply Agreements with MSD International GmbH&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2018, we entered into a clinical collaboration with MSD International GmbH (&#x201c;MSDIG&#x201d;), an affiliate of Merck &amp;amp; Co. Inc., (&#x201c;Merck&#x201d;) to evaluate IO102 in combination with KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&#x201c;pembrolizumab&#x201d;) in first-line treatment of patients with metastatic non-small cell lung cancer. Under the terms of the collaboration with MSDIG, we conducted an international Phase 1/2 study to evaluate a combination therapy of IO102 and KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. We sponsored the clinical trial and MSDIG provided KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to be used in the clinical trial free of charge. We and MSDIG were responsible for our own internal costs and expenses to support the study and we bore all other costs associated with conducting the study, including costs of providing IO102 for use in the study. The rights to the data from the clinical trial were shared by us and MSDIG and we maintain global commercial rights to IO102.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2021, we entered into a clinical collaboration with MSDIG and MSD International Business GmbH (&#x201c;MSDIB&#x201d;), another affiliate of Merck (collectively, &#x201c;MSD&#x201d;) to evaluate IO102-IO103 in combination with KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; versus KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; alone in treatment of patients with metastatic (advanced) melanoma. Under the terms of the collaboration with MSD, we are conducting an international Phase 3 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. We are the sponsor of the clinical trial and MSD is providing KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to be used in the clinical trial free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trial are shared by us and MSD and we maintain global commercial rights to IO102-IO103.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2021, we entered into a clinical collaboration with MSD to evaluate IO102-IO103 in combination with KEYTRUDA&#xae; in previously untreated patients with three different tumor types&#x2014; metastatic non-small cell lung cancer (&#x201c;NSCLC&#x201d;), squamous cell carcinoma of the head and neck (&#x201c;SCCHN&#x201d;), and urothelial bladder cancer (&#x201c;UBC&#x201d;). Under the terms of the collaboration with MSD, we are conducting an international Phase 2 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. We are the sponsor of the clinical trial and MSD is providing KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to be used in the clinical trial free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trial are shared by us and MSD and we maintain global commercial rights to IO102-IO103.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2022, we entered into a clinical collaboration with MSD to evaluate IO102-IO103 in combination with KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as a neoadjuvant/adjuvant therapy for patients with metastatic melanoma and SCCHN. Under the terms of the collaboration with MSD, we are conducting an international Phase 2 study to evaluate a combination therapy of IO102-IO103 and KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. We are sponsoring the clinical trial and MSD is providing KEYTRUDA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to be used in the clinical trial free of charge. We and MSD are responsible for our own internal costs and expenses to support the study and we bear all other costs associated with conducting the study, including costs of providing IO102-IO103 for use in the study. The rights to the data from the clinical trial are shared by us and MSD and we maintain global commercial rights to IO102-IO103.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_9661af7b-f902-453e-9946-8651c22b4b2b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred financing asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid contract research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credit receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Value-added tax refund receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</iobt:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_87f6dec2-b3e9-469a-a39b-ed939dab23a7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred financing asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid contract research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credit receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Value-added tax refund receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <iobt:DeferredFinancingAssets
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_2fdf621f-2973-451a-8c4b-5839baa27d0d"
      unitRef="U_USD">5657000</iobt:DeferredFinancingAssets>
    <us-gaap:PrepaidTaxes
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_c422677a-9146-4dc4-9a07-2489ce0a6189"
      unitRef="U_USD">1607000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_525b729f-c698-4da1-8506-ddef934b2645"
      unitRef="U_USD">1292000</us-gaap:PrepaidTaxes>
    <iobt:PrepaidContractResearchAndDevelopmentCostsCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_5d3afd05-1e03-419a-b2b1-d5eee3fba313"
      unitRef="U_USD">1109000</iobt:PrepaidContractResearchAndDevelopmentCostsCurrent>
    <iobt:PrepaidContractResearchAndDevelopmentCostsCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_1697a84d-a970-47de-9363-9722c347d485"
      unitRef="U_USD">1119000</iobt:PrepaidContractResearchAndDevelopmentCostsCurrent>
    <iobt:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_aa0b065b-7eb3-4f5d-9564-93355b4d5f2b"
      unitRef="U_USD">865000</iobt:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <iobt:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_8e51572d-985e-4c24-970f-3e800589ea97"
      unitRef="U_USD">573000</iobt:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_2863ac3e-7b38-4ccc-adaa-887b4e30ee57"
      unitRef="U_USD">639000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_485c2c7f-6d9a-46b7-83dc-994e714f6734"
      unitRef="U_USD">768000</us-gaap:PrepaidInsurance>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_29ac5aba-21d5-467d-b842-703753dc927e"
      unitRef="U_USD">276000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_88b5e1c5-55f1-483f-8fb6-2cdf047197ed"
      unitRef="U_USD">365000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_4ae30749-c7b1-4566-9976-591d7719bfef"
      unitRef="U_USD">696000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_831b3c39-e3c2-437b-9e37-c2f92aa81982"
      unitRef="U_USD">803000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_b8f4861f-ac44-4d06-91d4-3ded0e37a0fe"
      unitRef="U_USD">10849000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_f7054901-809a-4aa2-95e4-5c2ec93e09f1"
      unitRef="U_USD">4920000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_24ab4364-6bca-4726-9d2f-7877d47a57c0">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.527%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.057%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.057%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer hardware&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the three months ended June 30, 2025 and 2024, the Company recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of depreciation expense, respectively, in the consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of depreciation expense, respectively, in the consolidated statements of operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_b8866c10-d0a4-43f3-95ba-32251bdb0255">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.527%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.057%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.057%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer hardware&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5fa6d61c-8fbd-4763-8701-fc3239e4a315"
      decimals="-3"
      id="F_f5dc9f27-1155-4d20-8f7a-6523159b1ff5"
      unitRef="U_USD">927000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_be8705f1-03eb-4e49-85f3-b10301c865b3"
      decimals="-3"
      id="F_18295564-bdcb-4569-a86f-4797a5a35743"
      unitRef="U_USD">839000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_778386da-0eec-4652-a846-c64fb6f85ac0"
      decimals="-3"
      id="F_a916081a-b800-424f-abc5-f301cbcf5aa2"
      unitRef="U_USD">261000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_109f1d22-8cd3-493e-ab7e-5ad075bd7dcb"
      decimals="-3"
      id="F_b560b5ca-474e-4ad9-8367-1b4007f3bafc"
      unitRef="U_USD">235000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4b7ed800-ce67-458e-a181-b724431189ab"
      decimals="-3"
      id="F_50a641dc-8e56-46ee-b957-eee3df83af28"
      unitRef="U_USD">141000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c1ad9cef-5ed5-4764-8224-38b467103b9e"
      decimals="-3"
      id="F_df267ebe-745c-4b42-a2b5-d7669e67116f"
      unitRef="U_USD">141000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_6a76909e-3566-4983-9065-8a2ce1199a74"
      unitRef="U_USD">726000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_cc8d1c33-2e5a-4357-a5c4-4991abc2220e"
      unitRef="U_USD">577000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_0155c25d-12c9-429c-87ec-8d02aba7fa5d"
      unitRef="U_USD">603000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_edd19d03-118c-4381-95b0-0cc7db764704"
      unitRef="U_USD">638000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-5"
      id="F_88a58f5d-3dc1-4bee-94a5-81c704d791b6"
      unitRef="U_USD">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-5"
      id="F_faf4ea3c-b4ad-41b8-bca0-95767b595430"
      unitRef="U_USD">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-5"
      id="F_c5a2177c-9ef7-4911-b77d-f1f08fd1c5af"
      unitRef="U_USD">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-5"
      id="F_d1dd1fe1-4b3e-470a-bfd6-472e40ea8659"
      unitRef="U_USD">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_95c4eb53-cd9e-434f-8e1f-4b2fab71f5d4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued contract research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_bd5058fe-e927-4fa2-a010-ea4c924f4345">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued contract research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <iobt:AccruedContractResearchAndDevelopmentCostsCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_25e7ce94-7b1f-4743-a818-1d6ac8d7bfed"
      unitRef="U_USD">9133000</iobt:AccruedContractResearchAndDevelopmentCostsCurrent>
    <iobt:AccruedContractResearchAndDevelopmentCostsCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_8b5fe1ea-477d-4176-ad8f-a847a81bdd49"
      unitRef="U_USD">9070000</iobt:AccruedContractResearchAndDevelopmentCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_7e7b7b6c-0a5c-471b-8274-91b14f968bf0"
      unitRef="U_USD">3351000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_9d8897c1-e725-4428-9a84-554c4c948f0d"
      unitRef="U_USD">4311000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_03d43c5c-44c1-41b9-a582-f7178b770359"
      unitRef="U_USD">692000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_8f6f70ec-bd4c-4da6-a20e-9cd4030bd701"
      unitRef="U_USD">227000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_5578d8d3-2075-4909-b204-5be810644c7c"
      unitRef="U_USD">416000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_83b66003-236a-409b-9786-4fe9b140e248"
      unitRef="U_USD">500000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_79195fc1-9aa3-4810-9089-7d0129ef9e6a"
      unitRef="U_USD">13592000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="-3"
      id="F_137a2e6e-016e-455a-8f78-fa2971de1606"
      unitRef="U_USD">14108000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_a97a054b-3148-4a9d-9ff7-58e8bf461b31">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Term Loan Facility&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2024 EIB Term Loan Facility&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 19, 2024, IO Biotech ApS (the &#x201c;Borrower&#x201d;) entered into a Finance Contract with the EIB, establishing a loan facility of up to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million that includes three committed tranches of potential financing in an aggregate principal amount of up to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, subject to certain conditions precedent, and one uncommitted accordion tranche of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Finance Contract, the Company (through the Borrower) had &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million available to draw in an initial tranche of the term loan facility (&#x201c;Tranche A&#x201d;), subject to satisfaction of certain customary conditions and the issuance of warrants pursuant to a Warrant Issuance Agreement (described below). The Company satisfied the specified business conditions of the Tranche A loan to draw up to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and the specified business conditions of the loan to draw up to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (&#x201c;Tranche B&#x201d;) , before payment of certain fees and transaction expense. Tranche A and Tranche B were funded on May 6, 2025 and July 4, 2025, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Finance Contract provides for one potential additional term loan tranche in principal amount of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (&#x201c;Tranche C&#x201d; and, together with Tranche A and Tranche B, each a &#x201c;Tranche&#x201d;), respectively, which is subject to specified conditions, including, but not limited, the issuance of warrants and achievement of certain clinical trial and other milestones. The Borrower has thirty-six months to satisfy the conditions for Tranche C, which include raising an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in cash and submission of an application for marketing authorization for IO102-IO103, which in the U.S. is known as Cylembio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(imsapepimut and etimupepimut, adjuvanted), in the U.S. or the EU based on positive data from a Phase 3 trial.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Each of the Tranche A, Tranche B, and Tranche C loans bears or will bear interest at a fixed rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% that accrues annually and will become payable at their respective maturity dates, which will be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; after disbursement of such loan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Any unpaid balance owed under the Finance Contract may be accelerated upon an Investment Cost Reduction Event, a Change-of-Control Event, a Change-of-Law Event, an Illegality Event or a Voluntary Non-EIB Prepayment Event (each as defined in the Finance Contract included within Part IV - Item 15. Exhibits, Financial Statement Schedules of the Annual Report on Form 10-K filed on March 31, 2025).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the Borrower elects to voluntarily prepay any Tranche, the Borrower will be required to additionally pay to EIB a prepayment fee ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Tranche, if repaid within twelve months of disbursement of such Tranche, to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Tranche, if repaid after the third anniversary of disbursement of such Tranche. No such prepayment fee is payable after the fourth anniversary of disbursement of the applicable Tranche.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Finance Contract also contains various financial and non-financial covenants that the Borrower must comply with, including customary conditions with respect to material adverse changes and substantial changes to the general nature of business, which leave significant discretion on the side of the EIB.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concurrently with the execution of the Finance Contract, the Borrower entered into a non-binding side letter, pursuant to which EIB may, in its discretion and subject to approvals by its investment committee, make available to the Borrower an additional &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in funding related to the Company&#x2019;s ongoing clinical trials.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the Finance Contract, the Company also entered into a warrant issuance agreement (the &#x201c;Warrant Issuance Agreement&#x201d;) on December 19, 2024, pursuant to which the Company agreed to issue to EIB certain warrants to purchase shares of the Company&#x2019;s common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share (the &#x201c;Common Stock&#x201d;) in connection with the disbursement of each of the Tranche A loan (such warrants, the &#x201c;Tranche A Warrants&#x201d;), Tranche B loan (such warrants, the &#x201c;Tranche B Warrants&#x201d;) and Tranche C loan (such warrants, the &#x201c;Tranche C Warrants&#x201d; and, together with the Tranche A Warrants and the Tranche B Warrants, the &#x201c;Warrants&#x201d;). The number of shares for which the Warrants will be exercisable will be determined at the time of issuance of each Warrant in accordance with the formulas set forth in the Warrant Issuance Agreement, which formulas generally provide that the number of shares will decrease as the price of the Common Stock increases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of each Warrant, each share of Common Stock issuable upon exercise thereof shall have an exercise price equal to the greater of (x) the Company&#x2019;s 5-Day VWAP on the date of execution of the applicable Warrant and (y) the applicable &#x201c;Minimum Price&#x201d; as defined in Nasdaq Rule 5635(d), in each case subject to adjustment. The Tranche A Warrant shall become initially exercisable on the date of disbursement of the Tranche A loan; the Tranche B Warrant shall become initially exercisable on the date of disbursement of the Tranche B loan; and the Tranche C Warrant shall become initially exercisable on the date of disbursement of the Tranche C loan. Each Warrant shall be exercisable until the earlier of one day prior to the closing of an Acquisition (as such term is defined in the applicable Warrant included within Part IV - Item 15. Exhibits, Financial Statement Schedules of the Annual Report on Form 10-K filed with the SEC on March 31, 2025) and twenty years following the date of issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of each Warrant, the Company will have a call option to repurchase the Warrants upon a Change of Control Event, a Qualifying Tender Offer, or a Transformational Transaction (each, as defined in the Warrant).  In connection with an exercise of the Company&#x2019;s call option, the purchase price for the shares issuable upon exercise of the portion of the Warrant subject to the call option would be equal to the greater of (x) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the amount disbursed under the Finance Contract as of the date of the call option multiplied by a fraction, the numerator of which is (i) the number of Warrant Shares (as defined in the Warrant Agreement) purchasable under the Warrant Agreement and (ii) the denominator which is the number of shares of Common Stock purchasable with respect to all Warrants under the Warrant Issuance Agreement, whether or not remaining outstanding, and (y) the aggregate value of the Warrant Shares purchasable upon exercise of the call option in the event of any of a Qualifying Tender Offer, Transformational Transaction or other transaction, in each case as calculated in accordance with the terms of the Warrant Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Warrant Issuance Agreement, EIB will have a put option (&#x201c;EIB Put Option&#x201d;) to sell the Warrants to the Company on or following the maturity date of the applicable Tranche or upon the occurrence of an Event Date (as defined in the Warrant Issuance Agreement), subject to certain limitations in the event that the Company publishes a Material Press Release (as defined in the Warrant Issuance Agreement included within Part IV - Item 15. Exhibits, Financial Statement Schedules of the Annual Report on Form 10-K). The conditions for the EIB to exercise the EIB Put Option to have not been met as of June 30, 2025. In connection with an exercise of EIB&#x2019;s put option, the purchase price for the shares purchasable in connection with the put option would be equal to (x) in the case of a Qualifying Tender Offer (as defined in the Warrant Issuance Agreement), the aggregate price per share of Common Stock being offered minus the aggregate Strike Price (as defined in the Warrant Issuance Agreement) payable to the Company with respect to the Warrants for which the put option is being exercised and (y) in all other cases, an amount equal to the aggregate Fair Market Value (as defined in the Warrant Issuance Agreement) of the Warrant Shares purchasable upon exercise of the put option minus the aggregate Strike Price payable to the Company with respect to the Warrants for which the put option is being exercised. Due to the terms and conditions of the EIB Put Option, we consider the EIB Put Option and the Tranche A Warrants and Tranche B Warrants under each of the Tranches are to be treated as a single compound derivative.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company also entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;) with EIB related to the issuance of the Warrants. Under the terms of the Registration Rights Agreement, the Company has agreed to prepare and file, by the later of (i) 30 days after the date of issuance of any of the Warrants and (ii) May 15, 2025 (the &#x201c;Filing Deadline&#x201d;), one or more registration statements with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) to register for resale the common stock issued under the Warrant Issuance Agreement and to cause the applicable registration statements to become effective within a specified period after the Filing Deadline.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 24, 2025, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,623,664&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Tranche A Warrants to purchase shares of the Company&#x2019;s common stock at an exercise price of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.89&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. On June 24, 2025, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,221,868&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Tranche B Warrants to purchase shares of the Company&#x2019;s common stock at an exercise price of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.32&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share as a prerequisite to the Tranche B loan funding on July 4, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Tranche A and Tranche B Warrants were deemed to be a freestanding financial instruments as they were legally detachable and separately exercisable from the debt obligations. The Company evaluated the terms and conditions of the Warrants and concluded that they met the criteria to be classified as a liability. As such, the Company recorded the Warrants as a non-current liability on the consolidated balance sheet at fair value on the date of funding and as of June 30, 2025. On the date of funding, the Company has recorded a non-current liability related to the loan facilities based on the proceeds received less related debt issuance costs, including the fair value allocation to the respective Warrants. The Company valued the Tranche A Warrants and Tranche B Warrants at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, upon issuance using the Black-Scholes valuation model.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of outstanding term loan debt, net within non-current liabilities on the consolidated balance sheet as of June 30, 2025 related to the Tranche A loan. For the three and six months ended June 30, 2025, the Company has recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in non-cash interest expense related to the amortization of debt issuance costs and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in paid-in-kind interest with an effective interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; related to the Tranche A loan. The Tranche B loan was funded on July 4, 2025 and was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t outstanding term loan debt as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Term loan debt, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:78.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan debt principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortized paid-in-kind interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Currency adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total term loan debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future undiscounted minimum principal and interest payments under the EIB loan facility as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025, were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Future Minimum Debt Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remainder of 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total minimum payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Unamortized debt issuance costs and paid-in-kind interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Currency adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total term loan debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025, the Company had the following Tranche A and Tranche B Warrants issued and outstanding to purchase shares of the Company's common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:42.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tranche A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tranche B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,623,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,221,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
      contextRef="C_36ff792f-bd4e-446c-b141-ce575eb25023"
      decimals="-5"
      id="F_c6f980d2-42d4-4968-8ae9-f3e5ef800b04"
      unitRef="U_EUR">57500000</us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_84fe0d8c-d67b-4ce3-b0ba-ff27aff9c03f"
      decimals="-5"
      id="F_44aaa34d-fbbe-4e0a-a9da-6c4222bef066"
      unitRef="U_EUR">37500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <iobt:CertainConditionsPrecedentAndOneUncommittedAccordionTranche
      contextRef="C_36ff792f-bd4e-446c-b141-ce575eb25023"
      decimals="-5"
      id="F_a0fa4193-1eac-495b-8d86-9b82fc310dcf"
      unitRef="U_EUR">20000000</iobt:CertainConditionsPrecedentAndOneUncommittedAccordionTranche>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_ef72a604-f4f2-4a0d-adba-eaaf1803b560"
      decimals="-5"
      id="F_e7609e98-4499-472f-a81c-d77f96fb1b95"
      unitRef="U_EUR">10000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_a158b0d3-0349-47ae-a852-f27a63e1f600"
      decimals="-5"
      id="F_44dfacaa-f4fa-4a0c-96f5-ceee529e2208"
      unitRef="U_EUR">10000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_16b635b3-2fb2-4918-9590-c3e68b0c0739"
      decimals="-5"
      id="F_5b6bdcc8-cc55-490d-8b4d-1e3ad985f46f"
      unitRef="U_EUR">12500000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_7ae94389-ebe2-4996-bb29-68980b435b79"
      decimals="-5"
      id="F_40237934-9966-45d8-b889-33bc6ece8868"
      unitRef="U_EUR">15000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <iobt:LineOfCreditFacilityAdditionalBorrowingCapacity
      contextRef="C_84fe0d8c-d67b-4ce3-b0ba-ff27aff9c03f"
      decimals="-5"
      id="F_d06d1c73-4258-4852-955d-909ca931c60b"
      unitRef="U_USD">50000000</iobt:LineOfCreditFacilityAdditionalBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="C_9509aacb-0807-473e-b712-615fcaf1f276"
      decimals="2"
      id="F_3f8bd62a-2946-4db8-b02f-37daedc5081e"
      unitRef="U_pure">0.08</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="C_490dd48a-6429-4e12-b498-a5cc551a31c4"
      decimals="2"
      id="F_be4e8bcb-9b7f-4e08-85d8-cb3feab0bd02"
      unitRef="U_pure">0.08</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="C_d1ac30d3-46ee-4e40-ad99-548007da67c4"
      decimals="2"
      id="F_44190f16-e354-4a1b-8d2d-3425d22c112f"
      unitRef="U_pure">0.08</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="C_36ff792f-bd4e-446c-b141-ce575eb25023"
      id="F_1410390e-d837-429a-a46d-ce736e6f6a5a">P6Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <iobt:PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement
      contextRef="C_36ff792f-bd4e-446c-b141-ce575eb25023"
      decimals="2"
      id="F_0a4a0181-3e4f-4da3-9aa2-4f233d65e111"
      unitRef="U_pure">0.05</iobt:PercentageOfPrepaymentFeeOnRepaymentOfTrancheWithinTwelveMonthsOfDisbursement>
    <iobt:PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement
      contextRef="C_36ff792f-bd4e-446c-b141-ce575eb25023"
      decimals="2"
      id="F_f97e4c29-e582-4904-9e22-9880529c433b"
      unitRef="U_pure">0.01</iobt:PercentageOfPrepaymentFeeOnRepaymentOfTrancheAfterThirdAnniversryOfDisbursement>
    <iobt:LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails
      contextRef="C_84fe0d8c-d67b-4ce3-b0ba-ff27aff9c03f"
      decimals="-5"
      id="F_56d3b814-b6bb-404d-8ce3-40d8487119c4"
      unitRef="U_USD">20000000</iobt:LineOfCreditFacilityAdditionalBorrowingCapacityOngoingTrails>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_84fe0d8c-d67b-4ce3-b0ba-ff27aff9c03f"
      decimals="3"
      id="F_fd6f78c4-e794-4260-91a5-c010aa70c0d1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <iobt:PercentageOfAmountDisbursedUnderFinanceContract
      contextRef="C_36ff792f-bd4e-446c-b141-ce575eb25023"
      decimals="2"
      id="F_37af30bf-6be6-49b0-8c4e-83ca62d38243"
      unitRef="U_pure">0.30</iobt:PercentageOfAmountDisbursedUnderFinanceContract>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e6b863ab-f667-455a-800d-d455c93b3ab4"
      decimals="INF"
      id="F_d577e1c9-19dd-4020-a134-123c643a82c7"
      unitRef="U_shares">5623664</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <iobt:StrikePricePerShare
      contextRef="C_e6b863ab-f667-455a-800d-d455c93b3ab4"
      decimals="2"
      id="F_5cb610cb-deab-4ad9-9202-f931ff6c92cc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.89</iobt:StrikePricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f81c1fb3-24f9-45eb-95d6-3d58f5c1bf71"
      decimals="INF"
      id="F_cdf08516-faff-43c4-a2b1-38363fb1dba6"
      unitRef="U_shares">4221868</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <iobt:StrikePricePerShare
      contextRef="C_f81c1fb3-24f9-45eb-95d6-3d58f5c1bf71"
      decimals="2"
      id="F_227c1a5a-5d32-4ff7-9abe-e5ea1cb0a109"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.32</iobt:StrikePricePerShare>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_806e2b05-4b7e-4476-94b2-2b7dd866dc79"
      decimals="-5"
      id="F_98860f33-2ee7-4cac-a2ed-84a630566881"
      unitRef="U_EUR">5000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_83a70f6f-685c-4644-a42c-ad925d97fe65"
      decimals="-5"
      id="F_fd690832-b769-4147-8a87-fe1238979c4b"
      unitRef="U_EUR">5700000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_806e2b05-4b7e-4476-94b2-2b7dd866dc79"
      decimals="-5"
      id="F_9f4687b4-015f-4d49-9d44-deec1d884c6f"
      unitRef="U_EUR">6700000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_ea2ebe70-c654-4e26-87a4-0f7c15e0ea44"
      decimals="-5"
      id="F_491e3dab-5a5c-470b-b3e5-949d6fe0a940"
      unitRef="U_USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_c9ac1ffc-962f-4af6-b379-9a18ad414f27"
      decimals="-5"
      id="F_a0405221-feb5-411f-9aa8-498dd67cb3e9"
      unitRef="U_USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:PaidInKindInterest
      contextRef="C_c9ac1ffc-962f-4af6-b379-9a18ad414f27"
      decimals="-5"
      id="F_f5be43a1-5b7f-4010-8449-4afe41266491"
      unitRef="U_USD">200000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="C_ea2ebe70-c654-4e26-87a4-0f7c15e0ea44"
      decimals="-5"
      id="F_86a1f5fe-2219-4a14-b70d-cd26e77d8a08"
      unitRef="U_USD">200000</us-gaap:PaidInKindInterest>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_806e2b05-4b7e-4476-94b2-2b7dd866dc79"
      decimals="3"
      id="F_7beee349-6973-4b7b-8f85-c762e5a93cb8"
      unitRef="U_pure">0.143</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_83a70f6f-685c-4644-a42c-ad925d97fe65"
      decimals="-6"
      id="F_80847887-7827-40ce-a964-45be0176edfa"
      unitRef="U_EUR">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_0bb5957f-1c5b-468d-9b05-5a26323d2e1c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Term loan debt, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:78.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.68%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan debt principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortized paid-in-kind interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Currency adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total term loan debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_8af72bce-5d6e-48a6-847b-f741b845e1af"
      unitRef="U_USD">11720000</us-gaap:DebtInstrumentCarryingAmount>
    <iobt:DebtInstrumentAmortizedPaidInKindInterest
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_4d11104e-891e-45f6-b631-78b4ad4d5d0a"
      unitRef="U_USD">142000</iobt:DebtInstrumentAmortizedPaidInKindInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_121547ee-2136-4703-83cd-bfe28ad8cb42"
      unitRef="U_USD">5290000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <iobt:DebtInstrumentCurrencyAdjustments
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_35649409-6651-41e0-818f-6d5bd41d03da"
      unitRef="U_USD">148000</iobt:DebtInstrumentCurrencyAdjustments>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_816ef857-f398-480d-bcee-3a1332bc7471"
      unitRef="U_USD">6720000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_be8e84c0-026c-4637-a915-72ffe4d535ef">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future undiscounted minimum principal and interest payments under the EIB loan facility as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025, were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Future Minimum Debt Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remainder of 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total minimum payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Unamortized debt issuance costs and paid-in-kind interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Currency adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total term loan debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_fd360e5e-b036-4e1c-8cfc-6f6afa7abebf"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_a040be22-5122-4ee7-b6e3-10f0a822fc06"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_8ec1e867-a618-4043-b37a-b2511866a42c"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_2956a1f4-94c1-47a9-9e45-f21f0f63ba3d"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_690f7ecc-ba13-4b09-91e8-70d590061a39"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_bfd3c1ae-6528-46ed-aeb0-d9256ad9c284"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <iobt:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_c04fa7e2-a285-4335-8856-d7aa46792c4e"
      unitRef="U_USD">18597000</iobt:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix>
    <iobt:Long-TermDebtMaturityMinimumPayment
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_b74aaa1f-7a0c-4225-aabe-67d403a1a77c"
      unitRef="U_USD">18597000</iobt:Long-TermDebtMaturityMinimumPayment>
    <iobt:DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_423d8724-6d5f-4a96-8bd2-57848867187c"
      unitRef="U_USD">12025000</iobt:DebtInstrumentUnamortizedDebtIssuanceCostsAndPaidInKindInterest>
    <iobt:DebtInstrumentCurrencyAdjustments
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_e5ed1c65-a517-487e-b6e1-464801d3e5c7"
      unitRef="U_USD">148000</iobt:DebtInstrumentCurrencyAdjustments>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_c48dbf6f-c379-471b-9eaa-5cc81f7b8d1b"
      unitRef="U_USD">6720000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_020e2345-f09c-40b1-9579-740b3635d605">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025, the Company had the following Tranche A and Tranche B Warrants issued and outstanding to purchase shares of the Company's common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:42.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tranche A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Tranche B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,623,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,221,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c9ac1ffc-962f-4af6-b379-9a18ad414f27"
      decimals="0"
      id="F_d29f5ca2-e1d5-44b4-aef8-18b7a0049770"
      unitRef="U_shares">5623664</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_329921d0-d469-45e2-ae77-6ca463b6325e"
      decimals="0"
      id="F_502f1285-5007-4932-81ac-ef6249aaa020"
      unitRef="U_shares">4221868</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <iobt:StrikePricePerShare
      contextRef="C_c9ac1ffc-962f-4af6-b379-9a18ad414f27"
      decimals="2"
      id="F_4890d7ad-5849-4204-8783-3bc97387c6fd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.89</iobt:StrikePricePerShare>
    <iobt:StrikePricePerShare
      contextRef="C_329921d0-d469-45e2-ae77-6ca463b6325e"
      decimals="2"
      id="F_d2a84d7c-0e47-4e71-ac85-0fe5a6244a9e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.32</iobt:StrikePricePerShare>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_ff7748a1-8647-4af6-9ff8-b9baea06157a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company is party to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating leases for laboratory and office space. The Company&#x2019;s finance leases are immaterial both individually and in the aggregate. In the consolidated balance sheet as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025, the Company has a right-of-use lease asset (&#x201c;ROU&#x201d;) balance of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and a current and non-current lease liability of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, relating to the ROU lease asset. The balance of both the ROU lease asset and the lease liabilities primarily consists of future payments under the Company&#x2019;s office and laboratory space leased in New York, New York, Rockville, Maryland and Copenhagen, Denmark. Rent expense for the three months ended June 30, 2025 and 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. Rent expense for the six months ended June 30, 2025 and 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Qualitative information regarding the Company&#x2019;s leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:22.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Location&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease Type&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease Nature&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease Commencement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease Term Expiration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Annual Base Rent&lt;br/&gt;&#160;(in Millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Copenhagen, Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Office&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;March 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Copenhagen, Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Office&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Copenhagen, Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Lab&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Newport, United Kingdom&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Office&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;June 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;New York, New York&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Office&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;October 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rockville, Maryland&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Lab&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Quantitative information regarding the Company&#x2019;s leases for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025 and 2024 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities arising from obtaining right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remaining average lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future lease payments (undiscounted) under noncancelable leases are as follows as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Future Lease Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remainder of 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s leases do not provide an explicit rate. Therefore, the Company used its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company used the incremental borrowing rate on January 1, 2022 for operating leases that commenced prior to that date, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <iobt:NumberOfOperatingLease
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="INF"
      id="F_3714e51b-6652-4b10-84e4-ab27f6da4d6f"
      unitRef="U_Lease">5</iobt:NumberOfOperatingLease>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-5"
      id="F_4decd35e-0624-4d2c-b943-f4f966e4b090"
      unitRef="U_USD">1500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-5"
      id="F_5314da34-e15c-4f16-8fc5-53fa499e5e80"
      unitRef="U_USD">800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-5"
      id="F_54b3426a-bfd5-4915-acdc-26b3e6ca0e93"
      unitRef="U_USD">900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-5"
      id="F_37659ff9-c855-42f2-a96e-97330541d3d7"
      unitRef="U_USD">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-5"
      id="F_715916b2-f66e-43db-8f25-09dda3d8291b"
      unitRef="U_USD">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-5"
      id="F_a319fcc6-5949-49cb-9c3e-561af5794b29"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-5"
      id="F_8fc5d433-8e7c-45e1-84e6-7a82363ee311"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseExpense>
    <iobt:ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_06e4e4c5-5f5a-49b3-bdbf-2d94d3b0e7cf">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Qualitative information regarding the Company&#x2019;s leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 is as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:22.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Location&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease Type&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease Nature&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease Commencement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease Term Expiration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Annual Base Rent&lt;br/&gt;&#160;(in Millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Copenhagen, Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Office&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;March 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Copenhagen, Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Office&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Copenhagen, Denmark&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Lab&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Newport, United Kingdom&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Office&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;June 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;New York, New York&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Office&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;October 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rockville, Maryland&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Lab&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;May 2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</iobt:ScheduleOfQualitativeInformationRegardingLeasesTableTextBlock>
    <iobt:OperatingLeaseTermExpirationMonthYear
      contextRef="C_12c9ea54-3647-4df4-9107-48c806489a8f"
      id="F_d345b560-8142-4499-8b84-5fbfe3b30308">2021-03</iobt:OperatingLeaseTermExpirationMonthYear>
    <iobt:OperatingLeaseCommencementMonthYear
      contextRef="C_12c9ea54-3647-4df4-9107-48c806489a8f"
      id="F_8c00029d-e271-4bee-b16c-50a1c87a2211">2027-12</iobt:OperatingLeaseCommencementMonthYear>
    <iobt:OperatingLeaseAnnualBaseRent
      contextRef="C_12c9ea54-3647-4df4-9107-48c806489a8f"
      decimals="-2"
      id="F_b45b3b13-0118-41f6-96ed-f51c36c9f275"
      unitRef="U_USD">200</iobt:OperatingLeaseAnnualBaseRent>
    <iobt:OperatingLeaseTermExpirationMonthYear
      contextRef="C_d2d4d909-7247-47da-8942-e7d0085430d2"
      id="F_c90f7567-a7ec-4b47-b0e4-97450f40997b">2024-12</iobt:OperatingLeaseTermExpirationMonthYear>
    <iobt:OperatingLeaseCommencementMonthYear
      contextRef="C_d2d4d909-7247-47da-8942-e7d0085430d2"
      id="F_c85d344c-d63a-4e67-8888-e6b20ba80c93">2027-12</iobt:OperatingLeaseCommencementMonthYear>
    <iobt:OperatingLeaseAnnualBaseRent
      contextRef="C_d2d4d909-7247-47da-8942-e7d0085430d2"
      decimals="-1"
      id="F_af8d9a9e-8ac9-4e93-b2a9-46b4ac7cb5eb"
      unitRef="U_USD">40.00</iobt:OperatingLeaseAnnualBaseRent>
    <iobt:OperatingLeaseTermExpirationMonthYear
      contextRef="C_d7ad6dd6-35af-4f8a-aac7-f313a381b605"
      id="F_4d3defd0-b1b8-40ff-83aa-8e0d2b2e954f">2023-01</iobt:OperatingLeaseTermExpirationMonthYear>
    <iobt:OperatingLeaseCommencementMonthYear
      contextRef="C_d7ad6dd6-35af-4f8a-aac7-f313a381b605"
      id="F_a6950efe-a734-4598-9edd-a8058ff323cc">2027-12</iobt:OperatingLeaseCommencementMonthYear>
    <iobt:OperatingLeaseAnnualBaseRent
      contextRef="C_d7ad6dd6-35af-4f8a-aac7-f313a381b605"
      decimals="-1"
      id="F_44341be9-de7a-4067-b49e-df6ee97a2f51"
      unitRef="U_USD">40.00</iobt:OperatingLeaseAnnualBaseRent>
    <iobt:OperatingLeaseTermExpirationMonthYear
      contextRef="C_304a194f-57dd-4a19-bedc-cdfd57a688a1"
      id="F_a8fc691c-489a-4706-8ae8-9d7e10ad1498">2023-06</iobt:OperatingLeaseTermExpirationMonthYear>
    <iobt:OperatingLeaseCommencementMonthYear
      contextRef="C_304a194f-57dd-4a19-bedc-cdfd57a688a1"
      id="F_b65d1402-16f9-4778-af86-3faaaf35b964">2025-05</iobt:OperatingLeaseCommencementMonthYear>
    <iobt:OperatingLeaseAnnualBaseRent
      contextRef="C_304a194f-57dd-4a19-bedc-cdfd57a688a1"
      decimals="-1"
      id="F_aff981d6-b21c-42b9-9f1c-33a16845a434"
      unitRef="U_USD">40.00</iobt:OperatingLeaseAnnualBaseRent>
    <iobt:OperatingLeaseTermExpirationMonthYear
      contextRef="C_d1ac8d94-9bfe-4efa-86ce-70e44c8190dd"
      id="F_e78bcc38-721c-4e4f-9238-b73a6862f39a">2021-10</iobt:OperatingLeaseTermExpirationMonthYear>
    <iobt:OperatingLeaseCommencementMonthYear
      contextRef="C_d1ac8d94-9bfe-4efa-86ce-70e44c8190dd"
      id="F_cec8a779-6e1f-4c48-a3cc-4d6aaec749e3">2027-01</iobt:OperatingLeaseCommencementMonthYear>
    <iobt:OperatingLeaseAnnualBaseRent
      contextRef="C_d1ac8d94-9bfe-4efa-86ce-70e44c8190dd"
      decimals="-2"
      id="F_51101648-0aaa-4f4f-ac29-db0e13bac959"
      unitRef="U_USD">200</iobt:OperatingLeaseAnnualBaseRent>
    <iobt:OperatingLeaseTermExpirationMonthYear
      contextRef="C_60dc3163-f2cf-4d9a-bd0c-4ced094cf2aa"
      id="F_ef3db5a2-9c22-47f1-a112-e11de16888b1">2021-12</iobt:OperatingLeaseTermExpirationMonthYear>
    <iobt:OperatingLeaseCommencementMonthYear
      contextRef="C_60dc3163-f2cf-4d9a-bd0c-4ced094cf2aa"
      id="F_0963d945-26e8-4ccc-9458-8dc10c116792">2027-05</iobt:OperatingLeaseCommencementMonthYear>
    <iobt:OperatingLeaseAnnualBaseRent
      contextRef="C_60dc3163-f2cf-4d9a-bd0c-4ced094cf2aa"
      decimals="-2"
      id="F_94f63c35-4207-4292-acaf-0bf01af6644a"
      unitRef="U_USD">300</iobt:OperatingLeaseAnnualBaseRent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_f909c69b-a1d3-4241-8194-3c9e01d2e75a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Quantitative information regarding the Company&#x2019;s leases for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025 and 2024 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.882%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities arising from obtaining right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remaining average lease term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_241a3712-24b0-4966-aa17-28612b37547b"
      unitRef="U_USD">359000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_9e491cbf-7646-486d-a298-554742d693c9"
      unitRef="U_USD">369000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_753fb302-6233-40f4-b349-87fcec32dbe7"
      unitRef="U_USD">413000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_8c36ebdf-bf68-4e16-9d85-da09e35d70e0"
      unitRef="U_USD">385000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_6d99cb0d-e812-47b9-9225-2dc7c2b85e20"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_5d4b0154-c469-4464-a1bf-996c196045e0"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      id="F_1e2fb040-ff74-4f4b-bc46-6c0ae32d56be">P2Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f"
      id="F_68bd8b41-ba38-4f5e-916e-ad029e8291f8">P3Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="3"
      id="F_e5f2c534-4a2c-4142-926d-2073456af2a6"
      unitRef="U_pure">0.064</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_6c0dfbea-5705-4f01-91ec-a344114fb10f"
      decimals="3"
      id="F_fb265a60-7623-4d80-aa5a-e35b8ef98d9a"
      unitRef="U_pure">0.063</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_5eeed218-27f0-41bd-8013-035e3e555f5b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future lease payments (undiscounted) under noncancelable leases are as follows as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Future Lease Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remainder of 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_e1f2b344-bcf7-4e47-967a-a31d183e3060"
      unitRef="U_USD">419000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_695db5d5-b277-4b95-918c-1f511007c2aa"
      unitRef="U_USD">863000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_6b919347-0d8f-4dd6-91ef-611a5b9e3e22"
      unitRef="U_USD">470000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_d04242ab-fbf1-4e84-845a-2dbb7e9e8ccb"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_f571b47e-ef0a-4e4c-87eb-34abe5bb0230"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <iobt:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_56774f73-b767-4ed1-89e9-8b1ad9e1345f"
      unitRef="U_USD">0</iobt:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-3"
      id="F_65ba093a-50d7-49d5-b2e8-99479f44f3fa"
      unitRef="U_USD">1752000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_43fc3eae-4991-4980-93fb-b2c11564837b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, we may be party to litigation arising in the ordinary course of business. We were not subject to any material legal proceedings during the six months ended June 30, 2025 and the year ended December 31, 2024, and, to our knowledge, no material legal proceedings are currently pending or threatened.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Contractual Obligations and Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We enter into contracts in the ordinary course of business with third-party service providers for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days, and therefore, we believe that our noncancelable obligations under these agreements are not material and we cannot reasonably estimate whether they will occur. However, in the event of a termination of any contracts with clinical research organizations (&#x201c;CRO&#x201d;) or other institutions and with respect to active patients enrolled in our clinical trials, we may be financially obligated for a period beyond the contractual termination notice periods. We may also enter into additional research, manufacturing, supplier, lease and other agreements in the future, which may require up-front payments and even long-term commitments of cash.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Indemnification Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We enter into certain types of contracts that contingently require us to indemnify various parties against claims from third parties. These contracts primarily relate to procurement, service, consultancy or license agreements under which we may be required to indemnify vendors, service providers or licensees for certain claims, including claims that may be brought against them arising from our acts or omissions with respect to our products, technology, intellectual property or services. The Company, as permitted under Delaware law and in accordance with its amended and restated certificate of incorporation and amended and restated bylaws and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, in which the officer or director incurs losses or expenses because he or she is or was serving at the Company&#x2019;s request in such capacity. At the 2023 Annual Meeting of Stockholders, the Company&#x2019;s stockholders approved an amendment to, and the Company subsequently amended, its amended and restated certificate of incorporation to extend the indemnification of officers pursuant to recent amendments to the General Corporation Law of the State of Delaware.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, we may receive indemnification claims under existing contracts in the normal course of business. In the event that one or more of these matters were to result in a claim against us, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on our future business, operating results or financial condition. It is not possible to estimate the maximum amount potentially payable under these contracts since we have no history of prior indemnification claims and the unique facts and circumstances involved in each particular claim will be determinative.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <iobt:ContractualObligationsTerminationNoticePeriod
      contextRef="C_a6b6d898-f2a2-4264-a194-96e339c5adc0"
      id="F_7e713668-ecf4-4ab4-979f-31ecd4077086">P30D</iobt:ContractualObligationsTerminationNoticePeriod>
    <iobt:ContractualObligationsTerminationNoticePeriod
      contextRef="C_f08bf985-a9db-49be-bd46-d4eda7a2c58c"
      id="F_08043d24-e935-4a10-9890-503f99233da9">P90D</iobt:ContractualObligationsTerminationNoticePeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_d28d6ca2-5d70-4bbd-baf7-2b5702a067fe">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common and Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon the closing of our IPO in November 2021, we filed an amended and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;restated certificate of incorporation, which authorized us to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of preferred stock. The shares of preferred stock are currently undesignated. Common stockholders are entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. Common stockholders are entitled to receive dividends, if and when declared by the Company's board of directors (&#x201c;Board&#x201d;). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; dividends have been declared or paid by us through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;The Private Placement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 7, 2023, the Company entered into a Securities Purchase Agreement, (the &#x201c;Purchase Agreement&#x201d;), pursuant to which the Company agreed to sell and issue (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s Common Stock, and (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Warrants in the Private Placement. Each Purchaser&#x2019;s Warrant is exercisable for a number of shares of Common Stock equal to one hundred percent of the aggregate number of shares of Common Stock purchased by such Purchaser. The purchase price for each Common Stock and Warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Warrants are exercisable at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, subject to adjustment as set forth therein. The Warrants are exercisable until the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an acquisition, as defined in the Warrants. The Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the Warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Private Placement closed on August 9, 2023. The Company received &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in gross proceeds from the Private Placement, before deducting offering expenses of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Of the total proceeds, legal entities of certain related parties contributed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and members of management contributed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company used the net proceeds of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from the Private Placement for general corporate purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance using the Black-Scholes valuation model and allocated proceeds from the sale proportionately to the Common Stock and Warrants, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was allocated to the Warrants and recorded as a component of additional paid-in-capital. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants issued and outstanding at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share to purchase shares of the Company's common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the execution of the Purchase Agreement, the Company also entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;) with the Purchasers. Under the terms of the Registration Rights Agreement, the Company has filed the Registration Statement with the SEC to register for resale the Common Stock issued under the Purchase Agreement and the shares of Common Stock issuable upon conversion of the Warrants issued pursuant to the Purchase Agreement (the &#x201c;Registrable Securities&#x201d;), which Registration Statement was declared effective on September 8, 2023. The Company may be required to pay certain liquidated damages under the terms of the Registration Rights Agreement in the event sales cannot be made pursuant to the Registration Statement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As of June 30, 2025 and December 31, 2024, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,880,914&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares outstanding.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_7b18d373-032b-4323-90f2-5980a3f2eeb4"
      decimals="INF"
      id="F_644b3e31-e67f-486e-a3a7-dd7f82feb15a"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f19d5a95-b1ed-473d-a534-3f3d6090cd35"
      decimals="INF"
      id="F_8a78ebef-473a-409e-a57e-545117e7864b"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <iobt:NumberOfVotePerShare
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="INF"
      id="F_a59a7208-f47b-44cd-bfeb-b8b4817ae1c3"
      unitRef="U_Vote">1</iobt:NumberOfVotePerShare>
    <iobt:DividendsDeclared
      contextRef="C_d9eac608-430c-4093-aaf6-37dfe968a3a7"
      decimals="INF"
      id="F_e924aadd-4cfb-4b9a-8b55-303bbbb90c82"
      unitRef="U_USD">0</iobt:DividendsDeclared>
    <iobt:DividendsPaid
      contextRef="C_d9eac608-430c-4093-aaf6-37dfe968a3a7"
      decimals="INF"
      id="F_8a05e08b-4dc7-4df5-ac53-49a79d54e642"
      unitRef="U_USD">0</iobt:DividendsPaid>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_23f0e49a-26af-436d-a252-4c3c0051cbd9"
      decimals="INF"
      id="F_648d061c-4bfa-43ab-92bc-2ef4194063b9"
      unitRef="U_shares">37065647</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <iobt:WarrantsIssued
      contextRef="C_3312f560-ea95-4c4d-b954-f433c8050666"
      decimals="INF"
      id="F_c770008b-4e26-4d80-91bb-f5043586290d"
      unitRef="U_shares">37065647</iobt:WarrantsIssued>
    <iobt:PurchasePricePerShareOfCommonStockAndWarrant
      contextRef="C_3312f560-ea95-4c4d-b954-f433c8050666"
      decimals="INF"
      id="F_873c6ce0-8567-4382-93c7-06a217f3d109"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.025</iobt:PurchasePricePerShareOfCommonStockAndWarrant>
    <iobt:WarrantsExercisablePricePerShare
      contextRef="C_3312f560-ea95-4c4d-b954-f433c8050666"
      decimals="INF"
      id="F_7823828c-9337-43fe-b829-358528310721"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.47</iobt:WarrantsExercisablePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_d9cf7434-a99c-426e-ba30-efa367120587"
      decimals="-5"
      id="F_90a22bd6-395a-4469-929f-c44a3b71be51"
      unitRef="U_USD">75100000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_d9cf7434-a99c-426e-ba30-efa367120587"
      decimals="-5"
      id="F_8be56684-844d-4222-8057-5ab0c4bfc99a"
      unitRef="U_USD">3200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_527af978-7806-4a1e-8520-f96890860ee1"
      decimals="-5"
      id="F_3c5925e4-bb1f-4634-8972-b059fd1ceda9"
      unitRef="U_USD">33400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_cbc7cec8-5118-48e5-8682-ee34f6d86898"
      decimals="-5"
      id="F_c2d18a43-07e4-4e75-9a6d-521d43c6de73"
      unitRef="U_USD">200000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <iobt:NetProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_d9cf7434-a99c-426e-ba30-efa367120587"
      decimals="-5"
      id="F_2d750e68-be73-4917-84ab-fa7da19c979e"
      unitRef="U_USD">71900000</iobt:NetProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_444ecd94-9413-4f58-9283-c0e742cfcbad"
      decimals="-5"
      id="F_3a49565c-9e73-4415-9542-6edbf69f2330"
      unitRef="U_USD">29600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <iobt:WarrantsIssued
      contextRef="C_444ecd94-9413-4f58-9283-c0e742cfcbad"
      decimals="INF"
      id="F_64be5008-0e5d-4c84-ae34-fce5cb344db4"
      unitRef="U_shares">37065647</iobt:WarrantsIssued>
    <iobt:WarrantsExercisablePricePerShare
      contextRef="C_444ecd94-9413-4f58-9283-c0e742cfcbad"
      decimals="INF"
      id="F_997592cc-dfb0-4ef4-bc83-034c330912c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.47</iobt:WarrantsExercisablePricePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="INF"
      id="F_448bcbbf-ebcc-46cf-8808-ea9610966ae9"
      unitRef="U_shares">65880914</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1df79142-ea8b-41b1-a655-b2d3ed78f113"
      decimals="INF"
      id="F_ec00aa56-b2fd-4475-850b-9d2218985255"
      unitRef="U_shares">65880914</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_6077235e-10d2-4285-9156-b0296df1539c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Equity-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2021 Equity and Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2021, our Board adopted, and our stockholders approved, the 2021 Equity and Incentive Plan (the &#x201c;2021 Equity Plan&#x201d;), which became effective on November 4, 2021. The 2021 Equity Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. The number of shares of our common stock reserved for issuance under the 2021 Equity Plan is equal&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,496,934&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; subject to an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022 and continuing until, and including, the fiscal year ending December 31, 2031, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of common stock outstanding on the first day of such fiscal year or (ii) such other amount determined by our Board&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of June 30, 2025, we had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;486,563&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for future grant under the 2021 Equity Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2021, our Board adopted and our stockholders approved the 2021 Employee Stock Purchase Plan (the &#x201c;2021 ESPP&#x201d;), which became effective on November 4, 2021. The number of shares of our common stock reserved for issuance under the 2021 ESPP is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257,272&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, subject to an annual increase, to be added on the first day of each fiscal year, beginning January 1, 2023, equal to the lesser of (1) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of common stock outstanding on the first day of such fiscal year; (2) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257,272&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock; or (3) such other amount as determined by our Board. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025, the Board had not yet approved any offerings under the 2021 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2023 Inducement Award Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2023, our Board adopted the 2023 Inducement Award Plan (the &#x201c;2023 Inducement Plan&#x201d;), which became effective on September 28, 2023. The 2023 Inducement Plan provides for the grant of non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to eligible employees who satisfy the standards for inducement grants under Nasdaq Global Market rules. The number of shares of our common stock reserved for issuance under the 2023 Inducement Plan is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,976,427&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,666,427&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for future grant under the 2023 Inducement Plan.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes our stock options activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:49.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.020000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of &lt;br/&gt;stock &lt;br/&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;br/&gt;per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,967,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,709,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,539,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable, June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,537,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All share-based awards granted are measured based on the fair value on the date of the grant and compensation expense is recognized with respect to those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures related to equity-based compensation awards are recognized as they occur, and we reverse any previously recognized compensation cost associated with forfeited awards in the period the forfeiture occurs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2025, there was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized compensation cost related to unvested stock-based compensation arrangements that is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair values of the stock options granted during the period ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 were estimated based on the Black-Scholes model, using the following assumptions:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:76.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total equity-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any tax benefits for stock-based compensation during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025 and 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_31556d6d-fe87-49c2-bbf3-1900c78c9c40"
      decimals="INF"
      id="F_a2a3836e-ecc6-44e7-ae3f-e762107223e2"
      unitRef="U_shares">2496934</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_474458dc-a129-4f50-994f-7df9fe0827f4"
      decimals="2"
      id="F_e5a8a87c-b081-4802-998f-610b6d5156b5"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_934a4cc1-65a5-4fa7-9f5b-91cb5496af79"
      decimals="INF"
      id="F_d8ad704c-d4cc-4227-9a7f-f960d8d489bf"
      unitRef="U_shares">486563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_26bef08c-05c8-4a89-94f6-05ba69278969"
      decimals="INF"
      id="F_bfe9236d-036f-4f8c-a9d4-89918e3c7694"
      unitRef="U_shares">257272</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_556c8daa-bb23-4277-a055-75e799014084"
      decimals="2"
      id="F_121aaed8-d13d-4a77-afcd-29c5302b023a"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_26bef08c-05c8-4a89-94f6-05ba69278969"
      decimals="INF"
      id="F_de93750c-1f66-4c91-83e6-582707af50ce"
      unitRef="U_shares">257272</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f03f590f-3e44-4ac1-9039-13057aba247a"
      decimals="INF"
      id="F_8e09fd07-b070-4009-bb72-102c3627bf79"
      unitRef="U_shares">1976427</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_f03f590f-3e44-4ac1-9039-13057aba247a"
      decimals="INF"
      id="F_0d183103-a5e7-419f-9e19-f6d1d669e21e"
      unitRef="U_shares">1666427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_0f1ca77a-2abd-44b7-8d14-b5013fd6236b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes our stock options activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:49.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.020000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of &lt;br/&gt;stock &lt;br/&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;br/&gt;per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,967,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,709,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding, June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,539,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable, June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,537,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_a438d86c-ada7-4302-94e2-dc378d64a260"
      decimals="INF"
      id="F_7b2441f2-00d7-4a36-9f85-08277f59bc71"
      unitRef="U_shares">8967605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_a438d86c-ada7-4302-94e2-dc378d64a260"
      decimals="2"
      id="F_d26307ad-ba2b-406c-8780-21bfcf1a8dc1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_94559174-350f-4655-96db-1060692d7265"
      id="F_2327cf6b-a892-4085-86d5-1e568d222e35">P8Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_a438d86c-ada7-4302-94e2-dc378d64a260"
      decimals="-3"
      id="F_82adb09e-f150-4ef1-8e4b-3651667c452d"
      unitRef="U_USD">1000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7"
      decimals="INF"
      id="F_aa24937c-2050-490f-a5fc-ce4a755d5a91"
      unitRef="U_shares">2709284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7"
      decimals="2"
      id="F_9e66ff69-4b0b-42a0-930b-3d1cf7ae739c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7"
      decimals="INF"
      id="F_bf4d6bcf-347c-4c49-b66f-7409b847d0b2"
      unitRef="U_shares">137589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7"
      decimals="2"
      id="F_f2686103-0481-471b-8629-1b061c388ed5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_d039cccf-0ad2-4c2d-8c00-3f2cb7a6da02"
      decimals="INF"
      id="F_f53ed4c0-0136-4e18-aea2-89b76bc48eb5"
      unitRef="U_shares">11539300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_d039cccf-0ad2-4c2d-8c00-3f2cb7a6da02"
      decimals="2"
      id="F_d9e4cf9b-d495-4807-ba15-1386fd33908c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7"
      id="F_3563557b-4f03-4c07-84f3-1d25f8c0b1bd">P8Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_d039cccf-0ad2-4c2d-8c00-3f2cb7a6da02"
      decimals="-3"
      id="F_1d6ef9f0-b02e-4844-ad9e-1d68a89f4e04"
      unitRef="U_USD">821000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable
      contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7"
      decimals="INF"
      id="F_917883a0-cb1f-41dc-b48a-96f1cfbb36ca"
      unitRef="U_shares">5537588</iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable>
    <iobt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice
      contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7"
      decimals="2"
      id="F_2a383dbc-835d-45db-aed0-78a48e374d45"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.87</iobt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice>
    <iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm
      contextRef="C_56180ca1-a7f5-42bb-9570-5b13b8fea5b7"
      id="F_0e578eed-0086-440a-a140-2273f2d8b938">P7Y2M12D</iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm>
    <iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue
      contextRef="C_d039cccf-0ad2-4c2d-8c00-3f2cb7a6da02"
      decimals="-3"
      id="F_3d9e1eac-110c-41ac-a3a4-1517b3967782"
      unitRef="U_USD">57000</iobt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_f1ccc3b0-1ee9-4e08-be24-8ff434b23992"
      decimals="-5"
      id="F_b3bfa6d2-0d77-4fc5-90bd-642dc6c66813"
      unitRef="U_USD">7200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_fe0d3ca7-ffb9-4791-b1f5-9db4641c1936">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_0aa7bce6-cd34-4312-9b50-27aeaa9f905a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair values of the stock options granted during the period ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 were estimated based on the Black-Scholes model, using the following assumptions:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:76.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="3"
      id="F_a3d7e0f0-f0af-4dc1-bd64-a39d8df9b614"
      unitRef="U_pure">0.844</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="3"
      id="F_7bd7b2b0-8741-44fc-9a32-7e066231b7ec"
      unitRef="U_pure">0.852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="3"
      id="F_818311f8-a284-4b32-9341-9152f4244223"
      unitRef="U_pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="3"
      id="F_f6931b23-6f62-4082-ab5b-ccca24b45f4a"
      unitRef="U_pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a6b6d898-f2a2-4264-a194-96e339c5adc0"
      id="F_35d5f7bb-1e46-4205-97dd-8b96233f555d">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f08bf985-a9db-49be-bd46-d4eda7a2c58c"
      id="F_f78bc253-fbdd-4f79-84af-cdbaec083de2">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="2"
      id="F_3c1054e5-f014-4158-8331-15987b3143f6"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_3f55ae4e-c352-463f-bbd5-329cf32c1573">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total equity-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_86041aa9-6c80-4439-9ee6-0fefaad23a00"
      decimals="-3"
      id="F_c255029a-cdae-480a-975e-c8ecc6b13c20"
      unitRef="U_USD">644000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a14ce688-5adf-4041-9ce6-8681b682eb22"
      decimals="-3"
      id="F_a807e406-e4d4-470d-a160-3b5b16171cc6"
      unitRef="U_USD">677000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5d5c2036-4d47-45b2-abc2-ce62234c7b0d"
      decimals="-3"
      id="F_c29f506d-6ed6-41f6-8c40-fb666081f72b"
      unitRef="U_USD">1262000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ea4234a6-3d5f-4c04-b955-28240861f2c5"
      decimals="-3"
      id="F_c5684d55-20b4-4363-b13f-d9989e5a074b"
      unitRef="U_USD">1290000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_75fb5f36-7e2a-4032-ac5b-b93710ea8e93"
      decimals="-3"
      id="F_d7fa535b-9f9a-4b14-9220-7f237a2a2b75"
      unitRef="U_USD">963000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dcee008c-dfa3-43d1-b9c1-5d5957ec1dec"
      decimals="-3"
      id="F_72c5e024-a01a-4dd0-8d49-08fd9ea34775"
      unitRef="U_USD">965000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4fdff8d0-846c-4e02-aaa4-5c470eaf7625"
      decimals="-3"
      id="F_a5f081d0-f31e-4eb8-adaf-258825427b35"
      unitRef="U_USD">1914000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_37646e78-6337-438c-8dbe-8a3712d470ab"
      decimals="-3"
      id="F_452eb95d-68b5-4d0a-82ba-4b5db6ec928e"
      unitRef="U_USD">1920000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_193c3ccc-057b-4786-89a5-d0fab0161353"
      unitRef="U_USD">1607000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_92f2d5fd-d12a-4e6a-a559-c5fa2b35883a"
      unitRef="U_USD">1642000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_351efe03-f5ef-4795-828d-beb317c7fdc7"
      unitRef="U_USD">3176000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_e1821cf3-d7ca-435f-85df-92fd9defe672"
      unitRef="U_USD">3210000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="INF"
      id="F_83242bf9-7aa3-4104-bec7-ee51e3a3cb30"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="INF"
      id="F_21e57b3a-9b96-4859-abdc-a808b892f505"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="INF"
      id="F_610429df-63a0-4229-bf09-f1cc781651f8"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="INF"
      id="F_d8de2207-2cbd-4897-bbf9-60b86a6ac4c4"
      unitRef="U_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_8cdb80fa-9084-406a-8150-4821e326334b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are subject to taxes for earnings generated in multiple jurisdictions, both inside and outside of the United States and our tax expense is primarily affected by unrecognized tax benefits in Denmark due to the full valuation allowance. We recorded expense for income taxes of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the three months ended June 30, 2025 and 2024, respectively. We recorded expense for income taxes of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; during the six months ended June 30, 2025 and 2024, respectively. We continue to maintain a full valuation allowance against all of our deferred tax assets in IO Biotech ApS, IO Bio US, Inc., a wholly-owned subsidiary of IO Biotech ApS that was incorporated in Delaware in May 2021, and IO Biotech, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have evaluated the positive and negative evidence involving our ability to realize our deferred tax assets. We have considered our history of cumulative net losses incurred since inception and our lack of any commercial products. We have concluded that it is more likely than not that we will not realize the benefits of our deferred tax assets in IO Biotech ApS, IO Bio US, Inc. and IO Biotech, Inc. We reevaluate the positive and negative evidence at each reporting period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-5"
      id="F_7d94ddd7-9a73-483d-bcd2-67ceaefe98a4"
      unitRef="U_USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-5"
      id="F_50e91df0-6591-455c-b5ae-163ce9ae1f85"
      unitRef="U_USD">400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-5"
      id="F_91e50f6d-0cb8-428b-b112-9c30e7fd52fa"
      unitRef="U_USD">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-5"
      id="F_c538ce46-dd60-4f61-9ae7-8969ff73ee5e"
      unitRef="U_USD">800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_33990cbe-3a90-4253-84f7-54701c7acac4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14. Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per common share is calculated as follows (in thousands except share and per share amounts):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.95%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.982000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.982000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.982000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.982000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common shareholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average number of shares used in computing net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,880,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,880,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,880,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,880,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share, as their effect is anti-dilutive:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:49.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,539,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,992,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,539,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,992,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants issued in Private Placement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock warrants issued to the EIB&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,845,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,845,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_761dfb27-748e-4be3-ab2b-15d96757d35d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per common share is calculated as follows (in thousands except share and per share amounts):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.95%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.982000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.982000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.982000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.982000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common shareholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average number of shares used in computing net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,880,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,880,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,880,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,880,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_7de83e56-b9ba-41ed-a639-cd4fbe5ba066"
      unitRef="U_USD">-26217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_383d64d5-6cfe-4bdc-89f4-a7e3bf9f0d2e"
      unitRef="U_USD">-20686000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_82061338-5cc2-4a97-a29c-289516194eaf"
      unitRef="U_USD">-48638000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_386c1e67-5594-40cd-8556-c9f291ddd614"
      unitRef="U_USD">-40143000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="-3"
      id="F_b0a8bbba-db53-412a-958a-a4d80f5ad316"
      unitRef="U_USD">-26217000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="-3"
      id="F_ffefa60c-ab88-453e-9c51-92020c901114"
      unitRef="U_USD">-20686000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="-3"
      id="F_361b5578-f8b2-498d-85e6-074aa63e48ab"
      unitRef="U_USD">-48638000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="-3"
      id="F_c512ce33-50b3-4d93-abdc-10d1f90ce59d"
      unitRef="U_USD">-40143000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="2"
      id="F_da2332d1-b90d-40ba-b196-f03adf10f2cf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.4</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="2"
      id="F_cdc9fb21-7a20-4b7e-acd2-232001281b39"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.4</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="2"
      id="F_631081e1-f01a-489a-a7ce-1f920cfea990"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="2"
      id="F_12f031d6-da52-474e-8b17-573b683f8f6e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="2"
      id="F_27dd5a8c-a616-4076-bc88-f3458ae4751d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="2"
      id="F_fdb2a521-826b-4269-b7ab-e5fac73f9b12"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="2"
      id="F_6dd675e8-a764-4dcd-b90e-cf7605fb8519"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="2"
      id="F_b4dfb810-835a-4478-8d36-550e47833c53"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="0"
      id="F_ec119047-8c54-4b25-85ee-86bdcd6691e9"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a0871b16-5115-452a-8aa3-17c1815473f3"
      decimals="0"
      id="F_d605bca6-4966-439b-9c01-089e7444bdda"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="0"
      id="F_01ced59d-8f6b-4c5e-b99d-c6c5b89ff41a"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_61bb4edb-9b49-4f38-bc60-2cd07a95ee41"
      decimals="0"
      id="F_3e788e71-e1f1-4048-9bba-d3c69e0246ee"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="0"
      id="F_a8d44749-7d7f-4bc2-937b-768dfaeee365"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      decimals="0"
      id="F_ca2f6f05-534e-4f78-bf29-e2bad7b29c3b"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="0"
      id="F_eca2c9ba-b716-4369-8c8e-20076db4e54e"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_b0357848-8a70-4e7d-8b7c-77576974cdd3"
      decimals="0"
      id="F_434cac38-4952-46f0-bd54-7a00c2fd52e2"
      unitRef="U_shares">65880914</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_29d8f6fa-725c-459f-86d5-36db577a893a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per common share, as their effect is anti-dilutive:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:49.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,539,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,992,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,539,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,992,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants issued in Private Placement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,065,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock warrants issued to the EIB&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,845,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,845,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4e98906e-1cac-4433-be9f-7d243d541dcc"
      decimals="0"
      id="F_ed58107d-7a2b-4238-b03d-4a889122406d"
      unitRef="U_shares">11539300</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_73b1457e-202f-4b74-987b-acf3673e19af"
      decimals="0"
      id="F_9bac06e8-bbc6-4c1b-a6c9-a2d4b1a74372"
      unitRef="U_shares">8992635</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5b150492-18b8-4ea5-b79f-6a9eee4738eb"
      decimals="0"
      id="F_8d78ce85-efc4-4503-b1af-91a1658f6b7e"
      unitRef="U_shares">11539300</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_41b1f416-58f2-4b5c-99cf-ca18ff696ab3"
      decimals="0"
      id="F_89aa6813-84a3-463e-8f83-0e40e5b3a93a"
      unitRef="U_shares">8992635</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ab6be8c6-2dae-4f77-8832-45ca8119a732"
      decimals="0"
      id="F_ca480df5-499e-4437-bab0-ef2e203fa3cd"
      unitRef="U_shares">37065647</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d4e7dd4f-2821-44b8-998f-65cfe834fa7f"
      decimals="0"
      id="F_1e217762-67e7-4c9c-ba15-9cde0472184a"
      unitRef="U_shares">37065647</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5cc831a0-a0fc-49d9-95ba-356e8a3a7fb5"
      decimals="0"
      id="F_bded1c7f-fd5a-4b47-961d-c4a087401a8a"
      unitRef="U_shares">37065647</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_132052a7-d00c-4cb3-9ad6-e77324375e94"
      decimals="0"
      id="F_0e7b7081-68f9-4206-a4a5-88f405d504c0"
      unitRef="U_shares">37065647</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4f1f2469-2895-4c93-a281-ddfa3fa3a80f"
      decimals="0"
      id="F_6004d5f2-a4b3-45e7-8268-8c59a87c0757"
      unitRef="U_shares">9845532</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8d8a2973-4e93-4574-bc7f-1eb8bff4409d"
      decimals="0"
      id="F_90208480-c8df-4c31-835f-44f8f4ab7c7a"
      unitRef="U_shares">9845532</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_7f3734f2-68bc-4b31-a5b4-f19e7998f6bd">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15. Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We operate as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_abd02c4f-a3cd-4435-8a7f-dd7df01461bf;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment focused on developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on our T-win&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; platform. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As the chief operating decision maker (&#x201c;CODM&#x201d;), our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_aca2c24e-8e92-4826-9175-474c6929666f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; manages our company, reviews operating results, assesses performance and allocates resources on an aggregate basis using &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_ebc813a3-04f0-49f3-9868-9cfe7dc3008b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;consolidated net income or loss&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as the key measure of segment profit or loss.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As such, results of our operations are reported on a consolidated basis for purposes of management and segment reporting. Please refer to the consolidated financial statements for further information related to these measures of segment performance.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, research and development and general and administrative expenses are significant segment expenses regularly provided to the CEO with the following categories (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.91%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.318%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.718%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.318%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.318%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three months ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six months ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical trial-related activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Chemistry, manufacturing and control&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Preclinical studies and activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;General and Administrative&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.41%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three months ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six months ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_b84a72bb-e157-490d-8c62-88b031636437">As the chief operating decision maker (&#x201c;CODM&#x201d;), our Chief Executive Officer manages our company, reviews operating results, assesses performance and allocates resources on an aggregate basis using consolidated net income or loss as the key measure of segment profit or loss.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_263ea4fc-2fac-4da7-acc6-cf88f2b608b0">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, research and development and general and administrative expenses are significant segment expenses regularly provided to the CEO with the following categories (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.91%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.318%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.718%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.318%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.318%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three months ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six months ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical trial-related activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Chemistry, manufacturing and control&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Preclinical studies and activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;General and Administrative&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.41%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three months ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six months ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a1eaf344-05b7-4fe9-bc2d-b42ce849911a"
      decimals="-3"
      id="F_fca8dd3b-74fb-4f70-9ef3-b178ebc18bd2"
      unitRef="U_USD">6390000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2d7f3f8f-ddd0-48bc-b68a-50c26ed152f4"
      decimals="-3"
      id="F_25c34670-e750-4c1c-9b80-eb69004e61c3"
      unitRef="U_USD">6637000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_fc8b2cef-3f0c-4673-bc7b-e631da99dff6"
      decimals="-3"
      id="F_aa77463e-f0c4-488f-90f3-10c61faa9125"
      unitRef="U_USD">14081000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_55aaab1d-0030-4d3d-8a11-599b6fe6903f"
      decimals="-3"
      id="F_ab50ae34-3dfa-4dbe-86fb-82c2dee0059e"
      unitRef="U_USD">13785000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a1fefede-ee93-4a78-8157-b3a7150dc5ea"
      decimals="-3"
      id="F_eeb63c5d-3e35-4184-bd34-c3bea0ab6f1d"
      unitRef="U_USD">6531000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_65d8cb5b-0a18-41c9-981b-c844905fa72f"
      decimals="-3"
      id="F_6f292d5e-8c7d-494c-b5bd-fd5d2012cb90"
      unitRef="U_USD">5123000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6ef232e1-8f2b-4eec-9dd0-c1e56fcf4bb5"
      decimals="-3"
      id="F_05c8ac09-14cc-4af3-a2e6-bf60ef120d08"
      unitRef="U_USD">12714000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_41eb296d-58a9-41d3-ac9d-5e2d3cb0a7a2"
      decimals="-3"
      id="F_7a18be29-d4e9-4469-a106-08fbfd70999e"
      unitRef="U_USD">9917000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_cf6e89c2-68e9-4989-9bcc-71a8d4f206fa"
      decimals="-3"
      id="F_d7d712df-7499-4662-87f3-5ec12e983671"
      unitRef="U_USD">2484000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6561fedd-443a-4a83-8643-efd575ae4790"
      decimals="-3"
      id="F_d2545417-74c1-451e-820a-c87a8a590725"
      unitRef="U_USD">2994000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ac5e1a5c-cbf1-4bda-90cf-e92f72ffc842"
      decimals="-3"
      id="F_f7f9c5f9-4a3a-4ebc-9ae3-b650c7c559c8"
      unitRef="U_USD">4776000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e967bb70-74f8-4aa9-a3ea-389fe5eeaa26"
      decimals="-3"
      id="F_99801a0d-b63a-4c90-9355-bd15a2fa1332"
      unitRef="U_USD">5161000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1b0fada8-8afd-4aa2-8081-cb2a8058b81f"
      decimals="-3"
      id="F_b421df42-c841-43de-8500-a1dcfaa3b917"
      unitRef="U_USD">616000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e39d7aaf-45f1-49d8-b933-d2049d7a30c3"
      decimals="-3"
      id="F_7516a267-ef67-423f-a866-36030c908a99"
      unitRef="U_USD">295000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_785749e1-bfed-43d5-a943-0f70e8cc76bc"
      decimals="-3"
      id="F_c0ba5579-80fa-4c40-8c04-40104b3f7657"
      unitRef="U_USD">1028000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_438a86b3-b95d-4e7a-bf73-767445f988d8"
      decimals="-3"
      id="F_a686dca1-bc37-46dc-93ea-8a157d7909c4"
      unitRef="U_USD">632000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c467807b-b9cd-4abf-a2c2-779eebbaff94"
      decimals="-3"
      id="F_4ce6a0f3-acf4-413d-aa52-c77d007fee40"
      unitRef="U_USD">631000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_72045b9f-3820-4aad-a93e-3694b13e20c4"
      decimals="-3"
      id="F_90021deb-48ac-44af-934e-900b8cbd8407"
      unitRef="U_USD">799000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_da9f479f-4bef-4055-ba48-4ce7e429d95d"
      decimals="-3"
      id="F_05dbcf6c-4968-4009-bb04-bdde395238f1"
      unitRef="U_USD">428000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3764f78d-6235-4496-a19e-2de9bd33fad6"
      decimals="-3"
      id="F_0190e465-e289-4fd5-81ca-e59da9192fb0"
      unitRef="U_USD">664000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9056ec8b-e4b6-4e0a-a202-17751c0d78db"
      decimals="-3"
      id="F_3b86b619-df64-4741-95cc-48e91d18860a"
      unitRef="U_USD">16652000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_caf14b74-474c-4188-88f8-9d1a26cd9cf5"
      decimals="-3"
      id="F_ab58f577-084b-43d0-8a38-57c7c772f1ec"
      unitRef="U_USD">15848000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9e6bbdd8-4ed3-4cbf-a612-855c1debc82d"
      decimals="-3"
      id="F_99438376-54d6-4cb8-9bb5-4835bfd3ed7c"
      unitRef="U_USD">33027000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_fc2eaac8-ff9c-4b6b-9667-7650678ab73e"
      decimals="-3"
      id="F_bbed4d30-8d16-4294-bf57-6fd4fa4677d7"
      unitRef="U_USD">30159000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a1fefede-ee93-4a78-8157-b3a7150dc5ea"
      decimals="-3"
      id="F_c30aecb9-8c5b-4913-a677-921832ba9c52"
      unitRef="U_USD">2840000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_65d8cb5b-0a18-41c9-981b-c844905fa72f"
      decimals="-3"
      id="F_a399ca03-d3df-4f52-b71a-6d331030b4bc"
      unitRef="U_USD">2899000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6ef232e1-8f2b-4eec-9dd0-c1e56fcf4bb5"
      decimals="-3"
      id="F_87786d58-7d44-4459-ae54-cf4a950c5f1e"
      unitRef="U_USD">5852000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_41eb296d-58a9-41d3-ac9d-5e2d3cb0a7a2"
      decimals="-3"
      id="F_9ed0b22d-086f-4e0e-96d3-13ae9cbdbefd"
      unitRef="U_USD">5693000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_82fdbb77-bcb9-4016-b1f8-453bf41699c5"
      decimals="-3"
      id="F_094873d8-6ed2-4c93-924e-659c40bc96c3"
      unitRef="U_USD">1743000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_cda39673-240f-4ea4-b28d-573ba9ac932f"
      decimals="-3"
      id="F_52e8504b-d493-4192-9b56-b193927c3e9f"
      unitRef="U_USD">975000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1829c523-648e-4a02-8109-0deb1191ed06"
      decimals="-3"
      id="F_cb2c435d-c8b8-4329-b154-0f4b03265325"
      unitRef="U_USD">3124000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1e241c91-5715-488d-a31b-90976e18ef81"
      decimals="-3"
      id="F_83db6511-40f7-4be7-8b47-58f7f297fde1"
      unitRef="U_USD">2048000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_c467807b-b9cd-4abf-a2c2-779eebbaff94"
      decimals="-3"
      id="F_f97c38bc-99c3-4bfb-adbe-0d6cb6d2ed7b"
      unitRef="U_USD">1935000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_72045b9f-3820-4aad-a93e-3694b13e20c4"
      decimals="-3"
      id="F_5fce2a1d-b7d2-42fc-af86-e8717674aff2"
      unitRef="U_USD">1811000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_da9f479f-4bef-4055-ba48-4ce7e429d95d"
      decimals="-3"
      id="F_2530bbb6-a4c7-428b-9a90-c84d1c83b892"
      unitRef="U_USD">3751000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3764f78d-6235-4496-a19e-2de9bd33fad6"
      decimals="-3"
      id="F_f6e51c21-4648-4438-b0ff-6faca6e27757"
      unitRef="U_USD">3830000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_9056ec8b-e4b6-4e0a-a202-17751c0d78db"
      decimals="-3"
      id="F_f7845f71-67a0-4ed8-9dc9-f345cda730e1"
      unitRef="U_USD">6518000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_caf14b74-474c-4188-88f8-9d1a26cd9cf5"
      decimals="-3"
      id="F_fd91f5c5-ffc0-42ca-98b4-692a1eca719d"
      unitRef="U_USD">5685000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_9e6bbdd8-4ed3-4cbf-a612-855c1debc82d"
      decimals="-3"
      id="F_161ae31f-bae7-4452-9bad-e2a42b9584cf"
      unitRef="U_USD">12727000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_fc2eaac8-ff9c-4b6b-9667-7650678ab73e"
      decimals="-3"
      id="F_a6212654-4291-4cab-8399-d14a5cf9d202"
      unitRef="U_USD">11571000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_06f89407-ef8a-413d-a26d-7130bc667281">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;16. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;One Big Beautiful Bill Act&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the &#x201c;Act&#x201d;). The Act extends expiring, and in some cases expired, provisions of the 2017 Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;).  For taxable years beginning after December 31, 2024, the Act includes measures potentially affecting the Company&#x2019;s income tax provision including a permanent and immediate deduction for domestic research and development expenditures, 100 percent expensing for certain business property, the expansion of section 162(m) limits on deductions of certain executive compensation, and a floor for deductions for charitable contributions where deductions are now limited to contributions in excess of 1% of a corporation's taxable income. The Act allows taxpayers that capitalized domestic R&amp;amp;D expenditures after December 31, 2021, but before January 1 2025,  to elect to deduct any remaining unamortized amounts in the first tax year beginning after December 31, 2024, or ratably over the two-tax year period starting with the first tax year that begins after December 31, 2024. The Company is still evaluating the impact of the Act on its income tax provision.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;EIB Tranche B Funding&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Finance Contract, the Company (through the Borrower) satisfied the conditions to draw &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from the Tranche B loan facility. In connection therewith, on June 24, 2025, the Company issued to EIB the Tranche B Warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,221,867.59&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock. The Strike Price per share of common stock is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.32&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. On July 4, 2025, the Company (through the Borrower) drew upon the Tranche B loan facility to obtain &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before payment of certain fees and transaction related expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_1d4a8f2a-a146-4860-99dd-0f7ae3dbbe1b"
      decimals="-5"
      id="F_e6ee97b7-5817-4d24-a429-3b4df01b9625"
      unitRef="U_USD">12500000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2b8ecfa6-15a8-4675-8200-6867ed419829"
      decimals="2"
      id="F_c1c3608b-c916-4c92-b0c4-0e7ab87fc3fd"
      unitRef="U_shares">4221867.59</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <iobt:StrikePricePerShare
      contextRef="C_4d40a682-0751-4064-bb08-df58960d326c"
      decimals="2"
      id="F_38920728-f9a4-4378-a97c-5ba7d0c1551e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.32</iobt:StrikePricePerShare>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_1d4a8f2a-a146-4860-99dd-0f7ae3dbbe1b"
      decimals="-5"
      id="F_2836a24c-bd0c-4b70-9193-c79ba1eb6d5d"
      unitRef="U_USD">12500000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_c4ef9be2-9292-4f30-98e5-bcb0f8298e0e">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_946bc31e-d08a-4826-ab2a-be2ce6c77af2">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_ef1e176f-c0f1-4234-a0c3-56f800a861a6">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_1c31d0c7-7684-473b-9386-127c8dea9206"
      id="F_7d8dc95e-af90-4865-ad62-483372d4e92c">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
